3.4.21.7 Abortion, Habitual http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21614812&form=6&db=m [Effect of antiphospholipid antibodies on the formation and lysis of fibrin network in patients with recurrent miscarriage]. causal interaction,diagnostic usage,unassigned 1,4,0 3.4.21.7 Abortion, Spontaneous http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20823115&form=6&db=m Pregnancy-triggered antiphospholipid syndrome in a patient with multiple late miscarriages. unassigned - 3.4.21.7 Abscess http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8224366&form=6&db=m Stimulation of plasmin activity in cultured human fibroblast cells by Porphyromonas endodontalis. ongoing research,unassigned 4,0 3.4.21.7 Abscess http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=13442896&form=6&db=m The treatment of acute abscesses with human plasmin (fibrinolysin). causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.7 Abscess http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23801604&form=6&db=m Staphylokinase Promotes the Establishment of Staphylococcus aureus Skin Infections While Decreasing Disease Severity. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,2,1 3.4.21.7 Abscess http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28939652&form=6&db=m Skin infections are eliminated by cooperation of the fibrinolytic and innate immune systems. unassigned - 3.4.21.7 Acantholysis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2957965&form=6&db=m Plasmin induces acantholysis in skin organ cultures. ongoing research,therapeutic application,unassigned 4,2,0 3.4.21.7 Acantholysis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3117905&form=6&db=m Involvement of urokinase-type plasminogen activator in acantholysis induced by pemphigus IgG. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,1,3,2 3.4.21.7 Acantholysis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3902681&form=6&db=m Pathogenesis of pemphigus. The role of epidermal plasminogen activators in acantholysis. causal interaction,unassigned 1,0 3.4.21.7 Acantholysis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6539102&form=6&db=m Penicillamine-induced pemphigus. Immunoglobulin from this patient induces plasminogen activator synthesis by human epidermal cells in culture: mechanism for acantholysis in pemphigus. ongoing research,unassigned 4,0 3.4.21.7 Acantholysis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6681540&form=6&db=m Anti-cell surface pemphigus autoantibody stimulates plasminogen activator activity of human epidermal cells. A mechanism for the loss of epidermal cohesion and blister formation. causal interaction,ongoing research,unassigned 4,4,0 3.4.21.7 Acantholysis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7510121&form=6&db=m Cantharidin-induced acantholysis: adhesion molecules, proteases, and related proteins. causal interaction,diagnostic usage,ongoing research,unassigned 3,3,2,0 3.4.21.7 Acantholysis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9347794&form=6&db=m Pemphigus IgG induces expression of urokinase plasminogen activator receptor on the cell surface of cultured keratinocytes. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,4,1 3.4.21.7 Acantholysis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12675525&form=6&db=m Protease inhibitors prevent plasminogen-mediated, but not pemphigus vulgaris-induced, acantholysis in human epidermis. therapeutic application,unassigned 3,0 3.4.21.7 Acantholysis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12930304&form=6&db=m Urokinase plasminogen activator mRNA is induced by IL-1alpha and TNF-alpha in in vitro acantholysis. causal interaction,unassigned 2,0 3.4.21.7 Acidosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9488672&form=6&db=m Histidine-proline-rich glycoprotein as a plasma pH sensor. Modulation of its interaction with glycosaminoglycans by ph and metals. diagnostic usage,therapeutic application,unassigned 3,2,0 3.4.21.7 Acidosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23354242&form=6&db=m Recombinant tissue-type plasminogen activator-evoked hyperfibrinolysis is enhanced by acidosis and inhibited by hypothermia but still can be blocked by tranexamic acid. diagnostic usage,ongoing research,therapeutic application,unassigned 2,4,2,0 3.4.21.7 Acquired Immunodeficiency Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1398780&form=6&db=m Dysregulated proteolysis in AIDS. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.7 Acquired Immunodeficiency Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9856830&form=6&db=m Wound fluid from venous leg ulcers degrades plasminogen and reduces plasmin generation by keratinocytes. causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,3,0 3.4.21.7 Acquired Immunodeficiency Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22124123&form=6&db=m Haemophilus influenzae uses the surface protein E to acquire human plasminogen and to evade innate immunity. causal interaction,unassigned 2,0 3.4.21.7 Acquired Immunodeficiency Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27377187&form=6&db=m Proteolysis of plasminogen activator inhibitor-1 by Yersinia pestis remodulates the host environment to promote virulence. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,3,3,2 3.4.21.7 Acquired Immunodeficiency Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27569900&form=6&db=m Enolase of Mycobacterium tuberculosis is a surface exposed plasminogen binding protein. causal interaction,therapeutic application,unassigned 2,1,0 3.4.21.7 Activated Protein C Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7574192&form=6&db=m Prevalence of moderate hyperhomocysteinemia in patients with early-onset venous and arterial occlusive disease. causal interaction,diagnostic usage,ongoing research,unassigned 4,1,2,0 3.4.21.7 Activated Protein C Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8841318&form=6&db=m Coagulation studies, factor V Leiden, and anticardiolipin antibodies in 40 cases of cerebral venous thrombosis. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,1,1 3.4.21.7 Activated Protein C Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9544982&form=6&db=m Low risk of venous thrombosis in two families with combined type I plasminogen deficiency and factor V R506Q mutation. causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,1,0 3.4.21.7 Activated Protein C Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9865798&form=6&db=m Prothrombotic disorders in infants and children with cerebral thromboembolism. ongoing research,therapeutic application,unassigned 1,1,0 3.4.21.7 Activated Protein C Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9990817&form=6&db=m [Screening methods in genetic diagnosis of hereditary protein C deficiency] diagnostic usage,unassigned 2,0 3.4.21.7 Activated Protein C Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10448802&form=6&db=m Prethrombotic disorders in children with arterial ischemic stroke and sinovenous thrombosis. diagnostic usage,unassigned 3,0 3.4.21.7 Activated Protein C Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10726047&form=6&db=m Combined heterozygous plasminogen deficiency and factor V Leiden defect in the same kindred. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.7 Activated Protein C Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11108774&form=6&db=m Diagnostic testing for coagulopathies in patients with ischemic stroke. ongoing research,therapeutic application,unassigned 1,1,0 3.4.21.7 Activated Protein C Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11243145&form=6&db=m [Type I protein C deficiency caused by a novel protein C gene mutation] ongoing research,unassigned 3,0 3.4.21.7 Activated Protein C Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11486106&form=6&db=m Prothrombotic disorders in children with moyamoya syndrome. unassigned - 3.4.21.7 Activated Protein C Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12361206&form=6&db=m Primary thrombophilia in Mexico III: A prospective study of the sticky platelet syndrome. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,1,3,1 3.4.21.7 Activated Protein C Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12584224&form=6&db=m Thrombotic risk factors and extent of liver fibrosis in chronic viral hepatitis. unassigned - 3.4.21.7 Activated Protein C Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15041273&form=6&db=m Disturbances of anticoagulation and fibrinolytic systems in monoclonal gammopathies-another mechanism of M-protein interference with hemostasis. unassigned - 3.4.21.7 Activated Protein C Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15609280&form=6&db=m Primary thrombophilia in Mexico. V. A comprehensive prospective study indicates that most cases are multifactorial. diagnostic usage,therapeutic application,unassigned 2,1,0 3.4.21.7 Activated Protein C Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16390236&form=6&db=m A comparison of glass and plastic blood collection tubes for routine and specialized coagulation assays: a comprehensive study. diagnostic usage,unassigned 2,0 3.4.21.7 Activated Protein C Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16547717&form=6&db=m Changes in coagulation and fibrinolysis of post-SARS osteonecrosis in a Chinese population. diagnostic usage,ongoing research,therapeutic application,unassigned 1,1,1,0 3.4.21.7 Activated Protein C Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16601829&form=6&db=m Hyperprothrombinaemia-induced APC resistance: Differential influence on fibrin formation and fibrinolysis. causal interaction,unassigned 4,0 3.4.21.7 Activated Protein C Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16677567&form=6&db=m [Hematological changes and related gene mutation of post-severe acute respiratory syndrome patients with osteonecrosis] diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.7 Activated Protein C Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16682112&form=6&db=m Atherosclerosis in women with endometriosis. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,2,2,1 3.4.21.7 Activated Protein C Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16957675&form=6&db=m Haemocoagulative modifications correlated with pregnancy. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.7 Activated Protein C Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17969840&form=6&db=m [Primary thrombophilia in MĂ©xico. VI: lack of statistical association among the inherited thrombophilic conditions] diagnostic usage,ongoing research,unassigned 2,1,0 3.4.21.7 Activated Protein C Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21225090&form=6&db=m Haemostatic effects of a new combined oral contraceptive, nomegestrol acetate/17?-estradiol, compared with those of levonorgestrel/ethinyl estradiol. A double-blind, randomised study. unassigned - 3.4.21.7 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9883750&form=6&db=m Inflammation, the endothelium, and the acute coronary syndromes. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.7 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15849438&form=6&db=m Relationship between myocardial injury and soluble P-selectin in non-ST elevation acute coronary syndromes. diagnostic usage,therapeutic application,unassigned 2,2,0 3.4.21.7 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16102027&form=6&db=m Circulating inflammatory markers and risks of cardiovascular and non-cardiovascular disease. causal interaction,diagnostic usage,unassigned 1,3,0 3.4.21.7 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17315612&form=6&db=m [Haemostatic and inflammation markers in acute coronary syndromes and its relationship with adverse cardiovascular events] causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.7 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20959880&form=6&db=m Lack of an association between connexin-37, stromelysin-1, plasminogen activator-inhibitor type 1 and lymphotoxin-alpha genes and acute coronary syndrome in Czech Caucasians. causal interaction,ongoing research,unassigned 3,1,0 3.4.21.7 Acute Kidney Injury http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2424425&form=6&db=m The proteinase inhibitor complexes (antithrombin III-thrombin, alpha 2antiplasmin-plasmin and alpha 1antitrypsin-elastase) in septicemia, fulminant hepatic failure and cardiac shock: value for diagnosis and therapy control in DIC/F syndrome. unassigned - 3.4.21.7 Acute Kidney Injury http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2530187&form=6&db=m Reduced fibrinolytic capacity and its restoration by plasminogen substitution in acute renal failure. causal interaction,diagnostic usage,unassigned 1,4,0 3.4.21.7 Acute Kidney Injury http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4252658&form=6&db=m [Fibrinolysin (uroplasmin) therapy of initial manifestations of acute renal insufficiency transfusion] causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.7 Acute Lung Injury http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23919993&form=6&db=m Mechanisms of severe acute respiratory syndrome coronavirus-induced acute lung injury. causal interaction,diagnostic usage,therapeutic application,unassigned 3,3,1,0 3.4.21.7 Acute-On-Chronic Liver Failure http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32175919&form=6&db=m Plasminogen as a prognostic biomarker for HBV-related acute-on-chronic liver failure. diagnostic usage,therapeutic application,unassigned 4,2,0 3.4.21.7 adamts13 endopeptidase deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24449821&form=6&db=m Plasmin Cleavage of von Willebrand Factor as an Emergency Bypass for ADAMTS13 Deficiency in Thrombotic Microangiopathy. causal interaction,diagnostic usage,unassigned 4,3,0 3.4.21.7 adamts13 endopeptidase deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27604194&form=6&db=m ADAMTS13 deficiency promotes microthrombosis in a murine model of diet-induced liver steatosis. causal interaction,diagnostic usage,ongoing research,unassigned 3,2,3,0 3.4.21.7 adamts13 endopeptidase deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28981198&form=6&db=m Amplified endogenous plasmin activity resolves acute thrombotic thrombocytopenic purpura in mice. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,3,0 3.4.21.7 adamts13 endopeptidase deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29228282&form=6&db=m Proteolytic inactivation of ADAMTS13 by plasmin in human plasma: risk of thrombotic thrombocytopenic purpura. causal interaction,diagnostic usage,ongoing research,unassigned 3,4,4,0 3.4.21.7 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1850957&form=6&db=m Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,1 3.4.21.7 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1901119&form=6&db=m Immunohistochemical analysis of plasminogen activator expression in human colorectal carcinomas: correlation with CEA distribution and tumor cell kinetics. diagnostic usage,ongoing research,unassigned 4,4,0 3.4.21.7 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2433233&form=6&db=m The plasmin system in human adenocarcinomas and their metastases. A comparative immunofluorescence study. causal interaction,diagnostic usage,ongoing research,unassigned 3,3,4,0 3.4.21.7 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3102269&form=6&db=m Appearance of plasminogen activator activity during a synchronous cycle of a rat adenocarcinoma cell line, PA-III. ongoing research,unassigned 4,0 3.4.21.7 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3621160&form=6&db=m Plasminogen activators and tumor development in the human colon: activity levels in normal mucosa, adenomatous polyps, and adenocarcinomas. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,4,0 3.4.21.7 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3884145&form=6&db=m Localization of plasminogen activators in human colon cancer by immunoperoxidase staining. causal interaction,diagnostic usage,ongoing research,unassigned 3,3,4,0 3.4.21.7 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4042458&form=6&db=m Localization of plasminogen activator(s) in primary and secondary rat adenocarcinoma cells. diagnostic usage,ongoing research,unassigned 1,4,0 3.4.21.7 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6240998&form=6&db=m Proteases in human tumors. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,4,0 3.4.21.7 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6537899&form=6&db=m Biochemical methods for predicting metastatic ability of prostatic cancer utilizing the dunning R-3327 rat prostatic adenocarcinoma system as a model. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,1,0 3.4.21.7 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6684952&form=6&db=m Purification and properties of a plasminogen activator from cultured rat prostate adenocarcinoma cells. diagnostic usage,ongoing research,unassigned 3,4,0 3.4.21.7 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6686346&form=6&db=m Identification of the plasminogen activator(s) produced by the transformed liver cell line, SK-HEP-1. ongoing research,unassigned 4,0 3.4.21.7 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7557947&form=6&db=m Antigen levels of urokinase plasminogen activator and its receptor at the tumor-host interface of colorectal adenocarcinomas are related to tumor aggressiveness. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.7 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8514458&form=6&db=m Role of plasminogen activators, metalloproteinases and the tissue inhibitor of metalloproteinase-1 in the metastatic process of human salivary-gland adenocarcinoma cells. causal interaction,ongoing research,unassigned 1,4,0 3.4.21.7 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9143604&form=6&db=m Upregulation of urokinase-type plasminogen activator by endogenous and exogenous HIV-1 Tat protein in tumour cell lines derived from BK virus/tat-transgenic mice. diagnostic usage,ongoing research,therapeutic application,unassigned 3,4,1,0 3.4.21.7 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9422083&form=6&db=m Inhibitory effect of amiloride on the urokinase plasminogen activators in prostatic cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,3,4,1 3.4.21.7 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9464846&form=6&db=m Tamoxifen exerts oestrogen-agonistic effects on proliferation and plasminogen activation, but not on gelatinase activity, glycogen metabolism and p53 protein expression, in cultures of oestrogen-responsive human endometrial adenocarcinoma cells. diagnostic usage,ongoing research,unassigned 3,4,0 3.4.21.7 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11240744&form=6&db=m Plasminogen activators and inhibitors in ovarian adenocarcinomas. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.7 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15935835&form=6&db=m Iron-mediated stability of PAI-1 mRNA in adenocarcinoma cells-involvement of a mRNA-binding nuclear protein. ongoing research,therapeutic application,unassigned 2,4,0 3.4.21.7 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18366077&form=6&db=m Plasminogen-induced aggregation of PANC-1 cells requires conversion to plasmin and is inhibited by endogenous plasminogen activator inhibitor-1. ongoing research,unassigned 4,0 3.4.21.7 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19425054&form=6&db=m An integrated humoral and cellular response is elicited in pancreatic cancer by alpha-enolase, a novel pancreatic ductal adenocarcinoma-associated antigen. causal interaction,unassigned 3,0 3.4.21.7 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26504024&form=6&db=m Plasminogen Activation System in Rectal Adenocarcinoma. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,3,2,1 3.4.21.7 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28086938&form=6&db=m Alpha-enolase (ENO1) controls alpha v/beta 3 integrin expression and regulates pancreatic cancer adhesion, invasion, and metastasis. causal interaction,ongoing research,unassigned 4,1,0 3.4.21.7 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32177229&form=6&db=m Varying distribution of tissue plasminogen activators in gastrointestinal adenocarcinoma. ongoing research,unassigned 2,0 3.4.21.7 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32177230&form=6&db=m Tumor-associated universal inhibitors and free plasmin in adenocarcinoma of stomach and pancreatic head. causal interaction,therapeutic application,unassigned 3,2,0 3.4.21.7 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33355874&form=6&db=m Plasminogen/plasmin affects expression of glycolysis regulator TIGAR and induces autophagy in lung adenocarcinoma A549 cells. causal interaction,ongoing research,therapeutic application,unassigned 2,2,4,0 3.4.21.7 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34439251&form=6&db=m Experimental and Clinical Evidence Supports the Use of Urokinase Plasminogen Activation System Components as Clinically Relevant Biomarkers in Gastroesophageal Adenocarcinoma. causal interaction,ongoing research,therapeutic application,unassigned 3,2,3,0 3.4.21.7 Adenocarcinoma of Lung http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3926492&form=6&db=m Characterization of the high-affinity interaction between human plasminogen and pro-urokinase. ongoing research,unassigned 2,0 3.4.21.7 Adenocarcinoma of Lung http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21808809&form=6&db=m Rhenium-188 labeled recombinant human plasminogen kringle5 (rhk5) and preliminary biodistribution. Evaluation in mice bearing A549 tumours. ongoing research,therapeutic application,unassigned 4,2,0 3.4.21.7 Adenocarcinoma of Lung http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30765871&form=6&db=m HAI-2 as a novel inhibitor of plasmin represses lung cancer cell invasion and metastasis. causal interaction,ongoing research,therapeutic application,unassigned 4,2,4,0 3.4.21.7 Adenocarcinoma of Lung http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33355874&form=6&db=m Plasminogen/plasmin affects expression of glycolysis regulator TIGAR and induces autophagy in lung adenocarcinoma A549 cells. causal interaction,ongoing research,therapeutic application,unassigned 2,2,4,0 3.4.21.7 Adenocarcinoma, Follicular http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10524570&form=6&db=m Degradation of extracellular matrix by metastatic follicular thyroid carcinoma cell lines: role of the plasmin activation system. causal interaction,ongoing research,unassigned 4,4,0 3.4.21.7 Adenoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=233396&form=6&db=m [Blood coagulation disorder in islet cell adenoma] diagnostic usage,ongoing research,unassigned 4,2,0 3.4.21.7 Adenoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2232301&form=6&db=m [Protease activities in gastric and colon cancer tissues] causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,4,1 3.4.21.7 Adenoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3111578&form=6&db=m Role of urokinase in colorectal neoplasia. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,2,1 3.4.21.7 Adenoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7841059&form=6&db=m Plasminogen activators and inhibitor type 1 in neoplastic colonic tissue from patients with familial adenomatous polyposis. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,4,0 3.4.21.7 Adenoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9461001&form=6&db=m Alterations in plasminogen activation correlate with epithelial cell dysplasia grading in colorectal adenomas. causal interaction,diagnostic usage,ongoing research,unassigned 3,4,4,0 3.4.21.7 Adenoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16928445&form=6&db=m Differential expression of the components of the plasminogen activating system in human thyroid tumour derived cell lines and papillary carcinomas. diagnostic usage,ongoing research,unassigned 3,4,0 3.4.21.7 Adenoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20496126&form=6&db=m The Plasminogen System in Microdissected Colonic Mucosa Distant from an Isolated Adenoma. causal interaction,ongoing research,therapeutic application,unassigned 3,2,1,0 3.4.21.7 Adenoma, Islet Cell http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=233396&form=6&db=m [Blood coagulation disorder in islet cell adenoma] diagnostic usage,ongoing research,unassigned 4,2,0 3.4.21.7 Adenoma, Villous http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6423277&form=6&db=m A model for human colon carcinoma evolution based on the differential response of cultured preneoplastic, premalignant, and malignant cells to 12-O-tetradecanoylphorbol-13-acetate. causal interaction,diagnostic usage,ongoing research,unassigned 1,3,3,0 3.4.21.7 Adenomatous Polyposis Coli http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7841059&form=6&db=m Plasminogen activators and inhibitor type 1 in neoplastic colonic tissue from patients with familial adenomatous polyposis. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,4,0 3.4.21.7 Adenomatous Polyps http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3094628&form=6&db=m Plasminogen activators in human colorectal neoplasia. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,3,1 3.4.21.7 Adenomatous Polyps http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3621160&form=6&db=m Plasminogen activators and tumor development in the human colon: activity levels in normal mucosa, adenomatous polyps, and adenocarcinomas. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,4,0 3.4.21.7 Adenomatous Polyps http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7841059&form=6&db=m Plasminogen activators and inhibitor type 1 in neoplastic colonic tissue from patients with familial adenomatous polyposis. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,4,0 3.4.21.7 Afibrinogenemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3086385&form=6&db=m Plasminogen interacts with human platelets through two distinct mechanisms. unassigned - 3.4.21.7 Afibrinogenemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4234818&form=6&db=m [Plasmin and congenital afibrinogenemia] diagnostic usage,ongoing research,unassigned 4,4,0 3.4.21.7 Afibrinogenemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17722076&form=6&db=m Fibrinogen deficiency, but not plasminogen deficiency, increases mortality synergistically in combination with sickle hemoglobin SAD in transgenic mice. causal interaction,ongoing research,unassigned 4,2,0 3.4.21.7 Afibrinogenemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22815383&form=6&db=m Plasmin-driven fibrinolysis facilitates skin tumor growth in a gender-dependent manner. causal interaction,ongoing research,unassigned 4,4,0 3.4.21.7 Agammaglobulinemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6179481&form=6&db=m Intravenous administration of plasmin treated immunoglobulins in 10 patients with agammaglobulinemia. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.7 Aggressive Periodontitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25971786&form=6&db=m Periodontitis associated with plasminogen deficiency: a case report. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 Aggressive Periodontitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28548211&form=6&db=m A haplotype block downstream of plasminogen is associated with chronic and aggressive periodontitis. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.7 AIDS-Associated Nephropathy http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27335373&form=6&db=m Podocyte Injury: The Role of Proteinuria, Urinary Plasminogen and Oxidative Stress. causal interaction,unassigned 4,0 3.4.21.7 Airway Obstruction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32066472&form=6&db=m Treatment of patients with hereditary angioedema with the c.988A>G (p.Lys330Glu) variant in the plasminogen gene. causal interaction,therapeutic application,unassigned 2,1,0 3.4.21.7 Albinism, Ocular http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10382293&form=6&db=m Generation and chromosome mapping of expressed sequence tags (ESTs) from a human infant thymus. therapeutic application,unassigned 1,0 3.4.21.7 Albuminuria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9640077&form=6&db=m [Urinary excretion of extracellular matrix proteins in insulin dependent diabetes mellitus] causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.7 Albuminuria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25492830&form=6&db=m Amiloride lowers blood pressure and attenuates urine plasminogen activation in patients with treatment-resistant hypertension. ongoing research,therapeutic application,unassigned 2,2,0 3.4.21.7 Albuminuria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27214087&form=6&db=m Significant natriuretic and antihypertensive action of the epithelial sodium channel blocker amiloride in diabetic patients with and without nephropathy. causal interaction,diagnostic usage,therapeutic application,unassigned 2,3,1,0 3.4.21.7 Albuminuria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33070369&form=6&db=m Plasminogenuria is associated with podocyte injury, edema, and kidney dysfunction in incident glomerular disease. causal interaction,ongoing research,therapeutic application,unassigned 2,1,3,0 3.4.21.7 Albuminuria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33215566&form=6&db=m Plasminogen Deficiency and Amiloride Mitigate Angiotensin II-Induced Hypertension in Type 1 Diabetic Mice Suggesting Effects Through the Epithelial Sodium Channel. causal interaction,ongoing research,therapeutic application,unassigned 4,1,4,0 3.4.21.7 Alopecia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15161662&form=6&db=m Plasminogen mediates the pathological effects of urokinase-type plasminogen activator overexpression. ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.7 Alopecia Areata http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1899652&form=6&db=m The role of plasminogen activators in alopecia areata. unassigned - 3.4.21.7 Alveolar Bone Loss http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16579713&form=6&db=m Ligneous periodontitis and Ehlers-Danlos syndrome. causal interaction,unassigned 4,0 3.4.21.7 Alveolar Bone Loss http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17559626&form=6&db=m Association of gene polymorphisms for plasminogen activators with alveolar bone loss. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,3,0 3.4.21.7 Alzheimer Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10072300&form=6&db=m Activated alpha2macroglobulin increases beta-amyloid (25-35)-induced toxicity in LAN5 human neuroblastoma cells. diagnostic usage,unassigned 1,0 3.4.21.7 Alzheimer Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11263489&form=6&db=m Proteolysis in Alzheimer's disease. Can plasmin tip the balance? therapeutic application,unassigned 1,0 3.4.21.7 Alzheimer Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11263499&form=6&db=m Brain plasmin enhances APP alpha-cleavage and Abeta degradation and is reduced in Alzheimer's disease brains. causal interaction,unassigned 4,0 3.4.21.7 Alzheimer Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12112090&form=6&db=m Thrombolysis induces cerebral hemorrhage in a mouse model of cerebral amyloid angiopathy. causal interaction,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.7 Alzheimer Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12898287&form=6&db=m Association of late-onset Alzheimer disease with a genotype of PLAU, the gene encoding urokinase-type plasminogen activator on chromosome 10q22.2. diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.7 Alzheimer Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14618158&form=6&db=m Raft disorganization leads to reduced plasmin activity in Alzheimer's disease brains. causal interaction,diagnostic usage,unassigned 4,2,0 3.4.21.7 Alzheimer Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15649137&form=6&db=m The conflicting role of brain cholesterol in Alzheimer's disease: lessons from the brain plasminogen system. unassigned - 3.4.21.7 Alzheimer Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15749342&form=6&db=m Amyloid-beta-stimulated plasminogen activation by tissue-type plasminogen activator results in processing of neuroendocrine factors. causal interaction,therapeutic application,unassigned 1,2,0 3.4.21.7 Alzheimer Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16828203&form=6&db=m Association studies between the plasmin genes and late-onset Alzheimer's disease. causal interaction,unassigned 3,0 3.4.21.7 Alzheimer Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16908991&form=6&db=m Plasmin deficiency in Alzheimer's disease brains: causal or casual? causal interaction,unassigned 4,0 3.4.21.7 Alzheimer Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19222708&form=6&db=m Plasminogen activator activity is inhibited while neuroserpin is up-regulated in the Alzheimer disease brain. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.7 Alzheimer Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19407721&form=6&db=m Statins may act through increasing tissue plasminogen activator/plasmin activity to lower risk of Alzheimer's disease. causal interaction,diagnostic usage,unassigned 4,1,0 3.4.21.7 Alzheimer Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20709033&form=6&db=m Plasminogen and plasmin in Alzheimer's disease. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,4,0 3.4.21.7 Alzheimer Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21689108&form=6&db=m Amyloid-beta levels are significantly reduced and spatial memory defects are rescued in a novel neuroserpin-deficient Alzheimer's disease transgenic mouse model. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 Alzheimer Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21790972&form=6&db=m Activators and inhibitors of the plasminogen system in Alzheimer's disease. therapeutic application,unassigned 4,0 3.4.21.7 Alzheimer Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22415062&form=6&db=m Plasmin system of Alzheimer's disease patients: CSF analysis. diagnostic usage,unassigned 4,0 3.4.21.7 Alzheimer Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23650462&form=6&db=m Beta-amyloidolysis and glutathione in Alzheimer's disease. causal interaction,ongoing research,unassigned 1,2,0 3.4.21.7 Alzheimer Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24531161&form=6&db=m Analysis of Matrix Metallo-Proteases and the Plasminogen System in Mild Cognitive Impairment and Alzheimer's Disease Cerebrospinal Fluid. causal interaction,ongoing research,unassigned 3,2,0 3.4.21.7 Alzheimer Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30254165&form=6&db=m Blood-derived plasminogen drives brain inflammation and plaque deposition in a mouse model of Alzheimer's disease. ongoing research,unassigned 1,0 3.4.21.7 Alzheimer Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30403004&form=6&db=m Amyloid beta soluble forms and plasminogen activation system in Alzheimer's disease: Consequences on extracellular maturation of brain-derived neurotrophic factor and therapeutic implications. ongoing research,unassigned 2,0 3.4.21.7 Alzheimer Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33642369&form=6&db=m The plasminogen activating system in the pathogenesis of Alzheimer's disease. causal interaction,unassigned 3,0 3.4.21.7 Ameloblastoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=133998&form=6&db=m Fibrinolytic activity in cystic lesions of jaw bones. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.7 Amyloidosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1293845&form=6&db=m [The levels of antigens to plasminogen activators compared to their functional activity and inhibitor activity in patients with glomerulonephritis and amyloidosis] diagnostic usage,ongoing research,unassigned 4,2,0 3.4.21.7 Amyloidosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2253297&form=6&db=m Amyloidosis associated bleeding diatheses in the surgical patient. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,1,0 3.4.21.7 Amyloidosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4036990&form=6&db=m Fibrinolysis and acquired alpha-2 plasmin inhibitor deficiency in amyloidosis. causal interaction,therapeutic application,unassigned 4,2,0 3.4.21.7 Amyloidosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9254520&form=6&db=m [Activators and inhibitors of fibrinolysis in chronic glomerulonephritis and amyloidosis] causal interaction,diagnostic usage,ongoing research,unassigned 1,4,2,0 3.4.21.7 Amyloidosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10204025&form=6&db=m [Urokinase as a blood and urine plasminogen activator in chronic glomerulonephritis and amyloidosis] causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,2,1 3.4.21.7 Amyloidosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29520774&form=6&db=m Serum, salivary, and tissue levels of plasminogen in familial Mediterranean fever, amyloidosis, and chronic periodontitis. causal interaction,diagnostic usage,ongoing research,unassigned 4,2,3,0 3.4.21.7 Anaphylaxis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7691234&form=6&db=m Controlled insect-sting challenge in 55 patients: correlation between activation of plasminogen and the development of anaphylactic shock. causal interaction,unassigned 4,0 3.4.21.7 Anaphylaxis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=13688952&form=6&db=m Fibrinolysis and anaphylaxis. I. Activation of blood fibrinolysin during anaphylactic shock in guinea pigs. therapeutic application,unassigned 1,0 3.4.21.7 Anaphylaxis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=13703370&form=6&db=m Study of fibrinogen and plasminogen concentrations in rabbits during anaphylactic shock. ongoing research,unassigned 4,0 3.4.21.7 Anaphylaxis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=13965954&form=6&db=m Anaphylactic shock in dogs. Role of fibrinolysin and vasoactive polypeptide systems. ongoing research,unassigned 1,0 3.4.21.7 Anemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11086223&form=6&db=m Lonomia genus caterpillar toxins: biochemical aspects. diagnostic usage,unassigned 2,0 3.4.21.7 Anemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23376284&form=6&db=m Effect of a Congolese herbal medicine used in sickle cell anemia on the expression of plasminogen activators in human coronary aortic endothelial cells culture. ongoing research,unassigned 4,0 3.4.21.7 Anemia, Sickle Cell http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12616091&form=6&db=m Coagulopathies and arterial stroke. causal interaction,unassigned 4,0 3.4.21.7 Anemia, Sickle Cell http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23376284&form=6&db=m Effect of a Congolese herbal medicine used in sickle cell anemia on the expression of plasminogen activators in human coronary aortic endothelial cells culture. ongoing research,unassigned 4,0 3.4.21.7 Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=517175&form=6&db=m Spontaneous thrombosis of ruptured intracranial aneurysms during treatment with tranexamic acid (AMCA). Report of three cases. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.7 Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2098903&form=6&db=m Fibrinolytic activity of human brain. unassigned - 3.4.21.7 Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2144219&form=6&db=m Elastase-induced experimental aneurysms in rats. causal interaction,ongoing research,therapeutic application,unassigned 3,3,2,0 3.4.21.7 Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7526009&form=6&db=m Cellular localization of matrix metalloproteinases in the abdominal aortic aneurysm wall. ongoing research,unassigned 2,0 3.4.21.7 Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7737753&form=6&db=m Perioperative changes in coagulative and fibrinolytic function during surgical treatment of abdominal aortic aneurysm and arteriosclerosis obliterans. causal interaction,unassigned 2,0 3.4.21.7 Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9374741&form=6&db=m Molecular analysis of blood vessel formation and disease. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.7 Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9398846&form=6&db=m Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation. ongoing research,unassigned 1,0 3.4.21.7 Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9697825&form=6&db=m Prevention of aneurysm development and rupture by local overexpression of plasminogen activator inhibitor-1. causal interaction,ongoing research,therapeutic application,unassigned 4,4,2,0 3.4.21.7 Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9724118&form=6&db=m Vascular extracellular matrix remodeling in cerebral aneurysms. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,2,0 3.4.21.7 Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9819364&form=6&db=m Reduced transplant arteriosclerosis in plasminogen-deficient mice. causal interaction,ongoing research,unassigned 3,1,0 3.4.21.7 Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9852242&form=6&db=m Vascular cell-derived fibrinolytic regulators and atherothrombotic vascular disorders (Review). causal interaction,ongoing research,unassigned 4,4,0 3.4.21.7 Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10805895&form=6&db=m Association of the 4G/5G polymorphism in the promoter region of plasminogen activator inhibitor-1 with abdominal aortic aneurysms. causal interaction,unassigned 2,0 3.4.21.7 Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11213813&form=6&db=m Abnormal levels of urokinase plasminogen activator protein and tissue plasminogen activator activity in human aortic aneurysms. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,1,3,2 3.4.21.7 Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11487021&form=6&db=m Plasmin and matrix metalloproteinases in vascular remodeling. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16407226&form=6&db=m Identification of myxomaviral serpin reactive site loop sequences that regulate innate immune responses. causal interaction,therapeutic application,unassigned 1,3,0 3.4.21.7 Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16849017&form=6&db=m Intraluminal thrombus enhances proteolysis in abdominal aortic aneurysms. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,1,2,2 3.4.21.7 Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17182940&form=6&db=m Genes predisposing to rapid aneurysm growth. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,1,2,1 3.4.21.7 Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20016209&form=6&db=m Thrombus versus Wall Biological Activities in Experimental Aortic Aneurysms. unassigned - 3.4.21.7 Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24926188&form=6&db=m Role of matrix metalloproteinases (MMPs) and MMP inhibitors on intracranial aneurysms: a review article. unassigned - 3.4.21.7 Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25823216&form=6&db=m Vascular aneurysms: a perspective. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29149696&form=6&db=m Clearance of plasmin-PN-1 complexes by vascular smooth muscle cells in human aneurysm of the ascending aorta. unassigned - 3.4.21.7 Aneurysm, Dissecting http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1441858&form=6&db=m Thrombolytic therapy and acute aortic dissection. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.7 Angina Pectoris http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1607536&form=6&db=m Antecedent angina pectoris predicts worse outcome after myocardial infarction in patients receiving thrombolytic therapy: experience gleaned from the International Tissue Plasminogen Activator/Streptokinase Mortality Trial. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,4,3,4 3.4.21.7 Angina Pectoris http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1895656&form=6&db=m [Newly developed stenocardia: effect of intensive physical training on the indicators of the blood coagulation system and fibrinolysis] diagnostic usage,unassigned 3,0 3.4.21.7 Angina Pectoris http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3258521&form=6&db=m Lack of association between haemostatic variables and the presence or the extent of coronary atherosclerosis. diagnostic usage,unassigned 4,0 3.4.21.7 Angina, Stable http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18392332&form=6&db=m Time course of prothrombotic and proinflammatory substance release after intracoronary stent implantation. diagnostic usage,unassigned 4,0 3.4.21.7 Angina, Stable http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19707983&form=6&db=m Effect of ACE inhibition on the fibrinolytic system in patients requiring coronary artery bypass grafting. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.7 Angina, Unstable http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1676768&form=6&db=m [Unstable angina: tissue plasminogen activator, tissue plasminogen activator inhibitors, protein C and other factors of the blood fibrinolytic system] diagnostic usage,ongoing research,therapeutic application,unassigned 2,2,1,0 3.4.21.7 Angina, Unstable http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1892067&form=6&db=m Platelet activation in the pathogenesis of unstable angina: importance in determining the response to plasminogen activators. causal interaction,therapeutic application,unassigned 4,2,0 3.4.21.7 Angina, Unstable http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2649355&form=6&db=m Thrombolysis in the management of acute myocardial infarction and unstable angina pectoris. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 Angina, Unstable http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7594098&form=6&db=m One-year results of the Thrombolysis in Myocardial Infarction (TIMI) IIIB clinical trial. A randomized comparison of tissue-type plasminogen activator versus placebo and early invasive versus early conservative strategies in unstable angina and non-Q wave myocardial infarction. causal interaction,therapeutic application,unassigned 2,4,0 3.4.21.7 Angina, Unstable http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10404758&form=6&db=m Elevated levels of plasmin-alpha2 antiplasmin complexes in unstable angina. causal interaction,diagnostic usage,ongoing research,unassigned 3,3,4,0 3.4.21.7 Angina, Unstable http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14691435&form=6&db=m Association between plasmin activation system and intravascular ultrasound signs of plaque instability in patients with unstable angina and non-st-segment elevation myocardial infarction. causal interaction,diagnostic usage,unassigned 4,1,0 3.4.21.7 Angioedema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14572819&form=6&db=m Protease inhibitors in the treatment of hereditary angioedema. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 Angioedema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27174372&form=6&db=m A Novel Approach to the Treatment of Orolingual Angioedema After Tissue Plasminogen Activator Administration. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.7 Angioedema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30354988&form=6&db=m Angioedema and Hemorrhage After 4.5-Hour tPA (Tissue-Type Plasminogen Activator) Thrombolysis Ameliorated by T541 via Restoring Brain Microvascular Integrity. causal interaction,ongoing research,therapeutic application,unassigned 3,2,4,0 3.4.21.7 Angioedema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31182002&form=6&db=m Angioedema in Stroke Patients With Thrombolysis. causal interaction,therapeutic application,unassigned 3,2,0 3.4.21.7 Angioedema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31507620&form=6&db=m Plasminflammation-An Emerging Pathway to Bradykinin Production. causal interaction,therapeutic application,unassigned 1,3,0 3.4.21.7 Angioedema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31860755&form=6&db=m Impaired control of the contact system in hereditary angioedema with normal C1-inhibitor. causal interaction,unassigned 2,0 3.4.21.7 Angioedema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32766265&form=6&db=m Measurement of Bradykinin Formation and Degradation in Blood Plasma: Relevance for Acquired Angioedema Associated With Angiotensin Converting Enzyme Inhibition and for Hereditary Angioedema Due to Factor XII or Plasminogen Gene Variants. therapeutic application,unassigned 1,0 3.4.21.7 Angioedema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33233873&form=6&db=m Pathophysiology and underlying mechanisms in hereditary angioedema. therapeutic application,unassigned 1,0 3.4.21.7 Angioedema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33370942&form=6&db=m Unilateral orolingual angioedema in a patient with sarcoidosis after intravenous thrombolysis due to acute stroke without improvement after treatment with icatibant. causal interaction,ongoing research,therapeutic application,unassigned 3,1,4,0 3.4.21.7 Angioedema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33441533&form=6&db=m Tissue Plasminogen Activator-Induced Angioedema Involving a Posterior Cerebral Artery Infarct: A Case Presentation. causal interaction,therapeutic application,unassigned 4,3,0 3.4.21.7 Angioedema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33535668&form=6&db=m The Role of the Plasminogen Activation System in Angioedema: Novel Insights on the Pathogenesis. ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.7 Angioedema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33803235&form=6&db=m Assessing Plasmin Generation in Health and Disease. causal interaction,ongoing research,unassigned 4,1,0 3.4.21.7 Angioedemas, Hereditary http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=148134&form=6&db=m Role of the second component of complement (C2) and plasmin in kinin release in hereditary angioneurotic edema (H.A.N.E.) plasma. unassigned - 3.4.21.7 Angioedemas, Hereditary http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=621394&form=6&db=m Specific functional and immunologic assay of plasma plasminogen in hereditary angioedema, in hereditary angioedema treated with tranexamic acid, and in normal subjects. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.7 Angioedemas, Hereditary http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3965500&form=6&db=m Variability in purified dysfunctional C1(-)-inhibitor proteins from patients with hereditary angioneurotic edema. Functional and analytical gel studies. ongoing research,unassigned 2,0 3.4.21.7 Angioedemas, Hereditary http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6211203&form=6&db=m Complexes between C1-inhibitor, kallikrein, high molecular weight kininogen, plasma thromboplastin antecedent, and plasmin in normal human plasma and hereditary angioneurotic edema plasmas containing dysmorphic C1-inhibitors: role of cold activation. diagnostic usage,ongoing research,unassigned 3,3,0 3.4.21.7 Angioedemas, Hereditary http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8426075&form=6&db=m Plasminogen activation in hereditary angioneurotic edema. causal interaction,unassigned 1,0 3.4.21.7 Angioedemas, Hereditary http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8426080&form=6&db=m Generation of plasmin during acute attacks of hereditary angioedema. causal interaction,ongoing research,therapeutic application,unassigned 3,3,1,0 3.4.21.7 Angioedemas, Hereditary http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16217168&form=6&db=m Hereditary angioedema. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 Angioedemas, Hereditary http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22288590&form=6&db=m Alterations of coagulation and fibrinolysis in patients with angioedema due to C1-inhibitor deficiency. causal interaction,diagnostic usage,unassigned 4,3,0 3.4.21.7 Angioedemas, Hereditary http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27130860&form=6&db=m Plasmin is a natural trigger for bradykinin production in patients with hereditary angioedema with factor XII mutations. causal interaction,unassigned 3,0 3.4.21.7 Angioedemas, Hereditary http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27826093&form=6&db=m Cytokine and estrogen stimulation of endothelial cells augments activation of the prekallikrein-high molecular weight kininogen complex: Implications for hereditary angioedema. causal interaction,ongoing research,therapeutic application,unassigned 1,4,1,0 3.4.21.7 Angioedemas, Hereditary http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28795768&form=6&db=m Hereditary angioedema with a mutation in the plasminogen gene. causal interaction,ongoing research,unassigned 3,2,0 3.4.21.7 Angioedemas, Hereditary http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29548426&form=6&db=m A missense mutation in the plasminogen gene, within the plasminogen kringle 3 domain, in hereditary angioedema with normal C1 inhibitor. causal interaction,ongoing research,therapeutic application,unassigned 2,1,1,0 3.4.21.7 Angioedemas, Hereditary http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29952006&form=6&db=m Plasminogen gene mutation with normal C1 inhibitor hereditary angioedema: Three additional French families. unassigned - 3.4.21.7 Angioedemas, Hereditary http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29987869&form=6&db=m A missense mutation of the plasminogen gene in hereditary angioedema with normal C1 inhibitor in Japan. causal interaction,unassigned 2,0 3.4.21.7 Angioedemas, Hereditary http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30009523&form=6&db=m On the pathogenicity of the plasminogen K330E mutation for hereditary angioedema. causal interaction,unassigned 1,0 3.4.21.7 Angioedemas, Hereditary http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30809376&form=6&db=m Identification of the recently described plasminogen gene mutation p.Lys330Glu in a family from Northern Germany with hereditary angioedema. ongoing research,unassigned 1,0 3.4.21.7 Angioedemas, Hereditary http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31860755&form=6&db=m Impaired control of the contact system in hereditary angioedema with normal C1-inhibitor. causal interaction,unassigned 2,0 3.4.21.7 Angioedemas, Hereditary http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31955064&form=6&db=m sgp120 and the contact system in hereditary angioedema: A diagnostic tool in HAE with normal C1 inhibitor. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 Angioedemas, Hereditary http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32065705&form=6&db=m Hereditary angioedema in a single family with specific mutations in both plasminogen and SERPING1 genes. causal interaction,unassigned 3,0 3.4.21.7 Angioedemas, Hereditary http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32066472&form=6&db=m Treatment of patients with hereditary angioedema with the c.988A>G (p.Lys330Glu) variant in the plasminogen gene. causal interaction,therapeutic application,unassigned 2,1,0 3.4.21.7 Angioedemas, Hereditary http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32073435&form=6&db=m Angioedema without urticaria: novel findings which must be measured in clinical setting. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,3,2,3 3.4.21.7 Angioedemas, Hereditary http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32519288&form=6&db=m Proteomic Analysis of the Acid-Insoluble Fraction of Whole Saliva from Patients Affected by Different Forms of Non-histaminergic Angioedema. causal interaction,ongoing research,unassigned 1,1,0 3.4.21.7 Angioedemas, Hereditary http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32578786&form=6&db=m Study of angiopoietin and plasminogen genes in hereditary angioedema. ongoing research,unassigned 3,0 3.4.21.7 Angioedemas, Hereditary http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32766265&form=6&db=m Measurement of Bradykinin Formation and Degradation in Blood Plasma: Relevance for Acquired Angioedema Associated With Angiotensin Converting Enzyme Inhibition and for Hereditary Angioedema Due to Factor XII or Plasminogen Gene Variants. therapeutic application,unassigned 1,0 3.4.21.7 Angioedemas, Hereditary http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33109317&form=6&db=m Definition and classification of hereditary angioedema. unassigned - 3.4.21.7 Angioedemas, Hereditary http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33799813&form=6&db=m Screening for Plasminogen Mutations in Hereditary Angioedema Patients. causal interaction,diagnostic usage,unassigned 4,2,0 3.4.21.7 Anovulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8977761&form=6&db=m Ambulatory blood pressure profiles and plasminogen activator inhibitor (PAI-1) activity in lean women with and without the polycystic ovary syndrome. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,2,2 3.4.21.7 Anthracosilicosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=153880&form=6&db=m [Effect of fibrinolysin and heparin on the formation of fibrosis in experimental anthracosilicosis] ongoing research,therapeutic application,unassigned 2,2,0 3.4.21.7 Anthrax http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11278833&form=6&db=m Targeting of tumor cells by cell surface urokinase plasminogen activator-dependent anthrax toxin. causal interaction,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.7 Anthrax http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22843210&form=6&db=m Tumor therapy with a urokinase plasminogen activator-activated anthrax lethal toxin alone and in combination with paclitaxel. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.7 Antiphospholipid Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9134632&form=6&db=m The risk of recurrent venous thromboembolism in patients with and without factor V Leiden. ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.7 Antiphospholipid Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10652759&form=6&db=m [Diagnosis and treatment of coagulation disorders] causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.7 Antiphospholipid Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10917893&form=6&db=m Proteolytic cleavage of beta(2)-glycoprotein I: reduction of antigenicity and the structural relationship. unassigned - 3.4.21.7 Antiphospholipid Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11246666&form=6&db=m Autoantibodies to receptor induced neoepitopes of fibrinolytic proteins in rheumatic and vascular diseases. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,2,2 3.4.21.7 Antiphospholipid Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11916083&form=6&db=m Immunoglobulin G from patients with antiphospholipid syndrome impairs the fibrin dissolution with plasmin. diagnostic usage,therapeutic application,unassigned 1,1,0 3.4.21.7 Antiphospholipid Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12616091&form=6&db=m Coagulopathies and arterial stroke. causal interaction,unassigned 4,0 3.4.21.7 Antiphospholipid Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16099225&form=6&db=m The role of beta2-glycoprotein I (beta(2)GPI) in the activation of plasminogen. causal interaction,diagnostic usage,therapeutic application,unassigned 3,3,2,0 3.4.21.7 Antiphospholipid Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16480936&form=6&db=m The role of beta2-glycoprotein I (beta2GPI) in the activation of plasminogen. diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.7 Antiphospholipid Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18180621&form=6&db=m Modulation of fibrinolysis by the combined action of phospholipids and immunoglobulins. ongoing research,therapeutic application,unassigned 4,1,0 3.4.21.7 Antiphospholipid Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19180513&form=6&db=m beta2-glycoprotein i is a cofactor for tissue plasminogen activator-mediated plasminogen activation. diagnostic usage,ongoing research,unassigned 3,4,0 3.4.21.7 Antiphospholipid Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19790056&form=6&db=m Plasmin immunization preferentially induces potentially prothrombotic IgG anticardiolipin antibodies in MRL/MpJ mice. therapeutic application,unassigned 1,0 3.4.21.7 Antiphospholipid Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21614812&form=6&db=m [Effect of antiphospholipid antibodies on the formation and lysis of fibrin network in patients with recurrent miscarriage]. causal interaction,diagnostic usage,unassigned 1,4,0 3.4.21.7 Antiphospholipid Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22830213&form=6&db=m [The levels of plasminogen and inhibitor of plasminogen activators of type 1 in antiphospholipid syndrome]. causal interaction,ongoing research,therapeutic application,unassigned 1,1,1,0 3.4.21.7 Antiphospholipid Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22939813&form=6&db=m Antibodies against the N-terminal domain of annexin A2 in antiphospholipid syndrome. causal interaction,therapeutic application,unassigned 2,3,0 3.4.21.7 Antiphospholipid Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24749249&form=6&db=m [Polymorphism of the plasminogen activator inhibitor type 1 gene, plasminogen level and thrombosis in patients with antiphospholipid syndrome]. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,2,1 3.4.21.7 Antiphospholipid Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31059997&form=6&db=m Prevalence of anti-S100A10 antibodies in antiphospholipid syndrome patients. therapeutic application,unassigned 2,0 3.4.21.7 Antithrombin III Deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1766858&form=6&db=m [Molecular basis of thrombosis] therapeutic application,unassigned 1,0 3.4.21.7 Antithrombin III Deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2966450&form=6&db=m The frequency of type I heterozygous protein S and protein C deficiency in 141 unrelated young patients with venous thrombosis. diagnostic usage,ongoing research,unassigned 4,2,0 3.4.21.7 Antithrombin III Deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7359230&form=6&db=m Plasminogen and antithrombin III deficiencies in the childhood nephrotic syndrome associated with plasminogenuria and antithrombinuria. causal interaction,diagnostic usage,ongoing research,unassigned 3,4,2,0 3.4.21.7 Antithrombin III Deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8266926&form=6&db=m Hereditary thrombophilia among 217 consecutive patients with thromboembolic disease in Jordan. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 Antithrombin III Deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12616091&form=6&db=m Coagulopathies and arterial stroke. causal interaction,unassigned 4,0 3.4.21.7 Aortic Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12768368&form=6&db=m Doxycycline treatment in a model of early abdominal aortic aneurysm. ongoing research,unassigned 1,0 3.4.21.7 Aortic Aneurysm, Abdominal http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8048013&form=6&db=m Possible key role for plasmin in the pathogenesis of abdominal aortic aneurysms. causal interaction,unassigned 4,0 3.4.21.7 Aortic Aneurysm, Abdominal http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9013920&form=6&db=m Elevations of tissue-type plasminogen activator and differential expression of urokinase-type plasminogen activator in diseased aorta. causal interaction,unassigned 4,0 3.4.21.7 Aortic Aneurysm, Abdominal http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9046916&form=6&db=m Haemostasis during infrarenal aortic aneurysm surgery: effect of volume loading and cross-clamping. ongoing research,unassigned 2,0 3.4.21.7 Aortic Aneurysm, Abdominal http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11668313&form=6&db=m Plasma levels of plasmin-antiplasmin-complexes are predictive for small abdominal aortic aneurysms expanding to operation-recommendable sizes. causal interaction,diagnostic usage,unassigned 4,3,0 3.4.21.7 Aortic Aneurysm, Abdominal http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12787697&form=6&db=m Relationships between activators and inhibitors of plasminogen, and the progression of small abdominal aortic aneurysms. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.7 Aortic Aneurysm, Abdominal http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16127203&form=6&db=m Effect of combined therapy of danaparoid sodium and tranexamic acid on chronic disseminated intravascular coagulation associated with abdominal aortic aneurysm. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.7 Aortic Aneurysm, Abdominal http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17182930&form=6&db=m Activators of plasminogen and the progression of small abdominal aortic aneurysms. diagnostic usage,ongoing research,unassigned 1,4,0 3.4.21.7 Aortic Aneurysm, Abdominal http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22307671&form=6&db=m Increased PAI-1 in Females Compared to Males is Protective for Abdominal Aortic Aneurysm Formation in a Rodent Model. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 Aortic Aneurysm, Abdominal http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22545876&form=6&db=m Tissue plasminogen activator-assisted hematoma evacuation to relieve abdominal compartment syndrome after endovascular repair of ruptured abdominal aortic aneurysm. therapeutic application,unassigned 1,0 3.4.21.7 Aortic Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8170041&form=6&db=m Abnormal expression of plasminogen activators in aortic aneurysmal and occlusive disease. causal interaction,ongoing research,unassigned 3,2,0 3.4.21.7 Aortic Valve Stenosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9560548&form=6&db=m [A successful perioperative anticoagulation therapy and monitoring of a patient with hereditary plasminogen abnormality undergoing aortic valve replacement] unassigned - 3.4.21.7 Aortic Valve Stenosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24693431&form=6&db=m Expression of uPA, tPA, and PAI-1 in Calcified Aortic Valves. unassigned - 3.4.21.7 Arrhythmias, Cardiac http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1563856&form=6&db=m Biological risk factors for sudden death in patients with coronary artery disease and without heart failure. diagnostic usage,therapeutic application,unassigned 1,1,0 3.4.21.7 Arterial Occlusive Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4032349&form=6&db=m [Results of in situ arterial thrombolysis by the combination of urokinase and lysyl plasminogen in acute arterial occlusive diseases of the lower limbs] causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 Arteriosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1828324&form=6&db=m Effects of lipoprotein (a) on success rate of thrombolytic therapy in acute myocardial infarction. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,1,3,4 3.4.21.7 Arteriosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2147016&form=6&db=m [Lipoprotein (a)--a further risk factor in arteriosclerosis?] causal interaction,unassigned 3,0 3.4.21.7 Arteriosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4226999&form=6&db=m Treatment of experimental pulmonary arteriosclerosis with cortisone, heparin and fibrinolysin. therapeutic application,unassigned 4,0 3.4.21.7 Arteriosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4236435&form=6&db=m [Effect of fibrinolysin on the development of experimental cholesterol arteriosclerosis in rabbits] ongoing research,therapeutic application,unassigned 4,2,0 3.4.21.7 Arteriosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4247507&form=6&db=m [Lypolytic activity of aorta and liver under the effect of fibrinolysin in rabbits with experimental cholesterol arteriosclerosis] ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.7 Arteriosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8667502&form=6&db=m Elevated levels of plasminogen-activator inhibitor type 1 in atherosclerotic aorta. causal interaction,diagnostic usage,unassigned 3,3,0 3.4.21.7 Arteriosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9819364&form=6&db=m Reduced transplant arteriosclerosis in plasminogen-deficient mice. causal interaction,ongoing research,unassigned 3,1,0 3.4.21.7 Arteriosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=13949447&form=6&db=m [Symposium: Arteriosclerosis (with special reference to thrombosis and anticoagulants). 2. Significance of plasmin in arteriosclerosis.] diagnostic usage,unassigned 3,0 3.4.21.7 Arteriosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14963043&form=6&db=m Tumor necrosis factor alpha activates the human plasminogen activator inhibitor-1 gene through a distal nuclear factor kappaB site. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.7 Arteriosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16087677&form=6&db=m Plasmin- and thrombin-accelerated shedding of syndecan-4 ectodomain generates cleavage sites at Lys(114)-Arg(115) and Lys(129)-Val(130) bonds. causal interaction,unassigned 2,0 3.4.21.7 Arteriosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19132220&form=6&db=m Integration of non-SMAD and SMAD signaling in TGF-beta1-induced plasminogen activator inhibitor type-1 gene expression in vascular smooth muscle cells. causal interaction,therapeutic application,unassigned 2,1,0 3.4.21.7 Arteriosclerosis Obliterans http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31086587&form=6&db=m Efficacy of trimetazidine and plasmin combined with alprostadil in treatment of lower extremity arteriosclerosis obliterans. therapeutic application,unassigned 4,0 3.4.21.7 Arteriovenous Fistula http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2629155&form=6&db=m [The use of thrombolytic preparations for the functional restoration of the arteriovenous fistula in patients on programmed hemodialysis] therapeutic application,unassigned 4,0 3.4.21.7 Arteriovenous Fistula http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8738536&form=6&db=m Local fibrinolysis in native arteriovenous fistulas of haemodialysis patients. diagnostic usage,therapeutic application,unassigned 1,1,0 3.4.21.7 Arteritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28041642&form=6&db=m A Genome-wide Association Study Identifies Risk Alleles in Plasminogen and P4HA2 Associated with Giant Cell Arteritis. causal interaction,diagnostic usage,unassigned 3,3,0 3.4.21.7 Arteritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29411742&form=6&db=m [Indicators of homeostasis, inflammation and homocysteine in ischemic stroke in the young age]. causal interaction,unassigned 3,0 3.4.21.7 Arthritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1417121&form=6&db=m Plasminogen activators in synovial fluid and plasma from patients with arthritis. diagnostic usage,ongoing research,therapeutic application,unassigned 2,2,1,0 3.4.21.7 Arthritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3639668&form=6&db=m Mini-plasminogen-like fragments of plasminogen in synovial fluid in acute inflammatory arthritis. causal interaction,unassigned 3,0 3.4.21.7 Arthritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6221484&form=6&db=m [Experimental plasmin arthritis] causal interaction,ongoing research,therapeutic application,unassigned 1,4,4,0 3.4.21.7 Arthritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9117184&form=6&db=m Bone matrix degradation by the plasminogen activation system. Possible mechanism of bone destruction in arthritis. causal interaction,ongoing research,therapeutic application,unassigned 4,1,1,0 3.4.21.7 Arthritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9215148&form=6&db=m Differential expression of the urokinase receptor (CD87) in arthritic and normal synovial tissues. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,4,0 3.4.21.7 Arthritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9487248&form=6&db=m Tranexamic acid, an inhibitor of plasminogen activation, reduces urinary collagen cross-link excretion in both experimental and rheumatoid arthritis. ongoing research,therapeutic application,unassigned 2,4,0 3.4.21.7 Arthritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11583972&form=6&db=m Plasma apolipoprotein(a) co-deposits with fibrin in inflammatory arthritic joints. causal interaction,unassigned 3,0 3.4.21.7 Arthritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11859422&form=6&db=m Adenovirus-mediated gene transfer of urokinase plasminogen inhibitor inhibits angiogenesis in experimental arthritis. ongoing research,therapeutic application,unassigned 4,4,0 3.4.21.7 Arthritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=13157911&form=6&db=m Investigation of the enzymatic activity in rheumatoid arthritis. I. The activity of plasmin in plasma from patients with rheumatoid arthritis. diagnostic usage,ongoing research,unassigned 3,3,0 3.4.21.7 Arthritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15095009&form=6&db=m Novel aspects and new roles for the serine protease plasmin. causal interaction,unassigned 4,0 3.4.21.7 Arthritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15743790&form=6&db=m The plasminogen activator/plasmin system is essential for development of the joint inflammatory phase of collagen type II-induced arthritis. causal interaction,ongoing research,therapeutic application,unassigned 3,4,3,0 3.4.21.7 Arthritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16052596&form=6&db=m Contrasting roles of plasminogen deficiency in different rheumatoid arthritis models. causal interaction,diagnostic usage,therapeutic application,unassigned 4,1,4,0 3.4.21.7 Arthritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16505706&form=6&db=m Clinical Correlation with the PA/Plasmin System in Septic Arthritis of the Knee. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,3,2,1 3.4.21.7 Arthritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18311800&form=6&db=m Plasminogen activator/plasmin system in arthritis and inflammation: friend or foe? unassigned - 3.4.21.7 Arthritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18311818&form=6&db=m Protective effects of plasmin(ogen) in a mouse model of Staphylococcus aureus-induced arthritis. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,4,1 3.4.21.7 Arthritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18586671&form=6&db=m TSG-6 regulates bone remodeling through inhibition of osteoblastogenesis and osteoclast activation. therapeutic application,unassigned 2,0 3.4.21.7 Arthritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20144123&form=6&db=m Fibrin dissolution in synovial fluid. ongoing research,therapeutic application,unassigned 1,1,0 3.4.21.7 Arthritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24574269&form=6&db=m Plasminogen is a joint-specific positive- or negative-determinant of arthritis pathogenesis. causal interaction,ongoing research,therapeutic application,unassigned 3,4,1,0 3.4.21.7 Arthritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29296974&form=6&db=m Urokinase plasminogen activator and receptor promote collagen-induced arthritis through expression in hematopoietic cells. causal interaction,ongoing research,therapeutic application,unassigned 1,1,1,0 3.4.21.7 Arthritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30922783&form=6&db=m Role of plasminogen activator inhibitor - 1 (PAI-1) in regulating the pathogenesis of S. aureus arthritis via plasminogen pathway. therapeutic application,unassigned 2,0 3.4.21.7 Arthritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32548548&form=6&db=m Plasminogen activation in the musculoskeletal acute phase response: Injury, repair, and disease. ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.7 Arthritis, Experimental http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9487248&form=6&db=m Tranexamic acid, an inhibitor of plasminogen activation, reduces urinary collagen cross-link excretion in both experimental and rheumatoid arthritis. ongoing research,therapeutic application,unassigned 2,4,0 3.4.21.7 Arthritis, Experimental http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11859422&form=6&db=m Adenovirus-mediated gene transfer of urokinase plasminogen inhibitor inhibits angiogenesis in experimental arthritis. ongoing research,therapeutic application,unassigned 4,4,0 3.4.21.7 Arthritis, Experimental http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16052596&form=6&db=m Contrasting roles of plasminogen deficiency in different rheumatoid arthritis models. causal interaction,diagnostic usage,therapeutic application,unassigned 4,1,4,0 3.4.21.7 Arthritis, Infectious http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16505706&form=6&db=m Clinical Correlation with the PA/Plasmin System in Septic Arthritis of the Knee. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,3,2,1 3.4.21.7 Arthritis, Infectious http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18311818&form=6&db=m Protective effects of plasmin(ogen) in a mouse model of Staphylococcus aureus-induced arthritis. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,4,1 3.4.21.7 Arthritis, Infectious http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20100112&form=6&db=m Tranexamic acid, an inhibitor of plasminogen activation, aggravates staphylococcal septic arthritis and sepsis. causal interaction,ongoing research,therapeutic application,unassigned 4,4,3,0 3.4.21.7 Arthritis, Juvenile http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2628891&form=6&db=m [Disorders of the system of hemostasis in patients with juvenile rheumatoid arthritis and rheumatic fever] unassigned - 3.4.21.7 Arthritis, Rheumatoid http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=143941&form=6&db=m The primary plasmin inhibitor in rheumatoid synovial fluid. diagnostic usage,ongoing research,therapeutic application,unassigned 3,1,1,0 3.4.21.7 Arthritis, Rheumatoid http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1555050&form=6&db=m Effects of tiaprofenic acid on plasminogen activators and inhibitors in human OA and RA synovium. ongoing research,therapeutic application,unassigned 3,3,0 3.4.21.7 Arthritis, Rheumatoid http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6221484&form=6&db=m [Experimental plasmin arthritis] causal interaction,ongoing research,therapeutic application,unassigned 1,4,4,0 3.4.21.7 Arthritis, Rheumatoid http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6395323&form=6&db=m Lack of effect of tranexamic acid on rheumatoid arthritis. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.7 Arthritis, Rheumatoid http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7198342&form=6&db=m [Activity of plasminogen activators and plasmin inhibitors in the joint capsule in various articular diseases (author's transl)] causal interaction,unassigned 3,0 3.4.21.7 Arthritis, Rheumatoid http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7905877&form=6&db=m Characterization of the plasminogen receptors of normal and rheumatoid arthritis human synovial fibroblasts. causal interaction,diagnostic usage,ongoing research,unassigned 2,2,4,0 3.4.21.7 Arthritis, Rheumatoid http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8407906&form=6&db=m Plasminogen activation stimulates an increase in intracellular calcium in human synovial fibroblasts. ongoing research,unassigned 1,0 3.4.21.7 Arthritis, Rheumatoid http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8646430&form=6&db=m Difference in expression of the plasminogen activation system in synovial tissue of patients with rheumatoid arthritis and osteoarthritis. causal interaction,ongoing research,unassigned 3,3,0 3.4.21.7 Arthritis, Rheumatoid http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8733439&form=6&db=m Plasminogen activators and their inhibitors in synovial fluids from normal, osteoarthritis, and rheumatoid arthritis knees. causal interaction,therapeutic application,unassigned 2,1,0 3.4.21.7 Arthritis, Rheumatoid http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8872854&form=6&db=m Are plasminogen antibodies in rheumatoid arthritis of pathogenic significance? causal interaction,diagnostic usage,unassigned 4,3,0 3.4.21.7 Arthritis, Rheumatoid http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8872860&form=6&db=m Analysis of autoantibodies to plasminogen in the serum of patients with rheumatoid arthritis. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,4 3.4.21.7 Arthritis, Rheumatoid http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8895144&form=6&db=m Mobilization of fibrinolytic enzymes in synovial fluid and plasma of rheumatoid arthritis and spondyloarthropathy and their relation to radiological destruction. ongoing research,therapeutic application,unassigned 2,2,0 3.4.21.7 Arthritis, Rheumatoid http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9034981&form=6&db=m Plasma tetranectin levels and disease activity in patients with rheumatoid arthritis. diagnostic usage,ongoing research,unassigned 4,4,0 3.4.21.7 Arthritis, Rheumatoid http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9117184&form=6&db=m Bone matrix degradation by the plasminogen activation system. Possible mechanism of bone destruction in arthritis. causal interaction,ongoing research,therapeutic application,unassigned 4,1,1,0 3.4.21.7 Arthritis, Rheumatoid http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9181480&form=6&db=m Molecular abnormalities of human plasminogen isolated from synovial fluid of rheumatoid arthritis patients. causal interaction,diagnostic usage,ongoing research,unassigned 2,3,4,0 3.4.21.7 Arthritis, Rheumatoid http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9370880&form=6&db=m Plasminogen activation in synovial tissues: differences between normal, osteoarthritis, and rheumatoid arthritis joints. causal interaction,diagnostic usage,ongoing research,unassigned 1,2,4,0 3.4.21.7 Arthritis, Rheumatoid http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9487248&form=6&db=m Tranexamic acid, an inhibitor of plasminogen activation, reduces urinary collagen cross-link excretion in both experimental and rheumatoid arthritis. ongoing research,therapeutic application,unassigned 2,4,0 3.4.21.7 Arthritis, Rheumatoid http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9718068&form=6&db=m Synoviocytes from osteoarthritis and rheumatoid arthritis produce plasminogen activators and plasminogen activator inhibitor-1 and display u-PA receptors on their surface. ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.7 Arthritis, Rheumatoid http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9779299&form=6&db=m Serum matrix metalloproteinase-3 and fibrin degradation product levels correlate with clinical disease activity in rheumatoid arthritis. causal interaction,diagnostic usage,unassigned 2,4,0 3.4.21.7 Arthritis, Rheumatoid http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11246666&form=6&db=m Autoantibodies to receptor induced neoepitopes of fibrinolytic proteins in rheumatic and vascular diseases. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,2,2 3.4.21.7 Arthritis, Rheumatoid http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11891190&form=6&db=m Differing roles for urokinase and tissue-type plasminogen activator in collagen-induced arthritis. causal interaction,diagnostic usage,unassigned 3,1,0 3.4.21.7 Arthritis, Rheumatoid http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12355473&form=6&db=m Extravascular coagulation and the plasminogen activator/plasmin system in rheumatoid arthritis. unassigned - 3.4.21.7 Arthritis, Rheumatoid http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12456318&form=6&db=m Regulation of plasminogen receptors. causal interaction,unassigned 4,0 3.4.21.7 Arthritis, Rheumatoid http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12750940&form=6&db=m Plasminogen activator inhibitor-1 as a link between pathological fibrinolysis and arthritis of Behçet's disease. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.7 Arthritis, Rheumatoid http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12846058&form=6&db=m No therapeutic effect of plasmin antagonist tranexamic acid in rheumatoid arthritis. A double-blind placebo-controlled pilot study. diagnostic usage,ongoing research,therapeutic application,unassigned 3,4,2,0 3.4.21.7 Arthritis, Rheumatoid http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=13157911&form=6&db=m Investigation of the enzymatic activity in rheumatoid arthritis. I. The activity of plasmin in plasma from patients with rheumatoid arthritis. diagnostic usage,ongoing research,unassigned 3,3,0 3.4.21.7 Arthritis, Rheumatoid http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14388598&form=6&db=m Serum antiplasmin and plasmin in rheumatoid arthritis. causal interaction,diagnostic usage,unassigned 2,2,0 3.4.21.7 Arthritis, Rheumatoid http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15743776&form=6&db=m Plasminogen activation/plasmin in rheumatoid arthritis: matrix degradation and more. causal interaction,unassigned 2,0 3.4.21.7 Arthritis, Rheumatoid http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16052596&form=6&db=m Contrasting roles of plasminogen deficiency in different rheumatoid arthritis models. causal interaction,diagnostic usage,therapeutic application,unassigned 4,1,4,0 3.4.21.7 Arthritis, Rheumatoid http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18408252&form=6&db=m Targeted drug delivery by in vivo coupling to endogenous albumin: an albumin-binding prodrug of methotrexate (MTX) is better than MTX in the treatment of murine collagen-induced arthritis. causal interaction,unassigned 3,0 3.4.21.7 Arthritis, Rheumatoid http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27262798&form=6&db=m Argatroban more effectively inhibits the thrombin activity in synovial fluid than naturally occurring thrombin inhibitors. diagnostic usage,ongoing research,unassigned 1,3,0 3.4.21.7 Arthritis, Rheumatoid http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30516104&form=6&db=m The Urokinase Plasminogen Activation System in Rheumatoid Arthritis: Pathophysiological Roles and Prospective Therapeutic Targets. causal interaction,therapeutic application,unassigned 2,4,0 3.4.21.7 Arthus Reaction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1534318&form=6&db=m Role of thrombin and plasmin in development of delayed hypersensitivity reaction in guinea pig skin. causal interaction,ongoing research,unassigned 4,2,0 3.4.21.7 Aspergillosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18566672&form=6&db=m Plasminogen alleles influence susceptibility to invasive aspergillosis. causal interaction,unassigned 4,0 3.4.21.7 Asthma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6335325&form=6&db=m [Effectiveness of the calcium antagonist nifedipine and the protease inhibitor with plasmin inactivating effect para-aminomethylbenzoic acid on stress-induced bronchial asthma] ongoing research,unassigned 2,0 3.4.21.7 Asthma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12074598&form=6&db=m PAI-1 promotes extracellular matrix deposition in the airways of a murine asthma model. ongoing research,unassigned 2,0 3.4.21.7 Asthma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16236890&form=6&db=m Sputum cathelicidin, urokinase plasminogen activation system components, and cytokines discriminate cystic fibrosis, COPD, and asthma inflammation. ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.7 Asthma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17541016&form=6&db=m Plasminogen is an important regulator in the pathogenesis of a murine model of asthma. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 Asthma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18594148&form=6&db=m Plasmin system regulation in an ovalbumin-induced rat model of asthma. ongoing research,unassigned 4,0 3.4.21.7 Asthma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19638192&form=6&db=m Characterisation of urokinase plasminogen activator receptor variants in human airway and peripheral cells. causal interaction,diagnostic usage,unassigned 4,3,0 3.4.21.7 Asthma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20615166&form=6&db=m Up-regulation of the extrinsic coagulation pathway in acute asthma--a case study. therapeutic application,unassigned 1,0 3.4.21.7 Asthma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20693403&form=6&db=m Plasminogen Activation by Airway Smooth Muscle is Regulated by Type I Collagen. causal interaction,unassigned 4,0 3.4.21.7 Asthma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20816667&form=6&db=m Cyclic adenosine monophosphate induces plasminogen activator inhibitor-1 expression in human mast cells. unassigned - 3.4.21.7 Asthma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23408042&form=6&db=m Urokinase receptor orchestrates the plasminogen system in airway epithelial cell function. causal interaction,diagnostic usage,unassigned 3,3,0 3.4.21.7 Asthma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23735578&form=6&db=m The plasminogen activation system: new targets in lung inflammation and remodeling. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 Asthma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24111848&form=6&db=m Plasminogen-stimulated airway smooth muscle cell proliferation is mediated by urokinase and annexin A2, involving plasmin-activated cell signalling. causal interaction,unassigned 2,0 3.4.21.7 Asthma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28371335&form=6&db=m Genetic susceptibility to severe asthma with fungal sensitization. unassigned - 3.4.21.7 Astrocytoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11814314&form=6&db=m Epidermal growth factor and pro-inflammatory cytokines regulate the expression of components of plasminogen activation system in U373-MG astrocytoma cells. causal interaction,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.7 Astrocytoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11939722&form=6&db=m Cytokines regulate plasminogen activation system in astrocytoma cells. ongoing research,unassigned 3,0 3.4.21.7 Astrocytoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18563800&form=6&db=m Matrix metalloproteinase-9 interplays with the IGFBP2-IGFII complex to promote cell growth and motility in astrocytomas. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,2,4 3.4.21.7 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1309041&form=6&db=m Fibrin, lipoprotein(a), plasmin interactions: a model linking thrombosis and atherogenesis. ongoing research,therapeutic application,unassigned 1,1,0 3.4.21.7 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1337176&form=6&db=m Serum lipoprotein (a) in men with proteinuria due to idiopathic membranous nephropathy. causal interaction,unassigned 3,0 3.4.21.7 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1342292&form=6&db=m Assembly of plasmin-generating proteins on the surface of human endothelial cells. causal interaction,diagnostic usage,unassigned 1,3,0 3.4.21.7 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1381585&form=6&db=m Lipoprotein (a) promotes plasmin inhibition by alpha 2-antiplasmin. unassigned - 3.4.21.7 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1527946&form=6&db=m [Tissue plasminogen activator, its inhibitor and other factors of the blood fibrinolytic system in stable coronary heart disease] causal interaction,diagnostic usage,unassigned 1,4,0 3.4.21.7 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1840453&form=6&db=m Lipoprotein(a), atherosclerosis and thrombosis. causal interaction,unassigned 3,0 3.4.21.7 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1896711&form=6&db=m [The mysteries of lipoprotein (a): a bridge between thrombosis and atheroma] causal interaction,unassigned 1,0 3.4.21.7 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1902639&form=6&db=m Endothelial cell fibrinolytic assembly. causal interaction,unassigned 4,0 3.4.21.7 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2141241&form=6&db=m [Lipoprotein (a). An additional marker of atherosclerosis] causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.7 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3524931&form=6&db=m Fibrinogen, fibrin and fibrin degradation products in relation to atherosclerosis. causal interaction,unassigned 3,0 3.4.21.7 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4004989&form=6&db=m Fibrinolysis and plasminogen concentration in aortic intima in relation to death following myocardial infarction. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,1,1 3.4.21.7 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4222542&form=6&db=m [Protective effect of combined injection of fibrinolysin and heparin against thrombogenesis in animals during the pre-thrombotic state and in experimental atherosclerosis] therapeutic application,unassigned 3,0 3.4.21.7 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4231686&form=6&db=m [A study of problems of the diagnosis and pathogenesis of atherosclerosis using fibrinolysin labeled with I-131] diagnostic usage,therapeutic application,unassigned 2,1,0 3.4.21.7 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4234679&form=6&db=m [Experimental substantiation of the diagnosis of atherosclerosis by the use of fibrinolysin labeled with I-131] diagnostic usage,therapeutic application,unassigned 2,2,0 3.4.21.7 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4241591&form=6&db=m [Some biochemical indices of the blood under the effect of fibrinolysin in rabbits with experimental cholesterol atherosclerosis] causal interaction,ongoing research,therapeutic application,unassigned 1,2,2,0 3.4.21.7 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4807057&form=6&db=m [Relations between fibrinolysis and human atherosclerosis. Tissue activator of plasminogen of the arterial wall] ongoing research,unassigned 4,0 3.4.21.7 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=5531664&form=6&db=m A basic study on theglobal coagulation and fibrinolysis of hyperlipaemic and atherosclerotic patients.2. Plasminogen activator, plasminogen, a2-macroglobulin in atherosclerosis and endogenous hypertriglyceridaemia. ongoing research,therapeutic application,unassigned 1,2,0 3.4.21.7 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=5619432&form=6&db=m [The rate of activation of plasminogen and intrasvascular thrombus formation in rheumatism and atherosclerosis] causal interaction,unassigned 2,0 3.4.21.7 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=5671692&form=6&db=m [Plasminogen, antiplasmins and the rate of fibrinolysis in hypertension and atherosclerosis] causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7192889&form=6&db=m A new hypothesis: possible mechanisms in the involvement of the increased plasminogen activator activity in branching regions of the aorta in the initiation of atherosclerosis. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.7 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7585043&form=6&db=m Antifibrinolytic activity of apolipoprotein(a) in vivo: human apolipoprotein(a) transgenic mice are resistant to tissue plasminogen activator-mediated thrombolysis. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.7 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7641354&form=6&db=m Attenuation of the synthesis of plasminogen activator inhibitor type 1 by niacin. A potential link between lipid lowering and fibrinolysis. causal interaction,diagnostic usage,therapeutic application,unassigned 3,3,4,0 3.4.21.7 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7701477&form=6&db=m Regulation of baboon arterial smooth muscle cell plasminogen activators by heparin and growth factors. causal interaction,unassigned 1,0 3.4.21.7 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8302368&form=6&db=m Atherogenesis and fibrinogen: historical perspective and current status. causal interaction,unassigned 1,0 3.4.21.7 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8578490&form=6&db=m Lipoprotein(a), plasmin modulation, and atherogenesis. unassigned - 3.4.21.7 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8760360&form=6&db=m Cytokeratin 8 released by breast carcinoma cells in vitro binds plasminogen and tissue-type plasminogen activator and promotes plasminogen activation. causal interaction,ongoing research,therapeutic application,unassigned 4,4,2,0 3.4.21.7 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9011833&form=6&db=m [Lipoprotein (a) and plasminogen in atherosclerosis] causal interaction,diagnostic usage,ongoing research,unassigned 3,2,1,0 3.4.21.7 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9186598&form=6&db=m Insights in vessel development and vascular disorders using targeted inactivation and transfer of vascular endothelial growth factor, the tissue factor receptor, and the plasminogen system. causal interaction,ongoing research,therapeutic application,unassigned 4,2,3,0 3.4.21.7 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9192751&form=6&db=m Defensin stimulates the binding of lipoprotein (a) to human vascular endothelial and smooth muscle cells. causal interaction,ongoing research,unassigned 1,4,0 3.4.21.7 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9239402&form=6&db=m Modification of apolipoprotein(a) lysine binding site reduces atherosclerosis in transgenic mice. unassigned - 3.4.21.7 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9245111&form=6&db=m [Lipids and atherosclerosis] causal interaction,unassigned 3,0 3.4.21.7 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9245184&form=6&db=m [Lipoprotein(a). Its importance as an additional atherosclerosis marker] causal interaction,unassigned 4,0 3.4.21.7 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9275667&form=6&db=m [Expression of tissue-type plasminogen activator (t-PA) in smooth muscle cells of injured iliac arteries in rabbits] diagnostic usage,ongoing research,unassigned 4,1,0 3.4.21.7 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9294211&form=6&db=m Plasminogen deficiency accelerates vessel wall disease in mice predisposed to atherosclerosis. causal interaction,ongoing research,unassigned 4,3,0 3.4.21.7 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9374741&form=6&db=m Molecular analysis of blood vessel formation and disease. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.7 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9409325&form=6&db=m Changes in arterial expression of fibrinolytic system proteins in atherogenesis. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.7 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9520127&form=6&db=m Vascular accumulation of Lp(a): in vivo analysis of the role of lysine-binding sites using recombinant adenovirus. causal interaction,diagnostic usage,unassigned 1,2,0 3.4.21.7 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9799211&form=6&db=m Novel therapeutic strategy for atherosclerosis: ribozyme oligonucleotides against apolipoprotein(a) selectively inhibit apolipoprotein(a) but not plasminogen gene expression. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9915664&form=6&db=m Lipoprotein(a) as a risk factor for coronary artery disease. causal interaction,unassigned 4,0 3.4.21.7 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10073949&form=6&db=m Relationship of plasmin generation to cardiovascular disease risk factors in elderly men and women. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,1 3.4.21.7 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10375389&form=6&db=m Plasmin activation system in restenosis: role in pathogenesis and clinical prediction? causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10590062&form=6&db=m Induction of the plasminogen activator inhibitor-1 gene expression by mild hypoxia via a hypoxia response element binding the hypoxia-inducible factor-1 in rat hepatocytes. unassigned - 3.4.21.7 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10592111&form=6&db=m The rate of plasmin formation after in vitro clotting is inversely related to lipoprotein(a) plasma levels. causal interaction,therapeutic application,unassigned 4,3,0 3.4.21.7 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10608012&form=6&db=m Human Aortic Vascular Smooth Muscle Cells Digest Extracellular Matrix by Elaboration of Plasminogen Activators: Implications for Atherogenesis. causal interaction,ongoing research,therapeutic application,unassigned 1,4,3,0 3.4.21.7 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10695477&form=6&db=m A role of plasminogen in atherosclerosis and restenosis models in mice. causal interaction,ongoing research,therapeutic application,unassigned 3,4,1,0 3.4.21.7 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10712412&form=6&db=m Atherosclerosis progression in LDL receptor-deficient and apolipoprotein E-deficient mice is independent of genetic alterations in plasminogen activator inhibitor-1. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.7 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10767104&form=6&db=m Identification of a BamHI Polymorphism for the Urokinase Gene Associated with Symptomatic Coronary Artery Disease. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10980828&form=6&db=m Lipoprotein(a) and coronary heart disease risk. causal interaction,unassigned 1,0 3.4.21.7 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11001801&form=6&db=m Lipoprotein(a), atherosclerosis, and apolipoprotein(a) gene polymorphism. causal interaction,ongoing research,unassigned 1,3,0 3.4.21.7 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11061992&form=6&db=m Plasmin and kallikrein reduce HDL-induced cholesterol efflux from foam cells. causal interaction,unassigned 3,0 3.4.21.7 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11110693&form=6&db=m Plasminogen activator inhibitor-1 deficiency protects against atherosclerosis progression in the mouse carotid artery. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11265801&form=6&db=m Current understanding of pathogenesis of coronary artery disease and its future implications. causal interaction,unassigned 4,0 3.4.21.7 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11304480&form=6&db=m Prospective study of fibrinolytic factors and incident coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study. diagnostic usage,ongoing research,therapeutic application,unassigned 2,1,2,0 3.4.21.7 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11487021&form=6&db=m Plasmin and matrix metalloproteinases in vascular remodeling. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11573053&form=6&db=m Impact of atherosclerotic risk factors on the anatomical distribution of peripheral arterial disease. causal interaction,diagnostic usage,unassigned 1,2,0 3.4.21.7 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11739291&form=6&db=m Recombinant annexin II modulates impaired fibrinolytic activity in vitro and in rat carotid artery. causal interaction,ongoing research,therapeutic application,unassigned 1,1,1,0 3.4.21.7 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11841347&form=6&db=m Plasminogen activators in vascular remodeling and angiogenesis. causal interaction,unassigned 4,0 3.4.21.7 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11852811&form=6&db=m [Plasminogen activators (t-PA and u-PA) and other fibrinolysis parameters in patients with atherosclerosis obliterans and diabetic macroangiopathy] diagnostic usage,ongoing research,unassigned 2,2,0 3.4.21.7 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12419562&form=6&db=m Effects of lipids on thrombotic mechanisms in atherosclerosis. unassigned - 3.4.21.7 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12627747&form=6&db=m Lipoprotein(a): an emerging cardiovascular risk factor. causal interaction,unassigned 4,0 3.4.21.7 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12697748&form=6&db=m Inhibition of plasminogen activation by lipoprotein(a): critical domains in apolipoprotein(a) and mechanism of inhibition on fibrin and degraded fibrin surfaces. causal interaction,unassigned 1,0 3.4.21.7 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12715893&form=6&db=m Induction of apoptosis in vascular cells by plasminogen activator inhibitor-1 and high molecular weight kininogen correlates with their anti-adhesive properties. causal interaction,therapeutic application,unassigned 3,2,0 3.4.21.7 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=13462553&form=6&db=m Studies in experimental atherosclerosis. IV. Serum fibrinolysin activity in cholesterol atherosclerosis. diagnostic usage,ongoing research,therapeutic application,unassigned 2,2,1,0 3.4.21.7 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14039393&form=6&db=m [Experimental cholesterin atherosclerosis in the rabbit: action of a duodenal heparinoid. III. Modifications in the factors of hemocoagulation, plasmin and plasminogen, and in the thromboplastin and fibrinolytic activity of the aortic wall.] ongoing research,unassigned 2,0 3.4.21.7 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14515193&form=6&db=m Genetic deletion of tissue-type plasminogen activator (t-PA) in APOE3-Leiden mice reduces progression of cholesterol-induced atherosclerosis. causal interaction,ongoing research,therapeutic application,unassigned 4,4,2,0 3.4.21.7 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14751930&form=6&db=m A novel plasma proteinase potentiates alpha2-antiplasmin inhibition of fibrin digestion. causal interaction,therapeutic application,unassigned 3,3,0 3.4.21.7 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15095009&form=6&db=m Novel aspects and new roles for the serine protease plasmin. causal interaction,unassigned 4,0 3.4.21.7 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15166500&form=6&db=m The role of the fibrinolytic system in corneal angiogenesis. causal interaction,ongoing research,therapeutic application,unassigned 4,3,3,0 3.4.21.7 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15345515&form=6&db=m Enzymatic modification of low-density lipoprotein in the arterial wall: a new role for plasmin and matrix metalloproteinases in atherogenesis. ongoing research,unassigned 3,0 3.4.21.7 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15346794&form=6&db=m [Expression of urokinase plasminogen activator, its receptor and plasminogen activator inhibitor type 1 in different types of atherosclerotic lesion in human aorta] causal interaction,diagnostic usage,unassigned 2,3,0 3.4.21.7 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15364123&form=6&db=m Atherogenesis and vascular calcification in mice expressing the human LPA gene. unassigned - 3.4.21.7 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15379562&form=6&db=m Definition of the structural elements in plasminogen required for high-affinity binding to apolipoprotein(a): a study utilizing surface plasmon resonance. unassigned - 3.4.21.7 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15818457&form=6&db=m Overexpression of MMP9 and tissue factor in unstable carotid plaques associated with Chlamydia pneumoniae, inflammation, and apoptosis. causal interaction,unassigned 3,0 3.4.21.7 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16105483&form=6&db=m Lipoprotein(a) and atherosclerosis: new perspectives on the mechanism of action of an enigmatic lipoprotein. causal interaction,unassigned 1,0 3.4.21.7 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16478887&form=6&db=m Plasminogen inhibits TNFalpha-induced apoptosis in monocytes. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17606760&form=6&db=m Activation of plasminogen into plasmin at the surface of endothelial microparticles: a mechanism that modulates angiogenic properties of endothelial progenitor cells in vitro. causal interaction,ongoing research,unassigned 3,3,0 3.4.21.7 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17622568&form=6&db=m Angiostatin inhibits monocyte/macrophage migration via disruption of actin cytoskeleton. ongoing research,therapeutic application,unassigned 1,1,0 3.4.21.7 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17853709&form=6&db=m [Lipoprotein(a): a link between thrombogenesis and atherogenesis] causal interaction,unassigned 2,0 3.4.21.7 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18478967&form=6&db=m Quantitative trait locus on chromosome 12q14.1 influences variation in plasma plasminogen levels in the San Antonio Family Heart Study. ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.7 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18796547&form=6&db=m Transmembrane signaling pathway mediates oxidized low-density lipoprotein-induced expression of plasminogen activator inhibitor-1 in vascular endothelial cells. therapeutic application,unassigned 4,0 3.4.21.7 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18957535&form=6&db=m Plasminogen mediates the atherogenic effects of macrophage-expressed urokinase and accelerates atherosclerosis in apoE-knockout mice. ongoing research,therapeutic application,unassigned 3,1,0 3.4.21.7 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19593116&form=6&db=m Acute myocardial ischemia in a patient with heterozygous alpha-2-plasmin inhibitor deficiency. causal interaction,unassigned 4,0 3.4.21.7 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19729604&form=6&db=m Level of Macrophage uPA Expression Is an Important Determinant of Atherosclerotic Lesion Growth in Apoe-/- Mice. ongoing research,therapeutic application,unassigned 3,1,0 3.4.21.7 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19874473&form=6&db=m Human plasminogen kringle 1-5 reduces atherosclerosis and neointima formation in mice by suppressing the inflammatory signaling pathway. causal interaction,ongoing research,unassigned 1,2,0 3.4.21.7 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20056908&form=6&db=m Plasmin triggers chemotaxis of monocyte-derived dendritic cells through an Akt2-dependent pathway and promotes a T-helper type-1 response. causal interaction,ongoing research,therapeutic application,unassigned 2,1,1,0 3.4.21.7 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20106478&form=6&db=m Lipoprotein(a) and ischemic heart disease-A causal association? A review. unassigned - 3.4.21.7 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20379055&form=6&db=m Coagulation Factors II, V, IX, X, XI, and XII, Plasminogen, and alpha-2 Antiplasmin and Risk of Coronary Heart Disease. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,3,2,1 3.4.21.7 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20687444&form=6&db=m [New data about lipoprotein(a): a curious molecule or a causal cardiovascular risk factor?] unassigned - 3.4.21.7 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20888797&form=6&db=m Consistent differences in protein distribution along the longitudinal axis in symptomatic carotid atherosclerotic plaques. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20965889&form=6&db=m Lipoprotein(a) as a cardiovascular risk factor: current status. causal interaction,unassigned 1,0 3.4.21.7 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21529331&form=6&db=m Lipoprotein(a): Current Perspectives. causal interaction,unassigned 3,0 3.4.21.7 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21719525&form=6&db=m Role of fibrinolytic parameters and plasminogen activator inhibitor 1 (PAI-1) promoter polymorphism on premature atherosclerosis in SLE patients. ongoing research,therapeutic application,unassigned 4,1,0 3.4.21.7 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21740311&form=6&db=m Advanced oxidation protein products (AOPP): novel uremic toxins, or components of the non-enzymatic antioxidant system of the plasma proteome? causal interaction,therapeutic application,unassigned 3,2,0 3.4.21.7 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23576799&form=6&db=m Plasmin induces intercellular adhesion molecule 1 expression in human endothelial cells via nuclear factor-?B/mitogen-activated protein kinases-dependent pathways. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.7 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24478033&form=6&db=m Inhibition of plasminogen activation by apo(a): role of carboxyl-terminal lysines and identification of inhibitory domains in apo(a). causal interaction,unassigned 1,0 3.4.21.7 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26647358&form=6&db=m Lipoprotein(a): truly a direct prothrombotic factor in cardiovascular disease? causal interaction,therapeutic application,unassigned 3,3,0 3.4.21.7 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26855483&form=6&db=m Lipoprotein (a): a Unique Independent Risk Factor for Coronary Artery Disease. causal interaction,unassigned 3,0 3.4.21.7 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28548211&form=6&db=m A haplotype block downstream of plasminogen is associated with chronic and aggressive periodontitis. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.7 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29898827&form=6&db=m LDL extracellular vesicle coagulation protein levels change after initiation of statin therapy. Findings from the METEOR trial. causal interaction,diagnostic usage,unassigned 1,1,0 3.4.21.7 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33492784&form=6&db=m Plasminogen-induced foam cell formation by macrophages occurs through a histone 2B (H2B)-PAR1 pathway and requires integrity of clathrin-coated pits. causal interaction,ongoing research,therapeutic application,unassigned 1,1,1,0 3.4.21.7 Atrial Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1284251&form=6&db=m Influence of atrial fibrillation on coagulo-fibrinolytic markers in patients with cerebral infarction. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,2,3,1 3.4.21.7 Autoimmune Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8872860&form=6&db=m Analysis of autoantibodies to plasminogen in the serum of patients with rheumatoid arthritis. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,4 3.4.21.7 Autoimmune Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9603964&form=6&db=m alpha-enolase, a novel strong plasmin(ogen) binding protein on the surface of pathogenic streptococci. causal interaction,unassigned 1,0 3.4.21.7 Autoimmune Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11246666&form=6&db=m Autoantibodies to receptor induced neoepitopes of fibrinolytic proteins in rheumatic and vascular diseases. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,2,2 3.4.21.7 Autoimmune Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12871409&form=6&db=m A study on associations between antiprothrombin antibodies, antiplasminogen antibodies and thrombosis. diagnostic usage,ongoing research,unassigned 3,2,0 3.4.21.7 Autoimmune Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15841177&form=6&db=m Synergy between a plasminogen cascade and MMP-9 in autoimmune disease. causal interaction,ongoing research,unassigned 3,2,0 3.4.21.7 Autoimmune Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17425656&form=6&db=m Autoantibodies to plasminogen and tissue plasminogen activator in women with recurrent pregnancy loss. causal interaction,unassigned 3,0 3.4.21.7 Autoimmune Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22561604&form=6&db=m Plasmin as a proinflammatory cell activator. causal interaction,unassigned 4,0 3.4.21.7 Autoimmune Pancreatitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28412148&form=6&db=m No evidence to support a role for Helicobacter pylori infection and plasminogen binding protein in autoimmune pancreatitis and IgG4-related disease in a UK cohort. diagnostic usage,unassigned 3,0 3.4.21.7 Babesiosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28363279&form=6&db=m Blood markers of fibrinolysis and endothelial activation in canine babesiosis. diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.7 Bacteremia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8131448&form=6&db=m Elevated concentrations of cross-linked fibrin degradation products in plasma. An early marker of gram-negative bacteremia. unassigned - 3.4.21.7 Bacteremia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8454195&form=6&db=m Immobilization of plasminogen on Escherichia coli flagella. ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.7 Bacteremia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18308996&form=6&db=m Citrate 4% versus heparin and the reduction of thrombosis study (CHARTS). therapeutic application,unassigned 1,0 3.4.21.7 Bacteremia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19590902&form=6&db=m Prophylaxis of catheter-related bacteremia using tissue plasminogen activator-tobramycin locks. ongoing research,unassigned 3,0 3.4.21.7 Bacterial Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2530187&form=6&db=m Reduced fibrinolytic capacity and its restoration by plasminogen substitution in acute renal failure. causal interaction,diagnostic usage,unassigned 1,4,0 3.4.21.7 Bacterial Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9006351&form=6&db=m Urokinase-type plasminogen activator-deficient mice are predisposed to staphylococcal botryomycosis, pleuritis, and effacement of lymphoid follicles. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 Bacterial Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23853591&form=6&db=m A key role for the urokinase plasminogen activator (uPA) in invasive Group A streptococcal infection. causal interaction,therapeutic application,unassigned 4,3,0 3.4.21.7 Bacterial Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27377187&form=6&db=m Proteolysis of plasminogen activator inhibitor-1 by Yersinia pestis remodulates the host environment to promote virulence. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,3,3,2 3.4.21.7 Bacterial Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27683386&form=6&db=m Procalcitonin and Other Biomarkers of Sepsis in Newborns in the Intensive Care Unit. diagnostic usage,ongoing research,unassigned 3,2,0 3.4.21.7 Bacterial Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31422744&form=6&db=m The interaction of two novel putative proteins of Leptospira interrogans with E-cadherin, plasminogen and complement components with potential role in bacterial infection. unassigned - 3.4.21.7 Behcet Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11246666&form=6&db=m Autoantibodies to receptor induced neoepitopes of fibrinolytic proteins in rheumatic and vascular diseases. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,2,2 3.4.21.7 beta-Thalassemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30865135&form=6&db=m Impact of ?-thalassemia trait carrier state on inflammatory status in patients with newly diagnosed hypertension. diagnostic usage,ongoing research,therapeutic application,unassigned 3,2,1,0 3.4.21.7 Blister http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=88067&form=6&db=m The extra-articular deposition of fibrinogen antigenic material in patients with rheumatoid arthritis. unassigned - 3.4.21.7 Blister http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=912108&form=6&db=m [Coagulation factors in human born blisters (author's transl)] diagnostic usage,ongoing research,unassigned 4,1,0 3.4.21.7 Blister http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1375506&form=6&db=m Different effects of pemphigus antibody and plasmin on the distribution of keratin intermediate filaments and desmoplakins between cultured oral and epidermal keratinocytes. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,1,4,1 3.4.21.7 Blister http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2138159&form=6&db=m Fibrinolysis inhibition in human burn blister fluid. causal interaction,unassigned 4,0 3.4.21.7 Blister http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2498140&form=6&db=m Studies on two siblings with recessive dystrophic epidermolysis bullosa (Hallopeau-Siemens) and the plasminogen activator and its inhibitor in the lesion. causal interaction,therapeutic application,unassigned 1,2,0 3.4.21.7 Blister http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2575330&form=6&db=m Plasmin-like proteinase associated with high molecular weight complexes in blister fluid of bullous pemphigoid. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 Blister http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7510121&form=6&db=m Cantharidin-induced acantholysis: adhesion molecules, proteases, and related proteins. causal interaction,diagnostic usage,ongoing research,unassigned 3,3,2,0 3.4.21.7 Blister http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7519031&form=6&db=m Cantharidin-induced acantholysis in Darier's disease: does acantholysis initiate dyskeratosis? ongoing research,unassigned 1,0 3.4.21.7 Blister http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7682051&form=6&db=m Plasminogen activation in lesional skin of Pemphigus vulgaris type Neumann. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,3,2,1 3.4.21.7 Blister http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7688770&form=6&db=m The autoimmune blistering skin disease bullous pemphigoid. The presence of plasmin/alpha 2-antiplasmin complexes in skin blister fluid indicates plasmin generation in lesional skin. diagnostic usage,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.7 Blister http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8481985&form=6&db=m An immunohistochemical study of the distribution of plasminogen and plasminogen activators in bullous pemphigoid. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,2,4,2 3.4.21.7 Blister http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15008985&form=6&db=m Elevated expression and release of tissue-type, but not urokinase-type, plasminogen activator after binding of autoantibodies to bullous pemphigoid antigen 180 in cultured human keratinocytes. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,2,4 3.4.21.7 Blister http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15161662&form=6&db=m Plasminogen mediates the pathological effects of urokinase-type plasminogen activator overexpression. ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.7 Blister http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32039455&form=6&db=m Collagen XVII Processing and Blistering Skin Diseases. causal interaction,unassigned 4,0 3.4.21.7 Bone Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17888748&form=6&db=m Transgenic over-expression of plasminogen activator inhibitor-1 results in age-dependent and gender-specific increases in bone strength and mineralization. therapeutic application,unassigned 4,0 3.4.21.7 Bone Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17945547&form=6&db=m The roles of proteolytic enzymes in the development of tumour-induced bone disease in breast and prostate cancer. unassigned - 3.4.21.7 Bone Resorption http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1932892&form=6&db=m Regulation of the production of plasminogen activators by bone resorption enhancing and inhibiting factors in three types of osteoblast-like cells. ongoing research,unassigned 4,0 3.4.21.7 Bone Resorption http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2065216&form=6&db=m Modulation of plasminogen activators and plasminogen activator inhibitors by TGF-beta, IL-1 alpha and EGF in fetal rat calvaria cells at different times of culture. ongoing research,unassigned 3,0 3.4.21.7 Bone Resorption http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7495280&form=6&db=m Detection of mRNAs for urokinase-type plasminogen activator, its receptor, and type 1 inhibitor in giant cell tumors of bone with in situ hybridization. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,2,1 3.4.21.7 Bone Resorption http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7849104&form=6&db=m Effects of plasminogen and interleukin-1 beta on bone resorption in vitro. diagnostic usage,ongoing research,unassigned 3,4,0 3.4.21.7 Bone Resorption http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8079664&form=6&db=m Relationship of the plasminogen activator/plasmin cascade to osteoclast invasion and mineral resorption in explanted fetal metatarsal bones. therapeutic application,unassigned 1,0 3.4.21.7 Bone Resorption http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8393772&form=6&db=m Thrombomodulin is synthesized by osteoblasts, stimulated by 1,25-(OH)2D3 and activates protein C at their cell membrane. therapeutic application,unassigned 1,0 3.4.21.7 Bone Resorption http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8854251&form=6&db=m Bone resorption and response to calcium-regulating hormones in the absence of tissue or urokinase plasminogen activator or of their type 1 inhibitor. ongoing research,therapeutic application,unassigned 4,1,0 3.4.21.7 Bone Resorption http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10352103&form=6&db=m The role of the plasminogen system in bone resorption in vitro. diagnostic usage,ongoing research,therapeutic application,unassigned 3,4,2,0 3.4.21.7 Bone Resorption http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10934649&form=6&db=m Mice lacking the plasminogen activator inhibitor 1 are protected from trabecular bone loss induced by estrogen deficiency. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 Brain Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12023849&form=6&db=m Cellular mechanisms regulating non-haemostatic plasmin generation. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 Brain Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19827195&form=6&db=m [Change in the concentration of plasmin and its inhibitors in the blood of patients with dyscirculatory encephalopathy before and after treatment] causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.7 Brain Edema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8621740&form=6&db=m Proteolytic cascade enzymes increase in focal cerebral ischemia in rat. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,2,0 3.4.21.7 Brain Edema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9109878&form=6&db=m Metalloproteinase inhibition blocks edema in intracerebral hemorrhage in the rat. causal interaction,ongoing research,therapeutic application,unassigned 3,3,4,0 3.4.21.7 Brain Edema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9626295&form=6&db=m Plasminogen activators potentiate thrombin-induced brain injury. causal interaction,therapeutic application,unassigned 2,4,0 3.4.21.7 Brain Edema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12500707&form=6&db=m MRI predicts area of increased plasminogen activation in permanent focal cerebral ischemia. causal interaction,ongoing research,therapeutic application,unassigned 4,1,1,0 3.4.21.7 Brain Edema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26463967&form=6&db=m Epsilon Aminocaproic Acid Pretreatment Provides Neuroprotection Following Surgically Induced Brain Injury in a Rat Model. causal interaction,therapeutic application,unassigned 1,2,0 3.4.21.7 Brain Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1319650&form=6&db=m [Revising the principles and improving the methods of differential therapy of ischemic stroke] diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.7 Brain Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9626295&form=6&db=m Plasminogen activators potentiate thrombin-induced brain injury. causal interaction,therapeutic application,unassigned 2,4,0 3.4.21.7 Brain Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10696680&form=6&db=m [The permeability of the hemato-encephalic barrier and the proteolytic potential of the cerebrospinal fluid in severe craniocerebral trauma] causal interaction,diagnostic usage,ongoing research,unassigned 4,4,3,0 3.4.21.7 Brain Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10724108&form=6&db=m Reduction of tissue plasminogen activator-induced hemorrhage and brain injury by free radical spin trapping after embolic focal cerebral ischemia in rats. causal interaction,ongoing research,therapeutic application,unassigned 4,2,4,0 3.4.21.7 Brain Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12111810&form=6&db=m Extracellular proteolysis in brain injury and inflammation: role for plasminogen activators and matrix metalloproteinases. ongoing research,unassigned 2,0 3.4.21.7 Brain Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16099300&form=6&db=m Plasminogen activators contribute to age-dependent impairment of NMDA cerebrovasodilation after brain injury. therapeutic application,unassigned 1,0 3.4.21.7 Brain Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17455321&form=6&db=m Enhanced poly(ADP-ribose) polymerase-1 activation contributes to recombinant tissue plasminogen activator-induced aggravation of ischemic brain injury in vivo. causal interaction,ongoing research,therapeutic application,unassigned 4,2,4,0 3.4.21.7 Brain Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19298760&form=6&db=m Albumin ameliorates tissue plasminogen activator-mediated blood-brain barrier permeability and ischemic brain injury in rats. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,3,4,4 3.4.21.7 Brain Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25767491&form=6&db=m Tissue plasminogen activator-independent roles of neuroserpin in the central nervous system. causal interaction,unassigned 2,0 3.4.21.7 Brain Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26646459&form=6&db=m Platelet-Derived Growth Factor Receptor-? Regulates Vascular Smooth Muscle Cell Phenotypic Transformation and Neuroinflammation After Intracerebral Hemorrhage in Mice. diagnostic usage,ongoing research,therapeutic application,unassigned 3,3,1,0 3.4.21.7 Brain Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27319402&form=6&db=m Physiologic variations in blood plasminogen levels affect outcomes after acute cerebral thromboembolism in mice: a pathophysiologic role for microvascular thrombosis. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,1,4,3 3.4.21.7 Brain Injuries, Traumatic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22822039&form=6&db=m The tissue-type plasminogen activator-plasminogen activator inhibitor 1 complex promotes neurovascular injury in brain trauma: evidence from mice and humans. causal interaction,ongoing research,therapeutic application,unassigned 2,2,3,0 3.4.21.7 Brain Injuries, Traumatic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22964508&form=6&db=m Traumatic brain injury: Tissue-type plasminogen activator-harmful or beneficial? unassigned - 3.4.21.7 Brain Injuries, Traumatic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23231415&form=6&db=m tPA in the central nervous system: relations between tPA and cell surface LRPs. causal interaction,unassigned 3,0 3.4.21.7 Brain Injuries, Traumatic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25673638&form=6&db=m Endogenous plasminogen activators mediate progressive intracranial hemorrhage after traumatic brain injury. causal interaction,ongoing research,unassigned 2,2,0 3.4.21.7 Brain Injuries, Traumatic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28925023&form=6&db=m Fibrinolysis: from blood to the brain. causal interaction,ongoing research,therapeutic application,unassigned 1,2,3,0 3.4.21.7 Brain Injuries, Traumatic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31140372&form=6&db=m Tranexamic Acid Influences the Immune Response, but not Bacterial Clearance in a Model of Post-Traumatic Brain Injury Pneumonia. causal interaction,ongoing research,therapeutic application,unassigned 1,3,3,0 3.4.21.7 Brain Injuries, Traumatic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31362033&form=6&db=m Genotype and Injury Effect on the Expression of a Novel Hypothalamic Protein Sushi Repeat-Containing Protein X-Linked 2 (SRPX2). causal interaction,diagnostic usage,unassigned 2,2,0 3.4.21.7 Brain Injuries, Traumatic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32594031&form=6&db=m Using antifibrinolytics to tackle neuroinflammation. causal interaction,therapeutic application,unassigned 3,3,0 3.4.21.7 Brain Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2145826&form=6&db=m Altered coagulation in cerebral ischemia. Platelet, thrombin, and plasmin activity. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.7 Brain Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10375684&form=6&db=m The effect of age on expression of endogenous plasminogen activators after focal cerebral ischemia in mice. ongoing research,therapeutic application,unassigned 4,2,0 3.4.21.7 Brain Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10684070&form=6&db=m [Changes of serum TNF-alpha level, t-PA activivty and PAI activity in patients with silent myocardial ischemia or silent cerebral ischemia] diagnostic usage,ongoing research,unassigned 4,2,0 3.4.21.7 Brain Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10698071&form=6&db=m Plasminogen activation in focal cerebral ischemia and reperfusion. causal interaction,ongoing research,therapeutic application,unassigned 4,2,2,0 3.4.21.7 Brain Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10724108&form=6&db=m Reduction of tissue plasminogen activator-induced hemorrhage and brain injury by free radical spin trapping after embolic focal cerebral ischemia in rats. causal interaction,ongoing research,therapeutic application,unassigned 4,2,4,0 3.4.21.7 Brain Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11056180&form=6&db=m Plasminogen activation in experimental permanent focal cerebral ischemia. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,4,4,3 3.4.21.7 Brain Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12500707&form=6&db=m MRI predicts area of increased plasminogen activation in permanent focal cerebral ischemia. causal interaction,ongoing research,therapeutic application,unassigned 4,1,1,0 3.4.21.7 Brain Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14617754&form=6&db=m Tissue-type plasminogen activator induces opening of the blood-brain barrier via the LDL receptor-related protein. causal interaction,therapeutic application,unassigned 3,2,0 3.4.21.7 Brain Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15261888&form=6&db=m Tissue-type plasminogen activator and neuroserpin: a well-balanced act in the nervous system? causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.7 Brain Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17166729&form=6&db=m Doxycycline inhibits MMPs via modulation of plasminogen activators in focal cerebral ischemia. therapeutic application,unassigned 1,0 3.4.21.7 Brain Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22436003&form=6&db=m Combined therapy with PJ34, a poly(ADP-ribose)polymerase inhibitor, reduces tissue plasminogen activator-induced hemorrhagic transformations in cerebral ischemia in mice. causal interaction,ongoing research,therapeutic application,unassigned 2,2,4,0 3.4.21.7 Brain Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22791305&form=6&db=m Intracerebral transplantation of bone marrow stromal cells ameliorates tissue plasminogen activator-induced brain damage after cerebral ischemia in mice detected by in vivo and ex vivo optical imaging. diagnostic usage,ongoing research,therapeutic application,unassigned 1,3,4,0 3.4.21.7 Brain Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26646461&form=6&db=m Modulation by the Noble Gas Helium of Tissue Plasminogen Activator: Effects in a Rat Model of Thromboembolic Stroke. causal interaction,ongoing research,therapeutic application,unassigned 3,1,4,0 3.4.21.7 Brain Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28553165&form=6&db=m GSK-3? as a target for protection against transient cerebral ischemia. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 Brain Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29623912&form=6&db=m Cerebral ischemia and neuroregeneration. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.7 Brain Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32549050&form=6&db=m Neuroendocrine Targeting of Tissue Plasminogen Activator (t-PA). therapeutic application,unassigned 2,0 3.4.21.7 Brain Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33224099&form=6&db=m Plasmin Generation Potential and Recanalization in Acute Ischaemic Stroke; an Observational Cohort Study of Stroke Biobank Samples. diagnostic usage,ongoing research,therapeutic application,unassigned 3,3,3,0 3.4.21.7 Brain Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33720950&form=6&db=m Ischemic stroke in PAR1 KO mice: Decreased brain plasmin and thrombin activity along with decreased infarct volume. causal interaction,therapeutic application,unassigned 1,2,0 3.4.21.7 Brain Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1827214&form=6&db=m Plasma fibrinolytic profile in patients with brain tumors. ongoing research,therapeutic application,unassigned 1,2,0 3.4.21.7 Brain Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6239988&form=6&db=m Brain tumors and plasmin inhibitors. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,4,4 3.4.21.7 Brain Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7745466&form=6&db=m Activities, localizations, and roles of serine proteases and their inhibitors in human brain tumor progression. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 Brain Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8314304&form=6&db=m Induction of tissue-type plasminogen activator and 72-kDa type-IV collagenase by ionizing radiation in rat astrocytes. causal interaction,ongoing research,therapeutic application,unassigned 1,1,1,0 3.4.21.7 Brain Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9689330&form=6&db=m Production of urokinase-type plasminogen activator (u-PA) and plasminogen activator inhibitor-1 (PAI-1) in human brain tumours. diagnostic usage,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.7 Brain Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12241114&form=6&db=m Modulation of tissue-type plasminogen activator expression by platelet activating factor in human glioma cells. causal interaction,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.7 Brain Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16524486&form=6&db=m The fibrinolytic system facilitates tumor cell migration across the blood-brain barrier in experimental melanoma brain metastasis. causal interaction,ongoing research,therapeutic application,unassigned 3,4,3,0 3.4.21.7 Brain Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28524122&form=6&db=m [A plasminogen regulation system in brain tumors]. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,4,2,1 3.4.21.7 Brain Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30456442&form=6&db=m Genes Encoding Mammalian Oviductal Proteins Involved in Fertilization are Subjected to Gene Death and Positive Selection. unassigned - 3.4.21.7 Brain Stem Infarctions http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3440344&form=6&db=m [Defects of antithrombin III, protein C, and plasminogen in Wilson's disease with brainstem infarction] unassigned - 3.4.21.7 Breast Cyst http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3137078&form=6&db=m Urokinase and tissue-type plasminogen activators are present in breast cyst fluids. causal interaction,diagnostic usage,unassigned 2,3,0 3.4.21.7 Breast Cyst http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18181041&form=6&db=m Breast cyst fluid plasmin activity and its effect on TGF-beta2 activation. diagnostic usage,ongoing research,unassigned 3,4,0 3.4.21.7 Breast Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8227186&form=6&db=m Expression and localization of elements of the plasminogen activation system in benign breast disease and breast cancers. causal interaction,ongoing research,therapeutic application,unassigned 4,4,2,0 3.4.21.7 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=127716&form=6&db=m Characteristics of fibrinolysin secreted by cultured rat breast carcinoma cells. diagnostic usage,ongoing research,unassigned 3,4,0 3.4.21.7 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1730515&form=6&db=m Type-1 plasminogen activator inhibitor in human breast carcinomas. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,4,1 3.4.21.7 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1796300&form=6&db=m Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer. diagnostic usage,ongoing research,therapeutic application,unassigned 3,3,1,0 3.4.21.7 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1846311&form=6&db=m Occurrence of components of fibrinolysis pathways in situ in neoplastic and nonneoplastic human breast tissue. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,2,2 3.4.21.7 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1948823&form=6&db=m Increase in levels of plasminogen activator and type-1 plasminogen activator inhibitor in human breast cancer: possible roles in tumor progression and metastasis. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,1,4,2 3.4.21.7 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2133250&form=6&db=m Tumour-associated fibrinolysis: the prognostic relevance of plasminogen activators uPA and tPA in human breast cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,3,1 3.4.21.7 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2440556&form=6&db=m Increase of urokinase-type plasminogen activator gene expression in human lung and breast carcinomas. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,4,1 3.4.21.7 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3098408&form=6&db=m Glucocorticoid modulation of plasminogen activators and of one of their inhibitors in the human mammary carcinoma cell line MDA-MB-231. causal interaction,therapeutic application,unassigned 1,3,0 3.4.21.7 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3109062&form=6&db=m Tissue plasminogen activators in breast cancer. ongoing research,unassigned 4,0 3.4.21.7 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3141047&form=6&db=m Relationship of membrane-bound tissue type and urokinase type plasminogen activators in human breast cancers to estrogen and epidermal growth factor receptors. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,4,0 3.4.21.7 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3386280&form=6&db=m Plasminogen activators in human breast cancer cell lines: hormonal regulation and properties. ongoing research,unassigned 4,0 3.4.21.7 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6537799&form=6&db=m Bioactivities, estrogen receptor interactions, and plasminogen activator-inducing activities of tamoxifen and hydroxy-tamoxifen isomers in MCF-7 human breast cancer cells. ongoing research,unassigned 3,0 3.4.21.7 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6542103&form=6&db=m Estradiol preferentially enhances extracellular tissue plasminogen activators of MCF-7 breast cancer cells. ongoing research,therapeutic application,unassigned 3,1,0 3.4.21.7 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6989588&form=6&db=m Estrogen receptor cleavage and plasminogen activation by enzymes in human breast tumor cytosol. ongoing research,unassigned 4,0 3.4.21.7 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7201390&form=6&db=m Association of plasminogen activator activity and steroid receptors in human breast cancer. diagnostic usage,ongoing research,unassigned 1,4,0 3.4.21.7 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7618808&form=6&db=m Suppression of pulmonary metastases of rat mammary cancer by recombinant urokinase plasminogen activator inhibitor. causal interaction,ongoing research,therapeutic application,unassigned 2,4,1,0 3.4.21.7 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7974332&form=6&db=m Factors involved in the plasminogen activation system in human breast tumours. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,1,4,1 3.4.21.7 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8227186&form=6&db=m Expression and localization of elements of the plasminogen activation system in benign breast disease and breast cancers. causal interaction,ongoing research,therapeutic application,unassigned 4,4,2,0 3.4.21.7 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8313371&form=6&db=m The urokinase receptor is expressed in invasive breast cancer but not in normal breast tissue. causal interaction,ongoing research,unassigned 4,3,0 3.4.21.7 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8625226&form=6&db=m Thrombospondin and transforming growth factor-beta 1 increase expression of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in human MDA-MB-231 breast cancer cells. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,4,0 3.4.21.7 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8674284&form=6&db=m Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,4,4 3.4.21.7 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8694536&form=6&db=m Fibrinolysis components as prognostic markers in breast cancer and colorectal carcinoma. causal interaction,diagnostic usage,unassigned 4,2,0 3.4.21.7 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8760360&form=6&db=m Cytokeratin 8 released by breast carcinoma cells in vitro binds plasminogen and tissue-type plasminogen activator and promotes plasminogen activation. causal interaction,ongoing research,therapeutic application,unassigned 4,4,2,0 3.4.21.7 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8810346&form=6&db=m Cell-surface cytokeratin 8 is the major plasminogen receptor on breast cancer cells and is required for the accelerated activation of cell-associated plasminogen by tissue-type plasminogen activator. causal interaction,ongoing research,therapeutic application,unassigned 3,4,4,0 3.4.21.7 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8822115&form=6&db=m Clinicopathologic analysis of macrophage infiltrates in breast carcinoma. diagnostic usage,ongoing research,unassigned 3,1,0 3.4.21.7 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9142977&form=6&db=m Overview on human breast cancer with focus on prognostic and predictive factors with special attention on the tumour suppressor gene p53. diagnostic usage,therapeutic application,unassigned 1,4,0 3.4.21.7 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9176711&form=6&db=m A sensitive and robust assay for urokinase and tissue-type plasminogen activators (uPA and tPA) and their inhibitor type I (PAI-1) in breast tumor cytosols. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,1 3.4.21.7 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9233831&form=6&db=m Plasmin induces the formation of multicellular spheroids of breast cancer cells. causal interaction,diagnostic usage,ongoing research,unassigned 1,3,3,0 3.4.21.7 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9493971&form=6&db=m Low cathepsin D and low plasminogen activator type 1 inhibitor in tumor cytosols defines a group of node negative breast cancer patients with low risk of recurrence. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,4,4 3.4.21.7 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9568641&form=6&db=m The influence of antiestrogens on the release of plasminogen activator (uPA) by MDA-MB-231 and MCF-7 breast cancer cells. causal interaction,ongoing research,unassigned 4,4,0 3.4.21.7 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9635833&form=6&db=m Increased plasminogen binding is associated with metastatic breast cancer cells: differential expression of plasminogen binding proteins. causal interaction,diagnostic usage,ongoing research,unassigned 4,1,4,0 3.4.21.7 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9662256&form=6&db=m Oestradiol regulation of the components of the plasminogen-plasmin system in MDA-MB-231 human breast cancer cells stably expressing the oestrogen receptor. ongoing research,therapeutic application,unassigned 3,2,0 3.4.21.7 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9815678&form=6&db=m Plasminogen activator inhibitor type 1 in cytosolic tumor extracts predicts prognosis in low-risk breast cancer patients. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,3,1 3.4.21.7 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9816210&form=6&db=m Proteases as prognostic markers in cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,3,0 3.4.21.7 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9853425&form=6&db=m Prognosis and prediction of response in breast cancer: the current role of the main biological markers. diagnostic usage,unassigned 4,0 3.4.21.7 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10066075&form=6&db=m The urokinase plasminogen activator system as a target for prognostic studies in breast cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,2 3.4.21.7 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10085135&form=6&db=m Angiostatin formation involves disulfide bond reduction and proteolysis in kringle 5 of plasmin. ongoing research,unassigned 3,0 3.4.21.7 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10087312&form=6&db=m HER-2/neu gene amplification by fluorescence in situ hybridization allows risk-group assessment in node-negative breast cancer. diagnostic usage,ongoing research,unassigned 4,2,0 3.4.21.7 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10090848&form=6&db=m Role of urokinase plasminogen activator receptor in thrombospondin 1-mediated tumor cell invasion. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,3,3,2 3.4.21.7 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10225451&form=6&db=m ELISA for complexes of urokinase-type and tissue-type plasminogen activators with their type-1 inhibitor (uPA-PAI-1 and tPA-PAI-1). causal interaction,diagnostic usage,therapeutic application,unassigned 4,1,4,0 3.4.21.7 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10390010&form=6&db=m Prognostic value of tissue-type plasminogen activator (tPA) and its complex with the type-1 inhibitor (PAI-1) in breast cancer. diagnostic usage,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.7 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10487126&form=6&db=m [The clinical prospects for the study of the plasminogen activation system in breast cancer] causal interaction,diagnostic usage,ongoing research,unassigned 4,3,3,0 3.4.21.7 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10602713&form=6&db=m Synthesis and biological evaluation of novel prodrugs of anthracyclines for selective activation by the tumor-associated protease plasmin. ongoing research,unassigned 3,0 3.4.21.7 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10676647&form=6&db=m The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,1,0 3.4.21.7 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10704735&form=6&db=m Correlation of tissue and blood plasminogen activation system in breast cancer. causal interaction,ongoing research,therapeutic application,unassigned 3,3,2,0 3.4.21.7 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10763145&form=6&db=m Tumor-biological factors uPA and PAI-1 as stratification criteria of a multicenter adjuvant chemotherapy trial in node-negative breast cancer. causal interaction,ongoing research,therapeutic application,unassigned 3,2,4,0 3.4.21.7 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10763146&form=6&db=m Long-term follow-up confirms prognostic impact of PAI-1 and cathepsin D and L in primary breast cancer. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.7 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10766865&form=6&db=m Urokinase plasminogen activator/urokinase-specific surface receptor expression and matrix invasion by breast cancer cells requires constitutive p38alpha mitogen-activated protein kinase activity. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,3,1 3.4.21.7 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10770639&form=6&db=m Reduction of breast carcinoma tumor growth and lung colonization by overexpression of the soluble urokinase-type plasminogen activator receptor (CD87). causal interaction,unassigned 4,0 3.4.21.7 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10878926&form=6&db=m [The immunoenzyme determination of plasminogen activators and their inhibitor in breast tumors: the connection to clinico-morphological prognostic factors] diagnostic usage,ongoing research,unassigned 2,1,0 3.4.21.7 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10934293&form=6&db=m Tissue urokinase-type plasminogen activator receptor levels in breast cancer. diagnostic usage,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.7 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11245436&form=6&db=m Up-regulation of urokinase-type plasminogen activator by insulin-like growth factor-I depends upon phosphatidylinositol-3 kinase and mitogen-activated protein kinase kinase. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,1,4 3.4.21.7 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11352966&form=6&db=m Functional evaluation of plasmin formation in primary breast cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,1,1 3.4.21.7 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11556845&form=6&db=m The topology of plasminogen binding and activation on the surface of human breast cancer cells. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,4,1 3.4.21.7 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11689350&form=6&db=m Cytokeratin 8 functions as a major plasminogen receptor in select epithelial and carcinoma cells. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,2,3 3.4.21.7 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11956644&form=6&db=m Clinical implications of urokinase and tissue type plasminogen activators and their inhibitor (PAI-1) in breast cancer tissue. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,4,2 3.4.21.7 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12198113&form=6&db=m Regulation of DNA methylation in human breast cancer. Effect on the urokinase-type plasminogen activator gene production and tumor invasion. causal interaction,ongoing research,unassigned 4,2,0 3.4.21.7 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12230559&form=6&db=m Inhibition of human MDA-MB-231 breast cancer cell invasion by matrix metalloproteinase 3 involves degradation of plasminogen. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,1,4,2 3.4.21.7 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12354933&form=6&db=m Expression of proteinases and inhibitors in human breast cancer progression and survival. diagnostic usage,ongoing research,therapeutic application,unassigned 3,3,1,0 3.4.21.7 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12853975&form=6&db=m Metastasis of transgenic breast cancer in plasminogen activator inhibitor-1 gene-deficient mice. causal interaction,ongoing research,therapeutic application,unassigned 4,2,1,0 3.4.21.7 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14535592&form=6&db=m Limited prognostic value of c-erbB-2 compared to uPA and PAI-1 in primary breast carcinoma. diagnostic usage,ongoing research,unassigned 3,2,0 3.4.21.7 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14744782&form=6&db=m Predictive impact of urokinase-type plasminogen activator: plasminogen activator inhibitor type-1 complex on the efficacy of adjuvant systemic therapy in primary breast cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,4,2,4 3.4.21.7 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15333188&form=6&db=m Evidence for the clinical use of tumour markers. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,4 3.4.21.7 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15472905&form=6&db=m Reduced metastasis of transgenic mammary cancer in urokinase-deficient mice. causal interaction,unassigned 4,0 3.4.21.7 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15701164&form=6&db=m Human breast cancer cell-mediated bone collagen degradation requires plasminogen activation and matrix metalloproteinase activity. causal interaction,ongoing research,therapeutic application,unassigned 4,2,1,0 3.4.21.7 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15789064&form=6&db=m Full kringles of plasminogen (aa 1-566) mediate complete regression of human MDA-MB-231 breast tumor xenografted in nude mice. causal interaction,ongoing research,therapeutic application,unassigned 3,3,1,0 3.4.21.7 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16266990&form=6&db=m Proteolysis of CCN1 by plasmin: functional implications. causal interaction,therapeutic application,unassigned 4,2,0 3.4.21.7 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16643892&form=6&db=m Angiogenesis-associated protein annexin II in breast cancer: Selective expression in invasive breast cancer and contribution to tumor invasion and progression. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,1,0 3.4.21.7 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16945123&form=6&db=m Prognostic significance of urokinase plasminogen activator and plasminogen activator inhibitor-1 mRNA expression in lymph node- and hormone receptor-positive breast cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,2,2 3.4.21.7 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17257442&form=6&db=m Plasminogen binding and activation at the breast cancer cell surface: the integral role of urokinase activity. causal interaction,unassigned 2,0 3.4.21.7 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17290405&form=6&db=m Stromal cells associated with early invasive foci in human mammary ductal carcinoma in situ coexpress urokinase and urokinase receptor. causal interaction,ongoing research,unassigned 4,2,0 3.4.21.7 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18030361&form=6&db=m PEGylated DX-1000: pharmacokinetics and antineoplastic activity of a specific plasmin inhibitor. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,4,0 3.4.21.7 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18289119&form=6&db=m Peptides and small molecules targeting the plasminogen activation system: towards prophylactic anti-metastasis drugs for breast cancer. therapeutic application,unassigned 3,0 3.4.21.7 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18433993&form=6&db=m Monoclonal antibody to cytokeratin VKIALEVEIATY sequence motif reduces plasminogen activation in breast tumour cells. ongoing research,unassigned 4,0 3.4.21.7 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19042984&form=6&db=m National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,4,0 3.4.21.7 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19199430&form=6&db=m Pathway-Based Biomarker Search by High-Throughput Proteomics Profiling of Secretomes. causal interaction,unassigned 1,0 3.4.21.7 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19205379&form=6&db=m [The concentration of tissue--type plasminogen activator (t-PA) in extracts of breast cancer tissue] causal interaction,ongoing research,unassigned 3,3,0 3.4.21.7 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19845941&form=6&db=m Cytokeratin 8 ectoplasmic domain binds urokinase-type plasminogen activator to breast tumor cells and modulates their adhesion, growth and invasiveness. causal interaction,ongoing research,unassigned 4,2,0 3.4.21.7 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20065179&form=6&db=m Systemic fibrinolysis caused by tissue plasminogen activator-producing metastatic breast cancer. causal interaction,unassigned 2,0 3.4.21.7 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20079732&form=6&db=m Breast cancer cell surface annexin II induces cell migration and neoangiogenesis via tPA dependent plasmin generation. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,4,3 3.4.21.7 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20383413&form=6&db=m Silencing of the annexin II gene down-regulates the levels of S100A10, c-Myc, and plasmin and inhibits breast cancer cell proliferation and invasion. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,4,4 3.4.21.7 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20406904&form=6&db=m microRNA 17/20 inhibits cellular invasion and tumor metastasis in breast cancer by heterotypic signaling. unassigned - 3.4.21.7 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20858014&form=6&db=m Sialylated Lewis x Antigen Bearing Glycoproteins in Human Plasma. causal interaction,unassigned 1,0 3.4.21.7 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21391216&form=6&db=m Profiling signalling pathways in formalin-fixed and paraffin-embedded breast cancer tissues reveals cross-talk between EGFR, HER2, HER3 and uPAR. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,3,3,1 3.4.21.7 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21594500&form=6&db=m Immunolocalization of the components of the plasminogen activating system in breast carcinoma tissue. diagnostic usage,unassigned 3,0 3.4.21.7 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22044461&form=6&db=m Antibody-directed neutralization of annexin II (ANX II) inhibits neoangiogenesis and human breast tumor growth in a xenograft model. ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.7 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22348918&form=6&db=m Sanguisorba minor extract suppresses plasmin-mediated mechanisms of cancer cell migration. diagnostic usage,ongoing research,therapeutic application,unassigned 3,4,1,0 3.4.21.7 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22467324&form=6&db=m Expression of urokinase-type plasminogen activator (uPA), its receptor (uPAR), and inhibitor (PAI-1) in human breast carcinomas and their clinical relevance. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,4,1 3.4.21.7 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22677171&form=6&db=m Alendronate promotes plasmin-mediated MMP-9 inactivation by exposing cryptic plasmin degradation sites within the MMP-9 catalytic domain. causal interaction,ongoing research,therapeutic application,unassigned 4,3,4,0 3.4.21.7 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22996753&form=6&db=m Spontaneous metastasis in congenic mice with transgenic breast cancer is unaffected by plasminogen gene ablation. causal interaction,ongoing research,therapeutic application,unassigned 4,2,1,0 3.4.21.7 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23400595&form=6&db=m Targeting uPAR with Antagonistic Recombinant Human Antibodies in Aggressive Breast Cancer. causal interaction,ongoing research,unassigned 3,4,0 3.4.21.7 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24026424&form=6&db=m Cathepsin D stimulates the activities of secreted plasminogen activators in the breast cancer acidic environment. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,4,1 3.4.21.7 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24112688&form=6&db=m Synthetic substrates specific to activated plasmin can monitor the enzymatic functional status in situ in breast cancer cells. diagnostic usage,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.7 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24457100&form=6&db=m Angiogenin interacts with the plasminogen activation system at the cell surface of breast cancer cells to regulate plasmin formation and cell migration. causal interaction,ongoing research,unassigned 4,3,0 3.4.21.7 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24581498&form=6&db=m Serpins promote cancer cell survival and vascular co-option in brain metastasis. diagnostic usage,ongoing research,therapeutic application,unassigned 3,3,2,0 3.4.21.7 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25212966&form=6&db=m Interleukin-like epithelial-to-mesenchymal transition inducer activity is controlled by proteolytic processing and plasminogen-urokinase plasminogen activator receptor system-regulated secretion during breast cancer progression. diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.7 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25641046&form=6&db=m Urokinase is a negative modulator of Egf-dependent proliferation and motility in the two breast cancer cell lines MCF-7 and MDA-MB-231. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.7 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27221823&form=6&db=m Activated thrombin-activatable fibrinolysis inhibitor (TAFIa) attenuates breast cancer cell metastatic behaviors through inhibition of plasminogen activation and extracellular proteolysis. causal interaction,ongoing research,therapeutic application,unassigned 2,4,2,0 3.4.21.7 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28228690&form=6&db=m Human cytomegalovirus interleukin-10 enhances matrigel invasion of MDA-MB-231 breast cancer cells. causal interaction,diagnostic usage,therapeutic application,unassigned 3,3,2,0 3.4.21.7 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28524122&form=6&db=m [A plasminogen regulation system in brain tumors]. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,4,2,1 3.4.21.7 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28545187&form=6&db=m Enterolactone Suppresses Proliferation, Migration and Metastasis of MDA-MB-231 Breast Cancer Cells Through Inhibition of uPA Induced Plasmin Activation and MMPs-Mediated ECM Remodeling causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28612231&form=6&db=m Epsilon-aminocaproic acid prevents high glucose and insulin induced-invasiveness in MDA-MB-231 breast cancer cells, modulating the plasminogen activator system. causal interaction,ongoing research,therapeutic application,unassigned 3,4,2,0 3.4.21.7 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28924209&form=6&db=m HMGA1 regulates the Plasminogen activation system in the secretome of breast cancer cells. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.7 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30524164&form=6&db=m Correlation of Serum Levels of Urokinase Activation Plasminogen (uPA) and Its Inhibitor (PAI-1) with Hormonal and HER-2 Status in the Early Invasive Breast Cancer. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.7 Bronchiectasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9493662&form=6&db=m Potentiative effects of neutral proteinases in an inflamed lung: relationship of neutrophil procollagenase (proMMP-8) to plasmin, cathepsin G and tryptase in bronchiectasis in vivo. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,3,1 3.4.21.7 Bronchiolitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11931777&form=6&db=m Effective treatment of ligneous conjunctivitis with topical plasminogen. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,4,0 3.4.21.7 Bronchitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1475923&form=6&db=m [Plasminogen activators in assessing the reaction of patients with chronic obstructive bronchitis to physical loading] causal interaction,diagnostic usage,unassigned 1,3,0 3.4.21.7 Budd-Chiari Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9566843&form=6&db=m Post-traumatic membranous obstruction of the inferior vena cava associated with a hypercoagulable state. causal interaction,unassigned 3,0 3.4.21.7 Bundle-Branch Block http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8559200&form=6&db=m Electrocardiographic diagnosis of evolving acute myocardial infarction in the presence of left bundle-branch block. GUSTO-1 (Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries) Investigators. causal interaction,diagnostic usage,therapeutic application,unassigned 1,3,2,0 3.4.21.7 Bundle-Branch Block http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9426026&form=6&db=m Acute myocardial infarction and complete bundle branch block at hospital admission: clinical characteristics and outcome in the thrombolytic era. GUSTO-I Investigators. Global Utilization of Streptokinase and t-PA [tissue-type plasminogen activator] for Occluded Coronary Arteries. causal interaction,diagnostic usage,therapeutic application,unassigned 1,2,1,0 3.4.21.7 Bundle-Branch Block http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9725961&form=6&db=m [Fibrinolysis or angioplasty in acute myocardial infarction?] causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.7 Carcinogenesis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1955118&form=6&db=m Imbalance of plasminogen activators and their inhibitors in human colorectal neoplasia. Implications of urokinase in colorectal carcinogenesis. causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,2,0 3.4.21.7 Carcinogenesis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2290690&form=6&db=m [Endothelial cell proteases and their modulation by platelets] causal interaction,unassigned 4,0 3.4.21.7 Carcinogenesis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7577001&form=6&db=m Prognostic value of plasminogen activators and their inhibitors in colorectal cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,3,0 3.4.21.7 Carcinogenesis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7597708&form=6&db=m Post-transcriptional stabilization of urokinase plasminogen activator mRNA by 2,3,7,8-tetrachlorodibenzo-p-dioxin in a human keratinocyte cell line. causal interaction,unassigned 4,0 3.4.21.7 Carcinogenesis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7841059&form=6&db=m Plasminogen activators and inhibitor type 1 in neoplastic colonic tissue from patients with familial adenomatous polyposis. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,4,0 3.4.21.7 Carcinogenesis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7860221&form=6&db=m Increased urokinase receptor levels in human gastrointestinal neoplasia and related liver metastases. causal interaction,diagnostic usage,ongoing research,unassigned 2,1,3,0 3.4.21.7 Carcinogenesis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8033138&form=6&db=m Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,4,0 3.4.21.7 Carcinogenesis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10645173&form=6&db=m The molecular biology of colorectal cancer development and the associated genetic events. ongoing research,unassigned 3,0 3.4.21.7 Carcinogenesis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10816376&form=6&db=m Helicobacter pylori interactions with plasminogen. causal interaction,diagnostic usage,therapeutic application,unassigned 3,3,1,0 3.4.21.7 Carcinogenesis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18495253&form=6&db=m The plasminogen activator inhibitor "paradox" in cancer. causal interaction,therapeutic application,unassigned 4,3,0 3.4.21.7 Carcinogenesis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19245822&form=6&db=m Generation and characterization of transgenic mice hyper-expressing melanoma tumour antigen p97 (Melanotransferrin): No overt alteration in phenotype. causal interaction,unassigned 2,0 3.4.21.7 Carcinogenesis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19297327&form=6&db=m Active Plasma Kallikrein Localizes to Mast Cells and Regulates Epithelial Cell Apoptosis, Adipocyte Differentiation, and Stromal Remodeling during Mammary Gland Involution. causal interaction,therapeutic application,unassigned 3,3,0 3.4.21.7 Carcinogenesis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20549826&form=6&db=m SERPINE1 intron polymorphisms affecting gene expression are associated with diffuse-type gastric cancer susceptibility. causal interaction,therapeutic application,unassigned 3,3,0 3.4.21.7 Carcinogenesis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21191179&form=6&db=m Downregulation of uPAR inhibits migration, invasion, proliferation, FAK/PI3K/Akt signaling and induces senescence in papillary thyroid carcinoma cells. causal interaction,unassigned 3,0 3.4.21.7 Carcinogenesis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22593463&form=6&db=m The interplay between hemostasis and malignancy: the oral cancer paradigm. causal interaction,unassigned 3,0 3.4.21.7 Carcinogenesis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23118506&form=6&db=m The biochemistry and regulation of S100A10: a multifunctional plasminogen receptor involved in oncogenesis. therapeutic application,unassigned 1,0 3.4.21.7 Carcinogenesis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23594883&form=6&db=m Three are better than one: plasminogen receptors as cancer theranostic targets. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,3,0 3.4.21.7 Carcinogenesis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25525855&form=6&db=m On the contribution of S100A10 and annexin A2 to plasminogen activation and oncogenesis: an enduring ambiguity. therapeutic application,unassigned 1,0 3.4.21.7 Carcinogenesis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25767491&form=6&db=m Tissue plasminogen activator-independent roles of neuroserpin in the central nervous system. causal interaction,unassigned 2,0 3.4.21.7 Carcinogenesis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27935848&form=6&db=m Plasmin(ogen) serves as a favorable biomarker for prediction of survival in advanced high-grade serous ovarian cancer. diagnostic usage,unassigned 1,0 3.4.21.7 Carcinogenesis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28501622&form=6&db=m The role of plasmin in the pathogenesis of murine multiple myeloma. causal interaction,ongoing research,unassigned 4,2,0 3.4.21.7 Carcinogenesis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28612231&form=6&db=m Epsilon-aminocaproic acid prevents high glucose and insulin induced-invasiveness in MDA-MB-231 breast cancer cells, modulating the plasminogen activator system. causal interaction,ongoing research,therapeutic application,unassigned 3,4,2,0 3.4.21.7 Carcinogenesis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31218131&form=6&db=m Global transcriptomic analysis identifies SERPINE1 as a prognostic biomarker associated with epithelial-to-mesenchymal transition in gastric cancer. causal interaction,diagnostic usage,ongoing research,unassigned 2,1,2,0 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=133760&form=6&db=m Androgen-dependent fibrinolytic activity in a murine mammary carcinoma (Shionogi SC-115 cells) in vitro. ongoing research,unassigned 1,0 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=144345&form=6&db=m Fibrinolytic activity of in vitro cultivated human bladder cell lines. diagnostic usage,ongoing research,unassigned 3,4,0 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=152655&form=6&db=m An inhibitor from placenta specifically binds urokinase and inhibits plasminogen activator released from ovarian carcinoma in tissue culture. ongoing research,unassigned 4,0 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1312064&form=6&db=m Visualization of the plasmin receptor on carcinoma cells. ongoing research,therapeutic application,unassigned 4,1,0 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1322156&form=6&db=m Plasminogen receptors on rat colon carcinoma cells. diagnostic usage,ongoing research,unassigned 1,4,0 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1478614&form=6&db=m Specific stimulation by estradiol of tissue-type plasminogen activator production in 7,12-dimethylbenz[a]anthracene-induced rat mammary tumor cells. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,1,4,1 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1648562&form=6&db=m Cell signalling associated with fibrinolytic ligand binding to human colorectal carcinoma cells. diagnostic usage,ongoing research,unassigned 3,3,0 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1665926&form=6&db=m A receptor for plasminogen and plasmin on human and rat carcinoma cells. Evidence for strong interspecific reactivity. ongoing research,unassigned 4,0 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1764272&form=6&db=m Relationship between plasminogen activators and stomach carcinoma stage. diagnostic usage,ongoing research,unassigned 2,4,0 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2109745&form=6&db=m Plasminogen activator inhibitor-type 1 in Lewis lung carcinoma. causal interaction,diagnostic usage,ongoing research,unassigned 4,1,3,0 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2139349&form=6&db=m Role of plasmin in the degradation of the stroma-derived fibrin in human ovarian carcinoma. causal interaction,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2141196&form=6&db=m A comparative study of the localization of plasminogen and apolipoprotein(a) in human carcinomas. ongoing research,unassigned 4,0 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2142433&form=6&db=m Plasminogen activator mediated degradation of subendothelial extracellular matrix by human squamous carcinoma cell lines. causal interaction,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2169614&form=6&db=m Plasminogen-activator inhibitor type 1 is a potent natural inhibitor of extracellular matrix degradation by fibrosarcoma and colon carcinoma cells. ongoing research,unassigned 4,0 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2170280&form=6&db=m The presence of plasmin receptors on three mammary carcinoma MCF-7 sublines. diagnostic usage,ongoing research,unassigned 3,1,0 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2448891&form=6&db=m Effect of urokinase on the proliferation of primary cultures of human prostatic cells. ongoing research,unassigned 4,0 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2492025&form=6&db=m Simultaneous stimulation of urokinase and tissue-type plasminogen activators by phorbol esters in human ovarian carcinoma cells. ongoing research,unassigned 4,0 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2497975&form=6&db=m Regulation by epidermal growth factor of human squamous cell carcinoma plasminogen activator-mediated proteolysis of extracellular matrix. ongoing research,unassigned 4,0 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2500590&form=6&db=m Different mechanisms contribute to simultaneous inhibition of urokinase and tissue-type plasminogen activators by glucocorticoids in human ovarian carcinoma cells. causal interaction,ongoing research,unassigned 1,3,0 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2555056&form=6&db=m Synthesis and secretion of plasminogen activators and plasminogen activator inhibitors in cell lines of different groups of human lung tumors. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,3,4,4 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2838642&form=6&db=m Receptor for plasmin on human carcinoma cells. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,4,1 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2938648&form=6&db=m Analysis of elevated fibrin(ogen) degradation product levels in patients with liver disease. causal interaction,diagnostic usage,ongoing research,unassigned 3,2,1,0 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3091899&form=6&db=m Human primary colon carcinomas xenografted into nude mice. I. Characterization of plasminogen activators expressed by primary tumors and their xenografts. causal interaction,diagnostic usage,ongoing research,unassigned 1,3,4,0 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3095580&form=6&db=m Human primary colon carcinomas xenografted into nude mice. II. Modulation of tumor plasminogen activator activity by the host tissue environment. causal interaction,diagnostic usage,ongoing research,unassigned 1,3,4,0 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3098408&form=6&db=m Glucocorticoid modulation of plasminogen activators and of one of their inhibitors in the human mammary carcinoma cell line MDA-MB-231. causal interaction,therapeutic application,unassigned 1,3,0 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3117361&form=6&db=m Glucocorticoid sensitivity of OVCA 433 human ovarian carcinoma cells: inhibition of plasminogen activators, cell growth, and morphological alterations. ongoing research,unassigned 4,0 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3180347&form=6&db=m Mitogenic effect of urokinase on malignant and unaffected adjacent human renal cells. diagnostic usage,ongoing research,unassigned 3,4,0 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3410341&form=6&db=m Plasminogen activator secretion by established lines of human ovarian carcinoma cells in vitro. diagnostic usage,ongoing research,unassigned 1,4,0 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3434279&form=6&db=m Plasminogen activators in human xenografted oro-pharyngeal squamous cell carcinomas. diagnostic usage,ongoing research,therapeutic application,unassigned 3,3,1,0 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3855489&form=6&db=m Proteolytic enzymes in tumor metastasis. I. Plasminogen activator in clones of Lewis lung carcinoma and T10 sarcoma. diagnostic usage,ongoing research,unassigned 1,3,0 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4220790&form=6&db=m Alterations in fibrinogen, plasminogen, and inhibitors of plasmin with the growth of V2 carcinoma in rabbits. unassigned - 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6237065&form=6&db=m Characterization of plasminogen activators from normal human breast and colon and from breast and colon carcinomas. diagnostic usage,ongoing research,unassigned 3,4,0 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6423277&form=6&db=m A model for human colon carcinoma evolution based on the differential response of cultured preneoplastic, premalignant, and malignant cells to 12-O-tetradecanoylphorbol-13-acetate. causal interaction,diagnostic usage,ongoing research,unassigned 1,3,3,0 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6452764&form=6&db=m [Behavior of plasminogen in prostatic carcinoma treated with cytonal] causal interaction,diagnostic usage,therapeutic application,unassigned 2,4,1,0 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7011240&form=6&db=m Protease and antiprotease concentrations in serum and vaginal fluid of patients with carcinoma of the cervix. causal interaction,diagnostic usage,unassigned 4,2,0 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7192176&form=6&db=m Isolation and spontaneous transformation of cloned lines of hamster tracheal epithelial cells. unassigned - 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7558669&form=6&db=m Immunocytochemical localization of plasminogen activators in carcinomas in the cervix and vulva. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,2,1 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7639718&form=6&db=m Bound plasminogen is rate-limiting for cell-surface-mediated activation of plasminogen by urokinase. ongoing research,unassigned 4,0 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7657515&form=6&db=m Laminin degradation by human colon carcinoma cells: a role for urinary and tissue plasminogen activators. causal interaction,ongoing research,unassigned 3,4,0 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7677931&form=6&db=m Visualization of the plasmin receptor on sections of human mammary carcinoma cells. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,4,2 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7686838&form=6&db=m Immunohistochemical study of tumor cell-associated plasminogen activators and plasminogen activator inhibitors in lung carcinomas. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,4,4 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7707177&form=6&db=m [Immunohistological study of fibrinolytic factors of head and neck squamous cell carcinomas] unassigned - 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7841059&form=6&db=m Plasminogen activators and inhibitor type 1 in neoplastic colonic tissue from patients with familial adenomatous polyposis. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,4,0 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7860221&form=6&db=m Increased urokinase receptor levels in human gastrointestinal neoplasia and related liver metastases. causal interaction,diagnostic usage,ongoing research,unassigned 2,1,3,0 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7864083&form=6&db=m Characterization of plasminogen system on rat yolk sac carcinoma (L2) cells. diagnostic usage,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7882614&form=6&db=m Effects of suramin on metastatic ability, proliferation, and production of urokinase-type plasminogen activator and plasminogen activator inhibitor type 2 in human renal cell carcinoma cell line SN12C-PM6. causal interaction,ongoing research,therapeutic application,unassigned 2,4,2,0 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7926508&form=6&db=m Inactive urokinase and increased levels of its inhibitor type 1 in colorectal cancer liver metastasis. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,4,2 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7962113&form=6&db=m Human Co115 colon carcinoma cells potentiate the degradation of laminin mediated by tissue-type plasminogen activator. causal interaction,ongoing research,unassigned 3,4,0 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8074827&form=6&db=m In vitro urokinase type plasminogen activator levels and total plasminogen activator activity in squamous cell carcinomas of the head and neck. causal interaction,diagnostic usage,ongoing research,unassigned 3,4,4,0 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8112891&form=6&db=m Secretion of extracellular matrix-degrading proteinases is increased in epithelial ovarian carcinoma. diagnostic usage,ongoing research,unassigned 3,2,0 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8237943&form=6&db=m Expression of plasminogen activators and their inhibitors in human pancreatic carcinoma: immunohistochemical study. causal interaction,diagnostic usage,ongoing research,unassigned 1,1,4,0 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8331683&form=6&db=m Tumor cell procoagulant and urokinase expression in carcinoma of the ovary. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,3,4 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8432457&form=6&db=m Plasminogen activators in normal tissue and carcinomas of the human oesophagus and stomach. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,1,4,2 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8595156&form=6&db=m Genes related to growth and invasiveness are repressed by sodium butyrate in ovarian carcinoma cells. causal interaction,unassigned 1,0 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8635120&form=6&db=m Prognostic value of the plasminogen activation system in patients with gastric carcinoma. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,1 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8756739&form=6&db=m [Levels of plasminogen and alpha 2-antiplasmin in blood of patients with prostatic tumor] causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,1 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8756741&form=6&db=m [Tissue type plasminogen activator and its inhibition in blood of patients operated on for prostatic carcinoma] causal interaction,diagnostic usage,ongoing research,unassigned 4,2,4,0 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8778334&form=6&db=m Expression of plasminogen activators in basal cell carcinoma. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,4,1 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8826848&form=6&db=m Modulation of the plasminogen activation system by inflammatory cytokines in human colon carcinoma cells. causal interaction,ongoing research,therapeutic application,unassigned 1,4,1,0 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8845643&form=6&db=m Proteinase activity in invasive cancer of the breast. Correlation with tumor progression. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,1 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8869332&form=6&db=m Plasminogen activators in oesophageal carcinoma. causal interaction,diagnostic usage,ongoing research,unassigned 1,3,4,0 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8895739&form=6&db=m Human prostate carcinoma cells express enzymatic activity that converts human plasminogen to the angiogenesis inhibitor, angiostatin. diagnostic usage,ongoing research,therapeutic application,unassigned 3,4,1,0 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9023404&form=6&db=m Endothelial and macrophage upregulation of urokinase receptor expression in human renal cell carcinoma. causal interaction,ongoing research,unassigned 4,4,0 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9311602&form=6&db=m Surface-bound plasmin induces selective proteolysis of insulin-like-growth-factor (IGF)-binding protein-4 (IGFBP-4) and promotes autocrine IGF-II bio-availability in human colon-carcinoma cells. causal interaction,ongoing research,unassigned 1,2,0 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9323150&form=6&db=m Localization of plasminogen activators and their inhibitor in squamous cell carcinomas of the head and neck. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,4,1 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9373263&form=6&db=m Growth and dissemination of Lewis lung carcinoma in plasminogen-deficient mice. causal interaction,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9380726&form=6&db=m The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin. ongoing research,therapeutic application,unassigned 3,1,0 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9454902&form=6&db=m The expression of urokinase-related genes in superficial and invasive transitional cell carcinoma. ongoing research,unassigned 3,0 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9698533&form=6&db=m Angiostatin generation by human pancreatic cancer. ongoing research,unassigned 4,0 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9863356&form=6&db=m [Disseminated intravascular coagulation and hyperfibrinolysis in dogs with metastasizing mammary carcinoma] diagnostic usage,unassigned 2,0 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9872599&form=6&db=m Plasminogen activator system modulates invasive capacity and proliferation in prostatic tumor cells. causal interaction,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10085135&form=6&db=m Angiostatin formation involves disulfide bond reduction and proteolysis in kringle 5 of plasmin. ongoing research,unassigned 3,0 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10094378&form=6&db=m Urokinase and plasminogen activator-inhibitor (PAI-1) status in primary ovarian carcinomas and ovarian metastases compared to benign ovarian tumors as a function of histopathological parameters. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,3,0 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10340041&form=6&db=m Immunohistochemical analysis of PAI-2 (plasminogen activator inhibitor type 2) and p53 protein in early gastric cancer patients with recurrence: a preliminary report. unassigned - 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10390151&form=6&db=m Invasion by esophageal cancer cells: functional contribution of the urokinase plasminogen activation system, and inhibition by antisense oligonucleotides to urokinase or urokinase receptor. causal interaction,ongoing research,therapeutic application,unassigned 4,3,2,0 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10473828&form=6&db=m Proteolytic patterns of head and neck squamous cell carcinoma. causal interaction,diagnostic usage,ongoing research,unassigned 4,1,2,0 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10521987&form=6&db=m Urokinase-type plasminogen activator and plasminogen activator inhibitor-1 as a prognostic factor in human colorectal carcinomas. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,1 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10666386&form=6&db=m Cellular distribution and clinical value of urokinase-type plasminogen activator, its receptor, and plasminogen activator inhibitor-2 in esophageal squamous cell carcinoma. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,4,1 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10986284&form=6&db=m Angiostatin generation by cathepsin D secreted by human prostate carcinoma cells. causal interaction,diagnostic usage,ongoing research,unassigned 3,3,3,0 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10987285&form=6&db=m The surface of prostate carcinoma DU145 cells mediates the inhibition of urokinase-type plasminogen activator by maspin. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,3,0 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11422178&form=6&db=m Phosphatidylinositol-specific-phospholipase C cleaves urokinase plasminogen activator receptor from the cell surface and leads to inhibition of pemphigus-IgG-induced acantholysis in DJM-1 cells, a squamous cell carcinoma line. causal interaction,ongoing research,unassigned 4,4,0 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11555588&form=6&db=m The accumulation of angiostatin-like fragments in human prostate carcinoma. diagnostic usage,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11689350&form=6&db=m Cytokeratin 8 functions as a major plasminogen receptor in select epithelial and carcinoma cells. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,2,3 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11776308&form=6&db=m Localization of blood coagulation factors in situ in pancreatic carcinoma. causal interaction,ongoing research,therapeutic application,unassigned 3,3,1,0 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11928818&form=6&db=m Osteopontin modulates prostate carcinoma invasive capacity through RGD-dependent upregulation of plasminogen activators. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11957260&form=6&db=m Expression of oestrogen and progesterone receptors, Ki-67, p53 and BCL-2 proteins, cathepsin D, urokinase plasminogen activator and urokinase plasminogen activator-receptors in carcinomas of the female breast in an African population. diagnostic usage,ongoing research,therapeutic application,unassigned 3,4,1,0 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12384986&form=6&db=m Inhibition of epidermal growth factor-induced invasion by dexamethasone and AP-1 decoy in human squamous cell carcinoma cell lines. causal interaction,ongoing research,unassigned 3,3,0 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12757937&form=6&db=m Vitronectin in human breast carcinomas. causal interaction,ongoing research,unassigned 1,1,0 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12778766&form=6&db=m [Expression and significance of the urokinase-type plasminogen activator and its inhibitors in squamous cell carcinoma of human larynx] causal interaction,diagnostic usage,ongoing research,therapeutic application 1,3,4,3 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=13383444&form=6&db=m Effect of human plasmin on the toxic effects and growth of blood borne metastatis of the Brown-Pearce carcinoma and the V2 carcinoma of rabbit. ongoing research,unassigned 4,0 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=13509544&form=6&db=m Circulating fibrinolysin in a case of prostatic carcinoma with bony metastases. causal interaction,unassigned 1,0 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=13608345&form=6&db=m Circulating fibrinolysin in carcinoma of the prostate. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=13681662&form=6&db=m Effect of human fibrinolysin on hepatic metastases in simulated colon carcinoma in rats. ongoing research,unassigned 4,0 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14275618&form=6&db=m HEPATIC AND PULMONARY METASTASES FROM A RESECTABLE EXPERIMENTAL CECAL CARCINOMA: THE EFFECT OF HEPATIC PERFUSION WITH NITROGEN MUSTARD COMBINED WITH SYSTEMIC HEPARIN AND FIBRINOLYSIN. ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14644129&form=6&db=m Amiloride and urinary trypsin inhibitor inhibit urothelial cancer invasion. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,4 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14751142&form=6&db=m Plasminogen fragmentation and increased production of extracellular matrix-degrading proteinases are associated with serous epithelial ovarian cancer progression. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,1 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15138855&form=6&db=m [The prognostic importance of urinase type plasminogen activators (uPA) and plasminogen activator inhibitors (PAI-1) in the primary resection of oral squamous cell carcinoma] causal interaction,diagnostic usage,ongoing research,therapeutic application 1,1,3,4 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15138856&form=6&db=m [Comparison of urokinase type plasminogen activators (uPA) and plasminogen activator inhibitors (PAI-1) in primary resection of oral squamous cell carcinoma] causal interaction,diagnostic usage,ongoing research,therapeutic application 2,3,3,4 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15183949&form=6&db=m Prognostic value of uPA, PAI-1, and DNA content in adult renal cell carcinoma. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15509494&form=6&db=m Detection of plasminogen activators in oral cancer by laser capture microdissection combined with zymography. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,2,2,1 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15695395&form=6&db=m Activation of the {beta}-catenin/T-cell-specific transcription factor/lymphoid enhancer factor-1 pathway by plasminogen activators in ECV304 carcinoma cells. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16077918&form=6&db=m Plasminogen activator/plasmin system suppresses cell-cell adhesion of oral squamous cell carcinoma cells via proteolysis of E-cadherin. ongoing research,unassigned 3,0 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16524621&form=6&db=m Annexin 2 and hemorrhagic disorder in vascular intimal carcinomatosis. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,3,2,1 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16643891&form=6&db=m Antibody-directed targeting of angiostatin's receptor annexin II inhibits Lewis Lung Carcinoma tumor growth via blocking of plasminogen activation: Possible biochemical mechanism of angiostatin's action. causal interaction,ongoing research,therapeutic application,unassigned 4,1,4,0 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16826166&form=6&db=m Ganglioside GM3 promotes carcinoma cell proliferation via urokinase plasminogen activator-induced extracellular signal-regulated kinase-independent p70S6 kinase signaling. causal interaction,ongoing research,unassigned 4,2,0 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16928445&form=6&db=m Differential expression of the components of the plasminogen activating system in human thyroid tumour derived cell lines and papillary carcinomas. diagnostic usage,ongoing research,unassigned 3,4,0 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17203182&form=6&db=m Induction of alpha2-antiplasmin inhibits E-cadherin processing mediated by the plasminogen activator/plasmin system, leading to suppression of progression of oral squamous cell carcinoma via upregulation of cell-cell adhesion. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17390074&form=6&db=m Effects of hypoxia and reoxygenation on the expression levels of the urokinase-type plasminogen activator, its inhibitor plasminogen activator inhibitor type-1 and the urokinase-type plasminogen activator receptor in human head and neck tumour cells. causal interaction,ongoing research,therapeutic application,unassigned 3,4,2,0 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17628030&form=6&db=m Synthesis, cleavage profile, and antitumor efficacy of an albumin-binding prodrug of methotrexate that is cleaved by plasmin and cathepsin B. causal interaction,diagnostic usage,unassigned 4,1,0 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17671400&form=6&db=m Effect of reoxygenation on the hypoxia-induced up-regulation of serine protease inhibitor PAI-1 in head and neck cancer cells. causal interaction,ongoing research,therapeutic application,unassigned 3,1,1,0 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17680563&form=6&db=m Combination of human plasminogen kringle 5 with ionizing radiation significantly enhances the efficacy of antitumor effect. ongoing research,unassigned 4,0 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17695432&form=6&db=m S100A10 expression in thyroid neoplasms originating from the follicular epithelium: contribution to the aggressive characteristic of anaplastic carcinoma. unassigned - 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18593366&form=6&db=m Intramuscular electroporation of a plasmid encoding human plasminogen kringle 5 induces growth inhibition of Lewis lung carcinoma in mice. ongoing research,unassigned 3,0 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19836935&form=6&db=m Expression and activation of proteases in co-cultures. causal interaction,ongoing research,unassigned 4,4,0 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21129210&form=6&db=m Type 1 plasminogen activator inhibitor (PAI-1) in clear cell renal cell carcinoma (CCRCC) and its impact on angiogenesis, progression and patient survival after radical nephrectomy. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,4,3,2 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21573478&form=6&db=m Invasive neoplastic uroepithelial cells express high-levels of urokinase receptor and plasminogen receptor, alpha-enolase. causal interaction,unassigned 4,0 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21573587&form=6&db=m Reduction of tumor-associated fibrinolytic-activity by antimetastatic dosages of 2 ru(ii)-dmso complexes in mice bearing lewis lung-carcinoma. causal interaction,ongoing research,therapeutic application,unassigned 1,2,3,0 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21594500&form=6&db=m Immunolocalization of the components of the plasminogen activating system in breast carcinoma tissue. diagnostic usage,unassigned 3,0 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21969814&form=6&db=m Activation of pro-uPA is critical for initial escape from the primary tumor and hematogenous dissemination of human carcinoma cells. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,3,2 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22961872&form=6&db=m Synthesis and evaluation of tripeptidic plasmin inhibitors with nitrile as warhead. causal interaction,diagnostic usage,unassigned 4,1,0 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23261456&form=6&db=m Involvement of plasmin-mediated extracellular activation of progalanin in angiogenesis. causal interaction,ongoing research,unassigned 4,4,0 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24674618&form=6&db=m Expression of tissue factor in canine mammary tumours and correlation with grade, stage and markers of haemostasis and inflammation. causal interaction,diagnostic usage,ongoing research,unassigned 1,1,1,0 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27385000&form=6&db=m uPA/uPAR and SERPINE1 in head and neck cancer: role in tumor resistance, metastasis, prognosis and therapy. therapeutic application,unassigned 2,0 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28614640&form=6&db=m [[Gender Differences in Tissue Cascade of Activation of Plasminogen and PAI-1 in Esophageal Squamous Cell Carcinoma].] causal interaction,diagnostic usage,unassigned 4,1,0 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33488094&form=6&db=m Further Understanding of Urokinase Plasminogen Activator Overexpression in Urothelial Bladder Cancer Progression, Clinical Outcomes and Potential Therapeutic Targets. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,4,0 3.4.21.7 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34161866&form=6&db=m Si113-prodrugs selectively activated by plasmin against hepatocellular and ovarian carcinoma. causal interaction,diagnostic usage,ongoing research,unassigned 3,3,4,0 3.4.21.7 Carcinoma in Situ http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7011240&form=6&db=m Protease and antiprotease concentrations in serum and vaginal fluid of patients with carcinoma of the cervix. causal interaction,diagnostic usage,unassigned 4,2,0 3.4.21.7 Carcinoma, Basal Cell http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8778334&form=6&db=m Expression of plasminogen activators in basal cell carcinoma. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,4,1 3.4.21.7 Carcinoma, Bronchogenic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7686838&form=6&db=m Immunohistochemical study of tumor cell-associated plasminogen activators and plasminogen activator inhibitors in lung carcinomas. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,4,4 3.4.21.7 Carcinoma, Brown-Pearce http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=13383444&form=6&db=m Effect of human plasmin on the toxic effects and growth of blood borne metastatis of the Brown-Pearce carcinoma and the V2 carcinoma of rabbit. ongoing research,unassigned 4,0 3.4.21.7 Carcinoma, Ehrlich Tumor http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=123966&form=6&db=m Proteases during the growth of Ehrlich ascites tumor. I. The fibrinolysin system. diagnostic usage,ongoing research,unassigned 3,4,0 3.4.21.7 Carcinoma, Ehrlich Tumor http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=5832012&form=6&db=m Studies on the fibrinolysis in tumor bearing mice. 3. Demonstration of the plasminogen activator in Ehrlich ascites tumor cells. ongoing research,unassigned 4,0 3.4.21.7 Carcinoma, Ehrlich Tumor http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=13850239&form=6&db=m Action of antibodies and plasmin on Ehrlich ascites tumour cells. diagnostic usage,ongoing research,unassigned 3,4,0 3.4.21.7 Carcinoma, Embryonal http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6231928&form=6&db=m Plasmin regulating system from embryonal carcinoma F9 cells: plasminases A, B and embrinogen. ongoing research,therapeutic application,unassigned 3,1,0 3.4.21.7 Carcinoma, Hepatocellular http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1322401&form=6&db=m Identification and partial characterization by chemical cross-linking of a binding protein for tissue-type plasminogen activator (t-PA) on rat hepatoma cells. A plasminogen activator inhibitor type 1-independent t-PA receptor. ongoing research,therapeutic application,unassigned 4,1,0 3.4.21.7 Carcinoma, Hepatocellular http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2157975&form=6&db=m Cyclic nucleotide regulation of plasminogen activator and plasminogen activator-inhibitor messenger RNAs in rat hepatoma cells. ongoing research,therapeutic application,unassigned 3,1,0 3.4.21.7 Carcinoma, Hepatocellular http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2469009&form=6&db=m Glucocorticoid induction of plasminogen activator and plasminogen activator-inhibitor messenger RNA in rat hepatoma cells. causal interaction,ongoing research,therapeutic application,unassigned 2,4,1,0 3.4.21.7 Carcinoma, Hepatocellular http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2540181&form=6&db=m Catabolism of tissue-type plasminogen activator by the human hepatoma cell line Hep G2. Modulation by plasminogen activator inhibitor type 1. ongoing research,unassigned 4,0 3.4.21.7 Carcinoma, Hepatocellular http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2936742&form=6&db=m Characterization of the dexamethasone-induced inhibitor of plasminogen activator in HTC hepatoma cells. ongoing research,therapeutic application,unassigned 3,2,0 3.4.21.7 Carcinoma, Hepatocellular http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2987382&form=6&db=m Inhibition of plasminogen activators by conditioned medium of human hepatocytes and hepatoma cell line Hep G2. ongoing research,unassigned 4,0 3.4.21.7 Carcinoma, Hepatocellular http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3127913&form=6&db=m Immunoaffinity purification of HTC rat hepatoma cell plasminogen activator-inhibitor-1. ongoing research,therapeutic application,unassigned 3,2,0 3.4.21.7 Carcinoma, Hepatocellular http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3149611&form=6&db=m Cloning and sequencing of cDNA for the rat plasminogen activator inhibitor-1. ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.7 Carcinoma, Hepatocellular http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6308300&form=6&db=m [Clinical studies of serum protease inhibitors in hepatoma] causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,3,4 3.4.21.7 Carcinoma, Hepatocellular http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6461654&form=6&db=m The dexamethasone-induced inhibitor of fibrinolytic activity in hepatoma cells. A cellular product which specifically inhibits plasminogen activation. causal interaction,ongoing research,therapeutic application,unassigned 1,2,1,0 3.4.21.7 Carcinoma, Hepatocellular http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7482438&form=6&db=m Urokinase binding and catabolism by Hep G2 cells is plasminogen activator inhibitor-1 dependent, analogous to interactions of tissue-type plasminogen activator with these cells. ongoing research,unassigned 4,0 3.4.21.7 Carcinoma, Hepatocellular http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7563921&form=6&db=m [Blood coagulation and fibrinolysis in relation to endotoxemia in liver cirrhosis and hepatocellular carcinoma] causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,1,0 3.4.21.7 Carcinoma, Hepatocellular http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9116283&form=6&db=m Regulation of plasminogen gene expression by interleukin-6. ongoing research,unassigned 4,0 3.4.21.7 Carcinoma, Hepatocellular http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9603932&form=6&db=m Cyclic nucleotide regulation of type-1 plasminogen activator-inhibitor mRNA stability in rat hepatoma cells. Identification of cis-acting sequences. ongoing research,unassigned 2,0 3.4.21.7 Carcinoma, Hepatocellular http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9873066&form=6&db=m Cyclic nucleotide regulation of PAI-1 mRNA stability. Identification of cytosolic proteins that interact with an a-rich sequence. unassigned - 3.4.21.7 Carcinoma, Hepatocellular http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11204497&form=6&db=m Dietary administration of tannic acid lowers plasminogen activator activity in the liver of C3H hepatoma bearing male mice. ongoing research,therapeutic application,unassigned 4,1,0 3.4.21.7 Carcinoma, Hepatocellular http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11689350&form=6&db=m Cytokeratin 8 functions as a major plasminogen receptor in select epithelial and carcinoma cells. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,2,3 3.4.21.7 Carcinoma, Hepatocellular http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12412410&form=6&db=m [Enzymatic activity of cathepsin B, cathepsin B and L, plasmin, trypsin and collagenase in hepatocellular carcinoma] diagnostic usage,ongoing research,unassigned 4,4,0 3.4.21.7 Carcinoma, Hepatocellular http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12527708&form=6&db=m HGF, MET, and matrix-related proteases in hepatocellular carcinoma, fibrolamellar variant, cirrhotic and normal liver. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,2,1 3.4.21.7 Carcinoma, Hepatocellular http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16481742&form=6&db=m Kringle 5 of Human Plasminogen Suppresses Hepatocellular Carcinoma Growth Both in Grafted and Xenografted Mice by Anti-Angiogenic Activity. ongoing research,unassigned 3,0 3.4.21.7 Carcinoma, Hepatocellular http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16809420&form=6&db=m Plasminogen fragment K1-5 improves survival in a murine hepatocellular carcinoma model. diagnostic usage,therapeutic application,unassigned 1,4,0 3.4.21.7 Carcinoma, Hepatocellular http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22166587&form=6&db=m Hemostatic Abnormalities in Cirrhosis and Tumor-Related Portal Vein Thrombosis. diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.7 Carcinoma, Hepatocellular http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23300882&form=6&db=m Dual inhibition of plasminogen kringle 5 on angiogenesis and chemotaxis suppresses tumor metastasis by targeting HIF-1? pathway. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,3,2,2 3.4.21.7 Carcinoma, Hepatocellular http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24018669&form=6&db=m Suppression of Plasminogen Activators and the MMP-2/-9 Pathway by a Zanthoxylum avicennae Extract to Inhibit the HA22T Human Hepatocellular Carcinoma Cell Migration and Invasion Effects in Vitro and in Vivo via Phosphatase 2A Activation. ongoing research,unassigned 2,0 3.4.21.7 Carcinoma, Hepatocellular http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24895598&form=6&db=m Plasmid transfer of plasminogen K1-5 reduces subcutaneous hepatoma growth by affecting inflammatory factors. causal interaction,ongoing research,therapeutic application,unassigned 3,3,1,0 3.4.21.7 Carcinoma, Hepatocellular http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28003220&form=6&db=m Recycling of Apolipoprotein(a) After PlgRKT-Mediated Endocytosis of Lipoprotein(a). causal interaction,ongoing research,therapeutic application,unassigned 1,3,1,0 3.4.21.7 Carcinoma, Lewis Lung http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2109745&form=6&db=m Plasminogen activator inhibitor-type 1 in Lewis lung carcinoma. causal interaction,diagnostic usage,ongoing research,unassigned 4,1,3,0 3.4.21.7 Carcinoma, Lewis Lung http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3855489&form=6&db=m Proteolytic enzymes in tumor metastasis. I. Plasminogen activator in clones of Lewis lung carcinoma and T10 sarcoma. diagnostic usage,ongoing research,unassigned 1,3,0 3.4.21.7 Carcinoma, Lewis Lung http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9373263&form=6&db=m Growth and dissemination of Lewis lung carcinoma in plasminogen-deficient mice. causal interaction,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.7 Carcinoma, Lewis Lung http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16643891&form=6&db=m Antibody-directed targeting of angiostatin's receptor annexin II inhibits Lewis Lung Carcinoma tumor growth via blocking of plasminogen activation: Possible biochemical mechanism of angiostatin's action. causal interaction,ongoing research,therapeutic application,unassigned 4,1,4,0 3.4.21.7 Carcinoma, Lewis Lung http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17680563&form=6&db=m Combination of human plasminogen kringle 5 with ionizing radiation significantly enhances the efficacy of antitumor effect. ongoing research,unassigned 4,0 3.4.21.7 Carcinoma, Lewis Lung http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18593366&form=6&db=m Intramuscular electroporation of a plasmid encoding human plasminogen kringle 5 induces growth inhibition of Lewis lung carcinoma in mice. ongoing research,unassigned 3,0 3.4.21.7 Carcinoma, Lewis Lung http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21573587&form=6&db=m Reduction of tumor-associated fibrinolytic-activity by antimetastatic dosages of 2 ru(ii)-dmso complexes in mice bearing lewis lung-carcinoma. causal interaction,ongoing research,therapeutic application,unassigned 1,2,3,0 3.4.21.7 Carcinoma, Non-Small-Cell Lung http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8111706&form=6&db=m Plasminogen activators and their inhibitors in non-small cell lung cancer. Low content of type 2 plasminogen activator inhibitor associated with tumor dissemination. causal interaction,ongoing research,therapeutic application,unassigned 4,4,4,0 3.4.21.7 Carcinoma, Non-Small-Cell Lung http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9178585&form=6&db=m Changes in plasminogen activator inhibitor-1 levels in non-small cell lung cancer. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,4,0 3.4.21.7 Carcinoma, Non-Small-Cell Lung http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10325924&form=6&db=m The plasmin cascade and matrix metalloproteinases in non-small cell lung cancer. ongoing research,unassigned 2,0 3.4.21.7 Carcinoma, Non-Small-Cell Lung http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20300980&form=6&db=m Clinical significance of the ratio between the alpha 2 plasmin inhibitor-plasmin complex and the thrombin-antithrombin complex in advanced non-small cell lung cancer. causal interaction,diagnostic usage,unassigned 4,3,0 3.4.21.7 Carcinoma, Non-Small-Cell Lung http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20937265&form=6&db=m Association of polymorphisms in the genes of the urokinase plasminogen activation system with susceptibility to and severity of non-small cell lung cancer. causal interaction,diagnostic usage,unassigned 1,3,0 3.4.21.7 Carcinoma, Non-Small-Cell Lung http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21533361&form=6&db=m Presence of urokinase plasminogen activator, its inhibitor and receptor in small cell lung cancer and non-small cell lung cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,4,1 3.4.21.7 Carcinoma, Non-Small-Cell Lung http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31877562&form=6&db=m The D-dimer level predicts the postoperative prognosis in patients with non-small cell lung cancer. diagnostic usage,unassigned 4,0 3.4.21.7 Carcinoma, Ovarian Epithelial http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11872628&form=6&db=m Overexpression of alpha(v)beta6 integrin in serous epithelial ovarian cancer regulates extracellular matrix degradation via the plasminogen activation cascade. causal interaction,diagnostic usage,ongoing research,unassigned 3,3,1,0 3.4.21.7 Carcinoma, Ovarian Epithelial http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12217749&form=6&db=m Malignant ascites fluid (MAF), including ovarian-cancer-associated MAF, contains angiostatin and other factor(s) which inhibit angiogenesis. diagnostic usage,ongoing research,unassigned 1,3,0 3.4.21.7 Carcinoma, Ovarian Epithelial http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14751142&form=6&db=m Plasminogen fragmentation and increased production of extracellular matrix-degrading proteinases are associated with serous epithelial ovarian cancer progression. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,1 3.4.21.7 Carcinoma, Ovarian Epithelial http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25347092&form=6&db=m Pretreatment plasma D-dimer, fibrinogen, and platelet levels significantly impact prognosis in patients with epithelial ovarian cancer independently of venous thromboembolism. diagnostic usage,ongoing research,unassigned 4,2,0 3.4.21.7 Carcinoma, Ovarian Epithelial http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32682445&form=6&db=m Platelet count as a biomarker for monitoring treatment response and disease recurrence in recurrent epithelial ovarian cancer. diagnostic usage,ongoing research,unassigned 4,4,0 3.4.21.7 Carcinoma, Papillary http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16928445&form=6&db=m Differential expression of the components of the plasminogen activating system in human thyroid tumour derived cell lines and papillary carcinomas. diagnostic usage,ongoing research,unassigned 3,4,0 3.4.21.7 Carcinoma, Renal Cell http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3180347&form=6&db=m Mitogenic effect of urokinase on malignant and unaffected adjacent human renal cells. diagnostic usage,ongoing research,unassigned 3,4,0 3.4.21.7 Carcinoma, Renal Cell http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7882614&form=6&db=m Effects of suramin on metastatic ability, proliferation, and production of urokinase-type plasminogen activator and plasminogen activator inhibitor type 2 in human renal cell carcinoma cell line SN12C-PM6. causal interaction,ongoing research,therapeutic application,unassigned 2,4,2,0 3.4.21.7 Carcinoma, Renal Cell http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9023404&form=6&db=m Endothelial and macrophage upregulation of urokinase receptor expression in human renal cell carcinoma. causal interaction,ongoing research,unassigned 4,4,0 3.4.21.7 Carcinoma, Renal Cell http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15183949&form=6&db=m Prognostic value of uPA, PAI-1, and DNA content in adult renal cell carcinoma. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.7 Carcinoma, Renal Cell http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21129210&form=6&db=m Type 1 plasminogen activator inhibitor (PAI-1) in clear cell renal cell carcinoma (CCRCC) and its impact on angiogenesis, progression and patient survival after radical nephrectomy. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,4,3,2 3.4.21.7 Carcinoma, Squamous Cell http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1417524&form=6&db=m Plasminogen activators in normal and malignant oral epithelium in vivo and in vitro. ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.7 Carcinoma, Squamous Cell http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2142433&form=6&db=m Plasminogen activator mediated degradation of subendothelial extracellular matrix by human squamous carcinoma cell lines. causal interaction,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.7 Carcinoma, Squamous Cell http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2497975&form=6&db=m Regulation by epidermal growth factor of human squamous cell carcinoma plasminogen activator-mediated proteolysis of extracellular matrix. ongoing research,unassigned 4,0 3.4.21.7 Carcinoma, Squamous Cell http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3434279&form=6&db=m Plasminogen activators in human xenografted oro-pharyngeal squamous cell carcinomas. diagnostic usage,ongoing research,therapeutic application,unassigned 3,3,1,0 3.4.21.7 Carcinoma, Squamous Cell http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3692623&form=6&db=m Plasminogen activator production by human tumor cells: effect on tumor cell-extracellular matrix interactions. diagnostic usage,ongoing research,unassigned 2,4,0 3.4.21.7 Carcinoma, Squamous Cell http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7707177&form=6&db=m [Immunohistological study of fibrinolytic factors of head and neck squamous cell carcinomas] unassigned - 3.4.21.7 Carcinoma, Squamous Cell http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8074827&form=6&db=m In vitro urokinase type plasminogen activator levels and total plasminogen activator activity in squamous cell carcinomas of the head and neck. causal interaction,diagnostic usage,ongoing research,unassigned 3,4,4,0 3.4.21.7 Carcinoma, Squamous Cell http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9323150&form=6&db=m Localization of plasminogen activators and their inhibitor in squamous cell carcinomas of the head and neck. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,4,1 3.4.21.7 Carcinoma, Squamous Cell http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10473828&form=6&db=m Proteolytic patterns of head and neck squamous cell carcinoma. causal interaction,diagnostic usage,ongoing research,unassigned 4,1,2,0 3.4.21.7 Carcinoma, Squamous Cell http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11422178&form=6&db=m Phosphatidylinositol-specific-phospholipase C cleaves urokinase plasminogen activator receptor from the cell surface and leads to inhibition of pemphigus-IgG-induced acantholysis in DJM-1 cells, a squamous cell carcinoma line. causal interaction,ongoing research,unassigned 4,4,0 3.4.21.7 Carcinoma, Squamous Cell http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12384986&form=6&db=m Inhibition of epidermal growth factor-induced invasion by dexamethasone and AP-1 decoy in human squamous cell carcinoma cell lines. causal interaction,ongoing research,unassigned 3,3,0 3.4.21.7 Carcinoma, Squamous Cell http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17390074&form=6&db=m Effects of hypoxia and reoxygenation on the expression levels of the urokinase-type plasminogen activator, its inhibitor plasminogen activator inhibitor type-1 and the urokinase-type plasminogen activator receptor in human head and neck tumour cells. causal interaction,ongoing research,therapeutic application,unassigned 3,4,2,0 3.4.21.7 Carcinoma, Squamous Cell http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17671400&form=6&db=m Effect of reoxygenation on the hypoxia-induced up-regulation of serine protease inhibitor PAI-1 in head and neck cancer cells. causal interaction,ongoing research,therapeutic application,unassigned 3,1,1,0 3.4.21.7 Carcinoma, Squamous Cell http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27385000&form=6&db=m uPA/uPAR and SERPINE1 in head and neck cancer: role in tumor resistance, metastasis, prognosis and therapy. therapeutic application,unassigned 2,0 3.4.21.7 Carcinoma, Transitional Cell http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9454902&form=6&db=m The expression of urokinase-related genes in superficial and invasive transitional cell carcinoma. ongoing research,unassigned 3,0 3.4.21.7 Carcinoma, Transitional Cell http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14644129&form=6&db=m Amiloride and urinary trypsin inhibitor inhibit urothelial cancer invasion. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,4 3.4.21.7 Carcinosarcoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=13709068&form=6&db=m The effect of human fibrinolysin on survival of carcinosarcoma 256 Walker cells in the blood. ongoing research,unassigned 4,0 3.4.21.7 Carcinosarcoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=13829680&form=6&db=m The effect of human fibrinolysin on pulmonary metastases of Walker 256 carcinosarcoma. ongoing research,unassigned 4,0 3.4.21.7 Cardiomyopathies http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8841929&form=6&db=m Post-transcriptional regulation of extracellular matrix metalloproteinase in human heart end-stage failure secondary to ischemic cardiomyopathy. causal interaction,ongoing research,therapeutic application,unassigned 4,2,1,0 3.4.21.7 Cardiomyopathy, Dilated http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18277136&form=6&db=m Exercise-induced hemostatic activation in patients with dilated cardiomyopathy in sinus rhythm. causal interaction,unassigned 3,0 3.4.21.7 Cardiovascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=182348&form=6&db=m Response of plasma fibrinogen and plasminogen to hormone treatment and the relation of pretreatment values to mortality in patients with prostatic cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,2,1,4 3.4.21.7 Cardiovascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2686261&form=6&db=m New developments in thrombolytic therapy. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 Cardiovascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3524931&form=6&db=m Fibrinogen, fibrin and fibrin degradation products in relation to atherosclerosis. causal interaction,unassigned 3,0 3.4.21.7 Cardiovascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9374741&form=6&db=m Molecular analysis of blood vessel formation and disease. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.7 Cardiovascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9609231&form=6&db=m Intra- and interindividual variability of hemostatic factors and traditional cardiovascular risk factors in a three-year follow-up. therapeutic application,unassigned 3,0 3.4.21.7 Cardiovascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10073949&form=6&db=m Relationship of plasmin generation to cardiovascular disease risk factors in elderly men and women. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,1 3.4.21.7 Cardiovascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10452346&form=6&db=m Relation between long-term steroid treatment after heart transplantation, hypofibrinolysis and myocardial microthrombi generation. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 Cardiovascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11122772&form=6&db=m The role of proteinases in angiogenesis, heart development, restenosis, atherosclerosis, myocardial ischemia, and stroke: insights from genetic studies. causal interaction,unassigned 2,0 3.4.21.7 Cardiovascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11945121&form=6&db=m Recent developments in depsipeptide research. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 Cardiovascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12364443&form=6&db=m Sustained benefits of metformin therapy on markers of cardiovascular risk in human immunodeficiency virus-infected patients with fat redistribution and insulin resistance. diagnostic usage,ongoing research,unassigned 4,2,0 3.4.21.7 Cardiovascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12439349&form=6&db=m Alcohol, heart disease, and mortality: a review. causal interaction,diagnostic usage,therapeutic application,unassigned 2,3,1,0 3.4.21.7 Cardiovascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15261889&form=6&db=m The functions of plasminogen in cardiovascular disease. causal interaction,therapeutic application,unassigned 4,3,0 3.4.21.7 Cardiovascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15741799&form=6&db=m Hemostatic factors as predictors of stroke and cardiovascular diseases: the FINRISK '92 Hemostasis Study. diagnostic usage,ongoing research,unassigned 4,4,0 3.4.21.7 Cardiovascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15943975&form=6&db=m Understanding the enzymology of fibrinolysis and improving thrombolytic therapy. causal interaction,therapeutic application,unassigned 3,2,0 3.4.21.7 Cardiovascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16126968&form=6&db=m Plasminogen activator inhibitor-1 is associated with impaired endothelial function in women with systemic lupus erythematosus. causal interaction,unassigned 3,0 3.4.21.7 Cardiovascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16520158&form=6&db=m Reduced lung function in patients with abdominal aortic aneurysm is associated with activation of inflammation and hemostasis, not smoking or cardiovascular disease. causal interaction,diagnostic usage,unassigned 3,2,0 3.4.21.7 Cardiovascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16611153&form=6&db=m Plasminogen activator system and vascular disease. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,3,3 3.4.21.7 Cardiovascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17544386&form=6&db=m Biochemistry of protein tyrosine nitration in cardiovascular pathology. unassigned - 3.4.21.7 Cardiovascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17991725&form=6&db=m Proteolytic cleavage of human chromogranin a containing naturally occurring catestatin variants: differential processing at catestatin region by plasmin. causal interaction,unassigned 3,0 3.4.21.7 Cardiovascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18374997&form=6&db=m Cardiovascular diseases (CVD) risk factors, physical activity (PA) and plasma plasminogen (Plg) in a random sample of community-dwelling elderly. diagnostic usage,unassigned 2,0 3.4.21.7 Cardiovascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18559377&form=6&db=m A peptide accelerating the conversion of plasminogen activator inhibitor-1 to an inactive latent state. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.7 Cardiovascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21409315&form=6&db=m Effects of Different Protein Sources on Plasminogen Inhibitor-1 and Factor VII Coagulant Activity Added to a Fat-Rich Meal in Type 2 Diabetes. causal interaction,ongoing research,unassigned 4,3,0 3.4.21.7 Cardiovascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21740311&form=6&db=m Advanced oxidation protein products (AOPP): novel uremic toxins, or components of the non-enzymatic antioxidant system of the plasma proteome? causal interaction,therapeutic application,unassigned 3,2,0 3.4.21.7 Cardiovascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24650562&form=6&db=m Lp(a)/apo(a) Modulate MMP-9 Activation and Neutrophil Cytokines in Vivo in Inflammation to Regulate Leukocyte Recruitment. causal interaction,ongoing research,unassigned 3,1,0 3.4.21.7 Cardiovascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25617690&form=6&db=m A small molecule PAI-1 functional inhibitor attenuates neointimal hyperplasia and vascular smooth muscle cell survival by promoting PAI-1 cleavage. therapeutic application,unassigned 1,0 3.4.21.7 Cardiovascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27052059&form=6&db=m Soluble urokinase plasminogen activation receptor - An emerging new biomarker of cardiovascular disease and critical illness. unassigned - 3.4.21.7 Cardiovascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28403644&form=6&db=m The effect of basal insulin glargine on the fibrinolytic system and von Willebrand factor in people with dysglycaemia and high risk for cardiovascular events: Swedish substudy of the Outcome Reduction with an Initial Glargine Intervention trial. ongoing research,unassigned 1,0 3.4.21.7 Cardiovascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30351651&form=6&db=m [Biochemical markers of endothelial dysfunction and cardiovascular system state in patients with occupationai bronchopulmonary diseases]. therapeutic application,unassigned 1,0 3.4.21.7 Cardiovascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31858714&form=6&db=m Molecular mechanism of two nanobodies that inhibit PAI-1 activity reveals a modulation at distinct stages of the PAI-1/plasminogen activator interaction. causal interaction,therapeutic application,unassigned 3,3,0 3.4.21.7 Cardiovascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33714935&form=6&db=m A Multimodality Machine Learning Approach to Differentiate Severe and Nonsevere COVID-19: Model Development and Validation. diagnostic usage,ongoing research,unassigned 4,2,0 3.4.21.7 Caroli Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19025978&form=6&db=m Matrix proteins of basement membrane of intrahepatic bile ducts are degraded in congenital hepatic fibrosis and Caroli's disease. causal interaction,unassigned 3,0 3.4.21.7 Carotid Artery Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15156124&form=6&db=m Hemostatic function and carotid artery disease. diagnostic usage,unassigned 2,0 3.4.21.7 Carotid Artery Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10839966&form=6&db=m Endoluminal arterial injury in plasminogen-deficient mice. causal interaction,ongoing research,therapeutic application,unassigned 4,2,1,0 3.4.21.7 Carotid Artery Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=13889682&form=6&db=m Combined use of fibrinolysin and endarterectomy. Results in stenosis with recent carotid artery thrombosis. therapeutic application,unassigned 1,0 3.4.21.7 Carotid Artery Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30532017&form=6&db=m Antithrombotic effects and related mechanisms of Salvia deserta Schang root EtOAc extracts. diagnostic usage,ongoing research,therapeutic application,unassigned 1,4,1,0 3.4.21.7 Catalepsy http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6889186&form=6&db=m Lack of effects of fibrinogen degradation products on specific binding of [3H]spiroperidol and [3H]ADTN. unassigned - 3.4.21.7 Cataract http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=89778&form=6&db=m Fibrinolytic factors in aqueous humour and serum from patients with Fuchs' dystrophy and patients with cataract. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,3,0 3.4.21.7 Cataract http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9340414&form=6&db=m [Tissue plasminogen activator in treatment of fibrinous membranes after cataract surgery] diagnostic usage,ongoing research,therapeutic application,unassigned 3,4,4,0 3.4.21.7 Cataract http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9865179&form=6&db=m [The efficacy of using enzymes in treating toxic-allergic reactions after cataract extraction with intraocular lens implantation] causal interaction,unassigned 3,0 3.4.21.7 Cataract http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16927784&form=6&db=m [Densitometric analysis of changes in the vitreous body after cataract extraction] causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.7 Cataract http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29376008&form=6&db=m Tissue plasminogen activator-assisted vitrectomy in the early treatment of acute massive suprachoroidal hemorrhage complicating cataract surgery. causal interaction,therapeutic application,unassigned 3,3,0 3.4.21.7 Celiac Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21969282&form=6&db=m Duodenal ulceration in a patient with celiac disease and plasminogen I deficiency: coincidence or cofactors? causal interaction,unassigned 4,0 3.4.21.7 Central Nervous System Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9646779&form=6&db=m Interventional use of plasminogen activators in central nervous system diseases. ongoing research,therapeutic application,unassigned 1,4,0 3.4.21.7 Cerebral Amyloid Angiopathy http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12112090&form=6&db=m Thrombolysis induces cerebral hemorrhage in a mouse model of cerebral amyloid angiopathy. causal interaction,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.7 Cerebral Amyloid Angiopathy http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17662525&form=6&db=m Upregulation of tPA/plasminogen proteolytic system in the periphery of amyloid deposits in the Tg2576 mouse model of Alzheimer's disease. causal interaction,ongoing research,unassigned 1,1,0 3.4.21.7 Cerebral Amyloid Angiopathy http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26545113&form=6&db=m An Enzyme from Aristolochia indica Destabilizes Fibrin-? Amyloid Co-Aggregate: Implication in Cerebrovascular Diseases. unassigned - 3.4.21.7 Cerebral Amyloid Angiopathy http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34126761&form=6&db=m Cerebral Amyloid Angiopathy and the Fibrinolytic System: Is Plasmin a Therapeutic Target? therapeutic application,unassigned 3,0 3.4.21.7 Cerebral Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1746450&form=6&db=m Comparative safety of thrombolytic agents. causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,4,0 3.4.21.7 Cerebral Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1906646&form=6&db=m Cerebral hemorrhagic risk of aspirin or heparin therapy with thrombolytic treatment in rabbits. causal interaction,ongoing research,therapeutic application,unassigned 4,4,2,0 3.4.21.7 Cerebral Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2620588&form=6&db=m [Observation of plasma levels of antithrombin-III and plasminogen in acute cerebrovascular disease] causal interaction,diagnostic usage,ongoing research,unassigned 2,3,2,0 3.4.21.7 Cerebral Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8316193&form=6&db=m Coronary artery disease, myocardial infarction, and brain embolism. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 Cerebral Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8772682&form=6&db=m Suppression of plasminogen activator inhibitor-1 release from human cerebral endothelium by plasminogen activators. A factor potentially predisposing to intracranial bleeding. causal interaction,therapeutic application,unassigned 3,3,0 3.4.21.7 Cerebral Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9109878&form=6&db=m Metalloproteinase inhibition blocks edema in intracerebral hemorrhage in the rat. causal interaction,ongoing research,therapeutic application,unassigned 3,3,4,0 3.4.21.7 Cerebral Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9880385&form=6&db=m Serum glucose level and diabetes predict tissue plasminogen activator-related intracerebral hemorrhage in acute ischemic stroke. causal interaction,diagnostic usage,ongoing research,unassigned 3,4,3,0 3.4.21.7 Cerebral Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10471309&form=6&db=m Plasmin cleavage of the amyloid beta-protein: alteration of secondary structure and stimulation of tissue plasminogen activator activity. causal interaction,unassigned 1,0 3.4.21.7 Cerebral Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10961582&form=6&db=m Antithrombotic treatments in acute ischemic stroke. diagnostic usage,therapeutic application,unassigned 3,3,0 3.4.21.7 Cerebral Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11779904&form=6&db=m The nonpeptide glycoprotein IIb/IIIa platelet receptor antagonist SM-20302 reduces tissue plasminogen activator-induced intracerebral hemorrhage after thromboembolic stroke. causal interaction,ongoing research,therapeutic application,unassigned 4,4,4,0 3.4.21.7 Cerebral Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12112090&form=6&db=m Thrombolysis induces cerebral hemorrhage in a mouse model of cerebral amyloid angiopathy. causal interaction,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.7 Cerebral Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14615621&form=6&db=m Involvement of thrombolysis in recombinant tissue plasminogen activator-induced cerebral hemorrhages and effect on infarct volume and postischemic endothelial function. ongoing research,therapeutic application,unassigned 4,1,0 3.4.21.7 Cerebral Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14988581&form=6&db=m Hemostatic factors as risk markers for intracerebral hemorrhage: a prospective incident case-referent study. diagnostic usage,ongoing research,unassigned 2,4,0 3.4.21.7 Cerebral Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15823070&form=6&db=m Thrombolytic therapies: the current state of affairs. causal interaction,unassigned 3,0 3.4.21.7 Cerebral Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16126134&form=6&db=m Recombinant tissue plasminogen activator for minor strokes: the National Institute of Neurological Disorders and Stroke rt-PA Stroke Study experience. diagnostic usage,ongoing research,therapeutic application,unassigned 2,2,3,0 3.4.21.7 Cerebral Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16645131&form=6&db=m Blood-brain barrier disruption by low-frequency ultrasound. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.7 Cerebral Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17940541&form=6&db=m Plasminogen potentiates thrombin cytotoxicity and contributes to pathology of intracerebral hemorrhage in rats. ongoing research,unassigned 2,0 3.4.21.7 Cerebral Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19246695&form=6&db=m Intraventricular hemorrhage: severity factor and treatment target in spontaneous intracerebral hemorrhage. ongoing research,unassigned 2,0 3.4.21.7 Cerebral Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19412821&form=6&db=m An emerging role of mast cells in cerebral ischemia and hemorrhage. ongoing research,therapeutic application,unassigned 1,1,0 3.4.21.7 Cerebral Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20212195&form=6&db=m Symptomatic Intracerebral Hemorrhage Among Eligible Warfarin-Treated Patients Receiving Intravenous Tissue Plasminogen Activator for Acute Ischemic Stroke. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,1,1,3 3.4.21.7 Cerebral Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20595786&form=6&db=m Role of tissue-type plasminogen activator in ischemic stroke. causal interaction,ongoing research,therapeutic application,unassigned 4,1,3,0 3.4.21.7 Cerebral Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26646459&form=6&db=m Platelet-Derived Growth Factor Receptor-? Regulates Vascular Smooth Muscle Cell Phenotypic Transformation and Neuroinflammation After Intracerebral Hemorrhage in Mice. diagnostic usage,ongoing research,therapeutic application,unassigned 3,3,1,0 3.4.21.7 Cerebral Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27018013&form=6&db=m Hydrogen Sulfide Attenuates Tissue Plasminogen Activator-Induced Cerebral Hemorrhage Following Experimental Stroke. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,4,4 3.4.21.7 Cerebral Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28824910&form=6&db=m The Effects of the Contact Activation System on Hemorrhage. causal interaction,therapeutic application,unassigned 4,2,0 3.4.21.7 Cerebral Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28931617&form=6&db=m Normobaric Hyperoxia Reduces Blood Occludin Fragments in Rats and Patients With Acute Ischemic Stroke. causal interaction,therapeutic application,unassigned 4,3,0 3.4.21.7 Cerebral Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31595836&form=6&db=m Renal Dysfunction and In-Hospital Outcomes in Patients With Acute Ischemic Stroke After Intravenous Thrombolytic Therapy. causal interaction,ongoing research,therapeutic application,unassigned 3,2,3,0 3.4.21.7 Cerebral Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33872083&form=6&db=m The Relationship of the Type of Intracerebral Hemorrhage to Early Disease Evolution and Long-Term Prognosis After r-tPA Thrombolysis. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,2,4,2 3.4.21.7 Cerebral Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=60807&form=6&db=m Blood coagulation and plasma fibrinolytic enzyme system pathophysiology in stroke. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,1,0 3.4.21.7 Cerebral Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3120360&form=6&db=m Hemorrhagic complications of thrombolytic therapy in experimental stroke. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,1,4 3.4.21.7 Cerebral Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3721516&form=6&db=m Polymorphism of plasminogen in healthy individuals and patients with cerebral infarction. causal interaction,diagnostic usage,ongoing research,unassigned 4,2,4,0 3.4.21.7 Cerebral Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3731627&form=6&db=m [Frequency and clinical significance of congenital plasminogen abnormality in cerebral infarction] causal interaction,diagnostic usage,unassigned 4,3,0 3.4.21.7 Cerebral Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8248977&form=6&db=m Hematologic abnormalities occur in both cortical and lacunar infarction. diagnostic usage,ongoing research,therapeutic application,unassigned 2,2,1,0 3.4.21.7 Cerebral Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8381941&form=6&db=m Serum lipoprotein (a) concentrations in patients undergoing continuous ambulatory peritoneal dialysis. causal interaction,unassigned 3,0 3.4.21.7 Cerebral Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10456203&form=6&db=m Screening for aetiology of thrombophilia: a high prevalence of protein S abnormality. unassigned - 3.4.21.7 Cerebral Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10650849&form=6&db=m Prothrombotic risk factors in childhood stroke and venous thrombosis. causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,1,0 3.4.21.7 Cerebral Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12781064&form=6&db=m Coagulation and fibrinolytic activity in patients with acute cerebral infarction. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,2,2,2 3.4.21.7 Cerebral Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17143002&form=6&db=m Lp(a) lipoprotein and plasminogen activity in patients with different etiology of ischemic stroke. causal interaction,diagnostic usage,ongoing research,unassigned 3,3,4,0 3.4.21.7 Cerebral Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20135065&form=6&db=m Neuroserpin, a thrombolytic serine protease inhibitor (serpin), blocks transplant vasculopathy with associated modification of T-helper cell subsets. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.7 Cerebral Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24192639&form=6&db=m SMTP-7, a novel small-molecule thrombolytic for ischemic stroke: a study in rodents and primates. causal interaction,therapeutic application,unassigned 2,3,0 3.4.21.7 Cerebral Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25783009&form=6&db=m Early fibrinogen degradation coagulopathy: a predictive factor of parenchymal hematomas in cerebral rt-PA thrombolysis. diagnostic usage,ongoing research,therapeutic application,unassigned 2,2,1,0 3.4.21.7 Cerebral Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33280550&form=6&db=m Early Infarct Growth Rate Correlation With Endovascular Thrombectomy Clinical Outcomes: Analysis From the SELECT Study. unassigned - 3.4.21.7 Cerebral Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33872083&form=6&db=m The Relationship of the Type of Intracerebral Hemorrhage to Early Disease Evolution and Long-Term Prognosis After r-tPA Thrombolysis. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,2,4,2 3.4.21.7 Cerebrovascular Disorders http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2620588&form=6&db=m [Observation of plasma levels of antithrombin-III and plasminogen in acute cerebrovascular disease] causal interaction,diagnostic usage,ongoing research,unassigned 2,3,2,0 3.4.21.7 Cerebrovascular Disorders http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6810498&form=6&db=m A study of hemostasis in ischemic cerebrovascular disease. III. Abnormalities in vascular plasminogen activators, antiactivators and alpha 2-antiplasmin. causal interaction,unassigned 2,0 3.4.21.7 Cerebrovascular Disorders http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8248995&form=6&db=m Congenitally abnormal plasminogen in juvenile ischemic cerebrovascular disease. causal interaction,diagnostic usage,unassigned 4,2,0 3.4.21.7 Cerebrovascular Disorders http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=13700032&form=6&db=m Fibrinolysin in cerebrovascular diseases. diagnostic usage,unassigned 3,0 3.4.21.7 Cerebrovascular Disorders http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=13716052&form=6&db=m Therapeutic problems in cerebrovascular disease. The experimental use of plasmin in dogs. therapeutic application,unassigned 4,0 3.4.21.7 Cerebrovascular Disorders http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17143002&form=6&db=m Lp(a) lipoprotein and plasminogen activity in patients with different etiology of ischemic stroke. causal interaction,diagnostic usage,ongoing research,unassigned 3,3,4,0 3.4.21.7 Chagas Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22543060&form=6&db=m Serum proteomic signature of human chagasic patients for the identification of novel potential protein biomarkers of disease. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,1,0 3.4.21.7 Charcot-Marie-Tooth Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10382293&form=6&db=m Generation and chromosome mapping of expressed sequence tags (ESTs) from a human infant thymus. therapeutic application,unassigned 1,0 3.4.21.7 Cholangiocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22166587&form=6&db=m Hemostatic Abnormalities in Cirrhosis and Tumor-Related Portal Vein Thrombosis. diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.7 Cholelithiasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4040294&form=6&db=m [Hemostatic indices of oncological patients with different forms of jaundice] diagnostic usage,ongoing research,therapeutic application,unassigned 2,2,1,0 3.4.21.7 Cholera http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6997109&form=6&db=m Correlation between macrophages and their membrane fraction. Cytocidal activities on neoplastic cells. causal interaction,unassigned 2,0 3.4.21.7 Cholestasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15118576&form=6&db=m Changes of coagulation inhibitors and fibrinolysis system in newborn infants with transitory neonatal cholestasis. diagnostic usage,ongoing research,unassigned 3,3,0 3.4.21.7 Cholesteatoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10086616&form=6&db=m Expression pattern of the plasminogen activator-plasmin system in human cholesteatoma. ongoing research,unassigned 4,0 3.4.21.7 Cholesteatoma, Middle Ear http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7877421&form=6&db=m Plasminogen activators in tissue extract of aural cholesteatoma. ongoing research,unassigned 3,0 3.4.21.7 Chondrosarcoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8988726&form=6&db=m Expression of plasminogen activators and plasminogen activator inhibitor 1 in dedifferentiated chondrosarcoma. causal interaction,ongoing research,therapeutic application,unassigned 4,3,2,0 3.4.21.7 Chondrosarcoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11062719&form=6&db=m Prognostic relevance of urokinase type plasminogen activator, its receptor and inhibitors in chondrosarcoma. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,4,3 3.4.21.7 Chondrosarcoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11713566&form=6&db=m Plasminogen activators and their inhibitor in bone tumors and tumor-like damages. diagnostic usage,ongoing research,therapeutic application,unassigned 3,2,2,0 3.4.21.7 Choriocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7512520&form=6&db=m Plasmin modulators, aprotinin and anti-catalytic plasmin antibody, efficiently inhibit destruction of bovine vascular endothelial cells by choriocarcinoma cells. ongoing research,unassigned 2,0 3.4.21.7 Choroidal Neovascularization http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9373115&form=6&db=m Tissue plasminogen activator-assisted surgical excision of subfoveal choroidal neovascularization in age-related macular degeneration: a randomized, double-masked trial. diagnostic usage,ongoing research,therapeutic application,unassigned 3,3,1,0 3.4.21.7 Choroidal Neovascularization http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12657615&form=6&db=m Mice without uPA, tPA, or plasminogen genes are resistant to experimental choroidal neovascularization. ongoing research,therapeutic application,unassigned 4,2,0 3.4.21.7 Choroidal Neovascularization http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21357401&form=6&db=m Anti-inflammatory and anti-angiogenic effects of nanoparticle-mediated delivery of a natural angiogenic inhibitor. diagnostic usage,ongoing research,unassigned 1,4,0 3.4.21.7 Choroidal Neovascularization http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22752625&form=6&db=m [Intravitreal injection. Drugs to treat subretinal hemorrhage]. ongoing research,unassigned 2,0 3.4.21.7 Choroidal Neovascularization http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33918777&form=6&db=m Therapeutic Efficacy of a Novel Acetylated Tetrapeptide in Animal Models of Age-Related Macular Degeneration. causal interaction,therapeutic application,unassigned 1,3,0 3.4.21.7 Chronic Limb-Threatening Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27610138&form=6&db=m tPA-MMP-9 Axis Plays a Pivotal Role in Mobilization of Endothelial Progenitor Cells from Bone Marrow to Circulation and Ischemic Region for Angiogenesis. ongoing research,unassigned 4,0 3.4.21.7 Chronic Periodontitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17559629&form=6&db=m Neutrophil elastase is involved in the initial destruction of human periodontal ligament. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,2,0 3.4.21.7 Chronic Periodontitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21704601&form=6&db=m Plasmin is essential in preventing periodontitis in mice. causal interaction,ongoing research,therapeutic application,unassigned 4,4,4,0 3.4.21.7 Chronic Periodontitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29520774&form=6&db=m Serum, salivary, and tissue levels of plasminogen in familial Mediterranean fever, amyloidosis, and chronic periodontitis. causal interaction,diagnostic usage,ongoing research,unassigned 4,2,3,0 3.4.21.7 coagulation factor xia deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9391725&form=6&db=m Recurrent venous thromboembolic disease and factor XI concentrate in a patient with severe factor XI deficiency, chronic myelomonocytic leukaemia, factor V Leiden and heterozygous plasminogen deficiency. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 Coinfection http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16505739&form=6&db=m Syphilis and Human Immunodeficiency Virus (HIV)-1 Coinfection: Influence on CD4 T-Cell Count, HIV-1 Viral Load, and Treatment Response. ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.7 Colic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2012348&form=6&db=m Use of newly developed assays for protein C and plasminogen in horses with signs of colic. diagnostic usage,ongoing research,therapeutic application,unassigned 2,4,1,0 3.4.21.7 Colic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7591947&form=6&db=m Intravascular and peritoneal coagulation and fibrinolysis in horses with acute gastrointestinal tract diseases. causal interaction,diagnostic usage,therapeutic application,unassigned 3,1,1,0 3.4.21.7 Colitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25490065&form=6&db=m Inhibition of Plasmin Protects Against Colitis in Mice by Suppressing Matrix Metalloproteinase 9-Mediated Cytokine Release From Myeloid Cells. causal interaction,ongoing research,therapeutic application,unassigned 1,4,2,0 3.4.21.7 Colitis, Ulcerative http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3146142&form=6&db=m Plasminogen activators in the intestine of patients with inflammatory bowel disease. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,4,0 3.4.21.7 Colitis, Ulcerative http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10456203&form=6&db=m Screening for aetiology of thrombophilia: a high prevalence of protein S abnormality. unassigned - 3.4.21.7 Colonic Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7535283&form=6&db=m Expression of binding of plasminogen, thrombospondin, vitronectin, and fibrinogen, and adhesive properties by Escherichia coli strains isolated from patients with colonic diseases. ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.7 Colonic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1354271&form=6&db=m Tetranectin, a plasminogen kringle 4-binding protein. Cloning and gene expression pattern in human colon cancer. causal interaction,ongoing research,therapeutic application,unassigned 4,3,2,0 3.4.21.7 Colonic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1702928&form=6&db=m Localization of urokinase-type plasminogen activator in stromal cells in adenocarcinomas of the colon in humans. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,1,4,1 3.4.21.7 Colonic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1855221&form=6&db=m The plasminogen activation system in human colon cancer: messenger RNA for the inhibitor PAI-1 is located in endothelial cells in the tumor stroma. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,4,1 3.4.21.7 Colonic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2164413&form=6&db=m Invasion of extracellular matrix by cultured colon cancer cells: dependence on urokinase receptor display. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,4,2 3.4.21.7 Colonic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2232301&form=6&db=m [Protease activities in gastric and colon cancer tissues] causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,4,1 3.4.21.7 Colonic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2390419&form=6&db=m Insensitivity of laminin degradation directed by receptor bound urokinase to PAI-1 in cultured colon cancer. ongoing research,unassigned 3,0 3.4.21.7 Colonic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2965017&form=6&db=m Proenzyme to urokinase-type plasminogen activator in human colon cancer: in vitro inhibition by monocyte minactivin after proteolytic activation. causal interaction,ongoing research,unassigned 1,4,0 3.4.21.7 Colonic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3884145&form=6&db=m Localization of plasminogen activators in human colon cancer by immunoperoxidase staining. causal interaction,diagnostic usage,ongoing research,unassigned 3,3,4,0 3.4.21.7 Colonic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7664291&form=6&db=m Laminin-5 is a marker of invading cancer cells in some human carcinomas and is coexpressed with the receptor for urokinase plasminogen activator in budding cancer cells in colon adenocarcinomas. causal interaction,diagnostic usage,ongoing research,unassigned 3,1,3,0 3.4.21.7 Colonic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7665235&form=6&db=m Butyrate regulates gene expression of the plasminogen activating system in colon cancer cells. ongoing research,therapeutic application,unassigned 3,1,0 3.4.21.7 Colonic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7737909&form=6&db=m Localization of urokinase-type plasminogen activator, plasminogen activator inhibitor-1, 2 and plasminogen in colon cancer. causal interaction,ongoing research,therapeutic application,unassigned 3,3,3,0 3.4.21.7 Colonic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8181805&form=6&db=m Immunohistochemical detection of the receptor for urokinase plasminogen activator in human colon cancer. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,3,0 3.4.21.7 Colonic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8434636&form=6&db=m Messenger RNA for two type IV collagenases is located in stromal cells in human colon cancer. causal interaction,diagnostic usage,ongoing research,unassigned 4,2,3,0 3.4.21.7 Colonic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=13694103&form=6&db=m Cancer cells in the blood in simulated colon cancer, resectable and unresectable: effect of fibrinolysin and heparin on growth potential. ongoing research,therapeutic application,unassigned 3,1,0 3.4.21.7 Colonic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15325613&form=6&db=m NS-398 inhibits tumor growth and liver metastasis of colon cancer through induction of apoptosis and suppression of the plasminogen activation system in a mouse model. causal interaction,ongoing research,unassigned 4,4,0 3.4.21.7 Colonic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16631161&form=6&db=m Requirement of the enzymatic and signaling activities of plasmin for phorbol-ester-induced scattering of colon cancer cells. causal interaction,unassigned 4,0 3.4.21.7 Colonic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18237545&form=6&db=m Serum amyloid A enhances plasminogen activation: implication for a role in colon cancer. causal interaction,ongoing research,therapeutic application,unassigned 1,3,1,0 3.4.21.7 Colonic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18575722&form=6&db=m Mouse macrophage metalloelastase generates angiostatin from plasminogen and suppresses tumor angiogenesis in murine colon cancer. causal interaction,ongoing research,therapeutic application,unassigned 3,2,2,0 3.4.21.7 Colonic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20136087&form=6&db=m Benzyl isothiocyanate (BITC) inhibits migration and invasion of human colon cancer HT29 cells by inhibiting matrix metalloproteinase-2/-9 and urokinase plasminogen (uPA) through PKC and MAPK signaling pathway. ongoing research,therapeutic application,unassigned 2,2,0 3.4.21.7 Colonic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23710449&form=6&db=m Ulinastatin reduces cancer recurrence after resection of hepatic metastases from colon cancer by inhibiting MMP-9 activation via the antifibrinolytic pathway. diagnostic usage,therapeutic application,unassigned 1,1,0 3.4.21.7 Colonic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24674880&form=6&db=m Tissue-type plasminogen activator-induced fibrinolysis is enhanced in patients with breast, lung, pancreas and colon cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,4,1 3.4.21.7 Colorectal Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1648562&form=6&db=m Cell signalling associated with fibrinolytic ligand binding to human colorectal carcinoma cells. diagnostic usage,ongoing research,unassigned 3,3,0 3.4.21.7 Colorectal Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3094628&form=6&db=m Plasminogen activators in human colorectal neoplasia. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,3,1 3.4.21.7 Colorectal Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3111578&form=6&db=m Role of urokinase in colorectal neoplasia. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,2,1 3.4.21.7 Colorectal Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3115868&form=6&db=m Plasminogen activators in experimental colorectal neoplasia: a role in the adenoma-carcinoma sequence? causal interaction,diagnostic usage,ongoing research,unassigned 4,3,2,0 3.4.21.7 Colorectal Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3146142&form=6&db=m Plasminogen activators in the intestine of patients with inflammatory bowel disease. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,4,0 3.4.21.7 Colorectal Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7577001&form=6&db=m Prognostic value of plasminogen activators and their inhibitors in colorectal cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,3,0 3.4.21.7 Colorectal Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7768404&form=6&db=m Plasminogen activation system and colorectal cancer biology. diagnostic usage,unassigned 3,0 3.4.21.7 Colorectal Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7841059&form=6&db=m Plasminogen activators and inhibitor type 1 in neoplastic colonic tissue from patients with familial adenomatous polyposis. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,4,0 3.4.21.7 Colorectal Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8033138&form=6&db=m Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,4,0 3.4.21.7 Colorectal Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8518031&form=6&db=m Plasminogen activators and plasminogen activator inhibitors in human colorectal carcinoma tissues are not expressed by the tumour cells. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,1,4,2 3.4.21.7 Colorectal Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8694536&form=6&db=m Fibrinolysis components as prognostic markers in breast cancer and colorectal carcinoma. causal interaction,diagnostic usage,unassigned 4,2,0 3.4.21.7 Colorectal Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9192984&form=6&db=m Contribution of plasminogen activators and their inhibitors to the survival prognosis of patients with Dukes' stage B and C colorectal cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,4,4 3.4.21.7 Colorectal Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9583734&form=6&db=m Involvement of vascular endothelial growth factor and urokinase-type plasminogen activator receptor in microvessel invasion in human colorectal cancers. diagnostic usage,ongoing research,therapeutic application,unassigned 2,2,2,0 3.4.21.7 Colorectal Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10489782&form=6&db=m [The role of cathepsins and the plasminogen activator/inhibitor system in colorectal cancer] causal interaction,diagnostic usage,ongoing research,unassigned 3,4,4,0 3.4.21.7 Colorectal Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10737043&form=6&db=m [The role of proteolytic enzymes in skin neoplasm progression and development of metastasis] causal interaction,diagnostic usage,unassigned 3,3,0 3.4.21.7 Colorectal Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11027463&form=6&db=m Significance of coexpression of urokinase-type plasminogen activator, and matrix metalloproteinase 3 (stromelysin) and 9 (gelatinase B) in colorectal carcinoma. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,3,0 3.4.21.7 Colorectal Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11376560&form=6&db=m Urokinase receptor and vascular endothelial growth factor are synergistically associated with the liver metastasis of colorectal cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,2,1,1 3.4.21.7 Colorectal Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11782452&form=6&db=m Antiplasmin activity of a peptide that binds to the receptor-binding site of angiogenin. causal interaction,unassigned 1,0 3.4.21.7 Colorectal Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12405290&form=6&db=m Cyclooxygenase-2 expression correlates with uPAR levels and is responsible for poor prognosis of colorectal cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,1 3.4.21.7 Colorectal Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12619063&form=6&db=m Quantitative expression of protein markers of plasminogen activation system in prognosis of colorectal cancer. diagnostic usage,ongoing research,unassigned 4,4,0 3.4.21.7 Colorectal Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12817480&form=6&db=m Differences in the activation mechanism between the alpha and beta subunits of human meprin. causal interaction,diagnostic usage,therapeutic application,unassigned 4,1,1,0 3.4.21.7 Colorectal Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14570893&form=6&db=m RNA interference-mediated silencing of the S100A10 gene attenuates plasmin generation and invasiveness of Colo 222 colorectal cancer cells. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.7 Colorectal Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15333188&form=6&db=m Evidence for the clinical use of tumour markers. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,4 3.4.21.7 Colorectal Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17804466&form=6&db=m Polymorphisms in the genes of the urokinase plasminogen activation system in relation to colorectal cancer. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,3,0 3.4.21.7 Colorectal Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23484202&form=6&db=m Prognostic role of tumor-associated proteases in colorectal cancer. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,2,0 3.4.21.7 Colorectal Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24640092&form=6&db=m Tumor associated proteases -- prognostic markers of colorectal cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,3,1 3.4.21.7 Coma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=705694&form=6&db=m Quantitative estimation of coagulation factors in liver disease. The diagnostic and prognostic value of factor XIII, factor V and plasminogen. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 Communicable Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19432826&form=6&db=m Stroke in children: inherited and acquired factors and age-related variations in the presentation of 48 paediatric patients. causal interaction,ongoing research,unassigned 2,1,0 3.4.21.7 Communicable Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21429565&form=6&db=m Prospective evaluation of hemostatic abnormalities in overt DIC due to various underlying diseases. diagnostic usage,ongoing research,therapeutic application,unassigned 4,1,1,0 3.4.21.7 Communicable Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21781255&form=6&db=m Exploration of the host haemostatic system by group A streptococcus: implications in searching for novel antimicrobial therapies. therapeutic application,unassigned 3,0 3.4.21.7 Communicable Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22759687&form=6&db=m Inherited thrombophilia in pediatric ischemic stroke: an Egyptian study. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,1,1 3.4.21.7 Communicable Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32213794&form=6&db=m Use of Intraoperative Tranexamic Acid and Wound Complications in Spine Surgery: A Retrospective Cohort Study. causal interaction,unassigned 4,0 3.4.21.7 Congenital Abnormalities http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1826407&form=6&db=m Incidence and clinical characteristics of hereditary disorders associated with venous thrombosis. therapeutic application,unassigned 1,0 3.4.21.7 Congenital Abnormalities http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2526671&form=6&db=m Clinical disorders of fibrinolysis: a critical review. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 Congenital Abnormalities http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3270918&form=6&db=m [Congenital abnormality of plasminogen] causal interaction,diagnostic usage,ongoing research,unassigned 1,1,2,0 3.4.21.7 Congenital Abnormalities http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9734140&form=6&db=m Clinical application of fibrinolysis laboratory tests: a review. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.7 Congenital Abnormalities http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29411742&form=6&db=m [Indicators of homeostasis, inflammation and homocysteine in ischemic stroke in the young age]. causal interaction,unassigned 3,0 3.4.21.7 Conjunctivitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9242524&form=6&db=m Homozygous mutations in the plasminogen gene of two unrelated girls with ligneous conjunctivitis. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 Conjunctivitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9473227&form=6&db=m Ligneous conjunctivitis in plasminogen-deficient mice. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 Conjunctivitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9834305&form=6&db=m Therapy with a purified plasminogen concentrate in an infant with ligneous conjunctivitis and homozygous plasminogen deficiency. causal interaction,therapeutic application,unassigned 3,3,0 3.4.21.7 Conjunctivitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10066157&form=6&db=m Polymorphonuclear elastase in patients with homozygous type I plasminogen deficiency and ligneous conjunctivitis. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.7 Conjunctivitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10190281&form=6&db=m Human homozygous type I plasminogen deficiency and ligneous conjunctivitis. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,1,1,1 3.4.21.7 Conjunctivitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10233898&form=6&db=m Compound-heterozygous mutations in the plasminogen gene predispose to the development of ligneous conjunctivitis. causal interaction,diagnostic usage,unassigned 4,3,0 3.4.21.7 Conjunctivitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10360521&form=6&db=m Prenatal diagnosis in a family with severe type I plasminogen deficiency, ligneous conjunctivitis and congenital hydrocephalus. causal interaction,diagnostic usage,unassigned 4,2,0 3.4.21.7 Conjunctivitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11040483&form=6&db=m Ligneous conjunctivitis: a local manifestation of a systemic disorder? causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 Conjunctivitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11045349&form=6&db=m Ligneous conjunctivitis in a girl with severe type I plasminogen deficiency. causal interaction,unassigned 4,0 3.4.21.7 Conjunctivitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11250632&form=6&db=m Oral lesions indicative of plasminogen deficiency (hypoplasminogenemia). causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 Conjunctivitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11434676&form=6&db=m Homozygous and compound-heterozygous type I plasminogen deficiency is a common cause of ligneous conjunctivitis. causal interaction,unassigned 4,0 3.4.21.7 Conjunctivitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11477736&form=6&db=m Pulmonary involvement in a child with ligneous conjunctivitis and homozygous type I plasminogen deficiency. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 Conjunctivitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11931777&form=6&db=m Effective treatment of ligneous conjunctivitis with topical plasminogen. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,4,0 3.4.21.7 Conjunctivitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11987044&form=6&db=m [Ligneous conjunctivitis in a patient with plasminogen type I deficiency--case report with review of literature] causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,1,4 3.4.21.7 Conjunctivitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12421144&form=6&db=m Plasminogen and tissue-type plasminogen activator deficiency as risk factors for thromboembolic disease. causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,2,0 3.4.21.7 Conjunctivitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12623158&form=6&db=m Otolaryngological manifestations of ligneous conjunctivitis. causal interaction,unassigned 4,0 3.4.21.7 Conjunctivitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12719968&form=6&db=m Ligneous conjunctivitis, hydrocephalus, hydrocele, and pulmonary involvement in a child with homozygous type I plasminogen deficiency. causal interaction,unassigned 4,0 3.4.21.7 Conjunctivitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12850227&form=6&db=m Ligneous conjunctivitis. causal interaction,unassigned 4,0 3.4.21.7 Conjunctivitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12876630&form=6&db=m Contraceptive pills induce an improvement in congenital hypoplasminogenemia in two unrelated patients with ligneous conjunctivitis. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 Conjunctivitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14576528&form=6&db=m Treatment of ligneous conjunctivitis with topical plasmin and topical plasminogen. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 Conjunctivitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15488842&form=6&db=m Therapeutic approaches in the treatment of ligneous conjunctivitis, the most common clinical manifestation of a systemic disease, caused by severe type I plasminogen deficiency. causal interaction,therapeutic application,unassigned 4,3,0 3.4.21.7 Conjunctivitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15782857&form=6&db=m [Ligneous conjunctivitis: complication of inborn plasminogen deficiency (a case report)] causal interaction,diagnostic usage,unassigned 4,2,0 3.4.21.7 Conjunctivitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15822024&form=6&db=m Congenital hydrocephalus as a rare association with ligneous conjunctivitis and type I plasminogen deficiency. causal interaction,unassigned 4,0 3.4.21.7 Conjunctivitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16444438&form=6&db=m Difficulties in the mutation analysis of plasminogen gene: a study in two patients with ligneous conjunctivitis. causal interaction,ongoing research,therapeutic application,unassigned 4,2,1,0 3.4.21.7 Conjunctivitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17030725&form=6&db=m Ligneous conjunctivitis in a Mexican patient with a mutation in the plasminogen (PLG) gene. causal interaction,unassigned 1,0 3.4.21.7 Conjunctivitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17179833&form=6&db=m Molecular characterization of an Italian patient with plasminogen deficiency and ligneous conjunctivitis. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,1,0 3.4.21.7 Conjunctivitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17503307&form=6&db=m Management of hydrocephalus in children with plasminogen deficiency. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 Conjunctivitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17701212&form=6&db=m Ligneous conjunctivitis: a clinicopathological, immunohistochemical, and genetic study including the treatment of two sisters with multiorgan involvement. causal interaction,unassigned 2,0 3.4.21.7 Conjunctivitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17846386&form=6&db=m Difficulties in mutation screening of the plasminogen (PLG) gene in patients with ligneous conjunctivitis and severe hypoplasminogenemia. causal interaction,unassigned 2,0 3.4.21.7 Conjunctivitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18312178&form=6&db=m Ligneous conjunctivitis secondary to a congenital plasminogen deficiency in a dog. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 Conjunctivitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18434858&form=6&db=m Systemic and topical fresh-frozen plasma treatment in a newborn with ligneous conjunctivitis. unassigned - 3.4.21.7 Conjunctivitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19006564&form=6&db=m Ligneous conjunctivitis with plasminogen deficiency. causal interaction,unassigned 4,0 3.4.21.7 Conjunctivitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19011568&form=6&db=m Plasminogen deficiency as a rare cause of conjunctivitis and lymphadenopathy. causal interaction,unassigned 4,0 3.4.21.7 Conjunctivitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19132249&form=6&db=m Long-term efficacy of surgical removal of pseudomembranes in a child with ligneous conjunctivitis treated with plasminogen eyedrops. therapeutic application,unassigned 3,0 3.4.21.7 Conjunctivitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19141167&form=6&db=m Plasminogen deficiency. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,4,0 3.4.21.7 Conjunctivitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19373890&form=6&db=m The first two Japanese cases of severe type I congenital plasminogen deficiency with ligneous conjunctivitis: Successful treatment with direct thrombin inhibitor and fresh plasma. causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,3,0 3.4.21.7 Conjunctivitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19604341&form=6&db=m Ligneous conjunctivitis in a plasminogen-deficient dog: clinical management and 2-year follow-up. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.7 Conjunctivitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19689523&form=6&db=m Ligneous conjunctivitis with oral mucous membrane involvement and decreased plasminogen level. causal interaction,unassigned 4,0 3.4.21.7 Conjunctivitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21174000&form=6&db=m Identification of three novel plasminogen (PLG) gene mutations in a series of 23 patients with low PLG activity. causal interaction,therapeutic application,unassigned 4,3,0 3.4.21.7 Conjunctivitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21625933&form=6&db=m Management of ligneous conjunctivitis in a child with plasminogen deficiency. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 Conjunctivitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21859319&form=6&db=m Destructive Membranous Periodontal Disease (Ligneous Gingivitis): A Literature Review. causal interaction,unassigned 4,0 3.4.21.7 Conjunctivitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21885957&form=6&db=m Heparin in the long-term management of ligneous conjunctivitis: a case report and review of literature. causal interaction,unassigned 4,0 3.4.21.7 Conjunctivitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23629776&form=6&db=m Ligneous conjunctivitis in a young patient with homozygous K19E plasminogen gene mutation: a diagnostic and therapeutic challenge. causal interaction,unassigned 2,0 3.4.21.7 Conjunctivitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23684723&form=6&db=m Conjunctival instillation of plasminogen eliminates ocular lesion in B6.129P2-Plg(tm1Jld) transgenic mice, a model of ligneous conjunctivitis. causal interaction,ongoing research,therapeutic application,unassigned 4,4,3,0 3.4.21.7 Conjunctivitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25674820&form=6&db=m Adult-Onset Ligneous Conjunctivitis with Detection of a Novel Plasminogen Gene Mutation and Anti-Plasminogen IgA Antibody: A Clinicopathologic Study and Review of Literature. causal interaction,ongoing research,therapeutic application,unassigned 3,3,1,0 3.4.21.7 Conjunctivitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26036227&form=6&db=m Beyond hemostasis: the challenge of treating plasminogen deficiency. A report of three cases. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 Conjunctivitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26270466&form=6&db=m Letter Regarding "Adult-Onset Ligneous Conjunctivitis with Detection of a Novel Plasminogen Gene Mutation and Anti-Plasminogen IgA Antibody: A Clinicopathologic Study and Review of Literature" by Y. Tu et al. ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.7 Conjunctivitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27045067&form=6&db=m Novel plasminogen and hyaluronate sodium eye drop formulation for a patient with ligneous conjunctivitis. therapeutic application,unassigned 4,0 3.4.21.7 Conjunctivitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27065432&form=6&db=m Topical Plasminogen as Adjunctive Treatment in Recurrent Ligneous Conjunctivitis. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 Conjunctivitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27152037&form=6&db=m Features and outcome of a glomerulonephropathy associated with ligneous conjunctivitis in a Doberman pinscher dog. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.7 Conjunctivitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29379003&form=6&db=m Ligneous periodontitis in a child with plasminogen deficiency. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 Conjunctivitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30165199&form=6&db=m Fresh frozen plasma (Octaplas) and topical heparin in the management of ligneous conjunctivitis. causal interaction,unassigned 3,0 3.4.21.7 Conjunctivitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30180242&form=6&db=m Treatment of Ligneous Conjunctivitis Using Topical Plasminogen Therapy in an 8-Week-Old Female Infant. therapeutic application,unassigned 4,0 3.4.21.7 Conjunctivitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30442487&form=6&db=m Ligneous conjunctivitis due to plasminogen deficit: Diagnostic and therapeutic approach. With literature review. causal interaction,therapeutic application,unassigned 2,3,0 3.4.21.7 Conjunctivitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30513391&form=6&db=m Diagnosis of a case of ligneous gingivitis in a patient with moderate plasminogen deficiency. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,1,0 3.4.21.7 Conjunctivitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30574926&form=6&db=m Ligneous conjunctivitis in a Dandy-Walker syndrome: A rare case report. causal interaction,unassigned 3,0 3.4.21.7 Conjunctivitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30673103&form=6&db=m Retraction: Treatment of Ligneous Conjunctivitis Using Topical Plasminogen Therapy in An 8-Week-Old Female Infant. therapeutic application,unassigned 4,0 3.4.21.7 Conjunctivitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30994256&form=6&db=m Prophylactic protocol for dental care in ligneous gingivitis due to severe plasminogen deficiency: Case report and review of literature. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.7 Conjunctivitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32369847&form=6&db=m Functional Fibrinolysis Assays Reveal Different Mechanisms underlying Plasminogen Dysfunction in Ligneous Conjunctivitis. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,1,1 3.4.21.7 Conjunctivitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33260813&form=6&db=m Repurposing of Plasminogen: An Orphan Medicinal Product Suitable for SARS-CoV-2 Inhalable Therapeutics. causal interaction,therapeutic application,unassigned 1,2,0 3.4.21.7 Conjunctivitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33427557&form=6&db=m Novel homozygous mutation of plasminogen in ligneous conjunctivitis: a case report and literature review. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 Conjunctivitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34049718&form=6&db=m [Pharmaceutical supply of human plasminogen replacement therapy for the treatment of ligneous conjunctivitis: Logistics for a university hospital]. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.7 Conjunctivitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34308677&form=6&db=m Ligneous conjunctivitis associated with type I plasminogen deficiency: A rare case. causal interaction,unassigned 4,0 3.4.21.7 Conjunctivitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34370320&form=6&db=m A large deletion in the Plasminogen gene is associated with ligneous membranitis in a Maltese dog. causal interaction,diagnostic usage,unassigned 2,4,0 3.4.21.7 Conjunctivitis, Allergic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15790903&form=6&db=m Urokinase plasminogen activator, uPa receptor, and its inhibitor in vernal keratoconjunctivitis. causal interaction,therapeutic application,unassigned 4,2,0 3.4.21.7 Conjunctivitis, Bacterial http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11931777&form=6&db=m Effective treatment of ligneous conjunctivitis with topical plasminogen. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,4,0 3.4.21.7 Connective Tissue Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9122714&form=6&db=m The role of inflammatory cells and their proteases in extravascular fibrinolysis. causal interaction,therapeutic application,unassigned 3,3,0 3.4.21.7 Connective Tissue Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32945390&form=6&db=m Decrease in matrix metalloproteinase?3 activity in systemic sclerosis fibroblasts causes ?2?antiplasmin and extracellular matrix deposition, and contributes to fibrosis development. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.7 Corneal Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2973722&form=6&db=m Elevation of tear fluid plasmin in corneal disease. causal interaction,diagnostic usage,unassigned 4,3,0 3.4.21.7 Corneal Dystrophies, Hereditary http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2121316&form=6&db=m [Secretion of plasminogen activators and their inhibitors in corneal fibroblasts. Modification of this secretion in Schnyder's lens corneal dystrophy] causal interaction,ongoing research,unassigned 2,2,0 3.4.21.7 Corneal Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2115456&form=6&db=m Analysis of fibronectin, plasminogen activators and plasminogen in tear fluid as markers of corneal damage and repair. causal interaction,diagnostic usage,therapeutic application,unassigned 2,2,1,0 3.4.21.7 Corneal Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7689549&form=6&db=m The histochemical pattern of mechanically or chemically injured rabbit cornea after aprotinin treatment: relationships with the plasmin concentration of the tear fluid. causal interaction,unassigned 3,0 3.4.21.7 Corneal Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9589908&form=6&db=m Enzyme histochemistry of corneal wound healing. unassigned - 3.4.21.7 Corneal Neovascularization http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2150979&form=6&db=m Plasmin and epidermal growth factor in the tear fluid of contact-lens wearers: effect of wearing different types of contact lenses and association with clinical findings. diagnostic usage,unassigned 2,0 3.4.21.7 Corneal Neovascularization http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9342609&form=6&db=m Inhibitory effects of plasminogen fragment on experimentally induced neovascularization of rat corneas. therapeutic application,unassigned 1,0 3.4.21.7 Corneal Neovascularization http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10630375&form=6&db=m The inhibitory effects of recombinant plasminogen kringle 1-3 on the neovascularization of rabbit cornea induced by angiogenin, bFGF, and VEGF. diagnostic usage,ongoing research,therapeutic application,unassigned 1,1,1,0 3.4.21.7 Corneal Neovascularization http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10746455&form=6&db=m Recombinant kringle 1-3 of plasminogen inhibits rabbit corneal angiogenesis induced by angiogenin. ongoing research,therapeutic application,unassigned 4,2,0 3.4.21.7 Corneal Neovascularization http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11029550&form=6&db=m Towards a closed eye model of the pre-ocular tear layer. unassigned - 3.4.21.7 Corneal Neovascularization http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12920335&form=6&db=m Gene transfer of kringle 5 of plasminogen by electroporation inhibits corneal neovascularization. ongoing research,therapeutic application,unassigned 3,1,0 3.4.21.7 Corneal Neovascularization http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15106938&form=6&db=m Anti-angiogenic role of angiostatin during corneal wound healing. causal interaction,diagnostic usage,unassigned 4,2,0 3.4.21.7 Corneal Neovascularization http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15166500&form=6&db=m The role of the fibrinolytic system in corneal angiogenesis. causal interaction,ongoing research,therapeutic application,unassigned 4,3,3,0 3.4.21.7 Corneal Neovascularization http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16249481&form=6&db=m Plasminogen kringle 5 inhibits alkali-burn-induced corneal neovascularization. unassigned - 3.4.21.7 Corneal Neovascularization http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22994111&form=6&db=m [Fibrinolysis components and angiogenesis regulation by example of burn-induced corneal neovascularization in rabbits]. therapeutic application,unassigned 1,0 3.4.21.7 Corneal Neovascularization http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23343948&form=6&db=m Acidic/Neutral Amino Acid Residues Substitution in NH2 Terminal of Plasminogen Kringle 5 Exerts Enhanced Effects on Corneal Neovascularization. ongoing research,therapeutic application,unassigned 3,1,0 3.4.21.7 Corneal Opacity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10479896&form=6&db=m [Etiology of corneal opacities after plasminogen activator-induced fibrinolysis of the anterior chamber] unassigned - 3.4.21.7 Corneal Ulcer http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2437758&form=6&db=m Plasmin in tear fluid of patients with corneal ulcers: basis for new therapy. causal interaction,diagnostic usage,unassigned 3,3,0 3.4.21.7 Coronary Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15353919&form=6&db=m Decreased plasminogen activator inhibitor-1 levels in coronary artery aneurysmatic patients. causal interaction,unassigned 4,0 3.4.21.7 Coronary Artery Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1527946&form=6&db=m [Tissue plasminogen activator, its inhibitor and other factors of the blood fibrinolytic system in stable coronary heart disease] causal interaction,diagnostic usage,unassigned 1,4,0 3.4.21.7 Coronary Artery Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2444504&form=6&db=m Severity of coronary artery disease and basal fibrinolysis. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,3,1,1 3.4.21.7 Coronary Artery Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2972304&form=6&db=m Thrombin and plasmin activity in coronary artery disease. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,2,0 3.4.21.7 Coronary Artery Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4230197&form=6&db=m [The use of heparin and fibrinolysin in patients with coronary arteriosclerosis] causal interaction,diagnostic usage,therapeutic application,unassigned 1,3,3,0 3.4.21.7 Coronary Artery Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8138162&form=6&db=m The peculiar evolution of apolipoprotein(a) in human and rhesus macaque. causal interaction,unassigned 4,0 3.4.21.7 Coronary Artery Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8562864&form=6&db=m Lipoprotein (a) and fibrinolytic system in liver cirrhosis. Coagulation Abnormalities in Liver Cirrhosis (CALC) Study Group. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,1,0 3.4.21.7 Coronary Artery Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9236431&form=6&db=m Association of an acute reduction in lipoprotein(a) with coronary artery restenosis after percutaneous transluminal coronary angioplasty. causal interaction,unassigned 3,0 3.4.21.7 Coronary Artery Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9883750&form=6&db=m Inflammation, the endothelium, and the acute coronary syndromes. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.7 Coronary Artery Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10225148&form=6&db=m Urokinase plasminogen activator system in humans with stable coronary artery disease. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,2,4,2 3.4.21.7 Coronary Artery Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10452346&form=6&db=m Relation between long-term steroid treatment after heart transplantation, hypofibrinolysis and myocardial microthrombi generation. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 Coronary Artery Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10767104&form=6&db=m Identification of a BamHI Polymorphism for the Urokinase Gene Associated with Symptomatic Coronary Artery Disease. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 Coronary Artery Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11257559&form=6&db=m Effects of human tissue plasminogen gene transfer on allograft coronary atherosclerosis. causal interaction,ongoing research,therapeutic application,unassigned 4,4,2,0 3.4.21.7 Coronary Artery Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12423728&form=6&db=m Plasminogen levels and risk of coronary artery disease. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.7 Coronary Artery Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16706973&form=6&db=m Plasminogen and plasmin activity in patients with coronary artery disease. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,2,0 3.4.21.7 Coronary Artery Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22419885&form=6&db=m The interactions between hemostasis and resistance training: a review. diagnostic usage,therapeutic application,unassigned 1,2,0 3.4.21.7 Coronary Artery Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22538774&form=6&db=m Fibrinolytic status in acute coronary syndromes: evidence of differences in relation to clinical features and pathophysiological pathways. causal interaction,diagnostic usage,therapeutic application,unassigned 1,2,2,0 3.4.21.7 Coronary Artery Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23047269&form=6&db=m Plasminogen and fibrinogen plasma levels in coronary artery disease. diagnostic usage,ongoing research,unassigned 4,2,0 3.4.21.7 Coronary Artery Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23049444&form=6&db=m Plasminogen and fibrinogen plasma levels in coronary artery disease. causal interaction,diagnostic usage,ongoing research,unassigned 3,4,2,0 3.4.21.7 Coronary Artery Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25466412&form=6&db=m Genetic Evidence for PLASMINOGEN as a Shared Genetic Risk Factor of Coronary Artery Disease and Periodontitis. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.7 Coronary Artery Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26510751&form=6&db=m Circulating levels of plasminogen and oxidized phospholipids bound to plasminogen distinguish between atherothrombotic and non-atherothrombotic myocardial infarction. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,1,1,2 3.4.21.7 Coronary Artery Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30870703&form=6&db=m Identification of novel serum markers for the progression of coronary atherosclerosis in WHHLMI rabbits, an animal model of familial hypercholesterolemia. diagnostic usage,unassigned 3,0 3.4.21.7 Coronary Artery Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33776563&form=6&db=m Association of fibrinogen and plasmin inhibitor, but not coagulation factor XIII gene polymorphisms with coronary artery disease. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,1,0 3.4.21.7 Coronary Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1527946&form=6&db=m [Tissue plasminogen activator, its inhibitor and other factors of the blood fibrinolytic system in stable coronary heart disease] causal interaction,diagnostic usage,unassigned 1,4,0 3.4.21.7 Coronary Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2962911&form=6&db=m The effect of exercise on thrombin and plasmin generation in middle-aged men. causal interaction,diagnostic usage,therapeutic application,unassigned 3,2,1,0 3.4.21.7 Coronary Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2976021&form=6&db=m Genetic linkage between lipoprotein(a) phenotype and a DNA polymorphism in the plasminogen gene. unassigned - 3.4.21.7 Coronary Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7667818&form=6&db=m Association of variables of coagulation, fibrinolysis and acute-phase with atherosclerosis in coronary and peripheral arteries and those arteries supplying the brain. causal interaction,ongoing research,unassigned 1,2,0 3.4.21.7 Coronary Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7804733&form=6&db=m Lipid-thrombosis interface. causal interaction,diagnostic usage,unassigned 4,3,0 3.4.21.7 Coronary Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8243232&form=6&db=m [A study on the circadian variation of tissue-type plasminogen activator and its rapid inhibitor in patients with coronary heart disease] causal interaction,diagnostic usage,ongoing research,therapeutic application 1,3,3,3 3.4.21.7 Coronary Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11783153&form=6&db=m [Effect of puerarin on fibrinolytic activity and lipid peroxide in patients with coronary heart disease] ongoing research,therapeutic application,unassigned 4,2,0 3.4.21.7 Coronary Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20379055&form=6&db=m Coagulation Factors II, V, IX, X, XI, and XII, Plasminogen, and alpha-2 Antiplasmin and Risk of Coronary Heart Disease. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,3,2,1 3.4.21.7 Coronary Occlusion http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3068400&form=6&db=m [Blood coagulation shifts in patients with myocardial infarction treated with streptokinase] causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.7 Coronary Occlusion http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6450527&form=6&db=m Intracoronary thrombolysis in evolving myocardial infarction. ongoing research,therapeutic application,unassigned 1,2,0 3.4.21.7 Coronary Stenosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3136953&form=6&db=m Prevention of coronary artery reocclusion and reduction in late coronary artery stenosis after thrombolytic therapy in patients with acute myocardial infarction. A randomized study of maintenance infusion of recombinant human tissue-type plasminogen activator. causal interaction,ongoing research,therapeutic application,unassigned 4,2,4,0 3.4.21.7 Coronary Stenosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21043917&form=6&db=m Streptokinase inhibits acute platelet thrombus formation in stenosed dog coronary arteries. causal interaction,ongoing research,therapeutic application,unassigned 3,2,3,0 3.4.21.7 Coronary Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1909212&form=6&db=m Pathological basis of failure of concurrent glyceryl trinitrate therapy to improve efficacy of tissue type plasminogen activator in coronary thrombosis. ongoing research,therapeutic application,unassigned 4,4,0 3.4.21.7 Coronary Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1946598&form=6&db=m Prevention of reocclusion following tissue type plasminogen activator-induced thrombolysis by the RGD-containing peptide, echistatin, in a canine model of coronary thrombosis. ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.7 Coronary Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2114233&form=6&db=m Acceleration of recombinant tissue-type plasminogen activator-induced thrombolysis and prevention of reocclusion by the combination of heparin and the Arg-Gly-Asp-containing peptide bitistatin in a canine model of coronary thrombosis. diagnostic usage,ongoing research,therapeutic application,unassigned 1,2,3,0 3.4.21.7 Coronary Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2536903&form=6&db=m Dynamics of the multidomain fibrinolytic protein urokinase from two-dimensional NMR. causal interaction,unassigned 1,0 3.4.21.7 Coronary Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3120563&form=6&db=m Role of nitrates in acute myocardial infarction. therapeutic application,unassigned 4,0 3.4.21.7 Coronary Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7641354&form=6&db=m Attenuation of the synthesis of plasminogen activator inhibitor type 1 by niacin. A potential link between lipid lowering and fibrinolysis. causal interaction,diagnostic usage,therapeutic application,unassigned 3,3,4,0 3.4.21.7 Coronary Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7863968&form=6&db=m Novel antithrombotic approaches to coronary artery disease. causal interaction,therapeutic application,unassigned 2,4,0 3.4.21.7 Coronary Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8772682&form=6&db=m Suppression of plasminogen activator inhibitor-1 release from human cerebral endothelium by plasminogen activators. A factor potentially predisposing to intracranial bleeding. causal interaction,therapeutic application,unassigned 3,3,0 3.4.21.7 Coronary Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8891884&form=6&db=m Comparative studies of thrombolysis with single-chain and two-chain recombinant tissue-type plasminogen activators in canine coronary thrombosis. ongoing research,therapeutic application,unassigned 2,2,0 3.4.21.7 Coronary Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9531059&form=6&db=m Enhancement of tissue-type plasminogen activator-induced thrombolysis and prevention of reocclusion by combination with a humanized anti-glycoprotein IIb/IIIa monoclonal antibody, YM337, in a rhesus monkey model of coronary thrombosis. ongoing research,therapeutic application,unassigned 4,2,0 3.4.21.7 Coronary Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14085140&form=6&db=m FIBRINOLYSIN AND ITS RELATION TO THE MANAGEMENT OF CORONARY THROMBOSIS. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,2,0 3.4.21.7 Coronary Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14963043&form=6&db=m Tumor necrosis factor alpha activates the human plasminogen activator inhibitor-1 gene through a distal nuclear factor kappaB site. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.7 COVID-19 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32275753&form=6&db=m Plasminogen improves lung lesions and hypoxemia in patients with COVID-19. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,2,4,3 3.4.21.7 COVID-19 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32329246&form=6&db=m Fibrinolytic abnormalities in acute respiratory distress syndrome (ARDS) and versatility of thrombolytic drugs to treat COVID-19. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.7 COVID-19 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32543119&form=6&db=m Fibrinolysis and COVID-19: A plasmin paradox. causal interaction,therapeutic application,unassigned 1,2,0 3.4.21.7 COVID-19 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32619329&form=6&db=m Specific coagulation markers may provide more therapeutic targets in COVID-19 patients receiving prophylactic anticoagulant. causal interaction,diagnostic usage,therapeutic application,unassigned 3,2,1,0 3.4.21.7 COVID-19 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32676594&form=6&db=m Unique transcriptional changes in coagulation cascade genes in SARS-CoV-2-infected lung epithelial cells: A potential factor in COVID-19 coagulopathies. causal interaction,ongoing research,therapeutic application,unassigned 1,1,1,0 3.4.21.7 COVID-19 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32861744&form=6&db=m The multifaceted role of plasminogen in inflammation. ongoing research,unassigned 2,0 3.4.21.7 COVID-19 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32882718&form=6&db=m Circulating Plasminogen Concentration at Admission in Patients with Coronavirus Disease 2019 (COVID-19). causal interaction,diagnostic usage,unassigned 1,2,0 3.4.21.7 COVID-19 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33196292&form=6&db=m COVID-19 and Sepsis Are Associated With Different Abnormalities in Plasma Procoagulant and Fibrinolytic Activity. causal interaction,diagnostic usage,unassigned 4,1,0 3.4.21.7 COVID-19 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33564744&form=6&db=m A Matter of Caution: Coagulation Parameters in COVID-19 Do Not Differ from Patients with Ruled-Out SARS-CoV-2 Infection in the Emergency Department. causal interaction,diagnostic usage,unassigned 3,2,0 3.4.21.7 COVID-19 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33740387&form=6&db=m Lung Epithelial Cell Transcriptional Regulation as a Factor in COVID-19-associated Coagulopathies. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,3,3,1 3.4.21.7 COVID-19 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33803235&form=6&db=m Assessing Plasmin Generation in Health and Disease. causal interaction,ongoing research,unassigned 4,1,0 3.4.21.7 COVID-19 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33826233&form=6&db=m Biomarkers of coagulation, endothelial function, and fibrinolysis in critically ill patients with COVID-19: A single-center prospective longitudinal study. therapeutic application,unassigned 1,0 3.4.21.7 COVID-19 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34027292&form=6&db=m Comparison of the coagulopathies associated with COVID-19 and sepsis. diagnostic usage,ongoing research,therapeutic application,unassigned 2,4,1,0 3.4.21.7 COVID-19 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34177896&form=6&db=m Thromboplasminflammation in COVID-19 Coagulopathy: Three Viewpoints for Diagnostic and Therapeutic Strategies. causal interaction,ongoing research,therapeutic application,unassigned 4,1,4,0 3.4.21.7 COVID-19 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34354045&form=6&db=m Low level of plasminogen increases risk for mortality in COVID-19 patients. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,4,0 3.4.21.7 COVID-19 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34480127&form=6&db=m Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,4,0 3.4.21.7 Cowpox http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10873770&form=6&db=m The cowpox virus serpin SPI-3 complexes with and inhibits urokinase-type and tissue-type plasminogen activators and plasmin. ongoing research,therapeutic application,unassigned 1,2,0 3.4.21.7 Craniocerebral Trauma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8686939&form=6&db=m [The possible mechanisms of a fibrinolytic disorder in patients with severe craniocerebral trauma] diagnostic usage,unassigned 1,0 3.4.21.7 Creutzfeldt-Jakob Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15519749&form=6&db=m Plasminogen activities and concentrations in patients with sporadic Creutzfeldt-Jakob disease. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,3,0 3.4.21.7 Crohn Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3146142&form=6&db=m Plasminogen activators in the intestine of patients with inflammatory bowel disease. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,4,0 3.4.21.7 Crohn Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10524640&form=6&db=m Acute inflammatory intestinal vascular lesions and in situ abnormalities of the plasminogen activation system in Crohn's disease. causal interaction,diagnostic usage,ongoing research,unassigned 3,3,1,0 3.4.21.7 Cushing Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4082087&form=6&db=m Further studies on the hypercoagulable state of patients with Cushing's syndrome. causal interaction,diagnostic usage,unassigned 2,2,0 3.4.21.7 Cystic Fibrosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16236890&form=6&db=m Sputum cathelicidin, urokinase plasminogen activation system components, and cytokines discriminate cystic fibrosis, COPD, and asthma inflammation. ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.7 Cysts http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7514904&form=6&db=m Perturbations in the fibrinolytic pathway abolish cyst formation but not capillary-like organization of cultured murine endothelial cells. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,1,2,2 3.4.21.7 Cysts http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7675374&form=6&db=m Fluid characteristics of benign ovarian cysts: correlation with recurrence after puncture. causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,1,0 3.4.21.7 Cysts http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12017303&form=6&db=m Clinical value of components of the plasminogen activation system in ovarian cyst fluid. causal interaction,diagnostic usage,ongoing research,unassigned 1,3,3,0 3.4.21.7 Cysts http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17321054&form=6&db=m Role of tissue-plasminogen activator (t-PA) in a mouse model of neonatal white matter lesions: interaction with plasmin inhibitors and anti-inflammatory drugs. causal interaction,ongoing research,unassigned 2,3,0 3.4.21.7 Cysts http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20646237&form=6&db=m Urokinase and its receptor in follicular and inflammatory cysts of the jaws. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,3,1 3.4.21.7 Cysts http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24535412&form=6&db=m Plasminogen activators are involved in angiostatin generation in vivo in benign and malignant ovarian tumor cyst fluids. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,4,1 3.4.21.7 Cysts http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26717601&form=6&db=m PLASMINOGEN AND ANGIOSTATIN LEVELS IN FEMALE BENIGN BREAST LESIONS. causal interaction,diagnostic usage,ongoing research,unassigned 1,3,4,0 3.4.21.7 Cytomegalovirus Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9661834&form=6&db=m Human cytomegalovirus infection induces mRNA expression and secretion of plasminogen inhibitor type-1 in endothelial cells. causal interaction,diagnostic usage,ongoing research,unassigned 1,3,4,0 3.4.21.7 Darier Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1751348&form=6&db=m Cell adhesion in Hailey-Hailey disease and Darier's disease: immunocytological and explant-tissue-culture studies. causal interaction,unassigned 3,0 3.4.21.7 Darier Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2688736&form=6&db=m Darier's disease: an immunohistochemical study using antibodies to proteases. causal interaction,diagnostic usage,ongoing research,unassigned 1,3,4,0 3.4.21.7 Darier Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7510121&form=6&db=m Cantharidin-induced acantholysis: adhesion molecules, proteases, and related proteins. causal interaction,diagnostic usage,ongoing research,unassigned 3,3,2,0 3.4.21.7 Darier Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7519031&form=6&db=m Cantharidin-induced acantholysis in Darier's disease: does acantholysis initiate dyskeratosis? ongoing research,unassigned 1,0 3.4.21.7 Death, Sudden, Cardiac http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10621877&form=6&db=m Circadian fluctuations in the efficacy of thrombolysis with streptokinase. diagnostic usage,ongoing research,therapeutic application,unassigned 2,1,4,0 3.4.21.7 Death, Sudden, Cardiac http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25498839&form=6&db=m Unusual cause of aborted sudden cardiac death in a teen athlete: homozygosity for the 4G allele of the plasminogen activase inhibitor type 1 gene. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.7 Dehydration http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11045601&form=6&db=m Stress down regulates milk yield in cows by plasmin induced beta-casein product that blocks K+ channels on the apical membranes. causal interaction,unassigned 1,0 3.4.21.7 Dehydration http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20169734&form=6&db=m [Effects of dehydration and infusion of blood substitutes on the hemostasis system in an experiment with 21-hour bed rest] diagnostic usage,therapeutic application,unassigned 1,1,0 3.4.21.7 Dehydration http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29249727&form=6&db=m Expression, purification, and biological characterization of Anaplasma phagocytophilum enolase. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.7 Dementia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15519749&form=6&db=m Plasminogen activities and concentrations in patients with sporadic Creutzfeldt-Jakob disease. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,3,0 3.4.21.7 Dementia, Vascular http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20709033&form=6&db=m Plasminogen and plasmin in Alzheimer's disease. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,4,0 3.4.21.7 Dementia, Vascular http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23231415&form=6&db=m tPA in the central nervous system: relations between tPA and cell surface LRPs. causal interaction,unassigned 3,0 3.4.21.7 Demyelinating Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=568743&form=6&db=m The modification of experimental allergic encephalomyelitis with epsilon aminocaproic acid. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.7 Demyelinating Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2936427&form=6&db=m Complement potentiates the degradation of myelin proteins by plasmin: implications for a mechanism of inflammatory demyelination. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.7 Demyelinating Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6167674&form=6&db=m Degradation of the P0, P1, and Pr proteins in peripheral nervous system myelin by plasmin: implications regarding the role of macrophages in demyelinating diseases. causal interaction,ongoing research,therapeutic application,unassigned 3,4,2,0 3.4.21.7 Demyelinating Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6223865&form=6&db=m Plasminogen activator activity and plasmin inhibition in nerves. unassigned - 3.4.21.7 Demyelinating Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10376931&form=6&db=m Plasminogen activators and matrix metalloproteases, mediators of extracellular proteolysis in inflammatory demyelination of the central nervous system. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.7 Demyelinating Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10426151&form=6&db=m Tissue plasminogen activator gene expression in multiple sclerosis brain tissue. causal interaction,ongoing research,unassigned 3,4,0 3.4.21.7 Demyelinating Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10831618&form=6&db=m Tissue plasminogen activator-mediated fibrinolysis protects against axonal degeneration and demyelination after sciatic nerve injury. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.7 Demyelinating Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28275164&form=6&db=m Plasminogen Deficiency Delays the Onset and Protects from Demyelination and Paralysis in Autoimmune Neuroinflammatory Disease. causal interaction,ongoing research,therapeutic application,unassigned 3,3,2,0 3.4.21.7 Dengue http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1856477&form=6&db=m Development of cross-reactive antibodies to plasminogen during the immune response to dengue virus infection. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,1,2,2 3.4.21.7 Dengue http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7963733&form=6&db=m Correlation between detection of plasminogen cross-reactive antibodies and hemorrhage in dengue virus infection. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,2,1 3.4.21.7 Dengue http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9353146&form=6&db=m Antibodies against dengue virus E protein peptide bind to human plasminogen and inhibit plasmin activity. diagnostic usage,ongoing research,therapeutic application,unassigned 1,3,2,0 3.4.21.7 Dengue http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11129636&form=6&db=m Participation of the Dengue virus in the fibrinolytic process. diagnostic usage,therapeutic application,unassigned 2,2,0 3.4.21.7 Dengue http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12115093&form=6&db=m Coagulation abnormalities in dengue hemorrhagic Fever: serial investigations in 167 Vietnamese children with Dengue shock syndrome. diagnostic usage,unassigned 3,0 3.4.21.7 Dengue http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19331544&form=6&db=m GRP78: a multifunctional receptor on the cell surface. unassigned - 3.4.21.7 Dengue http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19401765&form=6&db=m Peptide Bbeta(15-42) preserves endothelial barrier function in shock. therapeutic application,unassigned 2,0 3.4.21.7 Dengue http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22079981&form=6&db=m Dengue virus-induced autoantibodies bind to plasminogen and enhance its activation. causal interaction,unassigned 4,0 3.4.21.7 Dengue http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23740201&form=6&db=m Antibodies against thrombin in dengue patients contain both anti-thrombotic and pro-fibrinolytic activities. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,2,1 3.4.21.7 Dengue http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25171719&form=6&db=m Modulation of ?-enolase post-translational modifications by dengue virus: increased secretion of the basic isoforms in infected hepatic cells. causal interaction,unassigned 1,0 3.4.21.7 Dengue http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26712948&form=6&db=m Dengue Virus Nonstructural Protein 1-Induced Antibodies Cross-React with Human Plasminogen and Enhance Its Activation. causal interaction,ongoing research,therapeutic application,unassigned 1,3,2,0 3.4.21.7 Dengue http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31726374&form=6&db=m Increased Mosquito Midgut Infection by Dengue Virus Recruitment of Plasmin Is Blocked by an Endogenous Kazal-type Inhibitor. ongoing research,therapeutic application,unassigned 2,2,0 3.4.21.7 Dengue http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33231723&form=6&db=m Current Understanding of the Pathogenesis of Dengue Virus Infection. causal interaction,therapeutic application,unassigned 2,1,0 3.4.21.7 Dental Plaque http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7593702&form=6&db=m Cellular source, activation and inhibition of dental plaque collagenase. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,4,3 3.4.21.7 Dental Plaque http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12558944&form=6&db=m Relationship between fibrinolytic activity and gingival inflammatory reaction in young individuals. causal interaction,unassigned 4,0 3.4.21.7 Dental Plaque http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18310038&form=6&db=m Plasminogen binding by oral streptococci from dental plaque and inflammatory lesions. diagnostic usage,ongoing research,unassigned 1,4,0 3.4.21.7 Dermatitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9257378&form=6&db=m The effect of tamol on human mast cell chymase and plasmin. therapeutic application,unassigned 1,0 3.4.21.7 Dermatitis, Atopic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2777445&form=6&db=m Plasminogen activators and antiplasmin activity in atopic dermatitis. unassigned - 3.4.21.7 Dermatitis, Atopic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29691836&form=6&db=m Early-life regional and temporal variation in filaggrin-derived natural moisturizing factor, filaggrin-processing enzyme activity, corneocyte phenotypes and plasmin activity: implications for atopic dermatitis. unassigned - 3.4.21.7 Dermatomyositis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8902649&form=6&db=m Circadian variations of plasma levels of blood coagulation/fibrinolysis molecular markers in progressive systemic sclerosis (PSS). causal interaction,diagnostic usage,ongoing research,unassigned 1,4,2,0 3.4.21.7 Diabetes Complications http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9201602&form=6&db=m Do tissue plasminogen activator-plasminogen activator inhibitor-1 complexes relate to the complications of insulin-dependent diabetes mellitus? Pittsburgh Epidemiology of Diabetes Complications Study. ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.7 Diabetes Complications http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10808060&form=6&db=m Importance of hypercoagulability over hyperglycemia for vascular complication in type 2 diabetes. causal interaction,diagnostic usage,unassigned 1,3,0 3.4.21.7 Diabetes Complications http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29075072&form=6&db=m Evaluation of Coagulation Profile in Children with Type 1 Diabetes Mellitus Using Rotational Thromboelastometry. diagnostic usage,unassigned 4,0 3.4.21.7 Diabetes Complications http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33215566&form=6&db=m Plasminogen Deficiency and Amiloride Mitigate Angiotensin II-Induced Hypertension in Type 1 Diabetic Mice Suggesting Effects Through the Epithelial Sodium Channel. causal interaction,ongoing research,therapeutic application,unassigned 4,1,4,0 3.4.21.7 Diabetes Mellitus http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1476075&form=6&db=m [Plasma fibrinopeptide A, fibrinopeptide B beta 15-42 and 4 other coagulation factors levels in patients with diabetic retinopathy] diagnostic usage,unassigned 3,0 3.4.21.7 Diabetes Mellitus http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1839461&form=6&db=m Plasminogen activation in diabetes mellitus: kinetics of plasmin formation with plasminogen and tissue plasminogen activator from diabetic donors. causal interaction,therapeutic application,unassigned 4,2,0 3.4.21.7 Diabetes Mellitus http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2934857&form=6&db=m Plasminogen activation in diabetes mellitus: normalization of blood sugar levels improves impaired enzyme kinetics in vitro. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,3,3,1 3.4.21.7 Diabetes Mellitus http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2971234&form=6&db=m Thrombin and plasmin activity in diabetes mellitus and their association with glycaemic control. causal interaction,ongoing research,therapeutic application,unassigned 3,2,2,0 3.4.21.7 Diabetes Mellitus http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2971532&form=6&db=m Plasminogen activation in diabetes mellitus. Kinetics of plasmin formation with tissue plasminogen activator and plasminogen from individual diabetic donors and with in vitro glucosylated plasminogen. causal interaction,ongoing research,therapeutic application,unassigned 3,2,2,0 3.4.21.7 Diabetes Mellitus http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3423401&form=6&db=m [Effect of venous stasis on plasminogen activation and plasma alpha 2-antiplasmin levels in type II diabetes mellitus] causal interaction,ongoing research,therapeutic application,unassigned 2,4,1,0 3.4.21.7 Diabetes Mellitus http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6230354&form=6&db=m Plasminogen activation in diabetes mellitus. Kinetic analysis of plasmin formation using components isolated from the plasma of diabetic donors. diagnostic usage,ongoing research,unassigned 3,2,0 3.4.21.7 Diabetes Mellitus http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7554780&form=6&db=m The association of fibrinolysis and hyperlipidaemia with quantitative sensory tests in an epidemiological study of Swedish type 1 diabetic patients. diagnostic usage,unassigned 2,0 3.4.21.7 Diabetes Mellitus http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7798804&form=6&db=m [Plasminogen activation and erythrocyte aggregation in diabetic patients] causal interaction,ongoing research,therapeutic application,unassigned 1,4,1,0 3.4.21.7 Diabetes Mellitus http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8354802&form=6&db=m Significance of diabetes mellitus in patients with acute myocardial infarction receiving thrombolytic therapy. Investigators of the International Tissue Plasminogen Activator/Streptokinase Mortality Trial. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,1,1,4 3.4.21.7 Diabetes Mellitus http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9207639&form=6&db=m Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. causal interaction,diagnostic usage,therapeutic application,unassigned 4,1,3,0 3.4.21.7 Diabetes Mellitus http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9290555&form=6&db=m Lipoprotein (a) and its relationship to risk factors and severity of atherosclerotic peripheral vascular disease. causal interaction,diagnostic usage,unassigned 1,2,0 3.4.21.7 Diabetes Mellitus http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10522403&form=6&db=m [Lipoprotein and plasminogen serum levels in patients with diabetes mellitus type 2: risk factors for macroangiopathy? Preliminary study] diagnostic usage,unassigned 4,0 3.4.21.7 Diabetes Mellitus http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10729302&form=6&db=m Regulation of plasminogen activation by TGF-beta in cultured human retinal endothelial cells. diagnostic usage,ongoing research,unassigned 3,4,0 3.4.21.7 Diabetes Mellitus http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11573053&form=6&db=m Impact of atherosclerotic risk factors on the anatomical distribution of peripheral arterial disease. causal interaction,diagnostic usage,unassigned 1,2,0 3.4.21.7 Diabetes Mellitus http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16124372&form=6&db=m [Lipoprotein(a) and plasminogen patients with diabetes mellitus complicated with peripheral angiopathy and hypertension] diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.7 Diabetes Mellitus http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16538489&form=6&db=m Molecular mechanisms involved in the resistance of fibrin to clot lysis by plasmin in subjects with type 2 diabetes mellitus. diagnostic usage,therapeutic application,unassigned 1,1,0 3.4.21.7 Diabetes Mellitus http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20045213&form=6&db=m Effects of Glimepiride on metabolic parameters and cardiovascular risk factors in patients with newly diagnosed type 2 diabetes mellitus. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,3,4,3 3.4.21.7 Diabetes Mellitus http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21537159&form=6&db=m Add-on rosiglitazone therapy improves plasminogen activity and high-density lipoprotein cholesterol in type 2 diabetes mellitus. diagnostic usage,ongoing research,therapeutic application,unassigned 2,1,2,0 3.4.21.7 Diabetes Mellitus http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24101699&form=6&db=m Association of PAI-1 and Fibrinogen with Diabetic Retinopathy in the Veterans Affairs Diabetes Trial (VADT). diagnostic usage,unassigned 3,0 3.4.21.7 Diabetes Mellitus http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24805959&form=6&db=m Plasmin in urine from patients with type 2 diabetes and treatment-resistant hypertension activates ENaC in vitro. causal interaction,diagnostic usage,ongoing research,unassigned 1,2,1,0 3.4.21.7 Diabetes Mellitus http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26315791&form=6&db=m Risk Factors for Thrombosis Development in Mexican Patients. diagnostic usage,unassigned 2,0 3.4.21.7 Diabetes Mellitus http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28495827&form=6&db=m Hyperbaric Oxygen Reduces Infarction Volume and Hemorrhagic Transformation Through ATP/NAD(+)/Sirt1 Pathway in Hyperglycemic Middle Cerebral Artery Occlusion Rats. therapeutic application,unassigned 4,0 3.4.21.7 Diabetes Mellitus http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33215566&form=6&db=m Plasminogen Deficiency and Amiloride Mitigate Angiotensin II-Induced Hypertension in Type 1 Diabetic Mice Suggesting Effects Through the Epithelial Sodium Channel. causal interaction,ongoing research,therapeutic application,unassigned 4,1,4,0 3.4.21.7 Diabetes Mellitus, Type 1 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9201602&form=6&db=m Do tissue plasminogen activator-plasminogen activator inhibitor-1 complexes relate to the complications of insulin-dependent diabetes mellitus? Pittsburgh Epidemiology of Diabetes Complications Study. ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.7 Diabetes Mellitus, Type 1 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17586991&form=6&db=m Hemostatic variables in Arab diabetics. causal interaction,diagnostic usage,unassigned 3,3,0 3.4.21.7 Diabetes Mellitus, Type 2 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1628764&form=6&db=m Free radical activity and hemostatic factors in NIDDM patients with and without microalbuminuria. diagnostic usage,ongoing research,unassigned 3,1,0 3.4.21.7 Diabetes Mellitus, Type 2 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2127812&form=6&db=m [Tissue-type plasminogen activator and its inhibitor (PAI-1) in plasma in cases of non-insulin-dependent diabetes mellitus (NIDDM)] causal interaction,diagnostic usage,ongoing research,therapeutic application 1,3,3,3 3.4.21.7 Diabetes Mellitus, Type 2 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7648783&form=6&db=m Blood coagulation and fibrinolysis in obese NIDDM patients. causal interaction,diagnostic usage,unassigned 2,1,0 3.4.21.7 Diabetes Mellitus, Type 2 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7833500&form=6&db=m Hemobiological properties of gliclazide. diagnostic usage,therapeutic application,unassigned 2,1,0 3.4.21.7 Diabetes Mellitus, Type 2 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10684070&form=6&db=m [Changes of serum TNF-alpha level, t-PA activivty and PAI activity in patients with silent myocardial ischemia or silent cerebral ischemia] diagnostic usage,ongoing research,unassigned 4,2,0 3.4.21.7 Diabetes Mellitus, Type 2 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10808060&form=6&db=m Importance of hypercoagulability over hyperglycemia for vascular complication in type 2 diabetes. causal interaction,diagnostic usage,unassigned 1,3,0 3.4.21.7 Diabetes Mellitus, Type 2 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16538489&form=6&db=m Molecular mechanisms involved in the resistance of fibrin to clot lysis by plasmin in subjects with type 2 diabetes mellitus. diagnostic usage,therapeutic application,unassigned 1,1,0 3.4.21.7 Diabetes Mellitus, Type 2 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17586991&form=6&db=m Hemostatic variables in Arab diabetics. causal interaction,diagnostic usage,unassigned 3,3,0 3.4.21.7 Diabetes Mellitus, Type 2 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20045213&form=6&db=m Effects of Glimepiride on metabolic parameters and cardiovascular risk factors in patients with newly diagnosed type 2 diabetes mellitus. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,3,4,3 3.4.21.7 Diabetes Mellitus, Type 2 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21409315&form=6&db=m Effects of Different Protein Sources on Plasminogen Inhibitor-1 and Factor VII Coagulant Activity Added to a Fat-Rich Meal in Type 2 Diabetes. causal interaction,ongoing research,unassigned 4,3,0 3.4.21.7 Diabetes Mellitus, Type 2 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21537159&form=6&db=m Add-on rosiglitazone therapy improves plasminogen activity and high-density lipoprotein cholesterol in type 2 diabetes mellitus. diagnostic usage,ongoing research,therapeutic application,unassigned 2,1,2,0 3.4.21.7 Diabetes Mellitus, Type 2 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24101699&form=6&db=m Association of PAI-1 and Fibrinogen with Diabetic Retinopathy in the Veterans Affairs Diabetes Trial (VADT). diagnostic usage,unassigned 3,0 3.4.21.7 Diabetes Mellitus, Type 2 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24805959&form=6&db=m Plasmin in urine from patients with type 2 diabetes and treatment-resistant hypertension activates ENaC in vitro. causal interaction,diagnostic usage,ongoing research,unassigned 1,2,1,0 3.4.21.7 Diabetic Foot http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11983003&form=6&db=m Mechanism of action of PROMOGRAN, a protease modulating matrix, for the treatment of diabetic foot ulcers. causal interaction,ongoing research,therapeutic application,unassigned 1,1,4,0 3.4.21.7 Diabetic Nephropathies http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2148199&form=6&db=m [Studies on coagulation-fibrinolytic system in diabetic nephropathy--with reference to plasma TAT and alpha 2PIC] diagnostic usage,ongoing research,unassigned 4,4,0 3.4.21.7 Diabetic Nephropathies http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2151230&form=6&db=m Fibrinolysis in patients with diabetic nephropathy determined by plasmin-alpha 2 plasmin inhibitor complexes in plasma. diagnostic usage,ongoing research,therapeutic application,unassigned 3,1,1,0 3.4.21.7 Diabetic Nephropathies http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2427398&form=6&db=m [The vascular wall and fibrinolysis--pathologic aspects] causal interaction,therapeutic application,unassigned 4,2,0 3.4.21.7 Diabetic Nephropathies http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8361049&form=6&db=m [Urinary-plasmin alpha 2 plasmin inhibitor complex (PIC) in patients with diabetic nephropathy] causal interaction,therapeutic application,unassigned 3,2,0 3.4.21.7 Diabetic Nephropathies http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8834126&form=6&db=m [Lipid metabolism and fibrinolysis in diabetic nephropathy in the course of diabetes type II] diagnostic usage,ongoing research,unassigned 3,1,0 3.4.21.7 Diabetic Nephropathies http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10997695&form=6&db=m Effects of glucose on matrix metalloproteinase and plasmin activities in mesangial cells: possible role in diabetic nephropathy. ongoing research,unassigned 4,0 3.4.21.7 Diabetic Nephropathies http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14530509&form=6&db=m Extracellular matrix degradation by cultured mesangial cells: mediators and modulators. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 Diabetic Nephropathies http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18580857&form=6&db=m The role of megsin, a serine protease inhibitor, in diabetic mesangial matrix accumulation. causal interaction,ongoing research,unassigned 3,1,0 3.4.21.7 Diabetic Nephropathies http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19166201&form=6&db=m [Effects of shear stress on expression of plasminogen activator (tPA and uPA) in cultured kidney proximal tubular epithelial cells and its significance] ongoing research,unassigned 4,0 3.4.21.7 Diabetic Nephropathies http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25609736&form=6&db=m Diabetic nephropathy is associated with increased urine excretion of proteases plasmin, prostasin and urokinase and activation of amiloride-sensitive current in collecting duct cells. causal interaction,unassigned 2,0 3.4.21.7 Diabetic Nephropathies http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27214087&form=6&db=m Significant natriuretic and antihypertensive action of the epithelial sodium channel blocker amiloride in diabetic patients with and without nephropathy. causal interaction,diagnostic usage,therapeutic application,unassigned 2,3,1,0 3.4.21.7 Diabetic Nephropathies http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33215566&form=6&db=m Plasminogen Deficiency and Amiloride Mitigate Angiotensin II-Induced Hypertension in Type 1 Diabetic Mice Suggesting Effects Through the Epithelial Sodium Channel. causal interaction,ongoing research,therapeutic application,unassigned 4,1,4,0 3.4.21.7 Diabetic Retinopathy http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1741410&form=6&db=m Human retinal vascular cells differ from umbilical cells in synthetic functions and their response to glucose. ongoing research,unassigned 4,0 3.4.21.7 Diabetic Retinopathy http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4227089&form=6&db=m [Studies on diabetic retinopathy and plasmin activity in the blood (with reference to duration and blood sugar)] ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.7 Diabetic Retinopathy http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6785097&form=6&db=m The metabolism of fibrinogen and plasminogen related to diabetic retinopathy in man. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.7 Diabetic Retinopathy http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11292663&form=6&db=m Influence of plasminogen activator inhibitor type 1 on choroidal neovascularization. causal interaction,ongoing research,therapeutic application,unassigned 3,3,4,0 3.4.21.7 Diabetic Retinopathy http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11581070&form=6&db=m Autologous plasmin enzyme in the surgical management of diabetic retinopathy. diagnostic usage,therapeutic application,unassigned 2,4,0 3.4.21.7 Diabetic Retinopathy http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14562162&form=6&db=m uPA, tPA and PAI-1 mRNA expression in periretinal membranes. causal interaction,ongoing research,unassigned 1,1,0 3.4.21.7 Diabetic Retinopathy http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18040248&form=6&db=m Plasmin-assisted vitrectomy for management of proliferative membrane in proliferative diabetic retinopathy: a pilot study. causal interaction,diagnostic usage,therapeutic application,unassigned 3,2,4,0 3.4.21.7 Diabetic Retinopathy http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20939804&form=6&db=m Pharmacologic Vitreolysis in Diabetic Retinopathy. therapeutic application,unassigned 4,0 3.4.21.7 Diabetic Retinopathy http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24101699&form=6&db=m Association of PAI-1 and Fibrinogen with Diabetic Retinopathy in the Veterans Affairs Diabetes Trial (VADT). diagnostic usage,unassigned 3,0 3.4.21.7 Diabetic Retinopathy http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24379923&form=6&db=m Enzymatic vitrectomy for diabetic retinopathy and diabetic macular edema. therapeutic application,unassigned 1,0 3.4.21.7 Diabetic Retinopathy http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31892939&form=6&db=m Utilizing network pharmacology to explore the underlying mechanism of Radix Salviae in diabetic retinopathy. unassigned - 3.4.21.7 Diabetic Retinopathy http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33338749&form=6&db=m Human plasminogen-derived N-acetyl-Arg-Leu-Tyr-Glu antagonizes VEGFR-2 to prevent blood-retinal barrier breakdown in diabetic mice. causal interaction,ongoing research,therapeutic application,unassigned 3,3,4,0 3.4.21.7 Diphtheria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6460384&form=6&db=m Antibody spectrum and anticomplementary activity of a plasmin-treated human immunoglobulin preparation. therapeutic application,unassigned 1,0 3.4.21.7 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=68962&form=6&db=m The behavior of alpha2-plasmin inhibitor in fibrinolytic states. causal interaction,diagnostic usage,unassigned 1,3,0 3.4.21.7 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=365218&form=6&db=m Characterization of serum fibrinogen and fibrin fragments produced during disseminated intravascular coagulation. therapeutic application,unassigned 3,0 3.4.21.7 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=428708&form=6&db=m The hemostatic defect of chronic liver disease. Kinetic studies using 75Se-selenomethionine. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,2,0 3.4.21.7 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1414164&form=6&db=m High plasma urokinase-type plasminogen activator levels are present in patients with acute nonlymphoblastic leukemia. causal interaction,diagnostic usage,ongoing research,unassigned 3,4,3,0 3.4.21.7 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1468720&form=6&db=m Imbalance between thrombin and plasmin activity in disseminated intravascular coagulation. Assessment by the thrombin-antithrombin-III complex/plasmin-alpha-2-antiplasmin complex ratio. causal interaction,diagnostic usage,ongoing research,unassigned 3,4,4,0 3.4.21.7 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1574711&form=6&db=m Pathways of coagulation/fibrinolysis activation in malignancy. causal interaction,unassigned 4,0 3.4.21.7 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1601644&form=6&db=m Massive pulmonary embolism presenting as disseminated intravascular coagulation. causal interaction,diagnostic usage,unassigned 1,2,0 3.4.21.7 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1689102&form=6&db=m Thrombin vs. plasmin generation in disseminated intravascular coagulation associated with various underlying disorders. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,1,1 3.4.21.7 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2304886&form=6&db=m Effects of intravenous infusion of human prostate tissue substances in dogs. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2457307&form=6&db=m Plasmin-alpha 2-plasmin inhibitor complex in plasma of patients with disseminated intravascular coagulation. diagnostic usage,ongoing research,unassigned 3,2,0 3.4.21.7 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2479264&form=6&db=m Thrombin generation in patients with thrombotic thrombocytopenic purpura. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.7 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2814942&form=6&db=m New rapid assay for factor XIa-alpha 1 antitrypsin complex--application to DIC. causal interaction,diagnostic usage,unassigned 1,4,0 3.4.21.7 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3260969&form=6&db=m [Serial changes in protein C, antithrombin III, alpha 2-plasmin inhibitor, plasminogen and von Willebrand factor during the course of disseminated intravascular coagulation (DIC)] causal interaction,unassigned 2,0 3.4.21.7 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4267735&form=6&db=m Experimental study of rabbit fibrinogen degradation products. Influence of plasminogen level for the interpretation of serum concentration of fibrinogen degradation products in consumption coagulopathies. ongoing research,unassigned 1,0 3.4.21.7 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4281540&form=6&db=m Comparative effects of proteinase inhibitors, plasminogen antiactivators, heparin and acetylsalicylic acid on the experimental disseminated intravascular coagulation induced by thormbin. diagnostic usage,ongoing research,therapeutic application,unassigned 2,1,3,0 3.4.21.7 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6201189&form=6&db=m Plasmin-alpha 2-antiplasmin complexes in bleeding disorders characterized by primary or secondary fibrinolysis. causal interaction,ongoing research,therapeutic application,unassigned 3,1,3,0 3.4.21.7 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6230075&form=6&db=m Fibrinogen proteolysis by thrombin, plasmin and platelet release in relation to disseminated intravascular coagulation. diagnostic usage,therapeutic application,unassigned 2,1,0 3.4.21.7 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6445089&form=6&db=m Studies on the purification and characterization of human urinary plasminogen and plasmin. causal interaction,diagnostic usage,ongoing research,unassigned 3,1,2,0 3.4.21.7 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6821696&form=6&db=m Hematin: unique effects of hemostasis. causal interaction,diagnostic usage,therapeutic application,unassigned 1,3,1,0 3.4.21.7 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7087244&form=6&db=m [Protease inhibitors and plasminogen in leukemia--with special reference to disseminated intravascular coagulation (author's transl)] therapeutic application,unassigned 3,0 3.4.21.7 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7263467&form=6&db=m Disseminated intravascular coagulation: antithrombin, plasminogen, and coagulation abnormalities in 41 dogs. causal interaction,diagnostic usage,unassigned 2,3,0 3.4.21.7 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7489960&form=6&db=m Disseminated intravascular coagulation in endemic hepatosplenic schistosomiasis. causal interaction,diagnostic usage,unassigned 3,2,0 3.4.21.7 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8257301&form=6&db=m Consumption coagulopathy associated with shock in acute African swine fever. diagnostic usage,unassigned 3,0 3.4.21.7 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8381885&form=6&db=m [Advancement in the diagnosis of disseminated intravascular coagulation for the surgeon] causal interaction,diagnostic usage,ongoing research,therapeutic application 1,3,3,1 3.4.21.7 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8710052&form=6&db=m Coagulation and fibrinolysis study after local thrombolysis of a cerebral artery with urokinase. diagnostic usage,unassigned 1,0 3.4.21.7 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8772240&form=6&db=m Endotoxin-induced intravascular coagulation in rabbits: effect of tissue plasminogen activator vs urokinase of PAI generation, fibrin deposits and mortality. ongoing research,therapeutic application,unassigned 3,1,0 3.4.21.7 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9097085&form=6&db=m Fibronectin, platelet factor 4 and beta-thromboglobulin in endemic hepatosplenic schistosomiasis: relation to acute hematemesis. causal interaction,diagnostic usage,therapeutic application,unassigned 1,2,1,0 3.4.21.7 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9760336&form=6&db=m Effect of urokinase on disseminated intravascular coagulation. causal interaction,ongoing research,therapeutic application,unassigned 2,4,4,0 3.4.21.7 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9864925&form=6&db=m Acute generalized, widespread bleeding. Diagnosis and management. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.7 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10226899&form=6&db=m Vitamin K reduces bleeding in left ventricular assist device recipients. unassigned - 3.4.21.7 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11299067&form=6&db=m Close relationship of tissue plasminogen activator-plasminogen activator inhibitor-1 complex with multiple organ dysfunction syndrome investigated by means of the artificial pancreas. diagnostic usage,ongoing research,therapeutic application,unassigned 1,2,1,0 3.4.21.7 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11308009&form=6&db=m Treatment of severe acute respiratory distress syndrome: a final report on a phase I study. therapeutic application,unassigned 1,0 3.4.21.7 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11460011&form=6&db=m Depressed plasma activity of plasminogen or alpha2 plasmin inhibitor is not due to consumption coagulopathy in septic patients with disseminated intravascular coagulation. diagnostic usage,ongoing research,therapeutic application,unassigned 3,2,1,0 3.4.21.7 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11740686&form=6&db=m Fibrinolysis in disseminated intravascular coagulation. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.7 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11740689&form=6&db=m Fibrin degradation products, fibrin monomer and soluble fibrin in disseminated intravascular coagulation. diagnostic usage,unassigned 4,0 3.4.21.7 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20655560&form=6&db=m Disseminated intravascular coagulation at an early phase of trauma is associated with consumption coagulopathy and excessive fibrinolysis both by plasmin and neutrophil elastase. causal interaction,diagnostic usage,therapeutic application,unassigned 3,3,2,0 3.4.21.7 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21804371&form=6&db=m Postoperative bleeding in a patient with normal screening coagulation tests. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,1,0 3.4.21.7 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22353215&form=6&db=m A low TAFI activity and insufficient activation of fibrinolysis by both plasmin and neutrophil elastase promote organ dysfunction in disseminated intravascular coagulation associated with sepsis. causal interaction,therapeutic application,unassigned 2,1,0 3.4.21.7 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24674618&form=6&db=m Expression of tissue factor in canine mammary tumours and correlation with grade, stage and markers of haemostasis and inflammation. causal interaction,diagnostic usage,ongoing research,unassigned 1,1,1,0 3.4.21.7 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28744465&form=6&db=m Role of Vascular Endothelial Cells in Disseminated Intravascular Coagulation Induced by Seawater Immersion in a Rat Trauma Model. diagnostic usage,unassigned 3,0 3.4.21.7 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30781907&form=6&db=m Studies on the Purification and Characterization of Human Urinary Plasminogen and Plasmin. diagnostic usage,unassigned 1,0 3.4.21.7 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31682515&form=6&db=m DNA-bound elastase of neutrophil extracellular traps degrades plasminogen, reduces plasmin formation, and decreases fibrinolysis: proof of concept in septic shock plasma. causal interaction,ongoing research,therapeutic application,unassigned 1,1,3,0 3.4.21.7 Down Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24519975&form=6&db=m Nerve growth factor metabolic dysfunction in Down's syndrome brains. causal interaction,unassigned 3,0 3.4.21.7 Down Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29342922&form=6&db=m Can EGCG Alleviate Symptoms of Down Syndrome by Altering Proteolytic Activity? causal interaction,ongoing research,unassigned 1,3,0 3.4.21.7 Dry Eye Syndromes http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9197558&form=6&db=m Tear fluid plasmin activity of dry eye patients with Sjögren's syndrome. diagnostic usage,unassigned 2,0 3.4.21.7 Dry Eye Syndromes http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31369467&form=6&db=m Tear Proteases and Protease Inhibitors: Potential Biomarkers and Disease Drivers in Ocular Surface Disease. causal interaction,therapeutic application,unassigned 2,3,0 3.4.21.7 Dry Socket http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17184232&form=6&db=m Plasminogen activators and inhibitor type-1 in alveolar osteitis. therapeutic application,unassigned 4,0 3.4.21.7 Duodenal Ulcer http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4040657&form=6&db=m [Vascular component of the fibrinolytic system of blood (plasminogen activator of vascular wall) in patients with duodenal ulcer with a history of hemorrhagic complications] diagnostic usage,unassigned 2,0 3.4.21.7 Duodenal Ulcer http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9149198&form=6&db=m Impaired fibrinolysis and increased protease levels in gastric and duodenal mucosa of patients with active duodenal ulcer. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,2,4,2 3.4.21.7 Dysentery http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=156400&form=6&db=m [Correlations of the level of plasmin system and blood serum hyaluronidase activity with pathology of the large intestine in dysentery] diagnostic usage,ongoing research,unassigned 4,1,0 3.4.21.7 Dysentery http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=159382&form=6&db=m [Activity of the plasmin enzymatic system and of serum hyaluronidase in dysentery] diagnostic usage,ongoing research,unassigned 4,1,0 3.4.21.7 Dyslipidemias http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9263663&form=6&db=m Metabolic abnormalities in hypertension. causal interaction,unassigned 1,0 3.4.21.7 Dyslipidemias http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14739372&form=6&db=m Impaired fibrinolytic activity is present in children with dyslipidemias. diagnostic usage,unassigned 2,0 3.4.21.7 Dyslipidemias http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23328907&form=6&db=m Dyslipidemia and the risk of Alzheimer's disease. unassigned - 3.4.21.7 Ehlers-Danlos Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10382293&form=6&db=m Generation and chromosome mapping of expressed sequence tags (ESTs) from a human infant thymus. therapeutic application,unassigned 1,0 3.4.21.7 Embolic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7507362&form=6&db=m Alterations of haemostatic markers in various subtypes and phases of stroke. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,4,0 3.4.21.7 Embolic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11739980&form=6&db=m Time course of tissue plasminogen activator-induced recanalization in acute cardioembolic stroke: a case-control study. diagnostic usage,ongoing research,therapeutic application,unassigned 2,4,1,0 3.4.21.7 Embolic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12902833&form=6&db=m Antiactin-targeted immunoliposomes ameliorate tissue plasminogen activator-induced hemorrhage after focal embolic stroke. causal interaction,ongoing research,therapeutic application,unassigned 4,2,4,0 3.4.21.7 Embolic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14629475&form=6&db=m Population-based distribution of plasminogen activity and estimated prevalence and relevance to thrombotic diseases of plasminogen deficiency in the Japanese: the Suita Study. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,2,1 3.4.21.7 Embolic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17143002&form=6&db=m Lp(a) lipoprotein and plasminogen activity in patients with different etiology of ischemic stroke. causal interaction,diagnostic usage,ongoing research,unassigned 3,3,4,0 3.4.21.7 Embolic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22792744&form=6&db=m [Changes of haemostatic parameters in patients with acute cardioembolic stroke]. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.7 Embolic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29844028&form=6&db=m Taurine Reduces tPA (Tissue-Type Plasminogen Activator)-Induced Hemorrhage and Microvascular Thrombosis After Embolic Stroke in Rat. causal interaction,ongoing research,therapeutic application,unassigned 3,4,4,0 3.4.21.7 Embolic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30571560&form=6&db=m PI3K? (Phosphoinositide 3-Kinase-?) Inhibition Attenuates Tissue-Type Plasminogen Activator-Induced Brain Hemorrhage and Improves Microvascular Patency After Embolic Stroke. causal interaction,therapeutic application,unassigned 2,3,0 3.4.21.7 Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=906903&form=6&db=m Non-penetrating trauma to the carotid artery with secondary thrombosis and embolism: treatment by thrombolysin. therapeutic application,unassigned 4,0 3.4.21.7 Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1223354&form=6&db=m [Physiopathological shifts in the blood coagulation system in embolism of major arteries of the limbs] therapeutic application,unassigned 1,0 3.4.21.7 Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1461528&form=6&db=m [Lipoprotein(a): structure, metabolism and atherosclerotic disease] causal interaction,diagnostic usage,unassigned 1,1,0 3.4.21.7 Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1802987&form=6&db=m Thrombolytic effect of tissue plasminogen activator in a cerebral embolic model. therapeutic application,unassigned 1,0 3.4.21.7 Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1814626&form=6&db=m Fibrinolytic effect of tissue plasminogen activator on cerebral embolism in stroke-prone spontaneously hypertensive rats. ongoing research,unassigned 2,0 3.4.21.7 Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4238463&form=6&db=m [The use of fibrinolysin and heparin in the treatment of acute thrombophlebitis, thrombosis and embolism] therapeutic application,unassigned 4,0 3.4.21.7 Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9395042&form=6&db=m Mechanisms by which thrombolytic therapy results in nonuniform lysis and residual thrombus after reperfusion. therapeutic application,unassigned 1,0 3.4.21.7 Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=13686464&form=6&db=m [Treatment of thrombosis and embolisms with human fibrinolysin.] therapeutic application,unassigned 4,0 3.4.21.7 Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=13783563&form=6&db=m Fibrinolysin (Actase) in the treatment of peripheral embolism. therapeutic application,unassigned 4,0 3.4.21.7 Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14167120&form=6&db=m LYSIS OF THE EXPERIMENTAL RADIOACTIVE PULMONARY EMBOLUS INDUCED BY STREPTOKINASE AND SK-ACTIVATED PLASMIN. therapeutic application,unassigned 1,0 3.4.21.7 Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14325708&form=6&db=m [EXPERIENCE WITH THE TREATMENT OF THROMBOSIS AND EMBOLISM WITH FIBRINOLYSIN AND HEPARIN.] therapeutic application,unassigned 4,0 3.4.21.7 Embolism and Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=906903&form=6&db=m Non-penetrating trauma to the carotid artery with secondary thrombosis and embolism: treatment by thrombolysin. therapeutic application,unassigned 4,0 3.4.21.7 Embolism and Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4238463&form=6&db=m [The use of fibrinolysin and heparin in the treatment of acute thrombophlebitis, thrombosis and embolism] therapeutic application,unassigned 4,0 3.4.21.7 Embolism and Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14325708&form=6&db=m [EXPERIENCE WITH THE TREATMENT OF THROMBOSIS AND EMBOLISM WITH FIBRINOLYSIN AND HEPARIN.] therapeutic application,unassigned 4,0 3.4.21.7 Embolism, Cholesterol http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1803250&form=6&db=m Cholesterol embolism after intravenous anisoylated plasminogen streptokinase activator complex (APSAC) therapeutic application,unassigned 3,0 3.4.21.7 Empyema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2027990&form=6&db=m Treatment of thoracic multiloculated empyemas with intracavitary urokinase: a prospective study. diagnostic usage,therapeutic application,unassigned 1,1,0 3.4.21.7 Empyema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33296057&form=6&db=m Management of Pleural Infection. therapeutic application,unassigned 4,0 3.4.21.7 Encephalitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8865527&form=6&db=m An alternative elastase-mediated degradation of fibrinogen and fibrin observed in a patient with herpes simplex encephalitis and pneumonia. unassigned - 3.4.21.7 Encephalitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27319402&form=6&db=m Physiologic variations in blood plasminogen levels affect outcomes after acute cerebral thromboembolism in mice: a pathophysiologic role for microvascular thrombosis. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,1,4,3 3.4.21.7 Encephalitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28236848&form=6&db=m The fibrinolytic system: A new target for treatment of depression with psychedelics. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 Encephalitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30254165&form=6&db=m Blood-derived plasminogen drives brain inflammation and plaque deposition in a mouse model of Alzheimer's disease. ongoing research,unassigned 1,0 3.4.21.7 Encephalitis, Herpes Simplex http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8865527&form=6&db=m An alternative elastase-mediated degradation of fibrinogen and fibrin observed in a patient with herpes simplex encephalitis and pneumonia. unassigned - 3.4.21.7 Encephalomyelitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28275164&form=6&db=m Plasminogen Deficiency Delays the Onset and Protects from Demyelination and Paralysis in Autoimmune Neuroinflammatory Disease. causal interaction,ongoing research,therapeutic application,unassigned 3,3,2,0 3.4.21.7 Encephalomyelitis, Autoimmune, Experimental http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=568743&form=6&db=m The modification of experimental allergic encephalomyelitis with epsilon aminocaproic acid. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.7 Encephalomyelitis, Autoimmune, Experimental http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6750429&form=6&db=m Observations on the effects of protease inhibitors on the suppression of experimental allergic encephalomyelitis. ongoing research,therapeutic application,unassigned 4,4,0 3.4.21.7 Encephalomyelitis, Autoimmune, Experimental http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28275164&form=6&db=m Plasminogen Deficiency Delays the Onset and Protects from Demyelination and Paralysis in Autoimmune Neuroinflammatory Disease. causal interaction,ongoing research,therapeutic application,unassigned 3,3,2,0 3.4.21.7 End Stage Liver Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32175919&form=6&db=m Plasminogen as a prognostic biomarker for HBV-related acute-on-chronic liver failure. diagnostic usage,therapeutic application,unassigned 4,2,0 3.4.21.7 Endarteritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25875022&form=6&db=m Fibrinolysis and proliferative endarteritis: two related processes in chronic infections? The model of the blood-borne pathogen Dirofilaria immitis. unassigned - 3.4.21.7 Endarteritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25888952&form=6&db=m Can the activation of plasminogen/plasmin system of the host by metabolic products of Dirofilaria immitis participate in heartworm disease endarteritis? unassigned - 3.4.21.7 Endarteritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27198784&form=6&db=m Glyceraldehyde 3-phosphate dehydrogenase and galectin from Dirofilaria immitis participate in heartworm disease endarteritis via plasminogen/plasmin system. ongoing research,unassigned 2,0 3.4.21.7 Endemic Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14665393&form=6&db=m Haemostatic abnormalities in hepatosplenic schistosomiasis mansoni. unassigned - 3.4.21.7 Endocarditis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15313170&form=6&db=m Activation of plasminogen by Streptococcus mutans. causal interaction,unassigned 3,0 3.4.21.7 Endocarditis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20835741&form=6&db=m The role of streptococcal plasmin(ogen) binding in infective endocarditis. causal interaction,therapeutic application,unassigned 2,1,0 3.4.21.7 Endocarditis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22037854&form=6&db=m Antibiotic modulation of the plasminogen binding ability of viridans group streptococci. causal interaction,unassigned 2,0 3.4.21.7 Endocarditis, Non-Infective http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20835741&form=6&db=m The role of streptococcal plasmin(ogen) binding in infective endocarditis. causal interaction,therapeutic application,unassigned 2,1,0 3.4.21.7 Endometrial Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14976916&form=6&db=m [Vascular endothelial growth factor and plasminogen activators in endometrial carcinoma and hyperplasia] causal interaction,diagnostic usage,ongoing research,therapeutic application 2,1,2,2 3.4.21.7 Endometrial Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9583736&form=6&db=m Discordant expression of mRNA and protein for urokinase and tissue plasminogen activators (u-PA, t-PA) in endometrial carcinoma. ongoing research,unassigned 2,0 3.4.21.7 Endometrial Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11063652&form=6&db=m Differential mRNA expression of urokinase-type plasminogen activator, plasminogen activator receptor and plasminogen activator inhibitor type-2 in normal human endometria and endometrial carcinomas. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,4,0 3.4.21.7 Endometrial Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11136569&form=6&db=m Clinical relevance of urokinase-type plasminogen activator, its receptor, and its inhibitor type 1 in endometrial cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,2,4 3.4.21.7 Endometrial Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11949838&form=6&db=m Plasminogen activator inhibitor type 2: potential prognostic factor for endometrial carcinomas. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,4,0 3.4.21.7 Endometrial Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12893190&form=6&db=m Three-dimensional coculture of endometrial cancer cells and fibroblasts in human placenta derived collagen sponges and expression matrix metalloproteinases in these cells. ongoing research,therapeutic application,unassigned 4,1,0 3.4.21.7 Endometrial Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14976916&form=6&db=m [Vascular endothelial growth factor and plasminogen activators in endometrial carcinoma and hyperplasia] causal interaction,diagnostic usage,ongoing research,therapeutic application 2,1,2,2 3.4.21.7 Endometrial Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22525297&form=6&db=m A potency of plasminogen activation system in long-term prognosis of endometrial cancer: a pilot study. ongoing research,therapeutic application,unassigned 4,2,0 3.4.21.7 Endometrial Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27085144&form=6&db=m High pretreatment plasma D-dimer levels are related to shorter overall survival in endometrial carcinoma. diagnostic usage,ongoing research,unassigned 4,4,0 3.4.21.7 Endometriosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3147926&form=6&db=m Fibrinolytic properties of peritoneal fluid in endometriosis. diagnostic usage,ongoing research,therapeutic application,unassigned 3,1,1,0 3.4.21.7 Endometriosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6594013&form=6&db=m Plasminogen activators in endometriosis. unassigned - 3.4.21.7 Endometriosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9591503&form=6&db=m Gonadotropin-releasing hormone agonist (GnRH-a) therapy alters activity of plasminogen activators, matrix metalloproteinases, and their inhibitors in rat models for adhesion formation and endometriosis: potential GnRH-a-regulated mechanisms reducing adhesion formation. therapeutic application,unassigned 4,0 3.4.21.7 Endometriosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9675606&form=6&db=m Fibrinolysis in the peritoneal fluid during adhesions, endometriosis and ongoing pelvic inflammatory disease. therapeutic application,unassigned 1,0 3.4.21.7 Endometriosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15652897&form=6&db=m A role for the fibrinolytic system in postsurgical adhesion formation. causal interaction,therapeutic application,unassigned 1,2,0 3.4.21.7 Endometriosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15769615&form=6&db=m Plasminogen activators and plasminogen activator inhibitors in endometriosis. ongoing research,therapeutic application,unassigned 3,4,0 3.4.21.7 Endometriosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17506371&form=6&db=m Local activation of TGF-beta1 at endometriosis sites. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 Endometritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14662133&form=6&db=m Involvement of the plasminogen activation system in cow endometritis. unassigned - 3.4.21.7 Endometritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29436075&form=6&db=m Ligneous cervicitis and endometritis: A gynaecological presentation of congenital plasminogen deficiency. causal interaction,therapeutic application,unassigned 4,2,0 3.4.21.7 Endotoxemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=126170&form=6&db=m Interaction of leukocytes and endotoxin with the plasmin and kinin systems. unassigned - 3.4.21.7 Endotoxemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2012348&form=6&db=m Use of newly developed assays for protein C and plasminogen in horses with signs of colic. diagnostic usage,ongoing research,therapeutic application,unassigned 2,4,1,0 3.4.21.7 Endotoxemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3011672&form=6&db=m Effect of polymyxin B and colimycin on induction of plasminogen antiactivator by lipopolysaccharide in human endothelial cell culture. causal interaction,unassigned 3,0 3.4.21.7 Endotoxemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7563921&form=6&db=m [Blood coagulation and fibrinolysis in relation to endotoxemia in liver cirrhosis and hepatocellular carcinoma] causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,1,0 3.4.21.7 Endotoxemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14739127&form=6&db=m Inhibition of plasmin activity by tranexamic acid does not influence inflammatory pathways during human endotoxemia. causal interaction,therapeutic application,unassigned 4,2,0 3.4.21.7 Eosinophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6768214&form=6&db=m Plasminogen levels in subjects with eosinophilia. diagnostic usage,ongoing research,unassigned 4,4,0 3.4.21.7 Epidermolysis Bullosa Dystrophica http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2498140&form=6&db=m Studies on two siblings with recessive dystrophic epidermolysis bullosa (Hallopeau-Siemens) and the plasminogen activator and its inhibitor in the lesion. causal interaction,therapeutic application,unassigned 1,2,0 3.4.21.7 Epilepsy, Rolandic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18718938&form=6&db=m Epileptic and developmental disorders of the speech cortex: ligand/receptor interaction of wild-type and mutant SRPX2 with the plasminogen activator receptor uPAR. unassigned - 3.4.21.7 Epiretinal Membrane http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1786916&form=6&db=m [Thrombospondin and its importance in proliferative retinal diseases] diagnostic usage,unassigned 1,0 3.4.21.7 Epiretinal Membrane http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8950585&form=6&db=m Plasminogen activation in epiretinal membranes. diagnostic usage,ongoing research,unassigned 3,3,0 3.4.21.7 Epiretinal Membrane http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9290376&form=6&db=m Plasminogen in proliferative vitreoretinal disorders. causal interaction,diagnostic usage,ongoing research,unassigned 2,4,2,0 3.4.21.7 Epiretinal Membrane http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18939350&form=6&db=m Components of the fibrinolytic system in the vitreous body in patients with vitreoretinal disorders. diagnostic usage,ongoing research,therapeutic application,unassigned 2,2,1,0 3.4.21.7 Epiretinal Membrane http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19253179&form=6&db=m [Enzymatic vitrectomy by intravitreal autologous plasmin injection as initial treatment for macular epiretinal membranes and vitreomacular traction syndrome.] therapeutic application,unassigned 4,0 3.4.21.7 Epiretinal Membrane http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19276871&form=6&db=m SURGICAL OUTCOMES OF EPIRETINAL MEMBRANES ASSOCIATED WITH COMBINED HAMARTOMA OF THE RETINA AND RETINAL PIGMENT EPITHELIUM. diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.7 Esophageal Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10390151&form=6&db=m Invasion by esophageal cancer cells: functional contribution of the urokinase plasminogen activation system, and inhibition by antisense oligonucleotides to urokinase or urokinase receptor. causal interaction,ongoing research,therapeutic application,unassigned 4,3,2,0 3.4.21.7 Esophageal Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11724279&form=6&db=m Serine proteinase activation in esophageal cancer. diagnostic usage,ongoing research,therapeutic application,unassigned 2,4,1,0 3.4.21.7 Esophageal Squamous Cell Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10666386&form=6&db=m Cellular distribution and clinical value of urokinase-type plasminogen activator, its receptor, and plasminogen activator inhibitor-2 in esophageal squamous cell carcinoma. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,4,1 3.4.21.7 Esophageal Squamous Cell Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28614640&form=6&db=m [[Gender Differences in Tissue Cascade of Activation of Plasminogen and PAI-1 in Esophageal Squamous Cell Carcinoma].] causal interaction,diagnostic usage,unassigned 4,1,0 3.4.21.7 Essential Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14816&form=6&db=m [Sympathetic responsiveness and antihypertensive effect of beta-receptor blockade in essential hypertension: the effect of atenolol (author's transl)] diagnostic usage,ongoing research,unassigned 3,2,0 3.4.21.7 Essential Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6242555&form=6&db=m Abnormalities of fibrinolysis in essential hypertension. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 Essential Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7489962&form=6&db=m Haemostatic variables in arterial hypertension. diagnostic usage,ongoing research,unassigned 2,2,0 3.4.21.7 Essential Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8243228&form=6&db=m [Changes in the fibrinolytic activity in hypertension and acute cerebral infarction] causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 Essential Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8522567&form=6&db=m Hemostatic disorders associated with arterial hypertension and peripheral arterial disease. diagnostic usage,ongoing research,unassigned 4,4,0 3.4.21.7 Essential Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17414587&form=6&db=m Fibrinolytic system in normotensive subjects and hypertensive patients. diagnostic usage,ongoing research,therapeutic application,unassigned 1,4,1,0 3.4.21.7 Essential Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27125108&form=6&db=m [The State of Coagulation Hemostasis and Fibrinolysis in Children With Essential Arterial Hypertension]. diagnostic usage,unassigned 2,0 3.4.21.7 Exostoses http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11713566&form=6&db=m Plasminogen activators and their inhibitor in bone tumors and tumor-like damages. diagnostic usage,ongoing research,therapeutic application,unassigned 3,2,2,0 3.4.21.7 Eye Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=13923524&form=6&db=m A study of plasmin in eye disease. ongoing research,therapeutic application,unassigned 4,4,0 3.4.21.7 Eye Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=156901&form=6&db=m [Phonophoresis of fibrinolysin and potassium iodide in complex treatment of hemophthalmos] causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.7 Eye Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6446068&form=6&db=m [Mechanism of action of fibrinolysin and a verification of the efficacy of its use in traumatic hemophthalmos] therapeutic application,unassigned 3,0 3.4.21.7 Eye Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31369467&form=6&db=m Tear Proteases and Protease Inhibitors: Potential Biomarkers and Disease Drivers in Ocular Surface Disease. causal interaction,therapeutic application,unassigned 2,3,0 3.4.21.7 Fabry Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24959362&form=6&db=m Amiloride as an Alternate Adjuvant Antiproteinuric Agent in Fabry Disease: The Potential Roles of Plasmin and uPAR. therapeutic application,unassigned 3,0 3.4.21.7 Factor V Deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10726026&form=6&db=m Familial association of hypoplasminogenemia and heterozygous factor V deficiency. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,1,0 3.4.21.7 Factor XI Deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9391725&form=6&db=m Recurrent venous thromboembolic disease and factor XI concentrate in a patient with severe factor XI deficiency, chronic myelomonocytic leukaemia, factor V Leiden and heterozygous plasminogen deficiency. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 Factor XII Deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7359011&form=6&db=m Chloroform-induced fibrinolysis. Its dependence on Hageman factor, plasma prekallikrein, and high molecular weight kininogen. diagnostic usage,unassigned 2,0 3.4.21.7 Factor XIII Deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6232970&form=6&db=m Differential binding of plasminogen to crosslinked and noncrosslinked fibrins: its significance in hemostatic defect in factor XIII deficiency. causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,4,0 3.4.21.7 Familial Mediterranean Fever http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29520774&form=6&db=m Serum, salivary, and tissue levels of plasminogen in familial Mediterranean fever, amyloidosis, and chronic periodontitis. causal interaction,diagnostic usage,ongoing research,unassigned 4,2,3,0 3.4.21.7 Familial Primary Pulmonary Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8358126&form=6&db=m A patient with congenital plasminogen deficiency manifesting primary pulmonary hypertension. causal interaction,unassigned 4,0 3.4.21.7 Familial Primary Pulmonary Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11522003&form=6&db=m Impairment of the plasmin activation system in primary pulmonary hypertension: evidence for gender differences. diagnostic usage,unassigned 3,0 3.4.21.7 Familial Primary Pulmonary Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12138369&form=6&db=m Plasminogen activation by blood monocytes and alveolar macrophages in primary pulmonary hypertension. ongoing research,therapeutic application,unassigned 1,1,0 3.4.21.7 Fatty Liver http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24070255&form=6&db=m Serum acute phase reactants hallmark healthy individuals at risk for acetaminophen-induced liver injury. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.7 Fatty Liver http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27604194&form=6&db=m ADAMTS13 deficiency promotes microthrombosis in a murine model of diet-induced liver steatosis. causal interaction,diagnostic usage,ongoing research,unassigned 3,2,3,0 3.4.21.7 Febrile Neutropenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23742830&form=6&db=m The significance of serum urokinase plasminogen activation receptor (suPAR) in the diagnosis and follow-up of febrile neutropenic patients with hematologic malignancies. causal interaction,diagnostic usage,ongoing research,unassigned 3,4,2,0 3.4.21.7 Fetal Alcohol Spectrum Disorders http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29885422&form=6&db=m Plasminogen activator system homeostasis and its dysregulation by ethanol in astrocyte cultures and the developing brain. causal interaction,unassigned 4,0 3.4.21.7 Fetal Death http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11239646&form=6&db=m Plasminogen activator system in serum and amniotic fluid of euploid and aneuploid pregnancies. causal interaction,unassigned 3,0 3.4.21.7 Fetal Growth Retardation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4002923&form=6&db=m [Hemostaseologic studies of maternal blood in intrauterine retardation and threatened premature labor] diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.7 Fetal Growth Retardation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8001867&form=6&db=m Evaluation of plasminogen activators and plasminogen activator inhibitors in plasma and amniotic fluid in pregnancies complicated with intrauterine fetal growth retardation. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.7 Fetal Growth Retardation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11239646&form=6&db=m Plasminogen activator system in serum and amniotic fluid of euploid and aneuploid pregnancies. causal interaction,unassigned 3,0 3.4.21.7 Fibroadenoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7974332&form=6&db=m Factors involved in the plasminogen activation system in human breast tumours. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,1,4,1 3.4.21.7 Fibroadenoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26717601&form=6&db=m PLASMINOGEN AND ANGIOSTATIN LEVELS IN FEMALE BENIGN BREAST LESIONS. causal interaction,diagnostic usage,ongoing research,unassigned 1,3,4,0 3.4.21.7 Fibrocystic Breast Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26717601&form=6&db=m PLASMINOGEN AND ANGIOSTATIN LEVELS IN FEMALE BENIGN BREAST LESIONS. causal interaction,diagnostic usage,ongoing research,unassigned 1,3,4,0 3.4.21.7 Fibrosarcoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1281156&form=6&db=m Release of transforming growth factor-beta 1 from the pericellular matrix of cultured fibroblasts and fibrosarcoma cells by plasmin and thrombin. diagnostic usage,ongoing research,unassigned 3,4,0 3.4.21.7 Fibrosarcoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1704320&form=6&db=m Forskolin down-regulates type-1 plasminogen activator inhibitor and tissue-type plasminogen activator and their mRNAs in human fibrosarcoma cells. causal interaction,ongoing research,therapeutic application,unassigned 2,4,2,0 3.4.21.7 Fibrosarcoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2538425&form=6&db=m Down-regulation of plasmin receptors on human sarcoma cells by glucocorticoids. causal interaction,ongoing research,unassigned 1,4,0 3.4.21.7 Fibrosarcoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2920477&form=6&db=m Plasminogen activator activity in clonogenic cell populations separated from a murine fibrosarcoma. causal interaction,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.7 Fibrosarcoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3081367&form=6&db=m Plasminogen activators catalyse conversion of inhibitor from fibrosarcoma cells to an inactive form with a lower apparent molecular mass. ongoing research,unassigned 4,0 3.4.21.7 Fibrosarcoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3126194&form=6&db=m Glucocorticoid-modulated gene expression of tissue- and urinary-type plasminogen activator and plasminogen activator inhibitor 1 and 2. ongoing research,therapeutic application,unassigned 3,1,0 3.4.21.7 Fibrosarcoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6295970&form=6&db=m Secretion of basement membrane collagen degrading enzyme and plasminogen activator by transformed cells--role in metastasis. causal interaction,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.7 Fibrosarcoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8613475&form=6&db=m Independent regulation of matrix metalloproteinases and plasminogen activators in human fibrosarcoma cells. ongoing research,therapeutic application,unassigned 4,1,0 3.4.21.7 Fibrosarcoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9610735&form=6&db=m HT-1080 fibrosarcoma cell matrix degradation and invasion are inhibited by the matrix-associated serine protease inhibitor TFPI-2/33 kDa MSPI. causal interaction,ongoing research,unassigned 3,1,0 3.4.21.7 Fibrosarcoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10082661&form=6&db=m Regulation of ProMMP-1 and ProMMP-3 activation by tissue factor pathway inhibitor-2/matrix-associated serine protease inhibitor. ongoing research,unassigned 2,0 3.4.21.7 Fibrosarcoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10085135&form=6&db=m Angiostatin formation involves disulfide bond reduction and proteolysis in kringle 5 of plasmin. ongoing research,unassigned 3,0 3.4.21.7 Fibrosarcoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11027624&form=6&db=m Prokaryotic expression, purification, and reconstitution of biological activities (Antiprotease, antitumor, and heparin-binding) for tissue factor pathway inhibitor-2. ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.7 Fibrosarcoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11130727&form=6&db=m Phosphoglycerate kinase acts in tumour angiogenesis as a disulphide reductase. causal interaction,ongoing research,therapeutic application,unassigned 3,4,2,0 3.4.21.7 Fibrosarcoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11592301&form=6&db=m Antibodies to PAI-1 alter the invasive and migratory properties of human tumour cells in vitro. causal interaction,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.7 Fibrosarcoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11782452&form=6&db=m Antiplasmin activity of a peptide that binds to the receptor-binding site of angiogenin. causal interaction,unassigned 1,0 3.4.21.7 Fibrosarcoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11964074&form=6&db=m Cumulative influence of elastin peptides and plasminogen on matrix metalloproteinase activation and type I collagen invasion by HT-1080 fibrosarcoma cells. causal interaction,ongoing research,unassigned 4,3,0 3.4.21.7 Fibrosarcoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12554702&form=6&db=m p11 regulates extracellular plasmin production and invasiveness of HT1080 fibrosarcoma cells. causal interaction,ongoing research,therapeutic application,unassigned 3,4,1,0 3.4.21.7 Fibrosarcoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12829586&form=6&db=m Plasminogen supports tumor growth through a fibrinogen-dependent mechanism linked to vascular patency. causal interaction,unassigned 3,0 3.4.21.7 Fibrosarcoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12848892&form=6&db=m Distal hinge of plasminogen activator inhibitor-1 involves its latency transition and specificities toward serine proteases. therapeutic application,unassigned 4,0 3.4.21.7 Fibrosarcoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19182372&form=6&db=m Thrombomodulin suppresses invasiveness of HT1080 tumor cells by reducing plasminogen activation on the cell surface through activation of thrombin-activatable fibrinolysis inhibitor. causal interaction,ongoing research,therapeutic application,unassigned 3,3,1,0 3.4.21.7 Fibrosarcoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24602611&form=6&db=m Seahorse-derived peptide suppresses invasive migration of HT1080 fibrosarcoma cells by competing with intracellular ?-enolase for plasminogen binding and inhibiting uPA-mediated activation of plasminogen. causal interaction,ongoing research,therapeutic application,unassigned 4,2,4,0 3.4.21.7 Follicular Cyst http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20646237&form=6&db=m Urokinase and its receptor in follicular and inflammatory cysts of the jaws. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,3,1 3.4.21.7 Foot Ulcer http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11983003&form=6&db=m Mechanism of action of PROMOGRAN, a protease modulating matrix, for the treatment of diabetic foot ulcers. causal interaction,ongoing research,therapeutic application,unassigned 1,1,4,0 3.4.21.7 Fuchs' Endothelial Dystrophy http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=89778&form=6&db=m Fibrinolytic factors in aqueous humour and serum from patients with Fuchs' dystrophy and patients with cataract. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,3,0 3.4.21.7 Galactosemias http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10382293&form=6&db=m Generation and chromosome mapping of expressed sequence tags (ESTs) from a human infant thymus. therapeutic application,unassigned 1,0 3.4.21.7 Gastritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9746606&form=6&db=m Plasminogen binding and activation at the surface of Helicobacter pylori CCUG 17874. causal interaction,unassigned 1,0 3.4.21.7 Gastritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23312025&form=6&db=m Glycoproteomic analysis of serum from patients with gastric precancerous lesions. causal interaction,diagnostic usage,unassigned 4,3,0 3.4.21.7 Gastrointestinal Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32574621&form=6&db=m Human Plasminogen Exacerbates Clostridioides difficile Enteric Disease and Alters the Spore Surface. causal interaction,ongoing research,therapeutic application,unassigned 3,2,4,0 3.4.21.7 Gastrointestinal Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2506920&form=6&db=m Plasminogen activators in endoscopic biopsies as indicators of gastrointestinal cancer: comparison with resection specimens. causal interaction,diagnostic usage,unassigned 1,2,0 3.4.21.7 gelatinase b deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22521821&form=6&db=m Matrix metalloproteinase-2 or -9 deletions protect against hemorrhagic transformation during early stage of cerebral ischemia and reperfusion. causal interaction,ongoing research,therapeutic application,unassigned 4,1,1,0 3.4.21.7 Genetic Diseases, Inborn http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32941296&form=6&db=m Type 1 Plasminogen Deficiency With Pulmonary Involvement: Novel Treatment and Novel Mutation. causal interaction,ongoing research,therapeutic application,unassigned 4,2,4,0 3.4.21.7 Giant Cell Arteritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28041642&form=6&db=m A Genome-wide Association Study Identifies Risk Alleles in Plasminogen and P4HA2 Associated with Giant Cell Arteritis. causal interaction,diagnostic usage,unassigned 3,3,0 3.4.21.7 Giardiasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28770921&form=6&db=m Insights into the Giardia intestinalis enolase and human plasminogen interaction. diagnostic usage,therapeutic application,unassigned 1,4,0 3.4.21.7 Gingival Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11931777&form=6&db=m Effective treatment of ligneous conjunctivitis with topical plasminogen. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,4,0 3.4.21.7 Gingival Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14653398&form=6&db=m Recurrent recalcitrant gingival hyperplasia and plasminogen deficiency: a case report. causal interaction,diagnostic usage,unassigned 4,2,0 3.4.21.7 Gingival Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25971786&form=6&db=m Periodontitis associated with plasminogen deficiency: a case report. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 Gingival Overgrowth http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11250632&form=6&db=m Oral lesions indicative of plasminogen deficiency (hypoplasminogenemia). causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 Gingival Overgrowth http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15191592&form=6&db=m Plasminogen activators and plasminogen activator inhibitors in gingival crevicular fluid of cyclosporin A-treated patients. causal interaction,unassigned 2,0 3.4.21.7 Gingivitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17032399&form=6&db=m Ligneous alveolar gingivitis in the absence of plasminogen deficiency. causal interaction,unassigned 4,0 3.4.21.7 Gingivitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18996031&form=6&db=m Successful treatment of ligneous gingivitis with warfarin. causal interaction,unassigned 3,0 3.4.21.7 Gingivitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21859319&form=6&db=m Destructive Membranous Periodontal Disease (Ligneous Gingivitis): A Literature Review. causal interaction,unassigned 4,0 3.4.21.7 Gingivitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25101505&form=6&db=m Ligneous periodontal lesions in a young child with severe plasminogen deficiency: a case report. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 Gingivitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25426793&form=6&db=m Ligneous gingivitis associated with plasminogen deficiency: a challenge in diagnosis. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.7 Gingivitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27552374&form=6&db=m Immunohistochemical analysis of the gingiva with periodontitis of type I plasminogen deficiency compared to gingiva with gingivitis and periodontitis and healthy gingiva. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,3,1 3.4.21.7 Gingivitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30513391&form=6&db=m Diagnosis of a case of ligneous gingivitis in a patient with moderate plasminogen deficiency. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,1,0 3.4.21.7 Gingivitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30994256&form=6&db=m Prophylactic protocol for dental care in ligneous gingivitis due to severe plasminogen deficiency: Case report and review of literature. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.7 Gingivitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32173395&form=6&db=m Ligneous gingivitis secondary to plasminogen deficiency: a multidisciplinary diagnostic challenge. causal interaction,unassigned 4,0 3.4.21.7 Glaucoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=673283&form=6&db=m [Use of fibrinolysin after microsurgical operations for glaucoma] therapeutic application,unassigned 4,0 3.4.21.7 Glaucoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24137977&form=6&db=m [Level of tear endothelin-1 and plasminogen in patients with glaucoma and proliferative diabetic retinopathy]. unassigned - 3.4.21.7 Glaucoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26474495&form=6&db=m Tissue and urokinase plasminogen activators instigate the degeneration of retinal ganglion cells in a mouse model of glaucoma. ongoing research,unassigned 3,0 3.4.21.7 Glaucoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28827627&form=6&db=m Glaucoma is associated with plasmin proteolytic activation mediated through oxidative inactivation of neuroserpin. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,4,3 3.4.21.7 Glaucoma, Open-Angle http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18615155&form=6&db=m Plasminogen activator inhibitor-1 4G/5G gene polymorphism and primary open-angle glaucoma. diagnostic usage,ongoing research,unassigned 1,1,0 3.4.21.7 Glioblastoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3003264&form=6&db=m Antifibrinolytic therapy of experimentally grown malignant brain tumors. ongoing research,unassigned 4,0 3.4.21.7 Glioblastoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6183313&form=6&db=m Plasminogen activating enzyme in cultured glioblastoma cells. An immunofluorescence study with monoclonal antibody. ongoing research,therapeutic application,unassigned 4,1,0 3.4.21.7 Glioblastoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6891264&form=6&db=m Purification of zymogen to plasminogen activator from human glioblastoma cells by affinity chromatography with monoclonal antibody. causal interaction,ongoing research,therapeutic application,unassigned 4,4,2,0 3.4.21.7 Glioblastoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12764090&form=6&db=m Exploitation of astrocytes by glioma cells to facilitate invasiveness: a mechanism involving matrix metalloproteinase-2 and the urokinase-type plasminogen activator-plasmin cascade. causal interaction,ongoing research,unassigned 2,3,0 3.4.21.7 Glioblastoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16823770&form=6&db=m Anthocyanidins inhibit migration of glioblastoma cells: structure-activity relationship and involvement of the plasminolytic system. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 Glioblastoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17570828&form=6&db=m Plasminogen-dependent internalization of soluble melanotransferrin involves the low-density lipoprotein receptor-related protein and annexin II. ongoing research,unassigned 4,0 3.4.21.7 Glioblastoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23431500&form=6&db=m Plasmin Activation of Glial Cells through Protease-Activated Receptor 1. ongoing research,unassigned 4,0 3.4.21.7 Glioblastoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28524122&form=6&db=m [A plasminogen regulation system in brain tumors]. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,4,2,1 3.4.21.7 Glioma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1696276&form=6&db=m Plasminogen carbohydrate side chains in receptor binding and enzyme activation: a study of C6 glioma cells and primary cultures of rat hepatocytes. ongoing research,therapeutic application,unassigned 4,1,0 3.4.21.7 Glioma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1712017&form=6&db=m Inhibition of cell surface receptor-bound plasmin by alpha 2-antiplasmin and alpha 2-macroglobulin. ongoing research,unassigned 4,0 3.4.21.7 Glioma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2379161&form=6&db=m Expression of heterogeneous profiles of plasminogen activators and plasminogen activator inhibitors by human glioma lines. causal interaction,ongoing research,therapeutic application,unassigned 1,3,2,0 3.4.21.7 Glioma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2548675&form=6&db=m Expression of plasminogen receptors on C6 glioma cells. ongoing research,unassigned 4,0 3.4.21.7 Glioma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2556124&form=6&db=m Binding of bovine, ovine, porcine, canine, and rat plasminogen to rat hepatocytes and rat C6 glioma cells in vitro. diagnostic usage,ongoing research,unassigned 3,4,0 3.4.21.7 Glioma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7675550&form=6&db=m [Biological profiles of malignant gliomas] causal interaction,unassigned 4,0 3.4.21.7 Glioma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7745467&form=6&db=m Proteolysis and invasiveness of brain tumors: role of urokinase-type plasminogen activator receptor. causal interaction,ongoing research,unassigned 3,3,0 3.4.21.7 Glioma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8159659&form=6&db=m Plasminogen activators and inhibitors in gliomas: an immunohistochemical study. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,3,4,4 3.4.21.7 Glioma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8280096&form=6&db=m Plasmin modulates the thrombin-evoked calcium response in C6 glioma cells. diagnostic usage,ongoing research,therapeutic application,unassigned 3,4,1,0 3.4.21.7 Glioma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8456423&form=6&db=m Protease nexin 1 is expressed in the human placenta. ongoing research,unassigned 3,0 3.4.21.7 Glioma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8917407&form=6&db=m Hyaluronic acid facilitates glioma cell invasion in vitro. ongoing research,unassigned 4,0 3.4.21.7 Glioma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9428707&form=6&db=m High-molecular-mass and low-molecular-mass kininogens block plasmin-induced platelet aggregation by forming a complex with kringle 5 of plasminogen/plasmin. ongoing research,unassigned 2,0 3.4.21.7 Glioma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10417767&form=6&db=m Inhibition of human malignant glioma growth in vivo by human recombinant plasminogen kringles 1-3. ongoing research,therapeutic application,unassigned 4,1,0 3.4.21.7 Glioma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10659985&form=6&db=m Lithium chloride inhibits thrombin-induced intracellular calcium mobilization in C6 rat glioma cells. therapeutic application,unassigned 1,0 3.4.21.7 Glioma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11095991&form=6&db=m Human glioma cell BT325 expresses a proteinase that converts human plasminogen to kringle 1-5-containing fragments. causal interaction,ongoing research,therapeutic application,unassigned 3,3,3,0 3.4.21.7 Glioma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12241114&form=6&db=m Modulation of tissue-type plasminogen activator expression by platelet activating factor in human glioma cells. causal interaction,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.7 Glioma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12637039&form=6&db=m The role of the plasminogen activation cascade in glioma cell invasion: a review. causal interaction,ongoing research,unassigned 4,2,0 3.4.21.7 Glioma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12764090&form=6&db=m Exploitation of astrocytes by glioma cells to facilitate invasiveness: a mechanism involving matrix metalloproteinase-2 and the urokinase-type plasminogen activator-plasmin cascade. causal interaction,ongoing research,unassigned 2,3,0 3.4.21.7 Glioma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16166313&form=6&db=m Plasminogen kringle 5-engineered glioma cells block migration of tumor-associated macrophages and suppress tumor vascularization and progression. causal interaction,unassigned 2,0 3.4.21.7 Glioma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18522221&form=6&db=m [Effects of plasminogen and streptokinase on the vital functions of nervous tissue cells in culture] causal interaction,ongoing research,unassigned 4,2,0 3.4.21.7 Glioma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19336886&form=6&db=m CXCL12-mediated induction of plasminogen activator inhibitor-1 expression in human CXCR4 positive astroglioma cells. ongoing research,therapeutic application,unassigned 3,3,0 3.4.21.7 Glioma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19383369&form=6&db=m Ebselen abrogates TNFalpha induced pro-inflammatory response in glioblastoma. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 Glioma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21976520&form=6&db=m Annexin A2 promotes glioma cell invasion and tumor progression. causal interaction,ongoing research,unassigned 4,1,0 3.4.21.7 Glioma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22684992&form=6&db=m Investigation of serum proteome alterations in human glioblastoma multiforme. causal interaction,diagnostic usage,unassigned 3,3,0 3.4.21.7 Glioma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25171813&form=6&db=m Endothelial cell-derived plasmin promotes human glioma cell proliferation. causal interaction,ongoing research,unassigned 2,4,0 3.4.21.7 Glioma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25556371&form=6&db=m Tristetraprolin Inhibits the Growth of Human Glioma Cells through Downregulation of Urokinase Plasminogen Activator/Urokinase Plasminogen Activator Receptor mRNAs. causal interaction,ongoing research,therapeutic application,unassigned 1,4,2,0 3.4.21.7 Glioma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33687124&form=6&db=m Plasminogen Activator Urokinase Receptor Implies Immunosuppressive Features and Acts as an Unfavorable Prognostic Biomarker in Glioma. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,2,2,3 3.4.21.7 Glioma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33947134&form=6&db=m Imbalance in Coagulation/Fibrinolysis Inhibitors Resulting in Extravascular Thrombin Generation in Gliomas of Varying Levels of Malignancy. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.7 Glomerulonephritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=160473&form=6&db=m [Urinary excretion of plasmin and fibrin-fibrinogen degradation products in various types of glomerulonephritis (author's transl)] unassigned - 3.4.21.7 Glomerulonephritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1293845&form=6&db=m [The levels of antigens to plasminogen activators compared to their functional activity and inhibitor activity in patients with glomerulonephritis and amyloidosis] diagnostic usage,ongoing research,unassigned 4,2,0 3.4.21.7 Glomerulonephritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2515608&form=6&db=m Urinary UK, t-PA and urinary trypsin inhibitor in health and glomerular diseases. diagnostic usage,ongoing research,unassigned 3,3,0 3.4.21.7 Glomerulonephritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3497077&form=6&db=m Further investigations on the significance of a plasma coagulation-accelerating factor in glomerular disease. diagnostic usage,unassigned 2,0 3.4.21.7 Glomerulonephritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4758287&form=6&db=m Urinary plasminogen and chronic glomerulonephritis. causal interaction,diagnostic usage,unassigned 2,4,0 3.4.21.7 Glomerulonephritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6445089&form=6&db=m Studies on the purification and characterization of human urinary plasminogen and plasmin. causal interaction,diagnostic usage,ongoing research,unassigned 3,1,2,0 3.4.21.7 Glomerulonephritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6535301&form=6&db=m Effects of a "single shot" of urokinase on fibrinolytic activities in patients with IgA nephropathy. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,4 3.4.21.7 Glomerulonephritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7642963&form=6&db=m Expression of plasminogen activator-inhibitor-1 (PAI-1) during cellular remodeling in proliferative glomerulonephritis in the rat. causal interaction,diagnostic usage,ongoing research,unassigned 1,3,2,0 3.4.21.7 Glomerulonephritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7795153&form=6&db=m Relationship between elevation in the plasma concentration of elastase-alpha 1 proteinase inhibitor complex (E-alpha 1 PI) and haemostatic parameters during haemodialysis. diagnostic usage,ongoing research,unassigned 3,4,0 3.4.21.7 Glomerulonephritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8067019&form=6&db=m [The effect of membrane-stabilizing therapy on the status of the hemostatic system in patients with glomerulonephritis with a hematuric component] diagnostic usage,unassigned 1,0 3.4.21.7 Glomerulonephritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8544402&form=6&db=m Induction of plasminogen activator inhibitor type 1 in murine lupus-like glomerulonephritis. diagnostic usage,ongoing research,therapeutic application,unassigned 3,4,1,0 3.4.21.7 Glomerulonephritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9120402&form=6&db=m Plasminogen and plasminogen activators protect against renal injury in crescentic glomerulonephritis. therapeutic application,unassigned 2,0 3.4.21.7 Glomerulonephritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9254520&form=6&db=m [Activators and inhibitors of fibrinolysis in chronic glomerulonephritis and amyloidosis] causal interaction,diagnostic usage,ongoing research,unassigned 1,4,2,0 3.4.21.7 Glomerulonephritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10204025&form=6&db=m [Urokinase as a blood and urine plasminogen activator in chronic glomerulonephritis and amyloidosis] causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,2,1 3.4.21.7 Glomerulonephritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11380816&form=6&db=m t-PA promotes glomerular plasmin generation and matrix degradation in experimental glomerulonephritis. diagnostic usage,ongoing research,therapeutic application,unassigned 4,2,1,0 3.4.21.7 Glomerulonephritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12897205&form=6&db=m A mutant, noninhibitory plasminogen activator inhibitor type 1 decreases matrix accumulation in experimental glomerulonephritis. causal interaction,ongoing research,therapeutic application,unassigned 3,3,2,0 3.4.21.7 Glomerulonephritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18216319&form=6&db=m A PAI-1 mutant, PAI-1R, slows progression of diabetic nephropathy. causal interaction,ongoing research,therapeutic application,unassigned 1,2,3,0 3.4.21.7 Glomerulonephritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18223261&form=6&db=m Elevated urinary plasmin activity resistant to alpha2-antiplasmin in acute poststreptococcal glomerulonephritis. causal interaction,diagnostic usage,therapeutic application,unassigned 1,3,3,0 3.4.21.7 Glomerulonephritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18612543&form=6&db=m Immune complex-mediated glomerulonephritis is ameliorated by thrombin-activatable fibrinolysis inhibitor deficiency. causal interaction,ongoing research,therapeutic application,unassigned 4,2,4,0 3.4.21.7 Glomerulonephritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21128779&form=6&db=m Attributes of antiangiogenic factor plasminogen kringle 5 in glomerulonephritis. diagnostic usage,unassigned 1,0 3.4.21.7 Glomerulonephritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30781907&form=6&db=m Studies on the Purification and Characterization of Human Urinary Plasminogen and Plasmin. diagnostic usage,unassigned 1,0 3.4.21.7 Glomerulonephritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32276523&form=6&db=m Glomerular Deposition of Nephritis-Associated Plasmin Receptor (NAPlr) and Related Plasmin Activity: Key Diagnostic Biomarkers of Bacterial Infection-related Glomerulonephritis. therapeutic application,unassigned 1,0 3.4.21.7 Glomerulonephritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33592898&form=6&db=m Galactose-deficient IgA1 and nephritis-associated plasmin receptors as markers for IgA-dominant infection-related glomerulonephritis: A case report. diagnostic usage,unassigned 1,0 3.4.21.7 Glomerulonephritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34389964&form=6&db=m Nephritis-associated plasmin receptor (NAPlr)-positive glomerulonephritis in a case of ANCA-negative small vessel vasculitis. unassigned - 3.4.21.7 Glomerulonephritis, IGA http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6535301&form=6&db=m Effects of a "single shot" of urokinase on fibrinolytic activities in patients with IgA nephropathy. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,4 3.4.21.7 Glomerulonephritis, IGA http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8938675&form=6&db=m Intraglomerular deposition of intact cross-linked fibrin in IgA nephropathy and Henoch-Schönlein purpura nephritis. diagnostic usage,ongoing research,unassigned 4,2,0 3.4.21.7 Glomerulonephritis, IGA http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25971850&form=6&db=m Role of tubulointerstitial plasmin in the progression of IgA nephropathy. therapeutic application,unassigned 1,0 3.4.21.7 Glomerulonephritis, Membranous http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1280065&form=6&db=m Analysis of plasmin binding and urokinase activation of plasminogen bound to the Heymann nephritis autoantigen, gp330. diagnostic usage,therapeutic application,unassigned 2,4,0 3.4.21.7 Glomerulonephritis, Membranous http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1645711&form=6&db=m Identification of the rat Heymann nephritis autoantigen (GP330) as a receptor site for plasminogen. therapeutic application,unassigned 1,0 3.4.21.7 Glomerulonephritis, Membranous http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7681839&form=6&db=m Analysis of a 45-kDa protein that binds to the Heymann nephritis autoantigen GP330. unassigned - 3.4.21.7 Glomerulonephritis, Membranous http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7864083&form=6&db=m Characterization of plasminogen system on rat yolk sac carcinoma (L2) cells. diagnostic usage,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.7 Glomerulonephritis, Membranous http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8020183&form=6&db=m A novel autoantibody to plasminogen and its characterization in Heymann nephritis. causal interaction,ongoing research,unassigned 1,2,0 3.4.21.7 Glomerulonephritis, Membranous http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8241286&form=6&db=m Effect of the nephritogenic autoantibody of Heymann's nephritis on plasminogen-binding to gp330 and activation by urokinase. therapeutic application,unassigned 1,0 3.4.21.7 Glomerulonephritis, Membranous http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9048336&form=6&db=m Effect of TGF-beta 1 and TNF-alpha on the plasminogen system of rat proximal tubular epithelial cells. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 Glomerulosclerosis, Focal Segmental http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30689221&form=6&db=m Identifying a potential biomarker for primary focal segmental glomerulosclerosis and its association with recurrence after transplantation. diagnostic usage,ongoing research,therapeutic application,unassigned 3,2,2,0 3.4.21.7 Glomerulosclerosis, Focal Segmental http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31594897&form=6&db=m Serum soluble urokinase type plasminogen activated receptor and focal segmental glomerulosclerosis: a systematic review and meta-analysis. ongoing research,therapeutic application,unassigned 3,1,0 3.4.21.7 Glomerulosclerosis, Focal Segmental http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33070369&form=6&db=m Plasminogenuria is associated with podocyte injury, edema, and kidney dysfunction in incident glomerular disease. causal interaction,ongoing research,therapeutic application,unassigned 2,1,3,0 3.4.21.7 Glucose Intolerance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=132455&form=6&db=m Assay of pig growth hormone preparations for metabolic activities in the rat and in man. ongoing research,unassigned 2,0 3.4.21.7 Glucose Intolerance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10073949&form=6&db=m Relationship of plasmin generation to cardiovascular disease risk factors in elderly men and women. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,1 3.4.21.7 Goiter http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=582337&form=6&db=m [Thyroid tissue link of hemostasis in diffuse toxic and euthyroid goiter] causal interaction,unassigned 3,0 3.4.21.7 Gout http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9181480&form=6&db=m Molecular abnormalities of human plasminogen isolated from synovial fluid of rheumatoid arthritis patients. causal interaction,diagnostic usage,ongoing research,unassigned 2,3,4,0 3.4.21.7 Gout http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20144123&form=6&db=m Fibrin dissolution in synovial fluid. ongoing research,therapeutic application,unassigned 1,1,0 3.4.21.7 Graft vs Host Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24791857&form=6&db=m Inhibition of plasmin attenuates murine acute graft-versus-host disease mortality by suppressing the matrix metalloproteinase-9-dependent inflammatory cytokine storm and effector cell trafficking. causal interaction,ongoing research,therapeutic application,unassigned 2,1,2,0 3.4.21.7 Granuloma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4040036&form=6&db=m Detection of granuloma-associated plasminogen activator in experimental murine schistosomiasis. diagnostic usage,ongoing research,therapeutic application,unassigned 1,2,1,0 3.4.21.7 Granuloma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7045310&form=6&db=m An immunoperoxidase study of immunological factors in high immune and low resistance granulomas in leprosy. unassigned - 3.4.21.7 Granuloma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7327427&form=6&db=m The monocyte-macrophage system in granulomatous inflammation. causal interaction,unassigned 2,0 3.4.21.7 Granuloma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28888036&form=6&db=m Exploring the interaction between Mycobacterium tuberculosisEnolase and human plasminogen using computational methods and experimental techniques. causal interaction,unassigned 1,0 3.4.21.7 Granulomatosis with Polyangiitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33427113&form=6&db=m Alterations of serum levels of plasminogen, TNF-?, and IDO in granulomatosis with polyangiitis patients. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.7 Gray Platelet Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3086385&form=6&db=m Plasminogen interacts with human platelets through two distinct mechanisms. unassigned - 3.4.21.7 Guillain-Barre Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6167674&form=6&db=m Degradation of the P0, P1, and Pr proteins in peripheral nervous system myelin by plasmin: implications regarding the role of macrophages in demyelinating diseases. causal interaction,ongoing research,therapeutic application,unassigned 3,4,2,0 3.4.21.7 Hamartoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19276871&form=6&db=m SURGICAL OUTCOMES OF EPIRETINAL MEMBRANES ASSOCIATED WITH COMBINED HAMARTOMA OF THE RETINA AND RETINAL PIGMENT EPITHELIUM. diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.7 Healthcare-Associated Pneumonia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34237624&form=6&db=m Klebsiella pneumoniae enolase-like membrane protein interacts with human plasminogen. ongoing research,therapeutic application,unassigned 1,3,0 3.4.21.7 Hearing Loss http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11729664&form=6&db=m [A case of Behçet's disease with chronic and repeated sudden hearing loss: successful treatment with intravenous cyclophosphamide pulse therapy] causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.7 Hearing Loss http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16500059&form=6&db=m Acute sensorineural hearing loss and vertigo in a young adult with congenital plasminogen disorder. causal interaction,ongoing research,therapeutic application,unassigned 4,1,1,0 3.4.21.7 Hearing Loss, Sensorineural http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16500059&form=6&db=m Acute sensorineural hearing loss and vertigo in a young adult with congenital plasminogen disorder. causal interaction,ongoing research,therapeutic application,unassigned 4,1,1,0 3.4.21.7 Hearing Loss, Sensorineural http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20828509&form=6&db=m Asymmetric sudden sensorineural hearing loss: is all this testing necessary? causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.7 Heart Arrest http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=705694&form=6&db=m Quantitative estimation of coagulation factors in liver disease. The diagnostic and prognostic value of factor XIII, factor V and plasminogen. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 Heart Arrest http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23499355&form=6&db=m Protective effect of plasmin in marginal donor lungs in an ex vivo lung perfusion model. causal interaction,unassigned 1,0 3.4.21.7 Heart Arrest http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29261563&form=6&db=m Pediatric In-Hospital Cardiac Arrest Secondary to Acute Pulmonary Embolism. causal interaction,ongoing research,therapeutic application,unassigned 1,1,2,0 3.4.21.7 Heart Arrest http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29866416&form=6&db=m Pulmonary thromboembolism after carbon monoxide poisoning. causal interaction,ongoing research,therapeutic application,unassigned 1,1,1,0 3.4.21.7 Heart Block http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22013113&form=6&db=m Binding of anti-SSA antibodies to apoptotic fetal cardiocytes stimulates urokinase plasminogen activator (uPA)/uPA receptor-dependent activation of TGF-? and potentiates fibrosis. causal interaction,unassigned 1,0 3.4.21.7 Heart Defects, Congenital http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4282367&form=6&db=m Pre- and post-operative studies of fibrinolysis and prothrombin in cyanotic congenital heart disease. unassigned - 3.4.21.7 Heart Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=52896&form=6&db=m Effect of anabolic steroids on plasma antithrombin III. alpha2 macroglobulin and alpha1 antitrypsin levels. ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.7 Heart Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=5929337&form=6&db=m Plasma fibrinogen and plasminogen levels in health and in ischaemic heart disease. diagnostic usage,ongoing research,unassigned 4,1,0 3.4.21.7 Heart Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7482412&form=6&db=m Plasminogen activator inhibitor type-1 determines plasmin formation in patients with ischaemic heart disease. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,3,4,2 3.4.21.7 Heart Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7585043&form=6&db=m Antifibrinolytic activity of apolipoprotein(a) in vivo: human apolipoprotein(a) transgenic mice are resistant to tissue plasminogen activator-mediated thrombolysis. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.7 Heart Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7952424&form=6&db=m Regulation of tissue-type plasminogen activator-mediated fibrinolysis by plasminogen activator inhibitor type-1 in patients with ischaemic heart disease: possible unfavourable effect of diuretics. therapeutic application,unassigned 3,0 3.4.21.7 Heart Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8009715&form=6&db=m [Plasmin-mediated activation of the coagulation system. A study of patients with acute ischemic heart disease treated with recombinant tissue-plasminogen activator] causal interaction,diagnostic usage,ongoing research,therapeutic application 1,1,4,3 3.4.21.7 Heart Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8067608&form=6&db=m Platelet function and antithrombin, plasminogen, and fibrinolytic activities in cats with heart disease. causal interaction,diagnostic usage,therapeutic application,unassigned 3,2,1,0 3.4.21.7 Heart Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8222763&form=6&db=m Fibrinolysis in patients with acute ischaemic heart disease. With particular reference to systemic effects of tissue-type plasminogen activator treatment on fibrinolysis, coagulation and complement pathways. ongoing research,therapeutic application,unassigned 1,2,0 3.4.21.7 Heart Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8381941&form=6&db=m Serum lipoprotein (a) concentrations in patients undergoing continuous ambulatory peritoneal dialysis. causal interaction,unassigned 3,0 3.4.21.7 Heart Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8622276&form=6&db=m [Chronic recurrent pulmonary thromboembolism associated with sedentary work] causal interaction,diagnostic usage,unassigned 3,2,0 3.4.21.7 Heart Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9069184&form=6&db=m Apolipoproteins(a): a puzzling evolutionary story. diagnostic usage,therapeutic application,unassigned 1,1,0 3.4.21.7 Heart Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19432826&form=6&db=m Stroke in children: inherited and acquired factors and age-related variations in the presentation of 48 paediatric patients. causal interaction,ongoing research,unassigned 2,1,0 3.4.21.7 Heart Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22543060&form=6&db=m Serum proteomic signature of human chagasic patients for the identification of novel potential protein biomarkers of disease. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,1,0 3.4.21.7 Heart Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22759687&form=6&db=m Inherited thrombophilia in pediatric ischemic stroke: an Egyptian study. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,1,1 3.4.21.7 Heart Failure http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10502816&form=6&db=m Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. causal interaction,ongoing research,therapeutic application,unassigned 3,4,4,0 3.4.21.7 Heart Failure http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18827445&form=6&db=m Prevention of incipient diabetic cardiomyopathy by high-dose thiamine. diagnostic usage,ongoing research,unassigned 3,3,0 3.4.21.7 Heart Failure http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19214913&form=6&db=m Pathogenesis of venous thromboembolism: when the cup runneth over. therapeutic application,unassigned 1,0 3.4.21.7 Heart Failure http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24681141&form=6&db=m Plasminogen regulates cardiac repair after myocardial infarction through its non-canonical function in stem cell homing to the infarcted heart. causal interaction,ongoing research,therapeutic application,unassigned 1,2,3,0 3.4.21.7 Heart Rupture http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10502816&form=6&db=m Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. causal interaction,ongoing research,therapeutic application,unassigned 3,4,4,0 3.4.21.7 Hemangioma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2754223&form=6&db=m Giant hemangioma of the liver (Kasabach-Merritt syndrome): successful suppression of intravascular coagulation permitting surgical removal. unassigned - 3.4.21.7 Hemangioma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7514904&form=6&db=m Perturbations in the fibrinolytic pathway abolish cyst formation but not capillary-like organization of cultured murine endothelial cells. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,1,2,2 3.4.21.7 Hemarthrosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31497612&form=6&db=m Does Tranexamic Acid Reduce Knee Swelling and Improve Early Function Following Arthroscopic Meniscectomy? A Double-Blind Randomized Controlled Trial. therapeutic application,unassigned 3,0 3.4.21.7 Hematocolpos http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26036227&form=6&db=m Beyond hemostasis: the challenge of treating plasminogen deficiency. A report of three cases. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 Hematologic Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8815842&form=6&db=m [Study of hemostasis in patients with a recent thromboembolic complication] diagnostic usage,unassigned 1,0 3.4.21.7 Hematologic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10190291&form=6&db=m Plasminogen activation in human leukemia and in normal hematopoietic cells. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,1 3.4.21.7 Hematologic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21429565&form=6&db=m Prospective evaluation of hemostatic abnormalities in overt DIC due to various underlying diseases. diagnostic usage,ongoing research,therapeutic application,unassigned 4,1,1,0 3.4.21.7 Hematologic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23742830&form=6&db=m The significance of serum urokinase plasminogen activation receptor (suPAR) in the diagnosis and follow-up of febrile neutropenic patients with hematologic malignancies. causal interaction,diagnostic usage,ongoing research,unassigned 3,4,2,0 3.4.21.7 Hematologic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29365403&form=6&db=m [The clinical value of soluble urokinase plasminogen activation receptor in febrile neutropenic patients with hematological malignancies after chemotherapy]. diagnostic usage,ongoing research,unassigned 2,1,0 3.4.21.7 Hematoma, Subdural http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=146730&form=6&db=m Fibrinolytic enzyme in the lining walls of chronic subdural hematoma. causal interaction,diagnostic usage,ongoing research,unassigned 2,2,3,0 3.4.21.7 Hematoma, Subdural, Chronic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=146730&form=6&db=m Fibrinolytic enzyme in the lining walls of chronic subdural hematoma. causal interaction,diagnostic usage,ongoing research,unassigned 2,2,3,0 3.4.21.7 Hematoma, Subdural, Chronic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3137677&form=6&db=m Tissue-type plasminogen activator in the chronic subdural hematoma. causal interaction,diagnostic usage,ongoing research,unassigned 4,2,2,0 3.4.21.7 Hematoma, Subdural, Chronic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6848682&form=6&db=m Factors affecting coagulation: fibrinolysis in chronic subdural fluid collections. causal interaction,diagnostic usage,unassigned 3,2,0 3.4.21.7 Hematoma, Subdural, Chronic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8137796&form=6&db=m Degradation of fibrinogen and fibrin by plasmin and nonplasmin proteases in the chronic subdural hematoma: evaluation by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and immunoblot. therapeutic application,unassigned 1,0 3.4.21.7 Hemoglobinuria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=13795055&form=6&db=m Effect of streptokinase, epinephrine and plasmin on the paroxysmal nocturnal hemoglobinuria serum hemolytic system. ongoing research,unassigned 1,0 3.4.21.7 Hemoglobinuria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18954937&form=6&db=m Increased soluble urokinase plasminogen activator receptor (suPAR) is associated with thrombosis and inhibition of plasmin generation in paroxysmal nocturnal hemoglobinuria (PNH) patients. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.7 Hemoglobinuria, Paroxysmal http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=13795055&form=6&db=m Effect of streptokinase, epinephrine and plasmin on the paroxysmal nocturnal hemoglobinuria serum hemolytic system. ongoing research,unassigned 1,0 3.4.21.7 Hemoglobinuria, Paroxysmal http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18954937&form=6&db=m Increased soluble urokinase plasminogen activator receptor (suPAR) is associated with thrombosis and inhibition of plasmin generation in paroxysmal nocturnal hemoglobinuria (PNH) patients. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.7 Hemolytic-Uremic Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28968817&form=6&db=m Streptococcus pneumoniae From Patients With Hemolytic Uremic Syndrome Binds Human Plasminogen via the Surface Protein PspC and Uses Plasmin to Damage Human Endothelial Cells. ongoing research,unassigned 4,0 3.4.21.7 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2444746&form=6&db=m [Evaluation of the results of studying fibrinase in patients with hemophilia A] causal interaction,diagnostic usage,therapeutic application,unassigned 1,2,2,0 3.4.21.7 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4223582&form=6&db=m Fibrinolysin studies in hemophilia. ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.7 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12112970&form=6&db=m Therapies for the treatment of abnormal uterine bleeding. therapeutic application,unassigned 4,0 3.4.21.7 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14280891&form=6&db=m THE ROLE OF FIBRINOLYSIN AND PROFIBRINOLYSIN ACTIVATOR IN HEMOPHILIA. ongoing research,unassigned 1,0 3.4.21.7 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15719893&form=6&db=m Does an enzyme other than thrombin contribute to unexpected changes in the levels of the different forms of thrombin activatable fibrinolysis inhibitor in patients with hemophilia A, hemophilia B and von Willebrand disease? causal interaction,diagnostic usage,therapeutic application,unassigned 3,3,3,0 3.4.21.7 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20542542&form=6&db=m Optimizing thrombelastography (TEG) assay conditions to monitor rFVIIa (NovoSeven) therapy in haemophilia A patients. diagnostic usage,ongoing research,therapeutic application,unassigned 3,4,1,0 3.4.21.7 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31989084&form=6&db=m Development and application of global assays of hyper- and hypofibrinolysis. causal interaction,diagnostic usage,unassigned 3,2,0 3.4.21.7 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32979031&form=6&db=m Pharmacodynamic monitoring of factor VIII replacement therapy in hemophilia A: combining thrombin and plasmin generation. therapeutic application,unassigned 2,0 3.4.21.7 Hemophilia A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33803235&form=6&db=m Assessing Plasmin Generation in Health and Disease. causal interaction,ongoing research,unassigned 4,1,0 3.4.21.7 Hemorrhagic Disorders http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=5933106&form=6&db=m Studies on the plasminogen proactivator of plasma in children with hemorrhagic disorders. diagnostic usage,ongoing research,unassigned 3,2,0 3.4.21.7 Hemorrhagic Disorders http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12152655&form=6&db=m A single thymine nucleotide deletion responsible for congenital deficiency of plasmin inhibitor. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,1,0 3.4.21.7 Hemorrhagic Disorders http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=13104458&form=6&db=m Prostatic fibrinolysin; study of a case illustrating role in hemorrhagic diathesis of cancer of the prostate. causal interaction,ongoing research,unassigned 1,2,0 3.4.21.7 Hemorrhagic Disorders http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20019599&form=6&db=m Decreased plasmin resistance by clots of a homophenotypic Aalpha R 16H fibrinogen (Kingsport, slower fibrinopeptide A than fibrinopeptide B release). causal interaction,unassigned 3,0 3.4.21.7 Hemorrhagic Fever with Renal Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1975230&form=6&db=m Epidemic hemorrhagic fever. The mechanism of coagulation and fibrinolysis. diagnostic usage,unassigned 4,0 3.4.21.7 Hemorrhagic Fever with Renal Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2906564&form=6&db=m [Detection of plasma AT-III and plasminogen in patients with epidemic hemorrhagic fever and its clinical significance] causal interaction,diagnostic usage,ongoing research,unassigned 1,4,2,0 3.4.21.7 Hemorrhagic Fever with Renal Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2907875&form=6&db=m [A dynamic study of plasminogen, antithrombin III, fibrinogen and DIC in epidemic hemorrhagic fever] ongoing research,therapeutic application,unassigned 1,1,0 3.4.21.7 Hemorrhagic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8222103&form=6&db=m After correcting for worse baseline characteristics, women treated with thrombolytic therapy for acute myocardial infarction have the same mortality and morbidity as men except for a higher incidence of hemorrhagic stroke. The Investigators of the International Tissue Plasminogen Activator/Streptokinase Mortality Study. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,2,1,4 3.4.21.7 Hemorrhagic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23219658&form=6&db=m Immunotherapy blocking the tissue plasminogen activator-dependent activation of N-methyl-d-aspartate glutamate receptors improves hemorrhagic stroke outcome. causal interaction,ongoing research,therapeutic application,unassigned 2,2,1,0 3.4.21.7 Hemorrhagic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29273597&form=6&db=m Intravenous Thrombolysis for Stroke and Presumed Stroke in Human Immunodeficiency Virus-Infected Adults: A Retrospective, Multicenter US Study. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,2,2,3 3.4.21.7 Hemorrhagic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30856303&form=6&db=m [The endothelial dysfunction in patients with arterial hypertension after old hemorrhagic stroke.] causal interaction,diagnostic usage,ongoing research,unassigned 3,4,1,0 3.4.21.7 Hemothorax http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=741568&form=6&db=m [Coagulative and fibrinolytic properties of blood effused into the pleural cavity after lung surgery] ongoing research,therapeutic application,unassigned 1,3,0 3.4.21.7 Hemothorax http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=13663725&form=6&db=m Treatment of clotted hemothorax with fibrinolysin. therapeutic application,unassigned 4,0 3.4.21.7 Hemothorax http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14205060&form=6&db=m STUDY OF FIBRINOLYSIN ON CLOTTED HEMOTHORAX. ongoing research,unassigned 3,0 3.4.21.7 Hepatic Encephalopathy http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32175919&form=6&db=m Plasminogen as a prognostic biomarker for HBV-related acute-on-chronic liver failure. diagnostic usage,therapeutic application,unassigned 4,2,0 3.4.21.7 Hepatic Insufficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2448897&form=6&db=m Plasminogen abnormalities in patients with Argentine hemorrhagic fever. unassigned - 3.4.21.7 Hepatic Insufficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30807053&form=6&db=m [The disorders of hemostasis system and thrombotic complications in oncologic patients having liver operation.] causal interaction,unassigned 3,0 3.4.21.7 Hepatic Veno-Occlusive Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10886975&form=6&db=m Hepatic Veno-Occlusive Disease: A Role for Tissue Plasminogen Activator? causal interaction,ongoing research,therapeutic application,unassigned 1,1,1,0 3.4.21.7 Hepatitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=122995&form=6&db=m Potency of fragmented IgG: two studies of postexposure prophylaxis in type A hepatitis. diagnostic usage,ongoing research,unassigned 2,2,0 3.4.21.7 Hepatitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=406338&form=6&db=m Abnormal fibrinogen heterogeneity and fibrinolytic activity in advanced liver disease. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.7 Hepatitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=935800&form=6&db=m Observations of increased levels of blood coagulation factors and other plasma proteins in cholestatic liver disease. causal interaction,diagnostic usage,unassigned 1,1,0 3.4.21.7 Hepatitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1754855&form=6&db=m Importance of measuring plasma thrombin-antithrombin III complex levels when using antithrombin III concentrate therapy in fulminant hepatic failure. causal interaction,ongoing research,therapeutic application,unassigned 4,2,2,0 3.4.21.7 Hepatitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1755947&form=6&db=m Bilirubin or plasminogen--which is better in the assessment of the severity of viral hepatitis? causal interaction,diagnostic usage,unassigned 4,1,0 3.4.21.7 Hepatitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3168900&form=6&db=m Prognostic significance of antithrombin III, plasminogen and proactivator of plasminogen activity in viral hepatitis. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,2,3,1 3.4.21.7 Hepatitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6564063&form=6&db=m Prekallikrein behaviour in chronic active hepatitis and in cirrhotic patients. causal interaction,diagnostic usage,unassigned 4,2,0 3.4.21.7 Hepatitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7241973&form=6&db=m [Diagnostic value of plasminogen in viral hepatitis] causal interaction,diagnostic usage,unassigned 2,4,0 3.4.21.7 Hepatitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=13669073&form=6&db=m [Reduced fibrinolysin activity in fatal epidemic hepatitis.] causal interaction,therapeutic application,unassigned 2,1,0 3.4.21.7 Hepatitis A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1154308&form=6&db=m Platelet and fibrinogen survival with 75Se selenomethionine in acute infectious hepatitis. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 Hepatitis A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2510345&form=6&db=m Plasminogen activators and plasminogen activator inhibitors in liver deficiencies caused by chronic alcoholism or infectious hepatitis. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.7 Hepatitis A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24485384&form=6&db=m Robustness of nanofiltration for increasing the viral safety margin of biological products. ongoing research,unassigned 3,0 3.4.21.7 Hepatitis B http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2859688&form=6&db=m Immunohistological investigations of PAS-negative globular intracisternal hyalin in human liver biopsy specimens. diagnostic usage,unassigned 3,0 3.4.21.7 Hepatitis B http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6624009&form=6&db=m Contributions to the optimal use of human blood. IX. Elimination of hepatitis B transmission by (potentially) infectious plasma derivatives. diagnostic usage,ongoing research,unassigned 3,2,0 3.4.21.7 Hepatitis B http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32175919&form=6&db=m Plasminogen as a prognostic biomarker for HBV-related acute-on-chronic liver failure. diagnostic usage,therapeutic application,unassigned 4,2,0 3.4.21.7 Hepatitis C http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16580606&form=6&db=m Monitor. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 Hepatitis C http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24076507&form=6&db=m Formulated Minimal-Length Synthetic Small Hairpin RNAs are Potent Inhibitors of Hepatitis C Virus in Mice with Humanized Livers. ongoing research,therapeutic application,unassigned 1,1,0 3.4.21.7 Hepatitis E http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24249579&form=6&db=m Hepatitis E virus open reading frame 3 protein interacts with porcine liver-specific plasminogen and ?2-antiplasmin. therapeutic application,unassigned 1,0 3.4.21.7 Hepatitis, Chronic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=935800&form=6&db=m Observations of increased levels of blood coagulation factors and other plasma proteins in cholestatic liver disease. causal interaction,diagnostic usage,unassigned 1,1,0 3.4.21.7 Hepatitis, Chronic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=5612931&form=6&db=m [The activity of fibrinase in cirrhosis of the liver and chronic hepatitis] ongoing research,unassigned 2,0 3.4.21.7 Hepatitis, Chronic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6564063&form=6&db=m Prekallikrein behaviour in chronic active hepatitis and in cirrhotic patients. causal interaction,diagnostic usage,unassigned 4,2,0 3.4.21.7 Hepatolenticular Degeneration http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3440344&form=6&db=m [Defects of antithrombin III, protein C, and plasminogen in Wilson's disease with brainstem infarction] unassigned - 3.4.21.7 Herpes Simplex http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22318336&form=6&db=m Herpesviruses enhance fibrin clot lysis. causal interaction,ongoing research,therapeutic application,unassigned 2,4,1,0 3.4.21.7 Herpes Zoster http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2533879&form=6&db=m The effects of plasminogen on in vitro ovine embryo development. ongoing research,therapeutic application,unassigned 3,1,0 3.4.21.7 Herpes Zoster http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9771654&form=6&db=m Changes in the bovine zona pellucida induced by plasmin or embryonic plasminogen activator. unassigned - 3.4.21.7 Herpes Zoster http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11239432&form=6&db=m nompA encodes a PNS-specific, ZP domain protein required to connect mechanosensory dendrites to sensory structures. unassigned - 3.4.21.7 Herpes Zoster http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11891925&form=6&db=m Localization of plasminogen in the extracellular matrix of hamster eggs: exogenous activation by streptokinase. diagnostic usage,ongoing research,unassigned 1,2,0 3.4.21.7 Herpes Zoster http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16128407&form=6&db=m Plasminogen detection in oocytes and plasminogen activator activities in the porcine oviduct during the estrous cycle. ongoing research,unassigned 3,0 3.4.21.7 Herpes Zoster http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16600531&form=6&db=m Effects of plasmin on sperm-oocyte interactions during in vitro fertilization in the pig. unassigned - 3.4.21.7 Herpes Zoster http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23420828&form=6&db=m How Is Plasminogen/Plasmin System Contributing to Regulate Sperm Entry Into the Oocyte? ongoing research,unassigned 2,0 3.4.21.7 Herpes Zoster http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30304664&form=6&db=m Tissue plasminogen activator (tPA) of paternal origin is necessary for the success of invitro but not of invivo fertilisation in the mouse. therapeutic application,unassigned 1,0 3.4.21.7 Histiocytosis, Langerhans-Cell http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3116952&form=6&db=m Cutaneous infiltrates of histiocytosis X contain plasminogen activator-bearing epidermotropic dendritic cells different from Langerhans cells. ongoing research,unassigned 3,0 3.4.21.7 Hodgkin Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14337322&form=6&db=m PLASMINOGEN DEFICIENCY IN HODGKIN'S DISEASE. causal interaction,unassigned 4,0 3.4.21.7 Homocystinuria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10650845&form=6&db=m Multicentre evaluation of combined prothrombotic defects associated with thrombophilia in childhood. Childhood Thrombophilia Study Group. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,2,0 3.4.21.7 Huntington Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2874190&form=6&db=m Changes in nine enzyme markers for neurons, glia, and endothelial cells in agonal state and Huntington's disease caudate nucleus. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,3,3,1 3.4.21.7 Hyaline Membrane Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=321823&form=6&db=m Prevention of hyaline membrane disease with plasminogen. A cooperative study. ongoing research,therapeutic application,unassigned 2,3,0 3.4.21.7 Hyaline Membrane Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=772595&form=6&db=m [Treatment of hyaline membrane disease with the plasminogen urokinase combination] causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.7 Hyaline Membrane Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=788079&form=6&db=m Prevention of hyaline membrane disease with plasminogen. Preliminary report of a cooperative study. causal interaction,ongoing research,therapeutic application,unassigned 3,1,3,0 3.4.21.7 Hyaline Membrane Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=798269&form=6&db=m Studies on the prevention of respiratory distress syndrome of infants due to hyaline membrane disease with plasminogen. ongoing research,therapeutic application,unassigned 1,1,0 3.4.21.7 Hyaline Membrane Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4582209&form=6&db=m Plasminogen in the prevention of hyaline membrane disease. therapeutic application,unassigned 2,0 3.4.21.7 Hyaline Membrane Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4589496&form=6&db=m Plasminogen in the prevention of hyaline membrane disease. therapeutic application,unassigned 2,0 3.4.21.7 Hyaline Membrane Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=5006574&form=6&db=m Ontogeny of fibrinolysin system and its role in pathogenesis of hyaline membrane disease of infants. causal interaction,unassigned 1,0 3.4.21.7 Hyaline Membrane Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14012535&form=6&db=m Studies on hyaline membrane disease. I. The fibrinolysin system in pathogenesis and therapy. ongoing research,therapeutic application,unassigned 1,4,0 3.4.21.7 Hyaline Membrane Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14223231&form=6&db=m STUDIES ON HYALINE MEMBRANE DISEASE. II. THE ONTOGENY OF THE FIBRINOLYSIN SYSTEM. ongoing research,unassigned 3,0 3.4.21.7 Hydatidiform Mole http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1000261&form=6&db=m Coagulation and fibrinolysis in intact hydatidiform molar pregnancy. diagnostic usage,unassigned 1,0 3.4.21.7 Hydrocephalus http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7488820&form=6&db=m Low levels of plasminogen in cerebrospinal fluid after intraventricular haemorrhage: a limiting factor for clot lysis? causal interaction,ongoing research,therapeutic application,unassigned 4,2,4,0 3.4.21.7 Hydrocephalus http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9343282&form=6&db=m Cerebrospinal fluid plasminogen activator inhibitor-1: a prognostic factor in posthaemorrhagic hydrocephalus. diagnostic usage,therapeutic application,unassigned 2,4,0 3.4.21.7 Hydrocephalus http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10360521&form=6&db=m Prenatal diagnosis in a family with severe type I plasminogen deficiency, ligneous conjunctivitis and congenital hydrocephalus. causal interaction,diagnostic usage,unassigned 4,2,0 3.4.21.7 Hydrocephalus http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11727237&form=6&db=m [Fibrinolytic treatment of cerebral intraventricular hemorrhage] therapeutic application,unassigned 4,0 3.4.21.7 Hydrocephalus http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12719968&form=6&db=m Ligneous conjunctivitis, hydrocephalus, hydrocele, and pulmonary involvement in a child with homozygous type I plasminogen deficiency. causal interaction,unassigned 4,0 3.4.21.7 Hydrocephalus http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15822024&form=6&db=m Congenital hydrocephalus as a rare association with ligneous conjunctivitis and type I plasminogen deficiency. causal interaction,unassigned 4,0 3.4.21.7 Hydrocephalus http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17503307&form=6&db=m Management of hydrocephalus in children with plasminogen deficiency. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 Hydrocephalus http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23445328&form=6&db=m The ventriculocholecystic shunt: two case reports and a review of the literature. causal interaction,unassigned 4,0 3.4.21.7 Hydronephrosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10629572&form=6&db=m Causes of venous thrombosis in fifty Chinese patients. causal interaction,diagnostic usage,therapeutic application,unassigned 2,2,1,0 3.4.21.7 Hydronephrosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29767556&form=6&db=m Hydronephrosis is associated with elevated plasmin in urine in pediatric patients and rats and changes in NCC and ?-ENaC abundance in rat kidney. causal interaction,diagnostic usage,unassigned 3,1,0 3.4.21.7 Hyperalgesia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18709654&form=6&db=m The p75 receptor is associated with inflammatory thermal hypersensitivity. causal interaction,therapeutic application,unassigned 1,3,0 3.4.21.7 Hypercholesterolemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16387571&form=6&db=m Cardiovascular issues in hypogonadism and testosterone therapy. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.7 Hyperemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17497605&form=6&db=m [Hirudo medicinalis-leech applications in plastic and reconstructive microsurgery--a literature review] therapeutic application,unassigned 4,0 3.4.21.7 Hyperglycemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4275231&form=6&db=m Biochemical pharmacology of the fibrinolysin system of the rat. I. The effect of alloxan-induced hyperglycemia. ongoing research,unassigned 2,0 3.4.21.7 Hyperglycemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12677014&form=6&db=m Effects of admission hyperglycemia on stroke outcome in reperfused tissue plasminogen activator--treated patients. causal interaction,ongoing research,therapeutic application,unassigned 1,4,2,0 3.4.21.7 Hyperglycemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18580857&form=6&db=m The role of megsin, a serine protease inhibitor, in diabetic mesangial matrix accumulation. causal interaction,ongoing research,unassigned 3,1,0 3.4.21.7 Hyperglycemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20561659&form=6&db=m Hyperglycemia modulates plasminogen activator inhibitor-1 expression and aortic diameter in experimental aortic aneurysm disease. causal interaction,diagnostic usage,therapeutic application,unassigned 3,3,1,0 3.4.21.7 Hyperglycemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22002675&form=6&db=m Hyperglycemia promotes tissue plasminogen activator-induced hemorrhage by Increasing superoxide production. causal interaction,diagnostic usage,therapeutic application,unassigned 2,4,1,0 3.4.21.7 Hyperglycemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25179235&form=6&db=m Hyperglycemia is associated with lower levels of urokinase-type plasminogen activator and urokinase-type plasminogen activator receptor in wound fluid. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,2,2,1 3.4.21.7 Hyperglycemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28612231&form=6&db=m Epsilon-aminocaproic acid prevents high glucose and insulin induced-invasiveness in MDA-MB-231 breast cancer cells, modulating the plasminogen activator system. causal interaction,ongoing research,therapeutic application,unassigned 3,4,2,0 3.4.21.7 Hyperhomocysteinemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11205719&form=6&db=m Prothrombotic disorders and ischemic stroke in children. causal interaction,unassigned 3,0 3.4.21.7 Hyperhomocysteinemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12616091&form=6&db=m Coagulopathies and arterial stroke. causal interaction,unassigned 4,0 3.4.21.7 Hyperhomocysteinemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19668753&form=6&db=m Thrombophilic screening in retinal artery occlusion patients. diagnostic usage,ongoing research,unassigned 3,3,0 3.4.21.7 Hyperhomocysteinemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29411742&form=6&db=m [Indicators of homeostasis, inflammation and homocysteine in ischemic stroke in the young age]. causal interaction,unassigned 3,0 3.4.21.7 Hyperinsulinism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=132455&form=6&db=m Assay of pig growth hormone preparations for metabolic activities in the rat and in man. ongoing research,unassigned 2,0 3.4.21.7 Hyperinsulinism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8565016&form=6&db=m Metabolic abnormalities in cardiac ischemia. causal interaction,diagnostic usage,unassigned 3,2,0 3.4.21.7 Hyperinsulinism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10073949&form=6&db=m Relationship of plasmin generation to cardiovascular disease risk factors in elderly men and women. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,1 3.4.21.7 Hyperinsulinism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18316629&form=6&db=m Hyperglycemia enhances coagulation and reduces neutrophil degranulation, whereas hyperinsulinemia inhibits fibrinolysis during human endotoxemia. diagnostic usage,therapeutic application,unassigned 2,1,0 3.4.21.7 Hyperkalemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24694588&form=6&db=m Deterioration of Kidney Function by the (Pro)renin Receptor Blocker Handle Region Peptide in Aliskiren-treated Diabetic Transgenic (mRen2)27 Rats. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,1,2,1 3.4.21.7 Hyperlipidemias http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1008913&form=6&db=m Influence of Etofibrate on plasma fibrinogen and plasminogen concentrations in patients with different forms of primary hyperlipoproteinemia. diagnostic usage,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.7 Hyperlipidemias http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1788455&form=6&db=m [Hemostasis profiles in thrombotic disease] therapeutic application,unassigned 1,0 3.4.21.7 Hyperlipidemias http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3388309&form=6&db=m Hyperlipemia, fibrinolysis and arteriosclerosis. ongoing research,unassigned 4,0 3.4.21.7 Hyperlipidemias http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3392435&form=6&db=m [Hemostatic changes during pregnancy in reference to hyperlipidemia] causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.7 Hyperlipidemias http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8292090&form=6&db=m Lipid-related hemostatic abnormalities in the elderly: imbalance between coagulation and fibrinolysis. unassigned - 3.4.21.7 Hyperlipidemias http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12416740&form=6&db=m Treatment with cerivastatin in primary mixed hyperlipidemia induces changes in platelet aggregation and coagulation system components. diagnostic usage,unassigned 2,0 3.4.21.7 Hyperlipidemias http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12633762&form=6&db=m Evaluation of a fully-automated particle-enhanced turbidimetric immunoassay for the measurement of plasma lipoprotein(a). population-based reference values in an area with low incidence of cardiovascular disease. unassigned - 3.4.21.7 Hyperlipoproteinemias http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1008913&form=6&db=m Influence of Etofibrate on plasma fibrinogen and plasminogen concentrations in patients with different forms of primary hyperlipoproteinemia. diagnostic usage,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.7 Hyperlipoproteinemias http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1308287&form=6&db=m [Changes in the level of certain hemostatic factors during treatment with lovastatin in patients with primary hyperlipoproteinemia and phenotype IIa and IIb] diagnostic usage,unassigned 1,0 3.4.21.7 Hyperpigmentation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16706756&form=6&db=m Localized intradermal microinjection of tranexamic acid for treatment of melasma in Asian patients: a preliminary clinical trial. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.7 Hypersensitivity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1725944&form=6&db=m Enzymatic investigation for delayed-type hypersensitivity reaction. Assay for thrombin and plasmin activities in tuberculin reaction sites. diagnostic usage,unassigned 4,0 3.4.21.7 Hypersensitivity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2964124&form=6&db=m [Allergic reactions to fibrinolysin] diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.7 Hypersensitivity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2971485&form=6&db=m Rapid appearance of plasmin in tear fluid after ocular allergen exposure. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,2,1,3 3.4.21.7 Hypersensitivity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4227339&form=6&db=m [Round table conference. V. Plasmin and allergy] unassigned - 3.4.21.7 Hypersensitivity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9164891&form=6&db=m Incidence and impact on outcome of streptokinase allergy in the GUSTO-I trial. Global Utilization of Streptokinase and t-PA in Occluded Coronary Arteries. therapeutic application,unassigned 1,0 3.4.21.7 Hypersensitivity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9865179&form=6&db=m [The efficacy of using enzymes in treating toxic-allergic reactions after cataract extraction with intraocular lens implantation] causal interaction,unassigned 3,0 3.4.21.7 Hypersensitivity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=13999103&form=6&db=m [On the role of plasmin in the mechanism of allergy.] causal interaction,ongoing research,unassigned 1,2,0 3.4.21.7 Hypersensitivity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16227196&form=6&db=m Review and application of serine protease inhibition in coronary artery bypass graft surgery. therapeutic application,unassigned 1,0 3.4.21.7 Hypersensitivity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31369467&form=6&db=m Tear Proteases and Protease Inhibitors: Potential Biomarkers and Disease Drivers in Ocular Surface Disease. causal interaction,therapeutic application,unassigned 2,3,0 3.4.21.7 Hypersensitivity, Delayed http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1534318&form=6&db=m Role of thrombin and plasmin in development of delayed hypersensitivity reaction in guinea pig skin. causal interaction,ongoing research,unassigned 4,2,0 3.4.21.7 Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1563856&form=6&db=m Biological risk factors for sudden death in patients with coronary artery disease and without heart failure. diagnostic usage,therapeutic application,unassigned 1,1,0 3.4.21.7 Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2532794&form=6&db=m The effect of experimental chronic hypertension on tissue plasminogen activator activity, plasminogen activator inhibition and plasmin inhibition. ongoing research,therapeutic application,unassigned 4,2,0 3.4.21.7 Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3852574&form=6&db=m [Levels of kallikrein, plasmin and thrombin precursors and the activity of their inhibitors in hypertension patients] causal interaction,unassigned 3,0 3.4.21.7 Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=5671692&form=6&db=m [Plasminogen, antiplasmins and the rate of fibrinolysis in hypertension and atherosclerosis] causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=5744902&form=6&db=m [Effect of heparin on the fibrinase activity of the blood in patients with hypertension] ongoing research,therapeutic application,unassigned 3,2,0 3.4.21.7 Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6223170&form=6&db=m [Comparative evaluation of the kallikrein-kinin, plasmin and thrombin blood systems in hypertension] therapeutic application,unassigned 2,0 3.4.21.7 Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6242555&form=6&db=m Abnormalities of fibrinolysis in essential hypertension. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7670855&form=6&db=m Comparison of plasma total plasmin activities in male and female hypertensive rats. causal interaction,unassigned 3,0 3.4.21.7 Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8824851&form=6&db=m Haemostatic and other cardiovascular risk factors, and socioeconomic status among middle-aged Finnish men and women. diagnostic usage,ongoing research,unassigned 4,1,0 3.4.21.7 Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9230618&form=6&db=m Haemostatic parameters in patients with primitive venous hypertension. ongoing research,therapeutic application,unassigned 4,1,0 3.4.21.7 Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9290555&form=6&db=m Lipoprotein (a) and its relationship to risk factors and severity of atherosclerotic peripheral vascular disease. causal interaction,diagnostic usage,unassigned 1,2,0 3.4.21.7 Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9710264&form=6&db=m Functional and morphologic evidence of the presence of tissue-plasminogen activator in vascular nerves: implications for a neurologic control of vessel wall fibrinolysis and rigidity. unassigned - 3.4.21.7 Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10485340&form=6&db=m Dexamethasone induced alterations in the levels of proteases involved in blood pressure homeostasis and blood coagulation in rats. diagnostic usage,ongoing research,unassigned 2,2,0 3.4.21.7 Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11317134&form=6&db=m Correlation between family history of hypertension and haemostatic disorders. diagnostic usage,ongoing research,unassigned 1,2,0 3.4.21.7 Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12372926&form=6&db=m Hemostasis and fibrinolysis factors in first-degree relatives of patients with Type 2 diabetes without hypertension. causal interaction,diagnostic usage,ongoing research,unassigned 4,1,2,0 3.4.21.7 Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12783694&form=6&db=m [Changes of relative variables about prethrombosis state and its clinical significance in patients with pregnancy induced hypertension] ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.7 Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15152450&form=6&db=m [Neurology in the 21st century--the era of preventive neurology utilizing new diagnostic and therapeutic techniques] causal interaction,unassigned 3,0 3.4.21.7 Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15647712&form=6&db=m Advances in diabetes for the millennium: the heart and diabetes. causal interaction,unassigned 4,0 3.4.21.7 Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16124372&form=6&db=m [Lipoprotein(a) and plasminogen patients with diabetes mellitus complicated with peripheral angiopathy and hypertension] diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.7 Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16584505&form=6&db=m The endocrine function of adipose tissue: an update. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.7 Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17132648&form=6&db=m Renal function and cardiovascular mortality in elderly men: the role of inflammatory, procoagulant, and endothelial biomarkers. causal interaction,diagnostic usage,unassigned 2,4,0 3.4.21.7 Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19140507&form=6&db=m [The influence of antihypertensive agents on plasmatic and vascular-thrombocytic homeostasis in metabolic syndrome] causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.7 Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22987920&form=6&db=m Urinary Plasmin Activates Collecting Duct ENaC Current in Preeclampsia. causal interaction,diagnostic usage,unassigned 2,3,0 3.4.21.7 Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23216619&form=6&db=m Mechanisms of renal NaCl retention in proteinuric disease. causal interaction,diagnostic usage,unassigned 3,1,0 3.4.21.7 Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24805959&form=6&db=m Plasmin in urine from patients with type 2 diabetes and treatment-resistant hypertension activates ENaC in vitro. causal interaction,diagnostic usage,ongoing research,unassigned 1,2,1,0 3.4.21.7 Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25492830&form=6&db=m Amiloride lowers blood pressure and attenuates urine plasminogen activation in patients with treatment-resistant hypertension. ongoing research,therapeutic application,unassigned 2,2,0 3.4.21.7 Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26315791&form=6&db=m Risk Factors for Thrombosis Development in Mexican Patients. diagnostic usage,unassigned 2,0 3.4.21.7 Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26818227&form=6&db=m Markers of fibrinolysis may predict development of lower extremity arterial disease in patients with diabetes: A longitudinal prospective cohort study with 10?years of follow-up. diagnostic usage,therapeutic application,unassigned 2,1,0 3.4.21.7 Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29305116&form=6&db=m Urine albumin is a superior predictor of preeclampsia compared to urine plasminogen in type I diabetes patients. causal interaction,diagnostic usage,unassigned 1,4,0 3.4.21.7 Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30856303&form=6&db=m [The endothelial dysfunction in patients with arterial hypertension after old hemorrhagic stroke.] causal interaction,diagnostic usage,ongoing research,unassigned 3,4,1,0 3.4.21.7 Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31230006&form=6&db=m Is urinary excretion of plasminogen associated with development of pre-eclampsia? An observational, explorative case-control study. causal interaction,unassigned 4,0 3.4.21.7 Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32965501&form=6&db=m Association of Red Blood Cell Distribution Width With Mortality Risk in Hospitalized Adults With SARS-CoV-2 Infection. unassigned - 3.4.21.7 Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33215566&form=6&db=m Plasminogen Deficiency and Amiloride Mitigate Angiotensin II-Induced Hypertension in Type 1 Diabetic Mice Suggesting Effects Through the Epithelial Sodium Channel. causal interaction,ongoing research,therapeutic application,unassigned 4,1,4,0 3.4.21.7 Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33714935&form=6&db=m A Multimodality Machine Learning Approach to Differentiate Severe and Nonsevere COVID-19: Model Development and Validation. diagnostic usage,ongoing research,unassigned 4,2,0 3.4.21.7 Hypertension, Pregnancy-Induced http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12783694&form=6&db=m [Changes of relative variables about prethrombosis state and its clinical significance in patients with pregnancy induced hypertension] ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.7 Hypertension, Pulmonary http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=138014&form=6&db=m [High-altitude pulmonary hypertension and fibrinolysis] causal interaction,therapeutic application,unassigned 1,2,0 3.4.21.7 Hypertension, Pulmonary http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4003389&form=6&db=m Recurring thromboembolic disease and pulmonary hypertension associated with severe hypoplasminogenemia. causal interaction,unassigned 4,0 3.4.21.7 Hypertension, Pulmonary http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11306532&form=6&db=m Deficiency of urokinase-type plasminogen activator-mediated plasmin generation impairs vascular remodeling during hypoxia-induced pulmonary hypertension in mice. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 Hypertension, Pulmonary http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24909805&form=6&db=m Association of plasma fibrinogen and plasminogen with prognosis of inoperable chronic thromboembolic pulmonary hypertension. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.7 Hypertension, Pulmonary http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26948867&form=6&db=m High Fibrinogen Plus Low Plasminogen Levels Predict Poor Post-Surgical Survival in Patients With Chronic Thromboembolic Pulmonary Hypertension. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.7 Hypertension, Pulmonary http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34539980&form=6&db=m Neutrophil extracellular traps (NETs): the role of inflammation and coagulation in COVID-19. unassigned - 3.4.21.7 Hyperthyroidism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=416638&form=6&db=m Coagulation and fibrinolysis in thyroid disease. diagnostic usage,unassigned 2,0 3.4.21.7 Hyperthyroidism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2466071&form=6&db=m Fibrinogen and fibrinolytic activity in hyperthyroidism before and after antithyroid treatment. diagnostic usage,ongoing research,unassigned 3,2,0 3.4.21.7 Hyperthyroidism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8332397&form=6&db=m [Disorders of hemostasis in dysthyroidism] causal interaction,diagnostic usage,unassigned 4,2,0 3.4.21.7 Hypertriglyceridemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10382293&form=6&db=m Generation and chromosome mapping of expressed sequence tags (ESTs) from a human infant thymus. therapeutic application,unassigned 1,0 3.4.21.7 Hypertrophy, Left Ventricular http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9005605&form=6&db=m [The indices of the fibrinolysis, blood coagulation and lipid transport systems in hypertension patients] ongoing research,therapeutic application,unassigned 3,2,0 3.4.21.7 Hypertrophy, Left Ventricular http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9406171&form=6&db=m Increased gene expression of plasminogen activators and inhibitors in left ventricular hypertrophy. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.7 Hypertrophy, Right Ventricular http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7473788&form=6&db=m Gene expression in a swine model of right ventricular hypertrophy: intercellular adhesion molecule, vascular endothelial growth factor and plasminogen activators are upregulated during pressure overload. ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.7 Hyphema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2120486&form=6&db=m Treatment of experimental vitreous hemorrhage with tissue plasminogen activator. causal interaction,ongoing research,therapeutic application,unassigned 4,2,4,0 3.4.21.7 Hyphema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4228702&form=6&db=m Treatment of total hyphema with fibrinolysin. therapeutic application,unassigned 4,0 3.4.21.7 Hyphema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4233240&form=6&db=m Fibrinolysin irrigation in traumatic secondary hyphema. causal interaction,therapeutic application,unassigned 2,1,0 3.4.21.7 Hyphema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4233770&form=6&db=m Fibrinolysin irrigation in traumatic secondary hyphema. causal interaction,therapeutic application,unassigned 2,1,0 3.4.21.7 Hyphema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4265276&form=6&db=m [Treatment of experimental hyphema in rabbits by Sevac plasmin] therapeutic application,unassigned 4,0 3.4.21.7 Hyphema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8351749&form=6&db=m [Thrombolytic effect of plasmin, miniplasmin and fibrinolysin in simulated intraocular hemorrhage] ongoing research,unassigned 1,0 3.4.21.7 Hyphema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14308841&form=6&db=m [TREATMENT OF TOTAL HYPHEMAS OF THE ANTERIOR CHAMBER WITH FIBRINOLYSIN.] therapeutic application,unassigned 4,0 3.4.21.7 Hyphema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14449118&form=6&db=m Fibrinolysis and hyphema. The effect of thrombolysin and Kabikinas on clotted blood in camera anterior of the eye in rabbits. ongoing research,therapeutic application,unassigned 1,1,0 3.4.21.7 Hypoglycemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4275232&form=6&db=m Biochemical pharmacology of the fibrinolysin system of the rat. II. The effect of insulin induced hypoglycemia. ongoing research,unassigned 3,0 3.4.21.7 Hypogonadism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16387571&form=6&db=m Cardiovascular issues in hypogonadism and testosterone therapy. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.7 Hypotension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1771172&form=6&db=m Acute blood pressure effects of selected serine proteases in normotensive rats and dogs. therapeutic application,unassigned 1,0 3.4.21.7 Hypotension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9253574&form=6&db=m Acute haemodilution and prostaglandin E1-induced hypotension: effects on the coagulation-fibrinolysis system. diagnostic usage,unassigned 3,0 3.4.21.7 Hypotension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10482282&form=6&db=m A stable prostacyclin-like substance produced by the medicinal leech Hirudo medicinalis. ongoing research,unassigned 4,0 3.4.21.7 Hypotension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14186988&form=6&db=m [ROLE OF PLASMIN IN PEPTONE-INDUCED ARTERIAL HYPOTENSION IN RATS.] causal interaction,ongoing research,unassigned 1,2,0 3.4.21.7 Hypothyroidism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8292731&form=6&db=m Experimental hypothyroidism increases plasminogen activator inhibitor activity in rat plasma. diagnostic usage,ongoing research,unassigned 1,4,0 3.4.21.7 Hypothyroidism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16075920&form=6&db=m Effect of levothyroxine replacement therapy on coagulation and fibrinolysis in severe hypothyroidism. diagnostic usage,ongoing research,therapeutic application,unassigned 3,2,1,0 3.4.21.7 Hypoxia-Ischemia, Brain http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18467699&form=6&db=m Deleterious effects of plasminogen activators in neonatal cerebral hypoxia-ischemia. ongoing research,unassigned 1,0 3.4.21.7 Hypoxia-Ischemia, Brain http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18947492&form=6&db=m [Changes and significance of endogenous tissue plasminogen activators in cerebral hypoxia-ischemia in neonatal rats] causal interaction,ongoing research,therapeutic application,unassigned 4,2,3,0 3.4.21.7 Idiopathic Pulmonary Fibrosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7624837&form=6&db=m Increased procoagulant and antifibrinolytic activities in the lungs with idiopathic pulmonary fibrosis. ongoing research,unassigned 2,0 3.4.21.7 Idiopathic Pulmonary Fibrosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16598647&form=6&db=m Matrix metalloproteinase-1 activation via plasmin generated on alveolar epithelial cell surfaces. causal interaction,unassigned 4,0 3.4.21.7 Idiopathic Pulmonary Fibrosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20501949&form=6&db=m The antifibrotic effects of plasminogen activation occur via prostaglandin E2 synthesis in humans and mice. causal interaction,diagnostic usage,ongoing research,unassigned 3,3,2,0 3.4.21.7 Idiopathic Pulmonary Fibrosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28139758&form=6&db=m The fibrogenic actions of lung fibroblast-derived urokinase: a potential drug target in IPF. unassigned - 3.4.21.7 Immunoglobulin G4-Related Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28412148&form=6&db=m No evidence to support a role for Helicobacter pylori infection and plasminogen binding protein in autoimmune pancreatitis and IgG4-related disease in a UK cohort. diagnostic usage,unassigned 3,0 3.4.21.7 Infant, Newborn, Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4236829&form=6&db=m Studies on the ontogeny and significance in neonatal disease of the fibrinolysin system and of fibrin stabilizing factor. diagnostic usage,ongoing research,unassigned 1,3,0 3.4.21.7 Infarction, Middle Cerebral Artery http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9445320&form=6&db=m PROACT: a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. PROACT Investigators. Prolyse in Acute Cerebral Thromboembolism. diagnostic usage,ongoing research,therapeutic application,unassigned 2,3,2,0 3.4.21.7 Infarction, Middle Cerebral Artery http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10698071&form=6&db=m Plasminogen activation in focal cerebral ischemia and reperfusion. causal interaction,ongoing research,therapeutic application,unassigned 4,2,2,0 3.4.21.7 Infarction, Middle Cerebral Artery http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17596135&form=6&db=m Stromelysin-1 (MMP-3) is critical for intracranial bleeding after t-PA treatment of stroke in mice. causal interaction,ongoing research,therapeutic application,unassigned 4,4,4,0 3.4.21.7 Infarction, Middle Cerebral Artery http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19275467&form=6&db=m Mechanistic insight into Neurotoxicity of Tissue Plasminogen Activator-Induced Thrombolysis Products in a Rat Intraluminal Middle Cerebral Artery Occlusion Model. causal interaction,ongoing research,therapeutic application,unassigned 4,2,4,0 3.4.21.7 Infarction, Middle Cerebral Artery http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19952306&form=6&db=m Combination therapy of 17beta-estradiol and recombinant tissue plasminogen activator for experimental ischemic stroke. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,1,4,4 3.4.21.7 Infarction, Middle Cerebral Artery http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20876504&form=6&db=m Thrombolysis with plasmin: implications for stroke treatment. causal interaction,ongoing research,therapeutic application,unassigned 3,2,4,0 3.4.21.7 Infarction, Middle Cerebral Artery http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23023418&form=6&db=m [Evaluation for antithrombotic agents by a thrombotic model in animals]. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 Infarction, Middle Cerebral Artery http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28824910&form=6&db=m The Effects of the Contact Activation System on Hemorrhage. causal interaction,therapeutic application,unassigned 4,2,0 3.4.21.7 Infarction, Middle Cerebral Artery http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30074208&form=6&db=m Recombinant Tissue Plasminogen Activator-conjugated Nanoparticles Effectively Targets Thrombolysis in a Rat Model of Middle Cerebral Artery Occlusion. ongoing research,therapeutic application,unassigned 4,2,0 3.4.21.7 Infarction, Middle Cerebral Artery http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32404037&form=6&db=m Protective Effect of ApoA1 (Apolipoprotein A1)-Milano in a Rat Model of Large Vessel Occlusion Stroke. ongoing research,therapeutic application,unassigned 3,1,0 3.4.21.7 Infarction, Middle Cerebral Artery http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33296953&form=6&db=m Increased brain plasmin levels following experimental ischemic stroke in male mice. causal interaction,ongoing research,therapeutic application,unassigned 4,2,4,0 3.4.21.7 Infarction, Middle Cerebral Artery http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33853408&form=6&db=m Plasminogen deficiency causes reduced angiogenesis and behavioral recovery after stroke in mice. causal interaction,ongoing research,therapeutic application,unassigned 4,4,2,0 3.4.21.7 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=349108&form=6&db=m Bacille Calmette-GuĂ©rin infection in the mouse. Regulation of macrophage plasminogen activator by T lymphocytes and specific antigen. unassigned - 3.4.21.7 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=654424&form=6&db=m Babesia bovis (= argentina): changes in erythrophylic and associated proteins during acute infection of splenectomized and intact calves. unassigned - 3.4.21.7 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=705694&form=6&db=m Quantitative estimation of coagulation factors in liver disease. The diagnostic and prognostic value of factor XIII, factor V and plasminogen. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1869838&form=6&db=m Streptokinases produced by pathogenic group C streptococci demonstrate species-specific plasminogen activation. causal interaction,unassigned 4,0 3.4.21.7 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2115024&form=6&db=m Secretion of tissue-type plasminogen activator and plasminogen activator inhibitor by Rickettsia conorii- and Rickettsia rickettsii-infected cultured endothelial cells. diagnostic usage,ongoing research,unassigned 3,4,0 3.4.21.7 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2386787&form=6&db=m Oligosaccharide processing in the expression of human plasminogen cDNA by lepidopteran insect (Spodoptera frugiperda) cells. ongoing research,therapeutic application,unassigned 4,1,0 3.4.21.7 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2568948&form=6&db=m Binding of plasminogen to Escherichia coli adhesion proteins. ongoing research,therapeutic application,unassigned 4,1,0 3.4.21.7 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2699101&form=6&db=m Influence of plasma protease activation on electroimmunoassay and nephelometry of plasma fibronectin in sepsis. causal interaction,diagnostic usage,ongoing research,unassigned 2,2,3,0 3.4.21.7 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2973722&form=6&db=m Elevation of tear fluid plasmin in corneal disease. causal interaction,diagnostic usage,unassigned 4,3,0 3.4.21.7 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3077022&form=6&db=m Plasmodium berghei: pulmonary oedema and changes in clotting and fibrinolysis during infection in mice. unassigned - 3.4.21.7 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6188103&form=6&db=m [Hemostasis in burn patients and treatment with heparin. Relation to prognosis and infection. Pattern of blood levels of prekallikrein, alpha-2-macroglobulin, antithrombin III, plasminogen and alpha-2-antiplasmin] causal interaction,diagnostic usage,therapeutic application,unassigned 3,2,3,0 3.4.21.7 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6461136&form=6&db=m [Cleavage of influenza virus hemagglutinin as affected by serum plasmin in cell culture and in vivo] causal interaction,diagnostic usage,ongoing research,unassigned 3,3,4,0 3.4.21.7 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7488820&form=6&db=m Low levels of plasminogen in cerebrospinal fluid after intraventricular haemorrhage: a limiting factor for clot lysis? causal interaction,ongoing research,therapeutic application,unassigned 4,2,4,0 3.4.21.7 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7810098&form=6&db=m [Hemostasis in patients with acute leukemia treated with high doses of cytosine-arabinoside: the effect of chemotherapy and infectious complications on hemostasis] causal interaction,diagnostic usage,unassigned 3,1,0 3.4.21.7 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7963733&form=6&db=m Correlation between detection of plasminogen cross-reactive antibodies and hemorrhage in dengue virus infection. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,2,1 3.4.21.7 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8017118&form=6&db=m [The results of the measured oral infection of white mice with strains of the causative agent of plague differing in their plasmid profile] unassigned - 3.4.21.7 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8156787&form=6&db=m A rapid fluorometric assay for tear fluid plasmin activity. causal interaction,diagnostic usage,unassigned 3,3,0 3.4.21.7 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8769282&form=6&db=m Gastric mucosal plasminogen activators in Helicobacter pylori infection. causal interaction,ongoing research,unassigned 3,2,0 3.4.21.7 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9178267&form=6&db=m Host urokinase-type plasminogen activator participates in the release of malaria merozoites from infected erythrocytes. causal interaction,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.7 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9646471&form=6&db=m The interaction of Streptococcus dysgalactiae with plasmin and plasminogen. causal interaction,unassigned 4,0 3.4.21.7 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9884337&form=6&db=m The plasminogen activation system enhances brain and heart invasion in murine relapsing fever borreliosis. ongoing research,unassigned 3,0 3.4.21.7 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10024547&form=6&db=m The staphylococcal transferrin-binding protein is a cell wall glyceraldehyde-3-phosphate dehydrogenase. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.7 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10816371&form=6&db=m Nonfibrinolytic functions of plasminogen. therapeutic application,unassigned 3,0 3.4.21.7 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10816375&form=6&db=m Analysis of plasminogen-binding M proteins of Streptococcus pyogenes. causal interaction,unassigned 1,0 3.4.21.7 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10816379&form=6&db=m Role of the pleiotropic effects of plasminogen deficiency in infection experiments with plasminogen-deficient mice. causal interaction,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.7 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11500461&form=6&db=m Delayed invasion of the kidney and brain by Borrelia crocidurae in plasminogen-deficient mice. ongoing research,unassigned 3,0 3.4.21.7 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12464265&form=6&db=m Enhanced expression of matrix metalloproteinase-9 by hepatitis B virus infection in liver cells. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,1,0 3.4.21.7 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12875972&form=6&db=m The fibrinolytic system in dissemination and matrix protein deposition during a mycobacterium infection. ongoing research,therapeutic application,unassigned 2,3,0 3.4.21.7 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14688117&form=6&db=m Plasminogen binding by group A streptococcal isolates from a region of hyperendemicity for streptococcal skin infection and a high incidence of invasive infection. causal interaction,diagnostic usage,unassigned 1,2,0 3.4.21.7 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15613028&form=6&db=m Interleukin-6-induced plasminogen gene expression in murine hepatocytes is mediated by transcription factor CCAAT/enhancer binding protein beta (C/EBPbeta). causal interaction,unassigned 4,0 3.4.21.7 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15680767&form=6&db=m Bacterial metastasis: the host plasminogen system in bacterial invasion. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.7 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15972548&form=6&db=m Structural diversity of streptokinase and activation of human plasminogen. causal interaction,unassigned 1,0 3.4.21.7 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16081064&form=6&db=m A study of cutaneous lesions caused by Leishmania mexicana in plasminogen-deficient mice. ongoing research,unassigned 3,0 3.4.21.7 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16103174&form=6&db=m Role of plasminogen in propagation of scrapie. causal interaction,ongoing research,therapeutic application,unassigned 2,2,4,0 3.4.21.7 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16505706&form=6&db=m Clinical Correlation with the PA/Plasmin System in Septic Arthritis of the Knee. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,3,2,1 3.4.21.7 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16505739&form=6&db=m Syphilis and Human Immunodeficiency Virus (HIV)-1 Coinfection: Influence on CD4 T-Cell Count, HIV-1 Viral Load, and Treatment Response. ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.7 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16790522&form=6&db=m Trigger for group A streptococcal M1T1 invasive disease. ongoing research,therapeutic application,unassigned 4,1,0 3.4.21.7 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16868317&form=6&db=m The interaction between pathogens and the host coagulation system. causal interaction,diagnostic usage,unassigned 4,2,0 3.4.21.7 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17179833&form=6&db=m Molecular characterization of an Italian patient with plasminogen deficiency and ligneous conjunctivitis. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,1,0 3.4.21.7 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17397009&form=6&db=m Staphylococcus aureus exploits cathelicidin antimicrobial peptides produced during early pneumonia to promote staphylokinase-dependent fibrinolysis. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17449317&form=6&db=m Role of secreted glyceraldehyde-3-phosphate dehydrogenase in the infection mechanism of enterohemorrhagic and enteropathogenic Escherichia coli: interaction of the extracellular enzyme with human plasminogen and fibrinogen. ongoing research,therapeutic application,unassigned 4,1,0 3.4.21.7 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17635705&form=6&db=m Fibrin and fibrinolysis in infection and host defense. causal interaction,therapeutic application,unassigned 2,2,0 3.4.21.7 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18467595&form=6&db=m M protein-mediated plasminogen binding is essential for the virulence of an invasive Streptococcus pyogenes isolate. causal interaction,unassigned 4,0 3.4.21.7 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18710460&form=6&db=m Molecular mechanisms underlying group A streptococcal pathogenesis. unassigned - 3.4.21.7 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19001079&form=6&db=m Borrelia burgdorferi infection-associated surface proteins ErpP, ErpA, and ErpC bind human plasminogen. causal interaction,unassigned 1,0 3.4.21.7 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19492051&form=6&db=m Surface-associated plasminogen binding of Cryptococcus neoformans promotes extracellular matrix invasion. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.7 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19589835&form=6&db=m Deletion of Braun lipoprotein gene (lpp) and curing of plasmid pPCP1 dramatically alter the virulence of Yersinia pestis CO92 in a mouse model of pneumonic plague. ongoing research,unassigned 3,0 3.4.21.7 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20702651&form=6&db=m Plasminogen promotes influenza A virus replication through an annexin 2-dependent pathway in the absence of neuraminidase. unassigned - 3.4.21.7 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20726765&form=6&db=m Activation of plasminogen by staphylokinase reduces the severity of Staphylococcus aureus systemic infection. causal interaction,ongoing research,therapeutic application,unassigned 2,1,1,0 3.4.21.7 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21072208&form=6&db=m Contribution of plasminogen activation towards the pathogenic potential of oral streptococci. causal interaction,therapeutic application,unassigned 4,2,0 3.4.21.7 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21346358&form=6&db=m Ischemic stroke outcome and early infection: its deleterious effect seems to operate also among tissue plasminogen activator-treated patients. causal interaction,diagnostic usage,unassigned 4,1,0 3.4.21.7 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21781255&form=6&db=m Exploration of the host haemostatic system by group A streptococcus: implications in searching for novel antimicrobial therapies. therapeutic application,unassigned 3,0 3.4.21.7 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21844229&form=6&db=m The novel leptospiral surface adhesin, Lsa20, binds laminin, human plasminogen and is probably expressed during infection. causal interaction,unassigned 2,0 3.4.21.7 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21931850&form=6&db=m Beneficial and detrimental effects of plasmin(ogen) during infection and sepsis in mice. causal interaction,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.7 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22268271&form=6&db=m Induction of plasminogen activators in pregnant women with Toxoplasma gondii infection. ongoing research,therapeutic application,unassigned 1,1,0 3.4.21.7 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22318336&form=6&db=m Herpesviruses enhance fibrin clot lysis. causal interaction,ongoing research,therapeutic application,unassigned 2,4,1,0 3.4.21.7 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22433988&form=6&db=m Secretion of the housekeeping protein glyceraldehyde-3-phosphate dehydrogenase by the LEE-encoded type III secretion system in enteropathogenic Escherichia coli. ongoing research,therapeutic application,unassigned 3,1,0 3.4.21.7 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22518846&form=6&db=m Streptococcus uberis plasminogen activator (SUPA) activates human plasminogen through novel species-specific and fibrin-targeted mechanisms. causal interaction,unassigned 1,0 3.4.21.7 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23031515&form=6&db=m Reevaluation of vitamin E supplementation of dairy cows: bioavailability, animal health and milk quality. unassigned - 3.4.21.7 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23490555&form=6&db=m Plasmin activity in the porcine airways is enhanced during experimental infection with Mycoplasma hyopneumoniae, is positively correlated with proinflammatory cytokine levels and is ameliorated by vaccination. causal interaction,therapeutic application,unassigned 3,2,0 3.4.21.7 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23529618&form=6&db=m Acquisition of the Sda1-encoding bacteriophage does not enhance virulence of the M1 Streptococcus pyogenes strain SF370. ongoing research,unassigned 1,0 3.4.21.7 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23555246&form=6&db=m Plasminogen controls inflammation and pathogenesis of influenza virus infections via fibrinolysis. causal interaction,ongoing research,therapeutic application,unassigned 4,1,1,0 3.4.21.7 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23801604&form=6&db=m Staphylokinase Promotes the Establishment of Staphylococcus aureus Skin Infections While Decreasing Disease Severity. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,2,1 3.4.21.7 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23850366&form=6&db=m The Bfp60 surface adhesin is an extracellular matrix and plasminogen protein interacting in Bacteroides fragilis. unassigned - 3.4.21.7 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23850506&form=6&db=m Parasitism in optima forma: Exploiting the host fibrinolytic system for invasion. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23906818&form=6&db=m The interaction between bacterial enolase and plasminogen promotes adherence of Streptococcus pneumoniae to epithelial and endothelial cells. causal interaction,diagnostic usage,therapeutic application,unassigned 3,1,1,0 3.4.21.7 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23919993&form=6&db=m Mechanisms of severe acute respiratory syndrome coronavirus-induced acute lung injury. causal interaction,diagnostic usage,therapeutic application,unassigned 3,3,1,0 3.4.21.7 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23969887&form=6&db=m Plasmin(ogen) Acquisition by Group A Streptococcus Protects against C3b-Mediated Neutrophil Killing. unassigned - 3.4.21.7 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24503144&form=6&db=m Plasmodium falciparum proteases hydrolyze plasminogen, generating angiostatin-like fragments. causal interaction,therapeutic application,unassigned 3,3,0 3.4.21.7 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24759132&form=6&db=m The procoagulant envelope virus surface: contribution to enhanced infection. causal interaction,therapeutic application,unassigned 2,1,0 3.4.21.7 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25103064&form=6&db=m Haemophilus ducreyi as a cause of skin ulcers in children from a yaws-endemic area of Papua New Guinea: a prospective cohort study. diagnostic usage,therapeutic application,unassigned 1,1,0 3.4.21.7 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25179235&form=6&db=m Hyperglycemia is associated with lower levels of urokinase-type plasminogen activator and urokinase-type plasminogen activator receptor in wound fluid. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,2,2,1 3.4.21.7 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25198697&form=6&db=m Production of outer membrane vesicles by the plague pathogen Yersinia pestis. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.7 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25434150&form=6&db=m [Enolase and parasitic infection]. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.7 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25507748&form=6&db=m [Enolase and parasitic infection]. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.7 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25515118&form=6&db=m Plasminogen activation by staphylokinase enhances local spreading of S. aureus in skin infections. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,3,2,1 3.4.21.7 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25627443&form=6&db=m The novel Leptospira interrogans protein Lsa32 is expressed during infection and binds laminin and plasminogen. causal interaction,unassigned 1,0 3.4.21.7 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25978044&form=6&db=m Subunits of the Pyruvate Dehydrogenase Cluster of Mycoplasma pneumoniae Are Surface-Displayed Proteins that Bind and Activate Human Plasminogen. causal interaction,unassigned 3,0 3.4.21.7 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26185887&form=6&db=m Early syphilitic hepatitis concomitant with nephrotic syndrome followed by acute kidney injury. causal interaction,diagnostic usage,unassigned 2,3,0 3.4.21.7 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26425363&form=6&db=m Expression, genetic localization and phylogenic analysis of NAPlr in piscine Streptococcus dysgalactiae subspecies dysgalactiae isolates and their patterns of adherence. diagnostic usage,ongoing research,unassigned 3,2,0 3.4.21.7 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26485450&form=6&db=m Bacterial pathogens activate plasminogen to breach tissue barriers and escape from innate immunity. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.7 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26590504&form=6&db=m Heparin versus 0.9% sodium chloride intermittent flushing for the prevention of occlusion in long term central venous catheters in infants and children. unassigned - 3.4.21.7 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26657108&form=6&db=m The recombinant LIC10508 is a plasma fibronectin, plasminogen, fibrinogen and C4BP-binding protein of Leptospira interrogans. unassigned - 3.4.21.7 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26667841&form=6&db=m Network of Surface-Displayed Glycolytic Enzymes in Mycoplasma pneumoniae and Their Interactions with Human Plasminogen. ongoing research,unassigned 2,0 3.4.21.7 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27377187&form=6&db=m Proteolysis of plasminogen activator inhibitor-1 by Yersinia pestis remodulates the host environment to promote virulence. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,3,3,2 3.4.21.7 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27514905&form=6&db=m Interaction of Trypanosoma evansi with the plasminogen-plasmin system. unassigned - 3.4.21.7 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28298336&form=6&db=m Moonlighting glycolytic protein glyceraldehyde-3-phosphate dehydrogenase (GAPDH): an evolutionarily conserved plasminogen receptor on mammalian cells. ongoing research,unassigned 2,0 3.4.21.7 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28412148&form=6&db=m No evidence to support a role for Helicobacter pylori infection and plasminogen binding protein in autoimmune pancreatitis and IgG4-related disease in a UK cohort. diagnostic usage,unassigned 3,0 3.4.21.7 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28888036&form=6&db=m Exploring the interaction between Mycobacterium tuberculosisEnolase and human plasminogen using computational methods and experimental techniques. causal interaction,unassigned 1,0 3.4.21.7 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28924140&form=6&db=m Linoleic and palmitoleic acid block streptokinase-mediated plasminogen activation and reduce severity of invasive group A streptococcal infection. causal interaction,therapeutic application,unassigned 2,1,0 3.4.21.7 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29273597&form=6&db=m Intravenous Thrombolysis for Stroke and Presumed Stroke in Human Immunodeficiency Virus-Infected Adults: A Retrospective, Multicenter US Study. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,2,2,3 3.4.21.7 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30557607&form=6&db=m Molecular cloning and expression analysis of coagulation factor VIII and plasminogen involved in immune response to GCRV, and immunity activity comparison of grass carp Ctenopharyngodon idella with different viral resistance. diagnostic usage,ongoing research,unassigned 1,3,0 3.4.21.7 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30571394&form=6&db=m Infections Increase the Risk of 30-Day Readmissions Among Stroke Survivors. diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.7 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30805192&form=6&db=m Successful management of pleural infection with very low dose intrapleural tissue plasminogen activator/deoxyribonuclease regime. therapeutic application,unassigned 4,0 3.4.21.7 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30972077&form=6&db=m t-PA Suppresses the Immune Response and Aggravates Neurological Deficit in a Murine Model of Ischemic Stroke. causal interaction,therapeutic application,unassigned 2,2,0 3.4.21.7 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31126915&form=6&db=m Tranexamic acid modulates the immune response and reduces postsurgical infection rates. causal interaction,therapeutic application,unassigned 4,2,0 3.4.21.7 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31384704&form=6&db=m Intracellular/surface moonlighting proteins that aid in the attachment of gut microbiota to the host. causal interaction,unassigned 1,0 3.4.21.7 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31502568&form=6&db=m Effect of ions and inhibitors on the catalytic activity and structural stability of S. aureus enolase. ongoing research,unassigned 1,0 3.4.21.7 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31528637&form=6&db=m Comparison of intrapleural use of urokinase and tissue plasminogen activator/DNAse in pleural infection. unassigned - 3.4.21.7 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31546590&form=6&db=m Vascular Leak and Hypercytokinemia Associated with Severe Fever with Thrombocytopenia Syndrome Virus Infection in Mice. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.7 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31726374&form=6&db=m Increased Mosquito Midgut Infection by Dengue Virus Recruitment of Plasmin Is Blocked by an Endogenous Kazal-type Inhibitor. ongoing research,therapeutic application,unassigned 2,2,0 3.4.21.7 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31806006&form=6&db=m Molecular characterization of a Trichinella spiralis enolase and its interaction with the host's plasminogen. causal interaction,unassigned 1,0 3.4.21.7 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32275753&form=6&db=m Plasminogen improves lung lesions and hypoxemia in patients with COVID-19. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,2,4,3 3.4.21.7 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32430832&form=6&db=m Humanized Plasminogen Mouse Model to Study Group A Streptococcus Invasive Disease. ongoing research,unassigned 2,0 3.4.21.7 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32574621&form=6&db=m Human Plasminogen Exacerbates Clostridioides difficile Enteric Disease and Alters the Spore Surface. causal interaction,ongoing research,therapeutic application,unassigned 3,2,4,0 3.4.21.7 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32610551&form=6&db=m Genetic Variants in the FGB and FGG Genes Mapping in the Beta and Gamma Nodules of the Fibrinogen Molecule in Congenital Quantitative Fibrinogen Disorders Associated with a Thrombotic Phenotype. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.7 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32972339&form=6&db=m Targeting host cell proteases to prevent SARS-CoV-2 invasion. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.7 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33115324&form=6&db=m Preventing Candida albicans from subverting host plasminogen for invasive infection treatment. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33231723&form=6&db=m Current Understanding of the Pathogenesis of Dengue Virus Infection. causal interaction,therapeutic application,unassigned 2,1,0 3.4.21.7 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33760094&form=6&db=m Comparison of Time to Clinical Improvement With vs Without Remdesivir Treatment in Hospitalized Patients With COVID-19. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.7 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34065949&form=6&db=m Plasmin, Immunity, and Surgical Site Infection. diagnostic usage,unassigned 1,0 3.4.21.7 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34089860&form=6&db=m Myxomavirus serpin alters macrophage function and prevents diffuse alveolar hemorrhage in pristane-induced lupus. causal interaction,unassigned 2,0 3.4.21.7 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34354045&form=6&db=m Low level of plasminogen increases risk for mortality in COVID-19 patients. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,4,0 3.4.21.7 Infertility http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8150119&form=6&db=m Tissue-type plasminogen activator level is decreased in human seminal plasma with abnormal liquefaction. diagnostic usage,ongoing research,therapeutic application,unassigned 4,2,1,0 3.4.21.7 Infertility http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9527420&form=6&db=m [Consequences for labile blood products of leukocyte depletion by whole blood filtration using the Leucoflex LST1 in-line filter. Evaluation of the Leucoflex LST1 filter] diagnostic usage,ongoing research,unassigned 1,2,0 3.4.21.7 Infertility http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17123524&form=6&db=m Possible role of the plasminogen activation system in human subfertility. ongoing research,unassigned 4,0 3.4.21.7 Infertility, Female http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6485627&form=6&db=m [Serum plasminogen levels and timing of ovulation] diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.7 Inflammatory Bowel Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3146142&form=6&db=m Plasminogen activators in the intestine of patients with inflammatory bowel disease. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,4,0 3.4.21.7 Inflammatory Bowel Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7785949&form=6&db=m D-dimer tests detect both plasmin and neutrophil elastase derived split products. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,1,0 3.4.21.7 Inflammatory Bowel Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9122714&form=6&db=m The role of inflammatory cells and their proteases in extravascular fibrinolysis. causal interaction,therapeutic application,unassigned 3,3,0 3.4.21.7 Inflammatory Bowel Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24995109&form=6&db=m Coagulation parameters in inflammatory bowel disease. causal interaction,diagnostic usage,unassigned 3,2,0 3.4.21.7 Inflammatory Bowel Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25490065&form=6&db=m Inhibition of Plasmin Protects Against Colitis in Mice by Suppressing Matrix Metalloproteinase 9-Mediated Cytokine Release From Myeloid Cells. causal interaction,ongoing research,therapeutic application,unassigned 1,4,2,0 3.4.21.7 Inflammatory Bowel Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28304250&form=6&db=m Tranexamic Acid and Supportive Measures to Treat Wasting Marmoset Syndrome. causal interaction,ongoing research,therapeutic application,unassigned 3,4,3,0 3.4.21.7 Inflammatory Bowel Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34095331&form=6&db=m Inflammatory Bowel Disease: A Gastrointestinal Presentation of Congenital Plasminogen Deficiency. causal interaction,unassigned 4,0 3.4.21.7 Influenza in Birds http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30173734&form=6&db=m Effect of annexin II-mediated conversion of plasmin from plasminogen on airborne transmission of H9N2 avian influenza virus. causal interaction,ongoing research,unassigned 1,2,0 3.4.21.7 Influenza in Birds http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33891662&form=6&db=m Neuraminidase-associated plasminogen recruitment enables systemic spread of natural avian Influenza viruses H3N1. unassigned - 3.4.21.7 Influenza, Human http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2522998&form=6&db=m Molecular mechanism of complex infection by bacteria and virus analyzed by a model using serratial protease and influenza virus in mice. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,4,2 3.4.21.7 Influenza, Human http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4795670&form=6&db=m Proteolytic cleavage by plasmin of the HA polypeptide of influenza virus: host cell activation of serum plasminogen. diagnostic usage,ongoing research,unassigned 2,2,0 3.4.21.7 Influenza, Human http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6461136&form=6&db=m [Cleavage of influenza virus hemagglutinin as affected by serum plasmin in cell culture and in vivo] causal interaction,diagnostic usage,ongoing research,unassigned 3,3,4,0 3.4.21.7 Influenza, Human http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10816377&form=6&db=m Assays for functional binding of plasminogen to viral proteins. diagnostic usage,ongoing research,therapeutic application,unassigned 3,4,1,0 3.4.21.7 Influenza, Human http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12924095&form=6&db=m [Role of neuraminidase in pathogenesis of influenza] causal interaction,ongoing research,unassigned 1,3,0 3.4.21.7 Influenza, Human http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18448517&form=6&db=m Annexin II incorporated into influenza virus particles supports virus replication by converting plasminogen into plasmin. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,3,1 3.4.21.7 Influenza, Human http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19158246&form=6&db=m Proteolytic activation of the 1918 influenza virus hemagglutinin. ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.7 Influenza, Human http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20702651&form=6&db=m Plasminogen promotes influenza A virus replication through an annexin 2-dependent pathway in the absence of neuraminidase. unassigned - 3.4.21.7 Influenza, Human http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23449787&form=6&db=m Plasmin-mediated activation of pandemic H1N1 influenza virus hemagglutinin independent of the viral neuraminidase. causal interaction,diagnostic usage,therapeutic application,unassigned 2,1,1,0 3.4.21.7 Influenza, Human http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23555246&form=6&db=m Plasminogen controls inflammation and pathogenesis of influenza virus infections via fibrinolysis. causal interaction,ongoing research,therapeutic application,unassigned 4,1,1,0 3.4.21.7 Influenza, Human http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23612974&form=6&db=m Cleavage activation of human-adapted influenza virus subtypes by kallikrein-related peptidases 5 and 12. causal interaction,diagnostic usage,therapeutic application,unassigned 1,3,2,0 3.4.21.7 Influenza, Human http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30173734&form=6&db=m Effect of annexin II-mediated conversion of plasmin from plasminogen on airborne transmission of H9N2 avian influenza virus. causal interaction,ongoing research,unassigned 1,2,0 3.4.21.7 Influenza, Human http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32676594&form=6&db=m Unique transcriptional changes in coagulation cascade genes in SARS-CoV-2-infected lung epithelial cells: A potential factor in COVID-19 coagulopathies. causal interaction,ongoing research,therapeutic application,unassigned 1,1,1,0 3.4.21.7 Insulin Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9215280&form=6&db=m Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. diagnostic usage,ongoing research,therapeutic application,unassigned 1,3,4,0 3.4.21.7 Insulin Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10762292&form=6&db=m Raised plasminogen activator inhibitor-1 (PAI-1) is not an independent risk factor in the polycystic ovary syndrome (PCOS). causal interaction,diagnostic usage,ongoing research,therapeutic application 4,1,1,2 3.4.21.7 Insulin Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10855542&form=6&db=m Variables of the insulin resistance syndrome are associated with reduced arterial distensibility in healthy non-diabetic middle-aged women. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.7 Insulin Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11340211&form=6&db=m Insulin resistance and elevated levels of tissue plasminogen activator in first-degree relatives of South Asian patients with ischemic cerebrovascular disease. causal interaction,diagnostic usage,unassigned 4,3,0 3.4.21.7 Insulin Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12660871&form=6&db=m Differential gene expression between visceral and subcutaneous fat depots. causal interaction,ongoing research,unassigned 1,1,0 3.4.21.7 Insulin Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16381506&form=6&db=m [Adipocitokines, adipose tissue and its relationship with immune system cells] unassigned - 3.4.21.7 Insulin Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16387571&form=6&db=m Cardiovascular issues in hypogonadism and testosterone therapy. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.7 Insulin Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22221092&form=6&db=m Role of PPARg2 transcription factor in thiazolidinedione-induced insulin sensitization. unassigned - 3.4.21.7 Insulin Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27365919&form=6&db=m Is There a Tendency for Thrombosis in Gestational Diabetes Mellitus? diagnostic usage,ongoing research,therapeutic application,unassigned 1,1,1,0 3.4.21.7 Insulin Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29278513&form=6&db=m Adiponectin levels may help assess the clinical repercussions of obesity irrespective of body mass index. diagnostic usage,unassigned 2,0 3.4.21.7 Insulin Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30429035&form=6&db=m Chemerin as a biomarker at the intersection of inflammation, chemotaxis, coagulation, fibrinolysis and metabolism in resectable non-small cell lung cancer. diagnostic usage,unassigned 3,0 3.4.21.7 Intervertebral Disc Displacement http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7745838&form=6&db=m [A Japanese family with congenital abnormal plasminogen] causal interaction,diagnostic usage,unassigned 2,4,0 3.4.21.7 Intestinal Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15634544&form=6&db=m [Clinical study of hemostatic molecular markers expression in patients with cancer.] causal interaction,diagnostic usage,unassigned 3,3,0 3.4.21.7 Intestinal Obstruction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=148541&form=6&db=m [Intraperitoneal administration of a solution of fibrinolysin, hydrocortisone and novocaine and its effect on blood coagulability in acute adhesive intestinal obstruction] ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.7 Intestinal Volvulus http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12818429&form=6&db=m Molecular cloning of an alpha-enolase from the human filarial parasite Onchocerca volvulus that binds human plasminogen. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,1,4,1 3.4.21.7 Intra-Abdominal Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22545876&form=6&db=m Tissue plasminogen activator-assisted hematoma evacuation to relieve abdominal compartment syndrome after endovascular repair of ruptured abdominal aortic aneurysm. therapeutic application,unassigned 1,0 3.4.21.7 Intracranial Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7195642&form=6&db=m Coagulation and fibrinolysis in blood and cerebrospinal fluid after aneurysmal subarachnoid haemorrhage: effect of tranexamic acid (AMCA). diagnostic usage,ongoing research,therapeutic application,unassigned 2,1,1,0 3.4.21.7 Intracranial Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21786025&form=6&db=m Effect of dietary ? carotene on cerebral aneurysm and subarachnoid haemorrhage in the brain apo E(-/-) mice. causal interaction,diagnostic usage,ongoing research,unassigned 1,3,3,0 3.4.21.7 Intracranial Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2148232&form=6&db=m Coagulation-fibrinolysis abnormalities in acute and chronic phases of cerebral thrombosis and embolism. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,1,0 3.4.21.7 Intracranial Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2496332&form=6&db=m Tissue plasminogen activator-mediated thrombolysis of cerebral emboli and its effect on hemorrhagic infarction in rabbits. causal interaction,ongoing research,therapeutic application,unassigned 4,2,4,0 3.4.21.7 Intracranial Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4245165&form=6&db=m [Cerebral embolism after electric depolarization of a patient with cardiac fibrillation treated with fibrinolysin] therapeutic application,unassigned 2,0 3.4.21.7 Intracranial Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8397927&form=6&db=m The thrombolytic effect of lumbrokinase is not as potent as urokinase in a rabbit cerebral embolism model. ongoing research,therapeutic application,unassigned 1,2,0 3.4.21.7 Intracranial Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30546622&form=6&db=m Successful treatment of cerebral emboli with tissue plasminogen activator in a patient with takotsubo cardiomyopathy: A case report. causal interaction,ongoing research,therapeutic application,unassigned 4,2,4,0 3.4.21.7 Intracranial Hemorrhages http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3785592&form=6&db=m Relationship between abnormalities of coagulation and fibrinolysis and postoperative intracranial hemorrhage in head injury. causal interaction,diagnostic usage,unassigned 1,4,0 3.4.21.7 Intracranial Hemorrhages http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9506593&form=6&db=m Thrombolysis-related intracranial hemorrhage: a radiographic analysis of 244 cases from the GUSTO-1 trial with clinical correlation. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. causal interaction,diagnostic usage,therapeutic application,unassigned 2,1,2,0 3.4.21.7 Intracranial Hemorrhages http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12446443&form=6&db=m Distinct dose-dependent effects of plasmin and TPA on coagulation and hemorrhage. causal interaction,unassigned 3,0 3.4.21.7 Intracranial Hemorrhages http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14564977&form=6&db=m Gender differences in the outcome of interventional cardiac procedures. causal interaction,unassigned 4,0 3.4.21.7 Intracranial Hemorrhages http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15112713&form=6&db=m Pharmacologic and clinical characteristics of thrombolytic agents. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 Intracranial Hemorrhages http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17072311&form=6&db=m Activated protein C inhibits tissue plasminogen activator-induced brain hemorrhage. ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.7 Intracranial Hemorrhages http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21645268&form=6&db=m Outcomes in acute ischemic strokes presenting with disabling neurologic deficits without intracranial vascular occlusion. causal interaction,ongoing research,therapeutic application,unassigned 2,2,1,0 3.4.21.7 Intracranial Hemorrhages http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22521821&form=6&db=m Matrix metalloproteinase-2 or -9 deletions protect against hemorrhagic transformation during early stage of cerebral ischemia and reperfusion. causal interaction,ongoing research,therapeutic application,unassigned 4,1,1,0 3.4.21.7 Intracranial Hemorrhages http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25613308&form=6&db=m Alteplase for Acute Ischemic Stroke: Outcomes by Clinically Important Subgroups in the Third International Stroke Trial. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,2,0 3.4.21.7 Intracranial Hemorrhages http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25673638&form=6&db=m Endogenous plasminogen activators mediate progressive intracranial hemorrhage after traumatic brain injury. causal interaction,ongoing research,unassigned 2,2,0 3.4.21.7 Intracranial Hemorrhages http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25677596&form=6&db=m Tenecteplase-tissue-type plasminogen activator evaluation for minor ischemic stroke with proven occlusion. causal interaction,therapeutic application,unassigned 1,2,0 3.4.21.7 Intracranial Hemorrhages http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26646461&form=6&db=m Modulation by the Noble Gas Helium of Tissue Plasminogen Activator: Effects in a Rat Model of Thromboembolic Stroke. causal interaction,ongoing research,therapeutic application,unassigned 3,1,4,0 3.4.21.7 Intracranial Hemorrhages http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29686025&form=6&db=m Shorter Intensive Care Unit Stays? The Majority of Post-Intravenous tPA (Tissue-Type Plasminogen Activator) Symptomatic Hemorrhages Occur Within 12 Hours of Treatment. causal interaction,diagnostic usage,therapeutic application,unassigned 3,1,4,0 3.4.21.7 Intracranial Hemorrhages http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30571560&form=6&db=m PI3K? (Phosphoinositide 3-Kinase-?) Inhibition Attenuates Tissue-Type Plasminogen Activator-Induced Brain Hemorrhage and Improves Microvascular Patency After Embolic Stroke. causal interaction,therapeutic application,unassigned 2,3,0 3.4.21.7 Intracranial Hemorrhages http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30964047&form=6&db=m Neurotherapeutic potential of erythropoietin after ischemic injury of the central nervous system. causal interaction,diagnostic usage,ongoing research,unassigned 1,3,4,0 3.4.21.7 Intracranial Hemorrhages http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31756041&form=6&db=m Rosiglitazone ameliorates tissue plasminogen activator-induced brain hemorrhage after stroke. causal interaction,ongoing research,therapeutic application,unassigned 4,1,4,0 3.4.21.7 Intracranial Hemorrhages http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31842706&form=6&db=m Risk of Intracranial Hemorrhage Following Intravenous tPA (Tissue-Type Plasminogen Activator) for Acute Stroke Is Low in Children. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,1,1,4 3.4.21.7 Intracranial Hemorrhages http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31986113&form=6&db=m Correction to: Risk of Intracranial Hemorrhage Following Intravenous tPA (Tissue-Type Plasminogen Activator) for Acute Stroke Is Low in Children. diagnostic usage,therapeutic application,unassigned 1,3,0 3.4.21.7 Intracranial Hemorrhages http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33493994&form=6&db=m Utilization of lysis percentage via thromboelastography for tissue plasminogen activator-induced symptomatic intracranial hemorrhage. unassigned - 3.4.21.7 Intracranial Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=115108&form=6&db=m Variations of alpha 2-plasmin inhibitor, antithrombin III, plasminogen in the serum of patients of cerebral thrombosis infused with urokinase. causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,1,0 3.4.21.7 Intracranial Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2148232&form=6&db=m Coagulation-fibrinolysis abnormalities in acute and chronic phases of cerebral thrombosis and embolism. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,1,0 3.4.21.7 Intracranial Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4241729&form=6&db=m [The use of fibrinolysin with heparin in developing cerebral thrombosis] therapeutic application,unassigned 4,0 3.4.21.7 Intracranial Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11877020&form=6&db=m [Preliminary study on the effects of coagulation factor XII on fibrinolysis] causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 Intracranial Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20894133&form=6&db=m Lysis of a Cerebral Thrombus with Fibrinolysin: A Case Report. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.7 Intracranial Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30878103&form=6&db=m Safety and efficacy of sonothrombolysis for acute ischaemic stroke: a multicentre, double-blind, phase 3, randomised controlled trial. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,1,3,3 3.4.21.7 Invasive Fungal Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18566672&form=6&db=m Plasminogen alleles influence susceptibility to invasive aspergillosis. causal interaction,unassigned 4,0 3.4.21.7 Invasive Fungal Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33115324&form=6&db=m Preventing Candida albicans from subverting host plasminogen for invasive infection treatment. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 Iridocyclitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=139578&form=6&db=m [Use of fibrinolysin in plastic iridocyclitis] therapeutic application,unassigned 1,0 3.4.21.7 Iron Overload http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30018160&form=6&db=m Iron Overload Exacerbates the Risk of Hemorrhagic Transformation After tPA (Tissue-Type Plasminogen Activator) Administration in Thromboembolic Stroke Mice. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,3,4 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9445320&form=6&db=m PROACT: a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. PROACT Investigators. Prolyse in Acute Cerebral Thromboembolism. diagnostic usage,ongoing research,therapeutic application,unassigned 2,3,2,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9553597&form=6&db=m Intravenous thrombolytic therapy for acute ischemic stroke. Weighing the risks and benefits of tissue plasminogen activator. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9880385&form=6&db=m Serum glucose level and diabetes predict tissue plasminogen activator-related intracerebral hemorrhage in acute ischemic stroke. causal interaction,diagnostic usage,ongoing research,unassigned 3,4,3,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10362821&form=6&db=m Effects of tissue plasminogen activator for acute ischemic stroke at one year. National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study Group. causal interaction,ongoing research,therapeutic application,unassigned 1,2,4,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10588458&form=6&db=m Hemostatic markers in ischemic stroke of undetermined etiology. causal interaction,diagnostic usage,ongoing research,unassigned 1,3,1,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11108774&form=6&db=m Diagnostic testing for coagulopathies in patients with ischemic stroke. ongoing research,therapeutic application,unassigned 1,1,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11139833&form=6&db=m LEX 032: a novel recombinant human protein for the treatment of ischaemic reperfusion injury. causal interaction,diagnostic usage,therapeutic application,unassigned 3,2,4,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11342434&form=6&db=m Depletion of circulating alpha(2)-antiplasmin by intravenous plasmin or immunoneutralization reduces focal cerebral ischemic injury in the absence of arterial recanalization. causal interaction,therapeutic application,unassigned 1,2,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11922137&form=6&db=m Neuroserpin, a neuroprotective factor in focal ischemic stroke. causal interaction,ongoing research,therapeutic application,unassigned 3,2,3,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14500967&form=6&db=m Medicine. Stroke--tPA and the clinic. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15102005&form=6&db=m Tissue-type plasminogen activator: a historical perspective and personal account. causal interaction,ongoing research,therapeutic application,unassigned 3,2,2,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15508942&form=6&db=m Cost-effectiveness analysis of tissue plasminogen activator for acute ischemic stroke: a comparative review. causal interaction,diagnostic usage,therapeutic application,unassigned 2,1,1,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15587776&form=6&db=m NXY-059: a neuroprotective agent in acute stroke. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15741799&form=6&db=m Hemostatic factors as predictors of stroke and cardiovascular diseases: the FINRISK '92 Hemostasis Study. diagnostic usage,ongoing research,unassigned 4,4,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15846799&form=6&db=m Fibrin-modifying serine proteases thrombin, tPA, and plasmin in ischemic stroke: a review. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15947260&form=6&db=m Predictors of early arterial reocclusion after tissue plasminogen activator-induced recanalization in acute ischemic stroke. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,4,3 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16534124&form=6&db=m Thrombolytic therapy of acute ischemic stroke during pregnancy. ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16631744&form=6&db=m Pharmacologic management of ischemic stroke: relevance to stem cell therapy. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16879324&form=6&db=m Melatonin decreases neurovascular oxidative/nitrosative damage and protects against early increases in the blood-brain barrier permeability after transient focal cerebral ischemia in mice. causal interaction,ongoing research,therapeutic application,unassigned 4,1,1,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17143002&form=6&db=m Lp(a) lipoprotein and plasminogen activity in patients with different etiology of ischemic stroke. causal interaction,diagnostic usage,ongoing research,unassigned 3,3,4,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17255548&form=6&db=m Association of pretreatment blood pressure with tissue plasminogen activator-induced arterial recanalization in acute ischemic stroke. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,2,3,3 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17355216&form=6&db=m Advances in ischemic stroke treatment: neuroprotective and combination therapies. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17425487&form=6&db=m Desmoteplase in the treatment of acute ischemic stroke. causal interaction,ongoing research,therapeutic application,unassigned 4,1,4,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17596135&form=6&db=m Stromelysin-1 (MMP-3) is critical for intracranial bleeding after t-PA treatment of stroke in mice. causal interaction,ongoing research,therapeutic application,unassigned 4,4,4,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17723126&form=6&db=m Influence of thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 gene polymorphisms on tissue-type plasminogen activator-induced recanalization in ischemic stroke patients. causal interaction,ongoing research,therapeutic application,unassigned 2,2,2,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17950617&form=6&db=m Optimized gene synthesis, expression and purification of active salivary plasminogen activator alpha2 (DSPAalpha2) of Desmodus rotundus in Pichia pastoris. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19131657&form=6&db=m Thrombolytic therapy for patients who wake-up with stroke. causal interaction,ongoing research,therapeutic application,unassigned 2,2,3,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19362319&form=6&db=m Stroke center characteristics which influence the administration of thrombolytic therapy for acute ischemic stroke: a national survey of stroke centers in Taiwan. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,4,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19412821&form=6&db=m An emerging role of mast cells in cerebral ischemia and hemorrhage. ongoing research,therapeutic application,unassigned 1,1,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19584397&form=6&db=m A nonfibrin macromolecular cofactor for tPA-mediated plasmin generation following cellular injury. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19909396&form=6&db=m Comparison of Partial (.6 mg/kg) versus Full-Dose (.9 mg/kg) Intravenous Recombinant Tissue Plasminogen Activator Followed by Endovascular Treatment for Acute Ischemic Stroke: A Meta-Analysis. causal interaction,diagnostic usage,therapeutic application,unassigned 3,1,3,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20212195&form=6&db=m Symptomatic Intracerebral Hemorrhage Among Eligible Warfarin-Treated Patients Receiving Intravenous Tissue Plasminogen Activator for Acute Ischemic Stroke. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,1,1,3 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20595786&form=6&db=m Role of tissue-type plasminogen activator in ischemic stroke. causal interaction,ongoing research,therapeutic application,unassigned 4,1,3,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20643037&form=6&db=m Neurovascular intervention in the acute phase of cerebral infarction. causal interaction,therapeutic application,unassigned 3,3,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20873445&form=6&db=m The Belgian experience with intravenous thrombolysis for acute ischemic stroke. causal interaction,ongoing research,therapeutic application,unassigned 1,2,4,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20876502&form=6&db=m Plasminogen activators in ischemic stroke: introduction. causal interaction,unassigned 2,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20876504&form=6&db=m Thrombolysis with plasmin: implications for stroke treatment. causal interaction,ongoing research,therapeutic application,unassigned 3,2,4,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21346358&form=6&db=m Ischemic stroke outcome and early infection: its deleterious effect seems to operate also among tissue plasminogen activator-treated patients. causal interaction,diagnostic usage,unassigned 4,1,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21498957&form=6&db=m Novel situations of endothelial injury in stroke--mechanisms of stroke and strategy of drug development: Intracranial bleeding associated with the treatment of ischemic stroke: thrombolytic treatment of ischemia-affected endothelial cells with tissue-type plasminogen activator. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21512172&form=6&db=m Thrombin mutant W215A/E217A treatment improves neurological outcome and reduces cerebral infarct size in a mouse model of ischemic stroke. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21610098&form=6&db=m HMGB-1 promotes fibrinolysis and reduces neurotoxicity mediated by tissue plasminogen activator. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21700944&form=6&db=m Comparison of plasmin with recombinant tissue-type plasminogen activator in lysis of cerebral thromboemboli retrieved from patients with acute ischemic stroke. causal interaction,ongoing research,therapeutic application,unassigned 3,3,1,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21707475&form=6&db=m Plasminogen Activation-Based Thrombolysis for Ischaemic Stroke: The Diversity of Targets may Demand New Approaches. causal interaction,therapeutic application,unassigned 2,4,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21926517&form=6&db=m Emergency department nurses' perceived barriers and facilitators to caring for stroke patients. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22023612&form=6&db=m Combination treatment with rt-PA is more effective than rt-PA alone in an in vitro human clot model. causal interaction,ongoing research,therapeutic application,unassigned 3,4,4,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22089410&form=6&db=m A qualitative assessment of practices associated with shorter door-to-needle time for thrombolytic therapy in acute ischemic stroke. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,4,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22261742&form=6&db=m Factors and outcomes associated with recanalization timing after thrombolysis. diagnostic usage,therapeutic application,unassigned 1,1,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22293605&form=6&db=m Neuroprotection by urokinase plasminogen activator in the hippocampus. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22314761&form=6&db=m [Development and response to intravenous treatment with tissue plasminogen activator with regard to referral hospitals. The experience of a stroke referral unit]. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22399862&form=6&db=m Lingual angioedema with macroglossia during the treatment of acute ischemic stroke with alteplase. causal interaction,ongoing research,therapeutic application,unassigned 4,1,4,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22463085&form=6&db=m Plasminogen activation and thrombolysis for ischemic stroke. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22591588&form=6&db=m Safety evaluation of a recombinant plasmin derivative lacking kringles 2-5 and rt-PA in a rat model of transient ischemic stroke. ongoing research,therapeutic application,unassigned 3,2,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22837724&form=6&db=m Clinical neuroprotective drugs for treatment and prevention of stroke. causal interaction,therapeutic application,unassigned 2,4,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22937735&form=6&db=m Plasminogen activator inhibitor-1 promotes synaptogenesis and protects against A?(1-42)-induced neurotoxicity in primary cultured hippocampal neurons. therapeutic application,unassigned 1,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23010678&form=6&db=m Will delays in treatment jeopardize the population benefit from extending the time window for stroke thrombolysis? causal interaction,therapeutic application,unassigned 2,4,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23023418&form=6&db=m [Evaluation for antithrombotic agents by a thrombotic model in animals]. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23049267&form=6&db=m Effects of alteplase in the treatment of acute ischemic stroke. causal interaction,ongoing research,therapeutic application,unassigned 4,3,4,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23231415&form=6&db=m tPA in the central nervous system: relations between tPA and cell surface LRPs. causal interaction,unassigned 3,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23326456&form=6&db=m The -7351C/T polymorphism in the TPA Gene and ischemic stroke risk: a meta-analysis. causal interaction,ongoing research,therapeutic application,unassigned 2,3,1,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23394532&form=6&db=m Complications associated with recombinant tissue plasminogen activator therapy for acute ischaemic stroke. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23493734&form=6&db=m Lipid Profile, Lipid-lowering Medications, and Intracerebral Hemorrhage After tPA in Get With The Guidelines-Stroke. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,1,3,2 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23539414&form=6&db=m Plasminogen Activators and Ischemic Stroke: Conditions for Acute Delivery. causal interaction,therapeutic application,unassigned 3,3,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23615379&form=6&db=m Thrombolytics in acute ischaemic stroke: historical perspective and future opportunities. therapeutic application,unassigned 4,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24083048&form=6&db=m Medicolegal Considerations with Intravenous Tissue Plasminogen Activator in Stroke: A Systematic Review. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,2,1,3 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24582784&form=6&db=m Alpha 1-Antitrypsin Therapy Mitigated Ischemic Stroke Damage in Rats. therapeutic application,unassigned 4,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24675027&form=6&db=m t-PA, but not desmoteplase, induces a plasmin-dependent opening of a blood-brain barrier model under normoxic and ischaemic conditions which can be reversed within a limited time frame. causal interaction,diagnostic usage,therapeutic application,unassigned 3,2,4,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24784550&form=6&db=m Time to angiographic reperfusion and clinical outcome after acute ischaemic stroke: an analysis of data from the Interventional Management of Stroke (IMS III) phase 3 trial. therapeutic application,unassigned 4,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24896566&form=6&db=m Plasmin-dependent modulation of the blood-brain barrier: a major consideration during tPA-induced thrombolysis? causal interaction,therapeutic application,unassigned 1,2,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25104843&form=6&db=m Does "time is brain" also mean "time is clot"? Time dependency of tissue-type plasminogen activator-induced recanalization in acute ischemic stroke. causal interaction,unassigned 2,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25104845&form=6&db=m Impact of time to treatment on tissue-type plasminogen activator-induced recanalization in acute ischemic stroke. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25267932&form=6&db=m Menstrual blood transplantation for ischemic stroke: Therapeutic mechanisms and practical issues. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25411015&form=6&db=m Plasmin-loaded echogenic liposomes for ultrasound-mediated thrombolysis. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25670675&form=6&db=m Efficacy of telemedicine for thrombolytic therapy in acute ischemic stroke: a meta-analysis. ongoing research,unassigned 4,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26138125&form=6&db=m Impact of General Anesthesia on Safety and Outcomes in the Endovascular Arm of Interventional Management of Stroke (IMS) III Trial. therapeutic application,unassigned 2,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26201547&form=6&db=m Perception Versus Actual Performance in Timely Tissue Plasminogen Activation Administration in the Management of Acute Ischemic Stroke. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26251162&form=6&db=m Intravenous Recombinant Tissue Plasminogen Activator Does Not Impact Mortality in Acute Ischemic Stroke at Any Time Point up to 6 Months: A Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,1,3 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26316344&form=6&db=m Relationships Between Imaging Assessments and Outcomes in Solitaire With the Intention for Thrombectomy as Primary Endovascular Treatment for Acute Ischemic Stroke. diagnostic usage,therapeutic application,unassigned 1,4,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26486246&form=6&db=m Detection of prothrombotic state in ischemic stroke by monitoring plasma molecular markers. diagnostic usage,ongoing research,unassigned 3,4,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26486266&form=6&db=m Releasable tissue plasminogen activators in ischemic stroke. causal interaction,diagnostic usage,ongoing research,unassigned 2,2,3,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26556826&form=6&db=m Estimating Weight of Patients With Acute Stroke When Dosing for Thrombolysis. diagnostic usage,unassigned 2,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26646461&form=6&db=m Modulation by the Noble Gas Helium of Tissue Plasminogen Activator: Effects in a Rat Model of Thromboembolic Stroke. causal interaction,ongoing research,therapeutic application,unassigned 3,1,4,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26846991&form=6&db=m The Plasminogen Activation System Promotes Dendritic Spine Recovery and Improvement in Neurological Function After an Ischemic Stroke. therapeutic application,unassigned 3,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26906917&form=6&db=m Direct Mechanical Intervention Versus Combined Intravenous and Mechanical Intervention in Large Artery Anterior Circulation Stroke: A Matched-Pairs Analysis. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26909366&form=6&db=m Structural basis of specific inhibition of tissue-type plasminogen activator by plasminogen activators inhibitor-1. causal interaction,therapeutic application,unassigned 1,3,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26958152&form=6&db=m Histopathological Characteristics of IV Recombinant Tissue Plasminogen -Resistant Thrombi in Patients with Acute Ischemic Stroke. ongoing research,unassigned 3,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27264767&form=6&db=m Looking for Our Ten Years Results for Coronary Heart Disease and Ischemic Stroke Group for the Standpoint of Haemostasis. causal interaction,diagnostic usage,ongoing research,unassigned 1,3,1,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27319402&form=6&db=m Physiologic variations in blood plasminogen levels affect outcomes after acute cerebral thromboembolism in mice: a pathophysiologic role for microvascular thrombosis. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,1,4,3 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27472428&form=6&db=m ?2-Antiplasmin: New Insights and Opportunities for Ischemic Stroke. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27793534&form=6&db=m Plasmin (Human) Administration in Acute Middle Cerebral Artery Ischemic Stroke: Phase 1/2a, Open-Label, Dose-Escalation, Safety Study. causal interaction,therapeutic application,unassigned 2,4,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27818918&form=6&db=m The fate of medications evaluated for ischemic stroke pharmacotherapy over the period 1995-2015. ongoing research,therapeutic application,unassigned 3,2,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27834742&form=6&db=m Results of the ICTuS 2 Trial (Intravascular Cooling in the Treatment of Stroke 2). causal interaction,therapeutic application,unassigned 2,2,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28116631&form=6&db=m Translational initiatives in thrombolytic therapy. therapeutic application,unassigned 3,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28119380&form=6&db=m Use of Intravenous Recombinant Tissue Plasminogen Activator in Patients With Acute Ischemic Stroke Who Take Non-Vitamin K Antagonist Oral Anticoagulants Before Stroke. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,2,1,4 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28183857&form=6&db=m Coexistent Sickle Cell Disease Has No Impact on the Safety or Outcome of Lytic Therapy in Acute Ischemic Stroke: Findings From Get With The Guidelines-Stroke. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,2,2,4 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28495827&form=6&db=m Hyperbaric Oxygen Reduces Infarction Volume and Hemorrhagic Transformation Through ATP/NAD(+)/Sirt1 Pathway in Hyperglycemic Middle Cerebral Artery Occlusion Rats. therapeutic application,unassigned 4,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28546326&form=6&db=m Regional Pediatric Acute Stroke Protocol: Initial Experience During 3 Years and 13 Recanalization Treatments in Children. therapeutic application,unassigned 3,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28612680&form=6&db=m Benefits of stroke treatment delivered using a mobile stroke unit trial. causal interaction,ongoing research,therapeutic application,unassigned 3,2,2,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28679847&form=6&db=m Safety Outcomes After Thrombolysis for Acute Ischemic Stroke in Patients With Recent Stroke. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,2,3 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28706119&form=6&db=m Disparities and Trends in Door-to-Needle Time: The FL-PR CReSD Study (Florida-Puerto Rico Collaboration to Reduce Stroke Disparities). causal interaction,therapeutic application,unassigned 2,3,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28748994&form=6&db=m [Intravenous thrombolysis for acute ischemic stroke. A four years? experience in a Chilean public hospital]. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28925023&form=6&db=m Fibrinolysis: from blood to the brain. causal interaction,ongoing research,therapeutic application,unassigned 1,2,3,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28944694&form=6&db=m Tissue plasminogen activator-based nanothrombolysis for ischemic stroke. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28973661&form=6&db=m Cerebral Ischemic Reperfusion Injury Following Recanalization of Large Vessel Occlusions. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29157263&form=6&db=m LDL receptor blockade reduces mortality in a mouse model of ischaemic stroke without improving tissue-type plasminogen activator-induced brain haemorrhage: towards pre-clinical simulation of symptomatic ICH. causal interaction,ongoing research,therapeutic application,unassigned 2,3,1,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29273597&form=6&db=m Intravenous Thrombolysis for Stroke and Presumed Stroke in Human Immunodeficiency Virus-Infected Adults: A Retrospective, Multicenter US Study. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,2,2,3 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29411742&form=6&db=m [Indicators of homeostasis, inflammation and homocysteine in ischemic stroke in the young age]. causal interaction,unassigned 3,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29626136&form=6&db=m Evolution of a US County System for Acute Comprehensive Stroke Care. causal interaction,diagnostic usage,therapeutic application,unassigned 1,1,2,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29683506&form=6&db=m Noncoding RNAs in ischemic stroke: time to translate. therapeutic application,unassigned 4,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29882711&form=6&db=m Cost-effectiveness analysis of mechanical thrombectomy with stent retriever in the treatment of acute ischemic stroke in Italy. therapeutic application,unassigned 2,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29911837&form=6&db=m Effects of Stroke Unit Care in Acute Ischemic Stroke Patient Ineligible for Thrombolytic Treatment. therapeutic application,unassigned 4,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30018160&form=6&db=m Iron Overload Exacerbates the Risk of Hemorrhagic Transformation After tPA (Tissue-Type Plasminogen Activator) Administration in Thromboembolic Stroke Mice. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,3,4 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30192506&form=6&db=m Tissue Plasminogen Activator-Porous Magnetic Microrods for Targeted Thrombolytic Therapy after Ischemic Stroke. causal interaction,ongoing research,therapeutic application,unassigned 4,1,4,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30268366&form=6&db=m Uneventful Pregnancy and Delivery after Thrombolysis Plus Thrombectomy for Acute Ischemic Stroke: Case Study and Literature Review. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30320448&form=6&db=m Therapeutic spectrum of interferon-? in ischemic stroke. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30354981&form=6&db=m Intravenous tPA (Tissue-Type Plasminogen Activator) in Patients With Acute Ischemic Stroke Taking Non-Vitamin K Antagonist Oral Anticoagulants Preceding Stroke. causal interaction,ongoing research,therapeutic application,unassigned 3,3,3,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30354988&form=6&db=m Angioedema and Hemorrhage After 4.5-Hour tPA (Tissue-Type Plasminogen Activator) Thrombolysis Ameliorated by T541 via Restoring Brain Microvascular Integrity. causal interaction,ongoing research,therapeutic application,unassigned 3,2,4,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30507392&form=6&db=m The role of plasminogen activators in stroke treatment: fibrinolysis and beyond. therapeutic application,unassigned 4,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30571394&form=6&db=m Infections Increase the Risk of 30-Day Readmissions Among Stroke Survivors. diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30606053&form=6&db=m Impact of Participation in a Telestroke Network on Clinical Outcomes. diagnostic usage,therapeutic application,unassigned 2,1,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30697429&form=6&db=m Angioedema after thrombolysis with tissue plasminogen activator: an airway emergency. causal interaction,ongoing research,therapeutic application,unassigned 4,1,4,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30744542&form=6&db=m Magnetic Resonance Imaging or Computed Tomography Before Treatment in Acute Ischemic Stroke. ongoing research,therapeutic application,unassigned 1,2,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30830111&form=6&db=m [Thrombolytic therapy of ischemic stroke]. causal interaction,ongoing research,therapeutic application,unassigned 4,2,4,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30838553&form=6&db=m Is lipoprotein(a) a risk factor for ischemic stroke and venous thromboembolism? causal interaction,unassigned 3,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30852962&form=6&db=m Outcomes Among Patients With Ischemic Stroke Treated With Intravenous tPA (Tissue-Type Plasminogen Activator) via Telemedicine. therapeutic application,unassigned 1,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31182002&form=6&db=m Angioedema in Stroke Patients With Thrombolysis. causal interaction,therapeutic application,unassigned 3,2,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31238832&form=6&db=m Frequency of Blood-Brain Barrier Disruption Post-Endovascular Therapy and Multiple Thrombectomy Passes in Acute Ischemic Stroke Patients. diagnostic usage,ongoing research,therapeutic application,unassigned 1,2,3,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31387512&form=6&db=m N-Acetyl-Seryl-Aspartyl-Lysyl-Proline Augments Thrombolysis of tPA (Tissue-Type Plasminogen Activator) in Aged Rats After Stroke. causal interaction,ongoing research,therapeutic application,unassigned 2,4,4,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31412730&form=6&db=m Intravenous Tissue Plasminogen Activator in Stroke Mimics. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,2,4 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31436141&form=6&db=m Intravenous Thrombolysis for Acute Ischemic Stroke After Recent Myocardial Infarction: Case Series and Systematic Review. causal interaction,therapeutic application,unassigned 3,3,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31529593&form=6&db=m Engineered Micro- and Nanoparticles for Fibrinolysis. causal interaction,therapeutic application,unassigned 4,2,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31587657&form=6&db=m Vepoloxamer Enhances Fibrinolysis of tPA (Tissue-Type Plasminogen Activator) on Acute Ischemic Stroke. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,4,4 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31595836&form=6&db=m Renal Dysfunction and In-Hospital Outcomes in Patients With Acute Ischemic Stroke After Intravenous Thrombolytic Therapy. causal interaction,ongoing research,therapeutic application,unassigned 3,2,3,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31842706&form=6&db=m Risk of Intracranial Hemorrhage Following Intravenous tPA (Tissue-Type Plasminogen Activator) for Acute Stroke Is Low in Children. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,1,1,4 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32114931&form=6&db=m Trends of r-tPA (Recombinant Tissue-Type Plasminogen Activator) Treatment and Treatment-Influencing Factors in Acute Ischemic Stroke. causal interaction,therapeutic application,unassigned 3,3,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32568648&form=6&db=m 3K3A-Activated Protein C Variant Does Not Interfere With the Plasma Clot Lysis Activity of Tenecteplase. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33070717&form=6&db=m tPA Mobilizes Immune Cells That Exacerbate Hemorrhagic Transformation in Stroke. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,3,4,3 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33224099&form=6&db=m Plasmin Generation Potential and Recanalization in Acute Ischaemic Stroke; an Observational Cohort Study of Stroke Biobank Samples. diagnostic usage,ongoing research,therapeutic application,unassigned 3,3,3,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33283576&form=6&db=m Antithrombotic Agents for tPA-Induced Cerebral Hemorrhage: A Systematic Review and Meta-Analysis of Preclinical Studies. causal interaction,therapeutic application,unassigned 2,4,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33296953&form=6&db=m Increased brain plasmin levels following experimental ischemic stroke in male mice. causal interaction,ongoing research,therapeutic application,unassigned 4,2,4,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33370942&form=6&db=m Unilateral orolingual angioedema in a patient with sarcoidosis after intravenous thrombolysis due to acute stroke without improvement after treatment with icatibant. causal interaction,ongoing research,therapeutic application,unassigned 3,1,4,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33477998&form=6&db=m Impact of SMTP Targeting Plasminogen and Soluble Epoxide Hydrolase on Thrombolysis, Inflammation, and Ischemic Stroke. causal interaction,ongoing research,unassigned 1,1,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33611941&form=6&db=m Intra-Arterial Adjunctive Medications for Acute Ischemic Stroke During Mechanical Thrombectomy: A Meta-Analysis. causal interaction,therapeutic application,unassigned 1,2,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33720950&form=6&db=m Ischemic stroke in PAR1 KO mice: Decreased brain plasmin and thrombin activity along with decreased infarct volume. causal interaction,therapeutic application,unassigned 1,2,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33787282&form=6&db=m Sex and Race-Ethnic Disparities in Door-to-CT Time in Acute Ischemic Stroke: The Florida Stroke Registry. causal interaction,ongoing research,unassigned 1,3,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34162400&form=6&db=m Phthalide derivative CD21 attenuates tissue plasminogen activator-induced hemorrhagic transformation in ischemic stroke by enhancing macrophage scavenger receptor 1-mediated DAMP (peroxiredoxin 1) clearance. causal interaction,ongoing research,therapeutic application,unassigned 3,4,4,0 3.4.21.7 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34443584&form=6&db=m The Nrf2 Pathway in Ischemic Stroke: A Review. therapeutic application,unassigned 4,0 3.4.21.7 Jaw Cysts http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20646237&form=6&db=m Urokinase and its receptor in follicular and inflammatory cysts of the jaws. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,3,1 3.4.21.7 Joint Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1379429&form=6&db=m Analysis of intraarticular fibrinolytic pathways in patients with inflammatory and noninflammatory joint diseases. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.7 Joint Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8646430&form=6&db=m Difference in expression of the plasminogen activation system in synovial tissue of patients with rheumatoid arthritis and osteoarthritis. causal interaction,ongoing research,unassigned 3,3,0 3.4.21.7 Joint Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9117184&form=6&db=m Bone matrix degradation by the plasminogen activation system. Possible mechanism of bone destruction in arthritis. causal interaction,ongoing research,therapeutic application,unassigned 4,1,1,0 3.4.21.7 Joint Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12750940&form=6&db=m Plasminogen activator inhibitor-1 as a link between pathological fibrinolysis and arthritis of Behçet's disease. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.7 Joint Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24574269&form=6&db=m Plasminogen is a joint-specific positive- or negative-determinant of arthritis pathogenesis. causal interaction,ongoing research,therapeutic application,unassigned 3,4,1,0 3.4.21.7 Keloid http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10222156&form=6&db=m Differential regulation of PAI-1 gene expression in human fibroblasts predisposed to a fibrotic phenotype. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.7 Keloid http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14644771&form=6&db=m Increased vascular endothelial growth factor may account for elevated level of plasminogen activator inhibitor-1 via activating ERK1/2 in keloid fibroblasts. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,2,1 3.4.21.7 Keratitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8156787&form=6&db=m A rapid fluorometric assay for tear fluid plasmin activity. causal interaction,diagnostic usage,unassigned 3,3,0 3.4.21.7 Keratoderma, Palmoplantar http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29023701&form=6&db=m Identification of novel homozygous SLURP1 mutation in a Javanese family with Mal de Meleda. causal interaction,unassigned 3,0 3.4.21.7 Kidney Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27335373&form=6&db=m Podocyte Injury: The Role of Proteinuria, Urinary Plasminogen and Oxidative Stress. causal interaction,unassigned 4,0 3.4.21.7 Kidney Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27773435&form=6&db=m A serine protease inhibitor attenuates aldosterone-induced kidney injuries via the suppression of plasmin activity. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 Kidney Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28656379&form=6&db=m Physiology and pathophysiology of the plasminogen system in the kidney. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 Kidney Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30679668&form=6&db=m Soluble urokinase plasminogen activation receptor and long-term outcomes in persons undergoing coronary angiography. causal interaction,diagnostic usage,therapeutic application,unassigned 1,3,2,0 3.4.21.7 Kidney Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33070369&form=6&db=m Plasminogenuria is associated with podocyte injury, edema, and kidney dysfunction in incident glomerular disease. causal interaction,ongoing research,therapeutic application,unassigned 2,1,3,0 3.4.21.7 Kidney Failure, Chronic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3096359&form=6&db=m Coagulation and fibrinolysis in chronic renal failure. Change in tissue-type plasminogen activator activity. causal interaction,diagnostic usage,therapeutic application,unassigned 1,3,2,0 3.4.21.7 Kidney Failure, Chronic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6137088&form=6&db=m Factor VIII complex in chronic renal failure: influence of protein C, fibrinolysis and diabetes mellitus. causal interaction,diagnostic usage,unassigned 3,3,0 3.4.21.7 Kidney Failure, Chronic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6526526&form=6&db=m Coagulation abnormalities in patients with end-stage renal disease treated with hemodialysis. diagnostic usage,ongoing research,unassigned 4,2,0 3.4.21.7 Kidney Failure, Chronic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8672026&form=6&db=m Coagulation, fibrinolysis and fibrinolysis inhibitors in haemodialysis patients: contribution of arteriovenous fistula. diagnostic usage,ongoing research,therapeutic application,unassigned 3,3,1,0 3.4.21.7 Kidney Failure, Chronic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9506272&form=6&db=m Increased thrombin and plasmin generation in chronic renal failure. causal interaction,unassigned 3,0 3.4.21.7 Kidney Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6779412&form=6&db=m Immunological analysis of plasminogen activators from cultured human cancer cells. diagnostic usage,ongoing research,therapeutic application,unassigned 3,4,1,0 3.4.21.7 Kidney Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9563880&form=6&db=m Expression of the plasminogen activation system in kidney cancer correlates with its aggressive phenotype. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,4,1 3.4.21.7 Laryngeal Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=5569849&form=6&db=m [Fibrinase and antifibrinolytic activity of the blood in patients with laryngeal cancer] diagnostic usage,ongoing research,therapeutic application,unassigned 2,2,1,0 3.4.21.7 Laryngeal Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9454229&form=6&db=m [Tissue and urokinase plasminogen activators (t-PA, u-PA) and their inhibitor PAI-1 in blood of patients with laryngeal neoplasms] ongoing research,therapeutic application,unassigned 4,2,0 3.4.21.7 Laryngeal Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10199063&form=6&db=m [Serum protein fractions in patients with laryngeal cancer undergoing radiation therapy. Possibility as a prognostic factor] causal interaction,diagnostic usage,therapeutic application,unassigned 2,4,1,0 3.4.21.7 Laryngitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14570069&form=6&db=m [A 50-year history of new drugs in Japan-the development and trends of hemostatics and antithrombotic drugs] diagnostic usage,therapeutic application,unassigned 3,3,0 3.4.21.7 Leg Ulcer http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4244179&form=6&db=m [Treatment of leg ulcers with plasmin and antibiotics] therapeutic application,unassigned 4,0 3.4.21.7 Leg Ulcer http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8518896&form=6&db=m Tissue and urokinase plasminogen activators in the environs of venous and ischaemic leg ulcers. causal interaction,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.7 Leg Ulcer http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8537156&form=6&db=m Plasminogen activators, venous leg ulcers and reepithelialization. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 Leg Ulcer http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9810889&form=6&db=m The safety and efficacy of a proteolytic ointment in the treatment of chronic ulcers of the lower extremity. ongoing research,therapeutic application,unassigned 1,2,0 3.4.21.7 Leg Ulcer http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9856830&form=6&db=m Wound fluid from venous leg ulcers degrades plasminogen and reduces plasmin generation by keratinocytes. causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,3,0 3.4.21.7 Leg Ulcer http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10202183&form=6&db=m Lipodermatosclerosis and the significance of proteolytic remodeling in the pathogenesis of venous ulceration (Review). causal interaction,unassigned 3,0 3.4.21.7 Leg Ulcer http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11069499&form=6&db=m Plasminogen activation in venous leg ulcers. causal interaction,ongoing research,therapeutic application,unassigned 4,4,2,0 3.4.21.7 Leg Ulcer http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11401675&form=6&db=m The role of the urokinase-type plasminogen activator (uPA) and its receptor (CD87) in lipodermatosclerosis. causal interaction,ongoing research,unassigned 3,2,0 3.4.21.7 Leg Ulcer http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11679140&form=6&db=m Differential effects of acute and chronic wound fluids on urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor, and tissue-type plasminogen activator in cultured human keratinocytes and fibroblasts. ongoing research,therapeutic application,unassigned 4,3,0 3.4.21.7 Leg Ulcer http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=13168830&form=6&db=m Local ambulatory treatment of chronic leg ulcers with hyaluronidase, plasminogen, and antibiotics. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.7 Leg Ulcer http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18494625&form=6&db=m Effect of oxidised regenerated cellulose/collagen matrix on proteases in wound exudate of patients with chronic venous ulceration. causal interaction,ongoing research,therapeutic application,unassigned 3,3,2,0 3.4.21.7 Leishmaniasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17653767&form=6&db=m Enolase as a plasminogen binding protein in Leishmania mexicana. therapeutic application,unassigned 2,0 3.4.21.7 Lens Subluxation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25397749&form=6&db=m Lens subluxation after plasmin and SF6 injections in rabbit eyes. diagnostic usage,ongoing research,therapeutic application,unassigned 1,2,1,0 3.4.21.7 Leprosy http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4241811&form=6&db=m Changes in the activity of blood plasmin after administration of 3-pyridyl acetic acid in leprosy patients. Correlation of activity changes with the Mitsuda reaction. diagnostic usage,unassigned 2,0 3.4.21.7 Leukemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=286849&form=6&db=m [Bleeding complications in acute myeloblastic leukemia (author's transl)] diagnostic usage,unassigned 2,0 3.4.21.7 Leukemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1724917&form=6&db=m Alpha 2-macroglobulin restricts plasminogen activation to the surface of RC2A leukemia cells. causal interaction,diagnostic usage,unassigned 2,3,0 3.4.21.7 Leukemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2287063&form=6&db=m [Plasminogen activator in leukemic cell homogenate] causal interaction,diagnostic usage,unassigned 4,1,0 3.4.21.7 Leukemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2363126&form=6&db=m A plasminogen activator inhibitor-2 from a promyelocytic leukemia cell line, PL-21, binds to the carboxy-terminal chain of plasminogen activators. ongoing research,therapeutic application,unassigned 3,1,0 3.4.21.7 Leukemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2469277&form=6&db=m Alpha-2 antiplasmin in acute nonlymphoblastic leukemia. diagnostic usage,ongoing research,therapeutic application,unassigned 1,3,1,0 3.4.21.7 Leukemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4861481&form=6&db=m Blood plasminogen (profibrinolysin) levels in patients with leukemia and lymphoma. diagnostic usage,unassigned 2,0 3.4.21.7 Leukemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6238843&form=6&db=m Plasminogen activator activity in differentiating leukemia cells. causal interaction,diagnostic usage,ongoing research,unassigned 4,2,4,0 3.4.21.7 Leukemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7531260&form=6&db=m In vivo thrombin and plasmin activities in patients with acute promyelocytic leukemia (APL): effect of all-trans retinoic acid (ATRA) therapy. causal interaction,unassigned 3,0 3.4.21.7 Leukemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8338954&form=6&db=m Abundant urokinase activity on the surface of mononuclear cells from blood and bone marrow of acute leukemia patients. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,4,1 3.4.21.7 Leukemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8428801&form=6&db=m Persistence of plasmin-mediated pro-urokinase activation on the surface of human monocytoid leukemia cells in vitro. causal interaction,ongoing research,unassigned 1,4,0 3.4.21.7 Leukemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8791680&form=6&db=m Plasminogen activation on tumor cell surface and its involvement in human leukemia. causal interaction,diagnostic usage,ongoing research,unassigned 3,3,4,0 3.4.21.7 Leukemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9519778&form=6&db=m Interferons and retinoids enhance and dexamethasone suppresses urokinase-mediated plasminogen activation in promyelocytic leukemia cells. causal interaction,diagnostic usage,therapeutic application,unassigned 4,1,3,0 3.4.21.7 Leukemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10190291&form=6&db=m Plasminogen activation in human leukemia and in normal hematopoietic cells. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,1 3.4.21.7 Leukemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10365741&form=6&db=m Blast cell-surface and plasma soluble urokinase receptor in acute leukemia patients: relationship to classification and response to therapy. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,3,2 3.4.21.7 Leukemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11098145&form=6&db=m Highly increased plasma concentrations of the nicked form of beta(2) glycoprotein I in patients with leukemia and with lupus anticoagulant: measurement with a monoclonal antibody specific for a nicked form of domain V. causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,1,0 3.4.21.7 Leukemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11815288&form=6&db=m Annexin II: a plasminogen-plasminogen activator co-receptor. causal interaction,diagnostic usage,ongoing research,unassigned 1,3,4,0 3.4.21.7 Leukemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15302870&form=6&db=m An annexin 2 phosphorylation switch mediates p11-dependent translocation of annexin 2 to the cell surface. unassigned - 3.4.21.7 Leukemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16741743&form=6&db=m Sudden death due to undiagnosed acute promyelocytic leukemia: a case report. unassigned - 3.4.21.7 Leukemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17393125&form=6&db=m Fribrinolysis kinetics and its application. causal interaction,diagnostic usage,ongoing research,unassigned 3,4,3,0 3.4.21.7 Leukemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20211283&form=6&db=m The endogenous peptides of normal human serum extracted from the acetonitrile-insoluble precipitate using modified aqueous buffer with analysis by LC-ESI-Paul ion trap and Qq-TOF. diagnostic usage,unassigned 2,0 3.4.21.7 Leukemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20349265&form=6&db=m The anti-invasive activity of synthetic alkaloid ethoxyfagaronine on L1210 leukemia cells is mediated by down-regulation of plasminogen activators and MT1-MMP expression and activity. unassigned - 3.4.21.7 Leukemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21310922&form=6&db=m Regulation of S100A10 by the PML-RAR-{alpha} oncoprotein. causal interaction,unassigned 3,0 3.4.21.7 Leukemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22649107&form=6&db=m Monoclonal antibodies against receptor-induced binding sites detect cell-bound plasminogen in blood. therapeutic application,unassigned 4,0 3.4.21.7 Leukemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25027324&form=6&db=m Discovery of serum protein biomarkers in the mdx mouse model and cross-species comparison to Duchenne muscular dystrophy patients. causal interaction,diagnostic usage,unassigned 1,1,0 3.4.21.7 Leukemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28303518&form=6&db=m Potentially life-threatening coagulopathy associated with simultaneous reduction in coagulation and fibrinolytic function in pediatric acute leukemia after hematopoietic stem-cell transplantation. diagnostic usage,ongoing research,unassigned 3,3,0 3.4.21.7 Leukemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29852400&form=6&db=m Inhibition of pericellular plasminogen activation by apolipoprotein(a): Roles of urokinase plasminogen activator receptor and integrins ?M?2 and ?V?3. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,3,4,1 3.4.21.7 Leukemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31949486&form=6&db=m Critical role and its underlying molecular events of the plasminogen receptor, S100A10 in malignant tumor and non-tumor diseases. causal interaction,ongoing research,therapeutic application,unassigned 3,1,1,0 3.4.21.7 Leukemia, Lymphoid http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8103371&form=6&db=m [Proteolytic enzymes in human lymphocytic leukemia cells. I. Activity of dipeptidylaminopeptidase IV, plasminogen activator and cathepsins B and L in cells with different immunologic phenotype] diagnostic usage,ongoing research,unassigned 3,4,0 3.4.21.7 Leukemia, Lymphoid http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18468424&form=6&db=m [T-PA and PAI-1 in lymphocytes of patients with chronic lymphoid leukemia] diagnostic usage,ongoing research,unassigned 1,3,0 3.4.21.7 Leukemia, Monocytic, Acute http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29852400&form=6&db=m Inhibition of pericellular plasminogen activation by apolipoprotein(a): Roles of urokinase plasminogen activator receptor and integrins ?M?2 and ?V?3. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,3,4,1 3.4.21.7 Leukemia, Myelogenous, Chronic, BCR-ABL Positive http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6572078&form=6&db=m The secretion of plasminogen activators by human myeloid leukemic cells in vitro. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,4,3 3.4.21.7 Leukemia, Myeloid, Acute http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2469277&form=6&db=m Alpha-2 antiplasmin in acute nonlymphoblastic leukemia. diagnostic usage,ongoing research,therapeutic application,unassigned 1,3,1,0 3.4.21.7 Leukemia, Myeloid, Acute http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6238445&form=6&db=m Changes in plasma levels of protease and fibrinolytic inhibitors induced by treatment in acute myeloid leukemia. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,4,0 3.4.21.7 Leukemia, Myeloid, Acute http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17393125&form=6&db=m Fribrinolysis kinetics and its application. causal interaction,diagnostic usage,ongoing research,unassigned 3,4,3,0 3.4.21.7 Leukemia, Myeloid, Acute http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31228869&form=6&db=m Hemostatic function on hyper-fibrinolytic disseminated intravascular coagulation. diagnostic usage,unassigned 2,0 3.4.21.7 Leukemia, Promyelocytic, Acute http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7531260&form=6&db=m In vivo thrombin and plasmin activities in patients with acute promyelocytic leukemia (APL): effect of all-trans retinoic acid (ATRA) therapy. causal interaction,unassigned 3,0 3.4.21.7 Leukemia, Promyelocytic, Acute http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11815288&form=6&db=m Annexin II: a plasminogen-plasminogen activator co-receptor. causal interaction,diagnostic usage,ongoing research,unassigned 1,3,4,0 3.4.21.7 Leukemia, Promyelocytic, Acute http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15302870&form=6&db=m An annexin 2 phosphorylation switch mediates p11-dependent translocation of annexin 2 to the cell surface. unassigned - 3.4.21.7 Leukemia, Promyelocytic, Acute http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16741743&form=6&db=m Sudden death due to undiagnosed acute promyelocytic leukemia: a case report. unassigned - 3.4.21.7 Leukemia, Promyelocytic, Acute http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22649107&form=6&db=m Monoclonal antibodies against receptor-induced binding sites detect cell-bound plasminogen in blood. therapeutic application,unassigned 4,0 3.4.21.7 Leukemia, Promyelocytic, Acute http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31949486&form=6&db=m Critical role and its underlying molecular events of the plasminogen receptor, S100A10 in malignant tumor and non-tumor diseases. causal interaction,ongoing research,therapeutic application,unassigned 3,1,1,0 3.4.21.7 Leukocytosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7589679&form=6&db=m Characteristics of blood hemostatic markers in a patient with ovarian hyperstimulation syndrome who actually developed thromboembolism. therapeutic application,unassigned 1,0 3.4.21.7 Leukocytosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22310207&form=6&db=m A mouse model to study the alterations in haemostatic and inflammatory parameters induced by Lonomia achelous caterpillar haemolymph. unassigned - 3.4.21.7 Linear IgA Bullous Dermatosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19158842&form=6&db=m Plasmin Plays a Role in the In Vitro Generation of the Linear IgA Dermatosis Antigen LADB97. diagnostic usage,ongoing research,unassigned 1,2,0 3.4.21.7 Liver Abscess http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12783404&form=6&db=m Hepatic artery thrombosis after adult liver transplantation. ongoing research,therapeutic application,unassigned 2,4,0 3.4.21.7 Liver Cirrhosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=406338&form=6&db=m Abnormal fibrinogen heterogeneity and fibrinolytic activity in advanced liver disease. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.7 Liver Cirrhosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1754855&form=6&db=m Importance of measuring plasma thrombin-antithrombin III complex levels when using antithrombin III concentrate therapy in fulminant hepatic failure. causal interaction,ongoing research,therapeutic application,unassigned 4,2,2,0 3.4.21.7 Liver Cirrhosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2436684&form=6&db=m The pathogenesis of accelerated fibrinolysis in liver cirrhosis: a critical role for tissue plasminogen activator inhibitor. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 Liver Cirrhosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2457543&form=6&db=m Fibrinopeptide A and B beta 15-42 in liver cirrhosis. diagnostic usage,ongoing research,unassigned 3,1,0 3.4.21.7 Liver Cirrhosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2703760&form=6&db=m Histidine-rich glycoprotein is elevated in mild liver cirrhosis and decreased in moderate and severe liver cirrhosis. causal interaction,diagnostic usage,ongoing research,unassigned 4,2,2,0 3.4.21.7 Liver Cirrhosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=5954763&form=6&db=m [Description of a new method of plasminogen determination. Its application to the study of liver cirrhosis] ongoing research,unassigned 3,0 3.4.21.7 Liver Cirrhosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6564063&form=6&db=m Prekallikrein behaviour in chronic active hepatitis and in cirrhotic patients. causal interaction,diagnostic usage,unassigned 4,2,0 3.4.21.7 Liver Cirrhosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7061918&form=6&db=m Kinetic and functional studies of platelets, fibrinogen, and plasminogen in patients with hepatic cirrhosis. diagnostic usage,ongoing research,therapeutic application,unassigned 4,1,1,0 3.4.21.7 Liver Cirrhosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7466742&form=6&db=m Catabolism of human fibrinogen fragment D in normal subjects and patients with liver cirrhosis. diagnostic usage,unassigned 3,0 3.4.21.7 Liver Cirrhosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7563921&form=6&db=m [Blood coagulation and fibrinolysis in relation to endotoxemia in liver cirrhosis and hepatocellular carcinoma] causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,1,0 3.4.21.7 Liver Cirrhosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8067185&form=6&db=m [Plasma serine protease inhibitors in patients with liver cirrhosis] causal interaction,diagnostic usage,ongoing research,unassigned 3,4,4,0 3.4.21.7 Liver Cirrhosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8314173&form=6&db=m Haemostasis unbalance in Pugh-scored liver cirrhosis: characteristic changes of plasma levels of protein C versus protein S. diagnostic usage,therapeutic application,unassigned 1,1,0 3.4.21.7 Liver Cirrhosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8586322&form=6&db=m Increased concentrations of tumor necrosis factor and interleukin-6 contribute to the hemostatic abnormalities in advanced liver disease. causal interaction,diagnostic usage,unassigned 4,1,0 3.4.21.7 Liver Cirrhosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8903394&form=6&db=m The plasminogen-activating system in hepatic stellate cells. unassigned - 3.4.21.7 Liver Cirrhosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9253235&form=6&db=m Plasminogen in patients with liver cirrhosis. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,3,0 3.4.21.7 Liver Cirrhosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9528205&form=6&db=m [Alterations of hemostasis in liver cirrhosis of the dog] causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.7 Liver Cirrhosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10551395&form=6&db=m Increased expression of plasminogen activator and plasminogen activator inhibitor during liver fibrogenesis of rats: role of stellate cells. ongoing research,unassigned 4,0 3.4.21.7 Liver Cirrhosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11779708&form=6&db=m Retinoids in liver fibrosis and cancer. causal interaction,unassigned 1,0 3.4.21.7 Liver Cirrhosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=13938813&form=6&db=m [The mechanism of plasmin activation in the blood of cases with liver cirrhosis.] diagnostic usage,therapeutic application,unassigned 2,1,0 3.4.21.7 Liver Cirrhosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17474886&form=6&db=m Fibrinolytic characteristics and their significance in malignant, tuberculous and cirrhotic pleural and ascitic fluids. causal interaction,therapeutic application,unassigned 2,1,0 3.4.21.7 Liver Cirrhosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21401519&form=6&db=m Fibrinolytic Factors in Liver Fibrosis. therapeutic application,unassigned 3,0 3.4.21.7 Liver Cirrhosis, Alcoholic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3943792&form=6&db=m Hemostasis and fibrinolysis in severe liver failure and their relation to hemorrhage. diagnostic usage,unassigned 3,0 3.4.21.7 Liver Cirrhosis, Alcoholic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6235248&form=6&db=m Plasminogen activators in alcoholic cirrhosis: demonstration of increased tissue type and urokinase type activator. causal interaction,diagnostic usage,ongoing research,unassigned 3,3,2,0 3.4.21.7 Liver Cirrhosis, Alcoholic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9253235&form=6&db=m Plasminogen in patients with liver cirrhosis. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,3,0 3.4.21.7 Liver Cirrhosis, Biliary http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=935800&form=6&db=m Observations of increased levels of blood coagulation factors and other plasma proteins in cholestatic liver disease. causal interaction,diagnostic usage,unassigned 1,1,0 3.4.21.7 Liver Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=76519&form=6&db=m The alpha2-plasmin inhibitor levels in liver diseases. diagnostic usage,ongoing research,unassigned 3,2,0 3.4.21.7 Liver Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=705694&form=6&db=m Quantitative estimation of coagulation factors in liver disease. The diagnostic and prognostic value of factor XIII, factor V and plasminogen. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 Liver Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1313384&form=6&db=m Clinical evaluation of tissue plasminogen activator (t-PA) levels in patients with liver diseases. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,2,1 3.4.21.7 Liver Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2147451&form=6&db=m [Clinical significance of thrombin-antithrombin III complex and plasmin-alpha 2 plasmin inhibitor complex in chronic liver diseases] causal interaction,diagnostic usage,ongoing research,therapeutic application 1,2,2,1 3.4.21.7 Liver Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2527002&form=6&db=m Thrombin and plasmin generation in patients with liver disease. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,2,1 3.4.21.7 Liver Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2938648&form=6&db=m Analysis of elevated fibrin(ogen) degradation product levels in patients with liver disease. causal interaction,diagnostic usage,ongoing research,unassigned 3,2,1,0 3.4.21.7 Liver Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2999239&form=6&db=m The immune response to mouse hepatitis virus: expression of monocyte procoagulant activity and plasminogen activator during infection in vivo. causal interaction,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.7 Liver Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3168900&form=6&db=m Prognostic significance of antithrombin III, plasminogen and proactivator of plasminogen activity in viral hepatitis. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,2,3,1 3.4.21.7 Liver Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3244179&form=6&db=m [Clinical evaluation of measurement of plasma antithrombin III, alpha 2-plasmin inhibitor and plasminogen in various liver disease] diagnostic usage,ongoing research,therapeutic application,unassigned 3,1,2,0 3.4.21.7 Liver Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3244988&form=6&db=m Plasminogen and plasminogen proactivator in liver diseases. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,2 3.4.21.7 Liver Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3672563&form=6&db=m Plasma antithrombin III, alpha 2-plasmin inhibitor and plasminogen activities in cases of various liver diseases. causal interaction,diagnostic usage,unassigned 1,2,0 3.4.21.7 Liver Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4049324&form=6&db=m Plasma histidine-rich glycoprotein and plasminogen in patients with liver disease. diagnostic usage,ongoing research,unassigned 2,3,0 3.4.21.7 Liver Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4954681&form=6&db=m [Research on the influence of vasculo-tissue factors on coagulation and on fibrinolysis. IX. Liberation of anticoagulants and plasminogen activators induced by venous stasis in subjects with chronic liver diseases] causal interaction,ongoing research,unassigned 1,2,0 3.4.21.7 Liver Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=5353833&form=6&db=m Low plasminogen levels and liver disease. diagnostic usage,unassigned 4,0 3.4.21.7 Liver Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6479679&form=6&db=m Antithrombin III, plasminogen and alpha 2 antiplasmin in jaundice. Clinical usefulness and prognostic significance. diagnostic usage,unassigned 4,0 3.4.21.7 Liver Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6515420&form=6&db=m Diagnostic efficacy of a simple radioimmunoassay test for fibrinogen/fibrin fragments containing the B beta 15-42 sequence. unassigned - 3.4.21.7 Liver Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6543067&form=6&db=m [Potential fibrinolytic activity of the blood in jaundice of parenchymal and mechanical origin] ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.7 Liver Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7061918&form=6&db=m Kinetic and functional studies of platelets, fibrinogen, and plasminogen in patients with hepatic cirrhosis. diagnostic usage,ongoing research,therapeutic application,unassigned 4,1,1,0 3.4.21.7 Liver Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8163691&form=6&db=m Tissue plasminogen activator, plasminogen activator inhibitors, and activator-inhibitor complex in liver disease. causal interaction,ongoing research,therapeutic application,unassigned 3,2,1,0 3.4.21.7 Liver Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8406370&form=6&db=m Contribution of sinusoidal endothelial liver cells to liver fibrosis: expression of transforming growth factor-beta 1 receptors and modulation of plasmin-generating enzymes by transforming growth factor-beta 1. causal interaction,ongoing research,unassigned 3,4,0 3.4.21.7 Liver Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8571309&form=6&db=m Outcome of disseminated intravascular coagulation in relation to the score when treatment was begun. Mie DIC Study Group. causal interaction,diagnostic usage,unassigned 1,2,0 3.4.21.7 Liver Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8578171&form=6&db=m The fibrinolytic system in human ascites. causal interaction,diagnostic usage,unassigned 4,2,0 3.4.21.7 Liver Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9306131&form=6&db=m Circadian rhythms of fibrinogen antithrombin III and plasminogen in chronic liver diseases of increasing severity. causal interaction,unassigned 3,0 3.4.21.7 Liver Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9361180&form=6&db=m The significance of colocalization of plasminogen activator inhibitor-1 and vitronectin in hepatic fibrosis. ongoing research,unassigned 3,0 3.4.21.7 Liver Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15118576&form=6&db=m Changes of coagulation inhibitors and fibrinolysis system in newborn infants with transitory neonatal cholestasis. diagnostic usage,ongoing research,unassigned 3,3,0 3.4.21.7 Liver Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32175919&form=6&db=m Plasminogen as a prognostic biomarker for HBV-related acute-on-chronic liver failure. diagnostic usage,therapeutic application,unassigned 4,2,0 3.4.21.7 Liver Diseases, Alcoholic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=428708&form=6&db=m The hemostatic defect of chronic liver disease. Kinetic studies using 75Se-selenomethionine. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,2,0 3.4.21.7 Liver Failure, Acute http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1754855&form=6&db=m Importance of measuring plasma thrombin-antithrombin III complex levels when using antithrombin III concentrate therapy in fulminant hepatic failure. causal interaction,ongoing research,therapeutic application,unassigned 4,2,2,0 3.4.21.7 Liver Failure, Acute http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3977392&form=6&db=m Treatment of severe coagulation disturbances as a condition of improved prognosis in fulminant liver failure. causal interaction,therapeutic application,unassigned 2,2,0 3.4.21.7 Liver Failure, Acute http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7841306&form=6&db=m Hepatocyte growth factor and plasminogen activation in fulminant hepatic failure. unassigned - 3.4.21.7 Liver Failure, Acute http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33827130&form=6&db=m Plasmin-mediated cleavage of high-molecular-weight kininogen contributes to acetaminophen-induced acute liver failure. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,1,0 3.4.21.7 Lung Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=576497&form=6&db=m Serum plasminogen and lung surfactant in the respiratory distress syndrome. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,2,1 3.4.21.7 Lung Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2314423&form=6&db=m Depressed bronchoalveolar urokinase activity in patients with adult respiratory distress syndrome. causal interaction,diagnostic usage,therapeutic application,unassigned 1,3,1,0 3.4.21.7 Lung Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7844912&form=6&db=m [Evaluation of serum thrombomodulin in patients with interstitial pneumonia] ongoing research,unassigned 3,0 3.4.21.7 Lung Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8368328&form=6&db=m Apoprotein-based synthetic surfactants inhibit plasmic cleavage of fibrinogen in vitro. causal interaction,unassigned 4,0 3.4.21.7 Lung Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9030096&form=6&db=m Inhibition of neutrophil elastase-induced interleukin-8 gene expression by urinary trypsin inhibitor in human bronchial epithelial cells. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.7 Lung Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16598647&form=6&db=m Matrix metalloproteinase-1 activation via plasmin generated on alveolar epithelial cell surfaces. causal interaction,unassigned 4,0 3.4.21.7 Lung Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17896953&form=6&db=m The plasminogen activation system in lung disease. unassigned - 3.4.21.7 Lung Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19638192&form=6&db=m Characterisation of urokinase plasminogen activator receptor variants in human airway and peripheral cells. causal interaction,diagnostic usage,unassigned 4,3,0 3.4.21.7 Lung Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32133621&form=6&db=m Plasmin improves oedematous blood-gas barrier by cleaving epithelial sodium channels. therapeutic application,unassigned 4,0 3.4.21.7 Lung Diseases, Interstitial http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23735578&form=6&db=m The plasminogen activation system: new targets in lung inflammation and remodeling. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 Lung Injury http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1850723&form=6&db=m Procollagen-III in serum, plasminogen activation and fibronectin in bronchoalveolar lavage fluid during and following irradiation of human lung. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,2,2,1 3.4.21.7 Lung Injury http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1902065&form=6&db=m Rat alveolar epithelial cells concomitantly express plasminogen activator inhibitor-1 and urokinase. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 Lung Injury http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8703482&form=6&db=m Plasmin regulates the activation of cell-associated latent TGF-beta 1 secreted by rat alveolar macrophages after in vivo bleomycin injury. causal interaction,unassigned 4,0 3.4.21.7 Lung Injury http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8750125&form=6&db=m Tranexamic acid attenuates oleic-acid-induced pulmonary extravasation. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.7 Lung Injury http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10487979&form=6&db=m Activation of rat alveolar macrophage-derived latent transforming growth factor beta-1 by plasmin requires interaction with thrombospondin-1 and its cell surface receptor, CD36. unassigned - 3.4.21.7 Lung Injury http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10880388&form=6&db=m The development of bleomycin-induced pulmonary fibrosis in mice deficient for components of the fibrinolytic system. ongoing research,therapeutic application,unassigned 4,2,0 3.4.21.7 Lung Injury http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11264657&form=6&db=m Suppression of superantigen-induced lung injury and vasculitis by preadministration of human urinary trypsin inhibitor. ongoing research,therapeutic application,unassigned 3,1,0 3.4.21.7 Lung Injury http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12376355&form=6&db=m Inducible lung-specific urokinase expression reduces fibrosis and mortality after lung injury in mice. causal interaction,ongoing research,therapeutic application,unassigned 3,3,2,0 3.4.21.7 Lung Injury http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15308506&form=6&db=m Plasminogen activator inhibitor-1 impairs alveolar epithelial repair by binding to vitronectin. causal interaction,therapeutic application,unassigned 3,2,0 3.4.21.7 Lung Injury http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18336273&form=6&db=m Pulmonary coagulopathy as a new target in lung injury--a review of available pre-clinical models. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 Lung Injury http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32524776&form=6&db=m Characterization of low-dose ozone-induced murine acute lung injury. ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.7 Lung Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=67586&form=6&db=m Serum levels of alpha1-antitrypsin and alpha2-macroglobulin in lung cancer. diagnostic usage,unassigned 2,0 3.4.21.7 Lung Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2222860&form=6&db=m Detection of cathepsin B, plasminogen activators and plasminogen activator inhibitor in human non-small lung cancer cell lines. diagnostic usage,ongoing research,therapeutic application,unassigned 3,4,2,0 3.4.21.7 Lung Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2467397&form=6&db=m Abnormal haemostasis in small cell lung cancer. diagnostic usage,ongoing research,unassigned 3,3,0 3.4.21.7 Lung Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6779412&form=6&db=m Immunological analysis of plasminogen activators from cultured human cancer cells. diagnostic usage,ongoing research,therapeutic application,unassigned 3,4,1,0 3.4.21.7 Lung Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7040369&form=6&db=m Urokinase-like plasminogen activators of unusually high molecular weight secreted by a cell line derived from a human lung cancer case. diagnostic usage,ongoing research,unassigned 3,4,0 3.4.21.7 Lung Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7600025&form=6&db=m The plasminogen activation system and its role in lung cancer. A review. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,2,3,2 3.4.21.7 Lung Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8111706&form=6&db=m Plasminogen activators and their inhibitors in non-small cell lung cancer. Low content of type 2 plasminogen activator inhibitor associated with tumor dissemination. causal interaction,ongoing research,therapeutic application,unassigned 4,4,4,0 3.4.21.7 Lung Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9122714&form=6&db=m The role of inflammatory cells and their proteases in extravascular fibrinolysis. causal interaction,therapeutic application,unassigned 3,3,0 3.4.21.7 Lung Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9178585&form=6&db=m Changes in plasminogen activator inhibitor-1 levels in non-small cell lung cancer. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,4,0 3.4.21.7 Lung Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9237155&form=6&db=m Levels of plasminogen activator inhibitor type 1 and urokinase plasminogen activator receptor in non-small cell lung cancer as measured by quantitative ELISA and semiquantitative immunohistochemistry. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,4,3 3.4.21.7 Lung Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9308901&form=6&db=m Cancer cells release a covalent complex containing disulfide-linked domains from urinary plasminogen activator, neural cell adhesion molecule, and haptoglobin alpha and beta chains. ongoing research,unassigned 4,0 3.4.21.7 Lung Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9337525&form=6&db=m Plasminogen activators and plasmin in lung cancer. diagnostic usage,unassigned 3,0 3.4.21.7 Lung Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9872602&form=6&db=m G-CSF increases secretion of urokinase-type plasminogen activator by human lung cancer cells. causal interaction,ongoing research,therapeutic application,unassigned 2,4,1,0 3.4.21.7 Lung Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9949291&form=6&db=m Modulation of tumor cell motility by plasmin. causal interaction,ongoing research,unassigned 1,4,0 3.4.21.7 Lung Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10325924&form=6&db=m The plasmin cascade and matrix metalloproteinases in non-small cell lung cancer. ongoing research,unassigned 2,0 3.4.21.7 Lung Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10473092&form=6&db=m Expression of plasminogen activator inhibitors 1 and 2 in lung cancer and their role in tumor progression. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,2,1 3.4.21.7 Lung Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11212282&form=6&db=m Nitrated and oxidized plasma proteins in smokers and lung cancer patients. diagnostic usage,ongoing research,unassigned 4,4,0 3.4.21.7 Lung Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11329087&form=6&db=m Urokinase and tissue plasminogen activators and their inhibitor PAI-1 in human tumors. causal interaction,diagnostic usage,ongoing research,unassigned 4,2,4,0 3.4.21.7 Lung Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11401062&form=6&db=m Prognostic significance of blood coagulation tests in lung cancer. diagnostic usage,ongoing research,therapeutic application,unassigned 3,1,1,0 3.4.21.7 Lung Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17208328&form=6&db=m Influence of MMP-2 and MMP-9 promoter polymorphisms on gene expression and clinical outcome of non-small cell lung cancer. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,4,0 3.4.21.7 Lung Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18568768&form=6&db=m Plasminogen derivatives encoding kringles 1-4 and kringles 1-5 exert indirect antiangiogenic and direct antitumoral effects in experimental lung cancer. causal interaction,ongoing research,therapeutic application,unassigned 4,4,3,0 3.4.21.7 Lung Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19117638&form=6&db=m Plasminogen activator inhibitor variants PAI-1 A15T and PAI-2 S413C influence lung cancer prognosis. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,1,1,4 3.4.21.7 Lung Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20300980&form=6&db=m Clinical significance of the ratio between the alpha 2 plasmin inhibitor-plasmin complex and the thrombin-antithrombin complex in advanced non-small cell lung cancer. causal interaction,diagnostic usage,unassigned 4,3,0 3.4.21.7 Lung Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20937265&form=6&db=m Association of polymorphisms in the genes of the urokinase plasminogen activation system with susceptibility to and severity of non-small cell lung cancer. causal interaction,diagnostic usage,unassigned 1,3,0 3.4.21.7 Lung Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21372205&form=6&db=m DLC1 interaction with S100A10 mediates inhibition of in vitro cell invasion and tumorigenicity of lung cancer cells through a RhoGAP-independent mechanism. causal interaction,ongoing research,therapeutic application,unassigned 4,1,1,0 3.4.21.7 Lung Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21533361&form=6&db=m Presence of urokinase plasminogen activator, its inhibitor and receptor in small cell lung cancer and non-small cell lung cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,4,1 3.4.21.7 Lung Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23894455&form=6&db=m Surface ?-enolase promotes extracellular matrix degradation and tumor metastasis and represents a new therapeutic target. ongoing research,unassigned 2,0 3.4.21.7 Lung Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24205446&form=6&db=m Influence of Stromal Components on Lung Cancer Carcinogenesis. ongoing research,therapeutic application,unassigned 4,1,0 3.4.21.7 Lung Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24581498&form=6&db=m Serpins promote cancer cell survival and vascular co-option in brain metastasis. diagnostic usage,ongoing research,therapeutic application,unassigned 3,3,2,0 3.4.21.7 Lung Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25060522&form=6&db=m ADAM9 promotes lung cancer metastases to brain by a plasminogen activator-based pathway. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,3,0 3.4.21.7 Lung Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25708333&form=6&db=m Autoantibodies to plasminogen and their role in tumor diseases. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,3,0 3.4.21.7 Lung Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30765871&form=6&db=m HAI-2 as a novel inhibitor of plasmin represses lung cancer cell invasion and metastasis. causal interaction,ongoing research,therapeutic application,unassigned 4,2,4,0 3.4.21.7 Lung Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31821791&form=6&db=m Clinical significance of urinary plasminogen and fibrinogen gamma chain as novel potential diagnostic markers for non-small-cell lung cancer. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.7 Lung Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31877562&form=6&db=m The D-dimer level predicts the postoperative prognosis in patients with non-small cell lung cancer. diagnostic usage,unassigned 4,0 3.4.21.7 Lung Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31949486&form=6&db=m Critical role and its underlying molecular events of the plasminogen receptor, S100A10 in malignant tumor and non-tumor diseases. causal interaction,ongoing research,therapeutic application,unassigned 3,1,1,0 3.4.21.7 Lupus Erythematosus, Systemic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1902623&form=6&db=m Disturbances in the tissue plasminogen activator/plasminogen activator inhibitor (TPA/PAI) system in systemic lupus erythematosus. ongoing research,therapeutic application,unassigned 1,1,0 3.4.21.7 Lupus Erythematosus, Systemic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2122531&form=6&db=m [Regulation of coagulo-fibrinolytic activity and lupus anticoagulants in systemic lupus erythematosus] diagnostic usage,ongoing research,unassigned 3,1,0 3.4.21.7 Lupus Erythematosus, Systemic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2512863&form=6&db=m Risk factors for thrombosis in lupus patients. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.7 Lupus Erythematosus, Systemic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2727550&form=6&db=m Plasminogen activation in plasma of patients with systemic lupus erythematosus. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,4,0 3.4.21.7 Lupus Erythematosus, Systemic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24749249&form=6&db=m [Polymorphism of the plasminogen activator inhibitor type 1 gene, plasminogen level and thrombosis in patients with antiphospholipid syndrome]. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,2,1 3.4.21.7 Lupus Nephritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7940365&form=6&db=m [The functional activity of plasminogen activators in the blood plasma and urine of patients with lupus nephritis] diagnostic usage,ongoing research,unassigned 4,2,0 3.4.21.7 Lupus Nephritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31319876&form=6&db=m Urinary pro-thrombotic, anti-thrombotic, and fibrinolytic molecules as biomarkers of lupus nephritis. diagnostic usage,ongoing research,therapeutic application,unassigned 2,3,2,0 3.4.21.7 Lupus Nephritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32237065&form=6&db=m ?2AP is associated with the development of lupus nephritis through the regulation of plasmin inhibition and inflammatory responses. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 Lyme Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7642282&form=6&db=m Binding of human plasminogen to Borrelia burgdorferi. ongoing research,unassigned 2,0 3.4.21.7 Lyme Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7751701&form=6&db=m Binding of human plasminogen and urokinase-type plasminogen activator to the Lyme disease spirochete, Borrelia burgdorferi. ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.7 Lyme Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9215633&form=6&db=m Plasminogen is required for efficient dissemination of B. burgdorferi in ticks and for enhancement of spirochetemia in mice. ongoing research,therapeutic application,unassigned 4,1,0 3.4.21.7 Lyme Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10417158&form=6&db=m Plasmin-coated borrelia Burgdorferi degrades soluble and insoluble components of the mammalian extracellular matrix. ongoing research,therapeutic application,unassigned 1,1,0 3.4.21.7 Lyme Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11119537&form=6&db=m Borrelia spirochetes upregulate release and activation of matrix metalloproteinase gelatinase B (MMP-9) and collagenase 1 (MMP-1) in human cells. causal interaction,ongoing research,therapeutic application,unassigned 1,2,1,0 3.4.21.7 Lyme Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33980587&form=6&db=m Endogenous and Borrowed Proteolytic Activity in the Borrelia. causal interaction,unassigned 1,0 3.4.21.7 Lymphadenopathy http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19011568&form=6&db=m Plasminogen deficiency as a rare cause of conjunctivitis and lymphadenopathy. causal interaction,unassigned 4,0 3.4.21.7 Lymphangioleiomyomatosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15514113&form=6&db=m Imbalanced plasminogen system in lymphangioleiomyomatosis: potential role of serum response factor. therapeutic application,unassigned 1,0 3.4.21.7 Lymphangioma, Cystic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6848682&form=6&db=m Factors affecting coagulation: fibrinolysis in chronic subdural fluid collections. causal interaction,diagnostic usage,unassigned 3,2,0 3.4.21.7 Lymphangioma, Cystic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7975983&form=6&db=m [The pathogenesis of chronic subdural hematomas and hydromas in children] unassigned - 3.4.21.7 Lymphatic Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2433233&form=6&db=m The plasmin system in human adenocarcinomas and their metastases. A comparative immunofluorescence study. causal interaction,diagnostic usage,ongoing research,unassigned 3,3,4,0 3.4.21.7 Lymphatic Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7707177&form=6&db=m [Immunohistological study of fibrinolytic factors of head and neck squamous cell carcinomas] unassigned - 3.4.21.7 Lymphatic Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24674618&form=6&db=m Expression of tissue factor in canine mammary tumours and correlation with grade, stage and markers of haemostasis and inflammation. causal interaction,diagnostic usage,ongoing research,unassigned 1,1,1,0 3.4.21.7 Lymphatic Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26504024&form=6&db=m Plasminogen Activation System in Rectal Adenocarcinoma. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,3,2,1 3.4.21.7 Lymphoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1562736&form=6&db=m A T-cell-related proteinase expressed by T-lymphoma cells activates their endogenous pro-urokinase. ongoing research,unassigned 4,0 3.4.21.7 Lymphoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2426287&form=6&db=m Involvement of both heparanase and plasminogen activator in lymphoma cell-mediated degradation of heparan sulfate in the subendothelial extracellular matrix. causal interaction,ongoing research,unassigned 2,4,0 3.4.21.7 Lymphoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4861481&form=6&db=m Blood plasminogen (profibrinolysin) levels in patients with leukemia and lymphoma. diagnostic usage,unassigned 2,0 3.4.21.7 Lymphoma, Non-Hodgkin http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6234471&form=6&db=m Enhancement of the radiation effect by fibrinolysin and quantitative pattern of the change of tumor radiosensitivity. causal interaction,ongoing research,therapeutic application,unassigned 3,2,4,0 3.4.21.7 Macrophage Activation Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28325863&form=6&db=m Pharmacological targeting of plasmin prevents lethality in a murine model of macrophage activation syndrome. ongoing research,therapeutic application,unassigned 3,2,0 3.4.21.7 Macrophage Activation Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32861744&form=6&db=m The multifaceted role of plasminogen in inflammation. ongoing research,unassigned 2,0 3.4.21.7 Macular Degeneration http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7898868&form=6&db=m Subretinal hemorrhage removal with multiple retinotomy sites in age-related macular degeneration. causal interaction,ongoing research,unassigned 1,1,0 3.4.21.7 Macular Degeneration http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9373115&form=6&db=m Tissue plasminogen activator-assisted surgical excision of subfoveal choroidal neovascularization in age-related macular degeneration: a randomized, double-masked trial. diagnostic usage,ongoing research,therapeutic application,unassigned 3,3,1,0 3.4.21.7 Macular Degeneration http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11292663&form=6&db=m Influence of plasminogen activator inhibitor type 1 on choroidal neovascularization. causal interaction,ongoing research,therapeutic application,unassigned 3,3,4,0 3.4.21.7 Macular Degeneration http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12871064&form=6&db=m Inhibitors of the proteolytic activity of urokinase type plasminogen activator. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.7 Macular Degeneration http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16496258&form=6&db=m Use of autologous plasmin during vitrectomy for diabetic maculopathy. diagnostic usage,therapeutic application,unassigned 3,3,0 3.4.21.7 Macular Degeneration http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17057793&form=6&db=m Vitrectomy for the treatment of submacular hemorrhages from macular degeneration: a comparison of submacular hemorrhage/membrane removal and submacular tissue plasminogen activator-assisted pneumatic displacement. therapeutic application,unassigned 1,0 3.4.21.7 Macular Degeneration http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19110965&form=6&db=m [The intravitreal application of the tissue plasminogen activator in the treatment of submacular hemorrhage--a case report] ongoing research,unassigned 2,0 3.4.21.7 Macular Degeneration http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23665864&form=6&db=m Intracameral concentrations of the fibrinolytic system components in patients with age-related macular degeneration. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.7 Macular Degeneration http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24044710&form=6&db=m Hemorrhagic age-related macular degeneration managed with vitrectomy, subretinal injection of tissue plasminogen activator, gas tamponade, and upright positioning. ongoing research,therapeutic application,unassigned 1,2,0 3.4.21.7 Macular Degeneration http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26079475&form=6&db=m OPTICAL COHERENCE TOMOGRAPHY FINDINGS AND SURGICAL OUTCOMES OF TISSUE PLASMINOGEN ACTIVATOR-ASSISTED VITRECTOMY FOR SUBMACULAR HEMORRHAGE SECONDARY TO AGE-RELATED MACULAR DEGENERATION. therapeutic application,unassigned 1,0 3.4.21.7 Macular Degeneration http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26107011&form=6&db=m Intravitreal Bevacizumab, Plasminogen, and Pneumatic Retinopexy for Subfoveal Hemorrhage in Age-Related Macular Degeneration. therapeutic application,unassigned 4,0 3.4.21.7 Macular Degeneration http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26107121&form=6&db=m Intravitreal Bevacizumab, Plasminogen, and Pneumatic Retinopexy for Subfoveal Hemorrhage in Age-Related Macular Degeneration. unassigned - 3.4.21.7 Macular Degeneration http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28643713&form=6&db=m Tissue plasminogen activator-assisted vitrectomy for submacular hemorrhage due to age-related macular degeneration. therapeutic application,unassigned 3,0 3.4.21.7 Macular Degeneration http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31870667&form=6&db=m [Treatment of hematomas in age related macular degeneration by vitrectomy and subretinal injection of r-tPA: Preliminary results (French translation of the article)]. ongoing research,therapeutic application,unassigned 1,2,0 3.4.21.7 Macular Edema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15019368&form=6&db=m Ultrastructure of internal limiting membrane removed during plasmin-assisted vitrectomy from eyes with diabetic macular edema. ongoing research,unassigned 1,0 3.4.21.7 Macular Edema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15488781&form=6&db=m Intrasurgical plasmin enzyme in diabetic macular edema. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,3,3,2 3.4.21.7 Macular Edema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15710817&form=6&db=m Effect of plasmin on laminin and fibronectin during plasmin-assisted vitrectomy. diagnostic usage,ongoing research,therapeutic application,unassigned 1,4,4,0 3.4.21.7 Macular Edema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15860323&form=6&db=m Intrasurgical plasmin enzyme in diabetic macular edema. unassigned - 3.4.21.7 Macular Edema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16496258&form=6&db=m Use of autologous plasmin during vitrectomy for diabetic maculopathy. diagnostic usage,therapeutic application,unassigned 3,3,0 3.4.21.7 Macular Edema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18260017&form=6&db=m [Enzymatic vitrectomy by intravitreal autologous plasmin injection, as initial treatment for diffuse diabetic macular edema.] therapeutic application,unassigned 4,0 3.4.21.7 Macular Edema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19650710&form=6&db=m Intravitreal plasmin without associated vitrectomy as a treatment for refractory diabetic macular edema. therapeutic application,unassigned 4,0 3.4.21.7 Macular Edema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20801424&form=6&db=m Intravitreal Injection of Autologous Plasmin Enzyme for Macular Edema Associated with Branch Retinal Vein Occlusion. diagnostic usage,ongoing research,therapeutic application,unassigned 3,3,3,0 3.4.21.7 Macular Edema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20939804&form=6&db=m Pharmacologic Vitreolysis in Diabetic Retinopathy. therapeutic application,unassigned 4,0 3.4.21.7 Macular Edema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21402982&form=6&db=m Intravitreal plasmin without vitrectomy for macular edema secondary to branch retinal vein occlusion. diagnostic usage,ongoing research,therapeutic application,unassigned 3,1,4,0 3.4.21.7 Macular Edema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21591862&form=6&db=m Predictability of vitreous detachment following intravitreal plasmin injection in diabetic macular edema associated with vitreomacular traction. diagnostic usage,therapeutic application,unassigned 1,2,0 3.4.21.7 Macular Edema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21784203&form=6&db=m Intravitreal injection of autologous plasmin enzyme for macular edema associated with branch retinal vein occlusion. diagnostic usage,therapeutic application,unassigned 3,2,0 3.4.21.7 Macular Edema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23271887&form=6&db=m Intravitreal autologous plasmin as a therapeutic modality for diffuse diabetic macular edema. diagnostic usage,therapeutic application,unassigned 2,4,0 3.4.21.7 Macular Edema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24379923&form=6&db=m Enzymatic vitrectomy for diabetic retinopathy and diabetic macular edema. therapeutic application,unassigned 1,0 3.4.21.7 Malaria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9178267&form=6&db=m Host urokinase-type plasminogen activator participates in the release of malaria merozoites from infected erythrocytes. causal interaction,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.7 Malaria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9879906&form=6&db=m Plasminogen activators are not required in the erythrocytic life cycle of malaria parasites. unassigned - 3.4.21.7 Malaria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10858190&form=6&db=m Delayed mortality and attenuated thrombocytopenia associated with severe malaria in urokinase- and urokinase receptor-deficient mice. causal interaction,ongoing research,therapeutic application,unassigned 3,2,2,0 3.4.21.7 Malaria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24503144&form=6&db=m Plasmodium falciparum proteases hydrolyze plasminogen, generating angiostatin-like fragments. causal interaction,therapeutic application,unassigned 3,3,0 3.4.21.7 Malaria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33022775&form=6&db=m Acquisition of human plasminogen facilitates complement evasion by the malaria parasite Plasmodium falciparum. ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.7 Mastitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2144392&form=6&db=m Effect of frequent milkings on milk NAGase, plasmin, trypsin inhibitory capacity and the quality of whey as the growth medium for mastitis pathogens. diagnostic usage,unassigned 1,0 3.4.21.7 Mastitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2526166&form=6&db=m Plasmin and plasminogen in bovine milk: a relationship with involution? causal interaction,therapeutic application,unassigned 2,1,0 3.4.21.7 Mastitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2947939&form=6&db=m Effect of subclinical mastitis on milk plasminogen and plasmin compared with that on sodium, antitrypsin and N-acetyl-beta-D-glucosaminidase. ongoing research,unassigned 4,0 3.4.21.7 Mastitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10575607&form=6&db=m Changes in milk protein fraction as affected by subclinical mastitis. diagnostic usage,unassigned 2,0 3.4.21.7 Mastitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11297366&form=6&db=m Characterization of hemolytic activity of Staphylococcus aureus strains isolated from bovine mastitic milk. diagnostic usage,unassigned 2,0 3.4.21.7 Mastitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12086040&form=6&db=m Effects of added plasmin on the formation and rheological properties of rennet-induced skim milk gels. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.7 Mastitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16045896&form=6&db=m E. coli proteolytic activity in milk and casein breakdown. unassigned - 3.4.21.7 Mastitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20800291&form=6&db=m Acute mastitis induces upregulation of expression of plasminogen activator-related genes by blood monocytes and neutrophils in dairy ewes. causal interaction,ongoing research,unassigned 2,1,0 3.4.21.7 Mastitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23031515&form=6&db=m Reevaluation of vitamin E supplementation of dairy cows: bioavailability, animal health and milk quality. unassigned - 3.4.21.7 Mastitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24997569&form=6&db=m Tailor made plasmin substrates as potential diagnostic tool to test for mastitis. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,4,0 3.4.21.7 Mastitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28219684&form=6&db=m Development of magnetic nanoparticle based calorimetric assay for the detection of bovine mastitis in cow milk. diagnostic usage,unassigned 2,0 3.4.21.7 Mastitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=100111758&form=6&db=m Polymorphonuclear neutrophils and Escherichia coli proteases involved in proteolysis of casein during experimental E. coli mastitis therapeutic application,unassigned 1,0 3.4.21.7 Mastocytoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2427454&form=6&db=m Plasminogen activator production from murine mastocytoma cells. Dissociation of plasminogen activator and histamine production by sodium butyrate. ongoing research,therapeutic application,unassigned 4,1,0 3.4.21.7 Measles http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6210342&form=6&db=m Measles antibodies, anti-proteinase and plasminogen distribution in serum and plasma from patients affected with multiple sclerosis and patients affected with non-neurological diseases. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,3,0 3.4.21.7 Measles http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6460384&form=6&db=m Antibody spectrum and anticomplementary activity of a plasmin-treated human immunoglobulin preparation. therapeutic application,unassigned 1,0 3.4.21.7 Measles http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15613000&form=6&db=m Avoidance of oxidative-stress perturbation in yeast bioprocesses by proteomic and genomic biostrategies? unassigned - 3.4.21.7 Melanoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=39088&form=6&db=m Proteolytic enzymes and plasminogen activator in melanoma. diagnostic usage,ongoing research,unassigned 3,2,0 3.4.21.7 Melanoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=632749&form=6&db=m Serine enzymes released by cultured neoplastic cells. ongoing research,unassigned 2,0 3.4.21.7 Melanoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1380952&form=6&db=m Fibrinolysis activity promotes tumor invasiveness of B16 melanoma cell lines through a reconstituted gel matrix. causal interaction,unassigned 1,0 3.4.21.7 Melanoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1531956&form=6&db=m Generation of cell surface-bound plasmin by cell-associated urokinase-type or secreted tissue-type plasminogen activator: a key event in melanoma cell invasiveness in vitro. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,4,1 3.4.21.7 Melanoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1712633&form=6&db=m Plasminogen activation by t-PA on the surface of human melanoma cells in the presence of alpha 2-macroglobulin secretion. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,4,0 3.4.21.7 Melanoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1829631&form=6&db=m A role for platelets and thrombin in the juvenile stroke of two siblings with defective thrombin-adsorbing capacity of fibrin(ogen). therapeutic application,unassigned 1,0 3.4.21.7 Melanoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1847824&form=6&db=m Modulation of plasminogen activation and type IV collagenase activity by a synthetic peptide derived from the laminin A chain. diagnostic usage,ongoing research,unassigned 3,1,0 3.4.21.7 Melanoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1899072&form=6&db=m Urokinase-type and tissue-type plasminogen activators are essential for in vitro invasion of human melanoma cells. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,4,0 3.4.21.7 Melanoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2129390&form=6&db=m Kinetic studies of plasminogen activation by epithelial tissue plasminogen activator. diagnostic usage,therapeutic application,unassigned 3,2,0 3.4.21.7 Melanoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2141793&form=6&db=m Glycosylation at Asn-184 inhibits the conversion of single-chain to two-chain tissue-type plasminogen activator by plasmin. diagnostic usage,ongoing research,unassigned 1,4,0 3.4.21.7 Melanoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2509088&form=6&db=m Partial purification and characterization of epidermal plasminogen activator and their inhibitor. ongoing research,unassigned 4,0 3.4.21.7 Melanoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2514121&form=6&db=m Synthesis and refolding of human tissue-type plasminogen activator in Bacillus subtilis. unassigned - 3.4.21.7 Melanoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2930896&form=6&db=m Different inhibition of one and two chain tissue plasminogen activator by a placental inhibitor studied with two tripeptide-p-nitroanilide substrates. ongoing research,therapeutic application,unassigned 4,2,0 3.4.21.7 Melanoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3091056&form=6&db=m Characterization of seven human melanoma cell lines: melanogenesis and secretion of plasminogen activators. causal interaction,ongoing research,unassigned 1,4,0 3.4.21.7 Melanoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3490474&form=6&db=m Purification of an active plasminogen activator inhibitor immunologically related to the endothelial type plasminogen activator inhibitor from the conditioned media of a human melanoma cell line. ongoing research,therapeutic application,unassigned 4,2,0 3.4.21.7 Melanoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3515850&form=6&db=m Immunological characterization of plasminogen activators in human mixed saliva. diagnostic usage,ongoing research,therapeutic application,unassigned 1,4,1,0 3.4.21.7 Melanoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3692623&form=6&db=m Plasminogen activator production by human tumor cells: effect on tumor cell-extracellular matrix interactions. diagnostic usage,ongoing research,unassigned 2,4,0 3.4.21.7 Melanoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3881480&form=6&db=m Immunohistochemical localisation of tissue plasminogen activator and urokinase in the vessel wall. diagnostic usage,ongoing research,therapeutic application,unassigned 1,4,1,0 3.4.21.7 Melanoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6342680&form=6&db=m Comparative electrophoretic analysis of human and porcine plasminogen activators in SDS-polyacrylamide gels containing plasminogen and casein. diagnostic usage,ongoing research,unassigned 3,4,0 3.4.21.7 Melanoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6374238&form=6&db=m Plasminogen activators in human malignant melanoma. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,3,4,1 3.4.21.7 Melanoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6538196&form=6&db=m Kinetics of the activation of plasminogen by natural and recombinant tissue-type plasminogen activator. therapeutic application,unassigned 2,0 3.4.21.7 Melanoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6538482&form=6&db=m Inactive proenzyme to tissue-type plasminogen activator from human melanoma cells, identified after affinity purification with a monoclonal antibody. ongoing research,therapeutic application,unassigned 4,1,0 3.4.21.7 Melanoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6538971&form=6&db=m Mechanism of the stimulatory effect of phorbol 12-myristate 13-acetate on cellular production of plasminogen activator. ongoing research,therapeutic application,unassigned 4,1,0 3.4.21.7 Melanoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6539166&form=6&db=m Relationship between multiple forms of plasminogen activator in human breast tumors and plasma and the presence of metastases in lymph nodes. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,4,2 3.4.21.7 Melanoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7193517&form=6&db=m Molecular species of plasminogen activators secreted by normal and neoplastic human cells. ongoing research,unassigned 3,0 3.4.21.7 Melanoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7553649&form=6&db=m Expression of plasminogen activators and plasminogen activator inhibitors in cutaneous melanomas of transgenic melanoma-susceptible mice. causal interaction,ongoing research,therapeutic application,unassigned 4,3,2,0 3.4.21.7 Melanoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7657514&form=6&db=m Plasmin in pericellular proteolysis and cellular invasion. causal interaction,diagnostic usage,ongoing research,unassigned 3,3,4,0 3.4.21.7 Melanoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7671626&form=6&db=m Tissue-type plasminogen activator-induced invasion and metastasis of murine melanomas. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,1,3,1 3.4.21.7 Melanoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7744600&form=6&db=m The involvement of thrombin RGD in metastasis: characterization of a cryptic adhesive site. causal interaction,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.7 Melanoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7747886&form=6&db=m Studies on functional and structural role of urokinase receptor and other components of the plasminogen activation system in malignancy. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,4,1 3.4.21.7 Melanoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8291613&form=6&db=m Plasminogen activators, their inhibitors, and urokinase receptor emerge in late stages of melanocytic tumor progression. causal interaction,ongoing research,therapeutic application,unassigned 4,4,3,0 3.4.21.7 Melanoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8501135&form=6&db=m Binding of tissue-type plasminogen activator to human melanoma cells. causal interaction,diagnostic usage,ongoing research,unassigned 1,3,4,0 3.4.21.7 Melanoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8774480&form=6&db=m Tetranectin and plasmin/plasminogen are similarly distributed at the invasive front of cutaneous melanoma lesions. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,4,0 3.4.21.7 Melanoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8791264&form=6&db=m The plasminogen activation system in melanoma cell lines and in melanocytic lesions. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,4,0 3.4.21.7 Melanoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8814995&form=6&db=m Different roles for plasminogen activators and metalloproteinases in melanoma metastasis. diagnostic usage,ongoing research,unassigned 3,4,0 3.4.21.7 Melanoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8836880&form=6&db=m Active transforming growth factor-beta in human melanoma cell lines: no evidence for plasmin-related activation of latent TGF-beta. ongoing research,therapeutic application,unassigned 4,2,0 3.4.21.7 Melanoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9096674&form=6&db=m Melanoma cell migration on vitronectin: regulation by components of the plasminogen activation system. causal interaction,ongoing research,unassigned 1,4,0 3.4.21.7 Melanoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9345318&form=6&db=m Spatial orientation of tissue-type plasminogen activator bound at the melanoma cell surface. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,3,3,1 3.4.21.7 Melanoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9714330&form=6&db=m The field bean protease inhibitor has the potential to suppress B16F10 melanoma cell lung metastasis in mice. causal interaction,ongoing research,therapeutic application,unassigned 3,4,4,0 3.4.21.7 Melanoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9949291&form=6&db=m Modulation of tumor cell motility by plasmin. causal interaction,ongoing research,unassigned 1,4,0 3.4.21.7 Melanoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10229661&form=6&db=m Angiostatin inhibits endothelial and melanoma cellular invasion by blocking matrix-enhanced plasminogen activation. causal interaction,ongoing research,therapeutic application,unassigned 2,3,1,0 3.4.21.7 Melanoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10574721&form=6&db=m A potential role for the plasmin(ogen) system in the posttranslational cleavage of the neural cell adhesion molecule L1. diagnostic usage,unassigned 3,0 3.4.21.7 Melanoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10596910&form=6&db=m Expression of angiogenic and immunosuppressive factors by uveal melanoma cell lines. diagnostic usage,ongoing research,unassigned 3,4,0 3.4.21.7 Melanoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10737043&form=6&db=m [The role of proteolytic enzymes in skin neoplasm progression and development of metastasis] causal interaction,diagnostic usage,unassigned 3,3,0 3.4.21.7 Melanoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10842189&form=6&db=m Angiogenic balance in human melanoma: expression of VEGF, bFGF, IL-8, PDGF and angiostatin in relation to vascular density of xenografts in vivo. diagnostic usage,ongoing research,unassigned 3,4,0 3.4.21.7 Melanoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11044361&form=6&db=m High tPA-expression in primary melanoma of the limb correlates with good prognosis. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,3,1 3.4.21.7 Melanoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11089882&form=6&db=m Inhibition of B16BL6 melanoma invasion by tyrosine and phenylalanine deprivation is associated with decreased secretion of plasminogen activators and increased plasminogen activator inhibitors. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.7 Melanoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11169951&form=6&db=m Regulation of urokinase plasminogen activator/plasmin-mediated invasion of melanoma cells by the integrin vitronectin receptor alphaVbeta3. causal interaction,ongoing research,unassigned 3,4,0 3.4.21.7 Melanoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11687850&form=6&db=m Tissue- and urokinase-type plasminogen activators and type 1 plasminogen activator inhibitor in melanomas and benign skin pigment neoplasms. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,3,1 3.4.21.7 Melanoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11912164&form=6&db=m Hypoxia promotes lymph node metastasis in human melanoma xenografts by up-regulating the urokinase-type plasminogen activator receptor. causal interaction,ongoing research,therapeutic application,unassigned 3,2,4,0 3.4.21.7 Melanoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12210068&form=6&db=m Spitz naevi may express components of the plasminogen activation system. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,1,3 3.4.21.7 Melanoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12750156&form=6&db=m Regulation of plasminogen activation: a role for melanotransferrin (p97) in cell migration. causal interaction,therapeutic application,unassigned 3,2,0 3.4.21.7 Melanoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14597403&form=6&db=m Transforming growth factor-beta1 inhibits tumor growth in a mouse melanoma model by down-regulating the plasminogen activation system. causal interaction,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.7 Melanoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15623988&form=6&db=m Low dose adjuvant angiostatin decreases hepatic micrometastasis in murine ocular melanoma model. ongoing research,unassigned 4,0 3.4.21.7 Melanoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15936756&form=6&db=m Stimulation of cell surface plasminogen activation by membrane-bound melanotransferrin: a key phenomenon for cell invasion. ongoing research,unassigned 4,0 3.4.21.7 Melanoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16524486&form=6&db=m The fibrinolytic system facilitates tumor cell migration across the blood-brain barrier in experimental melanoma brain metastasis. causal interaction,ongoing research,therapeutic application,unassigned 3,4,3,0 3.4.21.7 Melanoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16857721&form=6&db=m In vivo inhibition of angiogenesis by a soluble form of melanotransferrin. ongoing research,unassigned 1,0 3.4.21.7 Melanoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17196552&form=6&db=m Melanotransferrin induces human melanoma SK-Mel-28 cell invasion in vivo. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,4,0 3.4.21.7 Melanoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19605778&form=6&db=m The tissue-type plasminogen activator story. causal interaction,ongoing research,therapeutic application,unassigned 1,4,4,0 3.4.21.7 Melanoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23063511&form=6&db=m TGF-? signaling, activated stromal fibroblasts, and cysteine cathepsins B and L drive the invasive growth of human melanoma cells. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,4,0 3.4.21.7 Melanoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23085456&form=6&db=m TGF-beta inhibits human cutaneous melanoma cell migration and invasion through regulation of the plasminogen activator system. causal interaction,ongoing research,unassigned 4,3,0 3.4.21.7 Melanoma, Experimental http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6302253&form=6&db=m Plasmin-activated prodrugs for cancer chemotherapy. 2. Synthesis and biological activity of peptidyl derivatives of doxorubicin. ongoing research,therapeutic application,unassigned 1,1,0 3.4.21.7 Melanoma, Experimental http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7558459&form=6&db=m Differences in expression of metalloproteinases and plasminogen activators in murine melanocytes and B16 melanoma variants: lack of association with in vitro invasion. causal interaction,ongoing research,unassigned 1,3,0 3.4.21.7 Melanosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22329442&form=6&db=m Effect of tranexamic acid on melasma: a clinical trial with histological evaluation. causal interaction,therapeutic application,unassigned 1,2,0 3.4.21.7 Melanosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26177992&form=6&db=m Comparison of therapeutic effects of liposomal Tranexamic Acid and conventional Hydroquinone on melasma. therapeutic application,unassigned 4,0 3.4.21.7 Melanosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33174686&form=6&db=m Laser-assisted delivery of tranexamic acid for melasma: Pilot study using a novel 1927 nm fractional thulium fiber laser. unassigned - 3.4.21.7 Meningioma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28524122&form=6&db=m [A plasminogen regulation system in brain tumors]. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,4,2,1 3.4.21.7 Meningitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1678556&form=6&db=m Enhancement of tissue plasminogen activator-catalyzed plasminogen activation by Escherichia coli S fimbriae associated with neonatal septicaemia and meningitis. therapeutic application,unassigned 1,0 3.4.21.7 Meningitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15542096&form=6&db=m Elevation of plasminogen activators in cerebrospinal fluid of mice with eosinophilic meningitis caused by Angiostrongylus cantonensis. ongoing research,therapeutic application,unassigned 2,3,0 3.4.21.7 Meningitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16410005&form=6&db=m Angiostrongylus cantonensis: efficacy of albendazole-dexamethasone co-therapy against infection-induced plasminogen activators and eosinophilic meningitis. therapeutic application,unassigned 2,0 3.4.21.7 Meningitis, Bacterial http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12427882&form=6&db=m Role of the urokinase plasminogen activator system in patients with bacterial meningitis. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.7 Meningococcal Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2315889&form=6&db=m Plasminogen activator inhibitor 1 and 2, alpha-2-antiplasmin, plasminogen, and endotoxin levels in systemic meningococcal disease. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,1,4 3.4.21.7 Menorrhagia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2953634&form=6&db=m The fibrinolytic enzyme system in normal menstruation and excessive uterine bleeding and the effect of tranexamic acid. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,3,2 3.4.21.7 Menorrhagia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10785231&form=6&db=m Induction of endometrial plasminogen activator-inhibitor 1: a possible mechanism contributing to the effect of intrauterine levonorgestrel in the treatment of menorrhagia. therapeutic application,unassigned 3,0 3.4.21.7 Menorrhagia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10796518&form=6&db=m Antifibrinolytics for heavy menstrual bleeding. therapeutic application,unassigned 4,0 3.4.21.7 Menorrhagia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11034679&form=6&db=m Antifibrinolytics for heavy menstrual bleeding. therapeutic application,unassigned 4,0 3.4.21.7 Menorrhagia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12315173&form=6&db=m [Changes of peroxidase, plasminogen and fibrinolytic activity on menorrhagia induced by IUDS and the effect of treatment with vitamin E] therapeutic application,unassigned 3,0 3.4.21.7 Menorrhagia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12825966&form=6&db=m Tranexamic acid: a review of its use in the management of menorrhagia. therapeutic application,unassigned 1,0 3.4.21.7 Menorrhagia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17667546&form=6&db=m Tranexamic acid-associated necrosis and intralesional thrombosis of uterine leiomyomas: a clinicopathologic study of 147 cases emphasizing the importance of drug-induced necrosis and early infarcts in leiomyomas. therapeutic application,unassigned 1,0 3.4.21.7 Menorrhagia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28089737&form=6&db=m Browplasminin, a condensed tannin with anti-plasmin activity isolated from an aqueous extract of Brownea grandiceps Jacq. flowers. causal interaction,diagnostic usage,therapeutic application,unassigned 3,2,4,0 3.4.21.7 Mesenteric Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18442202&form=6&db=m Diagnostic value of plasminogen activity level in acute mesenteric ischemia. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,2 3.4.21.7 Mesothelioma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2555056&form=6&db=m Synthesis and secretion of plasminogen activators and plasminogen activator inhibitors in cell lines of different groups of human lung tumors. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,3,4,4 3.4.21.7 Mesothelioma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8443784&form=6&db=m Expression of plasminogen activator and plasminogen activator inhibitor by rat mesothelioma induced by asbestos. ongoing research,therapeutic application,unassigned 2,2,0 3.4.21.7 Metabolic Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19140507&form=6&db=m [The influence of antihypertensive agents on plasmatic and vascular-thrombocytic homeostasis in metabolic syndrome] causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.7 Metabolic Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19265043&form=6&db=m Sex-differences in the impact of metabolic syndrome on tissue plasminogen activator-induced recanalization. ongoing research,unassigned 1,0 3.4.21.7 Metabolic Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24718702&form=6&db=m Controlled Exposure of Humans with Metabolic Syndrome to Concentrated Ultrafine Ambient Particulate Matter Causes Cardiovascular Effects. unassigned - 3.4.21.7 Metabolic Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26451494&form=6&db=m Association of Metabolic Syndrome with Serum Adipokines in Community-Living Elderly Japanese Women: Independent Association with Plasminogen Activator-Inhibitor-1. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.7 Metabolic Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31529920&form=6&db=m [The markers of dysfunction of endothelium and cytokine profile in patients with metabolic syndrome and abdominal obesity.] causal interaction,ongoing research,therapeutic application,unassigned 3,2,1,0 3.4.21.7 Metabolism, Inborn Errors http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19432826&form=6&db=m Stroke in children: inherited and acquired factors and age-related variations in the presentation of 48 paediatric patients. causal interaction,ongoing research,unassigned 2,1,0 3.4.21.7 Metabolism, Inborn Errors http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22759687&form=6&db=m Inherited thrombophilia in pediatric ischemic stroke: an Egyptian study. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,1,1 3.4.21.7 Mouth Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15509494&form=6&db=m Detection of plasminogen activators in oral cancer by laser capture microdissection combined with zymography. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,2,2,1 3.4.21.7 Mouth Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17498910&form=6&db=m A metalloproteinase-9 polymorphism which affects its expression is associated with increased risk for oral squamous cell carcinoma. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,1,4,1 3.4.21.7 Mouth Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26004216&form=6&db=m Plasminogen activation system in oral cancer: Relevance in prognosis and therapy (Review). causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,4,0 3.4.21.7 Moyamoya Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10456203&form=6&db=m Screening for aetiology of thrombophilia: a high prevalence of protein S abnormality. unassigned - 3.4.21.7 Mucocele http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7473265&form=6&db=m Proteolytic enzymes in salivary extravasation mucoceles. ongoing research,unassigned 3,0 3.4.21.7 Mucocutaneous Lymph Node Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11441982&form=6&db=m Low tissue plasminogen activator relative to plasminogen activator inhibitor-1 as a marker of cardiac complication in children with Kawasaki disease. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,2,2,2 3.4.21.7 Mucositis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17889676&form=6&db=m Inherited plasminogen deficiency presenting as ligneous vaginitis: a case report with molecular correlation and review of the literature. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 Mucositis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26021226&form=6&db=m A controlled, cross-sectional exploratory study on markers for the plasminogen system and inflammation in crevicular fluid samples from healthy, mucositis and peri-implantitis sites. causal interaction,diagnostic usage,ongoing research,unassigned 3,4,3,0 3.4.21.7 Mucositis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27193180&form=6&db=m Molecular pathogenesis of plasminogen Hakodate: the second Japanese family case of severe type I plasminogen deficiency manifested late-onset multi-organic chronic pseudomembranous mucositis. causal interaction,unassigned 4,0 3.4.21.7 Multiple Myeloma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26869462&form=6&db=m Chromogranin A Is Preferentially Cleaved into Proangiogenic Peptides in the Bone Marrow of Multiple Myeloma Patients. therapeutic application,unassigned 1,0 3.4.21.7 Multiple Myeloma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28501622&form=6&db=m The role of plasmin in the pathogenesis of murine multiple myeloma. causal interaction,ongoing research,unassigned 4,2,0 3.4.21.7 Multiple Sclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2477972&form=6&db=m [The kinin and plasmin systems of the blood serum and cerebro- spinal fluid in patients with multiple sclerosis and schizophrenia] diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.7 Multiple Sclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3762956&form=6&db=m Plasminogen deficiency and thrombosis after plasmapheresis therapy for multiple sclerosis. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 Multiple Sclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6210342&form=6&db=m Measles antibodies, anti-proteinase and plasminogen distribution in serum and plasma from patients affected with multiple sclerosis and patients affected with non-neurological diseases. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,3,0 3.4.21.7 Multiple Sclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10376931&form=6&db=m Plasminogen activators and matrix metalloproteases, mediators of extracellular proteolysis in inflammatory demyelination of the central nervous system. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.7 Multiple Sclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10559777&form=6&db=m Chemokine modulation of matrix metalloproteinase and TIMP production in adult rat brain microglia and a human microglial cell line in vitro. causal interaction,unassigned 3,0 3.4.21.7 Multiple Sclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11571216&form=6&db=m Plasminogen activators in multiple sclerosis lesions: implications for the inflammatory response and axonal damage. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,2,3,3 3.4.21.7 Multiple Sclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11733372&form=6&db=m Coordinated induction of extracellular proteolysis systems during experimental autoimmune encephalomyelitis in mice. causal interaction,unassigned 3,0 3.4.21.7 Multiple Sclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23401127&form=6&db=m Altered expression of the plasminogen activation pathway in peripheral blood mononuclear cells in multiple sclerosis: possible pathomechanism of matrix metalloproteinase activation. causal interaction,diagnostic usage,ongoing research,unassigned 1,3,2,0 3.4.21.7 Multiple Sclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23897640&form=6&db=m Common genetic variants in the plasminogen activation pathway are not associated with multiple sclerosis. causal interaction,unassigned 3,0 3.4.21.7 Multiple Sclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25220760&form=6&db=m Plasminogen in cerebrospinal fluid originates from circulating blood. causal interaction,ongoing research,therapeutic application,unassigned 4,2,2,0 3.4.21.7 Multiple Sclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25406498&form=6&db=m Validation of semaphorin 7A and ala-?-his-dipeptidase as biomarkers associated with the conversion from clinically isolated syndrome to multiple sclerosis. diagnostic usage,ongoing research,unassigned 2,1,0 3.4.21.7 Multiple Sclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27194806&form=6&db=m Analysis of Plasminogen Genetic Variants in Multiple Sclerosis Patients. diagnostic usage,unassigned 4,0 3.4.21.7 Multiple Sclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28275164&form=6&db=m Plasminogen Deficiency Delays the Onset and Protects from Demyelination and Paralysis in Autoimmune Neuroinflammatory Disease. causal interaction,ongoing research,therapeutic application,unassigned 3,3,2,0 3.4.21.7 Mumps http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6460384&form=6&db=m Antibody spectrum and anticomplementary activity of a plasmin-treated human immunoglobulin preparation. therapeutic application,unassigned 1,0 3.4.21.7 Mumps http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15613000&form=6&db=m Avoidance of oxidative-stress perturbation in yeast bioprocesses by proteomic and genomic biostrategies? unassigned - 3.4.21.7 Muscular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15970552&form=6&db=m The plasminogen activation system in skeletal muscle regeneration: antagonistic roles of urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1). therapeutic application,unassigned 3,0 3.4.21.7 Muscular Dystrophies http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3160343&form=6&db=m Plasma plasmin inhibitors in Duchenne-type progressive muscular dystrophy. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,4,0 3.4.21.7 Muscular Dystrophy, Duchenne http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3160343&form=6&db=m Plasma plasmin inhibitors in Duchenne-type progressive muscular dystrophy. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,4,0 3.4.21.7 Muscular Dystrophy, Duchenne http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14515195&form=6&db=m Plasmin generation dependent on alpha-enolase-type plasminogen receptor is required for myogenesis. ongoing research,unassigned 2,0 3.4.21.7 Muscular Dystrophy, Duchenne http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15574344&form=6&db=m Alpha-enolase plasminogen receptor in myogenesis. ongoing research,unassigned 4,0 3.4.21.7 Musculoskeletal Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32548548&form=6&db=m Plasminogen activation in the musculoskeletal acute phase response: Injury, repair, and disease. ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=128203&form=6&db=m [Changes in the coagulation and anticoagulation systems of blood in myocardial infarct during the process of treatment with anticoagulants and fibrinolysin] causal interaction,therapeutic application,unassigned 1,3,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=128577&form=6&db=m Electrocardiogram during experimental coronary thrombolysis. unassigned - 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=136054&form=6&db=m [Intracoronary administration of fibrinolysin in acute myocardial infarct] causal interaction,therapeutic application,unassigned 3,3,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=141111&form=6&db=m [Changes in fibrinolysis system in patients with acute myocardial infarction in intracoronary administration of fibrinolysin with heparin] causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=146757&form=6&db=m [Effect of fibrinolysin and heparin on the kinetic properties of the thrombocytes and the oxidation-reduction processes in myocardial infarct] ongoing research,therapeutic application,unassigned 1,1,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=308597&form=6&db=m [Behavior of tissue plasminogen activators and plasmin inhibitors in experimental myocardial infarct with and without trasylol] therapeutic application,unassigned 4,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=491364&form=6&db=m [Content of fibrinogen degradation products, soluble fibrin and the fibrinolytic activity of blood in myocardial infarct] diagnostic usage,ongoing research,therapeutic application,unassigned 3,2,1,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=550980&form=6&db=m [Alterations of plasma plasminogen and fibrinogen, serum fibrin degradation products and degree of ADP induced platelet aggregation in acute myocardial infarction (author's transl)] diagnostic usage,unassigned 3,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1290642&form=6&db=m [Formation of left ventricular thrombus in acute myocardial infarction: significance of the determination of fibrinogen, of products of fibrinogen degradation, and of plasminogen] diagnostic usage,ongoing research,unassigned 4,2,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1300957&form=6&db=m [Study of new thrombolytic agents in myocardial infarction: a multicenter randomized trial (APSAC versus rt-PA)] therapeutic application,unassigned 1,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1372625&form=6&db=m Pharmacokinetics and fibrin specificity of alteplase during accelerated infusions in acute myocardial infarction. diagnostic usage,ongoing research,therapeutic application,unassigned 1,2,1,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1430680&form=6&db=m Pathophysiology and prognostic significance of Holter-detected ST segment depression after myocardial infarction. The Tissue Plasminogen Activator: Toronto (TPAT) Study Group. diagnostic usage,ongoing research,unassigned 2,1,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1441858&form=6&db=m Thrombolytic therapy and acute aortic dissection. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1521251&form=6&db=m [An echographic study of left ventricular function in acute myocardial infarct undergoing thrombolysis] causal interaction,diagnostic usage,ongoing research,unassigned 3,1,3,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1533349&form=6&db=m Platelet-dependent thrombin generation after in vitro fibrinolytic treatment. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,2,1,1 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1552106&form=6&db=m Improved thrombolysis in acute myocardial infarction with front-loaded administration of alteplase: results of the rt-PA-APSAC patency study (TAPS) causal interaction,diagnostic usage,ongoing research,therapeutic application 3,1,2,4 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1563856&form=6&db=m Biological risk factors for sudden death in patients with coronary artery disease and without heart failure. diagnostic usage,therapeutic application,unassigned 1,1,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1590225&form=6&db=m Effectiveness and safety of a single intravenous bolus injection of tissue-type plasminogen activator in acute myocardial infarction. Bolus Dose-Escalation Study of Tissue-Type Plasminogen Activator (BEST) Investigators. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,1,2,4 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1607536&form=6&db=m Antecedent angina pectoris predicts worse outcome after myocardial infarction in patients receiving thrombolytic therapy: experience gleaned from the International Tissue Plasminogen Activator/Streptokinase Mortality Trial. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,4,3,4 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1691750&form=6&db=m Plasmin inhibitors in the prevention of systemic effects during thrombolytic therapy: specific role of the plasminogen-binding form of alpha 2-antiplasmin. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1831932&form=6&db=m [The fibrinolysis system in recurrent myocardial infarction] diagnostic usage,unassigned 3,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1839691&form=6&db=m [The effect of fibrinolysin and streptokinase preparations on the course and prognosis of acute myocardial infarction] diagnostic usage,ongoing research,therapeutic application,unassigned 3,1,2,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1893056&form=6&db=m Histidine-rich glycoprotein in thrombolytic therapy: has it clinical relevance? diagnostic usage,ongoing research,therapeutic application,unassigned 3,4,1,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1894538&form=6&db=m Overview: rationale of thrombolysis in treating acute myocardial infarction. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,4,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1898952&form=6&db=m Cardiac tamponade early after thrombolysis for acute myocardial infarction: a rare but not reported hemorrhagic complication. ongoing research,therapeutic application,unassigned 2,4,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1899364&form=6&db=m Intracerebral hemorrhage, cerebral infarction, and subdural hematoma after acute myocardial infarction and thrombolytic therapy in the Thrombolysis in Myocardial Infarction Study. Thrombolysis in Myocardial Infarction, Phase II, pilot and clinical trial. causal interaction,ongoing research,therapeutic application,unassigned 4,2,4,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1899582&form=6&db=m Ventricular arrhythmias during treatment with alteplase (recombinant tissue plasminogen activator) in suspected acute myocardial infarction. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,2,1,4 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1904028&form=6&db=m Value of electrocardiographic scoring systems for the assessment of thrombolytic therapy in acute myocardial infarction. The European Cooperative Study Group for Recombinant Tissue Type Plasminogen Activator. diagnostic usage,ongoing research,therapeutic application,unassigned 3,2,4,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1909218&form=6&db=m Comparative effects of APSAC and rt-PA on infarct size and left ventricular function in acute myocardial infarction. A multicenter randomized study. causal interaction,ongoing research,therapeutic application,unassigned 2,4,4,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1968167&form=6&db=m Long-term effects of intravenous anistreplase in acute myocardial infarction: final report of the AIMS study. AIMS Trial Study Group. diagnostic usage,ongoing research,therapeutic application,unassigned 1,1,2,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2040318&form=6&db=m ST-segment analysis: a useful marker for reperfusion after thrombolysis with APSAC? The Belgian EMS Study Group. diagnostic usage,ongoing research,therapeutic application,unassigned 4,2,3,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2111665&form=6&db=m [Anisoylated plasminogen streptokinase complex during the acute phase of myocardial infarction. Results of a multicenter double-blind study versus heparin] causal interaction,diagnostic usage,therapeutic application,unassigned 1,3,4,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2112180&form=6&db=m Thrombolytic therapy in acute coronary thrombosis. diagnostic usage,ongoing research,therapeutic application,unassigned 1,2,2,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2115093&form=6&db=m Acute myocardial infarction: is streptokinase really as effective as tissue plasminogen activator? causal interaction,diagnostic usage,therapeutic application,unassigned 3,1,2,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2119263&form=6&db=m Significance of initial ST segment elevation and depression for the management of thrombolytic therapy in acute myocardial infarction. European Cooperative Study Group for Recombinant Tissue-Type Plasminogen Activator. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,1,3,4 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2119264&form=6&db=m Validity of enzyme-linked immunosorbent assays of cross-linked fibrin degradation products as a measure of clot lysis. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,3,1 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2121199&form=6&db=m Rapid resolution of ST elevation and prediction of clinical outcome in patients undergoing thrombolysis with alteplase (recombinant tissue-type plasminogen activator): results of the Israeli Study of Early Intervention in Myocardial Infarction. causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,3,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2123072&form=6&db=m Usefulness of late coronary thrombolysis (recombinant tissue-type plasminogen activator) in preserving left ventricular function in acute myocardial infarction. causal interaction,ongoing research,therapeutic application,unassigned 4,2,4,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2128661&form=6&db=m Design of novel thrombolytic agents via domain modifications. causal interaction,therapeutic application,unassigned 2,4,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2146038&form=6&db=m Effects of tissue-type plasminogen activator and anisoylated plasminogen streptokinase activator complex on mortality in acute myocardial infarction. ongoing research,therapeutic application,unassigned 2,4,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2182235&form=6&db=m Variability of thrombolytic coronary reperfusion: an angiographic study of streptokinase and anistreplase. diagnostic usage,ongoing research,therapeutic application,unassigned 1,1,2,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2182236&form=6&db=m The APSAC interventional mortality study (AIMS) trial: mortality data. diagnostic usage,ongoing research,therapeutic application,unassigned 2,2,2,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2182237&form=6&db=m The safety of anistreplase from the placebo-controlled AIMS study (anistreplase Intervention Mortality Study). The AIMS Study Group. ongoing research,therapeutic application,unassigned 2,3,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2182240&form=6&db=m Effects on infarct size and left ventricular function of early intravenous injection of anistreplase in acute myocardial infarction. The APSIM Study Investigators. ongoing research,therapeutic application,unassigned 1,3,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2191581&form=6&db=m Reocclusion three months after successful thrombolytic treatment of acute myocardial infarction with anisoylated plasminogen streptokinase activating complex. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2223309&form=6&db=m Rash after treatment with anistreplase. diagnostic usage,therapeutic application,unassigned 3,4,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2271340&form=6&db=m A systemic non-lytic state and local thrombolytic failure of anistreplase (anisoylated plasminogen streptokinase activator complex, APSAC) in acute myocardial infarction. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,2,2,2 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2306811&form=6&db=m Accelerated thrombolysis and reperfusion in a canine model of myocardial infarction by liposomal encapsulation of streptokinase. causal interaction,diagnostic usage,therapeutic application,unassigned 3,2,4,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2445540&form=6&db=m Haematological effects of anisoylated plasminogen streptokinase activator complex and streptokinase in patients with acute myocardial infarction. Interim report of the IRS II Study. causal interaction,ongoing research,therapeutic application,unassigned 1,3,4,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2448888&form=6&db=m Depression of tissue plasminogen activator (t-PA) activity and rise of t-PA inhibition and acute phase reactants in blood of patients with acute myocardial infarction (AMI). causal interaction,ongoing research,therapeutic application,unassigned 4,3,4,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2455358&form=6&db=m Monitoring of hemostasis parameters during coronary thrombolysis with recombinant tissue-type plasminogen activator. ongoing research,therapeutic application,unassigned 1,1,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2499016&form=6&db=m [Intravenous thrombolytic therapy in acute infarct of the myocardium] causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2502992&form=6&db=m Properties of molecular variants of tissue-type plasminogen activator. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2509190&form=6&db=m Tissue-type plasminogen activator. A review of its pharmacology and therapeutic use as a thrombolytic agent. causal interaction,therapeutic application,unassigned 2,4,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2518605&form=6&db=m [Plasminogen activators as thrombolytic agents in myocardial infarction] causal interaction,diagnostic usage,therapeutic application,unassigned 1,3,4,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2532081&form=6&db=m Human fibrinogen heterogeneity. A study of limited fibrinogen degradation. diagnostic usage,ongoing research,therapeutic application,unassigned 4,2,4,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2647817&form=6&db=m Multicenter trial of intravenous anisoylated plasminogen streptokinase activator complex (APSAC) in acute myocardial infarction: effects on infarct size and left ventricular function. ongoing research,therapeutic application,unassigned 4,4,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2662740&form=6&db=m Increased survival after APSAC: 30-day and 12-month mortality data from the APSAC Intervention Mortality Study. therapeutic application,unassigned 3,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2678331&form=6&db=m [A double-blind comparative study of intracoronary administration of GE-0943 and urokinase: multicenter study] causal interaction,diagnostic usage,ongoing research,unassigned 3,1,2,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2686261&form=6&db=m New developments in thrombolytic therapy. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2689138&form=6&db=m Use of thrombolytic drugs in non-coronary disorders. causal interaction,therapeutic application,unassigned 3,2,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2858711&form=6&db=m Randomised trial of intravenous recombinant tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction. Report from the European Cooperative Study Group for Recombinant Tissue-type Plasminogen Activator. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,1,4,4 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2894490&form=6&db=m Effect of intravenous APSAC on mortality after acute myocardial infarction: preliminary report of a placebo-controlled clinical trial. AIMS Trial Study Group. diagnostic usage,therapeutic application,unassigned 3,3,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2963655&form=6&db=m Vasculitis complicating treatment with intravenous anisoylated plasminogen streptokinase activator complex in acute myocardial infarction. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,1,1,4 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3042284&form=6&db=m Prehospital thrombolytic treatment of acute myocardial infarction with anisoylated plasminogen streptokinase activator complex. causal interaction,ongoing research,therapeutic application,unassigned 1,2,4,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3045271&form=6&db=m Value of myocardial defect size measured by thallium-201 SPECT: results of a multicenter trial comparing heparin and a new fibrinolytic agent. therapeutic application,unassigned 3,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3046283&form=6&db=m The German multicenter trial of anisoylated plasminogen streptokinase activator complex versus heparin for acute myocardial infarction. diagnostic usage,therapeutic application,unassigned 1,4,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3046294&form=6&db=m Dependence of assessment of coronary artery reperfusion during acute myocardial infarction on angiographic criteria and interobserver variability. ongoing research,therapeutic application,unassigned 2,3,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3051985&form=6&db=m Effect of reperfusion on electrocardiographic and enzymatic infarct size: results of a randomized multicenter study of intravenous anisoylated plasminogen streptokinase activator complex (APSAC) versus intracoronary streptokinase in acute myocardial infarction. ongoing research,therapeutic application,unassigned 1,4,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3056478&form=6&db=m Vasculitis complicating treatment with intravenous anisoylated plasminogen streptokinase activator complex in acute myocardial infarction. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3061290&form=6&db=m Intravenous thrombolytic treatment for acute myocardial infarction. Effects of early intervention and early examination. causal interaction,therapeutic application,unassigned 2,4,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3062719&form=6&db=m [Ischemic cardiopathy (VIII). Thrombolysis with plasminogen activator in myocardial infarct] causal interaction,therapeutic application,unassigned 2,2,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3086619&form=6&db=m Intravenous fibrinolytic therapy of acute myocardial infarction: new perspectives from plasminogen activators? causal interaction,therapeutic application,unassigned 2,4,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3094657&form=6&db=m Treatment of acute myocardial infarction with anisoylated plasminogen streptokinase activator complex. causal interaction,ongoing research,therapeutic application,unassigned 1,2,4,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3097100&form=6&db=m Pharmacology of thrombolytic drugs. causal interaction,therapeutic application,unassigned 4,3,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3122694&form=6&db=m [Electro-mechanical dissociation concomitant with myocardial reperfusion in the acute phase of myocardial infarction] unassigned - 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3126348&form=6&db=m [Comparative randomized study of the effectiveness of intravenous recombinant tissue-type plasminogen activator and intravenous streptokinase in patients with acute myocardial infarct. Report of the European Cooperative Study Group for Recombinant Tissue-Type Plasminogen Activator] causal interaction,diagnostic usage,ongoing research,therapeutic application 3,1,4,4 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3134813&form=6&db=m Discrepant changes in plasminogen by two different assays in patients receiving streptokinase. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,1,4 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3136953&form=6&db=m Prevention of coronary artery reocclusion and reduction in late coronary artery stenosis after thrombolytic therapy in patients with acute myocardial infarction. A randomized study of maintenance infusion of recombinant human tissue-type plasminogen activator. causal interaction,ongoing research,therapeutic application,unassigned 4,2,4,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3139325&form=6&db=m Randomized, double-blinded multicenter study. Comparison of intracoronary single-chain urokinase-type plasminogen activator, pro-urokinase (GE-0943), and intracoronary urokinase in patients with acute myocardial infarction. causal interaction,diagnostic usage,therapeutic application,unassigned 1,3,2,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3150044&form=6&db=m Recombinant tissue plasminogen activator: a brief review. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3279257&form=6&db=m [Results and limits of fibrin-unspecific thrombolysis in acute myocardial infarct] causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3284943&form=6&db=m Multicenter reperfusion trial of intravenous anisoylated plasminogen streptokinase activator complex (APSAC) in acute myocardial infarction: controlled comparison with intracoronary streptokinase. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3289357&form=6&db=m Comparison of intravenous anisoylated plasminogen streptokinase activator complex and intracoronary streptokinase in acute myocardial infarction. diagnostic usage,therapeutic application,unassigned 3,2,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3298360&form=6&db=m Anisoylated plasminogen streptokinase activator complex in acute myocardial infarction: a placebo-controlled arteriographic coronary recanalization study. diagnostic usage,ongoing research,therapeutic application,unassigned 1,1,2,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3308411&form=6&db=m Anisoylated plasminogen streptokinase activator complex (APSAC). A review of its mechanism of action, clinical pharmacology and therapeutic use in acute myocardial infarction. diagnostic usage,therapeutic application,unassigned 1,4,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3315574&form=6&db=m Summary of early clinical experience with anisoylated plasminogen streptokinase activator complex in the treatment of acute myocardial infarction. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3315575&form=6&db=m Early clinical evaluation of the intravenous treatment of acute myocardial infarction with anisoylated plasminogen streptokinase activator complex. causal interaction,diagnostic usage,therapeutic application,unassigned 3,2,4,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3315576&form=6&db=m Achievement of coronary artery patency by use of anisoylated plasminogen streptokinase activator complex in acute myocardial infarction. diagnostic usage,therapeutic application,unassigned 1,3,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3315577&form=6&db=m Dose-ranging studies of anisoylated plasminogen streptokinase activator complex. Studies in healthy volunteers and in patients with acute myocardial infarction. diagnostic usage,ongoing research,therapeutic application,unassigned 2,2,2,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3315580&form=6&db=m A placebo-controlled patency study of intravenous anisoylated plasminogen streptokinase activator complex 30U in acute myocardial infarction. ongoing research,therapeutic application,unassigned 2,3,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3315581&form=6&db=m Intravenous anisoylated plasminogen streptokinase activator complex versus intravenous streptokinase in evolving myocardial infarction. Preliminary data from a randomised multicentre study. diagnostic usage,ongoing research,therapeutic application,unassigned 1,1,4,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3315582&form=6&db=m An interim report of a double-blind placebo-controlled recanalisation study of anisoylated plasminogen streptokinase activator complex in acute myocardial infarction. causal interaction,ongoing research,therapeutic application,unassigned 2,1,3,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3315583&form=6&db=m Comparison of intravenous anisoylated plasminogen streptokinase activator complex with intracoronary streptokinase in acute myocardial infarction. diagnostic usage,ongoing research,therapeutic application,unassigned 1,1,3,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3315584&form=6&db=m Reperfusion in acute myocardial infarction. A multicentre randomised trial of early intracoronary streptokinase and intravenous anisoylated plasminogen streptokinase activator complex in the United States. causal interaction,therapeutic application,unassigned 2,4,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3315585&form=6&db=m Acute coronary occlusion and reperfusion. Reliability of angiographic classification and grading. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3315586&form=6&db=m Evaluation of 2 intravenous thrombolytic agents (anisoylated plasminogen streptokinase activator complex versus streptokinase) in patients with acute myocardial infarction. diagnostic usage,therapeutic application,unassigned 1,4,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3315587&form=6&db=m Anisoylated plasminogen streptokinase activator complex versus streptokinase in acute myocardial infarction. Preliminary results of a randomised study. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3315588&form=6&db=m Intracoronary streptokinase versus intravenous anisoylated plasminogen streptokinase activator complex in the treatment of acute myocardial infarction. causal interaction,diagnostic usage,therapeutic application,unassigned 1,2,4,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3315589&form=6&db=m Intravenous bolus application of streptokinase and of anisoylated plasminogen streptokinase activator complex in acute myocardial infarction. Clinical and haemostaseological findings. therapeutic application,unassigned 3,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3315590&form=6&db=m Evaluation of the efficacy and safety of anisoylated plasminogen streptokinase activator complex in early myocardial infarction. Preliminary results. therapeutic application,unassigned 4,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3315591&form=6&db=m Left ventricular function after anisoylated plasminogen streptokinase activator complex. ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3315592&form=6&db=m Electrocardiographic and enzymatic infarct size in a randomised study of intracoronary streptokinase and intravenous anisoylated plasminogen streptokinase activator complex in acute myocardial infarction. causal interaction,ongoing research,therapeutic application,unassigned 2,1,4,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3315593&form=6&db=m The effect of thrombolytic therapy with anisoylated plasminogen streptokinase activator complex on the indicators of myocardial salvage. therapeutic application,unassigned 4,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3315594&form=6&db=m Assessment of left ventricular function in a randomised study of intravenous anisoylated plasminogen streptokinase activator complex versus heparin in acute myocardial infarction. Preliminary results of the European Multicentre Study (Belgian Centres). ongoing research,therapeutic application,unassigned 2,4,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3315596&form=6&db=m Treatment of acute myocardial infarction with anisoylated plasminogen streptokinase activator complex in a district hospital. Efficacy data. causal interaction,therapeutic application,unassigned 2,4,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3315598&form=6&db=m AIMS. The design and conduct of a multicentre mortality study comparing placebo and anisoylated plasminogen streptokinase activator complex 30 units intravenously for the treatment of acute myocardial infarction of less than 6 hours duration. UK APSAC Advisory Committee. therapeutic application,unassigned 4,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3315600&form=6&db=m Prehospital administration of anisoylated plasminogen streptokinase activator complex in acute myocardial infarction. causal interaction,therapeutic application,unassigned 2,3,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3315602&form=6&db=m Systemic effects of anisoylated plasminogen streptokinase activator complex and streptokinase therapy in acute myocardial infarction. Coagulation aspects of the Dutch Invasive Reperfusion Study. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,1,2,4 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3315603&form=6&db=m Analysis of coagulation and fibrinolysis after intravenous anisoylated plasminogen streptokinase activator complex or heparin in patients with acute myocardial infarction. A Belgian multicentre study. causal interaction,diagnostic usage,therapeutic application,unassigned 1,3,4,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3315604&form=6&db=m Anisoylated plasminogen streptokinase activator complex versus placebo. A preliminary multicentre study of safety and early mortality in acute myocardial infarction. diagnostic usage,ongoing research,therapeutic application,unassigned 1,4,4,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3315605&form=6&db=m Biological study of intravenous anisoylated plasminogen streptokinase activator complex in acute myocardial infarction. diagnostic usage,ongoing research,therapeutic application,unassigned 1,2,4,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3315606&form=6&db=m Comparative tolerance and complications in a multicentre trial of intracoronary streptokinase and intravenous anisoylated plasminogen streptokinase activator complex in acute myocardial infarction. ongoing research,therapeutic application,unassigned 1,4,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3315607&form=6&db=m Comparison of the safety and tolerance of intravenous anisoylated plasminogen streptokinase activator complex and intracoronary streptokinase in acute myocardial infarction. therapeutic application,unassigned 3,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3315608&form=6&db=m Safety and side effects of anisoylated plasminogen streptokinase activator complex and streptokinase in patients with acute myocardial infarction. Interim report of the IRS II Study. causal interaction,ongoing research,therapeutic application,unassigned 1,3,4,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3315609&form=6&db=m Treatment of acute myocardial infarction with anisoylated plasminogen streptokinase activator complex in a district hospital. Tolerance data. causal interaction,therapeutic application,unassigned 2,4,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3315610&form=6&db=m Safety and tolerance data from the Belgian multicentre study of anisoylated plasminogen streptokinase activator complex versus heparin in acute myocardial infarction. diagnostic usage,ongoing research,therapeutic application,unassigned 1,3,3,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3315611&form=6&db=m Preliminary safety and tolerance data obtained in the comparative study of anisoylated plasminogen streptokinase activator complex versus heparin. therapeutic application,unassigned 4,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3315612&form=6&db=m An interim report of the efficacy and safety of anisoylated plasminogen streptokinase activator complex (APSAC). causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3511819&form=6&db=m Rapid lysis of coronary artery thrombi with anisoylated plasminogen: streptokinase activator complex. Treatment by bolus intravenous injection. diagnostic usage,therapeutic application,unassigned 2,3,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3531704&form=6&db=m [Bolus injection of anisoylated plasminogen-streptokinase activator complex (BRL 26921) as an alternative concept of systemic lysis in acute myocardial infarct] causal interaction,diagnostic usage,therapeutic application,unassigned 1,1,4,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3560609&form=6&db=m [Antithrombogenic properties of the vascular walls and intravascular platelet activation in ischemic heart disease] ongoing research,unassigned 4,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3678847&form=6&db=m Thrombolytic therapy in acute myocardial infarction in the elderly. diagnostic usage,therapeutic application,unassigned 2,3,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4004989&form=6&db=m Fibrinolysis and plasminogen concentration in aortic intima in relation to death following myocardial infarction. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,1,1 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4224692&form=6&db=m [Plasmin and streptokinase in the treatment of myocardial infarction] causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4236973&form=6&db=m An evaluation of fibrinolysin therapy in acute myocardial infarction. causal interaction,diagnostic usage,therapeutic application,unassigned 3,1,4,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4237953&form=6&db=m [Various problems in the therapy of myocardial infarcts with fibrinolysin and heparin] causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4238551&form=6&db=m [State of the blood coagulation system in patients with myocardial infarct and chest pain and the changes in it during the use of anticoagulants and fibrinolysin] diagnostic usage,ongoing research,therapeutic application,unassigned 3,1,1,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4240530&form=6&db=m [Effectiveness of early use of fibrinolysin in acute myocardial infarct under conditions of emergency aid] causal interaction,diagnostic usage,therapeutic application,unassigned 2,3,3,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4261359&form=6&db=m [The effect of fibrinolysin with heparin and thrombolytin on blood coagulation indices in myocardial infarct patients with thromboembolic complications] causal interaction,ongoing research,therapeutic application,unassigned 1,1,1,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=5335302&form=6&db=m [Study on the influence of vasculo-tissular factors on coagulation and fibrinolysis. X. Release of anticoagulants and plasminogen activators after induced venous stasis and behavior of the coagulative-fibrinolytic system in subjects with recent myocardial infarct] causal interaction,ongoing research,therapeutic application,unassigned 1,2,1,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=5568386&form=6&db=m [Functional disorders of thrombocytes and fibrinase activity in patients with myocardial infarct and chronic coronary insufficiency in the stage of exacerbation] causal interaction,diagnostic usage,unassigned 3,2,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6166776&form=6&db=m [Fibrinolytic and plasmin inhibitor activities in normal subjects and patients with acute myocardial infarction (author's transl)] causal interaction,diagnostic usage,ongoing research,unassigned 3,3,2,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6223519&form=6&db=m Intracoronary thrombolysis in acute myocardial infarction. causal interaction,unassigned 2,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6450527&form=6&db=m Intracoronary thrombolysis in evolving myocardial infarction. ongoing research,therapeutic application,unassigned 1,2,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6459470&form=6&db=m Fibrinolytic and plasmin inhibitor activities in patients with acute myocardial infarction. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,2,1 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6719393&form=6&db=m A sequential study of plasma histidine-rich glycoprotein and plasminogen in patients with acute myocardial infarction and deep vein thrombosis. diagnostic usage,ongoing research,therapeutic application,unassigned 3,4,1,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6911343&form=6&db=m [Interrelation of the blood kallikrein-kinin and anticoagulation systems in experimental myocardial infarct] unassigned - 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7250787&form=6&db=m Natural inhibitors and fibrinogen/fibrin degradation products in patients with myocardial infarction. diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7520209&form=6&db=m Importance of ST-segment depression as a determinant of ventricular premature complex frequency after thrombolysis for acute myocardial infarction. Tissue Plasminogen Activator: Toronto (TPAT) Study Group. causal interaction,diagnostic usage,therapeutic application,unassigned 3,1,4,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7547005&form=6&db=m Lingual haematoma after treatment with alteplase (recombinant tissue plasminogen activator) for acute myocardial infarction. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7572648&form=6&db=m Incomplete recanalization as an important determinant of Thrombolysis in Myocardial Infarction (TIMI) grade 2 flow after thrombolytic therapy for acute myocardial infarction. TEAM Investigators. Thrombolytic Trial of Eminase in Acute Myocardial Infarction. ongoing research,therapeutic application,unassigned 1,2,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7594098&form=6&db=m One-year results of the Thrombolysis in Myocardial Infarction (TIMI) IIIB clinical trial. A randomized comparison of tissue-type plasminogen activator versus placebo and early invasive versus early conservative strategies in unstable angina and non-Q wave myocardial infarction. causal interaction,therapeutic application,unassigned 2,4,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7623907&form=6&db=m Regional variation across the United States in the management of acute myocardial infarction. GUSTO-1 Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. causal interaction,ongoing research,therapeutic application,unassigned 2,3,1,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7745771&form=6&db=m Variations in patient management and outcomes for acute myocardial infarction in the United States and other countries. Results from the GUSTO trial. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. causal interaction,diagnostic usage,therapeutic application,unassigned 1,1,2,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7775709&form=6&db=m Current issues concerning thrombolytic therapy for acute myocardial infarction. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7789372&form=6&db=m Acute myocardial infarction in the young--the role of smoking. The Investigators of the International Tissue Plasminogen Activator/Streptokinase Mortality Trial. ongoing research,unassigned 3,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7860900&form=6&db=m Angiographic predictors of reocclusion after thrombolysis: results from the Thrombolysis in Myocardial Infarction (TIMI) 4 trial. ongoing research,therapeutic application,unassigned 3,3,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7942523&form=6&db=m Concurrent nitroglycerin therapy impairs tissue-type plasminogen activator-induced thrombolysis in patients with acute myocardial infarction. causal interaction,therapeutic application,unassigned 3,3,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7960248&form=6&db=m Lipoprotein(a) levels in patients with myocardial infarction treated with anistreplase: no prediction of efficacy but inverse correlation with plasminogen activation in non-patency. therapeutic application,unassigned 1,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7994805&form=6&db=m Mortality within 24 hours of thrombolysis for myocardial infarction. The importance of early reperfusion. The GUSTO Investigators, Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. causal interaction,therapeutic application,unassigned 4,3,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7994806&form=6&db=m Activation of complement and kinin systems after thrombolytic therapy in patients with acute myocardial infarction. A comparison between streptokinase and recombinant tissue-type plasminogen activator. causal interaction,ongoing research,therapeutic application,unassigned 1,3,4,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8023469&form=6&db=m [Actilyse (a recombinant tissue-type plasminogen activator] in the treatment of acute myocardial infarct. Comparison of the effects of Actilyse and streptokinase] causal interaction,ongoing research,therapeutic application,unassigned 3,1,3,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8210941&form=6&db=m The search for the ideal thrombolytic agent: maximize the benefit and minimize the risk. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8222103&form=6&db=m After correcting for worse baseline characteristics, women treated with thrombolytic therapy for acute myocardial infarction have the same mortality and morbidity as men except for a higher incidence of hemorrhagic stroke. The Investigators of the International Tissue Plasminogen Activator/Streptokinase Mortality Study. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,2,1,4 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8277068&form=6&db=m A randomized trial of intravenous heparin in conjunction with anistreplase (anisoylated plasminogen streptokinase activator complex) in acute myocardial infarction: the Duke University Clinical Cardiology Study (DUCCS) 1. ongoing research,therapeutic application,unassigned 2,3,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8316193&form=6&db=m Coronary artery disease, myocardial infarction, and brain embolism. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8325306&form=6&db=m Depression of factor XII-dependent fibrinolytic activity in survivors of acute myocardial infarction at risk of reinfarction. ongoing research,unassigned 2,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8329574&form=6&db=m Reocclusion after thrombolytic therapy: strategies for inhibiting thrombin-induced platelet aggregation. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8352178&form=6&db=m Impact of tissue plasminogen activator and heparin versus heparin alone on quantitative coronary angiographic findings in myocardial infarction. The Toronto Tissue Plasminogen Activator Trial Study Group. causal interaction,therapeutic application,unassigned 1,3,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8354802&form=6&db=m Significance of diabetes mellitus in patients with acute myocardial infarction receiving thrombolytic therapy. Investigators of the International Tissue Plasminogen Activator/Streptokinase Mortality Trial. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,1,1,4 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8377337&form=6&db=m [A trial of the use of a new thrombolytic preparation--recombinant tissue-type plasminogen activator--in myocardial infarct patients] therapeutic application,unassigned 3,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8403295&form=6&db=m Streptokinase induces intravascular release of platelet-activating factor in patients with acute myocardial infarction and stimulates its synthesis by cultured human endothelial cells. diagnostic usage,ongoing research,therapeutic application,unassigned 2,4,2,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8419024&form=6&db=m Significance of smoking in patients receiving thrombolytic therapy for acute myocardial infarction. Experience gleaned from the International Tissue Plasminogen Activator/Streptokinase Mortality Trial. causal interaction,ongoing research,therapeutic application,unassigned 4,1,3,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8420241&form=6&db=m Comparison in acute myocardial infarction of anisoylated plasminogen streptokinase activator complex versus heparin evaluated by simultaneous thallium-201/technetium-99m pyrophosphate tomography. diagnostic usage,therapeutic application,unassigned 2,3,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8427167&form=6&db=m Comparison of results of intravenous infusion of anistreplase versus streptokinase in acute myocardial infarction. causal interaction,therapeutic application,unassigned 1,3,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8454229&form=6&db=m [Effects of intravenous administration of nasaruplase, a plasminogen pro-activator, on left ventricular function and systemic hemodynamics in a canine model of acute myocardial infarction] ongoing research,therapeutic application,unassigned 4,4,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8471185&form=6&db=m Comparative tolerability profiles of thrombolytic agents. A review. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8475860&form=6&db=m Dose-related efficacy and bleeding complications of double-chain tissue plasminogen activator in acute myocardial infarction. The Wellcome Tissue Plasminogen Activator Study Group. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,3,4 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8504575&form=6&db=m Effects of intravenous SM-9527 (double-chain tissue plasminogen activator) on left ventricular function in the chronic stage of acute myocardial infarction. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,1,4,2 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8559200&form=6&db=m Electrocardiographic diagnosis of evolving acute myocardial infarction in the presence of left bundle-branch block. GUSTO-1 (Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries) Investigators. causal interaction,diagnostic usage,therapeutic application,unassigned 1,3,2,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8665962&form=6&db=m Progress culminating from ten years of clinical trials on thrombolysis for acute myocardial infarction. GUSTO-I Steering Committee. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. causal interaction,ongoing research,therapeutic application,unassigned 1,2,2,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8675487&form=6&db=m Third generation plasminogen activators in the treatment of acute myocardial infarction. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8705778&form=6&db=m Lingual haematoma after treatment with alteplase (recombinant tissue plasminogen activator) for acute myocardial infarction. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8790022&form=6&db=m Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction. The RAPID II Investigators. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,2,3 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8853112&form=6&db=m Thrombolytic agents--an overview. therapeutic application,unassigned 4,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8976567&form=6&db=m Thermal stability of the three domains of streptokinase studied by circular dichroism and nuclear magnetic resonance. causal interaction,therapeutic application,unassigned 1,3,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9014973&form=6&db=m Coronary revascularization surgery after myocardial infarction: impact of bypass surgery on survival after thrombolysis. GUSTO Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. therapeutic application,unassigned 3,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9034237&form=6&db=m Antiinflammatory activity of tissue plasminogen activator in the carrageenan rat footpad model. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9091523&form=6&db=m Thrombolysis and Q wave versus non-Q wave first acute myocardial infarction: a GUSTO-I substudy. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries Investigators. therapeutic application,unassigned 2,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9107158&form=6&db=m Restoration of coronary flow in myocardial infarction by intravenous chimeric 7E3 antibody without exogenous plasminogen activators. Observations in animals and humans. ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9184581&form=6&db=m Incidence and predictors of bleeding after contemporary thrombolytic therapy for myocardial infarction. The Global Utilization of Streptokinase and Tissue Plasminogen activator for Occluded coronary arteries (GUSTO) I Investigators. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9201663&form=6&db=m Long-term follow-up of gender-specific outcomes after thrombolytic therapy for acute myocardial infarction from the GUSTO-I trial. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. therapeutic application,unassigned 4,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9207639&form=6&db=m Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. causal interaction,diagnostic usage,therapeutic application,unassigned 4,1,3,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9261893&form=6&db=m Characterization of plasmin-induced platelet aggregation. causal interaction,therapeutic application,unassigned 2,1,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9285181&form=6&db=m Does long-term angiotensin converting enzyme inhibition affect the concentration of tissue-type plasminogen activator-plasminogen activator inhibitor-1 in the blood of patients with a previous myocardial infarction. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9340503&form=6&db=m A comparison of reteplase with alteplase for acute myocardial infarction. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) Investigators. causal interaction,diagnostic usage,therapeutic application,unassigned 3,1,4,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9426026&form=6&db=m Acute myocardial infarction and complete bundle branch block at hospital admission: clinical characteristics and outcome in the thrombolytic era. GUSTO-I Investigators. Global Utilization of Streptokinase and t-PA [tissue-type plasminogen activator] for Occluded Coronary Arteries. causal interaction,diagnostic usage,therapeutic application,unassigned 1,2,1,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9488629&form=6&db=m Antibodies to prothrombin crossreact with plasminogen in patients developing myocardial infarction. causal interaction,diagnostic usage,unassigned 3,3,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9527072&form=6&db=m Activation of coagulation and fibrinolysis after rehabilitative exercise in patients with coronary artery disease. diagnostic usage,unassigned 3,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9579244&form=6&db=m The safety of automatic versus manual blood pressure cuffs for patients receiving thrombolytic therapy. ongoing research,therapeutic application,unassigned 3,3,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9581714&form=6&db=m Clinical experience with primary percutaneous transluminal coronary angioplasty compared with alteplase (recombinant tissue-type plasminogen activator) in patients with acute myocardial infarction: a report from the Second National Registry of Myocardial Infarction (NRMI-2). causal interaction,diagnostic usage,ongoing research,therapeutic application 1,1,1,3 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9605045&form=6&db=m Higher T-wave amplitude associated with better prognosis in patients receiving thrombolytic therapy for acute myocardial infarction (a GUSTO-I substudy). Global Utilization of Streptokinase and Tissue plasminogen Activator for Occluded Coronary Arteries. causal interaction,diagnostic usage,therapeutic application,unassigned 4,1,4,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9725961&form=6&db=m [Fibrinolysis or angioplasty in acute myocardial infarction?] causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9733226&form=6&db=m Lipoprotein(a) and the significance of the association between platelet glycoprotein IIIa polymorphisms and the risk of premature myocardial infarction. causal interaction,diagnostic usage,unassigned 4,3,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9843458&form=6&db=m Thrombolytic therapy in acute myocardial infarction: comparison of procoagulant effects of streptokinase and alteplase regimens with focus on the kallikrein system and plasmin. ongoing research,therapeutic application,unassigned 3,4,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9875108&form=6&db=m Prevalence of factor V Leiden (APCR) and other inherited thrombophilias in young patients with myocardial infarction and normal coronary arteries. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,1,3,1 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9918523&form=6&db=m Effects of stroke on medical resource use and costs in acute myocardial infarction. GUSTO I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries Study. ongoing research,therapeutic application,unassigned 3,2,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10150180&form=6&db=m A double-blind randomised dose-effect trial of anisoylated plasminogen streptokinase activator complex (APSAC) in acute myocardial infarction. The APSAC Research Group. therapeutic application,unassigned 2,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10231672&form=6&db=m [An economic assessment of the use of abciximab as a coronary angioplasty preparation in the Italian health-care context] diagnostic usage,unassigned 1,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10474793&form=6&db=m Impairment of the blood-brain barrier: a potential surrogate delineating the determinants of cerebral bleeding caused by fibrinolytic drugs. causal interaction,ongoing research,therapeutic application,unassigned 1,3,2,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10559822&form=6&db=m Spinal epidural hematoma associated with tissue plasminogen activator treatment of acute myocardial infarction. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10621877&form=6&db=m Circadian fluctuations in the efficacy of thrombolysis with streptokinase. diagnostic usage,ongoing research,therapeutic application,unassigned 2,1,4,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10847427&form=6&db=m Textilinins from Pseudonaja textilis textilis. Characterization of two plasmin inhibitors that reduce bleeding in an animal model. therapeutic application,unassigned 4,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10854210&form=6&db=m Disruption of the plasminogen gene in mice abolishes wound healing after myocardial infarction. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,2,4,2 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10922430&form=6&db=m Fibrin specificity and procoagulant effect related to the kallikrein-contact phase system and to plasmin generation with double-bolus reteplase and front-loaded alteplase thrombolysis in acute myocardial infarction. ongoing research,therapeutic application,unassigned 4,2,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10938026&form=6&db=m Plasma levels of tissue plasminogen activator/plasminogen activator inhibitor-1 complex and von Willebrand factor are significant risk markers for recurrent myocardial infarction in the Stockholm Heart Epidemiology Program (SHEEP) study. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,2,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11269778&form=6&db=m Comparative efficacy of primary angioplasty with stent implantation and thrombolysis in restoring basal coronary artery flow in acute ST segment elevation myocardial infarction: quantitative assessment using the corrected TIMI frame count. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,1,3,2 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11479462&form=6&db=m A randomized trial confirming the efficacy of reduced dose recombinant tissue plasminogen activator in a Chinese myocardial infarction population and demonstrating superiority to usual dose urokinase: the TUCC trial. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11485970&form=6&db=m Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure? causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11567669&form=6&db=m The thrombolytic paradox. unassigned - 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11816707&form=6&db=m Imbalance of plasminogen activator inhibitor-I/ tissue plasminogen activator and tissue factor/tissue factor pathway inhibitor in young Japanese men with myocardial infarction. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,1,2,2 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11916074&form=6&db=m Antibodies to factor XII are distinct from antibodies to prothrombin in patients with the anti-phospholipid syndrome. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,1,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12109870&form=6&db=m Prolonged low-dose thrombolytic therapy: a novel adjunctive strategy in the management of an infected right atrial thrombus. unassigned - 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12738971&form=6&db=m Tenecteplase (TNK tissue plasminogen activator): A new fibrinolytic for the acute treatment of myocardial infarction. causal interaction,diagnostic usage,therapeutic application,unassigned 1,1,4,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12871223&form=6&db=m The membrane attack complex of complement contributes to plasmin-induced synthesis of platelet-activating factor by endothelial cells and neutrophils. ongoing research,unassigned 2,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=13803175&form=6&db=m Segmental perfusion of the coronary arteries with fibrinolysin in man following a myocardial infarction. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=13815624&form=6&db=m The fibrinolytic system and use of fibrinolysin in myocardial infarction; preliminary report. therapeutic application,unassigned 3,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14025213&form=6&db=m Value of fibrinolysin in management of myocardial infarction. A preliminary report. causal interaction,diagnostic usage,therapeutic application,unassigned 2,1,2,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14291859&form=6&db=m [STUDY OF THE EFFECTIVENESS OF THE USE OF FIBRINOLYSIN IN MYOCARDIAL INFARCT.] diagnostic usage,ongoing research,therapeutic application,unassigned 3,2,2,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14492041&form=6&db=m Thrombolysin therapy in myocardial infarction. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14537155&form=6&db=m Tissue-type plasminogen activator: characteristics, applications and production technology. causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,4,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14570069&form=6&db=m [A 50-year history of new drugs in Japan-the development and trends of hemostatics and antithrombotic drugs] diagnostic usage,therapeutic application,unassigned 3,3,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14691435&form=6&db=m Association between plasmin activation system and intravascular ultrasound signs of plaque instability in patients with unstable angina and non-st-segment elevation myocardial infarction. causal interaction,diagnostic usage,unassigned 4,1,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15077097&form=6&db=m Clinical outcome of percutaneous coronary intervention with antecedent mutant t-PA administration for acute myocardial infarction. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,1,3,1 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15102005&form=6&db=m Tissue-type plasminogen activator: a historical perspective and personal account. causal interaction,ongoing research,therapeutic application,unassigned 3,2,2,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15258347&form=6&db=m Improving thrombolysis with encapsulated plasminogen activators and clinical relevance to myocardial infarction and stroke. therapeutic application,unassigned 2,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15304049&form=6&db=m A proposed reference method for plasminogen activators that enables calculation of enzyme activities in SI units. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15792348&form=6&db=m Reduction of myocardial infarct size by doxycycline: a role for plasmin inhibition. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15943975&form=6&db=m Understanding the enzymology of fibrinolysis and improving thrombolytic therapy. causal interaction,therapeutic application,unassigned 3,2,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16055345&form=6&db=m Production and purification of urokinase: a comprehensive review. causal interaction,therapeutic application,unassigned 3,3,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16706983&form=6&db=m Increase in plasma plasminogen activators inhibitor type 1 concentration after fibrinolytic treatment in patients with acute myocardial infarction is associated with 4G/5G polymorphism of PAI-1 gene. causal interaction,diagnostic usage,therapeutic application,unassigned 3,3,1,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16708124&form=6&db=m Monitoring of plasmin and plasminogen activator activity in blood of patients under fibrinolytic treatment by reteplase. therapeutic application,unassigned 2,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17315612&form=6&db=m [Haemostatic and inflammation markers in acute coronary syndromes and its relationship with adverse cardiovascular events] causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17616171&form=6&db=m Regulation of nonproteolytic active site formation in plasminogen. unassigned - 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18160581&form=6&db=m Monitoring of Functional Plasminogen in Blood of Patients Receiving Fibrinolytics. diagnostic usage,ongoing research,therapeutic application,unassigned 3,1,1,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18688814&form=6&db=m Effects of Bulbus allii macrostemi on clinical outcomes and oxidized low-density lipoprotein and plasminogen in unstable angina/non-ST-segment elevation myocardial infarction patients. causal interaction,unassigned 1,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19100068&form=6&db=m [Clinical features in 65 patients with acute myocardial infarction underwent successful thrombolytic therapy post cardiopulmonary resuscitation] causal interaction,ongoing research,therapeutic application,unassigned 1,1,3,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19552570&form=6&db=m Thrombin activity throughout the acute phase of acute ST-elevation myocardial infarction and the relation to outcome. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,2,4 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19605778&form=6&db=m The tissue-type plasminogen activator story. causal interaction,ongoing research,therapeutic application,unassigned 1,4,4,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20413657&form=6&db=m Plasma levels of fibrinolytic proteins and the risk of myocardial infarction in men. causal interaction,diagnostic usage,therapeutic application,unassigned 1,1,1,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20625277&form=6&db=m Plasmin-induced procoagulant effects in the blood coagulation: a crucial role of coagulation factors V and VIII. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,4,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20807543&form=6&db=m Critical role for white blood cell NAD(P)H oxidase-mediated plasminogen activator inhibitor-1 oxidation and ventricular rupture following acute myocardial infarction. causal interaction,therapeutic application,unassigned 3,2,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21239343&form=6&db=m Antiplatelet and anticoagulant therapy during coronary thrombolysis. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22497821&form=6&db=m Oxidized phospholipids are present on plasminogen, affect fibrinolysis, and increase following acute myocardial infarction. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22538774&form=6&db=m Fibrinolytic status in acute coronary syndromes: evidence of differences in relation to clinical features and pathophysiological pathways. causal interaction,diagnostic usage,therapeutic application,unassigned 1,2,2,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24681141&form=6&db=m Plasminogen regulates cardiac repair after myocardial infarction through its non-canonical function in stem cell homing to the infarcted heart. causal interaction,ongoing research,therapeutic application,unassigned 1,2,3,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24954109&form=6&db=m Effect of post-solubilization conditions on the yield and efficiency of recombinant streptokinase purification at large-scale. causal interaction,therapeutic application,unassigned 3,3,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25143123&form=6&db=m Expression of a novel chimeric-truncated tPA in Pichia pastoris with improved biochemical properties. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26510751&form=6&db=m Circulating levels of plasminogen and oxidized phospholipids bound to plasminogen distinguish between atherothrombotic and non-atherothrombotic myocardial infarction. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,1,1,2 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26909366&form=6&db=m Structural basis of specific inhibition of tissue-type plasminogen activator by plasminogen activators inhibitor-1. causal interaction,therapeutic application,unassigned 1,3,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27680848&form=6&db=m Anti-clotting drugs best in afternoon. causal interaction,diagnostic usage,therapeutic application,unassigned 1,1,1,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28116631&form=6&db=m Translational initiatives in thrombolytic therapy. therapeutic application,unassigned 3,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28633085&form=6&db=m Biotechnological production of recombinant tissue plasminogen activator protein (reteplase) from transplastomic tobacco cell cultures. therapeutic application,unassigned 2,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28843245&form=6&db=m An Uncommon Complication of Streptokinase: Large Spontaneous Iliopsoas Hematoma. causal interaction,therapeutic application,unassigned 3,2,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30712409&form=6&db=m Making a case for the right "-ase" in acute ischemic stroke: alteplase, tenecteplase, and reteplase. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31436141&form=6&db=m Intravenous Thrombolysis for Acute Ischemic Stroke After Recent Myocardial Infarction: Case Series and Systematic Review. causal interaction,therapeutic application,unassigned 3,3,0 3.4.21.7 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32598807&form=6&db=m [Fibrinolytics: from the thrombolysis to the processes of blood vessels growth and remodeling, neurogenesis, carcinogenesis and fibrosis]. causal interaction,therapeutic application,unassigned 2,3,0 3.4.21.7 Myocardial Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=477957&form=6&db=m [Effect of agents used in the therapy of acute ischemic heart disease on the histomorphological changes in the myocardium in acute dystrophy] causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.7 Myocardial Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2119264&form=6&db=m Validity of enzyme-linked immunosorbent assays of cross-linked fibrin degradation products as a measure of clot lysis. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,3,1 3.4.21.7 Myocardial Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9011833&form=6&db=m [Lipoprotein (a) and plasminogen in atherosclerosis] causal interaction,diagnostic usage,ongoing research,unassigned 3,2,1,0 3.4.21.7 Myocardial Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10684070&form=6&db=m [Changes of serum TNF-alpha level, t-PA activivty and PAI activity in patients with silent myocardial ischemia or silent cerebral ischemia] diagnostic usage,ongoing research,unassigned 4,2,0 3.4.21.7 Myocardial Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12494145&form=6&db=m [Gender differences in the state of the system of hemostasis in patients with ischemic heart disease] ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.7 Myocardial Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15850606&form=6&db=m The impact of cardiac ischemia and reperfusion on markers of activated haemostasis and fibrinolysis during cardiopulmonary bypass: comparison of plasma levels in arterial and coronary venous blood. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,1 3.4.21.7 Myocardial Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19593116&form=6&db=m Acute myocardial ischemia in a patient with heterozygous alpha-2-plasmin inhibitor deficiency. causal interaction,unassigned 4,0 3.4.21.7 Myocardial Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20380835&form=6&db=m The role of macrophage-derived urokinase plasminogen activator in myocardial infarct repair Urokinase attenuates ventricular remodeling. causal interaction,therapeutic application,unassigned 3,2,0 3.4.21.7 Myocarditis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19957712&form=6&db=m [Fermental (plasmin) blood system in patients with acute viral myocarditis] causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,2,0 3.4.21.7 Myoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19593113&form=6&db=m The relationship between urokinase plasminogen activator/plasminogen activator inhibitor type-1 expression in myoma/myometrium and mechanism of uterine artery occlusion by laparoscopy for uterine myoma treatment. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,3,3,3 3.4.21.7 Myopia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33888814&form=6&db=m The plasminogen protein is associated with high myopia as revealed by the iTRAQ-based proteomic analysis of the aqueous humor. causal interaction,diagnostic usage,unassigned 2,2,0 3.4.21.7 Myotonic Dystrophy http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=132455&form=6&db=m Assay of pig growth hormone preparations for metabolic activities in the rat and in man. ongoing research,unassigned 2,0 3.4.21.7 Myxoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8416956&form=6&db=m Inhibition of plasmin, urokinase, tissue plasminogen activator, and C1S by a myxoma virus serine proteinase inhibitor. causal interaction,therapeutic application,unassigned 2,4,0 3.4.21.7 Myxoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11077219&form=6&db=m Transplant vasculopathy: viral anti-inflammatory serpin regulation of atherogenesis. therapeutic application,unassigned 1,0 3.4.21.7 Myxoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16525579&form=6&db=m Myxoma viral serpin, Serp-1, a unique interceptor of coagulation and innate immune pathways. ongoing research,unassigned 2,0 3.4.21.7 Myxoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20135065&form=6&db=m Neuroserpin, a thrombolytic serine protease inhibitor (serpin), blocks transplant vasculopathy with associated modification of T-helper cell subsets. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.7 Nasal Polyps http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9532638&form=6&db=m Plasminogen activators in human nasal polyps and mucosa. diagnostic usage,ongoing research,unassigned 1,4,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=769099&form=6&db=m Anticoagulants and cancer. A review. ongoing research,therapeutic application,unassigned 1,1,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1354271&form=6&db=m Tetranectin, a plasminogen kringle 4-binding protein. Cloning and gene expression pattern in human colon cancer. causal interaction,ongoing research,therapeutic application,unassigned 4,3,2,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1384825&form=6&db=m Effect of aprotinin on metastasis of Lewis lung tumor in mice. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,1,4,1 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1515091&form=6&db=m Tumor-associated urokinase-type plasminogen activator: biological and clinical significance. causal interaction,ongoing research,unassigned 3,3,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1730515&form=6&db=m Type-1 plasminogen activator inhibitor in human breast carcinomas. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,4,1 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1801751&form=6&db=m Biological and clinical relevance of the urokinase-type plasminogen activator (uPA) in breast cancer. causal interaction,diagnostic usage,ongoing research,unassigned 3,4,2,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1902292&form=6&db=m Heterogeneity in plasminogen activator (PA) levels in human prostate cancer cell lines: increased PA activity correlates with biologically aggressive behavior. causal interaction,diagnostic usage,ongoing research,unassigned 4,1,3,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1955118&form=6&db=m Imbalance of plasminogen activators and their inhibitors in human colorectal neoplasia. Implications of urokinase in colorectal carcinogenesis. causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,2,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1966799&form=6&db=m Influence of urokinase on cell proliferation and invasion. causal interaction,unassigned 1,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2133250&form=6&db=m Tumour-associated fibrinolysis: the prognostic relevance of plasminogen activators uPA and tPA in human breast cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,3,1 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2142402&form=6&db=m Dexamethasone-induced plasminogen activator inhibitor: characterization, purification, and preparation of monoclonal antibodies. causal interaction,ongoing research,unassigned 1,1,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2151710&form=6&db=m The elastase-mediated pathway of fibrinolysis. causal interaction,unassigned 3,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2151734&form=6&db=m Urokinase-dependent cell surface proteolysis and cancer. causal interaction,diagnostic usage,ongoing research,unassigned 1,3,3,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2433233&form=6&db=m The plasmin system in human adenocarcinomas and their metastases. A comparative immunofluorescence study. causal interaction,diagnostic usage,ongoing research,unassigned 3,3,4,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2541259&form=6&db=m Mechanisms of cellular invasiveness: a comparison of amnion invasion in vitro and metastatic behavior in vivo. diagnostic usage,unassigned 3,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2692282&form=6&db=m [Role of plasminogen activators in the development of tumors and the process of their metastasis] causal interaction,ongoing research,unassigned 4,2,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2747645&form=6&db=m Expression of human recombinant plasminogen activators enhances invasion and experimental metastasis of H-ras-transformed NIH 3T3 cells. ongoing research,unassigned 4,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2963689&form=6&db=m Modulation of metastatic potential by cell surface urokinase of murine melanoma cells. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,2,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2976309&form=6&db=m Plasminogen activation: biochemistry, physiology, and therapeutics. causal interaction,unassigned 3,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3524801&form=6&db=m Inhibition of proteolytic enzymes in the in vitro amnion model for basement membrane invasion. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3596983&form=6&db=m Correlation of fibrinolytic activity with invasion and metastasis of R3230 AC rat mammary carcinoma cell lines. unassigned - 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3855489&form=6&db=m Proteolytic enzymes in tumor metastasis. I. Plasminogen activator in clones of Lewis lung carcinoma and T10 sarcoma. diagnostic usage,ongoing research,unassigned 1,3,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6312282&form=6&db=m Hormonal regulation of plasminogen activator in rat hepatoma cells. causal interaction,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6348494&form=6&db=m The role of plasminogen activators in metastasis. causal interaction,unassigned 3,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6393101&form=6&db=m [Role of proteases, plasminogen activators, fibrin fibrinogen degradation products and fibrinopeptides in the growth and development of neoplasms and neoplasm metastases] unassigned - 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7525077&form=6&db=m Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. causal interaction,diagnostic usage,therapeutic application,unassigned 3,3,1,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7548000&form=6&db=m Chemical modification of the urokinase-type plasminogen activator and its receptor using tetranitromethane. Evidence for the involvement of specific tyrosine residues in both molecules during receptor-ligand interaction. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7671626&form=6&db=m Tissue-type plasminogen activator-induced invasion and metastasis of murine melanomas. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,1,3,1 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7707177&form=6&db=m [Immunohistological study of fibrinolytic factors of head and neck squamous cell carcinomas] unassigned - 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7713945&form=6&db=m Inhibitory effect of a conjugate between human urokinase and urinary trypsin inhibitor on tumor cell invasion in vitro. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,4,1 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7718296&form=6&db=m [Determination of plasminogen activator of the head and neck tumor tissue] causal interaction,diagnostic usage,ongoing research,unassigned 4,3,3,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7728751&form=6&db=m Inhibition of tumor cell invasion through matrigel by a peptide derived from the domain II region in urinary trypsin inhibition. causal interaction,ongoing research,unassigned 4,3,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7737909&form=6&db=m Localization of urokinase-type plasminogen activator, plasminogen activator inhibitor-1, 2 and plasminogen in colon cancer. causal interaction,ongoing research,therapeutic application,unassigned 3,3,3,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7803712&form=6&db=m Metastasis of human colon tumor cells in vivo: correlation with the overexpression of plasminogen activators and 72 kDa gelatinase. causal interaction,ongoing research,unassigned 3,4,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7841059&form=6&db=m Plasminogen activators and inhibitor type 1 in neoplastic colonic tissue from patients with familial adenomatous polyposis. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,4,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7926508&form=6&db=m Inactive urokinase and increased levels of its inhibitor type 1 in colorectal cancer liver metastasis. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,4,2 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8033138&form=6&db=m Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,4,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8051163&form=6&db=m Characterization of the cellular binding site for the urinary trypsin inhibitor. causal interaction,ongoing research,therapeutic application,unassigned 3,1,4,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8140655&form=6&db=m Urokinase-type plasminogen activator and its receptor: new targets for anti-metastatic therapy? causal interaction,ongoing research,unassigned 4,3,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8140679&form=6&db=m Plasminogen activators and plasminogen activator inhibitor 1 in urinary tract cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,3,4 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8227186&form=6&db=m Expression and localization of elements of the plasminogen activation system in benign breast disease and breast cancers. causal interaction,ongoing research,therapeutic application,unassigned 4,4,2,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8261421&form=6&db=m Inhibition of invasion of HT1080 sarcoma cells expressing recombinant plasminogen activator inhibitor 2. causal interaction,ongoing research,therapeutic application,unassigned 4,3,3,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8291613&form=6&db=m Plasminogen activators, their inhibitors, and urokinase receptor emerge in late stages of melanocytic tumor progression. causal interaction,ongoing research,therapeutic application,unassigned 4,4,3,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8306348&form=6&db=m Inhibition of the soluble and the tumor cell receptor-bound plasmin by urinary trypsin inhibitor and subsequent effects on tumor cell invasion and metastasis. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,4,3 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8362987&form=6&db=m Activation of hepatocyte growth factor by the plasminogen activators uPA and tPA. causal interaction,unassigned 3,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8436596&form=6&db=m Extracellular matrix produced by cultured corneal and aortic endothelial cells contains active tissue-type and urokinase-type plasminogen activators. causal interaction,unassigned 3,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8503981&form=6&db=m Molecular mechanisms of protease-mediated tumor invasiveness. diagnostic usage,ongoing research,unassigned 3,1,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8567114&form=6&db=m Phorbol-ester-stimulated human lymphoid cell lines produce a plasminogen activator modulator inducing cell-bound urokinase-type plasminogen activator in malignant tumor cell lines. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,4,1 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8615674&form=6&db=m Plasminogen activation system in active even in thyroid tumors; an immunohistochemical study. causal interaction,ongoing research,therapeutic application,unassigned 4,4,2,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8635120&form=6&db=m Prognostic value of the plasminogen activation system in patients with gastric carcinoma. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,1 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8674284&form=6&db=m Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,4,4 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8703368&form=6&db=m Expression of urokinase-type plasminogen activator, its receptor, and its inhibitor in gastric adenocarcinoma tissues. causal interaction,ongoing research,therapeutic application,unassigned 3,1,1,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8758932&form=6&db=m Induction of primary cutaneous melanocytic neoplasms in urokinase-type plasminogen activator (uPA)-deficient and wild-type mice: cellular blue nevi invade but do not progress to malignant melanoma in uPA-deficient animals. causal interaction,ongoing research,unassigned 4,2,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8774480&form=6&db=m Tetranectin and plasmin/plasminogen are similarly distributed at the invasive front of cutaneous melanoma lesions. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,4,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8808830&form=6&db=m [Mechanism of tumor cell-induced extracellular matrix degradation--inhibition of cell-surface proteolytic activity might have a therapeutic effect on tumor cell invasion and metastasis] causal interaction,ongoing research,therapeutic application,unassigned 3,3,4,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8814995&form=6&db=m Different roles for plasminogen activators and metalloproteinases in melanoma metastasis. diagnostic usage,ongoing research,unassigned 3,4,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8822588&form=6&db=m Inhibitory effect of a synthetic prostacyclin analogue, beraprost, on urokinase-type plasminogen activator expression in RC-K8 human lymphoma cells. causal interaction,ongoing research,unassigned 4,4,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8880873&form=6&db=m The plasminogen activation system in tumour invasion and metastasis. causal interaction,ongoing research,therapeutic application,unassigned 1,3,4,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8980909&form=6&db=m Urinary trypsin inhibitor efficiently inhibits urokinase production in tumor necrosis factor-stimulated cells. ongoing research,therapeutic application,unassigned 4,2,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9002223&form=6&db=m Angiostatin: an endogenous inhibitor of angiogenesis and of tumor growth. causal interaction,diagnostic usage,unassigned 3,3,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9096588&form=6&db=m Expression of urokinase-type plasminogen activator receptor in hepatocellular carcinoma. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,4,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9198168&form=6&db=m Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,4,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9212216&form=6&db=m The urokinase-type plasminogen activator system in cancer metastasis: a review. therapeutic application,unassigned 1,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9252380&form=6&db=m Generation of angiostatin by reduction and proteolysis of plasmin. Catalysis by a plasmin reductase secreted by cultured cells. causal interaction,unassigned 4,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9271229&form=6&db=m Defective cell migration in an ovarian cancer cell line is associated with impaired urokinase-induced tyrosine phosphorylation. ongoing research,therapeutic application,unassigned 2,2,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9323150&form=6&db=m Localization of plasminogen activators and their inhibitor in squamous cell carcinomas of the head and neck. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,4,1 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9326241&form=6&db=m Inhibition of metastasis of intraocular melanomas by adenovirus-mediated gene transfer of plasminogen activator inhibitor type 1 (PAI-1) in an athymic mouse model. causal interaction,ongoing research,therapeutic application,unassigned 3,3,3,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9330225&form=6&db=m Limited proteolysis of angiogenin by elastase is regulated by plasminogen. unassigned - 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9337523&form=6&db=m Proteolytic enzymes in proliferation and neoplastic metastases formation. causal interaction,unassigned 2,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9373263&form=6&db=m Growth and dissemination of Lewis lung carcinoma in plasminogen-deficient mice. causal interaction,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9380726&form=6&db=m The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin. ongoing research,therapeutic application,unassigned 3,1,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9422083&form=6&db=m Inhibitory effect of amiloride on the urokinase plasminogen activators in prostatic cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,3,4,1 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9454229&form=6&db=m [Tissue and urokinase plasminogen activators (t-PA, u-PA) and their inhibitor PAI-1 in blood of patients with laryngeal neoplasms] ongoing research,therapeutic application,unassigned 4,2,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9496254&form=6&db=m Cellular localization of urokinase-type plasminogen activator, its inhibitors, and their mRNAs in breast cancer tissues. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,2,4,1 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9524767&form=6&db=m Met-HGF/SF: tumorigenesis, invasion and metastasis. causal interaction,unassigned 1,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9528837&form=6&db=m Prognostic significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in primary breast cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,4,2 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9540288&form=6&db=m Cancer metastasis: biological and clinical aspects. causal interaction,diagnostic usage,unassigned 4,2,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9641882&form=6&db=m Molecular pattern of ductal pancreatic cancer. causal interaction,unassigned 4,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9671388&form=6&db=m Reduced metastasis of Polyoma virus middle T antigen-induced mammary cancer in plasminogen-deficient mice. causal interaction,diagnostic usage,ongoing research,unassigned 4,1,2,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9703913&form=6&db=m Guanidinobenzoatase and UPA in high-grade human astrocytomas and after xenografting cell suspensions into the rat cerebral cortex: proteases for metastasis and disease progression. unassigned - 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9714330&form=6&db=m The field bean protease inhibitor has the potential to suppress B16F10 melanoma cell lung metastasis in mice. causal interaction,ongoing research,therapeutic application,unassigned 3,4,4,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9772277&form=6&db=m Multifunctional potential of the plasminogen activation system in tumor invasion and metastasis (review). causal interaction,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9815990&form=6&db=m Cleavage of MĂĽllerian inhibiting substance activates antiproliferative effects in vivo. therapeutic application,unassigned 1,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9849413&form=6&db=m Quality control of immunohistochemical evaluation of tumour-associated plasminogen activators and related components. European BIOMED-1 Concerted Action on Clinical Relevance of Proteases in Tumour Invasion and Metastasis. diagnostic usage,unassigned 3,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9857663&form=6&db=m [Urokinase plasminogen activator /U-PA/in blood of patients with lung cancer] causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,2 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10094378&form=6&db=m Urokinase and plasminogen activator-inhibitor (PAI-1) status in primary ovarian carcinomas and ovarian metastases compared to benign ovarian tumors as a function of histopathological parameters. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,3,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10211984&form=6&db=m Expression and localization of urokinase-type plasminogen activator in human spinal column tumors. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,4,2 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10340907&form=6&db=m Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis. causal interaction,diagnostic usage,ongoing research,unassigned 3,4,3,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10347197&form=6&db=m Activation mechanisms of the urokinase-type plasminogen activator promoter by hepatocyte growth factor/scatter factor. causal interaction,unassigned 2,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10357086&form=6&db=m The role of the plasminogen activation system in cancer. causal interaction,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10390151&form=6&db=m Invasion by esophageal cancer cells: functional contribution of the urokinase plasminogen activation system, and inhibition by antisense oligonucleotides to urokinase or urokinase receptor. causal interaction,ongoing research,therapeutic application,unassigned 4,3,2,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10425106&form=6&db=m 4-Heterocyclohexanone-based inhibitors of the serine protease plasmin. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10487126&form=6&db=m [The clinical prospects for the study of the plasminogen activation system in breast cancer] causal interaction,diagnostic usage,ongoing research,unassigned 4,3,3,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10489782&form=6&db=m [The role of cathepsins and the plasminogen activator/inhibitor system in colorectal cancer] causal interaction,diagnostic usage,ongoing research,unassigned 3,4,4,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10496343&form=6&db=m Soluble urokinase receptor released from human carcinoma cells: a plasma parameter for xenograft tumour studies. causal interaction,diagnostic usage,ongoing research,unassigned 3,1,4,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10512718&form=6&db=m Structure of the complex of the antistasin-type inhibitor bdellastasin with trypsin and modelling of the bdellastasin-microplasmin system. causal interaction,therapeutic application,unassigned 4,2,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10524570&form=6&db=m Degradation of extracellular matrix by metastatic follicular thyroid carcinoma cell lines: role of the plasmin activation system. causal interaction,ongoing research,unassigned 4,4,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10604721&form=6&db=m Generation of angiostatin-like fragments from plasminogen by prostate-specific antigen. diagnostic usage,ongoing research,therapeutic application,unassigned 3,3,2,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10704735&form=6&db=m Correlation of tissue and blood plasminogen activation system in breast cancer. causal interaction,ongoing research,therapeutic application,unassigned 3,3,2,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10737043&form=6&db=m [The role of proteolytic enzymes in skin neoplasm progression and development of metastasis] causal interaction,diagnostic usage,unassigned 3,3,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10763146&form=6&db=m Long-term follow-up confirms prognostic impact of PAI-1 and cathepsin D and L in primary breast cancer. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10824888&form=6&db=m Clinical significance of urokinase-type plasminogen activator activity in hepatocellular carcinoma. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,1 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10949579&form=6&db=m The plasminogen activation system in tumor growth, invasion, and metastasis. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11008205&form=6&db=m Urokinase-type plasminogen activator and its receptor in colorectal cancer: independent prognostic factors of metastasis and cancer-specific survival and potential therapeutic targets. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,2,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11012100&form=6&db=m Clinical evidence for correlation of insufficient tissue oxygen supply (hypoxia) and tumor-associated proteolysis in squamous cell carcinoma of the head and neck. causal interaction,unassigned 4,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11027463&form=6&db=m Significance of coexpression of urokinase-type plasminogen activator, and matrix metalloproteinase 3 (stromelysin) and 9 (gelatinase B) in colorectal carcinoma. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,3,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11062719&form=6&db=m Prognostic relevance of urokinase type plasminogen activator, its receptor and inhibitors in chondrosarcoma. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,4,3 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11071621&form=6&db=m Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,3,4 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11136569&form=6&db=m Clinical relevance of urokinase-type plasminogen activator, its receptor, and its inhibitor type 1 in endometrial cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,2,4 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11223863&form=6&db=m The role and regulation of urokinase-type plasminogen activator receptor gene expression in cancer invasion and metastasis. causal interaction,unassigned 4,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11241411&form=6&db=m VEGF-B expression in human primary breast cancers is associated with lymph node metastasis but not angiogenesis. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,4,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11278833&form=6&db=m Targeting of tumor cells by cell surface urokinase plasminogen activator-dependent anthrax toxin. causal interaction,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11284727&form=6&db=m Interaction of plasminogen with dipeptidyl peptidase IV initiates a signal transduction mechanism which regulates expression of matrix metalloproteinase-9 by prostate cancer cells. causal interaction,diagnostic usage,ongoing research,unassigned 3,1,2,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11304683&form=6&db=m Dedifferentiation of serous ovarian cancer from cystic to solid tumors is associated with increased expression of mRNA for urokinase plasminogen activator (uPA), its receptor (uPAR) and its inhibitor (PAI-1). causal interaction,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11342530&form=6&db=m Identification of a target site in plasminogen activator inhibitor-1 that allows neutralization of its inhibitor properties concomitant with an allosteric up-regulation of its antiadhesive properties. causal interaction,therapeutic application,unassigned 4,3,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11376560&form=6&db=m Urokinase receptor and vascular endothelial growth factor are synergistically associated with the liver metastasis of colorectal cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,2,1,1 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11382594&form=6&db=m The role of the plasminogen activation system in angiogenesis and metastasis. causal interaction,unassigned 4,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11393999&form=6&db=m [Extracellular matrix degradation enzymes: important factors in liver metastasis of colorectal cancer and good targets for anticancer metastatic therapy] causal interaction,ongoing research,unassigned 3,1,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11555588&form=6&db=m The accumulation of angiostatin-like fragments in human prostate carcinoma. diagnostic usage,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11556845&form=6&db=m The topology of plasminogen binding and activation on the surface of human breast cancer cells. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,4,1 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11727504&form=6&db=m Interference with the urokinase plasminogen activator system: a promising therapy concept for solid tumours. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11742690&form=6&db=m Bacterial plasminogen activators and receptors. therapeutic application,unassigned 2,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11916069&form=6&db=m The mechanism of action of angiostatin: can you teach an old dog new tricks? causal interaction,unassigned 2,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11930939&form=6&db=m uPA-silica-Particles (SP-uPA): a novel analytical system to investigate uPA-uPAR interaction and to test synthetic uPAR antagonists as potential cancer therapeutics. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11970751&form=6&db=m Selection criteria for epirubicin-based adjuvant chemotherapy in node-negative breast cancer. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12014682&form=6&db=m u-PA expression in benign, borderline and malignant ovarian tumors. causal interaction,unassigned 4,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12023849&form=6&db=m Cellular mechanisms regulating non-haemostatic plasmin generation. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12085967&form=6&db=m The urokinase-type plasminogen activator system in prostate cancer metastasis. causal interaction,diagnostic usage,unassigned 4,2,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12142386&form=6&db=m Quantitative real-time reverse transcription-PCR assay for urokinase plasminogen activator, plasminogen activator inhibitor type 1, and tissue metalloproteinase inhibitor type 1 gene expressions in primary breast cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,4,1 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12210068&form=6&db=m Spitz naevi may express components of the plasminogen activation system. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,1,3 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12431980&form=6&db=m Secretion of Annexin II via activation of insulin receptor and insulin-like growth factor receptor. ongoing research,unassigned 3,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12456318&form=6&db=m Regulation of plasminogen receptors. causal interaction,unassigned 4,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12481411&form=6&db=m Design, synthesis, and biological evaluation of a dual tumor-specific motive containing integrin-targeted plasmin-cleavable doxorubicin prodrug. causal interaction,unassigned 3,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12529357&form=6&db=m Anti-angiogenic activity of the recombinant kringle domain of urokinase and its specific entry into endothelial cells. causal interaction,unassigned 3,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12569552&form=6&db=m Suppression of invasion and peritoneal carcinomatosis of ovarian cancer cell line by overexpression of bikunin. causal interaction,therapeutic application,unassigned 3,3,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12680193&form=6&db=m Reduced secretion of MMPs, plasminogen activators and TIMPS from prostate cancer cells derived by repeated metastasis. diagnostic usage,unassigned 3,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12700073&form=6&db=m Plasminogen binding and cancer: promises and pitfalls. causal interaction,diagnostic usage,unassigned 4,3,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12736046&form=6&db=m Association of plasma urokinase-type plasminogen activator and its receptor with clinical outcome in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,3,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12783107&form=6&db=m Posttranscriptional regulation of PAI-1 gene expression. causal interaction,unassigned 3,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12784997&form=6&db=m The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy. causal interaction,diagnostic usage,therapeutic application,unassigned 3,2,4,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12853975&form=6&db=m Metastasis of transgenic breast cancer in plasminogen activator inhibitor-1 gene-deficient mice. causal interaction,ongoing research,therapeutic application,unassigned 4,2,1,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12871066&form=6&db=m Urokinase-type plasminogen activator (uPA) and its receptor (uPAR): development of antagonists of uPA/uPAR interaction and their effects in vitro and in vivo. causal interaction,unassigned 4,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=13509544&form=6&db=m Circulating fibrinolysin in a case of prostatic carcinoma with bony metastases. causal interaction,unassigned 1,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=13681662&form=6&db=m Effect of human fibrinolysin on hepatic metastases in simulated colon carcinoma in rats. ongoing research,unassigned 4,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=13829680&form=6&db=m The effect of human fibrinolysin on pulmonary metastases of Walker 256 carcinosarcoma. ongoing research,unassigned 4,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14011261&form=6&db=m Decrease in pulmonary metastases: potentiation of nitrogen mustard effect by heparin and fibrinolysin. therapeutic application,unassigned 1,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14252642&form=6&db=m TRAUMA AS A CAUSE OF LOCALIZATION OF BLOOD-BORNE METASTASES: PREVENTIVE EFFECT OF HEPARIN AND FIBRINOLYSIN. unassigned - 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14275618&form=6&db=m HEPATIC AND PULMONARY METASTASES FROM A RESECTABLE EXPERIMENTAL CECAL CARCINOMA: THE EFFECT OF HEPATIC PERFUSION WITH NITROGEN MUSTARD COMBINED WITH SYSTEMIC HEPARIN AND FIBRINOLYSIN. ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14598883&form=6&db=m Growth factor-dependent activation of the MAPK pathway in human pancreatic cancer: MEK/ERK and p38 MAP kinase interaction in uPA synthesis. causal interaction,ongoing research,unassigned 4,4,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15325613&form=6&db=m NS-398 inhibits tumor growth and liver metastasis of colon cancer through induction of apoptosis and suppression of the plasminogen activation system in a mouse model. causal interaction,ongoing research,unassigned 4,4,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15472905&form=6&db=m Reduced metastasis of transgenic mammary cancer in urokinase-deficient mice. causal interaction,unassigned 4,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15490235&form=6&db=m A hybrid protein of the amino-terminal fragment of urokinase and mutant plasminogen activator inhibitor-2 efficiently inhibits tumor cell invasion and metastasis. causal interaction,unassigned 2,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15506985&form=6&db=m Annexin A2 expression during cellular differentiation in myeloid cell lines. unassigned - 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15509494&form=6&db=m Detection of plasminogen activators in oral cancer by laser capture microdissection combined with zymography. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,2,2,1 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15574370&form=6&db=m S100A10, annexin A2, and annexin a2 heterotetramer as candidate plasminogen receptors. causal interaction,unassigned 4,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15680767&form=6&db=m Bacterial metastasis: the host plasminogen system in bacterial invasion. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15688761&form=6&db=m [Urokinase-type plasminogen activator (uPA) and its inhibitor--new prognostic factors in oral squamous cell carcinoma] causal interaction,diagnostic usage,ongoing research,therapeutic application 3,2,3,1 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15711732&form=6&db=m Soluble and cleaved forms of the urokinase-receptor: degradation products or active molecules? causal interaction,unassigned 3,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15769664&form=6&db=m Plasminogen receptors: the sine qua non of cell surface plasminogen activation. causal interaction,ongoing research,therapeutic application,unassigned 3,2,1,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15788416&form=6&db=m Metastasis-associated protein S100A4 induces angiogenesis through interaction with Annexin II and accelerated plasmin formation. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15878520&form=6&db=m Tumour-associated urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in normal and neoplastic tissues of patients with squamous cell cancer of the oral cavity - clinical relevance and prognostic value. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,3,2 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15894933&form=6&db=m Expression of urokinase-type plasminogen activator receptor (uPAR) in primary central nervous system neoplasms. causal interaction,therapeutic application,unassigned 4,2,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15915389&form=6&db=m [Role of PAI-1 in gynaecological malignancies] causal interaction,unassigned 4,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16008557&form=6&db=m Inhibition of urokinase receptor gene expression and cell invasion by anti-uPAR DNAzymes in osteosarcoma cells. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,3,1 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16127174&form=6&db=m RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo. causal interaction,ongoing research,therapeutic application,unassigned 4,2,2,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16209572&form=6&db=m A comparison of cyclohexanone and tetrahydro-4H-thiopyran-4-one 1,1-dioxide as pharmacophores for the design of peptide-based inhibitors of the serine protease plasmin. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,3,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16424020&form=6&db=m Angiostatin is directly cytotoxic to tumor cells at low extracellular pH: a mechanism dependent on cell surface-associated ATP synthase. causal interaction,ongoing research,therapeutic application,unassigned 3,4,3,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16497155&form=6&db=m Interplay of human tissue kallikrein 4 (hK4) with the plasminogen activation system: hK4 regulates the structure and functions of the urokinase-type plasminogen activator receptor (uPAR). causal interaction,diagnostic usage,therapeutic application,unassigned 4,1,1,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16524486&form=6&db=m The fibrinolytic system facilitates tumor cell migration across the blood-brain barrier in experimental melanoma brain metastasis. causal interaction,ongoing research,therapeutic application,unassigned 3,4,3,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16569238&form=6&db=m Coordinate regulation of fibronectin matrix assembly by the plasminogen activator system and vitronectin in human osteosarcoma cells. causal interaction,ongoing research,therapeutic application,unassigned 4,3,4,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16643891&form=6&db=m Antibody-directed targeting of angiostatin's receptor annexin II inhibits Lewis Lung Carcinoma tumor growth via blocking of plasminogen activation: Possible biochemical mechanism of angiostatin's action. causal interaction,ongoing research,therapeutic application,unassigned 4,1,4,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16643892&form=6&db=m Angiogenesis-associated protein annexin II in breast cancer: Selective expression in invasive breast cancer and contribution to tumor invasion and progression. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,1,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16832089&form=6&db=m CSF levels of growth factors and plasminogen activators in leptomeningeal metastases. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,2,2 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17203182&form=6&db=m Induction of alpha2-antiplasmin inhibits E-cadherin processing mediated by the plasminogen activator/plasmin system, leading to suppression of progression of oral squamous cell carcinoma via upregulation of cell-cell adhesion. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17264329&form=6&db=m Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,4,1 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17489744&form=6&db=m Monitoring of chemotherapy successfulness of platina/taxol chemotherapy protocol by using determination of serum urokinase plasminogen activator (uPA) and soluble urokinase plasminogen activator receptor (suPAR) in patients with ovarian carcinoma FIGO II and III stage. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,2,3,2 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17549383&form=6&db=m PAI-1 induces cell detachment, downregulates nucleophosmin (B23) and fortilin (TCTP) in LnCAP prostate cancer cells. causal interaction,ongoing research,therapeutic application,unassigned 3,1,4,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17616807&form=6&db=m PAI-1 -675 4G/5G polymorphism as a prognostic biomarker in breast cancer. causal interaction,unassigned 4,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17695432&form=6&db=m S100A10 expression in thyroid neoplasms originating from the follicular epithelium: contribution to the aggressive characteristic of anaplastic carcinoma. unassigned - 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17804466&form=6&db=m Polymorphisms in the genes of the urokinase plasminogen activation system in relation to colorectal cancer. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,3,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17992475&form=6&db=m Role of hepatocyte growth factor/c-Met signaling in regulating urokinase plasminogen activator on invasiveness in human hepatocellular carcinoma: a potential therapeutic target. causal interaction,ongoing research,therapeutic application,unassigned 4,2,4,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18030361&form=6&db=m PEGylated DX-1000: pharmacokinetics and antineoplastic activity of a specific plasmin inhibitor. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,4,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18053161&form=6&db=m Tissue factor pathway inhibitor-2 was repressed by CpG hypermethylation through inhibition of KLF6 binding in highly invasive breast cancer cells. causal interaction,diagnostic usage,unassigned 4,2,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18095256&form=6&db=m Cancer invasion and metastasis: changing views. causal interaction,unassigned 4,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18220793&form=6&db=m The role of annexin II in angiogenesis and tumor progression: a potential therapeutic target. causal interaction,unassigned 4,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18495253&form=6&db=m The plasminogen activator inhibitor "paradox" in cancer. causal interaction,therapeutic application,unassigned 4,3,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18570058&form=6&db=m The effect of short-term estradiol therapy on clotting and inflammatory markers in older men receiving hormonal suppression therapy for prostate cancer. diagnostic usage,therapeutic application,unassigned 3,4,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18608216&form=6&db=m Annexin A2 regulates the levels of plasmin, S100A10 and Fascin in L5178Y cells. causal interaction,ongoing research,therapeutic application,unassigned 3,4,1,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19055748&form=6&db=m PAI-1 and functional blockade of SNAI1 in breast cancer cell migration. causal interaction,therapeutic application,unassigned 4,2,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19200050&form=6&db=m The urokinase plasminogen activator system: a target for anti-cancer therapy. causal interaction,unassigned 1,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19273372&form=6&db=m The urokinase receptor as an entertainer of signal transduction. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19492051&form=6&db=m Surface-associated plasminogen binding of Cryptococcus neoformans promotes extracellular matrix invasion. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19763915&form=6&db=m Prognostic significance of tissue factor pathway inhibitor-2 in pancreatic carcinoma and its effect on tumor invasion and metastasis. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19845941&form=6&db=m Cytokeratin 8 ectoplasmic domain binds urokinase-type plasminogen activator to breast tumor cells and modulates their adhesion, growth and invasiveness. causal interaction,ongoing research,unassigned 4,2,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20018303&form=6&db=m Expression of Tissue Factor Pathway Inhibitor 2 in Human Pancreatic Carcinoma and its Effect on Tumor Growth, Invasion, and Migration in vitro and in vivo. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20665448&form=6&db=m [Cell phenotype determines PAI-1 antiproliferative effect - suppressed proliferation of the lung cancer but not prostate cancer cells] causal interaction,unassigned 1,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21316840&form=6&db=m Molecular competition between plasminogen activator inhibitors type -1 and -2 for urokinase: Implications for cellular proteolysis and adhesion in cancer. causal interaction,therapeutic application,unassigned 3,3,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21454081&form=6&db=m Small molecule antagonists of the urokinase (uPA): urokinase receptor (uPAR) interaction with high reported potencies show only weak effects in cell-based competition assays employing the native uPAR ligand. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21874261&form=6&db=m Down-regulation of urokinase plasminogen activator and matrix metalloproteinases and up-regulation of their inhibitors by a novel nutrient mixture in human prostate cancer cell lines PC-3 and DU-145. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,2,3,2 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21969814&form=6&db=m Activation of pro-uPA is critical for initial escape from the primary tumor and hematogenous dissemination of human carcinoma cells. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,3,2 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22688892&form=6&db=m Global secretome analysis identifies novel mediators of bone metastasis. unassigned - 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22736175&form=6&db=m Modulation of u-PA, MMPs and their inhibitors by a novel nutrient mixture in human female cancer cell lines. causal interaction,diagnostic usage,unassigned 3,2,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22996753&form=6&db=m Spontaneous metastasis in congenic mice with transgenic breast cancer is unaffected by plasminogen gene ablation. causal interaction,ongoing research,therapeutic application,unassigned 4,2,1,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23063511&form=6&db=m TGF-? signaling, activated stromal fibroblasts, and cysteine cathepsins B and L drive the invasive growth of human melanoma cells. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,4,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23095556&form=6&db=m The urokinase plasminogen activating system in thyroid cancer: clinical implications. causal interaction,ongoing research,therapeutic application,unassigned 1,1,2,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23201006&form=6&db=m The urokinase plasminogen activator system in breast cancer invasion and metastasis. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,1,2,3 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23300882&form=6&db=m Dual inhibition of plasminogen kringle 5 on angiogenesis and chemotaxis suppresses tumor metastasis by targeting HIF-1? pathway. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,3,2,2 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23527289&form=6&db=m Gender affects skin wound healing in plasminogen deficient mice. causal interaction,ongoing research,therapeutic application,unassigned 4,2,1,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23594883&form=6&db=m Three are better than one: plasminogen receptors as cancer theranostic targets. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,3,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24205446&form=6&db=m Influence of Stromal Components on Lung Cancer Carcinogenesis. ongoing research,therapeutic application,unassigned 4,1,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24457100&form=6&db=m Angiogenin interacts with the plasminogen activation system at the cell surface of breast cancer cells to regulate plasmin formation and cell migration. causal interaction,ongoing research,unassigned 4,3,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24581498&form=6&db=m Serpins promote cancer cell survival and vascular co-option in brain metastasis. diagnostic usage,ongoing research,therapeutic application,unassigned 3,3,2,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24602611&form=6&db=m Seahorse-derived peptide suppresses invasive migration of HT1080 fibrosarcoma cells by competing with intracellular ?-enolase for plasminogen binding and inhibiting uPA-mediated activation of plasminogen. causal interaction,ongoing research,therapeutic application,unassigned 4,2,4,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24659483&form=6&db=m Recent Advances on Plasmin Inhibitors for the Treatment of Fibrinolysis-Related Disorders. causal interaction,unassigned 4,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24674618&form=6&db=m Expression of tissue factor in canine mammary tumours and correlation with grade, stage and markers of haemostasis and inflammation. causal interaction,diagnostic usage,ongoing research,unassigned 1,1,1,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24795021&form=6&db=m Serpins shield tumor cells from antimetastatic brain defenses. ongoing research,unassigned 1,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24867464&form=6&db=m Modulation of uPA, MMPs and their inhibitors by a novel nutrient mixture in human glioblastoma cell lines. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25060522&form=6&db=m ADAM9 promotes lung cancer metastases to brain by a plasminogen activator-based pathway. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,3,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25749705&form=6&db=m Selection and characterization of camelid nanobodies towards urokinase-type plasminogen activator. causal interaction,unassigned 2,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25860938&form=6&db=m Targeting of surface alpha-enolase inhibits the invasiveness of pancreatic cancer cells. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,2,1 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25937317&form=6&db=m Exploitation of plasmin(ogen) by bacterial pathogens of veterinary significance. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26279629&form=6&db=m New Insight on the Role of Plasminogen Receptor in Cancer Progression. causal interaction,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26504024&form=6&db=m Plasminogen Activation System in Rectal Adenocarcinoma. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,3,2,1 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26588878&form=6&db=m Cancer therapy targeting the fibrinolytic system. unassigned - 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26676222&form=6&db=m Decreased expression of the plasminogen activator inhibitor type 1 is involved in degradation of extracellular matrix surrounding cervical cancer stem cells. causal interaction,unassigned 3,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28086938&form=6&db=m Alpha-enolase (ENO1) controls alpha v/beta 3 integrin expression and regulates pancreatic cancer adhesion, invasion, and metastasis. causal interaction,ongoing research,unassigned 4,1,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28125743&form=6&db=m Activity Regulation by Fibrinogen and Fibrin of Streptokinase from Streptococcus Pyogenes. causal interaction,therapeutic application,unassigned 2,1,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28416743&form=6&db=m The urokinase plasminogen activation system in gastroesophageal cancer: A systematic review and meta-analysis. causal interaction,ongoing research,therapeutic application,unassigned 3,2,2,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28545187&form=6&db=m Enterolactone Suppresses Proliferation, Migration and Metastasis of MDA-MB-231 Breast Cancer Cells Through Inhibition of uPA Induced Plasmin Activation and MMPs-Mediated ECM Remodeling causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28697634&form=6&db=m The fibrinolysis inhibitor ?2-antiplasmin restricts lymphatic remodelling and metastasis in a mouse model of cancer. ongoing research,therapeutic application,unassigned 3,1,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28924209&form=6&db=m HMGA1 regulates the Plasminogen activation system in the secretome of breast cancer cells. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29336533&form=6&db=m Targeted Nanocurcumin Therapy Using Annexin A2 Anitbody Improves Tumor Accumulation and Therapeutic Efficacy Against Highly Metastatic Breast Cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 4,1,1,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30396051&form=6&db=m Rapid identification of urokinase plasminogen activator inhibitors from Traditional Chinese Medicines based on ultrafiltration, LC-MS and in silico docking. causal interaction,diagnostic usage,therapeutic application,unassigned 3,1,1,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30431071&form=6&db=m Proteolysis is the most fundamental property of malignancy and its inhibition may be used therapeutically (Review). causal interaction,unassigned 3,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30765871&form=6&db=m HAI-2 as a novel inhibitor of plasmin represses lung cancer cell invasion and metastasis. causal interaction,ongoing research,therapeutic application,unassigned 4,2,4,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31471691&form=6&db=m Specifically targeting cancer proliferation and metastasis processes: the development of matriptase inhibitors. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31949486&form=6&db=m Critical role and its underlying molecular events of the plasminogen receptor, S100A10 in malignant tumor and non-tumor diseases. causal interaction,ongoing research,therapeutic application,unassigned 3,1,1,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32115494&form=6&db=m Fibrinolytic Activity of Circulating Microvesicles Is Associated with Progression of Breast Cancer. causal interaction,diagnostic usage,unassigned 4,3,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32405608&form=6&db=m Model Combining Tumor Molecular and Clinicopathologic Risk Factors Predicts Sentinel Lymph Node Metastasis in Primary Cutaneous Melanoma. unassigned - 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32418644&form=6&db=m Modulation of Ion Channels and Receptors by p11 (S100A10). causal interaction,therapeutic application,unassigned 4,2,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32610551&form=6&db=m Genetic Variants in the FGB and FGG Genes Mapping in the Beta and Gamma Nodules of the Fibrinogen Molecule in Congenital Quantitative Fibrinogen Disorders Associated with a Thrombotic Phenotype. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33488094&form=6&db=m Further Understanding of Urokinase Plasminogen Activator Overexpression in Urothelial Bladder Cancer Progression, Clinical Outcomes and Potential Therapeutic Targets. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,4,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33584813&form=6&db=m Alpha-Enolase: Emerging Tumor-Associated Antigen, Cancer Biomarker, and Oncotherapeutic Target. causal interaction,diagnostic usage,therapeutic application,unassigned 4,1,1,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33669052&form=6&db=m The Multifaceted Role of Plasminogen in Cancer. causal interaction,unassigned 1,0 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33921488&form=6&db=m Plasmin and Plasminogen System in the Tumor Microenvironment: Implications for Cancer Diagnosis, Prognosis, and Therapy. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,3,4 3.4.21.7 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34336846&form=6&db=m High Migration and Invasion Ability of PGCCs and Their Daughter Cells Associated With the Nuclear Localization of S100A10 Modified by SUMOylation. causal interaction,ongoing research,unassigned 4,1,0 3.4.21.7 Neoplasm Micrometastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21901747&form=6&db=m Urokinase plasminogen activator receptor on invasive cancer cells: A prognostic factor in distal gastric adenocarcinoma. causal interaction,diagnostic usage,ongoing research,unassigned 4,1,2,0 3.4.21.7 Neoplasm, Residual http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12017303&form=6&db=m Clinical value of components of the plasminogen activation system in ovarian cyst fluid. causal interaction,diagnostic usage,ongoing research,unassigned 1,3,3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=49388&form=6&db=m Immunological analysis of plasminogen activators from normal and transformed hamster cells. Evidence that the plasminogen activators produced by SV40 virus-transformed hamster embryo cells and normal hamster lung cells are antigenically identical. ongoing research,unassigned 1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=94895&form=6&db=m [Tumor plasminogen activators and their clinical significance] causal interaction,diagnostic usage,ongoing research,therapeutic application 1,3,2,1 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=123966&form=6&db=m Proteases during the growth of Ehrlich ascites tumor. I. The fibrinolysin system. diagnostic usage,ongoing research,unassigned 3,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=156038&form=6&db=m Plasminogen activation transforms the morphology of quiescent 3T3 cell monolayers and initiates growth. causal interaction,unassigned 4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=306389&form=6&db=m Malignant mouse melanoma cells do not form tumors when mixed with cells of a non-malignant subclone: relationships between plasminogen activator expression by the tumor cells and the host's immune response. causal interaction,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=676749&form=6&db=m Thromboplastic and fibrinolytic activities of V2 and V7 carcinomas of rabbit, with special reference to fibrin deposition and thrombus formation in the tumors. unassigned - 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=708794&form=6&db=m Assessment of plasminogen synthesis in vitro by mouse tumor cells using a competition radioimmunoassay for mouse plasminogen. ongoing research,therapeutic application,unassigned 4,2,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=749260&form=6&db=m Release of various molecular forms of plasminogen activators during culture of human ovarian tumours. ongoing research,unassigned 4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=769099&form=6&db=m Anticoagulants and cancer. A review. ongoing research,therapeutic application,unassigned 1,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1146550&form=6&db=m Plasminogen activators in ovarian tumours. diagnostic usage,unassigned 1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1268844&form=6&db=m Demonstration of fibrin in early stages of experimental metastases. diagnostic usage,ongoing research,unassigned 3,2,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1275477&form=6&db=m [Blood coagulation system in oncological patients treated with rubomycin, adriamycin and carminomycin] ongoing research,unassigned 3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1306885&form=6&db=m RhGM-CSF in bone marrow transplantation: experience in pediatric patients. causal interaction,unassigned 1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1311745&form=6&db=m Urokinase expression in mononuclear phagocytes: cytokine-specific modulation by interferon-gamma and tumor necrosis factor-alpha. ongoing research,therapeutic application,unassigned 4,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1321752&form=6&db=m Flow cytofluorometry in tumour cell receptor analysis. Survey of the literature and recent developments concerning the urokinase-type plasminogen activator (uPA). ongoing research,unassigned 1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1342692&form=6&db=m [Role of plasminogen activators in cancer dissemination. Clinical perspectives] unassigned - 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1354271&form=6&db=m Tetranectin, a plasminogen kringle 4-binding protein. Cloning and gene expression pattern in human colon cancer. causal interaction,ongoing research,therapeutic application,unassigned 4,3,2,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1384825&form=6&db=m Effect of aprotinin on metastasis of Lewis lung tumor in mice. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,1,4,1 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1423820&form=6&db=m The plasminogen-plasmin system in malignancy. causal interaction,therapeutic application,unassigned 4,2,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1423826&form=6&db=m Clinical trials with anticoagulant and antiplatelet therapies. causal interaction,diagnostic usage,therapeutic application,unassigned 3,3,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1428126&form=6&db=m Synergism among oxidants, proteinases, phospholipases, microbial hemolysins, cationic proteins, and cytokines. causal interaction,unassigned 1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1480031&form=6&db=m Physiological mechanisms for metalloproteinase activation. unassigned - 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1511773&form=6&db=m Inhibitory effect of nafamostat mesilate on metastasis into the livers of mice and on invasion of the extracellular matrix by cancer cells. causal interaction,ongoing research,unassigned 3,3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1515091&form=6&db=m Tumor-associated urokinase-type plasminogen activator: biological and clinical significance. causal interaction,ongoing research,unassigned 3,3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1534983&form=6&db=m [Effect of high-dose medroxyprogesterone acetate on coagulative and fibrinolytic factors in patients with gynecological cancers] causal interaction,ongoing research,therapeutic application,unassigned 1,2,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1545144&form=6&db=m Urokinase plasminogen activator is immunocytochemically detectable in squamous cell but not basal cell carcinomas. causal interaction,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1551416&form=6&db=m Effective activation of the proenzyme form of the urokinase-type plasminogen activator (pro-uPA) by the cysteine protease cathepsin L. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1574711&form=6&db=m Pathways of coagulation/fibrinolysis activation in malignancy. causal interaction,unassigned 4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1648443&form=6&db=m Role of the urokinase receptor in facilitating extracellular matrix invasion by cultured colon cancer. causal interaction,diagnostic usage,ongoing research,unassigned 3,3,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1648983&form=6&db=m Effects of urokinase receptor occupancy on plasmin generation and proteolysis of basement membrane by human tumor cells. causal interaction,ongoing research,unassigned 3,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1660294&form=6&db=m Cell membrane receptors for urokinase plasminogen activator are increased in malignant ovarian tumours. causal interaction,diagnostic usage,ongoing research,unassigned 1,2,3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1687326&form=6&db=m Significance of fibrin formation and dissolution in the pathogenesis and treatment of cancer. causal interaction,unassigned 4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1701665&form=6&db=m Progress of fibrinolysis during tumor necrosis factor infusions in humans. Concomitant increase in tissue-type plasminogen activator, plasminogen activator inhibitor type-1, and fibrin(ogen) degradation products. causal interaction,therapeutic application,unassigned 2,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1712633&form=6&db=m Plasminogen activation by t-PA on the surface of human melanoma cells in the presence of alpha 2-macroglobulin secretion. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1730515&form=6&db=m Type-1 plasminogen activator inhibitor in human breast carcinomas. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,4,1 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1733647&form=6&db=m Inhibition of tumor invasion and extracellular matrix degradation by ubenimex (bestatin). causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1765431&form=6&db=m Correlation between urokinase-type plasminogen activator production and the metastatic ability of human rectal cancer cells. ongoing research,unassigned 4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1801751&form=6&db=m Biological and clinical relevance of the urokinase-type plasminogen activator (uPA) in breast cancer. causal interaction,diagnostic usage,ongoing research,unassigned 3,4,2,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1837419&form=6&db=m Human tumor cell urokinase-type plasminogen activator (uPA): degradation of the proenzyme form (pro-uPA) by granulocyte elastase prevents subsequent activation by plasmin. causal interaction,diagnostic usage,ongoing research,unassigned 2,3,3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1846311&form=6&db=m Occurrence of components of fibrinolysis pathways in situ in neoplastic and nonneoplastic human breast tissue. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,2,2 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1855221&form=6&db=m The plasminogen activation system in human colon cancer: messenger RNA for the inhibitor PAI-1 is located in endothelial cells in the tumor stroma. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,4,1 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1859826&form=6&db=m Characterization of a family of high-molecular-weight plasminogen activators secreted by a lung tumor cell line. ongoing research,unassigned 4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1899072&form=6&db=m Urokinase-type and tissue-type plasminogen activators are essential for in vitro invasion of human melanoma cells. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1901119&form=6&db=m Immunohistochemical analysis of plasminogen activator expression in human colorectal carcinomas: correlation with CEA distribution and tumor cell kinetics. diagnostic usage,ongoing research,unassigned 4,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1902292&form=6&db=m Heterogeneity in plasminogen activator (PA) levels in human prostate cancer cell lines: increased PA activity correlates with biologically aggressive behavior. causal interaction,diagnostic usage,ongoing research,unassigned 4,1,3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1902626&form=6&db=m Importance of viability and attachment to an ascites tumor in the release of plasminogen activator. causal interaction,unassigned 4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1902639&form=6&db=m Endothelial cell fibrinolytic assembly. causal interaction,unassigned 4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1905903&form=6&db=m Evidence for the functional similarity between tumour cell surface guanidinobenzoatase and tissue type plasminogen activator. diagnostic usage,ongoing research,therapeutic application,unassigned 2,1,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1906858&form=6&db=m Kinin-generating cascade in advanced cancer patients and in vitro study. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,4,1 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1913515&form=6&db=m Inhibition of tumor implantation at sites of trauma by plasminogen activators. causal interaction,ongoing research,therapeutic application,unassigned 2,4,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1918136&form=6&db=m Metastatic behavior of human melanoma cell lines in nude mice correlates with urokinase-type plasminogen activator, its type-1 inhibitor, and urokinase-mediated matrix degradation. diagnostic usage,ongoing research,therapeutic application,unassigned 3,4,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1918364&form=6&db=m Differential protease expression by cutaneous squamous and basal cell carcinomas. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,2,3,2 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1955118&form=6&db=m Imbalance of plasminogen activators and their inhibitors in human colorectal neoplasia. Implications of urokinase in colorectal carcinogenesis. causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,2,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1966799&form=6&db=m Influence of urokinase on cell proliferation and invasion. causal interaction,unassigned 1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2037625&form=6&db=m Plasminogen activators and inhibitors in the neuromuscular system: III. The serpin protease nexin I is synthesized by muscle and localized at neuromuscular synapses. causal interaction,ongoing research,unassigned 1,2,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2040418&form=6&db=m [Clinical and prognostic significance of tumor-associated proteases in gynecologic oncology] causal interaction,unassigned 4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2105839&form=6&db=m Protein and messenger RNA levels of plasminogen activators and inhibitors analyzed in 22 human tumor cell lines. causal interaction,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2114167&form=6&db=m Plasminogen activator regulation by transforming growth factor-beta in normal and neoplastic human urothelium. causal interaction,unassigned 3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2133247&form=6&db=m Plasminogen activators and cancer. diagnostic usage,unassigned 1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2133250&form=6&db=m Tumour-associated fibrinolysis: the prognostic relevance of plasminogen activators uPA and tPA in human breast cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,3,1 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2138329&form=6&db=m Prourokinase activation on the surface of human rhabdomyosarcoma cells: localization and inactivation of newly formed urokinase-type plasminogen activator by recombinant class 2 plasminogen activator inhibitor. ongoing research,therapeutic application,unassigned 4,2,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2141196&form=6&db=m A comparative study of the localization of plasminogen and apolipoprotein(a) in human carcinomas. ongoing research,unassigned 4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2144209&form=6&db=m Basement membrane type IV collagen degradation: evidence for the involvement of a proteolytic cascade independent of metalloproteinases. ongoing research,therapeutic application,unassigned 4,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2151710&form=6&db=m The elastase-mediated pathway of fibrinolysis. causal interaction,unassigned 3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2151734&form=6&db=m Urokinase-dependent cell surface proteolysis and cancer. causal interaction,diagnostic usage,ongoing research,unassigned 1,3,3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2153429&form=6&db=m Abnormal regulation of coagulation/fibrinolysis in small cell carcinoma of the lung. diagnostic usage,ongoing research,therapeutic application,unassigned 1,2,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2155139&form=6&db=m The relationship of plasminogen activators and oncogenes to tumour invasion. causal interaction,diagnostic usage,unassigned 1,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2164452&form=6&db=m Tumorigenicity of EJ-ras oncogene transformed NIH 3T3 cells and expression of plasminogen activators. unassigned - 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2232301&form=6&db=m [Protease activities in gastric and colon cancer tissues] causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,4,1 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2237828&form=6&db=m Production of plasminogen activator and plasminogen activator inhibitor by bovine lymphatic endothelial cells: modulation by TNF-alpha. ongoing research,unassigned 1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2274946&form=6&db=m [The role of proteases in the growth, invasion and spread of cancer cells] causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2290690&form=6&db=m [Endothelial cell proteases and their modulation by platelets] causal interaction,unassigned 4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2379161&form=6&db=m Expression of heterogeneous profiles of plasminogen activators and plasminogen activator inhibitors by human glioma lines. causal interaction,ongoing research,therapeutic application,unassigned 1,3,2,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2428483&form=6&db=m Detection of the plasmin system in human mammary pathology using immunofluorescence. causal interaction,diagnostic usage,unassigned 3,2,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2431485&form=6&db=m Plasminogen activators (urokinase) mediate neovascularization: possible role in tumor angiogenesis. causal interaction,unassigned 1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2433233&form=6&db=m The plasmin system in human adenocarcinomas and their metastases. A comparative immunofluorescence study. causal interaction,diagnostic usage,ongoing research,unassigned 3,3,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2440556&form=6&db=m Increase of urokinase-type plasminogen activator gene expression in human lung and breast carcinomas. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,4,1 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2466697&form=6&db=m Limited proteolysis of tumor cells increases their plasmin-binding ability. causal interaction,therapeutic application,unassigned 4,2,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2492205&form=6&db=m Comparative study of plasminogen activators in cancers and normal mucosae of human urinary bladder. diagnostic usage,ongoing research,unassigned 3,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2497975&form=6&db=m Regulation by epidermal growth factor of human squamous cell carcinoma plasminogen activator-mediated proteolysis of extracellular matrix. ongoing research,unassigned 4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2498314&form=6&db=m Effects of cellular transformation on expression of plasminogen activator inhibitors 1 and 2. Evidence for independent regulation. causal interaction,therapeutic application,unassigned 4,2,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2511260&form=6&db=m [Study on the plasma plasminogen activators in patients with malignant gynecologic tumors] causal interaction,diagnostic usage,ongoing research,unassigned 4,4,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2517455&form=6&db=m [Plasminogen activators in tumor tissue] causal interaction,ongoing research,unassigned 2,2,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2529137&form=6&db=m Elastase released from human granulocytes stimulated with N-formyl-chemotactic peptide prevents activation of tumor cell prourokinase (pro-uPA). ongoing research,unassigned 2,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2538425&form=6&db=m Down-regulation of plasmin receptors on human sarcoma cells by glucocorticoids. causal interaction,ongoing research,unassigned 1,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2541259&form=6&db=m Mechanisms of cellular invasiveness: a comparison of amnion invasion in vitro and metastatic behavior in vivo. diagnostic usage,unassigned 3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2547519&form=6&db=m Directed migration of murine and human tumor cells to collagenases and other proteases. causal interaction,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2555056&form=6&db=m Synthesis and secretion of plasminogen activators and plasminogen activator inhibitors in cell lines of different groups of human lung tumors. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,3,4,4 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2555368&form=6&db=m Regulation of endothelial cell coagulant properties. Modulation of tissue factor, plasminogen activator inhibitors, and thrombomodulin by phorbol 12-myristate 13-acetate and tumor necrosis factor. ongoing research,unassigned 3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2558473&form=6&db=m Plasminogen activator and plasmin-like activities in experimental rat tumours. diagnostic usage,ongoing research,therapeutic application,unassigned 1,4,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2579035&form=6&db=m The plasmin system in human colonic tumors: an immunofluorescence study. causal interaction,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2649380&form=6&db=m Plasminogen activators in (pre)malignant conditions of the colorectum. causal interaction,unassigned 4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2659823&form=6&db=m Plasminogen activators in human prostate cancer cell lines and tumors: correlation with the aggressive phenotype. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2692282&form=6&db=m [Role of plasminogen activators in the development of tumors and the process of their metastasis] causal interaction,ongoing research,unassigned 4,2,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2731232&form=6&db=m The role of plasminogen in cell-mediated collagen degradation. causal interaction,ongoing research,unassigned 1,2,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2838642&form=6&db=m Receptor for plasmin on human carcinoma cells. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,4,1 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2840088&form=6&db=m [Proteases and breast carcinoma] causal interaction,unassigned 3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2891140&form=6&db=m Plasminogen activator inhibitor type 1 gene is located at region q21.3-q22 of chromosome 7 and genetically linked with cystic fibrosis. causal interaction,diagnostic usage,therapeutic application,unassigned 3,3,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2920477&form=6&db=m Plasminogen activator activity in clonogenic cell populations separated from a murine fibrosarcoma. causal interaction,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2930999&form=6&db=m Plasminogen activators, tissue degradation, and cancer. ongoing research,unassigned 3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2941504&form=6&db=m [Studies on fibrinolysis and ascites accumulation associated with peritonitis carcinomatosa--inducer of plasminogen activator (IPA) in malignant ascites tumor] diagnostic usage,unassigned 3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2965017&form=6&db=m Proenzyme to urokinase-type plasminogen activator in human colon cancer: in vitro inhibition by monocyte minactivin after proteolytic activation. causal interaction,ongoing research,unassigned 1,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2976309&form=6&db=m Plasminogen activation: biochemistry, physiology, and therapeutics. causal interaction,unassigned 3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2979833&form=6&db=m Single-chain, urokinase-type plasminogen activator in a tumor model linked to metastatic potential. causal interaction,ongoing research,therapeutic application,unassigned 4,2,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3003264&form=6&db=m Antifibrinolytic therapy of experimentally grown malignant brain tumors. ongoing research,unassigned 4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3049065&form=6&db=m The relevance of plasminogen activators to neoplastic growth. A review of recent literature. unassigned - 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3091056&form=6&db=m Characterization of seven human melanoma cell lines: melanogenesis and secretion of plasminogen activators. causal interaction,ongoing research,unassigned 1,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3091899&form=6&db=m Human primary colon carcinomas xenografted into nude mice. I. Characterization of plasminogen activators expressed by primary tumors and their xenografts. causal interaction,diagnostic usage,ongoing research,unassigned 1,3,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3093069&form=6&db=m Relationship between circulating plasminogen activators and tumor development in mice. causal interaction,ongoing research,unassigned 1,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3094628&form=6&db=m Plasminogen activators in human colorectal neoplasia. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,3,1 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3095580&form=6&db=m Human primary colon carcinomas xenografted into nude mice. II. Modulation of tumor plasminogen activator activity by the host tissue environment. causal interaction,diagnostic usage,ongoing research,unassigned 1,3,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3096452&form=6&db=m Plasminogen activators in human colorectal neoplasia. diagnostic usage,ongoing research,unassigned 2,3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3099935&form=6&db=m Plasminogen activators in human colorectal neoplasia. diagnostic usage,ongoing research,unassigned 2,3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3110994&form=6&db=m Increased plasminogen activator inhibition levels in malignancy. causal interaction,diagnostic usage,ongoing research,unassigned 3,3,3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3115868&form=6&db=m Plasminogen activators in experimental colorectal neoplasia: a role in the adenoma-carcinoma sequence? causal interaction,diagnostic usage,ongoing research,unassigned 4,3,2,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3129275&form=6&db=m Plasminogen activators and tiaprofenic acid in inflammation. A preliminary study. ongoing research,unassigned 2,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3138024&form=6&db=m Differential regulation of plasminogen activators by epidermal growth factor in normal and neoplastic human urothelium. ongoing research,unassigned 3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3139480&form=6&db=m Inhibition of plasminogen activators and the growth of cultured human tumour cells. ongoing research,unassigned 4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3141047&form=6&db=m Relationship of membrane-bound tissue type and urokinase type plasminogen activators in human breast cancers to estrogen and epidermal growth factor receptors. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3148525&form=6&db=m Regulation of the synthesis and secretion of plasminogen activators by endothelial cells. causal interaction,unassigned 1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3156799&form=6&db=m An inhibitor of urokinase and tissue plasminogen activators in Dunning R3327H prostate tumors of rats treated with D-Trp6-LH-RH. causal interaction,ongoing research,therapeutic application,unassigned 3,2,2,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3208689&form=6&db=m [Plasminogen activators in malignant tissues and lungs of mice during metastatic spreading and administration of various pharmacological agents] diagnostic usage,ongoing research,therapeutic application,unassigned 2,4,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3244988&form=6&db=m Plasminogen and plasminogen proactivator in liver diseases. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,2 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3263185&form=6&db=m Modulation of plasminogen activator activity in human endometrial adenocarcinoma cells by basic fibroblast growth factor and transforming growth factor beta. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3321438&form=6&db=m Role of heparanase in platelet and tumor cell interactions with the subendothelial extracellular matrix. causal interaction,ongoing research,unassigned 1,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3334244&form=6&db=m Further inhibition studies on guanidinobenzoatase, a trypsin-like enzyme associated with tumour cells. causal interaction,therapeutic application,unassigned 2,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3409559&form=6&db=m Secretion of plasminogen activators by human colorectal and gastric tumor explants. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,2 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3434279&form=6&db=m Plasminogen activators in human xenografted oro-pharyngeal squamous cell carcinomas. diagnostic usage,ongoing research,therapeutic application,unassigned 3,3,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3490446&form=6&db=m Plasminogen activators, plasminogen activator inhibitors and procoagulant analyzed in twenty human tumor cell lines. ongoing research,therapeutic application,unassigned 4,3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3524801&form=6&db=m Inhibition of proteolytic enzymes in the in vitro amnion model for basement membrane invasion. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3621160&form=6&db=m Plasminogen activators and tumor development in the human colon: activity levels in normal mucosa, adenomatous polyps, and adenocarcinomas. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3692623&form=6&db=m Plasminogen activator production by human tumor cells: effect on tumor cell-extracellular matrix interactions. diagnostic usage,ongoing research,unassigned 2,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3692627&form=6&db=m Measurement of plasminogen activator activity from human fibrosarcoma cells by a new microassay. causal interaction,ongoing research,unassigned 4,3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3810552&form=6&db=m The fibrinolytic system in experimental prostate tumor. causal interaction,diagnostic usage,ongoing research,unassigned 3,3,3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3855489&form=6&db=m Proteolytic enzymes in tumor metastasis. I. Plasminogen activator in clones of Lewis lung carcinoma and T10 sarcoma. diagnostic usage,ongoing research,unassigned 1,3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3860687&form=6&db=m Inhibition of human tumor cell-associated fibrinolysis by vascular bovine smooth muscle cells. ongoing research,unassigned 4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3883653&form=6&db=m [Mechanism of formation of blocking factors and method of antiblocking immunotherapy in malignant tumors] causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3884145&form=6&db=m Localization of plasminogen activators in human colon cancer by immunoperoxidase staining. causal interaction,diagnostic usage,ongoing research,unassigned 3,3,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3927713&form=6&db=m Plasminogen-dependent fibrinolytic activity in normal human lymphocytes: diminished lymphocyte plasminogen activator in chronic lymphocytic leukemia. causal interaction,diagnostic usage,ongoing research,unassigned 1,3,3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4040294&form=6&db=m [Hemostatic indices of oncological patients with different forms of jaundice] diagnostic usage,ongoing research,therapeutic application,unassigned 2,2,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4220693&form=6&db=m Studies on the fibrinolysis in tumor bearing mice. IV. Mechanism of ascites retention with special reference to plasmin activity of tumor cell origin. ongoing research,unassigned 4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4224457&form=6&db=m Treatment of cancer patients with infusions of plasmin. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4233645&form=6&db=m [The influence of plasmin on the metastasizing of implanted tumors in the rat] causal interaction,ongoing research,unassigned 2,2,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4238525&form=6&db=m The role of lysosomes in cancer chemotherapy. 3. Influence of plasmin on the lysosomes of tumor cells and on the cytocidal effect of mitomycin-C. causal interaction,ongoing research,therapeutic application,unassigned 1,3,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4266268&form=6&db=m [Experimental and clinical studies on cancer chemotherapy--enhancement of the cytocidal effect of Mitomycin-C by one of lysosome labilizer, plasmin] ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4268001&form=6&db=m The secretion of fibrinolysin by cultured rat ovarian tumor cells. causal interaction,diagnostic usage,ongoing research,unassigned 1,1,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4274532&form=6&db=m [Effect of large fibrinolysin doses on the degree of hematogenous metastasizing of experimental tumors] ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4283651&form=6&db=m Effect of fibrinolysin on spread of cancer. ongoing research,unassigned 3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=5832012&form=6&db=m Studies on the fibrinolysis in tumor bearing mice. 3. Demonstration of the plasminogen activator in Ehrlich ascites tumor cells. ongoing research,unassigned 4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=5884701&form=6&db=m Action of heparin and plasminogen inhibitor (EACA) on metastatic tumour spread in an isologous system. therapeutic application,unassigned 4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=5958850&form=6&db=m Effect of heparin and plasminogen inhibitor (EACA) on intravenously injected ascites tumour cells. ongoing research,therapeutic application,unassigned 2,3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=5959842&form=6&db=m Effect of heparin and plasminogen inhibitor (EACA) in brief and prolonged treatment on intravenously injected tumour cells. therapeutic application,unassigned 4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6100805&form=6&db=m Proteolytic and metastatic activities of clones derived from a methylcholanthrene-induced murine fibrosarcoma. diagnostic usage,ongoing research,unassigned 2,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6100964&form=6&db=m Tumorigenicity of herpesvirus-transformed cells correlates with production of plasminogen activator. diagnostic usage,ongoing research,unassigned 3,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6156074&form=6&db=m Transferrin, C3 complement, haptoglobin, plasminogen and alpha 2-microglobulin in patients with urogenital tumors. causal interaction,diagnostic usage,unassigned 2,2,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6188588&form=6&db=m Simultaneous three color and electronic cell volume analysis with a single UV excitation source. causal interaction,diagnostic usage,unassigned 3,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6221099&form=6&db=m Plasmin-activated prodrugs for cancer chemotherapy. 1. Synthesis and biological activity of peptidylacivicin and peptidylphenylenediamine mustard. causal interaction,diagnostic usage,unassigned 4,2,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6234471&form=6&db=m Enhancement of the radiation effect by fibrinolysin and quantitative pattern of the change of tumor radiosensitivity. causal interaction,ongoing research,therapeutic application,unassigned 3,2,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6239988&form=6&db=m Brain tumors and plasmin inhibitors. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,4,4 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6240995&form=6&db=m Plasminogen activator and nuclear androgen receptor in rat prostate tumors after treatment with D-Trp-6-LH-RH. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,4 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6240998&form=6&db=m Proteases in human tumors. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6273336&form=6&db=m Rat mammary carcinoma cells secrete active collagenase and activate latent enzyme in the stroma via plasminogen activator. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,3,2 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6302253&form=6&db=m Plasmin-activated prodrugs for cancer chemotherapy. 2. Synthesis and biological activity of peptidyl derivatives of doxorubicin. ongoing research,therapeutic application,unassigned 1,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6312282&form=6&db=m Hormonal regulation of plasminogen activator in rat hepatoma cells. causal interaction,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6393101&form=6&db=m [Role of proteases, plasminogen activators, fibrin fibrinogen degradation products and fibrinopeptides in the growth and development of neoplasms and neoplasm metastases] unassigned - 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6417827&form=6&db=m A clinical study on the use of a fluorogenic substrate assay of plasminogen. diagnostic usage,unassigned 4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6418940&form=6&db=m Inhibition by bovine endothelial cells of degradation by HT-1080 fibrosarcoma cells of extracellular matrix proteins. unassigned - 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6455162&form=6&db=m Expression of the catalytic activity of plasminogen activator under physiologic conditions. unassigned - 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6460038&form=6&db=m Acetylcholine receptor: effects of proteolysis on receptor metabolism. causal interaction,unassigned 1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6493191&form=6&db=m [Hematological disorders in patients with gastric cancer] causal interaction,diagnostic usage,unassigned 2,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6515420&form=6&db=m Diagnostic efficacy of a simple radioimmunoassay test for fibrinogen/fibrin fragments containing the B beta 15-42 sequence. unassigned - 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6538971&form=6&db=m Mechanism of the stimulatory effect of phorbol 12-myristate 13-acetate on cellular production of plasminogen activator. ongoing research,therapeutic application,unassigned 4,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6539166&form=6&db=m Relationship between multiple forms of plasminogen activator in human breast tumors and plasma and the presence of metastases in lymph nodes. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,4,2 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6581358&form=6&db=m Role of plasminogen in matrix breakdown by neoplastic cells. causal interaction,ongoing research,unassigned 3,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6596319&form=6&db=m Microassay for the photometric quantitation of cell-associated plasminogen activator using a chromogenic tripeptide substrate. unassigned - 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6682008&form=6&db=m Cryptic and active plasminogen activators secreted by line 10 tumor cells in culture. ongoing research,unassigned 4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6689573&form=6&db=m Plasminogen activators as markers of tumor colonization potential. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6779412&form=6&db=m Immunological analysis of plasminogen activators from cultured human cancer cells. diagnostic usage,ongoing research,therapeutic application,unassigned 3,4,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6989588&form=6&db=m Estrogen receptor cleavage and plasminogen activation by enzymes in human breast tumor cytosol. ongoing research,unassigned 4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7000340&form=6&db=m Destruction of extracellular matrices containing glycoproteins, elastin, and collagen by metastatic human tumor cells. ongoing research,unassigned 2,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7021161&form=6&db=m Radioimmunoassay of urokinase for quantification of plasminogen activators released in ovarian tumour cultures. unassigned - 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7133990&form=6&db=m [Study of coagulation and fibrinolysis in 131 cases of recurrent deep vein thrombosis] causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7150358&form=6&db=m Aspartate carbamoyltransferase activity, drug concentrations, and pyrimidine nucleotides in tissue from patients treated with N-(phosphonacetyl)-L-aspartate. causal interaction,therapeutic application,unassigned 4,2,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7193258&form=6&db=m [The investigation on early diagnosis of the bladder tumor. II: A study on urinary cytology, urinary fibrin/fibrinogen degradation products, tissue fibrin deposition and tissue plasminogen activator activity in patients with bladder tumors (author's transl)] diagnostic usage,ongoing research,therapeutic application,unassigned 2,1,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7193515&form=6&db=m Content and characterization of plasminogen activators in human lung tumors and normal lung tissue. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,2,4,1 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7193517&form=6&db=m Molecular species of plasminogen activators secreted by normal and neoplastic human cells. ongoing research,unassigned 3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7341342&form=6&db=m Inhibition of growth of 3-methylcholanthrene-induced mouse skin tumor by protease inhibitor [N,N-dimethylcarbamoylmethyl 4-(4-guanidinobenzoyloxy)-phenylacetate] methanesulfate. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,2,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7397648&form=6&db=m Hemostatic function in cancer patients. diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7479001&form=6&db=m Differential regulation of plasminogen activator and inhibitor gene transcription by the tumor suppressor p53. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,2,1 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7489964&form=6&db=m Plasminogen activators and plasminogen activator inhibitor before and after surgery in patients with and without gastric malignancy. diagnostic usage,ongoing research,therapeutic application,unassigned 3,2,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7499022&form=6&db=m Lentinan augments skin reaction induced by bradykinin: its correlation with vascular dilatation and hemorrhage responses and antitumor activities. causal interaction,ongoing research,therapeutic application,unassigned 1,1,3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7524411&form=6&db=m Alpha 2-macroglobulin in the regulation of pericellular plasminogen activation of human tumor cells. causal interaction,ongoing research,unassigned 2,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7532156&form=6&db=m Immunohistochemical localization of the plasminogen activator inhibitor-1 in breast cancer. causal interaction,diagnostic usage,ongoing research,unassigned 2,3,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7535337&form=6&db=m Urokinase plasminogen activator receptor, beta 2-integrins, and Src-kinases within a single receptor complex of human monocytes. causal interaction,unassigned 3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7538364&form=6&db=m Surgical treatment of tumor metastases: general considerations and results. unassigned - 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7542667&form=6&db=m A cytokeratin 8-like protein with plasminogen-binding activity is present on the external surfaces of hepatocytes, HepG2 cells and breast carcinoma cell lines. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7547226&form=6&db=m Urokinase and macrophages in tumour angiogenesis. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7548000&form=6&db=m Chemical modification of the urokinase-type plasminogen activator and its receptor using tetranitromethane. Evidence for the involvement of specific tyrosine residues in both molecules during receptor-ligand interaction. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7553650&form=6&db=m Plasmin-catalyzed proteolysis in colorectal neoplasia. causal interaction,diagnostic usage,therapeutic application,unassigned 4,1,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7557947&form=6&db=m Antigen levels of urokinase plasminogen activator and its receptor at the tumor-host interface of colorectal adenocarcinomas are related to tumor aggressiveness. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7558669&form=6&db=m Immunocytochemical localization of plasminogen activators in carcinomas in the cervix and vulva. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,2,1 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7561846&form=6&db=m Components of the plasminogen activator system in astrocytes are modulated by tumor necrosis factor-alpha and interleukin-1 beta through similar signal transduction pathways. therapeutic application,unassigned 2,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7586807&form=6&db=m Increase of a urokinase receptor-related low-molecular-weight molecule in colorectal adenocarcinomas. ongoing research,unassigned 3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7588568&form=6&db=m Expression of the human urokinase-type plasminogen activator receptor in E. coli and Chinese hamster ovary cells: purification of the recombinant proteins and generation of polyclonal antibodies in chicken. causal interaction,ongoing research,unassigned 4,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7600025&form=6&db=m The plasminogen activation system and its role in lung cancer. A review. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,2,3,2 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7618808&form=6&db=m Suppression of pulmonary metastases of rat mammary cancer by recombinant urokinase plasminogen activator inhibitor. causal interaction,ongoing research,therapeutic application,unassigned 2,4,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7657514&form=6&db=m Plasmin in pericellular proteolysis and cellular invasion. causal interaction,diagnostic usage,ongoing research,unassigned 3,3,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7657515&form=6&db=m Laminin degradation by human colon carcinoma cells: a role for urinary and tissue plasminogen activators. causal interaction,ongoing research,unassigned 3,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7657517&form=6&db=m Metalloproteinases in tumor progression: the contribution of MMP-9. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,2,4,1 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7662169&form=6&db=m The structure and function of the urokinase receptor, a membrane protein governing plasminogen activation on the cell surface. causal interaction,ongoing research,therapeutic application,unassigned 3,3,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7664291&form=6&db=m Laminin-5 is a marker of invading cancer cells in some human carcinomas and is coexpressed with the receptor for urokinase plasminogen activator in budding cancer cells in colon adenocarcinomas. causal interaction,diagnostic usage,ongoing research,unassigned 3,1,3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7677931&form=6&db=m Visualization of the plasmin receptor on sections of human mammary carcinoma cells. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,4,2 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7686838&form=6&db=m Immunohistochemical study of tumor cell-associated plasminogen activators and plasminogen activator inhibitors in lung carcinomas. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,4,4 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7707177&form=6&db=m [Immunohistological study of fibrinolytic factors of head and neck squamous cell carcinomas] unassigned - 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7713945&form=6&db=m Inhibitory effect of a conjugate between human urokinase and urinary trypsin inhibitor on tumor cell invasion in vitro. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,4,1 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7718296&form=6&db=m [Determination of plasminogen activator of the head and neck tumor tissue] causal interaction,diagnostic usage,ongoing research,unassigned 4,3,3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7728751&form=6&db=m Inhibition of tumor cell invasion through matrigel by a peptide derived from the domain II region in urinary trypsin inhibition. causal interaction,ongoing research,unassigned 4,3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7737909&form=6&db=m Localization of urokinase-type plasminogen activator, plasminogen activator inhibitor-1, 2 and plasminogen in colon cancer. causal interaction,ongoing research,therapeutic application,unassigned 3,3,3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7745466&form=6&db=m Activities, localizations, and roles of serine proteases and their inhibitors in human brain tumor progression. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7745467&form=6&db=m Proteolysis and invasiveness of brain tumors: role of urokinase-type plasminogen activator receptor. causal interaction,ongoing research,unassigned 3,3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7747886&form=6&db=m Studies on functional and structural role of urokinase receptor and other components of the plasminogen activation system in malignancy. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,4,1 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7803712&form=6&db=m Metastasis of human colon tumor cells in vivo: correlation with the overexpression of plasminogen activators and 72 kDa gelatinase. causal interaction,ongoing research,unassigned 3,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7826985&form=6&db=m Plasminogen activators and their inhibitor in osteosarcomas and other bone tumors. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,1,3 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7872665&form=6&db=m Expression and release of plasminogen activators, their inhibitors and receptor by human tumor cell lines. causal interaction,ongoing research,therapeutic application,unassigned 3,4,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7891228&form=6&db=m Components of the plasminogen activation system in uveal melanoma--a clinico-pathological study. causal interaction,therapeutic application,unassigned 4,3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7929254&form=6&db=m Inactivation of human anaphylatoxin C5a and C5a des-Arg through cleavage by the plasminogen activator activity of a human fibrosarcoma cell line. causal interaction,ongoing research,therapeutic application,unassigned 3,3,2,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7962113&form=6&db=m Human Co115 colon carcinoma cells potentiate the degradation of laminin mediated by tissue-type plasminogen activator. causal interaction,ongoing research,unassigned 3,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7974332&form=6&db=m Factors involved in the plasminogen activation system in human breast tumours. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,1,4,1 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7997975&form=6&db=m Purification of the plasmin receptor from human carcinoma cells and comparison to alpha-enolase. ongoing research,unassigned 4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7999418&form=6&db=m Plasminogen activators and plasminogen activator inhibitors in blood and tumour fluids of patients with ovarian cancer. diagnostic usage,ongoing research,therapeutic application,unassigned 3,4,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8019904&form=6&db=m [Cell interactions in the extracellular matrix in tumoral invasion in mammary pathology] unassigned - 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8034659&form=6&db=m Differential induction of the interleukin-6 gene by tumor necrosis factor and interleukin-1. unassigned - 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8039304&form=6&db=m Expression of 72 kDa type IV collagenase and invasion activity of human glioma cells. causal interaction,ongoing research,therapeutic application,unassigned 4,4,3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8044805&form=6&db=m Plasminogen activation in melanocytic neoplasia. causal interaction,diagnostic usage,unassigned 2,3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8051163&form=6&db=m Characterization of the cellular binding site for the urinary trypsin inhibitor. causal interaction,ongoing research,therapeutic application,unassigned 3,1,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8077048&form=6&db=m Transcriptional activation of the urokinase receptor gene in invasive colon cancer. causal interaction,ongoing research,therapeutic application,unassigned 4,2,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8093068&form=6&db=m Thrombospondin (TSP) and transforming growth factor beta 1 (TGF-beta) promote human A549 lung carcinoma cell plasminogen activator inhibitor type 1 (PAI-1) production and stimulate tumor cell attachment in vitro. ongoing research,unassigned 4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8111706&form=6&db=m Plasminogen activators and their inhibitors in non-small cell lung cancer. Low content of type 2 plasminogen activator inhibitor associated with tumor dissemination. causal interaction,ongoing research,therapeutic application,unassigned 4,4,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8137563&form=6&db=m Immunologic detection of the cellular receptor for urokinase plasminogen activator. causal interaction,unassigned 4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8140655&form=6&db=m Urokinase-type plasminogen activator and its receptor: new targets for anti-metastatic therapy? causal interaction,ongoing research,unassigned 4,3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8140679&form=6&db=m Plasminogen activators and plasminogen activator inhibitor 1 in urinary tract cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,3,4 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8168999&form=6&db=m Effects of urinary trypsin inhibitor on the invasion of reconstituted basement membranes by ovarian cancer cells. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,4,1 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8227186&form=6&db=m Expression and localization of elements of the plasminogen activation system in benign breast disease and breast cancers. causal interaction,ongoing research,therapeutic application,unassigned 4,4,2,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8261421&form=6&db=m Inhibition of invasion of HT1080 sarcoma cells expressing recombinant plasminogen activator inhibitor 2. causal interaction,ongoing research,therapeutic application,unassigned 4,3,3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8261432&form=6&db=m Urokinase and plasminogen activator inhibitor type 1 in pulmonary adenocarcinoma. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,4,3 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8291613&form=6&db=m Plasminogen activators, their inhibitors, and urokinase receptor emerge in late stages of melanocytic tumor progression. causal interaction,ongoing research,therapeutic application,unassigned 4,4,3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8306348&form=6&db=m Inhibition of the soluble and the tumor cell receptor-bound plasmin by urinary trypsin inhibitor and subsequent effects on tumor cell invasion and metastasis. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,4,3 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8306525&form=6&db=m Urinary trypsin inhibitor (UTI) and fragments derived from UTI by limited proteolysis efficiently inhibit tumor cell invasion. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,4,2 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8313371&form=6&db=m The urokinase receptor is expressed in invasive breast cancer but not in normal breast tissue. causal interaction,ongoing research,unassigned 4,3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8331683&form=6&db=m Tumor cell procoagulant and urokinase expression in carcinoma of the ovary. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,3,4 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8342330&form=6&db=m On the regulation of the plasminogen activator inhibitor-1 gene expression. causal interaction,unassigned 4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8344749&form=6&db=m The plasminogen-activation system in ovarian tumors. causal interaction,ongoing research,unassigned 1,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8345579&form=6&db=m Plasminogen activators: regulators of tumor cell adherence to sites of lower urinary tract surgical trauma. diagnostic usage,ongoing research,therapeutic application,unassigned 2,3,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8348499&form=6&db=m Plasminogen activator inhibitors in endometrial adenocarcinoma. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8362987&form=6&db=m Activation of hepatocyte growth factor by the plasminogen activators uPA and tPA. causal interaction,unassigned 3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8380125&form=6&db=m Extracellular matrix production and degradation by adenoid cystic carcinoma cells: participation of plasminogen activator and its inhibitor in matrix degradation. causal interaction,ongoing research,unassigned 4,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8381885&form=6&db=m [Advancement in the diagnosis of disseminated intravascular coagulation for the surgeon] causal interaction,diagnostic usage,ongoing research,therapeutic application 1,3,3,1 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8388317&form=6&db=m High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,4,1 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8393802&form=6&db=m Comparative localization of receptors for plasmin and for urokinase on MCF 7 cells. unassigned - 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8434636&form=6&db=m Messenger RNA for two type IV collagenases is located in stromal cells in human colon cancer. causal interaction,diagnostic usage,ongoing research,unassigned 4,2,3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8436596&form=6&db=m Extracellular matrix produced by cultured corneal and aortic endothelial cells contains active tissue-type and urokinase-type plasminogen activators. causal interaction,unassigned 3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8503981&form=6&db=m Molecular mechanisms of protease-mediated tumor invasiveness. diagnostic usage,ongoing research,unassigned 3,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8504488&form=6&db=m Transformation of immortal, non-tumorigenic osteoblast-like human osteosarcoma cells to the tumorigenic phenotype by nickel sulfate. ongoing research,unassigned 4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8518031&form=6&db=m Plasminogen activators and plasminogen activator inhibitors in human colorectal carcinoma tissues are not expressed by the tumour cells. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,1,4,2 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8567114&form=6&db=m Phorbol-ester-stimulated human lymphoid cell lines produce a plasminogen activator modulator inducing cell-bound urokinase-type plasminogen activator in malignant tumor cell lines. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,4,1 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8578171&form=6&db=m The fibrinolytic system in human ascites. causal interaction,diagnostic usage,unassigned 4,2,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8578475&form=6&db=m Cellular receptors in the regulation of plasmin generation. causal interaction,ongoing research,therapeutic application,unassigned 3,4,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8590627&form=6&db=m A competitive chromogenic assay to study the functional interaction of urokinase-type plasminogen activator with its receptor. causal interaction,unassigned 1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8601416&form=6&db=m Upregulation of cell-surface-associated plasminogen activation in cultured keratinocytes by interleukin-1 beta and tumor necrosis factor-alpha. causal interaction,ongoing research,unassigned 1,2,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8603504&form=6&db=m Regulation of matrix metalloproteinases and plasminogen activator inhibitor-1 synthesis by plasminogen in cultured human vascular smooth muscle cells. ongoing research,unassigned 4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8615674&form=6&db=m Plasminogen activation system in active even in thyroid tumors; an immunohistochemical study. causal interaction,ongoing research,therapeutic application,unassigned 4,4,2,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8622276&form=6&db=m [Chronic recurrent pulmonary thromboembolism associated with sedentary work] causal interaction,diagnostic usage,unassigned 3,2,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8635120&form=6&db=m Prognostic value of the plasminogen activation system in patients with gastric carcinoma. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,1 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8639779&form=6&db=m Plasminogen activator inhibitor-1 secretion of endothelial cells increases fibrinolytic resistance of an in vitro fibrin clot: evidence for a key role of endothelial cells in thrombolytic resistance. ongoing research,unassigned 2,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8640836&form=6&db=m Decreased expression of both the low-density lipoprotein receptor-related protein/alpha(2)-macroglobulin receptor and its receptor-associated protein in late stages of cutaneous melanocytic tumor progression. causal interaction,ongoing research,therapeutic application,unassigned 4,2,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8658040&form=6&db=m Plasminogen activators and plasminogen activator inhibitor in portal blood from patients with and without gastric malignancy. diagnostic usage,ongoing research,therapeutic application,unassigned 3,3,2,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8674284&form=6&db=m Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,4,4 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8679225&form=6&db=m Differential expression of the urokinase receptor in fibroblasts from normal and fibrotic human lungs. causal interaction,ongoing research,unassigned 4,3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8694536&form=6&db=m Fibrinolysis components as prognostic markers in breast cancer and colorectal carcinoma. causal interaction,diagnostic usage,unassigned 4,2,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8703368&form=6&db=m Expression of urokinase-type plasminogen activator, its receptor, and its inhibitor in gastric adenocarcinoma tissues. causal interaction,ongoing research,therapeutic application,unassigned 3,1,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8729000&form=6&db=m Matrilysin: an epithelial matrix metalloproteinase with potentially novel functions. diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8756739&form=6&db=m [Levels of plasminogen and alpha 2-antiplasmin in blood of patients with prostatic tumor] causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,1 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8758932&form=6&db=m Induction of primary cutaneous melanocytic neoplasms in urokinase-type plasminogen activator (uPA)-deficient and wild-type mice: cellular blue nevi invade but do not progress to malignant melanoma in uPA-deficient animals. causal interaction,ongoing research,unassigned 4,2,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8760360&form=6&db=m Cytokeratin 8 released by breast carcinoma cells in vitro binds plasminogen and tissue-type plasminogen activator and promotes plasminogen activation. causal interaction,ongoing research,therapeutic application,unassigned 4,4,2,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8774480&form=6&db=m Tetranectin and plasmin/plasminogen are similarly distributed at the invasive front of cutaneous melanoma lesions. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8778334&form=6&db=m Expression of plasminogen activators in basal cell carcinoma. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,4,1 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8788547&form=6&db=m Blood and tissue fibrinolytic profiles in patients with colorectal carcinoma. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8791264&form=6&db=m The plasminogen activation system in melanoma cell lines and in melanocytic lesions. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8791680&form=6&db=m Plasminogen activation on tumor cell surface and its involvement in human leukemia. causal interaction,diagnostic usage,ongoing research,unassigned 3,3,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8796998&form=6&db=m Cooperation between matrix metalloproteinases and the plasminogen activator-plasmin system in tumor progression. unassigned - 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8808830&form=6&db=m [Mechanism of tumor cell-induced extracellular matrix degradation--inhibition of cell-surface proteolytic activity might have a therapeutic effect on tumor cell invasion and metastasis] causal interaction,ongoing research,therapeutic application,unassigned 3,3,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8812198&form=6&db=m Volume 223, Number 2 (1996), in the article "Upregulation of Cell-Surface-Associated Plasminogen Activation in Cultured Keratinocytes by Interleukin-1beta and Tumor Necrosis Factor-alpha," by Michael J. Bechtel, Jeannette Reinartz, Jutta M. Rox, Stefan Inndorf, Birgit M. Schaefer, and Michael D. Kramer, pages 395-404: On page 398 therapeutic application,unassigned 1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8818541&form=6&db=m The 9E3/CEF4 cytokine: kinetics of secretion, processing by plasmin, and interaction with extracellular matrix. causal interaction,unassigned 1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8822588&form=6&db=m Inhibitory effect of a synthetic prostacyclin analogue, beraprost, on urokinase-type plasminogen activator expression in RC-K8 human lymphoma cells. causal interaction,ongoing research,unassigned 4,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8826848&form=6&db=m Modulation of the plasminogen activation system by inflammatory cytokines in human colon carcinoma cells. causal interaction,ongoing research,therapeutic application,unassigned 1,4,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8845643&form=6&db=m Proteinase activity in invasive cancer of the breast. Correlation with tumor progression. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,1 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8856154&form=6&db=m Bradykinin and nitric oxide in infectious disease and cancer. ongoing research,therapeutic application,unassigned 3,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8872748&form=6&db=m Interaction of tissue plasminogen activator inhibitor with cell surface guanidinobenzoatase and urokinase plasminogen activator. therapeutic application,unassigned 1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8880873&form=6&db=m The plasminogen activation system in tumour invasion and metastasis. causal interaction,ongoing research,therapeutic application,unassigned 1,3,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8882727&form=6&db=m Purification and identification of a novel and four known serine proteinase inhibitors secreted by human glioblastoma cells. causal interaction,ongoing research,therapeutic application,unassigned 1,4,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8922633&form=6&db=m Identification of plasminogen in Matrigel and its activation by reconstitution of this basement membrane extract. diagnostic usage,unassigned 1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8980909&form=6&db=m Urinary trypsin inhibitor efficiently inhibits urokinase production in tumor necrosis factor-stimulated cells. ongoing research,therapeutic application,unassigned 4,2,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9002223&form=6&db=m Angiostatin: an endogenous inhibitor of angiogenesis and of tumor growth. causal interaction,diagnostic usage,unassigned 3,3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9023404&form=6&db=m Endothelial and macrophage upregulation of urokinase receptor expression in human renal cell carcinoma. causal interaction,ongoing research,unassigned 4,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9048336&form=6&db=m Effect of TGF-beta 1 and TNF-alpha on the plasminogen system of rat proximal tubular epithelial cells. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9079800&form=6&db=m Dimerization of Fab fragments enables ready screening of phage antibodies that affect hepatocyte growth factor/scatter factor activity on target cells. ongoing research,unassigned 3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9096588&form=6&db=m Expression of urokinase-type plasminogen activator receptor in hepatocellular carcinoma. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9096674&form=6&db=m Melanoma cell migration on vitronectin: regulation by components of the plasminogen activation system. causal interaction,ongoing research,unassigned 1,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9102221&form=6&db=m A recombinant human angiostatin protein inhibits experimental primary and metastatic cancer. diagnostic usage,ongoing research,therapeutic application,unassigned 3,1,2,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9131271&form=6&db=m Prognostic significance of PAI-1 and uPA in cytosolic extracts obtained from node-positive breast cancer patients. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9134632&form=6&db=m The risk of recurrent venous thromboembolism in patients with and without factor V Leiden. ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9142977&form=6&db=m Overview on human breast cancer with focus on prognostic and predictive factors with special attention on the tumour suppressor gene p53. diagnostic usage,therapeutic application,unassigned 1,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9143604&form=6&db=m Upregulation of urokinase-type plasminogen activator by endogenous and exogenous HIV-1 Tat protein in tumour cell lines derived from BK virus/tat-transgenic mice. diagnostic usage,ongoing research,therapeutic application,unassigned 3,4,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9151696&form=6&db=m Polyoma middle T-induced vascular tumor formation: the role of the plasminogen activator/plasmin system. causal interaction,ongoing research,unassigned 4,3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9168186&form=6&db=m Urokinase and the urokinase receptor: association with in vitro invasiveness of human bladder cancer cell lines. causal interaction,ongoing research,therapeutic application,unassigned 3,4,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9198168&form=6&db=m Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9212216&form=6&db=m The urokinase-type plasminogen activator system in cancer metastasis: a review. therapeutic application,unassigned 1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9237155&form=6&db=m Levels of plasminogen activator inhibitor type 1 and urokinase plasminogen activator receptor in non-small cell lung cancer as measured by quantitative ELISA and semiquantitative immunohistochemistry. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,4,3 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9252380&form=6&db=m Generation of angiostatin by reduction and proteolysis of plasmin. Catalysis by a plasmin reductase secreted by cultured cells. causal interaction,unassigned 4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9254899&form=6&db=m Plasminogen activator and matrix metalloproteinase production and extracellular matrix degradation by rat prostate cancer cells in vitro: correlation with metastatic behavior in vivo. causal interaction,ongoing research,unassigned 4,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9271229&form=6&db=m Defective cell migration in an ovarian cancer cell line is associated with impaired urokinase-induced tyrosine phosphorylation. ongoing research,therapeutic application,unassigned 2,2,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9275473&form=6&db=m [The role of urokinase type plasminogen activator in invasion of bile duct carcinoma] causal interaction,ongoing research,therapeutic application,unassigned 4,4,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9323150&form=6&db=m Localization of plasminogen activators and their inhibitor in squamous cell carcinomas of the head and neck. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,4,1 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9326241&form=6&db=m Inhibition of metastasis of intraocular melanomas by adenovirus-mediated gene transfer of plasminogen activator inhibitor type 1 (PAI-1) in an athymic mouse model. causal interaction,ongoing research,therapeutic application,unassigned 3,3,3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9337523&form=6&db=m Proteolytic enzymes in proliferation and neoplastic metastases formation. causal interaction,unassigned 2,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9337525&form=6&db=m Plasminogen activators and plasmin in lung cancer. diagnostic usage,unassigned 3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9357156&form=6&db=m Clot lysis: role of plasminogen activator inhibitors in haemostasis and therapy. causal interaction,diagnostic usage,therapeutic application,unassigned 3,3,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9373263&form=6&db=m Growth and dissemination of Lewis lung carcinoma in plasminogen-deficient mice. causal interaction,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9380726&form=6&db=m The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin. ongoing research,therapeutic application,unassigned 3,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9393589&form=6&db=m A prospective study on the prognostic significance of urokinase-type plasminogen activator levels in breast cancer tissue. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,4,1 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9395066&form=6&db=m Increased expression of alpha-enolase in c-jun transformed rat fibroblasts without increased activation of plasminogen. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9422083&form=6&db=m Inhibitory effect of amiloride on the urokinase plasminogen activators in prostatic cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,3,4,1 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9454229&form=6&db=m [Tissue and urokinase plasminogen activators (t-PA, u-PA) and their inhibitor PAI-1 in blood of patients with laryngeal neoplasms] ongoing research,therapeutic application,unassigned 4,2,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9454902&form=6&db=m The expression of urokinase-related genes in superficial and invasive transitional cell carcinoma. ongoing research,unassigned 3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9482108&form=6&db=m The plasminogen activator system in pancreas cancer: role of t-PA in the invasive potential in vitro. causal interaction,ongoing research,unassigned 3,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9496254&form=6&db=m Cellular localization of urokinase-type plasminogen activator, its inhibitors, and their mRNAs in breast cancer tissues. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,2,4,1 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9503357&form=6&db=m Hemostatic and fibrinolytic indices in neonatal foals with presumed septicemia. therapeutic application,unassigned 1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9521847&form=6&db=m Sulfated glycosaminoglycans enhance tumor cell invasion in vitro by stimulating plasminogen activation. causal interaction,therapeutic application,unassigned 3,2,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9528837&form=6&db=m Prognostic significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in primary breast cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,4,2 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9540288&form=6&db=m Cancer metastasis: biological and clinical aspects. causal interaction,diagnostic usage,unassigned 4,2,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9588874&form=6&db=m In vitro tumor angiogenesis assays: plasminogen lysine binding site 1 inhibits in vitro tumor-induced angiogenesis. causal interaction,diagnostic usage,ongoing research,unassigned 1,3,2,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9605771&form=6&db=m Expression of urokinase-type plasminogen activator (u-PA), u-PA receptor, and tissue-type PA messenger RNAs in human hepatocellular carcinoma. causal interaction,diagnostic usage,ongoing research,unassigned 3,3,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9610735&form=6&db=m HT-1080 fibrosarcoma cell matrix degradation and invasion are inhibited by the matrix-associated serine protease inhibitor TFPI-2/33 kDa MSPI. causal interaction,ongoing research,unassigned 3,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9622213&form=6&db=m Profibrinolytic properties characterize a stably transformed human endothelial cell line. therapeutic application,unassigned 1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9626814&form=6&db=m Time and dose dependency of the suppression of pulmonary metastases of rat mammary cancer by amiloride. causal interaction,unassigned 4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9654084&form=6&db=m A bifunctional hybrid molecule of the amino-terminal fragment of urokinase and domain II of bikunin efficiently inhibits tumor cell invasion and metastasis. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,2,1 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9665481&form=6&db=m Activation of the urokinase plasminogen activator/urokinase plasminogen activator receptor system and redistribution of E-cadherin are associated with hepatocyte growth factor-induced motility of pancreas tumor cells overexpressing Met. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9671388&form=6&db=m Reduced metastasis of Polyoma virus middle T antigen-induced mammary cancer in plasminogen-deficient mice. causal interaction,diagnostic usage,ongoing research,unassigned 4,1,2,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9679732&form=6&db=m Anti-urokinase-type plasminogen activator monoclonal antibodies inhibit the proliferation of human breast cancer cell lines in vitro. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9679953&form=6&db=m Tissue inhibitor of metalloproteinase-2 protection of matrix metalloproteinase-2 from degradation by plasmin is reversed by divalent cation chelator EDTA and the bisphosphonate alendronate. causal interaction,unassigned 4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9685160&form=6&db=m Combined effects of angiostatin and ionizing radiation in antitumour therapy. diagnostic usage,ongoing research,therapeutic application,unassigned 3,3,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9699667&form=6&db=m Viral vector-targeted antiangiogenic gene therapy utilizing an angiostatin complementary DNA. causal interaction,unassigned 1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9701244&form=6&db=m Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9710261&form=6&db=m Microglial cells prevent nitric oxide-induced neuronal apoptosis in vitro. causal interaction,unassigned 4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9714330&form=6&db=m The field bean protease inhibitor has the potential to suppress B16F10 melanoma cell lung metastasis in mice. causal interaction,ongoing research,therapeutic application,unassigned 3,4,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9772277&form=6&db=m Multifunctional potential of the plasminogen activation system in tumor invasion and metastasis (review). causal interaction,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9815897&form=6&db=m Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,2,1 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9816210&form=6&db=m Proteases as prognostic markers in cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9823336&form=6&db=m Role of the plasminogen activator and matrix metalloproteinase systems in epidermal growth factor- and scatter factor-stimulated invasion of carcinoma cells. causal interaction,ongoing research,therapeutic application,unassigned 1,2,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9849413&form=6&db=m Quality control of immunohistochemical evaluation of tumour-associated plasminogen activators and related components. European BIOMED-1 Concerted Action on Clinical Relevance of Proteases in Tumour Invasion and Metastasis. diagnostic usage,unassigned 3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9857663&form=6&db=m [Urokinase plasminogen activator /U-PA/in blood of patients with lung cancer] causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,2 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9861174&form=6&db=m Regulation of collagenolysis and cell death by plasmin within the formative stigma of preovulatory ovine follicles. causal interaction,therapeutic application,unassigned 4,2,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9862716&form=6&db=m Matrix metalloproteinases generate angiostatin: effects on neovascularization. causal interaction,unassigned 3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9865723&form=6&db=m Potentiation of the antitumor effect of ionizing radiation by brief concomitant exposures to angiostatin. diagnostic usage,unassigned 3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9872599&form=6&db=m Plasminogen activator system modulates invasive capacity and proliferation in prostatic tumor cells. causal interaction,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9949291&form=6&db=m Modulation of tumor cell motility by plasmin. causal interaction,ongoing research,unassigned 1,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9988531&form=6&db=m Characterization of the binding sites for plasminogen and tissue-type plasminogen activator in cytokeratin 8 and cytokeratin 18. ongoing research,therapeutic application,unassigned 2,2,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10025966&form=6&db=m Three receptor genes for plasminogen related growth factors in the genome of the puffer fish Fugu rubripes. unassigned - 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10066093&form=6&db=m Urokinase induces receptor mediated brain tumor cell migration and invasion. diagnostic usage,ongoing research,unassigned 3,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10086616&form=6&db=m Expression pattern of the plasminogen activator-plasmin system in human cholesteatoma. ongoing research,unassigned 4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10087312&form=6&db=m HER-2/neu gene amplification by fluorescence in situ hybridization allows risk-group assessment in node-negative breast cancer. diagnostic usage,ongoing research,unassigned 4,2,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10090848&form=6&db=m Role of urokinase plasminogen activator receptor in thrombospondin 1-mediated tumor cell invasion. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,3,3,2 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10094378&form=6&db=m Urokinase and plasminogen activator-inhibitor (PAI-1) status in primary ovarian carcinomas and ovarian metastases compared to benign ovarian tumors as a function of histopathological parameters. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10188903&form=6&db=m Comparison of immunohistochemistry with immunoassay (ELISA) for the detection of components of the plasminogen activation system in human tumour tissue. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,3,2,1 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10190291&form=6&db=m Plasminogen activation in human leukemia and in normal hematopoietic cells. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,1 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10190293&form=6&db=m The urokinase plasminogen activator receptor in blood from healthy individuals and patients with cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,4,1 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10190294&form=6&db=m Urokinase receptor antagonists: discovery and application to in vivo models of tumor growth. causal interaction,ongoing research,unassigned 4,3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10191831&form=6&db=m Revisiting the role of fat mass in the life extension induced by caloric restriction. unassigned - 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10199063&form=6&db=m [Serum protein fractions in patients with laryngeal cancer undergoing radiation therapy. Possibility as a prognostic factor] causal interaction,diagnostic usage,therapeutic application,unassigned 2,4,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10208979&form=6&db=m Plasmin cleaves tumor necrosis factor alpha exodomain from sheep follicular endothelium: implication in the ovulatory process. causal interaction,ongoing research,unassigned 1,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10211984&form=6&db=m Expression and localization of urokinase-type plasminogen activator in human spinal column tumors. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,4,2 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10340907&form=6&db=m Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis. causal interaction,diagnostic usage,ongoing research,unassigned 3,4,3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10347197&form=6&db=m Activation mechanisms of the urokinase-type plasminogen activator promoter by hepatocyte growth factor/scatter factor. causal interaction,unassigned 2,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10357086&form=6&db=m The role of the plasminogen activation system in cancer. causal interaction,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10361257&form=6&db=m Elevated plasminogen receptor expression occurs as a degradative phase event in cellular apoptosis. causal interaction,unassigned 4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10365741&form=6&db=m Blast cell-surface and plasma soluble urokinase receptor in acute leukemia patients: relationship to classification and response to therapy. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,3,2 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10408691&form=6&db=m Granulocyte, granulocyte-macrophage, and macrophage colony-stimulating factors can stimulate the invasive capacity of human lung cancer cells. causal interaction,diagnostic usage,ongoing research,unassigned 1,3,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10425106&form=6&db=m 4-Heterocyclohexanone-based inhibitors of the serine protease plasmin. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10480164&form=6&db=m [Urokinase plasminogen activation system and its role in cancer progression] therapeutic application,unassigned 1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10487126&form=6&db=m [The clinical prospects for the study of the plasminogen activation system in breast cancer] causal interaction,diagnostic usage,ongoing research,unassigned 4,3,3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10504054&form=6&db=m Effect of retinoic acid on plasminogen activator expression in human melanoma cells. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,4,1 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10506224&form=6&db=m Regulation of angiostatin production by matrix metalloproteinase-2 in a model of concomitant resistance. causal interaction,ongoing research,unassigned 3,3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10512718&form=6&db=m Structure of the complex of the antistasin-type inhibitor bdellastasin with trypsin and modelling of the bdellastasin-microplasmin system. causal interaction,therapeutic application,unassigned 4,2,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10524570&form=6&db=m Degradation of extracellular matrix by metastatic follicular thyroid carcinoma cell lines: role of the plasmin activation system. causal interaction,ongoing research,unassigned 4,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10529387&form=6&db=m The tumor-suppressing activity of angiostatin protein resides within kringles 1 to 3. therapeutic application,unassigned 3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10547582&form=6&db=m Urokinase gene expression indicates early invasive growth in squamous cell lesions of the uterine cervix. causal interaction,therapeutic application,unassigned 3,2,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10554801&form=6&db=m Plasminogen activation in human acute leukaemias. causal interaction,unassigned 4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10578524&form=6&db=m Role of annexin II tetramer in plasminogen activation. causal interaction,unassigned 4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10582698&form=6&db=m Inhibition of tumor growth correlates with the expression level of a human angiostatin transgene in transfected B16F10 melanoma cells. therapeutic application,unassigned 4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10604721&form=6&db=m Generation of angiostatin-like fragments from plasminogen by prostate-specific antigen. diagnostic usage,ongoing research,therapeutic application,unassigned 3,3,2,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10613657&form=6&db=m The procoagulant state of the VX-2 tumor in rabbit lung in vivo--relative accumulation of fibrinogen, prothrombin, plasminogen, antithrombin and heparin cofactor II within the tumor. ongoing research,therapeutic application,unassigned 1,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10628317&form=6&db=m Combined treatment with serine protease inhibitor aprotinin and matrix metalloproteinase inhibitor Batimastat (BB-94) does not prevent invasion of human esophageal and ovarian carcinoma cells in vivo. causal interaction,ongoing research,therapeutic application,unassigned 2,3,2,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10629572&form=6&db=m Causes of venous thrombosis in fifty Chinese patients. causal interaction,diagnostic usage,therapeutic application,unassigned 2,2,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10629628&form=6&db=m Angiostatin fragments in urine from patients with malignant disease. diagnostic usage,ongoing research,unassigned 3,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10642175&form=6&db=m Plasminogen-independent initiation of the pro-urokinase activation cascade in vivo. Activation of pro-urokinase by glandular kallikrein (mGK-6) in plasminogen-deficient mice. unassigned - 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10645173&form=6&db=m The molecular biology of colorectal cancer development and the associated genetic events. ongoing research,unassigned 3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10666386&form=6&db=m Cellular distribution and clinical value of urokinase-type plasminogen activator, its receptor, and plasminogen activator inhibitor-2 in esophageal squamous cell carcinoma. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,4,1 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10676647&form=6&db=m The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10681423&form=6&db=m Elevated matrix metalloprotease and angiostatin levels in integrin alpha 1 knockout mice cause reduced tumor vascularization. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,1,3,1 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10684070&form=6&db=m [Changes of serum TNF-alpha level, t-PA activivty and PAI activity in patients with silent myocardial ischemia or silent cerebral ischemia] diagnostic usage,ongoing research,unassigned 4,2,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10692867&form=6&db=m Plasmin-tumour necrosis factor interaction in the ovulatory process. causal interaction,unassigned 1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10704735&form=6&db=m Correlation of tissue and blood plasminogen activation system in breast cancer. causal interaction,ongoing research,therapeutic application,unassigned 3,3,2,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10737043&form=6&db=m [The role of proteolytic enzymes in skin neoplasm progression and development of metastasis] causal interaction,diagnostic usage,unassigned 3,3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10738907&form=6&db=m Molecular basis of specific inhibition of urokinase plasminogen activator by amiloride. causal interaction,unassigned 1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10763146&form=6&db=m Long-term follow-up confirms prognostic impact of PAI-1 and cathepsin D and L in primary breast cancer. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10810205&form=6&db=m Proteolytic and cellular death mechanisms in ovulatory ovarian rupture. causal interaction,unassigned 1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10811477&form=6&db=m A novel strategy for the tumor angiogenesis-targeted gene therapy: generation of angiostatin from endogenous plasminogen by protease gene transfer. causal interaction,ongoing research,therapeutic application,unassigned 3,2,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10824888&form=6&db=m Clinical significance of urokinase-type plasminogen activator activity in hepatocellular carcinoma. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,1 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10842188&form=6&db=m Angiostatin generation by human tumor cell lines: involvement of plasminogen activators. diagnostic usage,ongoing research,unassigned 2,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10849328&form=6&db=m Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor, and plasminogen activator inhibitor-1 and -2 in hepatocellular carcinoma. causal interaction,ongoing research,therapeutic application,unassigned 3,4,3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10894364&form=6&db=m Up-regulation of urokinase-type plasminogen activator and its receptor correlates with enhanced invasion activity of human glioma cells mediated by transforming growth factor-alpha or basic fibroblast growth factor. causal interaction,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10910058&form=6&db=m A plasmin-derived hexapeptide from the carboxyl end of osteocalcin counteracts oxytocin-mediated growth inhibition [corrected] of osteosarcoma cells. causal interaction,ongoing research,unassigned 1,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10917542&form=6&db=m Tumour cell thrombospondin-1 regulates tumour cell adhesion and invasion through the urokinase plasminogen activator receptor. causal interaction,ongoing research,therapeutic application,unassigned 2,3,2,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10949579&form=6&db=m The plasminogen activation system in tumor growth, invasion, and metastasis. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11008205&form=6&db=m Urokinase-type plasminogen activator and its receptor in colorectal cancer: independent prognostic factors of metastasis and cancer-specific survival and potential therapeutic targets. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,2,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11012100&form=6&db=m Clinical evidence for correlation of insufficient tissue oxygen supply (hypoxia) and tumor-associated proteolysis in squamous cell carcinoma of the head and neck. causal interaction,unassigned 4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11018544&form=6&db=m Synthesis and HPLC analysis of enzymatically cleavable linker consisting of poly(ethylene glycol) and dipeptide for the development of immunoconjugate. unassigned - 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11054636&form=6&db=m Beneficial effects of retinoic acid on extracellular matrix degradation and attachment behaviour in follicular thyroid carcinoma cell lines. causal interaction,ongoing research,unassigned 1,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11060794&form=6&db=m Cancer treatment with inhibitors of urokinase-type plasminogen activator and plasmin. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11062719&form=6&db=m Prognostic relevance of urokinase type plasminogen activator, its receptor and inhibitors in chondrosarcoma. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,4,3 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11063652&form=6&db=m Differential mRNA expression of urokinase-type plasminogen activator, plasminogen activator receptor and plasminogen activator inhibitor type-2 in normal human endometria and endometrial carcinomas. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11122773&form=6&db=m New concepts in fibrinolysis and angiogenesis. unassigned - 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11123326&form=6&db=m Borrelia burgdorferi and other bacterial products induce expression and release of the urokinase receptor (CD87). causal interaction,unassigned 3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11130727&form=6&db=m Phosphoglycerate kinase acts in tumour angiogenesis as a disulphide reductase. causal interaction,ongoing research,therapeutic application,unassigned 3,4,2,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11136569&form=6&db=m Clinical relevance of urokinase-type plasminogen activator, its receptor, and its inhibitor type 1 in endometrial cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,2,4 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11212246&form=6&db=m Direct evidence of the importance of stromal urokinase plasminogen activator (uPA) in the growth of an experimental human breast cancer using a combined uPA gene-disrupted and immunodeficient xenograft model. diagnostic usage,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11223863&form=6&db=m The role and regulation of urokinase-type plasminogen activator receptor gene expression in cancer invasion and metastasis. causal interaction,unassigned 4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11231925&form=6&db=m Impact of apolipoprotein(a) on in vitro angiogenesis. causal interaction,unassigned 3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11240701&form=6&db=m Clinical relevance of urokinase-type plasminogen activator, its receptor and inhibitor type 1 in ovarian cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,3 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11241411&form=6&db=m VEGF-B expression in human primary breast cancers is associated with lymph node metastasis but not angiogenesis. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11266468&form=6&db=m The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin. Implications for antiangiogenic strategies. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,3,3 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11278833&form=6&db=m Targeting of tumor cells by cell surface urokinase plasminogen activator-dependent anthrax toxin. causal interaction,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11283927&form=6&db=m Human macrophage metalloelastase gene expression in colorectal carcinoma and its clinicopathologic significance. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,3,3 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11304683&form=6&db=m Dedifferentiation of serous ovarian cancer from cystic to solid tumors is associated with increased expression of mRNA for urokinase plasminogen activator (uPA), its receptor (uPAR) and its inhibitor (PAI-1). causal interaction,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11312111&form=6&db=m The chicken Chemotactic and Angiogenic Factor (cCAF), a CXC chemokine. causal interaction,therapeutic application,unassigned 2,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11312674&form=6&db=m Polymeric prodrug for release of an antitumoral agent by specific enzymes. unassigned - 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11329087&form=6&db=m Urokinase and tissue plasminogen activators and their inhibitor PAI-1 in human tumors. causal interaction,diagnostic usage,ongoing research,unassigned 4,2,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11352966&form=6&db=m Functional evaluation of plasmin formation in primary breast cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,1,1 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11356130&form=6&db=m Regional differences in protein production by human adipose tissue. causal interaction,unassigned 1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11389038&form=6&db=m Plasmin-induced expression of cytokines and tissue factor in human monocytes involves AP-1 and IKKbeta-mediated NF-kappaB activation. therapeutic application,unassigned 2,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11393999&form=6&db=m [Extracellular matrix degradation enzymes: important factors in liver metastasis of colorectal cancer and good targets for anticancer metastatic therapy] causal interaction,ongoing research,unassigned 3,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11413046&form=6&db=m The urokinase receptor associated protein (uPARAP/endo180): a novel internalization receptor connected to the plasminogen activation system. unassigned - 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11472243&form=6&db=m Anticancer prodrugs for application in monotherapy: targeting hypoxia, tumor-associated enzymes, and receptors. causal interaction,unassigned 4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11510147&form=6&db=m [Plasminogen activators of urokinase and tissue types and their inhibitor (PAI-1) in cytosol fraction in thyroid diseases] causal interaction,diagnostic usage,ongoing research,unassigned 3,2,2,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11525425&form=6&db=m No association between the 4g/5G polymorphism of the plasminogen activator inhibitor-1 gene promoter and autistic disorder. causal interaction,therapeutic application,unassigned 2,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11544332&form=6&db=m Urokinase plasminogen activator and plasmin efficiently convert hemofiltrate CC chemokine 1 into its active. causal interaction,unassigned 2,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11549774&form=6&db=m Update on tumor cell procoagulant factors. therapeutic application,unassigned 1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11555588&form=6&db=m The accumulation of angiostatin-like fragments in human prostate carcinoma. diagnostic usage,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11556845&form=6&db=m The topology of plasminogen binding and activation on the surface of human breast cancer cells. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,4,1 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11592401&form=6&db=m Cyclo19,31[D-Cys19]-uPA19-31 is a potent competitive antagonist of the interaction of urokinase-type plasminogen activator with its receptor (CD87). causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11676260&form=6&db=m [Modern prospects for molecular-biochemical methods for evaluating biological "behavior" of breast neoplasms] diagnostic usage,ongoing research,therapeutic application,unassigned 1,2,2,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11683633&form=6&db=m p22 is a novel plasminogen fragment with antiangiogenic activity. ongoing research,therapeutic application,unassigned 4,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11687850&form=6&db=m Tissue- and urokinase-type plasminogen activators and type 1 plasminogen activator inhibitor in melanomas and benign skin pigment neoplasms. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,3,1 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11687895&form=6&db=m Angiostatin enhances B7.1-mediated cancer immunotherapy independently of effects on vascular endothelial growth factor expression. ongoing research,therapeutic application,unassigned 2,3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11687948&form=6&db=m The hemostatic system and angiogenesis in malignancy. causal interaction,therapeutic application,unassigned 1,2,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11689350&form=6&db=m Cytokeratin 8 functions as a major plasminogen receptor in select epithelial and carcinoma cells. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,2,3 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11692146&form=6&db=m Effect of earthworm (G-90) extract on formation and lysis of clots originated from venous blood of dogs with cardiopathies and with malignant tumors. causal interaction,unassigned 4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11713566&form=6&db=m Plasminogen activators and their inhibitor in bone tumors and tumor-like damages. diagnostic usage,ongoing research,therapeutic application,unassigned 3,2,2,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11724284&form=6&db=m Inhibition of tumor growth by plasminogen-related protein-B. ongoing research,therapeutic application,unassigned 4,2,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11727504&form=6&db=m Interference with the urokinase plasminogen activator system: a promising therapy concept for solid tumours. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11748970&form=6&db=m Role of integrins in invasion of endometrial cancer cell lines. diagnostic usage,ongoing research,unassigned 1,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11751520&form=6&db=m Glioma cells deficient in urokinase plaminogen activator receptor expression are susceptible to tumor necrosis factor-alpha-related apoptosis-inducing ligand-induced apoptosis. causal interaction,ongoing research,therapeutic application,unassigned 3,4,2,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11769462&form=6&db=m [Regulation of microglial cell function by ATP] therapeutic application,unassigned 1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11782484&form=6&db=m Plasmin reduction by phosphoglycerate kinase is a thiol-independent process. causal interaction,unassigned 2,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11795262&form=6&db=m A mediator of cell surface-specific plasmin generation. causal interaction,ongoing research,therapeutic application,unassigned 3,4,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11803470&form=6&db=m Low plasma levels of matrix metalloproteinase 9 permit increased tumor angiogenesis. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,4 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11806282&form=6&db=m [Role of plasminogen activator inhibitor type 1 in tumor angiogenesis] causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,4,4 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11814314&form=6&db=m Epidermal growth factor and pro-inflammatory cytokines regulate the expression of components of plasminogen activation system in U373-MG astrocytoma cells. causal interaction,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11815288&form=6&db=m Annexin II: a plasminogen-plasminogen activator co-receptor. causal interaction,diagnostic usage,ongoing research,unassigned 1,3,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11876553&form=6&db=m A C/T polymorphism in the urokinase-type plasminogen activator gene in colorectal cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,1,1 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11885021&form=6&db=m Treatment of malignancy by activation of the plasminogen system. causal interaction,ongoing research,therapeutic application,unassigned 3,3,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11912164&form=6&db=m Hypoxia promotes lymph node metastasis in human melanoma xenografts by up-regulating the urokinase-type plasminogen activator receptor. causal interaction,ongoing research,therapeutic application,unassigned 3,2,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11920633&form=6&db=m Urokinase receptor-associated protein (uPARAP) is expressed in connection with malignant as well as benign lesions of the human breast and occurs in specific populations of stromal cells. causal interaction,ongoing research,therapeutic application,unassigned 3,1,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11928810&form=6&db=m Plasmin produces an E-cadherin fragment that stimulates cancer cell invasion. unassigned - 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11930939&form=6&db=m uPA-silica-Particles (SP-uPA): a novel analytical system to investigate uPA-uPAR interaction and to test synthetic uPAR antagonists as potential cancer therapeutics. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11953898&form=6&db=m Expression pattern of the urokinase-plasminogen activator system in rat DS-sarcoma: role of oxygenation status and tumour size. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,2,3 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11970751&form=6&db=m Selection criteria for epirubicin-based adjuvant chemotherapy in node-negative breast cancer. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11990465&form=6&db=m Fibrinogen and tumor cell metastasis. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12014682&form=6&db=m u-PA expression in benign, borderline and malignant ovarian tumors. causal interaction,unassigned 4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12017303&form=6&db=m Clinical value of components of the plasminogen activation system in ovarian cyst fluid. causal interaction,diagnostic usage,ongoing research,unassigned 1,3,3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12023849&form=6&db=m Cellular mechanisms regulating non-haemostatic plasmin generation. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12115581&form=6&db=m Differential production of angiostatin by concomitant antitumoral resistance-inducing cancer cells. ongoing research,unassigned 4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12142386&form=6&db=m Quantitative real-time reverse transcription-PCR assay for urokinase plasminogen activator, plasminogen activator inhibitor type 1, and tissue metalloproteinase inhibitor type 1 gene expressions in primary breast cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,4,1 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12147175&form=6&db=m Adenoviral gene transfer of angiostatic ATF-BPTI inhibits tumour growth. therapeutic application,unassigned 1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12189052&form=6&db=m Biological regulation through protein disulfide bond cleavage. unassigned - 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12198113&form=6&db=m Regulation of DNA methylation in human breast cancer. Effect on the urokinase-type plasminogen activator gene production and tumor invasion. causal interaction,ongoing research,unassigned 4,2,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12217749&form=6&db=m Malignant ascites fluid (MAF), including ovarian-cancer-associated MAF, contains angiostatin and other factor(s) which inhibit angiogenesis. diagnostic usage,ongoing research,unassigned 1,3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12221535&form=6&db=m Differential regulation of collagen degradation by rabbit keratocytes and polymorphonuclear leukocytes. ongoing research,unassigned 4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12369939&form=6&db=m Inhibitors of the protease domain of urokinase-type plasminogen activator. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,1,3,4 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12384513&form=6&db=m Maspin inhibits cell migration in the absence of protease inhibitory activity. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,4,2 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12431980&form=6&db=m Secretion of Annexin II via activation of insulin receptor and insulin-like growth factor receptor. ongoing research,unassigned 3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12456318&form=6&db=m Regulation of plasminogen receptors. causal interaction,unassigned 4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12460914&form=6&db=m Spontaneous hematogenous and lymphatic metastasis, but not primary tumor growth or angiogenesis, is diminished in fibrinogen-deficient mice. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12461559&form=6&db=m uPAR: a versatile signalling orchestrator. therapeutic application,unassigned 1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12473585&form=6&db=m Soluble aminopeptidase N/CD13 in malignant and nonmalignant effusions and intratumoral fluid. causal interaction,ongoing research,unassigned 4,2,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12481411&form=6&db=m Design, synthesis, and biological evaluation of a dual tumor-specific motive containing integrin-targeted plasmin-cleavable doxorubicin prodrug. causal interaction,unassigned 3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12483152&form=6&db=m [Molecular pathways of pancreatic carcinogenesis] causal interaction,unassigned 4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12483535&form=6&db=m Plasminogen promotes sarcoma growth and suppresses the accumulation of tumor-infiltrating macrophages. causal interaction,ongoing research,therapeutic application,unassigned 3,3,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12494864&form=6&db=m A novel plasmin-inhibitor inhibits the growth of human tumor xenografts and decreases metastasis number. ongoing research,unassigned 4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12525700&form=6&db=m Potent antitumor activity of a urokinase-activated engineered anthrax toxin. diagnostic usage,ongoing research,therapeutic application,unassigned 3,3,2,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12527529&form=6&db=m [Assessment of variables relative to prethrombotic state after operation in patients with gynecological malignancies] diagnostic usage,ongoing research,therapeutic application,unassigned 3,2,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12529357&form=6&db=m Anti-angiogenic activity of the recombinant kringle domain of urokinase and its specific entry into endothelial cells. causal interaction,unassigned 3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12554702&form=6&db=m p11 regulates extracellular plasmin production and invasiveness of HT1080 fibrosarcoma cells. causal interaction,ongoing research,therapeutic application,unassigned 3,4,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12557575&form=6&db=m [Role of PAI-1 plasminogen activator inhibitor in tumor invasion and angiogenesis] causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12569552&form=6&db=m Suppression of invasion and peritoneal carcinomatosis of ovarian cancer cell line by overexpression of bikunin. causal interaction,therapeutic application,unassigned 3,3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12571629&form=6&db=m Lentivirus-mediated expression of angiostatin efficiently inhibits neovascularization in a murine proliferative retinopathy model. diagnostic usage,unassigned 3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12601681&form=6&db=m Effects of the ethyl acetate fraction of Spatholobi caulis on tumour cell aggregation and migration. unassigned - 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12619063&form=6&db=m Quantitative expression of protein markers of plasminogen activation system in prognosis of colorectal cancer. diagnostic usage,ongoing research,unassigned 4,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12700073&form=6&db=m Plasminogen binding and cancer: promises and pitfalls. causal interaction,diagnostic usage,unassigned 4,3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12708473&form=6&db=m Urokinase-type plasminogen activator expression correlates with tumor angiogenesis and poor outcome in gastric cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,3,1,1 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12720300&form=6&db=m Defective processing of the transforming growth factor-beta1 in azoxymethane-induced mouse colon tumors. causal interaction,ongoing research,therapeutic application,unassigned 3,2,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12736046&form=6&db=m Association of plasma urokinase-type plasminogen activator and its receptor with clinical outcome in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12737307&form=6&db=m Role of plasminogen activator-plasmin system in tumor angiogenesis. unassigned - 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12757937&form=6&db=m Vitronectin in human breast carcinomas. causal interaction,ongoing research,unassigned 1,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12764090&form=6&db=m Exploitation of astrocytes by glioma cells to facilitate invasiveness: a mechanism involving matrix metalloproteinase-2 and the urokinase-type plasminogen activator-plasmin cascade. causal interaction,ongoing research,unassigned 2,3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12783107&form=6&db=m Posttranscriptional regulation of PAI-1 gene expression. causal interaction,unassigned 3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12784997&form=6&db=m The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy. causal interaction,diagnostic usage,therapeutic application,unassigned 3,2,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12785198&form=6&db=m [Urokinase and tissue type plasminogen activators and their type-1 inhibitor (PAI-1) in gastric cancer] causal interaction,diagnostic usage,ongoing research,therapeutic application 2,3,3,1 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12789617&form=6&db=m Synthetic urokinase inhibitors as potential antitumor drugs. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12790317&form=6&db=m The urokinase receptor (uPAR, CD87) as a target for tumor therapy: uPA-silica particles (SP-uPA) as a new tool for assessing synthetic peptides to interfere with uPA/uPA-receptor interaction. causal interaction,ongoing research,therapeutic application,unassigned 2,3,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12790319&form=6&db=m Stromal cell involvement in cancer. unassigned - 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12790320&form=6&db=m Inhibition of the tumor-associated urokinase-type plasminogen activation system: effects of high-level synthesis of soluble urokinase receptor in ovarian and breast cancer cells in vitro and in vivo. causal interaction,ongoing research,therapeutic application,unassigned 3,4,3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12817471&form=6&db=m The protease inhibitor bikunin, a novel anti-metastatic agent. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12829586&form=6&db=m Plasminogen supports tumor growth through a fibrinogen-dependent mechanism linked to vascular patency. causal interaction,unassigned 3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12853975&form=6&db=m Metastasis of transgenic breast cancer in plasminogen activator inhibitor-1 gene-deficient mice. causal interaction,ongoing research,therapeutic application,unassigned 4,2,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12871064&form=6&db=m Inhibitors of the proteolytic activity of urokinase type plasminogen activator. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12871066&form=6&db=m Urokinase-type plasminogen activator (uPA) and its receptor (uPAR): development of antagonists of uPA/uPAR interaction and their effects in vitro and in vivo. causal interaction,unassigned 4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12888936&form=6&db=m Occurrence of components of fibrinolytic pathways in situ in laryngeal cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,1,4,1 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12893190&form=6&db=m Three-dimensional coculture of endometrial cancer cells and fibroblasts in human placenta derived collagen sponges and expression matrix metalloproteinases in these cells. ongoing research,therapeutic application,unassigned 4,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12942549&form=6&db=m Urokinase type plasminogen activator receptor is involved in insulin-like growth factor-induced migration of rhabdomyosarcoma cells in vitro. causal interaction,ongoing research,unassigned 1,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=13104458&form=6&db=m Prostatic fibrinolysin; study of a case illustrating role in hemorrhagic diathesis of cancer of the prostate. causal interaction,ongoing research,unassigned 1,2,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=13694103&form=6&db=m Cancer cells in the blood in simulated colon cancer, resectable and unresectable: effect of fibrinolysin and heparin on growth potential. ongoing research,therapeutic application,unassigned 3,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=13850239&form=6&db=m Action of antibodies and plasmin on Ehrlich ascites tumour cells. diagnostic usage,ongoing research,unassigned 3,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14008905&form=6&db=m On the changes of plasmin activity caused by radiation treatment in cancer patients and effects of antiplasmin (ipsilon) administration. therapeutic application,unassigned 4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14008906&form=6&db=m [On the changes of plasmin activity caused by radiation treatment in cancer patients and effects of antiplasmin (Ipsilon) administration.] therapeutic application,unassigned 4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14176120&form=6&db=m EFFECT OF PLASMIN THERAPY ON BLOOD COAGULATION AND ON PLASMA PROTEINS IN PATIENTS WITH CANCER. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,4,2 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14535592&form=6&db=m Limited prognostic value of c-erbB-2 compared to uPA and PAI-1 in primary breast carcinoma. diagnostic usage,ongoing research,unassigned 3,2,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14570893&form=6&db=m RNA interference-mediated silencing of the S100A10 gene attenuates plasmin generation and invasiveness of Colo 222 colorectal cancer cells. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14583633&form=6&db=m The antitumor properties of the alpha3(IV)-(185-203) peptide from the NC1 domain of type IV collagen (tumstatin) are conformation-dependent. causal interaction,unassigned 1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14593967&form=6&db=m [The location of components of fibrinolytic system in laryngeal cancer] diagnostic usage,ongoing research,unassigned 3,3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14597403&form=6&db=m Transforming growth factor-beta1 inhibits tumor growth in a mouse melanoma model by down-regulating the plasminogen activation system. causal interaction,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14598883&form=6&db=m Growth factor-dependent activation of the MAPK pathway in human pancreatic cancer: MEK/ERK and p38 MAP kinase interaction in uPA synthesis. causal interaction,ongoing research,unassigned 4,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14619979&form=6&db=m Regulation of matrix metalloproteinases: an overview. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14623925&form=6&db=m Decreased expression of the low-density lipoprotein receptor-related protein-1 (LRP-1) in rats with prostate cancer. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14644129&form=6&db=m Amiloride and urinary trypsin inhibitor inhibit urothelial cancer invasion. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,4 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14729620&form=6&db=m Cell surface-dependent generation of angiostatin4.5. ongoing research,unassigned 2,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14734647&form=6&db=m Plasmin-activated doxorubicin prodrugs containing a spacer reduce tumor growth and angiogenesis without systemic toxicity. ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14751142&form=6&db=m Plasminogen fragmentation and increased production of extracellular matrix-degrading proteinases are associated with serous epithelial ovarian cancer progression. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,1 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14757164&form=6&db=m Inhibition of plasmin-mediated prostromelysin-1 activation by interaction of long chain unsaturated fatty acids with kringle 5. therapeutic application,unassigned 4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14963743&form=6&db=m Plasminogen activation in neurofibromatosis 2-associated and sporadic schwannomas. causal interaction,diagnostic usage,unassigned 4,3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14976916&form=6&db=m [Vascular endothelial growth factor and plasminogen activators in endometrial carcinoma and hyperplasia] causal interaction,diagnostic usage,ongoing research,therapeutic application 2,1,2,2 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15041799&form=6&db=m Effect of human Angiostatin protein on human angiogenesis in vitro. diagnostic usage,ongoing research,unassigned 3,3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15053920&form=6&db=m Secretion of phosphoglycerate kinase from tumour cells is controlled by oxygen-sensing hydroxylases. diagnostic usage,ongoing research,unassigned 1,3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15084231&form=6&db=m Prognostic molecular markers in early breast cancer. diagnostic usage,therapeutic application,unassigned 2,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15099284&form=6&db=m Tumor growth and metastasis are not affected in thrombin-activatable fibrinolysis inhibitor-deficient mice. causal interaction,therapeutic application,unassigned 4,3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15150128&form=6&db=m Endothelial cell surface ATP synthase-triggered caspase-apoptotic pathway is essential for k1-5-induced antiangiogenesis. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15166500&form=6&db=m The role of the fibrinolytic system in corneal angiogenesis. causal interaction,ongoing research,therapeutic application,unassigned 4,3,3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15172186&form=6&db=m Thrombospondin-1 up-regulates tumor cell invasion through the urokinase plasminogen activator receptor in head and neck cancer cells. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,4,1 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15177278&form=6&db=m Characterization and biological activities of recombinant human plasminogen kringle 1-3 produced in Escherichia coli. unassigned - 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15183452&form=6&db=m Sequential dynamics of inflammatory cytokine, angiogenesis inducing factor and matrix degrading enzymes during spontaneous resorption of the herniated disc. therapeutic application,unassigned 1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15194650&form=6&db=m Specific interaction of tissue-type plasminogen activator (t-PA) with annexin II on the membrane of pancreatic cancer cells activates plasminogen and promotes invasion in vitro. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,3,1 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15220341&form=6&db=m Plasminogen is tethered with high affinity to the cell surface by the plasma protein, histidine-rich glycoprotein. causal interaction,unassigned 3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15240916&form=6&db=m Tetranectin Binds to the Kringle 1-4 Form of Angiostatin and Modifies Its Functional Activity. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15274061&form=6&db=m Complex of urokinase-type plasminogen activator with its type 1 inhibitor predicts poor outcome in 576 patients with lymph node-negative breast carcinoma. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,3,2,1 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15279614&form=6&db=m The urokinase receptor as a potential target in cancer therapy. causal interaction,diagnostic usage,therapeutic application,unassigned 4,1,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15325613&form=6&db=m NS-398 inhibits tumor growth and liver metastasis of colon cancer through induction of apoptosis and suppression of the plasminogen activation system in a mouse model. causal interaction,ongoing research,unassigned 4,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15333188&form=6&db=m Evidence for the clinical use of tumour markers. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,4 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15352048&form=6&db=m Anti-tumor activity of a combination of plasminogen activator and captopril in a human melanoma xenograft model. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,4,3 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15490235&form=6&db=m A hybrid protein of the amino-terminal fragment of urokinase and mutant plasminogen activator inhibitor-2 efficiently inhibits tumor cell invasion and metastasis. causal interaction,unassigned 2,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15509494&form=6&db=m Detection of plasminogen activators in oral cancer by laser capture microdissection combined with zymography. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,2,2,1 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15515049&form=6&db=m Expression of urokinase plasminogen activator, its receptor and type-1 inhibitor in malignant and benign prostate tissue. causal interaction,diagnostic usage,ongoing research,unassigned 3,2,3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15530861&form=6&db=m In vivo overexpression of tumstatin domains by tumor cells inhibits their invasive properties in a mouse melanoma model. causal interaction,therapeutic application,unassigned 3,2,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15572024&form=6&db=m Angiostatin directly inhibits human prostate tumor cell invasion by blocking plasminogen binding to its cellular receptor, CD26. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,4,1 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15574370&form=6&db=m S100A10, annexin A2, and annexin a2 heterotetramer as candidate plasminogen receptors. causal interaction,unassigned 4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15688761&form=6&db=m [Urokinase-type plasminogen activator (uPA) and its inhibitor--new prognostic factors in oral squamous cell carcinoma] causal interaction,diagnostic usage,ongoing research,therapeutic application 3,2,3,1 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15711732&form=6&db=m Soluble and cleaved forms of the urokinase-receptor: degradation products or active molecules? causal interaction,unassigned 3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15711734&form=6&db=m The urokinase plasminogen activator and its receptor: role in cell growth and apoptosis. therapeutic application,unassigned 1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15720817&form=6&db=m Host plasminogen activator inhibitor-1 promotes human skin carcinoma progression in a stage-dependent manner. causal interaction,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15761961&form=6&db=m Proteolytic-antiproteolytic balance and its regulation in carcinogenesis. causal interaction,unassigned 4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15769664&form=6&db=m Plasminogen receptors: the sine qua non of cell surface plasminogen activation. causal interaction,ongoing research,therapeutic application,unassigned 3,2,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15771956&form=6&db=m Effective gene-virotherapy for complete eradication of tumor mediated by the combination of hTRAIL (TNFSF10) and plasminogen k5. therapeutic application,unassigned 2,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15781388&form=6&db=m 3D-QSAR CoMFA studies on trypsin-like serine protease inhibitors: a comparative selectivity analysis. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15789064&form=6&db=m Full kringles of plasminogen (aa 1-566) mediate complete regression of human MDA-MB-231 breast tumor xenografted in nude mice. causal interaction,ongoing research,therapeutic application,unassigned 3,3,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15796165&form=6&db=m Antimetastatic activity of a synthetic serine protease inhibitor, FOY-305 (Foypan). unassigned - 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15840902&form=6&db=m Angiostatin is negatively associated with coronary collateral growth in patients with coronary artery disease. causal interaction,unassigned 3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15841311&form=6&db=m Plasminogen activation and cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,1,3,4 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15841327&form=6&db=m Suppression of rat breast cancer metastasis and reduction of primary tumour growth by the small synthetic urokinase inhibitor WX-UK1. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,1,4 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15875078&form=6&db=m Inhibitors of proteases as anticancer drugs. causal interaction,ongoing research,unassigned 1,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15878520&form=6&db=m Tumour-associated urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in normal and neoplastic tissues of patients with squamous cell cancer of the oral cavity - clinical relevance and prognostic value. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,3,2 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15894933&form=6&db=m Expression of urokinase-type plasminogen activator receptor (uPAR) in primary central nervous system neoplasms. causal interaction,therapeutic application,unassigned 4,2,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15911629&form=6&db=m Association of plasminogen with dipeptidyl peptidase IV and Na+/H+ exchanger isoform NHE3 regulates invasion of human 1-LN prostate tumor cells. causal interaction,ongoing research,unassigned 4,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15915389&form=6&db=m [Role of PAI-1 in gynaecological malignancies] causal interaction,unassigned 4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15917224&form=6&db=m Characterization of the interaction between tumor necrosis factor-stimulated gene-6 and heparin: implications for the inhibition of plasmin in extracellular matrix microenvironments. ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15930284&form=6&db=m Kringle 5 of human plasminogen induces apoptosis of endothelial and tumor cells through surface-expressed glucose-regulated protein 78. ongoing research,therapeutic application,unassigned 2,2,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15966325&form=6&db=m [Preparation and functional study of an adenovirus vector expressing human plasminogen kringle 5 gene] causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15987715&form=6&db=m 1alpha,25-dihydroxyvitamin D3 inhibits prostate cancer cell invasion via modulation of selective proteases. causal interaction,therapeutic application,unassigned 4,2,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16008557&form=6&db=m Inhibition of urokinase receptor gene expression and cell invasion by anti-uPAR DNAzymes in osteosarcoma cells. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,3,1 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16021996&form=6&db=m [Plasminogen activator inhibitor type 1 (PAI-1) in blood and tissue extracts of patients with non-small cell lung cancer] causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,4,1 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16113755&form=6&db=m [Tumor-associated prognostic factors of the plasminogen activator family: determination and clinical value of u-PA, t-PA, PAI-1, and PAI-2] causal interaction,diagnostic usage,ongoing research,unassigned 3,1,2,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16127174&form=6&db=m RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo. causal interaction,ongoing research,therapeutic application,unassigned 4,2,2,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16166313&form=6&db=m Plasminogen kringle 5-engineered glioma cells block migration of tumor-associated macrophages and suppress tumor vascularization and progression. causal interaction,unassigned 2,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16209572&form=6&db=m A comparison of cyclohexanone and tetrahydro-4H-thiopyran-4-one 1,1-dioxide as pharmacophores for the design of peptide-based inhibitors of the serine protease plasmin. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16223769&form=6&db=m Antiplasmin-cleaving enzyme is a soluble form of fibroblast activation protein. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16266990&form=6&db=m Proteolysis of CCN1 by plasmin: functional implications. causal interaction,therapeutic application,unassigned 4,2,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16270643&form=6&db=m Indication of a role of plasminogen activator inhibitor type I in protecting murine fibrosarcoma cells against apoptosis. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,4 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16279944&form=6&db=m Crystal structure of the beta-chain of human hepatocyte growth factor-like/macrophage stimulating protein. unassigned - 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16291590&form=6&db=m Role of melanotransferrin in iron metabolism: studies using targeted gene disruption in vivo. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16308974&form=6&db=m [Prognostic and predictive factors in breast cancer] causal interaction,unassigned 3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16395714&form=6&db=m Expression of plasminogen activator inhibitor-1, urokinase receptor and laminin gamma-2 chain is an early coordinated event in incipient oral squamous cell carcinoma. causal interaction,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16408192&form=6&db=m Plasminogen activators and their inhibitor gene expression in cutaneous NF1-related neurofibromas. causal interaction,ongoing research,therapeutic application,unassigned 1,2,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16424020&form=6&db=m Angiostatin is directly cytotoxic to tumor cells at low extracellular pH: a mechanism dependent on cell surface-associated ATP synthase. causal interaction,ongoing research,therapeutic application,unassigned 3,4,3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16497155&form=6&db=m Interplay of human tissue kallikrein 4 (hK4) with the plasminogen activation system: hK4 regulates the structure and functions of the urokinase-type plasminogen activator receptor (uPAR). causal interaction,diagnostic usage,therapeutic application,unassigned 4,1,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16524486&form=6&db=m The fibrinolytic system facilitates tumor cell migration across the blood-brain barrier in experimental melanoma brain metastasis. causal interaction,ongoing research,therapeutic application,unassigned 3,4,3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16547007&form=6&db=m A region in urokinase plasminogen receptor domain III controlling a functional association with alpha5beta1 integrin and tumor growth. causal interaction,ongoing research,unassigned 3,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16564525&form=6&db=m Stimulation of human breast carcinoma cell invasiveness and urokinase plasminogen activator activity by glucose deprivation. causal interaction,ongoing research,unassigned 4,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16569238&form=6&db=m Coordinate regulation of fibronectin matrix assembly by the plasminogen activator system and vitronectin in human osteosarcoma cells. causal interaction,ongoing research,therapeutic application,unassigned 4,3,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16598420&form=6&db=m Inhibition of matrix degrading enzymes and invasion in human glioblastoma (U87MG) cells by isoflavones. causal interaction,unassigned 3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16617562&form=6&db=m Overexpression of the plasminogen activator inhibitor type-1 in epithelial ovarian cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,3,3 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16643891&form=6&db=m Antibody-directed targeting of angiostatin's receptor annexin II inhibits Lewis Lung Carcinoma tumor growth via blocking of plasminogen activation: Possible biochemical mechanism of angiostatin's action. causal interaction,ongoing research,therapeutic application,unassigned 4,1,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16643892&form=6&db=m Angiogenesis-associated protein annexin II in breast cancer: Selective expression in invasive breast cancer and contribution to tumor invasion and progression. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16703752&form=6&db=m Plasminogen activator inhibitor-1 promoter polymorphism is not associated with the aggressiveness of disease in prostate cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 3,2,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16713448&form=6&db=m Melanotransferrin stimulates t-PA-dependent activation of plasminogen in endothelial cells leading to cell detachment. causal interaction,unassigned 3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16756907&form=6&db=m [New prognostic and predictive factors in advanced colorectal cancer] causal interaction,diagnostic usage,therapeutic application,unassigned 3,3,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16757692&form=6&db=m Conflicting results from clinical observations and murine models: what is the role of plasminogen activators in tumor growth? causal interaction,unassigned 4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16757700&form=6&db=m Protease activity of urokinase and tumor progression in a syngeneic mammary cancer model. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,4 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16809420&form=6&db=m Plasminogen fragment K1-5 improves survival in a murine hepatocellular carcinoma model. diagnostic usage,therapeutic application,unassigned 1,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16823770&form=6&db=m Anthocyanidins inhibit migration of glioblastoma cells: structure-activity relationship and involvement of the plasminolytic system. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16849568&form=6&db=m Differential binding of plasminogen, plasmin, and angiostatin4.5 to cell surface beta-actin: implications for cancer-mediated angiogenesis. diagnostic usage,ongoing research,therapeutic application,unassigned 3,1,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16928445&form=6&db=m Differential expression of the components of the plasminogen activating system in human thyroid tumour derived cell lines and papillary carcinomas. diagnostic usage,ongoing research,unassigned 3,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17196552&form=6&db=m Melanotransferrin induces human melanoma SK-Mel-28 cell invasion in vivo. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17203182&form=6&db=m Induction of alpha2-antiplasmin inhibits E-cadherin processing mediated by the plasminogen activator/plasmin system, leading to suppression of progression of oral squamous cell carcinoma via upregulation of cell-cell adhesion. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17258232&form=6&db=m Insights into the structure/function of hepatocyte growth factor/scatter factor from studies with individual domains. unassigned - 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17308045&form=6&db=m Plasminogen Kringle 5 blocks tumor progression by antiangiogenic and proinflammatory pathways. causal interaction,therapeutic application,unassigned 2,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17363527&form=6&db=m Primary tumor levels of human tissue kallikreins affect surgical success and survival in ovarian cancer patients. causal interaction,diagnostic usage,ongoing research,unassigned 1,3,3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17390074&form=6&db=m Effects of hypoxia and reoxygenation on the expression levels of the urokinase-type plasminogen activator, its inhibitor plasminogen activator inhibitor type-1 and the urokinase-type plasminogen activator receptor in human head and neck tumour cells. causal interaction,ongoing research,therapeutic application,unassigned 3,4,2,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17442497&form=6&db=m Lipoprotein[a] and cancer: anti-neoplastic effect besides its cardiovascular potency. causal interaction,unassigned 4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17474886&form=6&db=m Fibrinolytic characteristics and their significance in malignant, tuberculous and cirrhotic pleural and ascitic fluids. causal interaction,therapeutic application,unassigned 2,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17489744&form=6&db=m Monitoring of chemotherapy successfulness of platina/taxol chemotherapy protocol by using determination of serum urokinase plasminogen activator (uPA) and soluble urokinase plasminogen activator receptor (suPAR) in patients with ovarian carcinoma FIGO II and III stage. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,2,3,2 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17549305&form=6&db=m Murine monoclonal antibodies against murine uPA receptor produced in gene-deficient mice: inhibitory effects on receptor-mediated uPA activity in vitro and in vivo. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17606760&form=6&db=m Activation of plasminogen into plasmin at the surface of endothelial microparticles: a mechanism that modulates angiogenic properties of endothelial progenitor cells in vitro. causal interaction,ongoing research,unassigned 3,3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17616807&form=6&db=m PAI-1 -675 4G/5G polymorphism as a prognostic biomarker in breast cancer. causal interaction,unassigned 4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17628030&form=6&db=m Synthesis, cleavage profile, and antitumor efficacy of an albumin-binding prodrug of methotrexate that is cleaved by plasmin and cathepsin B. causal interaction,diagnostic usage,unassigned 4,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17637685&form=6&db=m Tissue level, activation and cellular localisation of TGF-beta1 and association with survival in gastric cancer patients. causal interaction,unassigned 3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17680563&form=6&db=m Combination of human plasminogen kringle 5 with ionizing radiation significantly enhances the efficacy of antitumor effect. ongoing research,unassigned 4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17692534&form=6&db=m Structural basis of specificity of a peptidyl urokinase inhibitor, upain-1. causal interaction,ongoing research,unassigned 1,3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17721886&form=6&db=m Osteopontin overexpression in breast cancer: Knowledge gained and possible implications for clinical management. unassigned - 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17804466&form=6&db=m Polymorphisms in the genes of the urokinase plasminogen activation system in relation to colorectal cancer. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17877801&form=6&db=m Common TNF-alpha, IL-1 beta, PAI-1, uPA, CD14 and TLR4 polymorphisms are not associated with disease severity or outcome from Gram negative sepsis. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17884004&form=6&db=m Endogenous peptides from biophysical and biochemical fractionation of serum analyzed by matrix-assisted laser desorption/ionization and electrospray ionization hybrid quadrupole time-of-flight. diagnostic usage,unassigned 1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17992475&form=6&db=m Role of hepatocyte growth factor/c-Met signaling in regulating urokinase plasminogen activator on invasiveness in human hepatocellular carcinoma: a potential therapeutic target. causal interaction,ongoing research,therapeutic application,unassigned 4,2,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18030361&form=6&db=m PEGylated DX-1000: pharmacokinetics and antineoplastic activity of a specific plasmin inhibitor. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18053161&form=6&db=m Tissue factor pathway inhibitor-2 was repressed by CpG hypermethylation through inhibition of KLF6 binding in highly invasive breast cancer cells. causal interaction,diagnostic usage,unassigned 4,2,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18077030&form=6&db=m PAI-1 levels predict response to fractionated irradiation in 10 human squamous cell carcinoma lines of the head and neck. diagnostic usage,ongoing research,unassigned 2,3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18095256&form=6&db=m Cancer invasion and metastasis: changing views. causal interaction,unassigned 4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18220793&form=6&db=m The role of annexin II in angiogenesis and tumor progression: a potential therapeutic target. causal interaction,unassigned 4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18239814&form=6&db=m Relationship between expression of NM23 protein and clinical morphological factors and content of plasminogen activation system components in tumors of patients with gastric cancer. causal interaction,diagnostic usage,ongoing research,unassigned 1,2,3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18310147&form=6&db=m A new ELISA for use in a 3-ELISA system to assess concentrations of VEGF splice variants and VEGF(110) in ovarian cancer tumors. unassigned - 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18318660&form=6&db=m A cyclic peptidylic inhibitor of murine urokinase-type plasminogen activator: changing species specificity by substitution of a single residue. causal interaction,therapeutic application,unassigned 2,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18392331&form=6&db=m Mutation of human plasminogen kringle 1-5 enhances anti-angiogenic action via increased interaction with integrin alpha(v)beta(3). causal interaction,unassigned 2,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18478967&form=6&db=m Quantitative trait locus on chromosome 12q14.1 influences variation in plasma plasminogen levels in the San Antonio Family Heart Study. ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18495253&form=6&db=m The plasminogen activator inhibitor "paradox" in cancer. causal interaction,therapeutic application,unassigned 4,3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18519796&form=6&db=m Matrix metalloproteinase-9 inhibition down-regulates radiation-induced nuclear factor-kappa B activity leading to apoptosis in breast tumors. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,4,1 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18528863&form=6&db=m A hybrid protein comprising ATF domain of pro-UK and VAS, an angiogenesis inhibitor, is a potent candidate for targeted cancer therapy. causal interaction,ongoing research,unassigned 1,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18541514&form=6&db=m [New molecular targets in pancreatic cancer] causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18549921&form=6&db=m Novel cardiovascular risk factors do not completely explain the higher prevalence of peripheral arterial disease among African Americans. The San Diego Population Study. diagnostic usage,unassigned 2,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18559377&form=6&db=m A peptide accelerating the conversion of plasminogen activator inhibitor-1 to an inactive latent state. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18563800&form=6&db=m Matrix metalloproteinase-9 interplays with the IGFBP2-IGFII complex to promote cell growth and motility in astrocytomas. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,2,4 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18566996&form=6&db=m Suppression of integrin alphaupsilonbeta6 by RNA interference in colon cancer cells inhibits extracellular matrix degradation through the MAPK pathway. causal interaction,ongoing research,unassigned 2,2,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18568768&form=6&db=m Plasminogen derivatives encoding kringles 1-4 and kringles 1-5 exert indirect antiangiogenic and direct antitumoral effects in experimental lung cancer. causal interaction,ongoing research,therapeutic application,unassigned 4,4,3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18575722&form=6&db=m Mouse macrophage metalloelastase generates angiostatin from plasminogen and suppresses tumor angiogenesis in murine colon cancer. causal interaction,ongoing research,therapeutic application,unassigned 3,2,2,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18608216&form=6&db=m Annexin A2 regulates the levels of plasmin, S100A10 and Fascin in L5178Y cells. causal interaction,ongoing research,therapeutic application,unassigned 3,4,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18636232&form=6&db=m How does blood glucose control with metformin influence intensive insulin protocols? Evidence for involvement of oxidative stress and inflammatory cytokines. causal interaction,diagnostic usage,unassigned 1,3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18656632&form=6&db=m Insulin-induced epidermal growth factor activation in vascular smooth muscle cells is ADAM-dependent. ongoing research,therapeutic application,unassigned 1,3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18808175&form=6&db=m Differential proteome expression associated with urokinase plasminogen activator receptor (uPAR) suppression in malignant epithelial cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,2,4 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18814280&form=6&db=m Phosphoglycerate kinase 1-overexpressing lung cancer cells reduce cyclooxygenase 2 expression and promote anti-tumor immunity in vivo. causal interaction,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19037107&form=6&db=m Mannose 6-phosphate/insulin-like growth factor 2 receptor limits cell invasion by controlling alphaVbeta3 integrin expression and proteolytic processing of urokinase-type plasminogen activator receptor. causal interaction,ongoing research,therapeutic application,unassigned 1,3,2,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19047064&form=6&db=m A novel mode of intervention with serine protease activity: targeting zymogen activation. unassigned - 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19055748&form=6&db=m PAI-1 and functional blockade of SNAI1 in breast cancer cell migration. causal interaction,therapeutic application,unassigned 4,2,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19117638&form=6&db=m Plasminogen activator inhibitor variants PAI-1 A15T and PAI-2 S413C influence lung cancer prognosis. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,1,1,4 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19176991&form=6&db=m The plasminogen activator system and cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,3,4 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19182372&form=6&db=m Thrombomodulin suppresses invasiveness of HT1080 tumor cells by reducing plasminogen activation on the cell surface through activation of thrombin-activatable fibrinolysis inhibitor. causal interaction,ongoing research,therapeutic application,unassigned 3,3,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19195683&form=6&db=m Angiotensin II infusion in man is proinflammatory but has no short-term effects on thrombin generation in vivo. ongoing research,therapeutic application,unassigned 3,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19200050&form=6&db=m The urokinase plasminogen activator system: a target for anti-cancer therapy. causal interaction,unassigned 1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19207486&form=6&db=m Tranexamic acid can inhibit tongue squamous cell carcinoma invasion in vitro. causal interaction,diagnostic usage,therapeutic application,unassigned 4,1,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19214913&form=6&db=m Pathogenesis of venous thromboembolism: when the cup runneth over. therapeutic application,unassigned 1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19245822&form=6&db=m Generation and characterization of transgenic mice hyper-expressing melanoma tumour antigen p97 (Melanotransferrin): No overt alteration in phenotype. causal interaction,unassigned 2,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19273372&form=6&db=m The urokinase receptor as an entertainer of signal transduction. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19377918&form=6&db=m The role of plasminogen-plasmin system in cancer. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19476873&form=6&db=m Serum proteomic biomarker discovery reflective of stage and obesity in breast cancer patients. diagnostic usage,unassigned 4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19492051&form=6&db=m Surface-associated plasminogen binding of Cryptococcus neoformans promotes extracellular matrix invasion. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19513384&form=6&db=m Analysis of NM23 protein and components of plasminogen activation system in tumors of patients with stomach cancer with consideration for disease clinical picture and morphology. diagnostic usage,ongoing research,unassigned 4,2,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19714528&form=6&db=m Preoperative radiotherapy and extracellular matrix remodeling in rectal mucosa and tumour matrix metalloproteinases and plasminogen components. causal interaction,diagnostic usage,ongoing research,unassigned 2,1,3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19735728&form=6&db=m Integrin alpha(v)beta(3), metalloproteinases, and sphingomyelinase-2 mediate urokinase mitogenic effect. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19763915&form=6&db=m Prognostic significance of tissue factor pathway inhibitor-2 in pancreatic carcinoma and its effect on tumor invasion and metastasis. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19776673&form=6&db=m Differential prognostic impact of uPA and PAI-1 in colon and rectal cancer. causal interaction,diagnostic usage,ongoing research,unassigned 3,4,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19845941&form=6&db=m Cytokeratin 8 ectoplasmic domain binds urokinase-type plasminogen activator to breast tumor cells and modulates their adhesion, growth and invasiveness. causal interaction,ongoing research,unassigned 4,2,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19863222&form=6&db=m Preoperative radiotherapy and extracellular matrix remodeling in rectal mucosa and tumour matrix metalloproteinases and plasminogen components. causal interaction,diagnostic usage,ongoing research,unassigned 2,1,3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19961492&form=6&db=m Angiostatic activity of human plasminogen fragments is highly dependent on glycosylation. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,3,2 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20018303&form=6&db=m Expression of Tissue Factor Pathway Inhibitor 2 in Human Pancreatic Carcinoma and its Effect on Tumor Growth, Invasion, and Migration in vitro and in vivo. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20133942&form=6&db=m Structure-based engineering of species selectivity in the interaction between urokinase and its receptor: implication for preclinical cancer therapy. therapeutic application,unassigned 4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20211283&form=6&db=m The endogenous peptides of normal human serum extracted from the acetonitrile-insoluble precipitate using modified aqueous buffer with analysis by LC-ESI-Paul ion trap and Qq-TOF. diagnostic usage,unassigned 2,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20232379&form=6&db=m Unimpeded skin carcinogenesis in K14-HPV16 transgenic mice deficient for plasminogen activator inhibitor. causal interaction,ongoing research,therapeutic application,unassigned 3,2,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20403162&form=6&db=m Increased expression of urokinase plasminogen activator and its cognate receptor in human seminomas. causal interaction,diagnostic usage,ongoing research,unassigned 3,3,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20414406&form=6&db=m Alteration of Antithrombin III and D-dimer Levels in Clinically Localized Prostate Cancer. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20424186&form=6&db=m S100A10 regulates plasminogen-dependent macrophage invasion. causal interaction,unassigned 1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20460372&form=6&db=m Parallel in vivo and in vitro selection using phage display identifies protease-dependent tumor-targeting peptides. therapeutic application,unassigned 4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20549826&form=6&db=m SERPINE1 intron polymorphisms affecting gene expression are associated with diffuse-type gastric cancer susceptibility. causal interaction,therapeutic application,unassigned 3,3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20553606&form=6&db=m Secretion of extracellular hsp90alpha via exosomes increases cancer cell motility: a role for plasminogen activation. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,4,1 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20646237&form=6&db=m Urokinase and its receptor in follicular and inflammatory cysts of the jaws. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,3,1 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20665448&form=6&db=m [Cell phenotype determines PAI-1 antiproliferative effect - suppressed proliferation of the lung cancer but not prostate cancer cells] causal interaction,unassigned 1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20680247&form=6&db=m A novel finding of a low-molecular-weight compound, SMTP-7, having thrombolytic and anti-inflammatory effects in cerebral infarction of mice. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,2,3,3 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20872264&form=6&db=m Mathematical modeling of cancer cell invasion of tissue: biological insight from mathematical analysis and computational simulation. ongoing research,unassigned 4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20964613&form=6&db=m Characteristics of the level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,1,3 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21106716&form=6&db=m High expression of the urokinase plasminogen activator and its cognate receptor associates with advanced stages and reduced disease-free interval in papillary thyroid carcinoma. causal interaction,diagnostic usage,therapeutic application,unassigned 4,1,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21129210&form=6&db=m Type 1 plasminogen activator inhibitor (PAI-1) in clear cell renal cell carcinoma (CCRCC) and its impact on angiogenesis, progression and patient survival after radical nephrectomy. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,4,3,2 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21191179&form=6&db=m Downregulation of uPAR inhibits migration, invasion, proliferation, FAK/PI3K/Akt signaling and induces senescence in papillary thyroid carcinoma cells. causal interaction,unassigned 3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21246098&form=6&db=m Urokinase and tissue plasminogen activators and their PAI-1 inhibitor in tumors of patients with oral mucosal cancer: relationship with the main clinical morphological factors. causal interaction,diagnostic usage,ongoing research,unassigned 3,2,3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21316840&form=6&db=m Molecular competition between plasminogen activator inhibitors type -1 and -2 for urokinase: Implications for cellular proteolysis and adhesion in cancer. causal interaction,therapeutic application,unassigned 3,3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21372205&form=6&db=m DLC1 interaction with S100A10 mediates inhibition of in vitro cell invasion and tumorigenicity of lung cancer cells through a RhoGAP-independent mechanism. causal interaction,ongoing research,therapeutic application,unassigned 4,1,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21382730&form=6&db=m Human and canine mammary tumors: A role for urokinase plasminogen activator? ongoing research,therapeutic application,unassigned 3,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21406197&form=6&db=m Induction of the fibrinolytic system by cartilage extract mediates its antiangiogenic effect in mouse glioma. causal interaction,therapeutic application,unassigned 3,3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21454081&form=6&db=m Small molecule antagonists of the urokinase (uPA): urokinase receptor (uPAR) interaction with high reported potencies show only weak effects in cell-based competition assays employing the native uPAR ligand. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21533361&form=6&db=m Presence of urokinase plasminogen activator, its inhibitor and receptor in small cell lung cancer and non-small cell lung cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,4,1 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21573587&form=6&db=m Reduction of tumor-associated fibrinolytic-activity by antimetastatic dosages of 2 ru(ii)-dmso complexes in mice bearing lewis lung-carcinoma. causal interaction,ongoing research,therapeutic application,unassigned 1,2,3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21584744&form=6&db=m Treatment of collagen-induced arthritis with recombinant plasminogen-related protein B: a novel inhibitor of angiogenesis. causal interaction,therapeutic application,unassigned 3,2,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21635223&form=6&db=m Targeting the autolysis loop of urokinase-type plasminogen activator with conformation-specific monoclonal antibodies. causal interaction,diagnostic usage,unassigned 2,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21641406&form=6&db=m Secretory leukocyte protease inhibitor (SLPI) expression and tumor invasion in oral squamous cell carcinoma. causal interaction,diagnostic usage,therapeutic application,unassigned 3,2,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21644280&form=6&db=m [Clinical and etiopathogenetic role of plasminogen and metaloproteinase systems in the tumor growth. Pericellular proteolysis of extracellular matrix and tumor growth]. causal interaction,ongoing research,unassigned 1,2,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21707521&form=6&db=m Plasmin: Its Role in the Extracellular Processing of Progalanin in Tumor Tissue. causal interaction,ongoing research,unassigned 1,2,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21744990&form=6&db=m Clinical significance of the plasminogen activator system in relation to grade of tumor and treatment response in colorectal carcinoma patients. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21755673&form=6&db=m Mechanisms and pathobiology of ovulation. causal interaction,unassigned 3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21768297&form=6&db=m Regulation of fibrinolysis by S100A10 in vivo. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21808809&form=6&db=m Rhenium-188 labeled recombinant human plasminogen kringle5 (rhk5) and preliminary biodistribution. Evaluation in mice bearing A549 tumours. ongoing research,therapeutic application,unassigned 4,2,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21931322&form=6&db=m Plasmin inhibitor reduces T-cell lymphoid tumor growth by suppressing matrix metalloproteinase-9-dependent CD11b(+)/F4/80(+) myeloid cell recruitment. causal interaction,ongoing research,therapeutic application,unassigned 2,2,3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21947232&form=6&db=m Remarkable extension of PAI-1 half-life surprisingly brings no changes to its structure. causal interaction,unassigned 1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21969814&form=6&db=m Activation of pro-uPA is critical for initial escape from the primary tumor and hematogenous dissemination of human carcinoma cells. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,3,2 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21976520&form=6&db=m Annexin A2 promotes glioma cell invasion and tumor progression. causal interaction,ongoing research,unassigned 4,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22042827&form=6&db=m Plasminogen receptor S100A10 is essential for the migration of tumor-promoting macrophages into tumor sites. causal interaction,diagnostic usage,therapeutic application,unassigned 4,1,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22044461&form=6&db=m Antibody-directed neutralization of annexin II (ANX II) inhibits neoangiogenesis and human breast tumor growth in a xenograft model. ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22166587&form=6&db=m Hemostatic Abnormalities in Cirrhosis and Tumor-Related Portal Vein Thrombosis. diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22179830&form=6&db=m Blocking of CDCP1 cleavage in vivo prevents Akt-dependent survival and inhibits metastatic colonization through PARP1-mediated apoptosis of cancer cells. causal interaction,ongoing research,therapeutic application,unassigned 1,1,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22198637&form=6&db=m ARNTL2 and SERPINE1: potential biomarkers for tumor aggressiveness in colorectal cancer. causal interaction,ongoing research,unassigned 3,3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22221092&form=6&db=m Role of PPARg2 transcription factor in thiazolidinedione-induced insulin sensitization. unassigned - 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22238174&form=6&db=m Natural and engineered plasmin inhibitors: applications and design strategies. causal interaction,therapeutic application,unassigned 3,3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22279761&form=6&db=m [Laser hyperthermia of tumors with the use of golden nanoparticles under the control of optical coherent tomography and acoustothermometry]. therapeutic application,unassigned 4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22287006&form=6&db=m Tumor Necrosis Factor Alpha Modulates the Dynamics of the Plasminogen-Mediated Early Interaction between Bifidobacterium animalis subsp. lactis and Human Enterocytes. therapeutic application,unassigned 1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22441882&form=6&db=m Matrix metalloproteinase-9, -10, and -12, MDM2 and p53 expression in mouse liver during dimethylnitrosamine-induced oxidative stress and genomic injury. causal interaction,ongoing research,unassigned 1,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22463093&form=6&db=m [Significance of urokinase and its inhibitors in the invasiveness and metastasing of malignant tumors]. causal interaction,therapeutic application,unassigned 4,2,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22525297&form=6&db=m A potency of plasminogen activation system in long-term prognosis of endometrial cancer: a pilot study. ongoing research,therapeutic application,unassigned 4,2,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22590653&form=6&db=m Modification of cyclic NGR tumor neovasculature-homing motif sequence to human plasminogen kringle 5 improves inhibition of tumor growth. causal interaction,diagnostic usage,ongoing research,unassigned 1,3,3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22684992&form=6&db=m Investigation of serum proteome alterations in human glioblastoma multiforme. causal interaction,diagnostic usage,unassigned 3,3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22736175&form=6&db=m Modulation of u-PA, MMPs and their inhibitors by a novel nutrient mixture in human female cancer cell lines. causal interaction,diagnostic usage,unassigned 3,2,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22742660&form=6&db=m Synthesis and biological characterization of protease-activated prodrugs of doxazolidine. causal interaction,diagnostic usage,unassigned 3,2,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22815383&form=6&db=m Plasmin-driven fibrinolysis facilitates skin tumor growth in a gender-dependent manner. causal interaction,ongoing research,unassigned 4,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22843210&form=6&db=m Tumor therapy with a urokinase plasminogen activator-activated anthrax lethal toxin alone and in combination with paclitaxel. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22984202&form=6&db=m Protumorigenic Activity of Plasminogen Activator Inhibitor-1 Through an Antiapoptotic Function. causal interaction,diagnostic usage,therapeutic application,unassigned 3,3,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22996753&form=6&db=m Spontaneous metastasis in congenic mice with transgenic breast cancer is unaffected by plasminogen gene ablation. causal interaction,ongoing research,therapeutic application,unassigned 4,2,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23095556&form=6&db=m The urokinase plasminogen activating system in thyroid cancer: clinical implications. causal interaction,ongoing research,therapeutic application,unassigned 1,1,2,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23097597&form=6&db=m Cell surface remodeling by plasmin: a new function for an old enzyme. causal interaction,ongoing research,therapeutic application,unassigned 2,1,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23143982&form=6&db=m Regulation of tumor dormancy and role of microenvironment: a mathematical model. diagnostic usage,unassigned 3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23201006&form=6&db=m The urokinase plasminogen activator system in breast cancer invasion and metastasis. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,1,2,3 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23226787&form=6&db=m PAI-1 promoter 4G/5G polymorphism (rs1799768) contributes to tumor susceptibility: Evidence from meta-analysis. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23261456&form=6&db=m Involvement of plasmin-mediated extracellular activation of progalanin in angiogenesis. causal interaction,ongoing research,unassigned 4,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23300882&form=6&db=m Dual inhibition of plasminogen kringle 5 on angiogenesis and chemotaxis suppresses tumor metastasis by targeting HIF-1? pathway. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,3,2,2 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23408042&form=6&db=m Urokinase receptor orchestrates the plasminogen system in airway epithelial cell function. causal interaction,diagnostic usage,unassigned 3,3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23484202&form=6&db=m Prognostic role of tumor-associated proteases in colorectal cancer. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,2,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23527289&form=6&db=m Gender affects skin wound healing in plasminogen deficient mice. causal interaction,ongoing research,therapeutic application,unassigned 4,2,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23594883&form=6&db=m Three are better than one: plasminogen receptors as cancer theranostic targets. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23905012&form=6&db=m Beneficial role of overexpression of TFPI-2 on tumour progression in human small cell lung cancer. causal interaction,unassigned 4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23984088&form=6&db=m Transforming growth factor-Beta and urokinase-type plasminogen activator: dangerous partners in tumorigenesis-implications in skin cancer. causal interaction,diagnostic usage,ongoing research,unassigned 3,3,3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24000664&form=6&db=m [Clinical prospects of tumor-associated proteases and their tissue inhibitors investigation in oncologic patient]. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24205446&form=6&db=m Influence of Stromal Components on Lung Cancer Carcinogenesis. ongoing research,therapeutic application,unassigned 4,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24338014&form=6&db=m Characterization of a reduced form of plasma plasminogen as the precursor for angiostatin formation. causal interaction,diagnostic usage,unassigned 4,3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24423664&form=6&db=m A site for direct integrin ?v?6·uPAR interaction from structural modelling and docking. causal interaction,unassigned 1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24457100&form=6&db=m Angiogenin interacts with the plasminogen activation system at the cell surface of breast cancer cells to regulate plasmin formation and cell migration. causal interaction,ongoing research,unassigned 4,3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24525212&form=6&db=m Serum proteomics for gastric cancer. diagnostic usage,therapeutic application,unassigned 1,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24535412&form=6&db=m Plasminogen activators are involved in angiostatin generation in vivo in benign and malignant ovarian tumor cyst fluids. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,4,1 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24581498&form=6&db=m Serpins promote cancer cell survival and vascular co-option in brain metastasis. diagnostic usage,ongoing research,therapeutic application,unassigned 3,3,2,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24602611&form=6&db=m Seahorse-derived peptide suppresses invasive migration of HT1080 fibrosarcoma cells by competing with intracellular ?-enolase for plasminogen binding and inhibiting uPA-mediated activation of plasminogen. causal interaction,ongoing research,therapeutic application,unassigned 4,2,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24640092&form=6&db=m Tumor associated proteases -- prognostic markers of colorectal cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,3,1 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24647588&form=6&db=m Baculovirus vector-mediated transfer of sodium iodide symporter and plasminogen kringle 5 genes for tumor radioiodide therapy. therapeutic application,unassigned 3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24791857&form=6&db=m Inhibition of plasmin attenuates murine acute graft-versus-host disease mortality by suppressing the matrix metalloproteinase-9-dependent inflammatory cytokine storm and effector cell trafficking. causal interaction,ongoing research,therapeutic application,unassigned 2,1,2,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24795021&form=6&db=m Serpins shield tumor cells from antimetastatic brain defenses. ongoing research,unassigned 1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24827562&form=6&db=m Novel patents and cancer therapies for transforming growth factor-beta and urokinase type plasminogen activator: potential use of their interplay in tumorigenesis. causal interaction,diagnostic usage,ongoing research,unassigned 2,3,2,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24867464&form=6&db=m Modulation of uPA, MMPs and their inhibitors by a novel nutrient mixture in human glioblastoma cell lines. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24895598&form=6&db=m Plasmid transfer of plasminogen K1-5 reduces subcutaneous hepatoma growth by affecting inflammatory factors. causal interaction,ongoing research,therapeutic application,unassigned 3,3,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25176506&form=6&db=m Targeting of the ?6 gene to suppress degradation of ECM via inactivation of the MAPK pathway in breast adenocarcinoma cells. causal interaction,ongoing research,unassigned 4,2,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25212966&form=6&db=m Interleukin-like epithelial-to-mesenchymal transition inducer activity is controlled by proteolytic processing and plasminogen-urokinase plasminogen activator receptor system-regulated secretion during breast cancer progression. diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25407528&form=6&db=m From plasminogen to plasmin: role of plasminogen receptors in human cancer. causal interaction,ongoing research,therapeutic application,unassigned 3,4,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25525855&form=6&db=m On the contribution of S100A10 and annexin A2 to plasminogen activation and oncogenesis: an enduring ambiguity. therapeutic application,unassigned 1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25618124&form=6&db=m Soluble urokinase-type plasminogen activator receptor and ferritin concentration in patients with advanced alimentary tract carcinoma. Relationship to localization, surgical treatment and the stage of the disease--preliminary report. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,2,1,2 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25643152&form=6&db=m Alpha-enolase is upregulated on the cell surface and responds to plasminogen activation in mice expressing a ?133p53? mimic. causal interaction,ongoing research,therapeutic application,unassigned 3,2,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25668817&form=6&db=m Plasmin releases the anti-tumor peptide from the NC1 domain of collagen XIX. unassigned - 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25708333&form=6&db=m Autoantibodies to plasminogen and their role in tumor diseases. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25749705&form=6&db=m Selection and characterization of camelid nanobodies towards urokinase-type plasminogen activator. causal interaction,unassigned 2,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25769452&form=6&db=m Quantification of autoantibodies to plasminogen in plasma of patients with cancer. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,2,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25805497&form=6&db=m STIM1/ORAI1-mediated Ca2+ Influx Regulates Enolase-1 Exteriorization. causal interaction,diagnostic usage,ongoing research,unassigned 1,3,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25950911&form=6&db=m Development of Recombinant Adeno-Associated Virus Serotype 2/8 Carrying Kringle Domains of Human Plasminogen for Sustained Expression and Cancer Therapy. ongoing research,therapeutic application,unassigned 3,3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26118878&form=6&db=m [Advance in the biology of pancreatic of cancer]. causal interaction,unassigned 3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26279629&form=6&db=m New Insight on the Role of Plasminogen Receptor in Cancer Progression. causal interaction,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26292086&form=6&db=m uPAR Expression Pattern in Patients with Urothelial Carcinoma of the Bladder--Possible Clinical Implications. causal interaction,diagnostic usage,unassigned 1,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26350342&form=6&db=m Role of mesenchymal stem cell-derived fibrinolytic factor in tissue regeneration and cancer progression. ongoing research,unassigned 3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26392776&form=6&db=m Association between the polymorphisms of urokinase plasminogen activation system and cancer risk: a meta-analysis. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,3,1,1 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26588878&form=6&db=m Cancer therapy targeting the fibrinolytic system. unassigned - 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26676222&form=6&db=m Decreased expression of the plasminogen activator inhibitor type 1 is involved in degradation of extracellular matrix surrounding cervical cancer stem cells. causal interaction,unassigned 3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26717601&form=6&db=m PLASMINOGEN AND ANGIOSTATIN LEVELS IN FEMALE BENIGN BREAST LESIONS. causal interaction,diagnostic usage,ongoing research,unassigned 1,3,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26899605&form=6&db=m The Function of ?2-glycoprotein I in Angiogenesis and Its in Vivo Distribution in Tumor Xenografts. diagnostic usage,ongoing research,unassigned 1,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27031717&form=6&db=m Combined use of haemostatic system indices for evaluation of upper respiratory tract cancer progression. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,1,1 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27161704&form=6&db=m PO-17 - Identification of IgG bound to plasminogen in oncologic diseases. causal interaction,diagnostic usage,ongoing research,unassigned 1,2,2,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27197170&form=6&db=m Inhibition of PAI-1 Limits Tumor Angiogenesis Regardless of Angiogenic Stimuli in Malignant Pleural Mesothelioma. causal interaction,diagnostic usage,therapeutic application,unassigned 3,3,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27221823&form=6&db=m Activated thrombin-activatable fibrinolysis inhibitor (TAFIa) attenuates breast cancer cell metastatic behaviors through inhibition of plasminogen activation and extracellular proteolysis. causal interaction,ongoing research,therapeutic application,unassigned 2,4,2,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27286449&form=6&db=m Cyr61 and YB-1 are novel interacting partners of uPAR and elevate the malignancy of triple-negative breast cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,2,2,2 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27351226&form=6&db=m Cell surface protease activation during RAS transformation: Critical role of the plasminogen receptor, S100A10. causal interaction,unassigned 3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28210916&form=6&db=m A Multiscale Mathematical Model of Tumour Invasive Growth. ongoing research,unassigned 3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28262301&form=6&db=m Effects of Alcohol on Postoperative Adhesion Formation in Ischemic Myocardium and Pericardium. unassigned - 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28416743&form=6&db=m The urokinase plasminogen activation system in gastroesophageal cancer: A systematic review and meta-analysis. causal interaction,ongoing research,therapeutic application,unassigned 3,2,2,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28524122&form=6&db=m [A plasminogen regulation system in brain tumors]. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,4,2,1 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28577299&form=6&db=m uPA/uPAR system activation drives a glycolytic phenotype in melanoma cells. causal interaction,ongoing research,unassigned 4,3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28630480&form=6&db=m Pro-invasive stimuli and the interacting protein Hsp70 favour the route of alpha-enolase to the cell surface. causal interaction,unassigned 3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28697634&form=6&db=m The fibrinolysis inhibitor ?2-antiplasmin restricts lymphatic remodelling and metastasis in a mouse model of cancer. ongoing research,therapeutic application,unassigned 3,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29072683&form=6&db=m Plasminogen kringle 5 suppresses gastric cancer via regulating HIF-1? and GRP78. causal interaction,ongoing research,therapeutic application,unassigned 3,3,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29086689&form=6&db=m Transforming Growth Factor-Beta and Urokinase Type Plasminogen Interplay in Cancer. causal interaction,diagnostic usage,ongoing research,unassigned 3,3,3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29123986&form=6&db=m Expression of a urokinase-type plasminogen activator during tumor growth leads to angiogenesis via galanin activation in tumor-bearing mice. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,4,3 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29336533&form=6&db=m Targeted Nanocurcumin Therapy Using Annexin A2 Anitbody Improves Tumor Accumulation and Therapeutic Efficacy Against Highly Metastatic Breast Cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 4,1,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29484286&form=6&db=m Multifaceted Role of the Urokinase-Type Plasminogen Activator (uPA) and Its Receptor (uPAR): Diagnostic, Prognostic, and Therapeutic Applications. causal interaction,ongoing research,therapeutic application,unassigned 3,1,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29500719&form=6&db=m Computational Approaches and Analysis for a Spatio-Structural-Temporal Invasive Carcinoma Model. causal interaction,unassigned 3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29505702&form=6&db=m Fibrinolytic abnormalities associated with progression of pediatric solid tumors. diagnostic usage,ongoing research,therapeutic application,unassigned 1,2,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29564448&form=6&db=m Intra-articular TSG-6 delivery from heparin-based microparticles reduces cartilage damage in a rat model of osteoarthritis. therapeutic application,unassigned 3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29669808&form=6&db=m Lactoferrin is a natural inhibitor of plasminogen activation. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29691683&form=6&db=m Angio-3, a 10-residue peptide derived from human plasminogen kringle 3, suppresses tumor growth in mice via impeding both angiogenesis and vascular permeability. ongoing research,unassigned 3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29916675&form=6&db=m [Change in endogeous hydrogen sulfide in patients with acute pancreatitis and its relationship to coagulation function]. diagnostic usage,unassigned 4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30009399&form=6&db=m S100A10, a novel biomarker in pancreatic ductal adenocarcinoma. causal interaction,diagnostic usage,ongoing research,unassigned 3,3,2,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30014470&form=6&db=m Fermented goat milk consumption improves cardiovascular health during anemia recovery. ongoing research,unassigned 3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30429035&form=6&db=m Chemerin as a biomarker at the intersection of inflammation, chemotaxis, coagulation, fibrinolysis and metabolism in resectable non-small cell lung cancer. diagnostic usage,unassigned 3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30431071&form=6&db=m Proteolysis is the most fundamental property of malignancy and its inhibition may be used therapeutically (Review). causal interaction,unassigned 3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30628661&form=6&db=m Cancer-associated stroke: Pathophysiology, detection and management (Review). causal interaction,therapeutic application,unassigned 3,2,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30632975&form=6&db=m [The urokinase-type plasminogen activator system and its role in tumor progression]. causal interaction,unassigned 3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30675195&form=6&db=m The prognostic value of S100A10 expression in cancer. causal interaction,unassigned 3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31041799&form=6&db=m Fibrin and Fibrinolysis in Cancer. causal interaction,ongoing research,therapeutic application,unassigned 1,3,2,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31317567&form=6&db=m TGF-?-mediated regulation of plasminogen activators is human telomerase reverse transcriptase dependent in cancer cells. causal interaction,ongoing research,therapeutic application,unassigned 3,3,2,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31424646&form=6&db=m Circulating plasminogen activator inhibitor-1 activity: a biomarker for resectable non-small cell lung cancer? unassigned - 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31471691&form=6&db=m Specifically targeting cancer proliferation and metastasis processes: the development of matriptase inhibitors. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31547271&form=6&db=m Effect of Diosmin Administration in Patients with Chronic Venous Disorders on Selected Factors Affecting Angiogenesis. diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31569879&form=6&db=m [Adipose tissue as an endocrine organ]. unassigned - 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31738890&form=6&db=m Micro RNA 146a gene variant / TNF-? / IL-6 / IL-1 ?; A cross-link axis inbetween oxidative stress, endothelial dysfunction and neuro-inflammation in acute ischemic stroke and chronic schizophrenic patients. diagnostic usage,unassigned 1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31755385&form=6&db=m Plasminogen Receptors in Human Malignancies: Effects on Prognosis and Feasibility as Targets for Drug Development. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,2,4,4 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31877562&form=6&db=m The D-dimer level predicts the postoperative prognosis in patients with non-small cell lung cancer. diagnostic usage,unassigned 4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31949486&form=6&db=m Critical role and its underlying molecular events of the plasminogen receptor, S100A10 in malignant tumor and non-tumor diseases. causal interaction,ongoing research,therapeutic application,unassigned 3,1,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32068332&form=6&db=m Effect of autologous transplant of peripheral blood mononuclear cells in combination with proangiogenic factors during experimental revascularization of lower limb ischemia. causal interaction,unassigned 4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32115494&form=6&db=m Fibrinolytic Activity of Circulating Microvesicles Is Associated with Progression of Breast Cancer. causal interaction,diagnostic usage,unassigned 4,3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32205839&form=6&db=m Plasminogen is a master regulator and a potential drug candidate for the healing of radiation wounds. therapeutic application,unassigned 4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32418644&form=6&db=m Modulation of Ion Channels and Receptors by p11 (S100A10). causal interaction,therapeutic application,unassigned 4,2,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32610551&form=6&db=m Genetic Variants in the FGB and FGG Genes Mapping in the Beta and Gamma Nodules of the Fibrinogen Molecule in Congenital Quantitative Fibrinogen Disorders Associated with a Thrombotic Phenotype. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32780555&form=6&db=m Deficiency of plasminogen activator inhibitor-2 results in accelerated tumor growth. causal interaction,unassigned 4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32822576&form=6&db=m Therapy-Induced Evolution of Human Lung Cancer Revealed by Single-Cell RNA Sequencing. causal interaction,unassigned 2,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33108695&form=6&db=m Mortality and major complications after emergency laparotomy: A pilot study of risk prediction model development by preoperative blood-based immune parameters. diagnostic usage,ongoing research,therapeutic application,unassigned 2,2,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33141604&form=6&db=m Diagnostic and Prognostic Value of TAT, PIC, TM, and t-PAIC in Malignant Tumor Patients With Venous Thrombosis. diagnostic usage,ongoing research,unassigned 3,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33219560&form=6&db=m Comparative proteomic analysis reveals cytotoxicity induced by graphene oxide exposure in A549 cells. causal interaction,unassigned 1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33297495&form=6&db=m S100A10 Has a Critical Regulatory Function in Mammary Tumor Growth and Metastasis: Insights Using MMTV-PyMT Oncomice and Clinical Patient Sample Analysis. causal interaction,ongoing research,therapeutic application,unassigned 3,2,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33488094&form=6&db=m Further Understanding of Urokinase Plasminogen Activator Overexpression in Urothelial Bladder Cancer Progression, Clinical Outcomes and Potential Therapeutic Targets. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33496742&form=6&db=m Plasminogen activator inhibitor 1 and venous thrombosis in pancreatic cancer. causal interaction,ongoing research,therapeutic application,unassigned 3,4,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33571221&form=6&db=m Assessment of breast cancer surgical margins with multimodal optical microscopy: A feasibility clinical study. therapeutic application,unassigned 3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33584813&form=6&db=m Alpha-Enolase: Emerging Tumor-Associated Antigen, Cancer Biomarker, and Oncotherapeutic Target. causal interaction,diagnostic usage,therapeutic application,unassigned 4,1,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33669052&form=6&db=m The Multifaceted Role of Plasminogen in Cancer. causal interaction,unassigned 1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33687124&form=6&db=m Plasminogen Activator Urokinase Receptor Implies Immunosuppressive Features and Acts as an Unfavorable Prognostic Biomarker in Glioma. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,2,2,3 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33827473&form=6&db=m Significance of coagulation and fibrinolysis markers for benign and malignant soft tissue tumors. diagnostic usage,ongoing research,unassigned 3,2,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33838456&form=6&db=m Diagnosis of primary hyperfibrinolysis and in vitro investigation of the inhibitory effects of tranexamic acid in a group of dogs with sarcomas - A pilot study. diagnostic usage,ongoing research,therapeutic application,unassigned 2,3,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33921488&form=6&db=m Plasmin and Plasminogen System in the Tumor Microenvironment: Implications for Cancer Diagnosis, Prognosis, and Therapy. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,3,4 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33923400&form=6&db=m The Urokinase Receptor: A Multifunctional Receptor in Cancer Cell Biology. Therapeutic Implications. causal interaction,ongoing research,therapeutic application,unassigned 1,1,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33947134&form=6&db=m Imbalance in Coagulation/Fibrinolysis Inhibitors Resulting in Extravascular Thrombin Generation in Gliomas of Varying Levels of Malignancy. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34057113&form=6&db=m Urokinase type plasminogen activator receptor (uPAR) and human epidermal growth factor receptor 2 (HER2) expression in metastasis of breast cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,2,4,2 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34086061&form=6&db=m The role of 5-lipoxygenase in the pathophysiology of COVID-19 and its therapeutic implications. causal interaction,ongoing research,therapeutic application,unassigned 1,1,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34094663&form=6&db=m ENO1 monoclonal antibody inhibits invasion, proliferation and clone formation of cervical cancer cells. unassigned - 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34136381&form=6&db=m A Novel Invadopodia-Specific Marker for Invasive and Pro-Metastatic Cancer Stem Cells. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34161866&form=6&db=m Si113-prodrugs selectively activated by plasmin against hepatocellular and ovarian carcinoma. causal interaction,diagnostic usage,ongoing research,unassigned 3,3,4,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34175457&form=6&db=m Serum amyloid A - A prime candidate for identification of neonatal sepsis. diagnostic usage,unassigned 1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34336846&form=6&db=m High Migration and Invasion Ability of PGCCs and Their Daughter Cells Associated With the Nuclear Localization of S100A10 Modified by SUMOylation. causal interaction,ongoing research,unassigned 4,1,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34356598&form=6&db=m Regulation of S100A10 Gene Expression. causal interaction,unassigned 3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34439251&form=6&db=m Experimental and Clinical Evidence Supports the Use of Urokinase Plasminogen Activation System Components as Clinically Relevant Biomarkers in Gastroesophageal Adenocarcinoma. causal interaction,ongoing research,therapeutic application,unassigned 3,2,3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=100591529&form=6&db=m Plasminogen activators in human colorectal neoplasia: Authors' reply. ongoing research,unassigned 2,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=100591530&form=6&db=m Plasminogen activators in human colorectal neoplasia. diagnostic usage,ongoing research,unassigned 2,3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=100591628&form=6&db=m Plasminogen activators in human colorectal neoplasia. diagnostic usage,ongoing research,unassigned 2,3,0 3.4.21.7 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=100591629&form=6&db=m Plasminogen activators in human colorectal neoplasia. diagnostic usage,ongoing research,unassigned 2,3,0 3.4.21.7 Neoplasms, Germ Cell and Embryonal http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15333188&form=6&db=m Evidence for the clinical use of tumour markers. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,4 3.4.21.7 Nephritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=495336&form=6&db=m Participation of kallikrein, coagulation/fibrinolysis parameters in the development of glomerulonephritis. causal interaction,diagnostic usage,unassigned 1,2,0 3.4.21.7 Nephritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2311307&form=6&db=m IgA nephritis associated with plasminogen abnormalities. causal interaction,diagnostic usage,unassigned 4,3,0 3.4.21.7 Nephritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8340765&form=6&db=m Identification of an extracellular plasmin binding protein from nephritogenic streptococci. therapeutic application,unassigned 1,0 3.4.21.7 Nephritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8938675&form=6&db=m Intraglomerular deposition of intact cross-linked fibrin in IgA nephropathy and Henoch-Schönlein purpura nephritis. diagnostic usage,ongoing research,unassigned 4,2,0 3.4.21.7 Nephritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9208283&form=6&db=m Opposing effects of interleukin-1 and transforming growth factor-beta on the regulation of tissue-type plasminogen activator and plasminogen activator inhibitor type-1 expression by human mesangial cells. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.7 Nephritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9331620&form=6&db=m The occurrence of nephritis plasmin binding protein (SPEB) in the extracellular products of group C nephritogenic Streptococcus zooepidemicus. unassigned - 3.4.21.7 Nephritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16788698&form=6&db=m Noninhibitory PAI-1 enhances plasmin-mediated matrix degradation both in vitro and in experimental nephritis. ongoing research,therapeutic application,unassigned 2,2,0 3.4.21.7 Nephrosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25482671&form=6&db=m Urinary serine proteases and activation of ENaC in kidney-implications for physiological renal salt handling and hypertensive disorders with albuminuria. causal interaction,diagnostic usage,therapeutic application,unassigned 3,3,1,0 3.4.21.7 Nephrotic Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1836241&form=6&db=m [Concentration of thrombin antithrombin III complex and plasmin alpha 2-plasmin inhibitor complex in nephrotic syndrome] diagnostic usage,ongoing research,therapeutic application,unassigned 3,1,2,0 3.4.21.7 Nephrotic Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2465229&form=6&db=m Plasminogen activator in nephrotic syndrome. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,3,2,2 3.4.21.7 Nephrotic Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3933871&form=6&db=m Nephrotic syndrome with renal vein thrombosis: pathogenetic importance of a plasmin inhibitor (alpha 2-antiplasmin). diagnostic usage,ongoing research,therapeutic application,unassigned 4,1,3,0 3.4.21.7 Nephrotic Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6731499&form=6&db=m Use of noninvasive laboratory testing in the prediction of thrombosis in the nephrotic syndrome. diagnostic usage,therapeutic application,unassigned 3,2,0 3.4.21.7 Nephrotic Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7359230&form=6&db=m Plasminogen and antithrombin III deficiencies in the childhood nephrotic syndrome associated with plasminogenuria and antithrombinuria. causal interaction,diagnostic usage,ongoing research,unassigned 3,4,2,0 3.4.21.7 Nephrotic Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7518491&form=6&db=m Plasma levels and urinary excretion of fibrinolytic and protease inhibitory proteins in nephrotic syndrome. causal interaction,diagnostic usage,ongoing research,unassigned 2,4,4,0 3.4.21.7 Nephrotic Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9134831&form=6&db=m [A coagulation of fibrinolytic study in children with nephrotic syndrome: evaluation of hypercoagulability by measuring with plasmin- alpha 2 plasmin inhibitor complex and FDP D-dimer] therapeutic application,unassigned 3,0 3.4.21.7 Nephrotic Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9278113&form=6&db=m Nephrotic syndrome resulting in thromboembolic disease and disseminated intravascular coagulation in a dog. diagnostic usage,unassigned 4,0 3.4.21.7 Nephrotic Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10669658&form=6&db=m Effect of individual plasma lipoprotein(a) variations in vivo on its competition with plasminogen for fibrin and cell binding: An in vitro study using plasma from children with idiopathic nephrotic syndrome. diagnostic usage,ongoing research,therapeutic application,unassigned 3,4,2,0 3.4.21.7 Nephrotic Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11460483&form=6&db=m Inhibition of fibrinolysis by lipoprotein(a). therapeutic application,unassigned 1,0 3.4.21.7 Nephrotic Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12439147&form=6&db=m Markers of endothelial cell injury and thrombin activatable fibrinolysis inhibitor in nephrotic syndrome. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,3,0 3.4.21.7 Nephrotic Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19073825&form=6&db=m Plasmin in nephrotic urine activates the epithelial sodium channel. therapeutic application,unassigned 1,0 3.4.21.7 Nephrotic Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19176698&form=6&db=m Plasmin and sodium retention in nephrotic syndrome. ongoing research,unassigned 1,0 3.4.21.7 Nephrotic Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19996890&form=6&db=m Regulation of sodium transport by ENaC in the kidney. causal interaction,unassigned 3,0 3.4.21.7 Nephrotic Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21466573&form=6&db=m Proteinuric diseases with sodium retention: Is plasmin the link? diagnostic usage,ongoing research,unassigned 1,3,0 3.4.21.7 Nephrotic Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22987920&form=6&db=m Urinary Plasmin Activates Collecting Duct ENaC Current in Preeclampsia. causal interaction,diagnostic usage,unassigned 2,3,0 3.4.21.7 Nephrotic Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23216619&form=6&db=m Mechanisms of renal NaCl retention in proteinuric disease. causal interaction,diagnostic usage,unassigned 3,1,0 3.4.21.7 Nephrotic Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23503750&form=6&db=m Remission of nephrotic syndrome diminishes urinary plasmin content and abolishes activation of ENaC. diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.7 Nephrotic Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23529637&form=6&db=m Over- or underfill: not all nephrotic states are created equal. causal interaction,unassigned 1,0 3.4.21.7 Nephrotic Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25482671&form=6&db=m Urinary serine proteases and activation of ENaC in kidney-implications for physiological renal salt handling and hypertensive disorders with albuminuria. causal interaction,diagnostic usage,therapeutic application,unassigned 3,3,1,0 3.4.21.7 Nephrotic Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25972510&form=6&db=m Aberrant glomerular filtration of urokinase-type plasminogen activator in nephrotic syndrome leads to amiloride-sensitive plasminogen activation in urine. causal interaction,therapeutic application,unassigned 2,2,0 3.4.21.7 Nephrotic Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26933188&form=6&db=m Association of Plasminuria with Overhydration in Patients with CKD. diagnostic usage,therapeutic application,unassigned 1,1,0 3.4.21.7 Nephrotic Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29042083&form=6&db=m Aprotinin prevents proteolytic epithelial sodium channel (ENaC) activation and volume retention in nephrotic syndrome. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,1,3,4 3.4.21.7 Nephrotic Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31006168&form=6&db=m Urokinase-type plasminogen activator (uPA) is not essential for epithelial sodium channel (ENaC)-mediated sodium retention in experimental nephrotic syndrome. therapeutic application,unassigned 1,0 3.4.21.7 Nephrotic Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31269481&form=6&db=m Association of Urinary Plasminogen-Plasmin with Edema and Epithelial Sodium Channel Activation in Patients with Nephrotic Syndrome. unassigned - 3.4.21.7 Nephrotic Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32455507&form=6&db=m Plasminogen deficiency does not prevent sodium retention in a genetic mouse model of experimental nephrotic syndrome. unassigned - 3.4.21.7 Nervous System Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10362821&form=6&db=m Effects of tissue plasminogen activator for acute ischemic stroke at one year. National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study Group. causal interaction,ongoing research,therapeutic application,unassigned 1,2,4,0 3.4.21.7 Nervous System Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11061250&form=6&db=m Predicting prognosis after stroke: a placebo group analysis from the National Institute of Neurological Disorders and Stroke rt-PA Stroke Trial. ongoing research,therapeutic application,unassigned 1,2,0 3.4.21.7 Nervous System Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11387492&form=6&db=m A modified National Institutes of Health Stroke Scale for use in stroke clinical trials: preliminary reliability and validity. therapeutic application,unassigned 1,0 3.4.21.7 Nervous System Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11735758&form=6&db=m Lack of clinical significance of early ischemic changes on computed tomography in acute stroke. diagnostic usage,ongoing research,therapeutic application,unassigned 2,3,2,0 3.4.21.7 Nervous System Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24591838&form=6&db=m Current perspectives on the use of intravenous recombinant tissue plasminogen activator (tPA) for treatment of acute ischemic stroke. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.7 Nervous System Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31311465&form=6&db=m Magnitude of Benefit of Combined Endovascular Thrombectomy and Intravenous Fibrinolysis in Large Vessel Occlusion Ischemic Stroke. diagnostic usage,ongoing research,therapeutic application,unassigned 2,3,2,0 3.4.21.7 Nervous System Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15894933&form=6&db=m Expression of urokinase-type plasminogen activator receptor (uPAR) in primary central nervous system neoplasms. causal interaction,therapeutic application,unassigned 4,2,0 3.4.21.7 Neuralgia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15780477&form=6&db=m Induction of plasminogen activator inhibitor-1 and -2 in dorsal root ganglion neurons after peripheral nerve injury. causal interaction,unassigned 3,0 3.4.21.7 Neurilemmoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14963743&form=6&db=m Plasminogen activation in neurofibromatosis 2-associated and sporadic schwannomas. causal interaction,diagnostic usage,unassigned 4,3,0 3.4.21.7 Neuritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6167674&form=6&db=m Degradation of the P0, P1, and Pr proteins in peripheral nervous system myelin by plasmin: implications regarding the role of macrophages in demyelinating diseases. causal interaction,ongoing research,therapeutic application,unassigned 3,4,2,0 3.4.21.7 Neuritis, Autoimmune, Experimental http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6167674&form=6&db=m Degradation of the P0, P1, and Pr proteins in peripheral nervous system myelin by plasmin: implications regarding the role of macrophages in demyelinating diseases. causal interaction,ongoing research,therapeutic application,unassigned 3,4,2,0 3.4.21.7 Neuroblastoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1386577&form=6&db=m Regulation of neuronal migration and neuritogenesis by distinct surface proteases. Relative contribution of plasmin and a thrombin-like protease. diagnostic usage,unassigned 2,0 3.4.21.7 Neuroblastoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9003003&form=6&db=m Role of insulin-like growth factor binding protein-2 and its limited proteolysis in neuroblastoma cell proliferation: modulation by transforming growth factor-beta and retinoic acid. diagnostic usage,ongoing research,therapeutic application,unassigned 3,4,1,0 3.4.21.7 Neuroblastoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9893662&form=6&db=m Modulation of the proteolytic balance plasminogen activator/plasminogen activator inhibitor by enhanced N-myc oncogene expression or application of genistein. diagnostic usage,ongoing research,unassigned 3,4,0 3.4.21.7 Neuroblastoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15737740&form=6&db=m Beta-amyloid (Abeta) causes detachment of N1E-115 neuroblastoma cells by acting as a scaffold for cell-associated plasminogen activation. ongoing research,therapeutic application,unassigned 4,1,0 3.4.21.7 Neuroblastoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17926561&form=6&db=m [Effects of plasminogen, streptokinase and their equimolar complexes with pyruvate kinase on the human neuroblastoma IMR-32 cells] ongoing research,therapeutic application,unassigned 4,1,0 3.4.21.7 Neuroblastoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18522221&form=6&db=m [Effects of plasminogen and streptokinase on the vital functions of nervous tissue cells in culture] causal interaction,ongoing research,unassigned 4,2,0 3.4.21.7 Neuroblastoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19322640&form=6&db=m Changes in gene expression of kringle domain-containing proteins in murine brains and neuroblastoma cells infected by prions. ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.7 Neuroblastoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25059665&form=6&db=m Binding of tissue-type plasminogen activator to the glucose-regulated protein 78 (GRP78) modulates plasminogen activation and promotes human neuroblastoma cell proliferation in vitro. causal interaction,ongoing research,therapeutic application,unassigned 3,4,1,0 3.4.21.7 Neuroblastoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30031899&form=6&db=m Degradation of fibrin-? amyloid co-aggregate: A novel function attributed to ubiquitin. diagnostic usage,ongoing research,unassigned 3,1,0 3.4.21.7 Neuroblastoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31602645&form=6&db=m A multimolecular signaling complex including PrPC and LRP1 is strictly dependent on lipid rafts and is essential for the function of tissue plasminogen activator. ongoing research,unassigned 2,0 3.4.21.7 Neurodegenerative Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17035547&form=6&db=m An inhibitor of serine proteases, neuroserpin, acts as a neuroprotective agent in a mouse model of neurodegenerative disease. ongoing research,unassigned 2,0 3.4.21.7 Neurodegenerative Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23650462&form=6&db=m Beta-amyloidolysis and glutathione in Alzheimer's disease. causal interaction,ongoing research,unassigned 1,2,0 3.4.21.7 Neurodegenerative Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33922229&form=6&db=m Plasminogen Activators in Neurovascular and Neurodegenerative Disorders. unassigned - 3.4.21.7 Neuroendocrine Tumors http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12297497&form=6&db=m Cleavage of chromogranin A N-terminal domain by plasmin provides a new mechanism for regulating cell adhesion. causal interaction,unassigned 3,0 3.4.21.7 Neurofibroma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16408192&form=6&db=m Plasminogen activators and their inhibitor gene expression in cutaneous NF1-related neurofibromas. causal interaction,ongoing research,therapeutic application,unassigned 1,2,1,0 3.4.21.7 Neurofibromatoses http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3082686&form=6&db=m Von Recklinghausen neurofibromatosis and hereditary plasminogen deficiency. causal interaction,unassigned 4,0 3.4.21.7 Neurofibromatoses http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14963743&form=6&db=m Plasminogen activation in neurofibromatosis 2-associated and sporadic schwannomas. causal interaction,diagnostic usage,unassigned 4,3,0 3.4.21.7 Neuroinflammatory Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17664291&form=6&db=m Fibrin deposition accelerates neurovascular damage and neuroinflammation in mouse models of Alzheimer's disease. ongoing research,therapeutic application,unassigned 1,4,0 3.4.21.7 Neuroinflammatory Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24281743&form=6&db=m Hemorrhagic transformation after ischemic stroke in animals and humans. causal interaction,therapeutic application,unassigned 2,1,0 3.4.21.7 Neuroinflammatory Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26493446&form=6&db=m The plasminogen activation system in neuroinflammation. unassigned - 3.4.21.7 Neuroinflammatory Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28275164&form=6&db=m Plasminogen Deficiency Delays the Onset and Protects from Demyelination and Paralysis in Autoimmune Neuroinflammatory Disease. causal interaction,ongoing research,therapeutic application,unassigned 3,3,2,0 3.4.21.7 Neuroinflammatory Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28417010&form=6&db=m Astrocytes regulate the balance between plasminogen activation and plasmin clearance via cell-surface actin. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.7 Neuroinflammatory Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32594031&form=6&db=m Using antifibrinolytics to tackle neuroinflammation. causal interaction,therapeutic application,unassigned 3,3,0 3.4.21.7 Nevus http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2477958&form=6&db=m [Histochemical studies of transepidermal elimination of nevus cells in nevus cell nevi of the corium] therapeutic application,unassigned 1,0 3.4.21.7 Nevus http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23063511&form=6&db=m TGF-? signaling, activated stromal fibroblasts, and cysteine cathepsins B and L drive the invasive growth of human melanoma cells. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,4,0 3.4.21.7 Nevus http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25831901&form=6&db=m [Indicators of plasminogen activation system and growth factors in the tissue of nevi and skin melanoma]. ongoing research,unassigned 2,0 3.4.21.7 Noonan Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20686427&form=6&db=m Imbalance of plasminogen activator inhibitor type-1 (PAI-1) and tissue plasminogen activator (t-PA) activity in patients with Noonan syndrome. diagnostic usage,ongoing research,therapeutic application,unassigned 3,2,2,0 3.4.21.7 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1788455&form=6&db=m [Hemostasis profiles in thrombotic disease] therapeutic application,unassigned 1,0 3.4.21.7 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8622276&form=6&db=m [Chronic recurrent pulmonary thromboembolism associated with sedentary work] causal interaction,diagnostic usage,unassigned 3,2,0 3.4.21.7 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8824851&form=6&db=m Haemostatic and other cardiovascular risk factors, and socioeconomic status among middle-aged Finnish men and women. diagnostic usage,ongoing research,unassigned 4,1,0 3.4.21.7 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10225688&form=6&db=m Role of adipocytokines on the pathogenesis of atherosclerosis in visceral obesity. unassigned - 3.4.21.7 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12083480&form=6&db=m In vivo plasminogen deficiency reduces fat accumulation. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15319168&form=6&db=m Relation between the tumor necrosis factor-alpha (TNF-alpha) gene and protein expression, and clinical, biochemical, and genetic markers: age, body mass index and uric acid are independent predictors for an elevated TNF-alpha plasma level in a complex risk model. diagnostic usage,unassigned 2,0 3.4.21.7 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17145652&form=6&db=m Comparison of fibrinolytic and metabolic system parameters in obese patients with polycystic ovary syndrome and women with simple obesity. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.7 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18359942&form=6&db=m Protection from high fat diet-induced increase in ceramide in mice lacking plasminogen activator inhibitor 1. causal interaction,ongoing research,therapeutic application,unassigned 1,3,2,0 3.4.21.7 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19214913&form=6&db=m Pathogenesis of venous thromboembolism: when the cup runneth over. therapeutic application,unassigned 1,0 3.4.21.7 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20190422&form=6&db=m Strain- and tissue-dependent induction of plasminogen activator inhibitor-1 gene expression in fasted mice. therapeutic application,unassigned 3,0 3.4.21.7 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26315791&form=6&db=m Risk Factors for Thrombosis Development in Mexican Patients. diagnostic usage,unassigned 2,0 3.4.21.7 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28262235&form=6&db=m The effect of BMI on haemostasis: Implications for thrombosis in women's health. causal interaction,unassigned 4,0 3.4.21.7 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32827201&form=6&db=m Reductions in plasmin inhibitor and fibrinogen predict the improved fibrin clot lysis 6?months after obesity surgery. diagnostic usage,therapeutic application,unassigned 3,4,0 3.4.21.7 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33803235&form=6&db=m Assessing Plasmin Generation in Health and Disease. causal interaction,ongoing research,unassigned 4,1,0 3.4.21.7 Obesity, Abdominal http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16387571&form=6&db=m Cardiovascular issues in hypogonadism and testosterone therapy. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.7 Obesity, Abdominal http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31529920&form=6&db=m [The markers of dysfunction of endothelium and cytokine profile in patients with metabolic syndrome and abdominal obesity.] causal interaction,ongoing research,therapeutic application,unassigned 3,2,1,0 3.4.21.7 Obstetric Labor, Premature http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4002923&form=6&db=m [Hemostaseologic studies of maternal blood in intrauterine retardation and threatened premature labor] diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.7 Obstetric Labor, Premature http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17403427&form=6&db=m Progestin inhibits and thrombin stimulates the plasminogen activator/inhibitor system in term decidual stromal cells: implications for parturition. causal interaction,unassigned 2,0 3.4.21.7 Obstetric Labor, Premature http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30268366&form=6&db=m Uneventful Pregnancy and Delivery after Thrombolysis Plus Thrombectomy for Acute Ischemic Stroke: Case Study and Literature Review. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 Oral Manifestations http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17944666&form=6&db=m Hypoplasminogenaemia, gingival swelling and ulceration. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 Osteoarthritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1555050&form=6&db=m Effects of tiaprofenic acid on plasminogen activators and inhibitors in human OA and RA synovium. ongoing research,therapeutic application,unassigned 3,3,0 3.4.21.7 Osteoarthritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7198342&form=6&db=m [Activity of plasminogen activators and plasmin inhibitors in the joint capsule in various articular diseases (author's transl)] causal interaction,unassigned 3,0 3.4.21.7 Osteoarthritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8441174&form=6&db=m Plasminogen activators and plasminogen activator inhibitors in synovial fluid. Difference between inflammatory joint disorders and osteoarthritis. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.7 Osteoarthritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8646430&form=6&db=m Difference in expression of the plasminogen activation system in synovial tissue of patients with rheumatoid arthritis and osteoarthritis. causal interaction,ongoing research,unassigned 3,3,0 3.4.21.7 Osteoarthritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8733439&form=6&db=m Plasminogen activators and their inhibitors in synovial fluids from normal, osteoarthritis, and rheumatoid arthritis knees. causal interaction,therapeutic application,unassigned 2,1,0 3.4.21.7 Osteoarthritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8877916&form=6&db=m Thrombin in the synovial fluid of patients with rheumatoid arthritis mediates proliferation of synovial fibroblast-like cells by induction of platelet derived growth factor. causal interaction,diagnostic usage,ongoing research,unassigned 1,2,3,0 3.4.21.7 Osteoarthritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9181480&form=6&db=m Molecular abnormalities of human plasminogen isolated from synovial fluid of rheumatoid arthritis patients. causal interaction,diagnostic usage,ongoing research,unassigned 2,3,4,0 3.4.21.7 Osteoarthritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9370880&form=6&db=m Plasminogen activation in synovial tissues: differences between normal, osteoarthritis, and rheumatoid arthritis joints. causal interaction,diagnostic usage,ongoing research,unassigned 1,2,4,0 3.4.21.7 Osteoarthritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9718068&form=6&db=m Synoviocytes from osteoarthritis and rheumatoid arthritis produce plasminogen activators and plasminogen activator inhibitor-1 and display u-PA receptors on their surface. ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.7 Osteoarthritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11518356&form=6&db=m Activities of plasminogen activator, plasmin and kallikrein in synovial fluid from patients with temporomandibular joint disorders. causal interaction,unassigned 3,0 3.4.21.7 Osteoarthritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19589338&form=6&db=m Variation patterns of two degradation enzyme systems in articular cartilage in different stages of osteoarthritis: regulation by dehydroepiandrosterone. ongoing research,unassigned 3,0 3.4.21.7 Osteoarthritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20144123&form=6&db=m Fibrin dissolution in synovial fluid. ongoing research,therapeutic application,unassigned 1,1,0 3.4.21.7 Osteoarthritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27262798&form=6&db=m Argatroban more effectively inhibits the thrombin activity in synovial fluid than naturally occurring thrombin inhibitors. diagnostic usage,ongoing research,unassigned 1,3,0 3.4.21.7 Osteoarthritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29564448&form=6&db=m Intra-articular TSG-6 delivery from heparin-based microparticles reduces cartilage damage in a rat model of osteoarthritis. therapeutic application,unassigned 3,0 3.4.21.7 Osteonecrosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30783528&form=6&db=m Long-term direct oral anticoagulation in primary osteonecrosis with elevated plasminogen activation inhibitor. causal interaction,ongoing research,unassigned 4,2,0 3.4.21.7 Osteoporosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24664548&form=6&db=m Fibrin accumulation secondary to loss of plasmin-mediated fibrinolysis drives inflammatory osteoporosis. causal interaction,therapeutic application,unassigned 3,3,0 3.4.21.7 Osteoporosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32548548&form=6&db=m Plasminogen activation in the musculoskeletal acute phase response: Injury, repair, and disease. ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.7 Osteoporosis, Postmenopausal http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26094563&form=6&db=m ??-Antiplasmin is involved in bone loss induced by ovariectomy in mice. causal interaction,unassigned 3,0 3.4.21.7 Osteosarcoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1371448&form=6&db=m Involvement of the plasmin system in dissociation of the insulin-like growth factor-binding protein complex. diagnostic usage,ongoing research,unassigned 3,3,0 3.4.21.7 Osteosarcoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1888137&form=6&db=m Induction of morphological transformation, anchorage-independent growth and plasminogen activators in non-tumorigenic human osteosarcoma cells by lead chromate. causal interaction,ongoing research,unassigned 1,2,0 3.4.21.7 Osteosarcoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2331805&form=6&db=m Humoral hypercalcemia of malignancy. unassigned - 3.4.21.7 Osteosarcoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2561462&form=6&db=m Synthesis and secretion of plasminogen activators and collagenases in human cells transformed by Kirsten murine sarcoma virus and N-methyl-N'-nitro-N-nitrosoguanidine. ongoing research,unassigned 4,0 3.4.21.7 Osteosarcoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2693318&form=6&db=m Humoral hypercalcemia of malignancy. unassigned - 3.4.21.7 Osteosarcoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7502710&form=6&db=m Regulation of plasminogen activation, matrix metalloproteinases and urokinase-type plasminogen activator-mediated extracellular matrix degradation in human osteosarcoma cell line MG63 by interleukin-1 alpha. causal interaction,ongoing research,therapeutic application,unassigned 3,4,1,0 3.4.21.7 Osteosarcoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7511144&form=6&db=m Binding and activation of plasminogen on the surface of osteosarcoma cells. diagnostic usage,ongoing research,therapeutic application,unassigned 3,4,1,0 3.4.21.7 Osteosarcoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7527330&form=6&db=m Interactions between insulin-like growth factor-I (IGF-I) and the system of plasminogen activators and their inhibitors in the control of IGF-binding protein-3 production and proteolysis in human osteosarcoma cells. diagnostic usage,ongoing research,unassigned 3,2,0 3.4.21.7 Osteosarcoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7683547&form=6&db=m Localization of plasmin activity on osteosarcoma cells: cell surface proteolysis of insulin-like growth factor binding proteins. diagnostic usage,ongoing research,unassigned 3,4,0 3.4.21.7 Osteosarcoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7826985&form=6&db=m Plasminogen activators and their inhibitor in osteosarcomas and other bone tumors. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,1,3 3.4.21.7 Osteosarcoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10650857&form=6&db=m The course of fibrinolytic proteins in children with malignant bone tumours. ongoing research,therapeutic application,unassigned 2,3,0 3.4.21.7 Osteosarcoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11713566&form=6&db=m Plasminogen activators and their inhibitor in bone tumors and tumor-like damages. diagnostic usage,ongoing research,therapeutic application,unassigned 3,2,2,0 3.4.21.7 Otitis Media http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=95383&form=6&db=m The fibrinolysin system in otitis media with effusion. unassigned - 3.4.21.7 Otitis Media http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3835889&form=6&db=m Fibrinolytic activity of middle ear fluid in otitis media with effusion. diagnostic usage,unassigned 2,0 3.4.21.7 Otitis Media http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16956791&form=6&db=m Spontaneous development of otitis media in plasminogen-deficient mice. ongoing research,unassigned 4,0 3.4.21.7 Otitis Media with Effusion http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=95383&form=6&db=m The fibrinolysin system in otitis media with effusion. unassigned - 3.4.21.7 Otitis Media with Effusion http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2521200&form=6&db=m Plasmin and fibronectin degradation in chronic secretory otitis media. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,2,0 3.4.21.7 Otitis Media with Effusion http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3835889&form=6&db=m Fibrinolytic activity of middle ear fluid in otitis media with effusion. diagnostic usage,unassigned 2,0 3.4.21.7 Otitis Media with Effusion http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6237294&form=6&db=m Antifibrinolytic activity in middle ear effusion. unassigned - 3.4.21.7 Out-of-Hospital Cardiac Arrest http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32571089&form=6&db=m Relationship Between Severity of Fibrinolysis Based on Rotational Thromboelastometry and Conventional Fibrinolysis Markers. diagnostic usage,unassigned 1,0 3.4.21.7 Ovarian Cysts http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7675374&form=6&db=m Fluid characteristics of benign ovarian cysts: correlation with recurrence after puncture. causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,1,0 3.4.21.7 Ovarian Cysts http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12017303&form=6&db=m Clinical value of components of the plasminogen activation system in ovarian cyst fluid. causal interaction,diagnostic usage,ongoing research,unassigned 1,3,3,0 3.4.21.7 Ovarian Cysts http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24535412&form=6&db=m Plasminogen activators are involved in angiostatin generation in vivo in benign and malignant ovarian tumor cyst fluids. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,4,1 3.4.21.7 Ovarian Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2139349&form=6&db=m Role of plasmin in the degradation of the stroma-derived fibrin in human ovarian carcinoma. causal interaction,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.7 Ovarian Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7999418&form=6&db=m Plasminogen activators and plasminogen activator inhibitors in blood and tumour fluids of patients with ovarian cancer. diagnostic usage,ongoing research,therapeutic application,unassigned 3,4,4,0 3.4.21.7 Ovarian Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8168999&form=6&db=m Effects of urinary trypsin inhibitor on the invasion of reconstituted basement membranes by ovarian cancer cells. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,4,1 3.4.21.7 Ovarian Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11240701&form=6&db=m Clinical relevance of urokinase-type plasminogen activator, its receptor and inhibitor type 1 in ovarian cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,3 3.4.21.7 Ovarian Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15149846&form=6&db=m Expression of active plasminogen activator inhibitor-1 reduces cell migration and invasion in breast and gynecological cancer cells. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,4,1 3.4.21.7 Ovarian Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15333188&form=6&db=m Evidence for the clinical use of tumour markers. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,4 3.4.21.7 Ovarian Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15798771&form=6&db=m Ascites induces modulation of alpha6beta1 integrin and urokinase plasminogen activator receptor expression and associated functions in ovarian carcinoma. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,1,3,2 3.4.21.7 Ovarian Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20200565&form=6&db=m Adeno-associated virus-mediated delivery of kringle 5 of human plasminogen inhibits orthotopic growth of ovarian cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,3,3,1 3.4.21.7 Ovarian Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21559638&form=6&db=m Expression of urokinase-type plasminogen-activator (upa) and its receptor (upar) in human ovarian-cancer cells and in-vitro invasion capacity. diagnostic usage,ongoing research,unassigned 3,4,0 3.4.21.7 Ovarian Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21909879&form=6&db=m The role of annexin A2 in tumorigenesis and cancer progression. causal interaction,unassigned 4,0 3.4.21.7 Ovarian Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30621740&form=6&db=m Anti-tumour effects of all-trans retinoid acid on serous ovarian cancer. ongoing research,therapeutic application,unassigned 4,1,0 3.4.21.7 Overweight http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16015415&form=6&db=m Hemostatic status and fibrinolytic response potential at different phases of the menstrual cycle. diagnostic usage,therapeutic application,unassigned 2,1,0 3.4.21.7 Overweight http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26595150&form=6&db=m Comprehensive Assessment of the Hemostatic System in Polycystic Ovarian Syndrome. ongoing research,therapeutic application,unassigned 1,2,0 3.4.21.7 Pancreatic Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=13431997&form=6&db=m Plasminogen in pancreatic disease and in pancreatic secretion. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,2,0 3.4.21.7 Pancreatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9641882&form=6&db=m Molecular pattern of ductal pancreatic cancer. causal interaction,unassigned 4,0 3.4.21.7 Pancreatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11585769&form=6&db=m Generation of multiple angiogenesis inhibitors by human pancreatic cancer. ongoing research,unassigned 3,0 3.4.21.7 Pancreatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15194650&form=6&db=m Specific interaction of tissue-type plasminogen activator (t-PA) with annexin II on the membrane of pancreatic cancer cells activates plasminogen and promotes invasion in vitro. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,3,1 3.4.21.7 Pancreatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15631784&form=6&db=m [Effects of human plasminogen Kringle 5 gene therapy on pancreatic cancer] ongoing research,therapeutic application,unassigned 4,1,0 3.4.21.7 Pancreatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16504015&form=6&db=m Interleukin-1alpha enhances the aggressive behavior of pancreatic cancer cells by regulating the alpha6beta1-integrin and urokinase plasminogen activator receptor expression. ongoing research,unassigned 4,0 3.4.21.7 Pancreatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17496331&form=6&db=m Quantitative proteomics analysis reveals that proteins differentially expressed in chronic pancreatitis are also frequently involved in pancreatic cancer. causal interaction,diagnostic usage,unassigned 3,3,0 3.4.21.7 Pancreatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30009399&form=6&db=m S100A10, a novel biomarker in pancreatic ductal adenocarcinoma. causal interaction,diagnostic usage,ongoing research,unassigned 3,3,2,0 3.4.21.7 Pancreatitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2469582&form=6&db=m Peritoneal lavage efficiently eliminates protease-alpha-2-macroglobulin complexes and components of the contact system from the peritoneal cavity in patients with severe acute pancreatitis. diagnostic usage,ongoing research,unassigned 3,2,0 3.4.21.7 Pancreatitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4040294&form=6&db=m [Hemostatic indices of oncological patients with different forms of jaundice] diagnostic usage,ongoing research,therapeutic application,unassigned 2,2,1,0 3.4.21.7 Pancreatitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6515420&form=6&db=m Diagnostic efficacy of a simple radioimmunoassay test for fibrinogen/fibrin fragments containing the B beta 15-42 sequence. unassigned - 3.4.21.7 Pancreatitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7509867&form=6&db=m Indirect strong inhibition by acid-stable trypsin-plasmin inhibitor (ASTPI) of the activations of elastase and plasma fibrinolysis in a dog model of acute pancreatitis. causal interaction,ongoing research,therapeutic application,unassigned 1,1,1,0 3.4.21.7 Pancreatitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9663255&form=6&db=m The plasminogen activator/plasmin system is up-regulated after acute necrotizing pancreatitis in human beings. diagnostic usage,ongoing research,therapeutic application,unassigned 1,4,3,0 3.4.21.7 Pancreatitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10838811&form=6&db=m [Changes in some of the kallikrein-kinin system indices in patients with acute pancreatitis] causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,1,1 3.4.21.7 Pancreatitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12003423&form=6&db=m Acute pancreatitis in Soweto, South Africa: relationship between trypsinogen load, trypsinogen activation, and fibrinolysis. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,1,0 3.4.21.7 Pancreatitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=13897898&form=6&db=m Experimental pancreatitis and fibrinolysin. ongoing research,therapeutic application,unassigned 4,3,0 3.4.21.7 Pancreatitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15796165&form=6&db=m Antimetastatic activity of a synthetic serine protease inhibitor, FOY-305 (Foypan). unassigned - 3.4.21.7 Pancreatitis, Acute Hemorrhagic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4243299&form=6&db=m Prevention of hemorrhagic pancreatitis with fibrinolysin or heparin. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.7 Pancreatitis, Acute Necrotizing http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9663255&form=6&db=m The plasminogen activator/plasmin system is up-regulated after acute necrotizing pancreatitis in human beings. diagnostic usage,ongoing research,therapeutic application,unassigned 1,4,3,0 3.4.21.7 Pancreatitis, Chronic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9287983&form=6&db=m Enhanced urokinase plasminogen activation in chronic pancreatitis suggests a role in its pathogenesis. causal interaction,ongoing research,unassigned 4,4,0 3.4.21.7 Pancreatitis, Chronic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17496331&form=6&db=m Quantitative proteomics analysis reveals that proteins differentially expressed in chronic pancreatitis are also frequently involved in pancreatic cancer. causal interaction,diagnostic usage,unassigned 3,3,0 3.4.21.7 Paralysis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19214913&form=6&db=m Pathogenesis of venous thromboembolism: when the cup runneth over. therapeutic application,unassigned 1,0 3.4.21.7 Paralysis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28275164&form=6&db=m Plasminogen Deficiency Delays the Onset and Protects from Demyelination and Paralysis in Autoimmune Neuroinflammatory Disease. causal interaction,ongoing research,therapeutic application,unassigned 3,3,2,0 3.4.21.7 Paraproteinemias http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12633762&form=6&db=m Evaluation of a fully-automated particle-enhanced turbidimetric immunoassay for the measurement of plasma lipoprotein(a). population-based reference values in an area with low incidence of cardiovascular disease. unassigned - 3.4.21.7 Parasitemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1402463&form=6&db=m Hematological and coagulation studies in malaria. causal interaction,diagnostic usage,unassigned 3,1,0 3.4.21.7 Parasitemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7886582&form=6&db=m A new method for factor VII deficient substrate preparation and coagulation studies in malaria. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,1,0 3.4.21.7 Parasitic Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28443086&form=6&db=m Complete Molecular and Immunoprotective Characterization of Babesia microti Enolase. causal interaction,unassigned 3,0 3.4.21.7 Parkinson Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22619171&form=6&db=m Proteolytic cleavage of extracellular ?-synuclein by plasmin: implications for Parkinson disease. unassigned - 3.4.21.7 Pemphigoid Gestationis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8481985&form=6&db=m An immunohistochemical study of the distribution of plasminogen and plasminogen activators in bullous pemphigoid. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,2,4,2 3.4.21.7 Pemphigoid, Bullous http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1390172&form=6&db=m Enhanced association of plasminogen/plasmin with lesional epidermis of bullous pemphigoid. diagnostic usage,ongoing research,unassigned 1,2,0 3.4.21.7 Pemphigoid, Bullous http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2575330&form=6&db=m Plasmin-like proteinase associated with high molecular weight complexes in blister fluid of bullous pemphigoid. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 Pemphigoid, Bullous http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7523283&form=6&db=m [The autoimmune dermatosis bullous pemphigoid: deposition and activation of plasminogen in affected epidermis] causal interaction,unassigned 4,0 3.4.21.7 Pemphigoid, Bullous http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7688770&form=6&db=m The autoimmune blistering skin disease bullous pemphigoid. The presence of plasmin/alpha 2-antiplasmin complexes in skin blister fluid indicates plasmin generation in lesional skin. diagnostic usage,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.7 Pemphigoid, Bullous http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8481985&form=6&db=m An immunohistochemical study of the distribution of plasminogen and plasminogen activators in bullous pemphigoid. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,2,4,2 3.4.21.7 Pemphigoid, Bullous http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8874752&form=6&db=m Interleukin-1 beta upregulates tissue-type plasminogen activator in a keratinocyte cell line (HaCaT). therapeutic application,unassigned 1,0 3.4.21.7 Pemphigoid, Bullous http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8879451&form=6&db=m Plasminogen activation in bullous pemphigoid immunohistology reveals urokinase type plasminogen activator, its receptor and plasminogen activator inhibitor type-2 in lesional epidermis. causal interaction,ongoing research,therapeutic application,unassigned 3,2,4,0 3.4.21.7 Pemphigoid, Bullous http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32039455&form=6&db=m Collagen XVII Processing and Blistering Skin Diseases. causal interaction,unassigned 4,0 3.4.21.7 Pemphigus http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1375506&form=6&db=m Different effects of pemphigus antibody and plasmin on the distribution of keratin intermediate filaments and desmoplakins between cultured oral and epidermal keratinocytes. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,1,4,1 3.4.21.7 Pemphigus http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2957965&form=6&db=m Plasmin induces acantholysis in skin organ cultures. ongoing research,therapeutic application,unassigned 4,2,0 3.4.21.7 Pemphigus http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3117905&form=6&db=m Involvement of urokinase-type plasminogen activator in acantholysis induced by pemphigus IgG. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,1,3,2 3.4.21.7 Pemphigus http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3335823&form=6&db=m Complement fixation by pemphigus antibody. IV. Enhanced epidermal cell detachment in the absence of human plasminogen. ongoing research,unassigned 4,0 3.4.21.7 Pemphigus http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3745932&form=6&db=m Complement fixation by pemphigus antibody. III. Altered epidermal cell membrane integrity mediated by pemphigus antibody and complement. ongoing research,unassigned 2,0 3.4.21.7 Pemphigus http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3902681&form=6&db=m Pathogenesis of pemphigus. The role of epidermal plasminogen activators in acantholysis. causal interaction,unassigned 1,0 3.4.21.7 Pemphigus http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3907901&form=6&db=m Complement fixation by pemphigus antibody. II. Complement enhanced detachment of epidermal cells. ongoing research,therapeutic application,unassigned 3,1,0 3.4.21.7 Pemphigus http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6539102&form=6&db=m Penicillamine-induced pemphigus. Immunoglobulin from this patient induces plasminogen activator synthesis by human epidermal cells in culture: mechanism for acantholysis in pemphigus. ongoing research,unassigned 4,0 3.4.21.7 Pemphigus http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6681540&form=6&db=m Anti-cell surface pemphigus autoantibody stimulates plasminogen activator activity of human epidermal cells. A mechanism for the loss of epidermal cohesion and blister formation. causal interaction,ongoing research,unassigned 4,4,0 3.4.21.7 Pemphigus http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7682051&form=6&db=m Plasminogen activation in lesional skin of Pemphigus vulgaris type Neumann. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,3,2,1 3.4.21.7 Pemphigus http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8874752&form=6&db=m Interleukin-1 beta upregulates tissue-type plasminogen activator in a keratinocyte cell line (HaCaT). therapeutic application,unassigned 1,0 3.4.21.7 Pemphigus http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9347794&form=6&db=m Pemphigus IgG induces expression of urokinase plasminogen activator receptor on the cell surface of cultured keratinocytes. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,4,1 3.4.21.7 Pemphigus http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11422178&form=6&db=m Phosphatidylinositol-specific-phospholipase C cleaves urokinase plasminogen activator receptor from the cell surface and leads to inhibition of pemphigus-IgG-induced acantholysis in DJM-1 cells, a squamous cell carcinoma line. causal interaction,ongoing research,unassigned 4,4,0 3.4.21.7 Pemphigus http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12675525&form=6&db=m Protease inhibitors prevent plasminogen-mediated, but not pemphigus vulgaris-induced, acantholysis in human epidermis. therapeutic application,unassigned 3,0 3.4.21.7 Pemphigus, Benign Familial http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1751348&form=6&db=m Cell adhesion in Hailey-Hailey disease and Darier's disease: immunocytological and explant-tissue-culture studies. causal interaction,unassigned 3,0 3.4.21.7 Pemphigus, Benign Familial http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2957965&form=6&db=m Plasmin induces acantholysis in skin organ cultures. ongoing research,therapeutic application,unassigned 4,2,0 3.4.21.7 Pemphigus, Benign Familial http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7510121&form=6&db=m Cantharidin-induced acantholysis: adhesion molecules, proteases, and related proteins. causal interaction,diagnostic usage,ongoing research,unassigned 3,3,2,0 3.4.21.7 Peptic Ulcer http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9746606&form=6&db=m Plasminogen binding and activation at the surface of Helicobacter pylori CCUG 17874. causal interaction,unassigned 1,0 3.4.21.7 Peri-Implantitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26021226&form=6&db=m A controlled, cross-sectional exploratory study on markers for the plasminogen system and inflammation in crevicular fluid samples from healthy, mucositis and peri-implantitis sites. causal interaction,diagnostic usage,ongoing research,unassigned 3,4,3,0 3.4.21.7 Peri-Implantitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27743595&form=6&db=m Relevance of the plasminogen system in physiology, pathology, and regeneration of oral tissues - From the perspective of dental specialties. therapeutic application,unassigned 2,0 3.4.21.7 Peri-Implantitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33425781&form=6&db=m Discriminating Microbial Community Structure Between Peri-Implantitis and Periodontitis With Integrated Metagenomic, Metatranscriptomic, and Network Analysis. diagnostic usage,unassigned 2,0 3.4.21.7 Pericarditis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26036227&form=6&db=m Beyond hemostasis: the challenge of treating plasminogen deficiency. A report of three cases. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 Perinatal Death http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8313495&form=6&db=m Syphilis-associated perinatal and infant mortality in rural Malawi. causal interaction,diagnostic usage,therapeutic application,unassigned 2,1,1,0 3.4.21.7 Periodontal Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1836266&form=6&db=m Gingival crevicular fluid plasmin activity in different clinical conditions and after periodontal treatment. causal interaction,therapeutic application,unassigned 4,2,0 3.4.21.7 Periodontal Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1908672&form=6&db=m Plasminogen activator in human periodontal health and disease. therapeutic application,unassigned 4,0 3.4.21.7 Periodontal Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11842939&form=6&db=m Plasminogen activating capacity in gingival fluid from deteriorating and stable periodontal pockets. diagnostic usage,ongoing research,therapeutic application,unassigned 2,4,1,0 3.4.21.7 Periodontal Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15547600&form=6&db=m Destructive membranous periodontal disease (ligneous periodontitis): a case report and 3 years follow-up. causal interaction,unassigned 3,0 3.4.21.7 Periodontal Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17296163&form=6&db=m Plasminogen activation by fibroblasts from periodontal ligament and gingiva is not directly affected by chemokines in vitro. causal interaction,diagnostic usage,unassigned 4,2,0 3.4.21.7 Periodontal Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17507267&form=6&db=m Ligneous periodontitis and gingival antioxidant status: report of two cases. causal interaction,unassigned 3,0 3.4.21.7 Periodontal Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17559626&form=6&db=m Association of gene polymorphisms for plasminogen activators with alveolar bone loss. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,3,0 3.4.21.7 Periodontal Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21704601&form=6&db=m Plasmin is essential in preventing periodontitis in mice. causal interaction,ongoing research,therapeutic application,unassigned 4,4,4,0 3.4.21.7 Periodontal Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21859319&form=6&db=m Destructive Membranous Periodontal Disease (Ligneous Gingivitis): A Literature Review. causal interaction,unassigned 4,0 3.4.21.7 Periodontal Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25101505&form=6&db=m Ligneous periodontal lesions in a young child with severe plasminogen deficiency: a case report. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 Periodontal Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25971786&form=6&db=m Periodontitis associated with plasminogen deficiency: a case report. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 Periodontal Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29379003&form=6&db=m Ligneous periodontitis in a child with plasminogen deficiency. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 Periodontal Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32274221&form=6&db=m Ligneous Periodontitis in a Patient with Type 1 Plasminogen Deficiency: A Case Report and Review of the Literature. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.7 Periodontal Pocket http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11842939&form=6&db=m Plasminogen activating capacity in gingival fluid from deteriorating and stable periodontal pockets. diagnostic usage,ongoing research,therapeutic application,unassigned 2,4,1,0 3.4.21.7 Periodontitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2163444&form=6&db=m Salivary collagenase. Origin, characteristics and relationship to periodontal health. causal interaction,ongoing research,therapeutic application,unassigned 4,2,4,0 3.4.21.7 Periodontitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7593702&form=6&db=m Cellular source, activation and inhibition of dental plaque collagenase. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,4,3 3.4.21.7 Periodontitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10569761&form=6&db=m Acquisition of plasmin activity by Fusobacterium nucleatum subsp. nucleatum and potential contribution to tissue destruction during periodontitis. unassigned - 3.4.21.7 Periodontitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16579713&form=6&db=m Ligneous periodontitis and Ehlers-Danlos syndrome. causal interaction,unassigned 4,0 3.4.21.7 Periodontitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17449295&form=6&db=m A ligneous periodontitis and conjunctival lesions in a patient with plasminogen deficiency. causal interaction,unassigned 4,0 3.4.21.7 Periodontitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17507267&form=6&db=m Ligneous periodontitis and gingival antioxidant status: report of two cases. causal interaction,unassigned 3,0 3.4.21.7 Periodontitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19689523&form=6&db=m Ligneous conjunctivitis with oral mucous membrane involvement and decreased plasminogen level. causal interaction,unassigned 4,0 3.4.21.7 Periodontitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21704601&form=6&db=m Plasmin is essential in preventing periodontitis in mice. causal interaction,ongoing research,therapeutic application,unassigned 4,4,4,0 3.4.21.7 Periodontitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21716989&form=6&db=m Altered functional activity patterns of fibroblasts related to periodontitis by systemic plasminogen deficiency (ligneous periodontitis). causal interaction,unassigned 2,0 3.4.21.7 Periodontitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24535478&form=6&db=m The plasminogen activation system in periodontal tissue (Review). causal interaction,unassigned 3,0 3.4.21.7 Periodontitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25101505&form=6&db=m Ligneous periodontal lesions in a young child with severe plasminogen deficiency: a case report. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 Periodontitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25466412&form=6&db=m Genetic Evidence for PLASMINOGEN as a Shared Genetic Risk Factor of Coronary Artery Disease and Periodontitis. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.7 Periodontitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25971786&form=6&db=m Periodontitis associated with plasminogen deficiency: a case report. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 Periodontitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26172848&form=6&db=m Pathogenic potential of Tannerella forsythia enolase. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 Periodontitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27552374&form=6&db=m Immunohistochemical analysis of the gingiva with periodontitis of type I plasminogen deficiency compared to gingiva with gingivitis and periodontitis and healthy gingiva. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,3,1 3.4.21.7 Periodontitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27743595&form=6&db=m Relevance of the plasminogen system in physiology, pathology, and regeneration of oral tissues - From the perspective of dental specialties. therapeutic application,unassigned 2,0 3.4.21.7 Periodontitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27781272&form=6&db=m Gingival crevicular fluid tissue/blood vessel-type plasminogen activator and plasminogen activator inhibitor-2 levels in patients with rheumatoid arthritis: effects of nonsurgical periodontal therapy. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,2,4,2 3.4.21.7 Periodontitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29243487&form=6&db=m Assessing a multiplex-targeted proteomics approach for the clinical diagnosis of periodontitis using saliva samples. diagnostic usage,unassigned 2,0 3.4.21.7 Periodontitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29379003&form=6&db=m Ligneous periodontitis in a child with plasminogen deficiency. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 Periodontitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32274221&form=6&db=m Ligneous Periodontitis in a Patient with Type 1 Plasminogen Deficiency: A Case Report and Review of the Literature. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.7 Peripheral Arterial Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11246539&form=6&db=m Activation products of the haemostatic system in coronary, cerebrovascular and peripheral arterial disease. causal interaction,diagnostic usage,therapeutic application,unassigned 1,3,1,0 3.4.21.7 Peripheral Arterial Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19015166&form=6&db=m Hypercoagulability Markers in Patients With Peripheral Arterial Disease: Association to Ankle-brachial Index. diagnostic usage,ongoing research,therapeutic application,unassigned 4,2,1,0 3.4.21.7 Peripheral Arterial Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28116631&form=6&db=m Translational initiatives in thrombolytic therapy. therapeutic application,unassigned 3,0 3.4.21.7 Peripheral Nerve Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14750967&form=6&db=m Tissue plasminogen activator in primary afferents induces dorsal horn excitability and pain response after peripheral nerve injury. causal interaction,ongoing research,therapeutic application,unassigned 3,2,1,0 3.4.21.7 Peripheral Vascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11419606&form=6&db=m Inhibition of human plasmin activity using humic acids with arsenic. causal interaction,unassigned 3,0 3.4.21.7 Peripheral Vascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16124372&form=6&db=m [Lipoprotein(a) and plasminogen patients with diabetes mellitus complicated with peripheral angiopathy and hypertension] diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.7 Peritonitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9648067&form=6&db=m PAI-1 secretion and matrix deposition in human peritoneal mesothelial cell cultures: transcriptional regulation by TGF-beta 1. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.7 Peritonitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15880275&form=6&db=m Protein C as an early marker of severe septic complications in diffuse secondary peritonitis. diagnostic usage,ongoing research,unassigned 4,1,0 3.4.21.7 Peritonitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24650562&form=6&db=m Lp(a)/apo(a) Modulate MMP-9 Activation and Neutrophil Cytokines in Vivo in Inflammation to Regulate Leukocyte Recruitment. causal interaction,ongoing research,unassigned 3,1,0 3.4.21.7 Persistent Infection http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23312025&form=6&db=m Glycoproteomic analysis of serum from patients with gastric precancerous lesions. causal interaction,diagnostic usage,unassigned 4,3,0 3.4.21.7 Persistent Infection http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24535478&form=6&db=m The plasminogen activation system in periodontal tissue (Review). causal interaction,unassigned 3,0 3.4.21.7 Persistent Infection http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26775037&form=6&db=m Plasmin in Parasitic Chronic Infections: Friend or Foe? causal interaction,diagnostic usage,unassigned 3,1,0 3.4.21.7 Pharyngitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14570069&form=6&db=m [A 50-year history of new drugs in Japan-the development and trends of hemostatics and antithrombotic drugs] diagnostic usage,therapeutic application,unassigned 3,3,0 3.4.21.7 Pharyngitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18867850&form=6&db=m Streptococcal fibrinolysin; a study of this substance and its antibody in group A hemolytic streptococcus sore throat. ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.7 Pheochromocytoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6666493&form=6&db=m Increased vascular plasminogen activity in patients with pheochromocytoma. causal interaction,diagnostic usage,unassigned 4,2,0 3.4.21.7 Pituitary ACTH Hypersecretion http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12876630&form=6&db=m Contraceptive pills induce an improvement in congenital hypoplasminogenemia in two unrelated patients with ligneous conjunctivitis. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 Plague http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2526282&form=6&db=m A Yersinia pestis-specific DNA fragment encodes temperature-dependent coagulase and fibrinolysin-associated phenotypes. unassigned - 3.4.21.7 Plague http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6194044&form=6&db=m [Detection and characterization of the plasmids of the plague microbe which determine the synthesis of pesticin I, fraction I antigen and "mouse" toxin exotoxin] ongoing research,unassigned 1,0 3.4.21.7 Plague http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8360901&form=6&db=m Mutation in the pla gene of Yersinia pestis alters the course of the plague bacillus-flea (Siphonaptera: Ceratophyllidae) interaction. unassigned - 3.4.21.7 Plague http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14651623&form=6&db=m Lack of O-antigen is essential for plasminogen activation by Yersinia pestis and Salmonella enterica. causal interaction,unassigned 4,0 3.4.21.7 Plague http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16320702&form=6&db=m [Extracellular resistance of Yersinia pestis to phagocytosis] causal interaction,unassigned 1,0 3.4.21.7 Plague http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17635705&form=6&db=m Fibrin and fibrinolysis in infection and host defense. causal interaction,therapeutic application,unassigned 2,2,0 3.4.21.7 Plague http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18988866&form=6&db=m Proteolytic inactivation of tissue factor pathway inhibitor by bacterial omptins. unassigned - 3.4.21.7 Plague http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19725923&form=6&db=m Polyphosphate and omptins: novel bacterial procoagulant agents. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.7 Plague http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20368351&form=6&db=m Temperature-Induced Changes in the Lipopolysaccharide of Yersinia pestis Affect Plasminogen Activation by the Pla Surface Protease. causal interaction,unassigned 2,0 3.4.21.7 Plague http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24686064&form=6&db=m Deletion of Braun lipoprotein and plasminogen activating protease-encoding genes attenuates Yersinia pestis in mouse models of bubonic and pneumonic plague. unassigned - 3.4.21.7 Plague http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26438794&form=6&db=m Impact of the Pla protease substrate ?2-antiplasmin on the progression of primary pneumonic plague. causal interaction,diagnostic usage,therapeutic application,unassigned 4,1,3,0 3.4.21.7 Plague http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26484539&form=6&db=m Dissociation of Tissue Destruction and Bacterial Expansion during Bubonic Plague. causal interaction,therapeutic application,unassigned 2,3,0 3.4.21.7 Plague http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27377187&form=6&db=m Proteolysis of plasminogen activator inhibitor-1 by Yersinia pestis remodulates the host environment to promote virulence. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,3,3,2 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1621238&form=6&db=m Type I congenital plasminogen deficiency is not a risk factor for thrombosis. causal interaction,unassigned 4,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2003311&form=6&db=m Cerebral venous thrombosis with plasminogen deficiency. causal interaction,unassigned 4,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2311307&form=6&db=m IgA nephritis associated with plasminogen abnormalities. causal interaction,diagnostic usage,unassigned 4,3,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2363094&form=6&db=m [Plasminogen deficiencies in 2 Spanish families. Response to the administration of DDAVP] causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2366339&form=6&db=m [Congenital plasminogen deficiency in a Japanese family] causal interaction,unassigned 4,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2491930&form=6&db=m Severe thrombotic tendency associated with a type I plasminogen deficiency. causal interaction,unassigned 4,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2509107&form=6&db=m Lupus-like anticoagulants and lower extremity arterial occlusive disease. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2521908&form=6&db=m Hypercoagulable states and lower limb ischemia in young adults. causal interaction,unassigned 3,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2524095&form=6&db=m [Protein-S deficiency in young patients with thrombotic brain infarction] causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2526671&form=6&db=m Clinical disorders of fibrinolysis: a critical review. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2966450&form=6&db=m The frequency of type I heterozygous protein S and protein C deficiency in 141 unrelated young patients with venous thrombosis. diagnostic usage,ongoing research,unassigned 4,2,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3082686&form=6&db=m Von Recklinghausen neurofibromatosis and hereditary plasminogen deficiency. causal interaction,unassigned 4,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3088889&form=6&db=m Congenital heterozygous plasminogen deficiency associated with a severe thrombotic tendency. causal interaction,unassigned 4,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3158265&form=6&db=m Antithrombin III, plasminogen, plasmin, and alpha-2-antiplasmin in donor blood and plasma components. causal interaction,diagnostic usage,unassigned 3,3,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3219292&form=6&db=m Thrombovascular disease and familial plasminogen deficiency: a report of three kindreds. causal interaction,unassigned 4,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3238658&form=6&db=m Thrombotic manifestations in plasminogen deficiency and in plasminogen abnormalities. causal interaction,unassigned 4,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3388298&form=6&db=m Congenital deficiency of plasminogen and its relationship to venous thrombosis. causal interaction,diagnostic usage,unassigned 4,1,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3730296&form=6&db=m Congenital plasminogen deficiency associated with venous thromboembolism: therapeutic trial with stanozolol. causal interaction,unassigned 4,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3762956&form=6&db=m Plasminogen deficiency and thrombosis after plasmapheresis therapy for multiple sclerosis. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=5856132&form=6&db=m Fibrinase deficiency. causal interaction,unassigned 4,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=5989036&form=6&db=m [On the demonstration of plasmin deficiency in retracted clots of full blood and on its significance in the lysis with streptokinase] causal interaction,unassigned 1,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6221323&form=6&db=m [Molecular abnormalities in recurrent thromboembolic disease] causal interaction,unassigned 4,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7192289&form=6&db=m Increased neurite development and plasminogen activator expression by exposure of human neuroblastoma cells to plasminogen-deficient growth medium. causal interaction,ongoing research,unassigned 4,3,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7574192&form=6&db=m Prevalence of moderate hyperhomocysteinemia in patients with early-onset venous and arterial occlusive disease. causal interaction,diagnostic usage,ongoing research,unassigned 4,1,2,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7665859&form=6&db=m Familial occurrence of membranous obstruction of the inferior vena cava: arguments in favor of a congenital etiology. causal interaction,unassigned 4,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7705657&form=6&db=m Plasminogen deficiency causes severe thrombosis but is compatible with development and reproduction. causal interaction,unassigned 4,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7890263&form=6&db=m Symptomatic versus asymptomatic patients in congenital hypoplasminogenemia: a statistical analysis. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,4,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7893926&form=6&db=m Heterozygous type I plasminogen deficiency is associated with an increased risk for thrombosis: a statistical analysis in 20 kindreds. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,2,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8258756&form=6&db=m Unusual thrombotic-like retinopathy (Coats' disease) associated with congenital plasminogen deficiency type I. causal interaction,unassigned 4,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8322279&form=6&db=m Spontaneous versus secondary thrombosis in congenital heterozygous plasminogen deficiency. causal interaction,unassigned 4,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8358126&form=6&db=m A patient with congenital plasminogen deficiency manifesting primary pulmonary hypertension. causal interaction,unassigned 4,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8392398&form=6&db=m Congenital plasminogen deficiency caused by a Ser572 to Pro mutation. causal interaction,unassigned 4,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8442350&form=6&db=m Hypercoagulable states. causal interaction,unassigned 3,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8585045&form=6&db=m Central retinal vein and branch artery occlusion associated with inherited plasminogen deficiency and high lipoprotein(a) levels: a case report. causal interaction,unassigned 4,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8681773&form=6&db=m [Recurrent arterial thromboembolism in hereditary hypoplasminogenaemia] causal interaction,unassigned 3,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8713786&form=6&db=m A novel missense mutation in two families with congenital plasminogen deficiency: identification of an Ala675 to Thr675 substitution. causal interaction,unassigned 4,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8739849&form=6&db=m Pathophysiology of the plasminogen/plasmin system. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8795351&form=6&db=m Phase I study of intraventricular recombinant tissue plasminogen activator for treatment of posthaemorrhagic hydrocephalus. causal interaction,ongoing research,therapeutic application,unassigned 4,4,3,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8816063&form=6&db=m [Molecular biological approach for congenital abnormality of blood coagulation] causal interaction,unassigned 3,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8883289&form=6&db=m Plasminogen deficiency: an additional risk factor for thrombosis in a family with factor V R506Q mutation? causal interaction,unassigned 3,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8913958&form=6&db=m Familial coagulation-inhibiting and fibrinolytic protein deficiencies in juvenile transient ischaemic attacks. diagnostic usage,ongoing research,therapeutic application,unassigned 4,2,1,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8929539&form=6&db=m Loss of fibrinogen rescues mice from the pleiotropic effects of plasminogen deficiency. causal interaction,ongoing research,therapeutic application,unassigned 4,2,1,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8972025&form=6&db=m Isolated familial plasminogen deficiency may not be a risk factor for thrombosis. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8978291&form=6&db=m Molecular pathogenesis of type I congenital plasminogen deficiency: expression of recombinant human mutant plasminogens in mammalian cells. causal interaction,ongoing research,unassigned 4,4,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9065991&form=6&db=m Laboratory evaluation and clinical characteristics of 2,132 consecutive unselected patients with venous thromboembolism--results of the Spanish Multicentric Study on Thrombophilia (EMET-Study). causal interaction,unassigned 4,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9167021&form=6&db=m Asymptomatic coinheritance of heterozygous plasminogen deficiency and the factor VLeiden mutation. causal interaction,ongoing research,unassigned 4,3,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9184396&form=6&db=m Fibrinogen heterogeneity in homozygous plasminogen deficiency type I: further evidence that plasmin is not involved in formation of LMW- and LMW'-fibrinogen. causal interaction,diagnostic usage,unassigned 4,1,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9242524&form=6&db=m Homozygous mutations in the plasminogen gene of two unrelated girls with ligneous conjunctivitis. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9255907&form=6&db=m Homozygous type I plasminogen deficiency. causal interaction,unassigned 4,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9294211&form=6&db=m Plasminogen deficiency accelerates vessel wall disease in mice predisposed to atherosclerosis. causal interaction,ongoing research,unassigned 4,3,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9391725&form=6&db=m Recurrent venous thromboembolic disease and factor XI concentrate in a patient with severe factor XI deficiency, chronic myelomonocytic leukaemia, factor V Leiden and heterozygous plasminogen deficiency. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9409444&form=6&db=m Thrombophilia found in patients with moyamoya disease. causal interaction,diagnostic usage,unassigned 2,2,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9457624&form=6&db=m Coagulation disorders in young adults with acute cerebral ischaemia. causal interaction,unassigned 4,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9473227&form=6&db=m Ligneous conjunctivitis in plasminogen-deficient mice. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9490683&form=6&db=m Plasminogen deficiency differentially affects recruitment of inflammatory cell populations in mice. causal interaction,unassigned 4,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9544982&form=6&db=m Low risk of venous thrombosis in two families with combined type I plasminogen deficiency and factor V R506Q mutation. causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,1,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9564763&form=6&db=m [Clinical diagnosis of thrombosis and blood coagulation tests] diagnostic usage,unassigned 3,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9566843&form=6&db=m Post-traumatic membranous obstruction of the inferior vena cava associated with a hypercoagulable state. causal interaction,unassigned 3,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9684804&form=6&db=m Is plasminogen deficiency a thrombotic risk factor? A study on 23 thrombophilic patients and their family members. causal interaction,unassigned 4,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9686815&form=6&db=m Cerebral venous sinus thrombosis in infancy and childhood: role of genetic and acquired risk factors of thrombophilia. causal interaction,unassigned 4,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9834305&form=6&db=m Therapy with a purified plasminogen concentrate in an infant with ligneous conjunctivitis and homozygous plasminogen deficiency. causal interaction,therapeutic application,unassigned 3,3,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10066157&form=6&db=m Polymorphonuclear elastase in patients with homozygous type I plasminogen deficiency and ligneous conjunctivitis. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10190281&form=6&db=m Human homozygous type I plasminogen deficiency and ligneous conjunctivitis. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,1,1,1 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10233898&form=6&db=m Compound-heterozygous mutations in the plasminogen gene predispose to the development of ligneous conjunctivitis. causal interaction,diagnostic usage,unassigned 4,3,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10360521&form=6&db=m Prenatal diagnosis in a family with severe type I plasminogen deficiency, ligneous conjunctivitis and congenital hydrocephalus. causal interaction,diagnostic usage,unassigned 4,2,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10469644&form=6&db=m Functional overlap between two classes of matrix-degrading proteases in wound healing. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10544934&form=6&db=m Transient ischaemic attacks in two sisters with plasminogen deficiency and factor V Leiden. causal interaction,unassigned 3,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10548072&form=6&db=m Treatment of hereditary and acquired thrombophilic disorders. causal interaction,unassigned 4,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10611352&form=6&db=m Plasminogen deficiency leads to impaired remodeling after a toxic injury to the liver. causal interaction,unassigned 4,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10629572&form=6&db=m Causes of venous thrombosis in fifty Chinese patients. causal interaction,diagnostic usage,therapeutic application,unassigned 2,2,1,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10650845&form=6&db=m Multicentre evaluation of combined prothrombotic defects associated with thrombophilia in childhood. Childhood Thrombophilia Study Group. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,2,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10650871&form=6&db=m Plasma values for u-PA in children. causal interaction,diagnostic usage,unassigned 3,3,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10726026&form=6&db=m Familial association of hypoplasminogenemia and heterozygous factor V deficiency. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,1,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10726047&form=6&db=m Combined heterozygous plasminogen deficiency and factor V Leiden defect in the same kindred. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10816379&form=6&db=m Role of the pleiotropic effects of plasminogen deficiency in infection experiments with plasminogen-deficient mice. causal interaction,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10839966&form=6&db=m Endoluminal arterial injury in plasminogen-deficient mice. causal interaction,ongoing research,therapeutic application,unassigned 4,2,1,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10885855&form=6&db=m Growth and behavioral development in plasminogen gene-targeted mice. causal interaction,unassigned 3,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10893060&form=6&db=m Screening for thrombophilic risk factors among 25 German patients with cerebral venous thrombosis. causal interaction,unassigned 4,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10912662&form=6&db=m Inflammatory bowel disease promotes venous thrombosis earlier in life. causal interaction,diagnostic usage,unassigned 4,2,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10973672&form=6&db=m Protein C and protein S deficiencies are the most important risk factors associated with thrombosis in Chinese venous thrombophilic patients in Taiwan. diagnostic usage,ongoing research,unassigned 4,2,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11040483&form=6&db=m Ligneous conjunctivitis: a local manifestation of a systemic disorder? causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11045349&form=6&db=m Ligneous conjunctivitis in a girl with severe type I plasminogen deficiency. causal interaction,unassigned 4,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11250632&form=6&db=m Oral lesions indicative of plasminogen deficiency (hypoplasminogenemia). causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11434676&form=6&db=m Homozygous and compound-heterozygous type I plasminogen deficiency is a common cause of ligneous conjunctivitis. causal interaction,unassigned 4,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11477736&form=6&db=m Pulmonary involvement in a child with ligneous conjunctivitis and homozygous type I plasminogen deficiency. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11733368&form=6&db=m Plasminogen deficiency leads to impaired lobular reorganization and matrix accumulation after chronic liver injury. causal interaction,unassigned 4,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11738106&form=6&db=m Plasminogen deficiency results in poor clearance of non-fibrin matrix and persistent activation of hepatic stellate cells after an acute injury. causal interaction,unassigned 4,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11931777&form=6&db=m Effective treatment of ligneous conjunctivitis with topical plasminogen. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,4,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11987044&form=6&db=m [Ligneous conjunctivitis in a patient with plasminogen type I deficiency--case report with review of literature] causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,1,4 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12083480&form=6&db=m In vivo plasminogen deficiency reduces fat accumulation. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12091052&form=6&db=m Combined Ala601-Thr-type dysplasminogenaemia and antiphospholipid antibody syndrome in a patient with recurrent thrombosis. causal interaction,unassigned 4,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12428098&form=6&db=m Influence of plasminogen deficiency on the contribution of polymorphonuclear leucocytes to fibrin/ogenolysis: studies in plasminogen knock-out mice. causal interaction,ongoing research,therapeutic application,unassigned 3,2,2,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12431907&form=6&db=m Plasminogen directs the pleiotropic effects of uPA in liver injury and repair. causal interaction,unassigned 3,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12616091&form=6&db=m Coagulopathies and arterial stroke. causal interaction,unassigned 4,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12623158&form=6&db=m Otolaryngological manifestations of ligneous conjunctivitis. causal interaction,unassigned 4,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12719968&form=6&db=m Ligneous conjunctivitis, hydrocephalus, hydrocele, and pulmonary involvement in a child with homozygous type I plasminogen deficiency. causal interaction,unassigned 4,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12829586&form=6&db=m Plasminogen supports tumor growth through a fibrinogen-dependent mechanism linked to vascular patency. causal interaction,unassigned 3,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12850227&form=6&db=m Ligneous conjunctivitis. causal interaction,unassigned 4,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12876630&form=6&db=m Contraceptive pills induce an improvement in congenital hypoplasminogenemia in two unrelated patients with ligneous conjunctivitis. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12900459&form=6&db=m A functional overlap of plasminogen and MMPs regulates vascularization during placental development. causal interaction,unassigned 1,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12945885&form=6&db=m A K19E missense mutation in the plasminogen gene is a common cause of familial hypoplasminogenaemia. causal interaction,unassigned 4,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14337322&form=6&db=m PLASMINOGEN DEFICIENCY IN HODGKIN'S DISEASE. causal interaction,unassigned 4,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14576528&form=6&db=m Treatment of ligneous conjunctivitis with topical plasmin and topical plasminogen. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14629475&form=6&db=m Population-based distribution of plasminogen activity and estimated prevalence and relevance to thrombotic diseases of plasminogen deficiency in the Japanese: the Suita Study. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,2,1 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14653398&form=6&db=m Recurrent recalcitrant gingival hyperplasia and plasminogen deficiency: a case report. causal interaction,diagnostic usage,unassigned 4,2,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15213608&form=6&db=m Ligneous (pseudomembranous) inflammation involving the female genital tract associated with type-1 plasminogen deficiency. causal interaction,unassigned 4,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15269832&form=6&db=m Characterization of plasminogen variants in healthy subjects and plasminogen mutants in patients with inherited plasminogen deficiency by isoelectric focusing gel electrophoresis. ongoing research,therapeutic application,unassigned 1,1,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15289146&form=6&db=m Prevention of ligneous conjunctivitis by topical and subconjunctival fresh frozen plasma. causal interaction,unassigned 4,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15364412&form=6&db=m Plasmin deficiency does not alter endogenous murine amyloid beta levels in mice. causal interaction,ongoing research,unassigned 4,3,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15472905&form=6&db=m Reduced metastasis of transgenic mammary cancer in urokinase-deficient mice. causal interaction,unassigned 4,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15488842&form=6&db=m Therapeutic approaches in the treatment of ligneous conjunctivitis, the most common clinical manifestation of a systemic disease, caused by severe type I plasminogen deficiency. causal interaction,therapeutic application,unassigned 4,3,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15547600&form=6&db=m Destructive membranous periodontal disease (ligneous periodontitis): a case report and 3 years follow-up. causal interaction,unassigned 3,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15692255&form=6&db=m The fibrinolytic system and thrombotic tendency. unassigned - 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15782857&form=6&db=m [Ligneous conjunctivitis: complication of inborn plasminogen deficiency (a case report)] causal interaction,diagnostic usage,unassigned 4,2,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15822024&form=6&db=m Congenital hydrocephalus as a rare association with ligneous conjunctivitis and type I plasminogen deficiency. causal interaction,unassigned 4,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16052596&form=6&db=m Contrasting roles of plasminogen deficiency in different rheumatoid arthritis models. causal interaction,diagnostic usage,therapeutic application,unassigned 4,1,4,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16579713&form=6&db=m Ligneous periodontitis and Ehlers-Danlos syndrome. causal interaction,unassigned 4,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16849641&form=6&db=m Molecular and clinical spectrum of type I plasminogen deficiency: A series of 50 patients. causal interaction,unassigned 4,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16908991&form=6&db=m Plasmin deficiency in Alzheimer's disease brains: causal or casual? causal interaction,unassigned 4,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17032399&form=6&db=m Ligneous alveolar gingivitis in the absence of plasminogen deficiency. causal interaction,unassigned 4,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17179833&form=6&db=m Molecular characterization of an Italian patient with plasminogen deficiency and ligneous conjunctivitis. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,1,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17301181&form=6&db=m Proteolytic activation of monocyte chemoattractant protein-1 by plasmin underlies excitotoxic neurodegeneration in mice. unassigned - 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17367037&form=6&db=m Clinical manifestations due to severe plasminogen deficiency: a case report. causal interaction,unassigned 4,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17414214&form=6&db=m Fibrinolysis and the risk of venous and arterial thrombosis. causal interaction,diagnostic usage,therapeutic application,unassigned 3,2,2,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17449295&form=6&db=m A ligneous periodontitis and conjunctival lesions in a patient with plasminogen deficiency. causal interaction,unassigned 4,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17503307&form=6&db=m Management of hydrocephalus in children with plasminogen deficiency. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17507267&form=6&db=m Ligneous periodontitis and gingival antioxidant status: report of two cases. causal interaction,unassigned 3,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17722076&form=6&db=m Fibrinogen deficiency, but not plasminogen deficiency, increases mortality synergistically in combination with sickle hemoglobin SAD in transgenic mice. causal interaction,ongoing research,unassigned 4,2,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17889676&form=6&db=m Inherited plasminogen deficiency presenting as ligneous vaginitis: a case report with molecular correlation and review of the literature. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17900274&form=6&db=m Plasminogen deficiency. causal interaction,unassigned 4,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17944666&form=6&db=m Hypoplasminogenaemia, gingival swelling and ulceration. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18312178&form=6&db=m Ligneous conjunctivitis secondary to a congenital plasminogen deficiency in a dog. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18434858&form=6&db=m Systemic and topical fresh-frozen plasma treatment in a newborn with ligneous conjunctivitis. unassigned - 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18996031&form=6&db=m Successful treatment of ligneous gingivitis with warfarin. causal interaction,unassigned 3,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19006564&form=6&db=m Ligneous conjunctivitis with plasminogen deficiency. causal interaction,unassigned 4,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19011568&form=6&db=m Plasminogen deficiency as a rare cause of conjunctivitis and lymphadenopathy. causal interaction,unassigned 4,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19141167&form=6&db=m Plasminogen deficiency. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,4,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19297327&form=6&db=m Active Plasma Kallikrein Localizes to Mast Cells and Regulates Epithelial Cell Apoptosis, Adipocyte Differentiation, and Stromal Remodeling during Mammary Gland Involution. causal interaction,therapeutic application,unassigned 3,3,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19302964&form=6&db=m Pseudomembranous disease (ligneous inflammation) of the female genital tract, peritoneum, gingiva, and paranasal sinuses associated with plasminogen deficiency. causal interaction,diagnostic usage,unassigned 4,1,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19350108&form=6&db=m Serine proteases, inhibitors and receptors in renal fibrosis. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19373890&form=6&db=m The first two Japanese cases of severe type I congenital plasminogen deficiency with ligneous conjunctivitis: Successful treatment with direct thrombin inhibitor and fresh plasma. causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,3,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19604341&form=6&db=m Ligneous conjunctivitis in a plasminogen-deficient dog: clinical management and 2-year follow-up. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20524141&form=6&db=m Induction of bilateral ligneous conjunctivitis with the use of a prosthetic eye. causal interaction,unassigned 4,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21174000&form=6&db=m Identification of three novel plasminogen (PLG) gene mutations in a series of 23 patients with low PLG activity. causal interaction,therapeutic application,unassigned 4,3,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21625933&form=6&db=m Management of ligneous conjunctivitis in a child with plasminogen deficiency. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21716989&form=6&db=m Altered functional activity patterns of fibroblasts related to periodontitis by systemic plasminogen deficiency (ligneous periodontitis). causal interaction,unassigned 2,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21859319&form=6&db=m Destructive Membranous Periodontal Disease (Ligneous Gingivitis): A Literature Review. causal interaction,unassigned 4,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21885957&form=6&db=m Heparin in the long-term management of ligneous conjunctivitis: a case report and review of literature. causal interaction,unassigned 4,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21969282&form=6&db=m Duodenal ulceration in a patient with celiac disease and plasminogen I deficiency: coincidence or cofactors? causal interaction,unassigned 4,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21993334&form=6&db=m Extensive fibrin accumulation and accompanying epithelial changes in the pathogenesis of ligneous mucosal disease (ligneous periodontitis). causal interaction,unassigned 4,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22056679&form=6&db=m Plasminogen deficiency attenuates postnatal erythropoiesis in male C57BL/6 mice through decreased activity of the LH-testosterone axis. causal interaction,ongoing research,unassigned 4,4,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22328462&form=6&db=m Laryngeal obstruction in congenital plasminogen deficiency. causal interaction,unassigned 4,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22815383&form=6&db=m Plasmin-driven fibrinolysis facilitates skin tumor growth in a gender-dependent manner. causal interaction,ongoing research,unassigned 4,4,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23445328&form=6&db=m The ventriculocholecystic shunt: two case reports and a review of the literature. causal interaction,unassigned 4,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23518917&form=6&db=m Ligneous Cervicitis in a Woman With Plasminogen Deficiency Associated With an Atypical Form of Microglandular Hyperplasia: A Case Report and Review of Literature. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23527289&form=6&db=m Gender affects skin wound healing in plasminogen deficient mice. causal interaction,ongoing research,therapeutic application,unassigned 4,2,1,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23684723&form=6&db=m Conjunctival instillation of plasminogen eliminates ocular lesion in B6.129P2-Plg(tm1Jld) transgenic mice, a model of ligneous conjunctivitis. causal interaction,ongoing research,therapeutic application,unassigned 4,4,3,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24029428&form=6&db=m Comprehensive Genetic Analysis of Complement and Coagulation Genes in Atypical Hemolytic Uremic Syndrome. causal interaction,unassigned 3,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24612416&form=6&db=m Plasmin Deficiency Leads to Fibrin Accumulation and a Compromised Inflammatory Response in the Mouse Brain. unassigned - 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24732409&form=6&db=m Plasminogen deficiency causes reduced corticospinal axonal plasticity and functional recovery after stroke in mice. causal interaction,ongoing research,therapeutic application,unassigned 3,4,1,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25101505&form=6&db=m Ligneous periodontal lesions in a young child with severe plasminogen deficiency: a case report. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25281489&form=6&db=m Root dentin anomaly and a PLG mutation. causal interaction,unassigned 4,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25426793&form=6&db=m Ligneous gingivitis associated with plasminogen deficiency: a challenge in diagnosis. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25622808&form=6&db=m Orthomolecular nutritional therapy for plasminogen deficiency: report of a case that showed positive results. causal interaction,therapeutic application,unassigned 4,3,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25893677&form=6&db=m The Tissue Fibrinolytic System Contributes to the Induction of Macrophage Function and CCL3 during Bone Repair in Mice. unassigned - 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25971786&form=6&db=m Periodontitis associated with plasminogen deficiency: a case report. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26036227&form=6&db=m Beyond hemostasis: the challenge of treating plasminogen deficiency. A report of three cases. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26142234&form=6&db=m [Ligneous conjunctivitis]. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26187944&form=6&db=m Recurrence of superficial vein thrombosis in patients with varicose veins. diagnostic usage,unassigned 2,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26340456&form=6&db=m Novel plasminogen gene mutations in Turkish patients with type I plasminogen deficiency. causal interaction,unassigned 4,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26466233&form=6&db=m Successful treatment of ligneous conjunctivitis with topical fresh frozen plasma in an infant. causal interaction,diagnostic usage,unassigned 4,3,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26637181&form=6&db=m Minor Role of Plasminogen in Complement Activation on Cell Surfaces. causal interaction,unassigned 2,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26710586&form=6&db=m Oral and Maxillofacial Pathology Case of the Month. Plasminogen Deficiency (Ligneous Periodontitis). causal interaction,unassigned 3,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27152037&form=6&db=m Features and outcome of a glomerulonephropathy associated with ligneous conjunctivitis in a Doberman pinscher dog. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27193180&form=6&db=m Molecular pathogenesis of plasminogen Hakodate: the second Japanese family case of severe type I plasminogen deficiency manifested late-onset multi-organic chronic pseudomembranous mucositis. causal interaction,unassigned 4,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27319402&form=6&db=m Physiologic variations in blood plasminogen levels affect outcomes after acute cerebral thromboembolism in mice: a pathophysiologic role for microvascular thrombosis. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,1,4,3 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27417437&form=6&db=m A lethal phenotype associated with tissue plasminogen deficiency in humans. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27552374&form=6&db=m Immunohistochemical analysis of the gingiva with periodontitis of type I plasminogen deficiency compared to gingiva with gingivitis and periodontitis and healthy gingiva. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,3,1 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27592166&form=6&db=m Plasminogen deficiency is associated with improved glucose tolerance, and lower DPP-4 activity. causal interaction,unassigned 4,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27629020&form=6&db=m Plasminogen deficiency. causal interaction,unassigned 4,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27712638&form=6&db=m Calciphylaxis: A Disease of Pannicular Thrombosis. causal interaction,unassigned 4,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27976734&form=6&db=m The Unravelling of the Genetic Architecture of Plasminogen Deficiency and its Relation to Thrombotic Disease. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,1,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28275164&form=6&db=m Plasminogen Deficiency Delays the Onset and Protects from Demyelination and Paralysis in Autoimmune Neuroinflammatory Disease. causal interaction,ongoing research,therapeutic application,unassigned 3,3,2,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28416508&form=6&db=m HUS and atypical HUS. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28552473&form=6&db=m Dysfunctional fibrinolysis and cerebral venous thrombosis. diagnostic usage,unassigned 3,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28876531&form=6&db=m Treatment of plasminogen deficiency patients with fresh frozen plasma. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29271612&form=6&db=m The search for new approaches to treating type 1 plasminogen deficiency. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29321155&form=6&db=m Plasminogen replacement therapy for the treatment of children and adults with congenital plasminogen deficiency. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29379003&form=6&db=m Ligneous periodontitis in a child with plasminogen deficiency. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29436075&form=6&db=m Ligneous cervicitis and endometritis: A gynaecological presentation of congenital plasminogen deficiency. causal interaction,therapeutic application,unassigned 4,2,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30058940&form=6&db=m Clinical, histopathological, and genetic aspects in one case of ligneous conjunctivitis. causal interaction,unassigned 4,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30229498&form=6&db=m Novel preclinical murine model of trauma-induced elbow stiffness. causal interaction,unassigned 3,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30459211&form=6&db=m Absence of functional compensation between coagulation factor VIII and plasminogen in double-knockout mice. causal interaction,diagnostic usage,therapeutic application,unassigned 4,1,1,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30513391&form=6&db=m Diagnosis of a case of ligneous gingivitis in a patient with moderate plasminogen deficiency. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,1,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30574926&form=6&db=m Ligneous conjunctivitis in a Dandy-Walker syndrome: A rare case report. causal interaction,unassigned 3,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30581935&form=6&db=m Congenital plasminogen deficiency with long standing pseudomembranous conjunctival and genital lesions. causal interaction,unassigned 4,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30783057&form=6&db=m Replacement Therapy with Glu-Plasminogen for the Treatment of Severe Respiratory and Auditory Complications of Congenital Plasminogen Deficiency. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30994256&form=6&db=m Prophylactic protocol for dental care in ligneous gingivitis due to severe plasminogen deficiency: Case report and review of literature. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31393041&form=6&db=m Tranexamic acid modulates the cellular immune profile after traumatic brain injury in mice without hyperfibrinolysis. ongoing research,unassigned 1,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31469483&form=6&db=m Thrombin and plasmin generation in patients with plasminogen or plasminogen activator inhibitor type 1 deficiency. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31682330&form=6&db=m A novel combined treatment for plasminogen deficiency with lung involvement. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31806727&form=6&db=m Nonsynonymous SNPs in LPA homologous to plasminogen deficiency mutants represent novel null apo(a) alleles. causal interaction,unassigned 2,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31989084&form=6&db=m Development and application of global assays of hyper- and hypofibrinolysis. causal interaction,diagnostic usage,unassigned 3,2,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32001536&form=6&db=m An international registry of patients with plasminogen deficiency (HISTORY). causal interaction,diagnostic usage,therapeutic application,unassigned 4,1,1,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32173395&form=6&db=m Ligneous gingivitis secondary to plasminogen deficiency: a multidisciplinary diagnostic challenge. causal interaction,unassigned 4,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32274221&form=6&db=m Ligneous Periodontitis in a Patient with Type 1 Plasminogen Deficiency: A Case Report and Review of the Literature. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32369847&form=6&db=m Functional Fibrinolysis Assays Reveal Different Mechanisms underlying Plasminogen Dysfunction in Ligneous Conjunctivitis. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,1,1 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32455507&form=6&db=m Plasminogen deficiency does not prevent sodium retention in a genetic mouse model of experimental nephrotic syndrome. unassigned - 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32897963&form=6&db=m Atypical Microglandular Hyperplasia of Endocervix as the Presenting Feature of Plasminogen Deficiency. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32941296&form=6&db=m Type 1 Plasminogen Deficiency With Pulmonary Involvement: Novel Treatment and Novel Mutation. causal interaction,ongoing research,therapeutic application,unassigned 4,2,4,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33215566&form=6&db=m Plasminogen Deficiency and Amiloride Mitigate Angiotensin II-Induced Hypertension in Type 1 Diabetic Mice Suggesting Effects Through the Epithelial Sodium Channel. causal interaction,ongoing research,therapeutic application,unassigned 4,1,4,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33290319&form=6&db=m Anterior Segment Surgeries Under Topical Fresh Frozen Plasma Treatment in Ligneous Conjunctivitis. causal interaction,therapeutic application,unassigned 3,3,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33348042&form=6&db=m Treatment of ligneous conjunctivitis with fresh frozen plasm in twin babies. causal interaction,unassigned 4,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33427557&form=6&db=m Novel homozygous mutation of plasminogen in ligneous conjunctivitis: a case report and literature review. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33827130&form=6&db=m Plasmin-mediated cleavage of high-molecular-weight kininogen contributes to acetaminophen-induced acute liver failure. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,1,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33853408&form=6&db=m Plasminogen deficiency causes reduced angiogenesis and behavioral recovery after stroke in mice. causal interaction,ongoing research,therapeutic application,unassigned 4,4,2,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34049718&form=6&db=m [Pharmaceutical supply of human plasminogen replacement therapy for the treatment of ligneous conjunctivitis: Logistics for a university hospital]. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34095331&form=6&db=m Inflammatory Bowel Disease: A Gastrointestinal Presentation of Congenital Plasminogen Deficiency. causal interaction,unassigned 4,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34308677&form=6&db=m Ligneous conjunctivitis associated with type I plasminogen deficiency: A rare case. causal interaction,unassigned 4,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34342632&form=6&db=m First Treatment for Plasminogen Deficiency Is Approved. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 plasmin deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34370320&form=6&db=m A large deletion in the Plasminogen gene is associated with ligneous membranitis in a Maltese dog. causal interaction,diagnostic usage,unassigned 2,4,0 3.4.21.7 Pleural Effusion http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1787678&form=6&db=m [Assessment of the activity of plasminogen activators in the differential diagnosis of pleural effusion] diagnostic usage,unassigned 4,0 3.4.21.7 Pleural Effusion http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7489803&form=6&db=m Fibrinolytic and inflammatory processes in pleural effusions. ongoing research,therapeutic application,unassigned 2,2,0 3.4.21.7 Pleural Effusion http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17275887&form=6&db=m Thrombin-thrombomodulin inhibits prourokinase-mediated pleural mesothelial cell-dependent fibrinolysis. therapeutic application,unassigned 1,0 3.4.21.7 Pleural Effusion http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19319640&form=6&db=m The dynamics and clinical significance of alpha 2 plasmin inhibitor-plasmin complex and thrombin-antithrombin complex in postoperative pleural effusion following a pulmonary lobectomy. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,1,1 3.4.21.7 Pleural Effusion http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20079281&form=6&db=m [The effect of intrapleural pingyangmycin administration on activity of fibrinolytic system and transforming growth factor-beta1 in malignant pleural effusion] diagnostic usage,ongoing research,therapeutic application,unassigned 3,2,1,0 3.4.21.7 Pleural Effusion http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27343192&form=6&db=m Dose dependency of outcomes of intrapleural fibrinolytic therapy in new rabbit empyema models. unassigned - 3.4.21.7 Pleurisy http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15313437&form=6&db=m Effect of invertebrate serine proteinase inhibitors on carrageenan-induced pleural exudation and bradykinin release. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.7 Pneumoconiosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=133886&form=6&db=m [Blood coagulating system in miners and the effectiveness of the therapeutic use of fibrinolysin with heparin in pneumoconiosis] therapeutic application,unassigned 4,0 3.4.21.7 Pneumonia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6230794&form=6&db=m [Comparative evaluation of the efficacy of electrophoresis of heparin and heparin combined with fibrinolysin in protracted pneumonias] therapeutic application,unassigned 4,0 3.4.21.7 Pneumonia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7200401&form=6&db=m The development of granulomatous pulmonary inflammation in rabbits by aerosol challenge. I. Release of plasminogen activator by alveolar macrophages. unassigned - 3.4.21.7 Pneumonia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8865527&form=6&db=m An alternative elastase-mediated degradation of fibrinogen and fibrin observed in a patient with herpes simplex encephalitis and pneumonia. unassigned - 3.4.21.7 Pneumonia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23555246&form=6&db=m Plasminogen controls inflammation and pathogenesis of influenza virus infections via fibrinolysis. causal interaction,ongoing research,therapeutic application,unassigned 4,1,1,0 3.4.21.7 Pneumonia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23735578&form=6&db=m The plasminogen activation system: new targets in lung inflammation and remodeling. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 Pneumonia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24749306&form=6&db=m [Evaluation of haemostasis and endothelial dysfunction characteristics in patient with community-acquired pneumonia]. diagnostic usage,ongoing research,therapeutic application,unassigned 1,1,1,0 3.4.21.7 Pneumonia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30571394&form=6&db=m Infections Increase the Risk of 30-Day Readmissions Among Stroke Survivors. diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.7 Pneumonia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31140372&form=6&db=m Tranexamic Acid Influences the Immune Response, but not Bacterial Clearance in a Model of Post-Traumatic Brain Injury Pneumonia. causal interaction,ongoing research,therapeutic application,unassigned 1,3,3,0 3.4.21.7 Pneumonia, Ventilator-Associated http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20473240&form=6&db=m Plasminogen activation inhibitor concentrations in bronchoalveolar lavage fluid distinguishes ventilator-associated pneumonia from colonization in mechanically ventilated pediatric patients. therapeutic application,unassigned 1,0 3.4.21.7 Pneumonia, Viral http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2427398&form=6&db=m [The vascular wall and fibrinolysis--pathologic aspects] causal interaction,therapeutic application,unassigned 4,2,0 3.4.21.7 Poliomyelitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=13796972&form=6&db=m Activator of plasminogen and protease from various cell cultures and present in poliomyelitis vaccine. ongoing research,therapeutic application,unassigned 4,1,0 3.4.21.7 Polycystic Ovary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30878040&form=6&db=m Expression of the plasminogen system in the physiological mouse ovary and in the pathological polycystic ovary syndrome (PCOS) state. unassigned - 3.4.21.7 Polymicrogyria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18718938&form=6&db=m Epileptic and developmental disorders of the speech cortex: ligand/receptor interaction of wild-type and mutant SRPX2 with the plasminogen activator receptor uPAR. unassigned - 3.4.21.7 Porphyria, Variegate http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10382293&form=6&db=m Generation and chromosome mapping of expressed sequence tags (ESTs) from a human infant thymus. therapeutic application,unassigned 1,0 3.4.21.7 Postpartum Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14043394&form=6&db=m PATHOPHYSIOLOGY OF PLASMIN SYSTEM. V. PLASMIN SYSTEM AND POSTPARTUM HEMORRHAGE. unassigned - 3.4.21.7 Postpartum Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32005192&form=6&db=m TRAAP2 - TRAnexamic Acid for Preventing postpartum hemorrhage after cesarean delivery: a multicenter randomized, doubleblind, placebo- controlled trial - a study protocol. therapeutic application,unassigned 3,0 3.4.21.7 Postthrombotic Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2427398&form=6&db=m [The vascular wall and fibrinolysis--pathologic aspects] causal interaction,therapeutic application,unassigned 4,2,0 3.4.21.7 Prader-Willi Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10382293&form=6&db=m Generation and chromosome mapping of expressed sequence tags (ESTs) from a human infant thymus. therapeutic application,unassigned 1,0 3.4.21.7 Pre-Eclampsia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6445089&form=6&db=m Studies on the purification and characterization of human urinary plasminogen and plasmin. causal interaction,diagnostic usage,ongoing research,unassigned 3,1,2,0 3.4.21.7 Pre-Eclampsia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6450509&form=6&db=m Urinary fibrinolysis in toxemia of pregnancy. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,1,1 3.4.21.7 Pre-Eclampsia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6625637&form=6&db=m Influence of pre-eclampsia on concentrations of haemostatic factors in mothers and infants. causal interaction,diagnostic usage,therapeutic application,unassigned 1,1,1,0 3.4.21.7 Pre-Eclampsia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6652168&form=6&db=m Coagulation, fibrinolysis, platelet and kinin-forming systems during toxemia of pregnancy. causal interaction,diagnostic usage,unassigned 3,2,0 3.4.21.7 Pre-Eclampsia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8330765&form=6&db=m Plasminogen activators, plasminogen activator inhibitors and markers of intravascular coagulation in pre-eclampsia. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,3,1,4 3.4.21.7 Pre-Eclampsia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8624901&form=6&db=m The imbalance of plasminogen activators and inhibitor in preeclampsia. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,2,3 3.4.21.7 Pre-Eclampsia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8825219&form=6&db=m Increased blood flow resistance in placental circulation and levels of plasminogen activator inhibitors types 1 and 2 in severe preeclampsia. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,3,2 3.4.21.7 Pre-Eclampsia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8878712&form=6&db=m Fibrinolysis during normal pregnancy and severe preeclampsia relationships between plasma levels of plasminogen activators and inhibitors. causal interaction,ongoing research,therapeutic application,unassigned 3,3,3,0 3.4.21.7 Pre-Eclampsia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10625201&form=6&db=m Coagulation/fibrinolysis disorder in patients with severe preeclampsia. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,2,0 3.4.21.7 Pre-Eclampsia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12388999&form=6&db=m Levels of plasminogen activators and their inhibitors in maternal and umbilical cord plasma in severe preeclampsia. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,1 3.4.21.7 Pre-Eclampsia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21694445&form=6&db=m Fibronectin, plasminogen activator inhibitor type 1 (PAI-1) and uterine artery Doppler velocimetry as markers of preeclampsia. diagnostic usage,ongoing research,therapeutic application,unassigned 4,2,1,0 3.4.21.7 Pre-Eclampsia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22987920&form=6&db=m Urinary Plasmin Activates Collecting Duct ENaC Current in Preeclampsia. causal interaction,diagnostic usage,unassigned 2,3,0 3.4.21.7 Pre-Eclampsia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23216619&form=6&db=m Mechanisms of renal NaCl retention in proteinuric disease. causal interaction,diagnostic usage,unassigned 3,1,0 3.4.21.7 Pre-Eclampsia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24793974&form=6&db=m Hyperglycemia impairs cytotrophoblast function via stress signaling. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.7 Pre-Eclampsia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25482671&form=6&db=m Urinary serine proteases and activation of ENaC in kidney-implications for physiological renal salt handling and hypertensive disorders with albuminuria. causal interaction,diagnostic usage,therapeutic application,unassigned 3,3,1,0 3.4.21.7 Pre-Eclampsia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29305116&form=6&db=m Urine albumin is a superior predictor of preeclampsia compared to urine plasminogen in type I diabetes patients. causal interaction,diagnostic usage,unassigned 1,4,0 3.4.21.7 Pre-Eclampsia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30781907&form=6&db=m Studies on the Purification and Characterization of Human Urinary Plasminogen and Plasmin. diagnostic usage,unassigned 1,0 3.4.21.7 Precursor Cell Lymphoblastic Leukemia-Lymphoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2287063&form=6&db=m [Plasminogen activator in leukemic cell homogenate] causal interaction,diagnostic usage,unassigned 4,1,0 3.4.21.7 Precursor Cell Lymphoblastic Leukemia-Lymphoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6953221&form=6&db=m A syndrome of thrombosis and hemorrhage complicating L-asparaginase therapy for childhood acute lymphoblastic leukemia. causal interaction,diagnostic usage,therapeutic application,unassigned 3,3,4,0 3.4.21.7 Precursor Cell Lymphoblastic Leukemia-Lymphoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6953222&form=6&db=m The effect of L-asparaginase on antithrombin, plasminogen, and plasma coagulation during therapy for acute lymphoblastic leukemia. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,3,4 3.4.21.7 Precursor Cell Lymphoblastic Leukemia-Lymphoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31556233&form=6&db=m Disordered hemostasis associated with severely depressed fibrinolysis demonstrated using a simultaneous thrombin and plasmin generation assay during L-asparaginase induction therapy in pediatric acute lymphoblastic leukemia. causal interaction,ongoing research,therapeutic application,unassigned 2,3,2,0 3.4.21.7 Pregnancy, Ectopic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11844340&form=6&db=m Difference in mRNA expression and occurrence of plasminogen activator inhibitors in intrauterine decidua of normal and ectopic human pregnancies. ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.7 Pressure Ulcer http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11937475&form=6&db=m Prospective randomized double-blind study of the wound-debriding effects of collagenase and fibrinolysin/deoxyribonuclease in pressure ulcers. diagnostic usage,ongoing research,therapeutic application,unassigned 2,3,2,0 3.4.21.7 Pressure Ulcer http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15659039&form=6&db=m Cultured pressure ulcer fibroblasts show replicative senescence with elevated production of plasmin, plasminogen activator inhibitor-1, and transforming growth factor-beta1. causal interaction,diagnostic usage,ongoing research,unassigned 3,3,2,0 3.4.21.7 Pressure Ulcer http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17173553&form=6&db=m Involvement of proteolytic enzymes--plasminogen activators and matrix metalloproteinases--in the pathophysiology of pressure ulcers. ongoing research,unassigned 4,0 3.4.21.7 Pressure Ulcer http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26011241&form=6&db=m Prospective and randomised evaluation of the protease-modulating effect of oxidised regenerated cellulose/collagen matrix treatment in pressure sore ulcers. causal interaction,ongoing research,therapeutic application,unassigned 4,1,3,0 3.4.21.7 Priapism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=419377&form=6&db=m Priapism: surgical or medical treatment? causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 Priapism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14241200&form=6&db=m FIBRINOLYSIN THERAPY FOR THROMBOSIS OF PRIAPISM. causal interaction,therapeutic application,unassigned 2,4,0 3.4.21.7 Primary Myelofibrosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3144769&form=6&db=m Enhanced expression of urokinase activity on U 937 cell line by 1,25-dihydroxyvitamin D3 induction. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 Prion Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12023849&form=6&db=m Cellular mechanisms regulating non-haemostatic plasmin generation. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 Prion Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12033920&form=6&db=m Plasminogen activation is stimulated by prion protein and regulated in a copper-dependent manner. causal interaction,therapeutic application,unassigned 4,3,0 3.4.21.7 Prion Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17659071&form=6&db=m A novel real-time ultrasonic method for prion protein detection using plasminogen as a capture molecule. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,3,3 3.4.21.7 Prion Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21288569&form=6&db=m The suppression of prion propagation using poly-L-lysine by targeting plasminogen that stimulates prion protein conversion. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.7 Progeria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7862176&form=6&db=m Reduction of unscheduled DNA synthesis and plasminogen activator activity in Hutchinson-Gilford fibroblasts during passaging in vitro: partial correction by interferon-beta. diagnostic usage,ongoing research,unassigned 1,1,0 3.4.21.7 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=70942&form=6&db=m [Histochemical studies on the content of plasmin in the normal and hyperplastic prostate (author's transl)] causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,1,0 3.4.21.7 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2448891&form=6&db=m Effect of urokinase on the proliferation of primary cultures of human prostatic cells. ongoing research,unassigned 4,0 3.4.21.7 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6197164&form=6&db=m Plasminogen activator content and secretion in explants of neoplastic and benign human prostate tissues. causal interaction,diagnostic usage,ongoing research,unassigned 3,1,2,0 3.4.21.7 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8756739&form=6&db=m [Levels of plasminogen and alpha 2-antiplasmin in blood of patients with prostatic tumor] causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,1 3.4.21.7 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9240188&form=6&db=m Lack of correlation between blood fibrinolysis and the immediate or post-operative blood loss in transurethral resection of the prostate. causal interaction,diagnostic usage,unassigned 1,3,0 3.4.21.7 Prostatic Hyperplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25708333&form=6&db=m Autoantibodies to plasminogen and their role in tumor diseases. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,3,0 3.4.21.7 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=182348&form=6&db=m Response of plasma fibrinogen and plasminogen to hormone treatment and the relation of pretreatment values to mortality in patients with prostatic cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,2,1,4 3.4.21.7 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1641370&form=6&db=m The relationship between cardiovascular complications of estrogen therapy and fibrinolysis in patients with prostatic cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,1,1,4 3.4.21.7 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2659823&form=6&db=m Plasminogen activators in human prostate cancer cell lines and tumors: correlation with the aggressive phenotype. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,4,0 3.4.21.7 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3810552&form=6&db=m The fibrinolytic system in experimental prostate tumor. causal interaction,diagnostic usage,ongoing research,unassigned 3,3,3,0 3.4.21.7 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6197164&form=6&db=m Plasminogen activator content and secretion in explants of neoplastic and benign human prostate tissues. causal interaction,diagnostic usage,ongoing research,unassigned 3,1,2,0 3.4.21.7 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6537899&form=6&db=m Biochemical methods for predicting metastatic ability of prostatic cancer utilizing the dunning R-3327 rat prostatic adenocarcinoma system as a model. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,1,0 3.4.21.7 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9422083&form=6&db=m Inhibitory effect of amiloride on the urokinase plasminogen activators in prostatic cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,3,4,1 3.4.21.7 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11284727&form=6&db=m Interaction of plasminogen with dipeptidyl peptidase IV initiates a signal transduction mechanism which regulates expression of matrix metalloproteinase-9 by prostate cancer cells. causal interaction,diagnostic usage,ongoing research,unassigned 3,1,2,0 3.4.21.7 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11449410&form=6&db=m Variations of components of the plasminogen activation system with the cell cycle in benign prostate tissue and prostate cancer. causal interaction,diagnostic usage,ongoing research,unassigned 4,1,3,0 3.4.21.7 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11533645&form=6&db=m Bioassay of prostate-specific antigen (PSA) using microcantilevers. diagnostic usage,ongoing research,unassigned 3,3,0 3.4.21.7 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11944897&form=6&db=m The role of angiostatin in the spontaneous bone and prostate cancers of pet dogs. therapeutic application,unassigned 1,0 3.4.21.7 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11953871&form=6&db=m 213Bi-PAI2 conjugate selectively induces apoptosis in PC3 metastatic prostate cancer cell line and shows anti-cancer activity in a xenograft animal model. ongoing research,therapeutic application,unassigned 4,3,0 3.4.21.7 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12036889&form=6&db=m Tissue factor is the receptor for plasminogen type 1 on 1-LN human prostate cancer cells. causal interaction,diagnostic usage,ongoing research,unassigned 3,1,3,0 3.4.21.7 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12680193&form=6&db=m Reduced secretion of MMPs, plasminogen activators and TIMPS from prostate cancer cells derived by repeated metastasis. diagnostic usage,unassigned 3,0 3.4.21.7 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12806374&form=6&db=m Growth factor regulation of secreted matrix metalloproteinase and plasminogen activators in prostate cancer cells, normal prostate fibroblasts and normal osteoblasts. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.7 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12888934&form=6&db=m Role of coagulation and fibrinolytic system in prostate cancer. causal interaction,diagnostic usage,ongoing research,unassigned 3,3,2,0 3.4.21.7 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=13104458&form=6&db=m Prostatic fibrinolysin; study of a case illustrating role in hemorrhagic diathesis of cancer of the prostate. causal interaction,ongoing research,unassigned 1,2,0 3.4.21.7 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15016824&form=6&db=m Cell surface adenosine deaminase binds and stimulates plasminogen activation on 1-LN human prostate cancer cells. causal interaction,ongoing research,therapeutic application,unassigned 1,4,1,0 3.4.21.7 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16849568&form=6&db=m Differential binding of plasminogen, plasmin, and angiostatin4.5 to cell surface beta-actin: implications for cancer-mediated angiogenesis. diagnostic usage,ongoing research,therapeutic application,unassigned 3,1,1,0 3.4.21.7 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17264329&form=6&db=m Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,4,1 3.4.21.7 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17629406&form=6&db=m Tissue kallikrein proteolytic cascade pathways in normal physiology and cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,3,1 3.4.21.7 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17698116&form=6&db=m Plasminogen activation inhibitor-1 improves the predictive accuracy of prostate cancer nomograms. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,2 3.4.21.7 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17941930&form=6&db=m New blood-based biomarkers for the diagnosis, staging and prognosis of prostate cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,3,2 3.4.21.7 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17998918&form=6&db=m New circulating biomarkers for prostate cancer. diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.7 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18570058&form=6&db=m The effect of short-term estradiol therapy on clotting and inflammatory markers in older men receiving hormonal suppression therapy for prostate cancer. diagnostic usage,therapeutic application,unassigned 3,4,0 3.4.21.7 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19229851&form=6&db=m Pre-treatment biomarker levels improve the accuracy of post-prostatectomy nomogram for prediction of biochemical recurrence. diagnostic usage,ongoing research,therapeutic application,unassigned 2,3,2,0 3.4.21.7 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20414406&form=6&db=m Alteration of Antithrombin III and D-dimer Levels in Clinically Localized Prostate Cancer. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.7 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21728122&form=6&db=m Specific isoforms of plasminogen in patients with prostate cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,2,0 3.4.21.7 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21874261&form=6&db=m Down-regulation of urokinase plasminogen activator and matrix metalloproteinases and up-regulation of their inhibitors by a novel nutrient mixture in human prostate cancer cell lines PC-3 and DU-145. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,2,3,2 3.4.21.7 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22354665&form=6&db=m Prostate Cancer Cell Surface-Associated Keratin 8 and Its Implications for Enhanced Plasmin Activity. causal interaction,diagnostic usage,therapeutic application,unassigned 3,3,1,0 3.4.21.7 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23157267&form=6&db=m Separation and study of the range of plasminogen isoforms in patients with prostate cancer. causal interaction,diagnostic usage,ongoing research,unassigned 1,3,1,0 3.4.21.7 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25708333&form=6&db=m Autoantibodies to plasminogen and their role in tumor diseases. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,3,0 3.4.21.7 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30903509&form=6&db=m Increased Blood Concentration of IgG Degradation Products in Prostate Cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,2,2 3.4.21.7 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32256177&form=6&db=m A piece in prostate cancer puzzle: Future perspective of novel molecular signatures. causal interaction,diagnostic usage,therapeutic application,unassigned 1,2,1,0 3.4.21.7 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34440049&form=6&db=m Proteolyzed Variant of IgG with Free C-Terminal Lysine as a Biomarker of Prostate Cancer. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,4,0 3.4.21.7 Protein C Deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2509107&form=6&db=m Lupus-like anticoagulants and lower extremity arterial occlusive disease. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.7 Protein C Deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2521908&form=6&db=m Hypercoagulable states and lower limb ischemia in young adults. causal interaction,unassigned 3,0 3.4.21.7 Protein C Deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2524095&form=6&db=m [Protein-S deficiency in young patients with thrombotic brain infarction] causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 Protein C Deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3840289&form=6&db=m Homozygous protein C deficiency combined with heterozygous dysplasminogenemia found in a 21-year-old thrombophilic male. causal interaction,unassigned 3,0 3.4.21.7 Protein C Deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8266926&form=6&db=m Hereditary thrombophilia among 217 consecutive patients with thromboembolic disease in Jordan. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 Protein C Deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9065991&form=6&db=m Laboratory evaluation and clinical characteristics of 2,132 consecutive unselected patients with venous thromboembolism--results of the Spanish Multicentric Study on Thrombophilia (EMET-Study). causal interaction,unassigned 4,0 3.4.21.7 Protein C Deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10629572&form=6&db=m Causes of venous thrombosis in fifty Chinese patients. causal interaction,diagnostic usage,therapeutic application,unassigned 2,2,1,0 3.4.21.7 Protein C Deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10650849&form=6&db=m Prothrombotic risk factors in childhood stroke and venous thrombosis. causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,1,0 3.4.21.7 Protein C Deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12950126&form=6&db=m Clinical and functional assessment after anticoagulant therapy of acute deep vein thrombosis involving the lower limb. causal interaction,diagnostic usage,unassigned 4,3,0 3.4.21.7 Protein Deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7944258&form=6&db=m Massive acute pulmonary embolism in protein S deficiency--a case report. unassigned - 3.4.21.7 Protein Deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19764408&form=6&db=m [Proteasome degradation of protein C and plasmin inhibitor mutants: molecular mechanism of congenital protein deficiency] causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 Protein Deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20169944&form=6&db=m [Analyses on activation and regulation of blood coagulation] causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 Protein S Deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2509107&form=6&db=m Lupus-like anticoagulants and lower extremity arterial occlusive disease. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.7 Protein S Deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2524095&form=6&db=m [Protein-S deficiency in young patients with thrombotic brain infarction] causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 Protein S Deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2966450&form=6&db=m The frequency of type I heterozygous protein S and protein C deficiency in 141 unrelated young patients with venous thrombosis. diagnostic usage,ongoing research,unassigned 4,2,0 3.4.21.7 Protein S Deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8266926&form=6&db=m Hereditary thrombophilia among 217 consecutive patients with thromboembolic disease in Jordan. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 Protein S Deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8303733&form=6&db=m Prothrombotic states in young people with idiopathic stroke. A prospective study. causal interaction,unassigned 3,0 3.4.21.7 Protein S Deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8442350&form=6&db=m Hypercoagulable states. causal interaction,unassigned 3,0 3.4.21.7 Protein S Deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9048471&form=6&db=m The surgical implications of primary hypercoagulable states. diagnostic usage,therapeutic application,unassigned 1,1,0 3.4.21.7 Protein S Deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9065991&form=6&db=m Laboratory evaluation and clinical characteristics of 2,132 consecutive unselected patients with venous thromboembolism--results of the Spanish Multicentric Study on Thrombophilia (EMET-Study). causal interaction,unassigned 4,0 3.4.21.7 Protein S Deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9457624&form=6&db=m Coagulation disorders in young adults with acute cerebral ischaemia. causal interaction,unassigned 4,0 3.4.21.7 Protein S Deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10548072&form=6&db=m Treatment of hereditary and acquired thrombophilic disorders. causal interaction,unassigned 4,0 3.4.21.7 Protein S Deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10629572&form=6&db=m Causes of venous thrombosis in fifty Chinese patients. causal interaction,diagnostic usage,therapeutic application,unassigned 2,2,1,0 3.4.21.7 Protein S Deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12950126&form=6&db=m Clinical and functional assessment after anticoagulant therapy of acute deep vein thrombosis involving the lower limb. causal interaction,diagnostic usage,unassigned 4,3,0 3.4.21.7 protein-glutamine gamma-glutamyltransferase deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6232970&form=6&db=m Differential binding of plasminogen to crosslinked and noncrosslinked fibrins: its significance in hemostatic defect in factor XIII deficiency. causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,4,0 3.4.21.7 Proteinuria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1337176&form=6&db=m Serum lipoprotein (a) in men with proteinuria due to idiopathic membranous nephropathy. causal interaction,unassigned 3,0 3.4.21.7 Proteinuria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1836241&form=6&db=m [Concentration of thrombin antithrombin III complex and plasmin alpha 2-plasmin inhibitor complex in nephrotic syndrome] diagnostic usage,ongoing research,therapeutic application,unassigned 3,1,2,0 3.4.21.7 Proteinuria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6445089&form=6&db=m Studies on the purification and characterization of human urinary plasminogen and plasmin. causal interaction,diagnostic usage,ongoing research,unassigned 3,1,2,0 3.4.21.7 Proteinuria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6813992&form=6&db=m Factor XII and other hemostatic protein abnormalities in nephrotic syndrome patients. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,3,0 3.4.21.7 Proteinuria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8250027&form=6&db=m Elevated lipoprotein (a) levels in primary nephrotic syndrome. diagnostic usage,unassigned 3,0 3.4.21.7 Proteinuria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12439147&form=6&db=m Markers of endothelial cell injury and thrombin activatable fibrinolysis inhibitor in nephrotic syndrome. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,3,0 3.4.21.7 Proteinuria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18981180&form=6&db=m Plasmin activates epithelial Na+ channels by cleaving the gamma subunit. causal interaction,unassigned 4,0 3.4.21.7 Proteinuria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19604341&form=6&db=m Ligneous conjunctivitis in a plasminogen-deficient dog: clinical management and 2-year follow-up. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.7 Proteinuria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23024298&form=6&db=m Urinary plasmin inhibits TRPV5 in nephrotic-range proteinuria. causal interaction,ongoing research,therapeutic application,unassigned 1,3,3,0 3.4.21.7 Proteinuria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23529637&form=6&db=m Over- or underfill: not all nephrotic states are created equal. causal interaction,unassigned 1,0 3.4.21.7 Proteinuria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25482671&form=6&db=m Urinary serine proteases and activation of ENaC in kidney-implications for physiological renal salt handling and hypertensive disorders with albuminuria. causal interaction,diagnostic usage,therapeutic application,unassigned 3,3,1,0 3.4.21.7 Proteinuria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25972510&form=6&db=m Aberrant glomerular filtration of urokinase-type plasminogen activator in nephrotic syndrome leads to amiloride-sensitive plasminogen activation in urine. causal interaction,therapeutic application,unassigned 2,2,0 3.4.21.7 Proteinuria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26933188&form=6&db=m Association of Plasminuria with Overhydration in Patients with CKD. diagnostic usage,therapeutic application,unassigned 1,1,0 3.4.21.7 Proteinuria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27335373&form=6&db=m Podocyte Injury: The Role of Proteinuria, Urinary Plasminogen and Oxidative Stress. causal interaction,unassigned 4,0 3.4.21.7 Proteinuria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28656379&form=6&db=m Physiology and pathophysiology of the plasminogen system in the kidney. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 Proteinuria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30781907&form=6&db=m Studies on the Purification and Characterization of Human Urinary Plasminogen and Plasmin. diagnostic usage,unassigned 1,0 3.4.21.7 Proteinuria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31368174&form=6&db=m Cathepsin B increases ENaC activity leading to hypertension early in nephrotic syndrome. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 Proteinuria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31423748&form=6&db=m Urokinase-type plasminogen activator contributes to amiloride-sensitive sodium retention in nephrotic range glomerular proteinuria in mice. diagnostic usage,ongoing research,therapeutic application,unassigned 3,2,2,0 3.4.21.7 Proteinuria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32985236&form=6&db=m Salt-Sensitive Hypertension in Chronic Kidney Disease: Distal Tubular Mechanisms. causal interaction,unassigned 2,0 3.4.21.7 Proteinuria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33070369&form=6&db=m Plasminogenuria is associated with podocyte injury, edema, and kidney dysfunction in incident glomerular disease. causal interaction,ongoing research,therapeutic application,unassigned 2,1,3,0 3.4.21.7 Proteinuria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33215566&form=6&db=m Plasminogen Deficiency and Amiloride Mitigate Angiotensin II-Induced Hypertension in Type 1 Diabetic Mice Suggesting Effects Through the Epithelial Sodium Channel. causal interaction,ongoing research,therapeutic application,unassigned 4,1,4,0 3.4.21.7 Proteinuria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33427113&form=6&db=m Alterations of serum levels of plasminogen, TNF-?, and IDO in granulomatosis with polyangiitis patients. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.7 Pseudorabies http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1367489&form=6&db=m Expression of three recombinant proteins using baculovirus vectors in 23 insect cell lines. diagnostic usage,ongoing research,unassigned 1,4,0 3.4.21.7 Psoriasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9031&form=6&db=m Human skin proteases. Fractionation of psoriasis scale proteases and separation of a plasminogen activator and a histone hydrolysing protease. unassigned - 3.4.21.7 Psoriasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2514542&form=6&db=m Plasminogen activation in psoriasis. causal interaction,ongoing research,unassigned 4,3,0 3.4.21.7 Psoriasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7416799&form=6&db=m A further study on the mechanism of deposition of plasma protein in psoriasis scale. ongoing research,unassigned 3,0 3.4.21.7 Psoriasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8120416&form=6&db=m Expression of plasminogen activator enzymes in psoriatic epidermis. causal interaction,diagnostic usage,ongoing research,unassigned 3,3,3,0 3.4.21.7 Psoriasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8874752&form=6&db=m Interleukin-1 beta upregulates tissue-type plasminogen activator in a keratinocyte cell line (HaCaT). therapeutic application,unassigned 1,0 3.4.21.7 Psoriasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15461347&form=6&db=m Composition and mechanism of deposition of the intercellular substance in parakeratotic psoriatic epidermis. diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.7 Psoriasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21311769&form=6&db=m Plasmin plays an essential role in amplification of psoriasiform skin inflammation in mice. causal interaction,unassigned 3,0 3.4.21.7 Psoriasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22803790&form=6&db=m Concepts in psoriasis: psoriasis and the extracellular matrix. unassigned - 3.4.21.7 Psoriasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25557337&form=6&db=m Reduction in tissue plasmin: a new mechanism of action of narrowband ultraviolet B in psoriasis. unassigned - 3.4.21.7 Pulmonary Disease, Chronic Obstructive http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7855781&form=6&db=m Hypercoagulability state in patients with chronic obstructive pulmonary disease. Chronic Obstructive Bronchitis and Haemostasis Group. diagnostic usage,ongoing research,unassigned 4,2,0 3.4.21.7 Pulmonary Disease, Chronic Obstructive http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11929177&form=6&db=m Elevated plasma procoagulant and fibrinolytic markers in patients with chronic obstructive pulmonary disease. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.7 Pulmonary Disease, Chronic Obstructive http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16236890&form=6&db=m Sputum cathelicidin, urokinase plasminogen activation system components, and cytokines discriminate cystic fibrosis, COPD, and asthma inflammation. ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.7 Pulmonary Disease, Chronic Obstructive http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19638192&form=6&db=m Characterisation of urokinase plasminogen activator receptor variants in human airway and peripheral cells. causal interaction,diagnostic usage,unassigned 4,3,0 3.4.21.7 Pulmonary Disease, Chronic Obstructive http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23735578&form=6&db=m The plasminogen activation system: new targets in lung inflammation and remodeling. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 Pulmonary Disease, Chronic Obstructive http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26099590&form=6&db=m Moraxella catarrhalis Binds Plasminogen To Evade Host Innate Immunity. causal interaction,therapeutic application,unassigned 1,2,0 3.4.21.7 Pulmonary Edema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33278189&form=6&db=m Is Spironolactone the Preferred Renin-Angiotensin-Aldosterone Inhibitor for Protection Against COVID-19? causal interaction,diagnostic usage,therapeutic application,unassigned 3,1,1,0 3.4.21.7 Pulmonary Edema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34503474&form=6&db=m Might life-threatening acute pulmonary edema occur after using recombinant tissue plasminogen activator? A case report. causal interaction,ongoing research,therapeutic application,unassigned 4,3,4,0 3.4.21.7 Pulmonary Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=426316&form=6&db=m Plasminogen and moderate doses of urokinase in the treatment of acute pulmonary embolism. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.7 Pulmonary Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1387724&form=6&db=m [Measurements of plasmin-alpha 2 plasmin inhibitor complex and FDP.D dimer levels in the fibrinolytic therapy of acute pulmonary thromboembolism] causal interaction,diagnostic usage,ongoing research,therapeutic application 3,1,4,4 3.4.21.7 Pulmonary Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1512328&form=6&db=m PAIMS 2: alteplase combined with heparin versus heparin in the treatment of acute pulmonary embolism. Plasminogen activator Italian multicenter study 2. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,2,3,4 3.4.21.7 Pulmonary Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1650681&form=6&db=m Effect of low-molecular-weight heparin on recombinant tissue plasminogen activator-induced thrombolysis in canine pulmonary embolism. ongoing research,therapeutic application,unassigned 4,2,0 3.4.21.7 Pulmonary Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1757368&form=6&db=m Effects of flow on recombinant tissue plasminogen activator-induced pulmonary thrombolysis. ongoing research,therapeutic application,unassigned 4,2,0 3.4.21.7 Pulmonary Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1899825&form=6&db=m Effects of hydralazine and increased cardiac output on recombinant tissue plasminogen activator-induced thrombolysis in canine pulmonary embolism. causal interaction,ongoing research,therapeutic application,unassigned 1,4,2,0 3.4.21.7 Pulmonary Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2105682&form=6&db=m Thrombolytic therapy in canine pulmonary embolism. Comparative effects of urokinase and recombinant tissue plasminogen activator. ongoing research,therapeutic application,unassigned 4,4,0 3.4.21.7 Pulmonary Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2965086&form=6&db=m Congenital abnormal plasminogen, Frankfurt I, a cause for recurrent venous thrombosis. causal interaction,unassigned 3,0 3.4.21.7 Pulmonary Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3193619&form=6&db=m [Abnormal plasminogen accompanying pulmonary embolism] causal interaction,unassigned 2,0 3.4.21.7 Pulmonary Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3892994&form=6&db=m Prevention of postoperative deep venous thrombosis. Low-dose heparin versus graded pressure stockings. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.7 Pulmonary Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4220599&form=6&db=m [Experimental pulmonary embolisms treated with fibrinolysin and epsilon-aminocaproic acid] ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.7 Pulmonary Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6539000&form=6&db=m Dysfibrinogenemia (fibrinogen Dusard) associated with impaired fibrin-enhanced plasminogen activation. causal interaction,unassigned 3,0 3.4.21.7 Pulmonary Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6665749&form=6&db=m Subacute massive pulmonary embolism treated with plasminogen and streptokinase. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.7 Pulmonary Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8115321&form=6&db=m [Thrombolysis in massive pulmonary embolism with moderate doses of plasminogen tissue activator in 2 octagenarians] ongoing research,therapeutic application,unassigned 1,1,0 3.4.21.7 Pulmonary Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8162778&form=6&db=m Life-threatening pulmonary embolism with right-sided heart thrombus. Rapid recovery with recombinant tissue plasminogen activator. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 Pulmonary Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8292717&form=6&db=m The mutation in fibrinogen BicĂŞtre II (gamma Asn308-->Lys) does not affect the binding of t-PA and plasminogen to fibrin. ongoing research,unassigned 4,0 3.4.21.7 Pulmonary Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8471185&form=6&db=m Comparative tolerability profiles of thrombolytic agents. A review. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 Pulmonary Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8698274&form=6&db=m Thrombin-antithrombin III complexes as an additional diagnostic aid in pulmonary embolism. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.7 Pulmonary Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8853112&form=6&db=m Thrombolytic agents--an overview. therapeutic application,unassigned 4,0 3.4.21.7 Pulmonary Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8930213&form=6&db=m Targeting of antibody-conjugated plasminogen activators to the pulmonary vasculature. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 Pulmonary Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9107177&form=6&db=m Alpha 2-antiplasmin causes thrombi to resist fibrinolysis induced by tissue plasminogen activator in experimental pulmonary embolism. causal interaction,unassigned 4,0 3.4.21.7 Pulmonary Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9522614&form=6&db=m [Fibrinolytic treatment of thrombus of the right atrium causing severe pulmonary embolism] causal interaction,therapeutic application,unassigned 3,2,0 3.4.21.7 Pulmonary Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9558384&form=6&db=m Factor XIIIa cross-linking of the Marburg fibrin: formation of alpham.gamman-heteromultimers and the alpha-chain-linked albumin. gamma complex, and disturbed protofibril assembly resulting in acquisition of plasmin resistance relevant to thrombophila. therapeutic application,unassigned 2,0 3.4.21.7 Pulmonary Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9598841&form=6&db=m Elevated expression of urokinase-like plasminogen activator and plasminogen activator inhibitor type 1 during the vascular remodeling associated with pulmonary thromboembolism. causal interaction,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.7 Pulmonary Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10456203&form=6&db=m Screening for aetiology of thrombophilia: a high prevalence of protein S abnormality. unassigned - 3.4.21.7 Pulmonary Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10540842&form=6&db=m [Pulmonary thromboembolism accompanied by abnormal plasminogen] causal interaction,diagnostic usage,unassigned 4,3,0 3.4.21.7 Pulmonary Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11210347&form=6&db=m [Fibrinolytic therapy of patients with pulmonary artery thromboembolism by tissue plasminogen activator and streptokinase preparations] causal interaction,ongoing research,therapeutic application,unassigned 4,3,4,0 3.4.21.7 Pulmonary Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=13881735&form=6&db=m [Treatment of pulmonary embolism by fibrinolysin. Experimental research.] therapeutic application,unassigned 4,0 3.4.21.7 Pulmonary Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14084574&form=6&db=m COMBINED FIBRINOLYSIN AND ANTICOAGULANT THERAPY OF VENOUS THROMBOSIS AND PULMONARY EMBOLISM. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 Pulmonary Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14158901&form=6&db=m THROMBOLYSIN TREATMENT OF PULMONARY EMBOLISM FOLLOWING SURGERY. A REPORT OF TWO CASES. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.7 Pulmonary Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14307887&form=6&db=m [SUCCESSFUL USE OF FIBRINOLYSIN IN PULMONARY THROMBOEMBOLISM.] therapeutic application,unassigned 2,0 3.4.21.7 Pulmonary Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14445734&form=6&db=m The treatment of pulmonary embolism with fibrinolysin. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.7 Pulmonary Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15102005&form=6&db=m Tissue-type plasminogen activator: a historical perspective and personal account. causal interaction,ongoing research,therapeutic application,unassigned 3,2,2,0 3.4.21.7 Pulmonary Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15298807&form=6&db=m [Level of tissue plasminogen activator protein in pulmonary artery in acute pulmonary thromboembolism in rabbit] causal interaction,diagnostic usage,ongoing research,unassigned 4,4,4,0 3.4.21.7 Pulmonary Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20327660&form=6&db=m Fibrinolysin Therapy of Thrombophlebitis and Pulmonary Embolism. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 Pulmonary Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20327661&form=6&db=m Fibrinolysin Therapy of Thrombophlebitis and Pulmonary Embolism. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 Pulmonary Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22230042&form=6&db=m SMTP (Stachybotrys microspora triprenyl phenol) enhances clot clearance in a pulmonary embolism model in rats. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.7 Pulmonary Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23098998&form=6&db=m Clot penetration and retention by plasminogen activators promote fibrinolysis. therapeutic application,unassigned 4,0 3.4.21.7 Pulmonary Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24975773&form=6&db=m Massive pulmonary embolism in a young boy with T-cell leukaemia. Successful thrombolytic therapy by recombinant tissue plasminogen activator (rtPA). causal interaction,therapeutic application,unassigned 2,3,0 3.4.21.7 Pulmonary Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28028005&form=6&db=m Releasing the Brakes on the Fibrinolytic System in Pulmonary Emboli: Unique Effects of Plasminogen Activation and ?2-Antiplasmin Inactivation. causal interaction,ongoing research,therapeutic application,unassigned 3,4,3,0 3.4.21.7 Pulmonary Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32757658&form=6&db=m One-Year Echocardiographic, Functional, and Quality of Life Outcomes After Ultrasound-Facilitated Catheter-Based Fibrinolysis for Pulmonary Embolism. diagnostic usage,ongoing research,therapeutic application,unassigned 2,2,2,0 3.4.21.7 Pulmonary Fibrosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10880388&form=6&db=m The development of bleomycin-induced pulmonary fibrosis in mice deficient for components of the fibrinolytic system. ongoing research,therapeutic application,unassigned 4,2,0 3.4.21.7 Pulmonary Fibrosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12376355&form=6&db=m Inducible lung-specific urokinase expression reduces fibrosis and mortality after lung injury in mice. causal interaction,ongoing research,therapeutic application,unassigned 3,3,2,0 3.4.21.7 Pulmonary Fibrosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12765340&form=6&db=m A plasminogen activator inhibitor-1 promoter polymorphism and idiopathic interstitial pneumonia. causal interaction,therapeutic application,unassigned 3,3,0 3.4.21.7 Pulmonary Fibrosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14982862&form=6&db=m The plasminogen activation system reduces fibrosis in the lung by a hepatocyte growth factor-dependent mechanism. causal interaction,unassigned 3,0 3.4.21.7 Pulmonary Fibrosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15308506&form=6&db=m Plasminogen activator inhibitor-1 impairs alveolar epithelial repair by binding to vitronectin. causal interaction,therapeutic application,unassigned 3,2,0 3.4.21.7 Pulmonary Fibrosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15634280&form=6&db=m A novel mechanism of plasmin-induced mitogenesis in fibroblasts. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.7 Pulmonary Fibrosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20501949&form=6&db=m The antifibrotic effects of plasminogen activation occur via prostaglandin E2 synthesis in humans and mice. causal interaction,diagnostic usage,ongoing research,unassigned 3,3,2,0 3.4.21.7 Pulmonary Fibrosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29474926&form=6&db=m The fibrogenic actions of the coagulant and plasminogen activation systems in pulmonary fibrosis. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 Pulmonary Fibrosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31831767&form=6&db=m Glycogen Synthase Kinase-3? Inhibition with 9-ING-41 Attenuates the Progression of Pulmonary Fibrosis. causal interaction,therapeutic application,unassigned 4,2,0 3.4.21.7 Pulmonary Heart Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12239160&form=6&db=m Lack of alpha2-antiplasmin promotes pulmonary heart failure via overrelease of VEGF after acute myocardial infarction. causal interaction,ongoing research,unassigned 3,3,0 3.4.21.7 Pulpitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27743595&form=6&db=m Relevance of the plasminogen system in physiology, pathology, and regeneration of oral tissues - From the perspective of dental specialties. therapeutic application,unassigned 2,0 3.4.21.7 Purpura http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2139773&form=6&db=m Painful purpura: an adverse effect to a thrombolysin. unassigned - 3.4.21.7 Purpura http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2223309&form=6&db=m Rash after treatment with anistreplase. diagnostic usage,therapeutic application,unassigned 3,4,0 3.4.21.7 Purpura http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8938675&form=6&db=m Intraglomerular deposition of intact cross-linked fibrin in IgA nephropathy and Henoch-Schönlein purpura nephritis. diagnostic usage,ongoing research,unassigned 4,2,0 3.4.21.7 Purpura http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14615621&form=6&db=m Involvement of thrombolysis in recombinant tissue plasminogen activator-induced cerebral hemorrhages and effect on infarct volume and postischemic endothelial function. ongoing research,therapeutic application,unassigned 4,1,0 3.4.21.7 Purpura, Thrombotic Thrombocytopenic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8266913&form=6&db=m Increased levels of vascular endothelial cell markers in thrombotic thrombocytopenic purpura. causal interaction,diagnostic usage,unassigned 3,2,0 3.4.21.7 Purpura, Thrombotic Thrombocytopenic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20553378&form=6&db=m Inactivation of ADAMTS13 by plasmin as a potential cause of thrombotic thrombocytopenic purpura. causal interaction,therapeutic application,unassigned 4,3,0 3.4.21.7 Purpura, Thrombotic Thrombocytopenic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28279966&form=6&db=m Plasmin Cleaves Von Willebrand Factor at K1491-R1492 in the A1-A2 Linker Region in a Shear- and Glycan-Dependent Manner In Vitro. unassigned - 3.4.21.7 Purpura, Thrombotic Thrombocytopenic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28981198&form=6&db=m Amplified endogenous plasmin activity resolves acute thrombotic thrombocytopenic purpura in mice. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,3,0 3.4.21.7 Purpura, Thrombotic Thrombocytopenic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29228282&form=6&db=m Proteolytic inactivation of ADAMTS13 by plasmin in human plasma: risk of thrombotic thrombocytopenic purpura. causal interaction,diagnostic usage,ongoing research,unassigned 3,4,4,0 3.4.21.7 Purpura, Thrombotic Thrombocytopenic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30551950&form=6&db=m Comparison of ADAMTS13 and Von Willebrand factor levels and activities, and plasminogen levels, in plasma products currently available for the treatment of thrombotic thrombocytopenic purpura in South Africa. diagnostic usage,unassigned 4,0 3.4.21.7 Radicular Cyst http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=133998&form=6&db=m Fibrinolytic activity in cystic lesions of jaw bones. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.7 Radicular Cyst http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15128057&form=6&db=m Immunohistochemical localization of tissue-type plasminogen activator and type I plasminogen activator inhibitor in radicular cysts. causal interaction,ongoing research,therapeutic application,unassigned 3,4,3,0 3.4.21.7 Radiodermatitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30323258&form=6&db=m Plasminogen activation is required for the development of radiation-induced dermatitis. causal interaction,ongoing research,therapeutic application,unassigned 4,3,4,0 3.4.21.7 Rectal Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25993872&form=6&db=m [Changes in markers of proliferation, neoangiogenesis and plasminogen activation system in rectal cancer tissue]. causal interaction,diagnostic usage,ongoing research,unassigned 3,1,1,0 3.4.21.7 Rectal Prolapse http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8929539&form=6&db=m Loss of fibrinogen rescues mice from the pleiotropic effects of plasminogen deficiency. causal interaction,ongoing research,therapeutic application,unassigned 4,2,1,0 3.4.21.7 Rectal Prolapse http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30459211&form=6&db=m Absence of functional compensation between coagulation factor VIII and plasminogen in double-knockout mice. causal interaction,diagnostic usage,therapeutic application,unassigned 4,1,1,0 3.4.21.7 Relapsing Fever http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9884337&form=6&db=m The plasminogen activation system enhances brain and heart invasion in murine relapsing fever borreliosis. ongoing research,unassigned 3,0 3.4.21.7 Relapsing Fever http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17513779&form=6&db=m Dual binding specificity of a Borrelia hermsii-associated complement regulator-acquiring surface protein for factor H and plasminogen discloses a putative virulence factor of relapsing fever spirochetes. unassigned - 3.4.21.7 Relapsing Fever http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18299341&form=6&db=m Identification of an antiparallel coiled-coil/loop domain required for ligand binding by the Borrelia hermsii FhbA protein: additional evidence for the role of FhbA in the host-pathogen interaction. diagnostic usage,unassigned 1,0 3.4.21.7 Relapsing Fever http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33980587&form=6&db=m Endogenous and Borrowed Proteolytic Activity in the Borrelia. causal interaction,unassigned 1,0 3.4.21.7 Renal Insufficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1695043&form=6&db=m [Effect of hemodialysis on the concentration of beta 2-microglobulin and acute phase proteins in the serum of patients with chronic renal failure] causal interaction,diagnostic usage,unassigned 2,3,0 3.4.21.7 Renal Insufficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6230118&form=6&db=m Fibrinogen proteolysis and platelet alpha-granule release in preeclampsia/eclampsia. causal interaction,diagnostic usage,unassigned 3,3,0 3.4.21.7 Renal Insufficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7525635&form=6&db=m Alteration in insulin-like growth factor-binding proteins (IGFBPs) and IGFBP-3 protease activity in serum and urine from acute and chronic renal failure. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,4,0 3.4.21.7 Renal Insufficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9610957&form=6&db=m Endothelial cell markers in chronic uremia: relationship with hemostatic defects and severity of renal failure. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,2,0 3.4.21.7 Renal Insufficiency, Chronic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2424120&form=6&db=m Impaired fibrinolysis and protein C increase after cadaver kidney transplantation. causal interaction,diagnostic usage,unassigned 4,1,0 3.4.21.7 Renal Insufficiency, Chronic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31319876&form=6&db=m Urinary pro-thrombotic, anti-thrombotic, and fibrinolytic molecules as biomarkers of lupus nephritis. diagnostic usage,ongoing research,therapeutic application,unassigned 2,3,2,0 3.4.21.7 Reperfusion Injury http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2555642&form=6&db=m Tissue plasminogen activator and plasmin independently decrease human neutrophil activation. ongoing research,therapeutic application,unassigned 3,1,0 3.4.21.7 Reperfusion Injury http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9101117&form=6&db=m Direct induction of complement activation by pharmacologic activation of plasminogen. causal interaction,therapeutic application,unassigned 3,2,0 3.4.21.7 Reperfusion Injury http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10221476&form=6&db=m Reduction of post-ischemic lung reperfusion injury by fibrinolytic activity suppression. ongoing research,unassigned 4,0 3.4.21.7 Reperfusion Injury http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17646593&form=6&db=m Tissue plasminogen activator-induced reperfusion injury after stroke revisited. ongoing research,therapeutic application,unassigned 1,1,0 3.4.21.7 Reperfusion Injury http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25043623&form=6&db=m Plasmin administration during ex vivo lung perfusion ameliorates lung ischemia-reperfusion injury. ongoing research,therapeutic application,unassigned 2,3,0 3.4.21.7 Respiratory Distress Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=161694&form=6&db=m The fibrinolysin system and its relationship to disease in the newborn. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 Respiratory Distress Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=576497&form=6&db=m Serum plasminogen and lung surfactant in the respiratory distress syndrome. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,2,1 3.4.21.7 Respiratory Distress Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=798269&form=6&db=m Studies on the prevention of respiratory distress syndrome of infants due to hyaline membrane disease with plasminogen. ongoing research,therapeutic application,unassigned 1,1,0 3.4.21.7 Respiratory Distress Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2145377&form=6&db=m Changes in the fibrinolysin system in infantile and adult respiratory distress syndrome (ARDS), caused by trauma and/or septic shock in patients and in experimental animals. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,2,4,4 3.4.21.7 Respiratory Distress Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3867124&form=6&db=m Fibrinolysis inhibition in acute respiratory distress syndrome. diagnostic usage,therapeutic application,unassigned 1,1,0 3.4.21.7 Respiratory Distress Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4991804&form=6&db=m [Fibrinolysis in respiratory distress syndrome. Plasminogen levels in the plasma of premature infants] causal interaction,diagnostic usage,unassigned 4,2,0 3.4.21.7 Respiratory Distress Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8701484&form=6&db=m Plasma plasminogen levels in early respiratory distress syndrome. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,1,0 3.4.21.7 Respiratory Distress Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9667494&form=6&db=m Tissue plasminogen activator (tPA) inhibits interleukin-1 induced acute lung leak. causal interaction,unassigned 3,0 3.4.21.7 Respiratory Distress Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11044771&form=6&db=m Plasminogen did not affect lung function in surfactant-treated preterm lambs. causal interaction,unassigned 4,0 3.4.21.7 Respiratory Distress Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14243480&form=6&db=m THE USE OF FIBRINOLYSIN IN THE TREATMENT OF RESPIRATORY DISTRESS SYNDROME. therapeutic application,unassigned 4,0 3.4.21.7 Respiratory Insufficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3274732&form=6&db=m [Serum plasminogen and alpha-2-antiplasmin levels in chronic bronchopneumopathology with respiratory insufficiency] causal interaction,diagnostic usage,unassigned 2,2,0 3.4.21.7 Respiratory Tract Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26667841&form=6&db=m Network of Surface-Displayed Glycolytic Enzymes in Mycoplasma pneumoniae and Their Interactions with Human Plasminogen. ongoing research,unassigned 2,0 3.4.21.7 Retinal Arterial Macroaneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9744368&form=6&db=m Management of submacular hemorrhage associated with retinal arterial macroaneurysms. ongoing research,therapeutic application,unassigned 2,2,0 3.4.21.7 Retinal Artery Occlusion http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=13712671&form=6&db=m Central retinal artery occlusion successfully treated with plasmin. unassigned - 3.4.21.7 Retinal Detachment http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2523285&form=6&db=m Tissue-type plasminogen activator in subretinal fluid. diagnostic usage,ongoing research,therapeutic application,unassigned 2,2,3,0 3.4.21.7 Retinal Detachment http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8079628&form=6&db=m Secretion of plasminogen activators by cells cultured from subretinal fluid. diagnostic usage,ongoing research,unassigned 1,4,0 3.4.21.7 Retinal Detachment http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10979587&form=6&db=m [Coagulation factors and fibrinolytic system in subretinal liquid in patients with rheumatogenous retinal detachment] causal interaction,diagnostic usage,therapeutic application,unassigned 1,1,1,0 3.4.21.7 Retinal Detachment http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18939350&form=6&db=m Components of the fibrinolytic system in the vitreous body in patients with vitreoretinal disorders. diagnostic usage,ongoing research,therapeutic application,unassigned 2,2,1,0 3.4.21.7 Retinal Detachment http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25797990&form=6&db=m High osmolarity effect of intravitreal plasmin enzyme on rabbit retina. therapeutic application,unassigned 3,0 3.4.21.7 Retinal Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12813409&form=6&db=m Inhibition of plasminogen activation protects against ganglion cell loss in a mouse model of retinal damage. causal interaction,unassigned 4,0 3.4.21.7 Retinal Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16051695&form=6&db=m Plasminogen activators promote excitotoxicity-induced retinal damage. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.7 Retinal Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28060316&form=6&db=m An Alternative and Validated Injection Method for Accessing the Subretinal Space via a Transcleral Posterior Approach. ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.7 Retinal Neovascularization http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11440369&form=6&db=m Intravitreal injection of plasminogen kringle 5, an endogenous angiogenic inhibitor, arrests retinal neovascularization in rats. therapeutic application,unassigned 2,0 3.4.21.7 Retinal Neovascularization http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11782462&form=6&db=m Down-regulation of vascular endothelial growth factor and up-regulation of pigment epithelium-derived factor: a possible mechanism for the anti-angiogenic activity of plasminogen kringle 5. ongoing research,therapeutic application,unassigned 2,4,0 3.4.21.7 Retinal Neovascularization http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23300882&form=6&db=m Dual inhibition of plasminogen kringle 5 on angiogenesis and chemotaxis suppresses tumor metastasis by targeting HIF-1? pathway. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,3,2,2 3.4.21.7 Retinal Neovascularization http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32063854&form=6&db=m Inhibition of Pathological Retinal Neovascularization by a Small Peptide Derived from Human Tissue-Type Plasminogen Kringle 2. ongoing research,unassigned 3,0 3.4.21.7 Retinal Perforations http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9754166&form=6&db=m Plasmin enzyme-assisted vitrectomy in traumatic pediatric macular holes. therapeutic application,unassigned 4,0 3.4.21.7 Retinal Perforations http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10919918&form=6&db=m A new approach to stage 3 macular holes. therapeutic application,unassigned 3,0 3.4.21.7 Retinal Perforations http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15710817&form=6&db=m Effect of plasmin on laminin and fibronectin during plasmin-assisted vitrectomy. diagnostic usage,ongoing research,therapeutic application,unassigned 1,4,4,0 3.4.21.7 Retinal Perforations http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16329067&form=6&db=m Efficacy of autologous plasmin for idiopathic macular hole surgery. ongoing research,therapeutic application,unassigned 3,4,0 3.4.21.7 Retinal Perforations http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17870044&form=6&db=m Pediatric traumatic macular hole: results of autologous plasmin enzyme-assisted vitrectomy. causal interaction,therapeutic application,unassigned 2,3,0 3.4.21.7 Retinal Perforations http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18040248&form=6&db=m Plasmin-assisted vitrectomy for management of proliferative membrane in proliferative diabetic retinopathy: a pilot study. causal interaction,diagnostic usage,therapeutic application,unassigned 3,2,4,0 3.4.21.7 Retinal Perforations http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18939350&form=6&db=m Components of the fibrinolytic system in the vitreous body in patients with vitreoretinal disorders. diagnostic usage,ongoing research,therapeutic application,unassigned 2,2,1,0 3.4.21.7 Retinal Perforations http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22929326&form=6&db=m Ocriplasmin for pharmacologic vitreolysis. unassigned - 3.4.21.7 Retinal Perforations http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24795342&form=6&db=m Autolytic degradation of ocriplasmin: a complex mechanism unraveled by mutational analysis. therapeutic application,unassigned 2,0 3.4.21.7 Retinal Vein Occlusion http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4223398&form=6&db=m Experimental retinal vein occlusion and treatment with fibrinolysin. therapeutic application,unassigned 4,0 3.4.21.7 Retinal Vein Occlusion http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8191655&form=6&db=m [Clinical significance of the determination of several hemostatic parameters in the lacrimal fluid of patients with vascular diseases of the retina] causal interaction,diagnostic usage,therapeutic application,unassigned 1,3,1,0 3.4.21.7 Retinal Vein Occlusion http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10634554&form=6&db=m Activated protein C resistance and anticoagulant proteins in young adults with central retinal vein occlusion. causal interaction,diagnostic usage,therapeutic application,unassigned 2,2,2,0 3.4.21.7 Retinal Vein Occlusion http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=13762298&form=6&db=m Therapy of retinal vein occlusion. Use of fibrinolysin and anticoagulants. therapeutic application,unassigned 4,0 3.4.21.7 Retinal Vein Occlusion http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14403478&form=6&db=m The successful treatment of a case of central retinal vein thrombosis with intravenous fibrinolysin. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.7 Retinal Vein Occlusion http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14473782&form=6&db=m Fibrinolytic treatment of retinal vein thrombosis. The use of Fibrinolysin Human Lyovac (Merck). therapeutic application,unassigned 3,0 3.4.21.7 Retinal Vein Occlusion http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14473783&form=6&db=m [Fibrinolysin (Merck) treatment of retinal vein thrombosis.] therapeutic application,unassigned 4,0 3.4.21.7 Retinal Vein Occlusion http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14476400&form=6&db=m An unusual case of central retinal vein occlusion, treated successfully with intravenous fibrinolysin. therapeutic application,unassigned 2,0 3.4.21.7 Retinal Vein Occlusion http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20801424&form=6&db=m Intravitreal Injection of Autologous Plasmin Enzyme for Macular Edema Associated with Branch Retinal Vein Occlusion. diagnostic usage,ongoing research,therapeutic application,unassigned 3,3,3,0 3.4.21.7 Retinal Vein Occlusion http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21402982&form=6&db=m Intravitreal plasmin without vitrectomy for macular edema secondary to branch retinal vein occlusion. diagnostic usage,ongoing research,therapeutic application,unassigned 3,1,4,0 3.4.21.7 Retinal Vein Occlusion http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21784203&form=6&db=m Intravitreal injection of autologous plasmin enzyme for macular edema associated with branch retinal vein occlusion. diagnostic usage,therapeutic application,unassigned 3,2,0 3.4.21.7 Retinal Vein Occlusion http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23948948&form=6&db=m Intravitreal functional plasminogen is elevated in central retinal vein occlusion. causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,1,0 3.4.21.7 Retinal Vein Occlusion http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25059575&form=6&db=m Intravitreal functional plasminogen in eyes with branch retinal vein occlusion. diagnostic usage,unassigned 2,0 3.4.21.7 Retinal Vein Occlusion http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28085526&form=6&db=m Prothrombin polymorphism A19911G, factor V HR2 haplotype A4070G, and plasminogen activator-inhibitor-1 polymorphism 4G/5G and the risk of retinal vein occlusion. causal interaction,diagnostic usage,unassigned 2,3,0 3.4.21.7 Retinopathy of Prematurity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17601440&form=6&db=m Autologous plasmin-assisted vitrectomy for stage 5 retinopathy of prematurity: a preliminary trial. diagnostic usage,unassigned 2,0 3.4.21.7 Retinopathy of Prematurity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18317350&form=6&db=m Plasmin enzyme-assisted vitrectomy for primary and reoperated eyes with stage 5 retinopathy of prematurity. diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.7 Retinoschisis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18040249&form=6&db=m Plasmin enzyme-assisted vitreoretinal surgery in congenital X-linked retinoschisis: surgical techniques based on a new classification system. therapeutic application,unassigned 3,0 3.4.21.7 Rhabdomyosarcoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=632749&form=6&db=m Serine enzymes released by cultured neoplastic cells. ongoing research,unassigned 2,0 3.4.21.7 Rhabdomyosarcoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1839080&form=6&db=m Stimulation of cell surface plasminogen activation by heparin and related polyionic substances. causal interaction,unassigned 1,0 3.4.21.7 Rheumatic Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2681762&form=6&db=m Regulation of plasminogen activators and their inhibitors in rheumatic diseases: new understanding and the potential for new directions. causal interaction,therapeutic application,unassigned 2,4,0 3.4.21.7 Rheumatic Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4223819&form=6&db=m Serum inhibitors of elastase, trypsin, and plasmin in chronic rheumatic diseases. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.7 Rheumatic Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=5619432&form=6&db=m [The rate of activation of plasminogen and intrasvascular thrombus formation in rheumatism and atherosclerosis] causal interaction,unassigned 2,0 3.4.21.7 Rheumatic Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10464565&form=6&db=m The urokinase-type plasminogen activator system and inflammatory joint diseases. ongoing research,therapeutic application,unassigned 4,1,0 3.4.21.7 Rheumatic Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11246666&form=6&db=m Autoantibodies to receptor induced neoepitopes of fibrinolytic proteins in rheumatic and vascular diseases. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,2,2 3.4.21.7 Rheumatic Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14219262&form=6&db=m [BLOOD LEVEL OF PLASMINOGEN IN CHRONIC PROTOTYPIC RHEUMATISM.] diagnostic usage,ongoing research,unassigned 3,2,0 3.4.21.7 Rheumatic Fever http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14217419&form=6&db=m [ON FIBRINOLYSIS IN THE FIELD OF ORTHOPEDIC SURGERY. (2) ON CHANGES IN PLASMIN IN CHRONIC RHEUMATIC FEVER.] causal interaction,diagnostic usage,ongoing research,unassigned 1,1,2,0 3.4.21.7 Rheumatic Fever http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18110885&form=6&db=m Quantitative studies on the total plasmin and the trypsin inhibitor of human blood serum; variations in the blood concentration of total plasmin and of trypsin inhibitor in streptococcal diseases with special reference to rheumatic fever. diagnostic usage,ongoing research,therapeutic application,unassigned 1,4,1,0 3.4.21.7 Rheumatic Fever http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20144123&form=6&db=m Fibrin dissolution in synovial fluid. ongoing research,therapeutic application,unassigned 1,1,0 3.4.21.7 Rubella http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6460384&form=6&db=m Antibody spectrum and anticomplementary activity of a plasmin-treated human immunoglobulin preparation. therapeutic application,unassigned 1,0 3.4.21.7 Rubella http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15613000&form=6&db=m Avoidance of oxidative-stress perturbation in yeast bioprocesses by proteomic and genomic biostrategies? unassigned - 3.4.21.7 Sarcoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1325952&form=6&db=m Clonal variation of expression of the genes coding for plasminogen activators, their inhibitors and the urokinase receptor in HT1080 sarcoma cells. ongoing research,unassigned 4,0 3.4.21.7 Sarcoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1634121&form=6&db=m High-level secretion of the four salivary plasminogen activators from the vampire bat Desmodus rotundus by stably transfected baby hamster kidney cells. ongoing research,unassigned 2,0 3.4.21.7 Sarcoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2523891&form=6&db=m Activation of pro-urokinase and plasminogen on human sarcoma cells: a proteolytic system with surface-bound reactants. causal interaction,ongoing research,therapeutic application,unassigned 1,4,1,0 3.4.21.7 Sarcoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2538425&form=6&db=m Down-regulation of plasmin receptors on human sarcoma cells by glucocorticoids. causal interaction,ongoing research,unassigned 1,4,0 3.4.21.7 Sarcoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2561462&form=6&db=m Synthesis and secretion of plasminogen activators and collagenases in human cells transformed by Kirsten murine sarcoma virus and N-methyl-N'-nitro-N-nitrosoguanidine. ongoing research,unassigned 4,0 3.4.21.7 Sarcoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3855489&form=6&db=m Proteolytic enzymes in tumor metastasis. I. Plasminogen activator in clones of Lewis lung carcinoma and T10 sarcoma. diagnostic usage,ongoing research,unassigned 1,3,0 3.4.21.7 Sarcoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4248884&form=6&db=m [Studies on the cytolytic action of plasmin on Yoshida ascites sarcoma] diagnostic usage,ongoing research,unassigned 1,2,0 3.4.21.7 Sarcoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6234471&form=6&db=m Enhancement of the radiation effect by fibrinolysin and quantitative pattern of the change of tumor radiosensitivity. causal interaction,ongoing research,therapeutic application,unassigned 3,2,4,0 3.4.21.7 Sarcoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6459937&form=6&db=m Peptides cleaved from fibrinogen by plasmin enhance the progression of L-1 sarcoma in BALB/c mice. ongoing research,therapeutic application,unassigned 1,1,0 3.4.21.7 Sarcoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6460038&form=6&db=m Acetylcholine receptor: effects of proteolysis on receptor metabolism. causal interaction,unassigned 1,0 3.4.21.7 Sarcoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6891264&form=6&db=m Purification of zymogen to plasminogen activator from human glioblastoma cells by affinity chromatography with monoclonal antibody. causal interaction,ongoing research,therapeutic application,unassigned 4,4,2,0 3.4.21.7 Sarcoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7826985&form=6&db=m Plasminogen activators and their inhibitor in osteosarcomas and other bone tumors. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,1,3 3.4.21.7 Sarcoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8922633&form=6&db=m Identification of plasminogen in Matrigel and its activation by reconstitution of this basement membrane extract. diagnostic usage,unassigned 1,0 3.4.21.7 Sarcoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10919728&form=6&db=m Horse v-fes feline sarcoma viral oncogene homologue; pyruvate kinase, muscle type 2; plasminogen; beta spectrin, non-erythrocytic 1; thymidylate synthetase; and microsatellite LEX078 map to 1q14-q15, 1q21, 31q12-q14, 15q22, 8q12-q14, and 14q27, respectively. therapeutic application,unassigned 1,0 3.4.21.7 Sarcoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11713566&form=6&db=m Plasminogen activators and their inhibitor in bone tumors and tumor-like damages. diagnostic usage,ongoing research,therapeutic application,unassigned 3,2,2,0 3.4.21.7 Sarcoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12483535&form=6&db=m Plasminogen promotes sarcoma growth and suppresses the accumulation of tumor-infiltrating macrophages. causal interaction,ongoing research,therapeutic application,unassigned 3,3,4,0 3.4.21.7 Sarcoma, Avian http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=165484&form=6&db=m Plasminogen-independent fibrinolysis by proteases produced by transformed chick embryo fibroblasts. ongoing research,unassigned 3,0 3.4.21.7 Sarcoma, Avian http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2981611&form=6&db=m Receptors for plasminogen activator, urokinase, in normal and Rous sarcoma virus-transformed mouse fibroblasts. ongoing research,unassigned 2,0 3.4.21.7 Sarcoma, Avian http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2997235&form=6&db=m The extracellular matrix of normal chick embryo fibroblasts: its effect on transformed chick fibroblasts and its proteolytic degradation by the transformants. unassigned - 3.4.21.7 Sarcoma, Avian http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6221099&form=6&db=m Plasmin-activated prodrugs for cancer chemotherapy. 1. Synthesis and biological activity of peptidylacivicin and peptidylphenylenediamine mustard. causal interaction,diagnostic usage,unassigned 4,2,0 3.4.21.7 Sarcoma, Avian http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6302253&form=6&db=m Plasmin-activated prodrugs for cancer chemotherapy. 2. Synthesis and biological activity of peptidyl derivatives of doxorubicin. ongoing research,therapeutic application,unassigned 1,1,0 3.4.21.7 Sarcoma, Avian http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6783654&form=6&db=m An inhibitor of plasminogen activator in rabbit endothelial cells. unassigned - 3.4.21.7 Sarcoma, Ewing http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10650857&form=6&db=m The course of fibrinolytic proteins in children with malignant bone tumours. ongoing research,therapeutic application,unassigned 2,3,0 3.4.21.7 Sarcoma, Yoshida http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4183690&form=6&db=m [The cytotoxic effect of plasmin on yoshida sarcoma cells] ongoing research,unassigned 4,0 3.4.21.7 Sarcoma, Yoshida http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4243799&form=6&db=m The cytotoxic effect of plasmin on Yoshida sarcoma cells. ongoing research,unassigned 4,0 3.4.21.7 Schistosomiasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1489902&form=6&db=m The pathogenesis of accelerated fibrinolysis in hepatosplenic schistosomiasis. causal interaction,ongoing research,therapeutic application,unassigned 4,2,3,0 3.4.21.7 Schistosomiasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7489960&form=6&db=m Disseminated intravascular coagulation in endemic hepatosplenic schistosomiasis. causal interaction,diagnostic usage,unassigned 3,2,0 3.4.21.7 Schistosomiasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14665393&form=6&db=m Haemostatic abnormalities in hepatosplenic schistosomiasis mansoni. unassigned - 3.4.21.7 Schistosomiasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28207534&form=6&db=m A case control study on the structural equation model of the mechanism of coagulation and fibrinolysis imbalance in chronic schistosomiasis. diagnostic usage,ongoing research,therapeutic application,unassigned 1,2,1,0 3.4.21.7 Scleroderma, Diffuse http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8902649&form=6&db=m Circadian variations of plasma levels of blood coagulation/fibrinolysis molecular markers in progressive systemic sclerosis (PSS). causal interaction,diagnostic usage,ongoing research,unassigned 1,4,2,0 3.4.21.7 Scleroderma, Systemic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2125582&form=6&db=m Cutaneous and plasma fibrinolytic activity in systemic sclerosis. Evidence of normal plasminogen activation. diagnostic usage,ongoing research,therapeutic application,unassigned 3,3,1,0 3.4.21.7 Scleroderma, Systemic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9373715&form=6&db=m Gene expression of types I and III collagen, decorin, matrix metalloproteinases and tissue inhibitors of metalloproteinases in skin fibroblasts from patients with systemic sclerosis. ongoing research,unassigned 4,0 3.4.21.7 Scleroderma, Systemic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32945390&form=6&db=m Decrease in matrix metalloproteinase?3 activity in systemic sclerosis fibroblasts causes ?2?antiplasmin and extracellular matrix deposition, and contributes to fibrosis development. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.7 Scrapie http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16103174&form=6&db=m Role of plasminogen in propagation of scrapie. causal interaction,ongoing research,therapeutic application,unassigned 2,2,4,0 3.4.21.7 Scrapie http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17659071&form=6&db=m A novel real-time ultrasonic method for prion protein detection using plasminogen as a capture molecule. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,3,3 3.4.21.7 Scrapie http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20732953&form=6&db=m Plasminogen stimulates propagation of protease-resistant prion protein in vitro. ongoing research,therapeutic application,unassigned 1,1,0 3.4.21.7 Seizures http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12070304&form=6&db=m Regulation of seizure spreading by neuroserpin and tissue-type plasminogen activator is plasminogen-independent. causal interaction,therapeutic application,unassigned 1,2,0 3.4.21.7 Seizures http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15261888&form=6&db=m Tissue-type plasminogen activator and neuroserpin: a well-balanced act in the nervous system? causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.7 Seizures http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18647637&form=6&db=m Plasmin-mediated processing of protein tyrosine phosphatase receptor type Z in the mouse brain. unassigned - 3.4.21.7 Seizures http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25030857&form=6&db=m Propofol treatment modulates neurite extension regulated by immunologically challenged rat primary astrocytes: a possible role of PAI-1. therapeutic application,unassigned 1,0 3.4.21.7 Seizures http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28872451&form=6&db=m Incidence of seizure in stroke patients treated with recombinant tissue plasminogen activator: A systematic review and meta-analysis. causal interaction,ongoing research,therapeutic application,unassigned 4,4,4,0 3.4.21.7 Seizures http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31431399&form=6&db=m Incidence of early poststroke seizures during reperfusion therapies in patients with acute ischemic stroke: An observational prospective study: (TESI study: "Trombolisi/Trombectomia e crisi Epilettiche precoci nello Stroke Ischemico"). unassigned - 3.4.21.7 Seizures http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32772682&form=6&db=m Incidence and Association of Reperfusion Therapies With Poststroke Seizures: A Systematic Review and Meta-Analysis. ongoing research,therapeutic application,unassigned 2,2,0 3.4.21.7 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=399895&form=6&db=m Proteinase inhibitors in severe inflammatory processes (septic shock and experimental endotoxaemia): biochemical, pathophysiological and therapeutic aspects. unassigned - 3.4.21.7 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1627018&form=6&db=m Modulators of coagulation. A critical appraisal of their role in sepsis. causal interaction,therapeutic application,unassigned 4,3,0 3.4.21.7 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1832675&form=6&db=m Actin accelerates plasmin generation by tissue plasminogen activator. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2315889&form=6&db=m Plasminogen activator inhibitor 1 and 2, alpha-2-antiplasmin, plasminogen, and endotoxin levels in systemic meningococcal disease. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,1,4 3.4.21.7 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2445046&form=6&db=m Mini-plasminogen like molecule in septic patients. diagnostic usage,unassigned 1,0 3.4.21.7 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2938648&form=6&db=m Analysis of elevated fibrin(ogen) degradation product levels in patients with liver disease. causal interaction,diagnostic usage,ongoing research,unassigned 3,2,1,0 3.4.21.7 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3672437&form=6&db=m Changes in fibrinolysis in the intensive care patient. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,2,0 3.4.21.7 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3867124&form=6&db=m Fibrinolysis inhibition in acute respiratory distress syndrome. diagnostic usage,therapeutic application,unassigned 1,1,0 3.4.21.7 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6187146&form=6&db=m Treatment of sepsis in the surgical patient evaluated by means of chromogenic peptide substrate assays. causal interaction,diagnostic usage,therapeutic application,unassigned 2,4,1,0 3.4.21.7 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6373297&form=6&db=m Evaluation of severity and prognosis in early stages of septicemia by means of chromogenic peptide substrate assays. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,2,1 3.4.21.7 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6464515&form=6&db=m [Effect on hemostasis and thrombogenesis by septic processes especially in childhood] causal interaction,diagnostic usage,therapeutic application,unassigned 3,2,1,0 3.4.21.7 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8381885&form=6&db=m [Advancement in the diagnosis of disseminated intravascular coagulation for the surgeon] causal interaction,diagnostic usage,ongoing research,therapeutic application 1,3,3,1 3.4.21.7 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8585005&form=6&db=m Comparison of immunological and functional assays for measurement of soluble fibrin. diagnostic usage,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.7 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9122714&form=6&db=m The role of inflammatory cells and their proteases in extravascular fibrinolysis. causal interaction,therapeutic application,unassigned 3,3,0 3.4.21.7 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9241738&form=6&db=m Plasminogen: an important hemostatic parameter in septic patients. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,4,4,1 3.4.21.7 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9499291&form=6&db=m [Usefulness of plasminogen activating factor in meningococcal sepsis] causal interaction,unassigned 2,0 3.4.21.7 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9565810&form=6&db=m Fibrinolytic changes in a patient with toxic shock syndrome; release of active u-PA. diagnostic usage,ongoing research,unassigned 2,2,0 3.4.21.7 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9806364&form=6&db=m Degradation of fibrinogen and cross-linked fibrin by human neutrophil elastase generates D-like fragments detected by ELISA but not latex D-dimer test. diagnostic usage,unassigned 3,0 3.4.21.7 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10848822&form=6&db=m Plasminogen activator inhibitor 2 and urokinase-type plasminogen activator in plasma and leucocytes in patients with severe sepsis. causal interaction,ongoing research,therapeutic application,unassigned 4,3,4,0 3.4.21.7 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11740686&form=6&db=m Fibrinolysis in disseminated intravascular coagulation. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.7 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11797019&form=6&db=m Activation of the fibrinolytic system and utilization of the coagulation inhibitors in sepsis: comparison with severe sepsis and septic shock. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,4,0 3.4.21.7 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12168568&form=6&db=m Plasminogen activators in inflammation and sepsis. causal interaction,unassigned 1,0 3.4.21.7 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15880275&form=6&db=m Protein C as an early marker of severe septic complications in diffuse secondary peritonitis. diagnostic usage,ongoing research,unassigned 4,1,0 3.4.21.7 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16818777&form=6&db=m Endogenous tissue-type plasminogen activator is protective during Escherichia coli-induced abdominal sepsis in mice. causal interaction,ongoing research,therapeutic application,unassigned 4,3,3,0 3.4.21.7 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17397908&form=6&db=m The activation of neutrophil elastase-mediated fibrinolysis is not sufficient to overcome the fibrinolytic shutdown of disseminated intravascular coagulation associated with systemic inflammation. diagnostic usage,therapeutic application,unassigned 1,2,0 3.4.21.7 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17644733&form=6&db=m Thrombin-thrombomodulin connects coagulation and fibrinolysis: more than an in vitro phenomenon. ongoing research,unassigned 1,0 3.4.21.7 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19334478&form=6&db=m [Approbation of a new test system determining the activity of a plasmin inhibitor in patients with sepsis] diagnostic usage,therapeutic application,unassigned 3,4,0 3.4.21.7 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20100112&form=6&db=m Tranexamic acid, an inhibitor of plasminogen activation, aggravates staphylococcal septic arthritis and sepsis. causal interaction,ongoing research,therapeutic application,unassigned 4,4,3,0 3.4.21.7 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21253429&form=6&db=m Elevated levels of activated and inactivated thrombin-activatable fibrinolysis inhibitor in patients with sepsis. causal interaction,diagnostic usage,unassigned 1,4,0 3.4.21.7 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21931850&form=6&db=m Beneficial and detrimental effects of plasmin(ogen) during infection and sepsis in mice. causal interaction,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.7 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22353215&form=6&db=m A low TAFI activity and insufficient activation of fibrinolysis by both plasmin and neutrophil elastase promote organ dysfunction in disseminated intravascular coagulation associated with sepsis. causal interaction,therapeutic application,unassigned 2,1,0 3.4.21.7 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26971636&form=6&db=m Combined biomarkers discriminate a low likelihood of bacterial infection among surgical intensive care unit patients with suspected sepsis. causal interaction,diagnostic usage,ongoing research,unassigned 1,2,1,0 3.4.21.7 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29912095&form=6&db=m Combined Biomarkers Predict Acute Mortality Among Critically Ill Patients With Suspected Sepsis. unassigned - 3.4.21.7 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30571394&form=6&db=m Infections Increase the Risk of 30-Day Readmissions Among Stroke Survivors. diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.7 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31061709&form=6&db=m Neutrophils are a main source of circulating suPAR predicting outcome in critical illness. causal interaction,diagnostic usage,therapeutic application,unassigned 1,2,1,0 3.4.21.7 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31401267&form=6&db=m Binding to carboxypeptidase M mediates protective effects of fibrinopeptide B?15-42. unassigned - 3.4.21.7 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31855152&form=6&db=m D-dimer corrected for thrombin and plasmin generation is a strong predictor of mortality in patients with sepsis. therapeutic application,unassigned 1,0 3.4.21.7 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33196292&form=6&db=m COVID-19 and Sepsis Are Associated With Different Abnormalities in Plasma Procoagulant and Fibrinolytic Activity. causal interaction,diagnostic usage,unassigned 4,1,0 3.4.21.7 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33296057&form=6&db=m Management of Pleural Infection. therapeutic application,unassigned 4,0 3.4.21.7 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34237624&form=6&db=m Klebsiella pneumoniae enolase-like membrane protein interacts with human plasminogen. ongoing research,therapeutic application,unassigned 1,3,0 3.4.21.7 Severe Acute Respiratory Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33760094&form=6&db=m Comparison of Time to Clinical Improvement With vs Without Remdesivir Treatment in Hospitalized Patients With COVID-19. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.7 Severe Dengue http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19401765&form=6&db=m Peptide Bbeta(15-42) preserves endothelial barrier function in shock. therapeutic application,unassigned 2,0 3.4.21.7 Sexually Transmitted Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8313495&form=6&db=m Syphilis-associated perinatal and infant mortality in rural Malawi. causal interaction,diagnostic usage,therapeutic application,unassigned 2,1,1,0 3.4.21.7 Sexually Transmitted Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15550139&form=6&db=m Lues maligna. diagnostic usage,unassigned 3,0 3.4.21.7 Sexually Transmitted Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15613000&form=6&db=m Avoidance of oxidative-stress perturbation in yeast bioprocesses by proteomic and genomic biostrategies? unassigned - 3.4.21.7 Shock, Cardiogenic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2018650&form=6&db=m Successful surgical management of left ventricular free wall rupture in the course of myocardial infarction. causal interaction,therapeutic application,unassigned 2,2,0 3.4.21.7 Shock, Cardiogenic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7642857&form=6&db=m Contemporary reperfusion therapy for cardiogenic shock: the GUSTO-I trial experience. The GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. therapeutic application,unassigned 4,0 3.4.21.7 Shock, Cardiogenic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9232304&form=6&db=m Recombinant tissue type plasminogen activator treatment of thrombosed mitral valve prosthesis during pregnancy. causal interaction,diagnostic usage,unassigned 1,1,0 3.4.21.7 Shock, Cardiogenic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17315612&form=6&db=m [Haemostatic and inflammation markers in acute coronary syndromes and its relationship with adverse cardiovascular events] causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.7 Shock, Septic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=75792&form=6&db=m Changes in plasminogen levels, plasmin activity and activity of antiplasmins during endotoxin shock in dogs. diagnostic usage,ongoing research,unassigned 2,3,0 3.4.21.7 Shock, Septic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=77807&form=6&db=m Alterations of plasmin activity, plasminogen levels and activity of antiplasmins during endotoxin shock in dogs. diagnostic usage,ongoing research,unassigned 2,2,0 3.4.21.7 Shock, Septic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2145377&form=6&db=m Changes in the fibrinolysin system in infantile and adult respiratory distress syndrome (ARDS), caused by trauma and/or septic shock in patients and in experimental animals. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,2,4,4 3.4.21.7 Shock, Septic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2396772&form=6&db=m [Characteristics of hemostatic disorders in septic shock in children] therapeutic application,unassigned 1,0 3.4.21.7 Shock, Septic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2502362&form=6&db=m Coagulation, fibrinolysis, and kallikrein systems in sepsis: relation to outcome. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,3,0 3.4.21.7 Shock, Septic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2977523&form=6&db=m Neutrophil elastase, thrombin and plasmin in septic shock. unassigned - 3.4.21.7 Shock, Septic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4223377&form=6&db=m Endotoxin shock in the New Zealand white rabbit. An evaluation of fibrinolysin therapy. diagnostic usage,therapeutic application,unassigned 3,4,0 3.4.21.7 Shock, Septic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6158114&form=6&db=m Plasminogen concentrations and functional activities and concentrations of plasmin inhibitors in plasma samples from normal subjects and patients with septic shock. diagnostic usage,ongoing research,unassigned 2,4,0 3.4.21.7 Shock, Septic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9122714&form=6&db=m The role of inflammatory cells and their proteases in extravascular fibrinolysis. causal interaction,therapeutic application,unassigned 3,3,0 3.4.21.7 Shock, Septic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11797019&form=6&db=m Activation of the fibrinolytic system and utilization of the coagulation inhibitors in sepsis: comparison with severe sepsis and septic shock. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,4,0 3.4.21.7 Shock, Septic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14310039&form=6&db=m INTRAVASCULAR COAGULATION AND FIBRINOLYSIN THERAPY IN ENDOTOXIN SHOCK. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,4,0 3.4.21.7 Shock, Septic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31682515&form=6&db=m DNA-bound elastase of neutrophil extracellular traps degrades plasminogen, reduces plasmin formation, and decreases fibrinolysis: proof of concept in septic shock plasma. causal interaction,ongoing research,therapeutic application,unassigned 1,1,3,0 3.4.21.7 Silicosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=5735961&form=6&db=m [Changes in the activity of the phagocytosis stimulating centers in the hypothalamus and fibrinolysin in silicosis] unassigned - 3.4.21.7 Sinus Thrombosis, Intracranial http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9127024&form=6&db=m Direct endovascular thrombolytic therapy for dural sinus thrombosis: infusion of alteplase. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 Sinusitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6686718&form=6&db=m Studies on proactivator from the paranasal mucous membrane in chronic sinusitis. unassigned - 3.4.21.7 Skin Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7523283&form=6&db=m [The autoimmune dermatosis bullous pemphigoid: deposition and activation of plasminogen in affected epidermis] causal interaction,unassigned 4,0 3.4.21.7 Skin Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7688770&form=6&db=m The autoimmune blistering skin disease bullous pemphigoid. The presence of plasmin/alpha 2-antiplasmin complexes in skin blister fluid indicates plasmin generation in lesional skin. diagnostic usage,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.7 Skin Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8120416&form=6&db=m Expression of plasminogen activator enzymes in psoriatic epidermis. causal interaction,diagnostic usage,ongoing research,unassigned 3,3,3,0 3.4.21.7 Skin Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15161662&form=6&db=m Plasminogen mediates the pathological effects of urokinase-type plasminogen activator overexpression. ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.7 Skin Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19158842&form=6&db=m Plasmin Plays a Role in the In Vitro Generation of the Linear IgA Dermatosis Antigen LADB97. diagnostic usage,ongoing research,unassigned 1,2,0 3.4.21.7 Skin Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31604367&form=6&db=m Expression and ultrastructural localization of plasmin(ogen) in the terminally differentiated layers of normal human epidermis. therapeutic application,unassigned 1,0 3.4.21.7 Skin Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22815383&form=6&db=m Plasmin-driven fibrinolysis facilitates skin tumor growth in a gender-dependent manner. causal interaction,ongoing research,unassigned 4,4,0 3.4.21.7 Skin Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23527289&form=6&db=m Gender affects skin wound healing in plasminogen deficient mice. causal interaction,ongoing research,therapeutic application,unassigned 4,2,1,0 3.4.21.7 Sleep Apnea, Obstructive http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26265606&form=6&db=m Obstructive Sleep Apnea Hypopnea Syndrome as a Reason for Active Management of Pulmonary Embolism. diagnostic usage,unassigned 3,0 3.4.21.7 Sleep Apnea, Obstructive http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26286733&form=6&db=m The Plasminogen System and Transforming Growth Factor-? in Subjects With Obstructive Sleep Apnea Syndrome: Effects of CPAP Treatment. diagnostic usage,ongoing research,unassigned 3,3,0 3.4.21.7 Sleep Deprivation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34488434&form=6&db=m Negative Influence of Insufficient Sleep on Endothelial Vasodilator and Fibrinolytic Function in Hypertensive Adults. causal interaction,unassigned 4,0 3.4.21.7 Small Cell Lung Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2467397&form=6&db=m Abnormal haemostasis in small cell lung cancer. diagnostic usage,ongoing research,unassigned 3,3,0 3.4.21.7 Small Cell Lung Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2555056&form=6&db=m Synthesis and secretion of plasminogen activators and plasminogen activator inhibitors in cell lines of different groups of human lung tumors. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,3,4,4 3.4.21.7 Small Cell Lung Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21533361&form=6&db=m Presence of urokinase plasminogen activator, its inhibitor and receptor in small cell lung cancer and non-small cell lung cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,4,1 3.4.21.7 Small Cell Lung Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23261456&form=6&db=m Involvement of plasmin-mediated extracellular activation of progalanin in angiogenesis. causal interaction,ongoing research,unassigned 4,4,0 3.4.21.7 Soft Tissue Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30229498&form=6&db=m Novel preclinical murine model of trauma-induced elbow stiffness. causal interaction,unassigned 3,0 3.4.21.7 Spasm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7511130&form=6&db=m Plasmin and thrombin inhibitors in essentially untreated patients with coronary artery spasm. causal interaction,ongoing research,therapeutic application,unassigned 3,1,4,0 3.4.21.7 Spinal Cord Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18000864&form=6&db=m tPA-mediated generation of plasmin is catalyzed by the proteoglycan NG2. causal interaction,ongoing research,therapeutic application,unassigned 3,2,4,0 3.4.21.7 Spinal Cord Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19240037&form=6&db=m The Serine Protease Plasmin Cleaves the Amino-terminal Domain of the NR2A Subunit to Relieve Zinc Inhibition of the N-Methyl-D-aspartate Receptors. causal interaction,therapeutic application,unassigned 4,3,0 3.4.21.7 Spinal Cord Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19651246&form=6&db=m Role of plasminogen activator in spinal cord remodeling after spinal cord injury. therapeutic application,unassigned 2,0 3.4.21.7 Spinal Cord Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21573723&form=6&db=m Plasminogen activator promotes recovery following spinal cord injury. unassigned - 3.4.21.7 Spinal Cord Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31848365&form=6&db=m Tissue-type plasminogen activator-primed human iPSC-derived neural progenitor cells promote motor recovery after severe spinal cord injury. ongoing research,unassigned 2,0 3.4.21.7 Spondylarthropathies http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8895144&form=6&db=m Mobilization of fibrinolytic enzymes in synovial fluid and plasma of rheumatoid arthritis and spondyloarthropathy and their relation to radiological destruction. ongoing research,therapeutic application,unassigned 2,2,0 3.4.21.7 Squamous Cell Carcinoma of Head and Neck http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7707177&form=6&db=m [Immunohistological study of fibrinolytic factors of head and neck squamous cell carcinomas] unassigned - 3.4.21.7 Squamous Cell Carcinoma of Head and Neck http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10473828&form=6&db=m Proteolytic patterns of head and neck squamous cell carcinoma. causal interaction,diagnostic usage,ongoing research,unassigned 4,1,2,0 3.4.21.7 Squamous Cell Carcinoma of Head and Neck http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15138855&form=6&db=m [The prognostic importance of urinase type plasminogen activators (uPA) and plasminogen activator inhibitors (PAI-1) in the primary resection of oral squamous cell carcinoma] causal interaction,diagnostic usage,ongoing research,therapeutic application 1,1,3,4 3.4.21.7 Squamous Cell Carcinoma of Head and Neck http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15138856&form=6&db=m [Comparison of urokinase type plasminogen activators (uPA) and plasminogen activator inhibitors (PAI-1) in primary resection of oral squamous cell carcinoma] causal interaction,diagnostic usage,ongoing research,therapeutic application 2,3,3,4 3.4.21.7 Squamous Cell Carcinoma of Head and Neck http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15509494&form=6&db=m Detection of plasminogen activators in oral cancer by laser capture microdissection combined with zymography. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,2,2,1 3.4.21.7 Squamous Cell Carcinoma of Head and Neck http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16077918&form=6&db=m Plasminogen activator/plasmin system suppresses cell-cell adhesion of oral squamous cell carcinoma cells via proteolysis of E-cadherin. ongoing research,unassigned 3,0 3.4.21.7 Squamous Cell Carcinoma of Head and Neck http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17203182&form=6&db=m Induction of alpha2-antiplasmin inhibits E-cadherin processing mediated by the plasminogen activator/plasmin system, leading to suppression of progression of oral squamous cell carcinoma via upregulation of cell-cell adhesion. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.7 Squamous Cell Carcinoma of Head and Neck http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27385000&form=6&db=m uPA/uPAR and SERPINE1 in head and neck cancer: role in tumor resistance, metastasis, prognosis and therapy. therapeutic application,unassigned 2,0 3.4.21.7 ST Elevation Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11269778&form=6&db=m Comparative efficacy of primary angioplasty with stent implantation and thrombolysis in restoring basal coronary artery flow in acute ST segment elevation myocardial infarction: quantitative assessment using the corrected TIMI frame count. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,1,3,2 3.4.21.7 ST Elevation Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15380963&form=6&db=m Routine invasive strategy within 24 hours of thrombolysis versus ischaemia-guided conservative approach for acute myocardial infarction with ST-segment elevation (GRACIA-1): a randomised controlled trial. ongoing research,therapeutic application,unassigned 2,2,0 3.4.21.7 ST Elevation Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19552570&form=6&db=m Thrombin activity throughout the acute phase of acute ST-elevation myocardial infarction and the relation to outcome. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,2,4 3.4.21.7 ST Elevation Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22013562&form=6&db=m Recombinant tissue-type plasminogen activators: "time matters". ongoing research,therapeutic application,unassigned 1,2,0 3.4.21.7 ST Elevation Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22538774&form=6&db=m Fibrinolytic status in acute coronary syndromes: evidence of differences in relation to clinical features and pathophysiological pathways. causal interaction,diagnostic usage,therapeutic application,unassigned 1,2,2,0 3.4.21.7 ST Elevation Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28843245&form=6&db=m An Uncommon Complication of Streptokinase: Large Spontaneous Iliopsoas Hematoma. causal interaction,therapeutic application,unassigned 3,2,0 3.4.21.7 Staphylococcal Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20100112&form=6&db=m Tranexamic acid, an inhibitor of plasminogen activation, aggravates staphylococcal septic arthritis and sepsis. causal interaction,ongoing research,therapeutic application,unassigned 4,4,3,0 3.4.21.7 Stevens-Johnson Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15008985&form=6&db=m Elevated expression and release of tissue-type, but not urokinase-type, plasminogen activator after binding of autoantibodies to bullous pemphigoid antigen 180 in cultured human keratinocytes. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,2,4 3.4.21.7 Stillbirth http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8313495&form=6&db=m Syphilis-associated perinatal and infant mortality in rural Malawi. causal interaction,diagnostic usage,therapeutic application,unassigned 2,1,1,0 3.4.21.7 Stomach Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1902201&form=6&db=m Plasminogen activators in human gastric cancers: correlation with DNA ploidy and immunohistochemical staining. causal interaction,diagnostic usage,ongoing research,unassigned 3,3,4,0 3.4.21.7 Stomach Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2232301&form=6&db=m [Protease activities in gastric and colon cancer tissues] causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,4,1 3.4.21.7 Stomach Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2565016&form=6&db=m [Wound healing, blood coagulation and fibrinolysis during operations involving gastric cancer surgery] causal interaction,unassigned 1,0 3.4.21.7 Stomach Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6779412&form=6&db=m Immunological analysis of plasminogen activators from cultured human cancer cells. diagnostic usage,ongoing research,therapeutic application,unassigned 3,4,1,0 3.4.21.7 Stomach Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7600025&form=6&db=m The plasminogen activation system and its role in lung cancer. A review. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,2,3,2 3.4.21.7 Stomach Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12785198&form=6&db=m [Urokinase and tissue type plasminogen activators and their type-1 inhibitor (PAI-1) in gastric cancer] causal interaction,diagnostic usage,ongoing research,therapeutic application 2,3,3,1 3.4.21.7 Stomach Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18239814&form=6&db=m Relationship between expression of NM23 protein and clinical morphological factors and content of plasminogen activation system components in tumors of patients with gastric cancer. causal interaction,diagnostic usage,ongoing research,unassigned 1,2,3,0 3.4.21.7 Stomach Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19513384&form=6&db=m Analysis of NM23 protein and components of plasminogen activation system in tumors of patients with stomach cancer with consideration for disease clinical picture and morphology. diagnostic usage,ongoing research,unassigned 4,2,0 3.4.21.7 Stomach Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19609941&form=6&db=m Urokinase plasminogen activator receptor is expressed in invasive cells in gastric carcinomas from high- and low-risk countries. causal interaction,ongoing research,unassigned 4,3,0 3.4.21.7 Stomach Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21901747&form=6&db=m Urokinase plasminogen activator receptor on invasive cancer cells: A prognostic factor in distal gastric adenocarcinoma. causal interaction,diagnostic usage,ongoing research,unassigned 4,1,2,0 3.4.21.7 Stomach Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28643742&form=6&db=m In vitro activity of probiotic Lactobacillus reuteri against gastric cancer progression by downregulation of urokinase plasminogen activator/urokinase plasminogen activator receptor gene expression. causal interaction,ongoing research,therapeutic application,unassigned 4,2,1,0 3.4.21.7 Stomach Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29072683&form=6&db=m Plasminogen kringle 5 suppresses gastric cancer via regulating HIF-1? and GRP78. causal interaction,ongoing research,therapeutic application,unassigned 3,3,4,0 3.4.21.7 Stomach Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31218131&form=6&db=m Global transcriptomic analysis identifies SERPINE1 as a prognostic biomarker associated with epithelial-to-mesenchymal transition in gastric cancer. causal interaction,diagnostic usage,ongoing research,unassigned 2,1,2,0 3.4.21.7 Stomach Ulcer http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=807&form=6&db=m Gastric fibrinolysis. diagnostic usage,ongoing research,unassigned 1,3,0 3.4.21.7 Stomatitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9239167&form=6&db=m [Inhibition of 5-fluorouracil-cisplatin-induced stomatitis by oral cryotherapy: use of an ice-bar containing fibrinolysin and deoxyribonuclease combine (Elase)] ongoing research,therapeutic application,unassigned 4,3,0 3.4.21.7 Strabismus http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30180242&form=6&db=m Treatment of Ligneous Conjunctivitis Using Topical Plasminogen Therapy in an 8-Week-Old Female Infant. therapeutic application,unassigned 4,0 3.4.21.7 Streptococcal Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15333838&form=6&db=m Plasminogen is a critical host pathogenicity factor for group A streptococcal infection. causal interaction,unassigned 3,0 3.4.21.7 Streptococcal Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25921659&form=6&db=m In Vivo Tracking of Streptococcal Infections of Subcutaneous Origin in a Murine Model. unassigned - 3.4.21.7 Streptococcal Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26485450&form=6&db=m Bacterial pathogens activate plasminogen to breach tissue barriers and escape from innate immunity. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.7 Streptococcal Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28924140&form=6&db=m Linoleic and palmitoleic acid block streptokinase-mediated plasminogen activation and reduce severity of invasive group A streptococcal infection. causal interaction,therapeutic application,unassigned 2,1,0 3.4.21.7 Streptococcal Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32276523&form=6&db=m Glomerular Deposition of Nephritis-Associated Plasmin Receptor (NAPlr) and Related Plasmin Activity: Key Diagnostic Biomarkers of Bacterial Infection-related Glomerulonephritis. therapeutic application,unassigned 1,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1284251&form=6&db=m Influence of atrial fibrillation on coagulo-fibrinolytic markers in patients with cerebral infarction. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,2,3,1 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1319650&form=6&db=m [Revising the principles and improving the methods of differential therapy of ischemic stroke] diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1478053&form=6&db=m Organ damage in shock, disseminated intravascular coagulation, and stroke. causal interaction,therapeutic application,unassigned 3,2,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1579958&form=6&db=m Urgent therapy for stroke. Part I. Pilot study of tissue plasminogen activator administered within 90 minutes. therapeutic application,unassigned 4,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1579959&form=6&db=m Urgent therapy for stroke. Part II. Pilot study of tissue plasminogen activator administered 91-180 minutes from onset. causal interaction,ongoing research,therapeutic application,unassigned 4,1,4,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1962336&form=6&db=m Stroke in a young adult with familial plasminogen disorder. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,2,3 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2620588&form=6&db=m [Observation of plasma levels of antithrombin-III and plasminogen in acute cerebrovascular disease] causal interaction,diagnostic usage,ongoing research,unassigned 2,3,2,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7585043&form=6&db=m Antifibrinolytic activity of apolipoprotein(a) in vivo: human apolipoprotein(a) transgenic mice are resistant to tissue plasminogen activator-mediated thrombolysis. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7653207&form=6&db=m Hemostatic disturbances in acute ischemic stroke: a study of 86 patients. diagnostic usage,therapeutic application,unassigned 2,2,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7865679&form=6&db=m The coagulopathy of heat stroke: alterations in coagulation and fibrinolysis in heat stroke patients during the pilgrimage (Haj) to Makkah. causal interaction,diagnostic usage,unassigned 3,2,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8316193&form=6&db=m Coronary artery disease, myocardial infarction, and brain embolism. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8322373&form=6&db=m Pilot randomized trial of tissue plasminogen activator in acute ischemic stroke. The TPA Bridging Study Group. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,2,1,4 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8329574&form=6&db=m Reocclusion after thrombolytic therapy: strategies for inhibiting thrombin-induced platelet aggregation. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8621740&form=6&db=m Proteolytic cascade enzymes increase in focal cerebral ischemia in rat. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,2,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8692437&form=6&db=m Lys-plasminogen as an adjunct to local intra-arterial fibrinolysis for carotid territory stroke: laboratory and clinical findings. diagnostic usage,therapeutic application,unassigned 1,2,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8777766&form=6&db=m Medical therapy for ischemic stroke. therapeutic application,unassigned 3,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8832673&form=6&db=m The effect of oral antiplatelet agents on tissue plasminogen activator-mediated thrombolysis in a rabbit model of thromboembolic stroke. ongoing research,therapeutic application,unassigned 3,2,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8889383&form=6&db=m New interventions in cerebrovascular disease: the role of thrombolytic therapy and balloon angioplasty. ongoing research,therapeutic application,unassigned 1,3,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9198150&form=6&db=m Antithrombotic therapy of acute stroke: thrombolytic agents. diagnostic usage,therapeutic application,unassigned 2,4,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9340503&form=6&db=m A comparison of reteplase with alteplase for acute myocardial infarction. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) Investigators. causal interaction,diagnostic usage,therapeutic application,unassigned 3,1,4,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9710264&form=6&db=m Functional and morphologic evidence of the presence of tissue-plasminogen activator in vascular nerves: implications for a neurologic control of vessel wall fibrinolysis and rigidity. unassigned - 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9918523&form=6&db=m Effects of stroke on medical resource use and costs in acute myocardial infarction. GUSTO I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries Study. ongoing research,therapeutic application,unassigned 3,2,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10362821&form=6&db=m Effects of tissue plasminogen activator for acute ischemic stroke at one year. National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study Group. causal interaction,ongoing research,therapeutic application,unassigned 1,2,4,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10456616&form=6&db=m Thrombophilic predisposition in stroke and venous thromboembolism in Danish patients. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10625711&form=6&db=m Tissue plasminogen activator, plasminogen activator inhibitor-1, and tissue plasminogen activator/plasminogen activator inhibitor-1 complex as risk factors for the development of a first stroke. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,4,4,2 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10706931&form=6&db=m Thrombolytic properties of leukocytes from peripheral blood in healthy subjects and in patients with acute cerebral ischemia. diagnostic usage,ongoing research,therapeutic application,unassigned 3,4,1,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11032907&form=6&db=m Tissue plasminogen activator requires plasminogen to modulate amyloid-beta neurotoxicity and deposition. causal interaction,ongoing research,therapeutic application,unassigned 1,2,1,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11061250&form=6&db=m Predicting prognosis after stroke: a placebo group analysis from the National Institute of Neurological Disorders and Stroke rt-PA Stroke Trial. ongoing research,therapeutic application,unassigned 1,2,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11108768&form=6&db=m Metalloproteinase inhibition reduces thrombolytic (tissue plasminogen activator)-induced hemorrhage after thromboembolic stroke. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11126912&form=6&db=m 16(R)-hydroxyeicosatetraenoic acid, a novel cytochrome P450 product of arachidonic acid, suppresses activation of human polymorphonuclear leukocyte and reduces intracranial pressure in a rabbit model of thromboembolic stroke. causal interaction,ongoing research,therapeutic application,unassigned 3,3,1,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11205719&form=6&db=m Prothrombotic disorders and ischemic stroke in children. causal interaction,unassigned 3,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11322449&form=6&db=m Effects of nitric oxide on reactive oxygen species production and infarction size after brain reperfusion injury. ongoing research,therapeutic application,unassigned 3,3,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11340211&form=6&db=m Insulin resistance and elevated levels of tissue plasminogen activator in first-degree relatives of South Asian patients with ischemic cerebrovascular disease. causal interaction,diagnostic usage,unassigned 4,3,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11387492&form=6&db=m A modified National Institutes of Health Stroke Scale for use in stroke clinical trials: preliminary reliability and validity. therapeutic application,unassigned 1,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11591835&form=6&db=m The Clomethiazole Acute Stroke Study in tissue-type plasminogen activator-treated stroke (CLASS-T): final results. diagnostic usage,ongoing research,therapeutic application,unassigned 2,3,4,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11735758&form=6&db=m Lack of clinical significance of early ischemic changes on computed tomography in acute stroke. diagnostic usage,ongoing research,therapeutic application,unassigned 2,3,2,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11779904&form=6&db=m The nonpeptide glycoprotein IIb/IIIa platelet receptor antagonist SM-20302 reduces tissue plasminogen activator-induced intracerebral hemorrhage after thromboembolic stroke. causal interaction,ongoing research,therapeutic application,unassigned 4,4,4,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12088338&form=6&db=m Blood coagulation and fibrinolysis in acute ischaemic and haemorrhagic (intracerebral and subarachnoid haemorrhage) stroke: does decreased plasmin inhibitor indicate increased fibrinolysis in subarachnoid haemorrhage compared to other types of stroke? diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12384244&form=6&db=m Combined X-ray angiography and diffusion-perfusion MRI for studying stroke evolution after rt-PA treatment in rats. causal interaction,diagnostic usage,therapeutic application,unassigned 3,3,4,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12437508&form=6&db=m Development of thrombolytic therapy for stroke: a perspective. therapeutic application,unassigned 4,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12496672&form=6&db=m Strokes and their relationship to hypertension. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12677014&form=6&db=m Effects of admission hyperglycemia on stroke outcome in reperfused tissue plasminogen activator--treated patients. causal interaction,ongoing research,therapeutic application,unassigned 1,4,2,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12818323&form=6&db=m [Blood-brain barrier pathophysiology and ischaemic brain oedema] causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12849182&form=6&db=m Ultrasound in the treatment of ischaemic stroke. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14537155&form=6&db=m Tissue-type plasminogen activator: characteristics, applications and production technology. causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,4,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14581912&form=6&db=m Misdiagnosis of stroke in tissue plasminogen activator-treated patients: characteristics and outcomes. diagnostic usage,ongoing research,therapeutic application,unassigned 1,2,2,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14644783&form=6&db=m HandiStroke: a handheld tool for the emergent evaluation of acute stroke patients. therapeutic application,unassigned 4,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14707233&form=6&db=m Differential pattern of tissue plasminogen activator-induced proximal middle cerebral artery recanalization among stroke subtypes. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,2,4,3 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14747742&form=6&db=m Intracerebral hirudin injection attenuates ischemic damage and neurologic deficits without altering local cerebral blood flow. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14973136&form=6&db=m Plasmin-mediated activation of platelets occurs by cleavage of protease-activated receptor 4. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15258347&form=6&db=m Improving thrombolysis with encapsulated plasminogen activators and clinical relevance to myocardial infarction and stroke. therapeutic application,unassigned 2,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15727269&form=6&db=m Extracellular proteolytic pathophysiology in the neurovascular unit after stroke. causal interaction,therapeutic application,unassigned 4,2,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15943975&form=6&db=m Understanding the enzymology of fibrinolysis and improving thrombolytic therapy. causal interaction,therapeutic application,unassigned 3,2,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16055345&form=6&db=m Production and purification of urokinase: a comprehensive review. causal interaction,therapeutic application,unassigned 3,3,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16102027&form=6&db=m Circulating inflammatory markers and risks of cardiovascular and non-cardiovascular disease. causal interaction,diagnostic usage,unassigned 1,3,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16126134&form=6&db=m Recombinant tissue plasminogen activator for minor strokes: the National Institute of Neurological Disorders and Stroke rt-PA Stroke Study experience. diagnostic usage,ongoing research,therapeutic application,unassigned 2,2,3,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16639158&form=6&db=m Update on stroke. therapeutic application,unassigned 4,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16728683&form=6&db=m Thrombolysis (tissue plasminogen activator) in stroke: a medicolegal quagmire. diagnostic usage,ongoing research,therapeutic application,unassigned 1,1,3,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16960292&form=6&db=m Paradoxically accelerated fatal brain herniation following thrombolytic therapy in acute ischemic stroke. therapeutic application,unassigned 4,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17143002&form=6&db=m Lp(a) lipoprotein and plasminogen activity in patients with different etiology of ischemic stroke. causal interaction,diagnostic usage,ongoing research,unassigned 3,3,4,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17217849&form=6&db=m Role of transcranial Doppler ultrasonography in evaluation of patients with cerebrovascular disease. therapeutic application,unassigned 2,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17355216&form=6&db=m Advances in ischemic stroke treatment: neuroprotective and combination therapies. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17386975&form=6&db=m Induction of matrix metalloproteinase, cytokines and chemokines in rat cortical astrocytes exposed to plasminogen activators. therapeutic application,unassigned 4,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17646593&form=6&db=m Tissue plasminogen activator-induced reperfusion injury after stroke revisited. ongoing research,therapeutic application,unassigned 1,1,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17702959&form=6&db=m Mouse model of in situ thromboembolic stroke and reperfusion. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18048844&form=6&db=m Cholesterol measured before stroke thrombolysis is not associated with tissue plasminogen activator-related hemorrhagic transformation. therapeutic application,unassigned 1,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18406998&form=6&db=m Antithrombotic and thrombolytic therapy for ischemic stroke. causal interaction,ongoing research,therapeutic application,unassigned 4,3,3,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18556588&form=6&db=m Early disruption of the blood-brain barrier after thrombolytic therapy predicts hemorrhage in patients with acute stroke. causal interaction,unassigned 3,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18597942&form=6&db=m Acute changes of coagulation and fibrinolysis parameters after experimental thromboembolic stroke and thrombolytic therapy. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,4,4 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18673209&form=6&db=m Tissue plasminogen activator (tPA) and matrix metalloproteinases in the pathogenesis of stroke: therapeutic strategies. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19006853&form=6&db=m Molecule of the Month. PDGFR-alpha antagonist Gleevec reduces blood vessel leakage and increases the therapeutic window associated with tissue plasminogen activator stroke treatment. therapeutic application,unassigned 3,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19110148&form=6&db=m Sequential combination of two intravenous thrombolytics (recombinant tissue plasminogen activator/tenecteplase) in a patient with stroke and cardioembolic basilar artery occlusion. therapeutic application,unassigned 2,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19362319&form=6&db=m Stroke center characteristics which influence the administration of thrombolytic therapy for acute ischemic stroke: a national survey of stroke centers in Taiwan. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,4,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19407232&form=6&db=m 4.5 Hours. The New Time Window for Tissue Plasminogen Activator in Stroke. diagnostic usage,therapeutic application,unassigned 2,2,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19442825&form=6&db=m The intranigral injection of tissue plasminogen activator induced blood-brain barrier disruption, inflammatory process and degeneration of the dopaminergic system of the rat. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19551314&form=6&db=m Role of fibrinolytic markers in acute stroke. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19630790&form=6&db=m Tissue plasminogen activator-mediated PDGF signaling and neurovascular coupling in stroke. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19941428&form=6&db=m Acute 'strokenomics': efficacy and economic analyses of alteplase for acute ischemic stroke. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,1,3,4 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20185784&form=6&db=m Oxidative stress after thrombolysis-induced reperfusion in human stroke. causal interaction,ongoing research,therapeutic application,unassigned 2,4,1,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20189087&form=6&db=m Does mild deficit for patients with stroke justify the use of intravenous tissue plasminogen activator? causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,1,4 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20554592&form=6&db=m Efficacy and safety of i.v. alteplase therapy up to 4.5 hours after acute ischemic stroke onset. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,2,2,4 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20689081&form=6&db=m Lack of association between pretreatment neurology consultation and subsequent protocol deviation in tissue plasminogen activator-treated patients with stroke. causal interaction,ongoing research,unassigned 1,1,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20842548&form=6&db=m Thrombi of different pathologies: implications for diagnosis and treatment. causal interaction,therapeutic application,unassigned 3,2,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20876504&form=6&db=m Thrombolysis with plasmin: implications for stroke treatment. causal interaction,ongoing research,therapeutic application,unassigned 3,2,4,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20947857&form=6&db=m Safety of intravenous fibrinolysis in imaging-confirmed single penetrator artery infarcts. unassigned - 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21300353&form=6&db=m Differential expression of oxidized/native lipoprotein(a) and plasminogen in human carotid and cerebral artery plaques. causal interaction,diagnostic usage,unassigned 4,3,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21371270&form=6&db=m Validation assessment of risk scores to predict postthrombolysis intracerebral haemorrhage. ongoing research,therapeutic application,unassigned 3,2,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21852612&form=6&db=m Impact of the Extended Thrombolysis Time Window on the Proportion of Recombinant Tissue-Type Plasminogen Activator-Treated Stroke Patients and on Door-to-Needle Time. ongoing research,therapeutic application,unassigned 3,3,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21926519&form=6&db=m The impact of a statewide stroke quality improvement program: Colorado Stroke Alliance and Colorado Stroke Registry. causal interaction,therapeutic application,unassigned 4,3,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22267526&form=6&db=m Telemedicine versus face-to-face evaluation in the delivery of thrombolysis for acute ischaemic stroke: a single centre experience. causal interaction,ongoing research,therapeutic application,unassigned 1,1,2,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22463085&form=6&db=m Plasminogen activation and thrombolysis for ischemic stroke. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22811464&form=6&db=m Patients with the malignant profile within 3 hours of symptom onset have very poor outcomes after intravenous tissue-type plasminogen activator therapy. diagnostic usage,ongoing research,therapeutic application,unassigned 2,3,1,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22841181&form=6&db=m Can Quality-Adjusted Life-Years and Subgroups Help Us Decide Whether to Treat Late-Arriving Stroke Patients With Tissue Plasminogen Activator? therapeutic application,unassigned 1,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23280993&form=6&db=m Recombinant ADAMTS13 reduces tissue plasminogen activator-induced hemorrhage after stroke in mice. causal interaction,ongoing research,therapeutic application,unassigned 4,4,4,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23411790&form=6&db=m Simplified modified Rankin Scale questionnaire correlates with stroke severity. therapeutic application,unassigned 1,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23781399&form=6&db=m Mild Hypothermia Reduces Tissue Plasminogen Activator-Related Hemorrhage and Blood Brain Barrier Disruption After Experimental Stroke. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,2,4 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24103663&form=6&db=m Imaging Negative Stroke: Diagnoses and Outcomes in Intravenous Tissue Plasminogen Activator-Treated Patients. causal interaction,therapeutic application,unassigned 3,2,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24172579&form=6&db=m Does sex influence the response to intravenous thrombolysis in ischemic stroke?: answers from safe implementation of treatments in Stroke-International Stroke Thrombolysis Register. ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24198521&form=6&db=m Mesenchymal stem cells in the treatment of ischemic stroke: progress and possibilities. causal interaction,therapeutic application,unassigned 2,3,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24582784&form=6&db=m Alpha 1-Antitrypsin Therapy Mitigated Ischemic Stroke Damage in Rats. therapeutic application,unassigned 4,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24591838&form=6&db=m Current perspectives on the use of intravenous recombinant tissue plasminogen activator (tPA) for treatment of acute ischemic stroke. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24732409&form=6&db=m Plasminogen deficiency causes reduced corticospinal axonal plasticity and functional recovery after stroke in mice. causal interaction,ongoing research,therapeutic application,unassigned 3,4,1,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24834949&form=6&db=m Mild hypothermia reduces tissue plasminogen activator-related hemorrhage and blood brain barrier disruption after experimental stroke: editorial commentary on tang et Al., 2013. ongoing research,unassigned 2,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25525855&form=6&db=m On the contribution of S100A10 and annexin A2 to plasminogen activation and oncogenesis: an enduring ambiguity. therapeutic application,unassigned 1,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26138125&form=6&db=m Impact of General Anesthesia on Safety and Outcomes in the Endovascular Arm of Interventional Management of Stroke (IMS) III Trial. therapeutic application,unassigned 2,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26246166&form=6&db=m Results of a preclinical randomized controlled multicenter trial (pRCT): Anti-CD49d treatment for acute brain ischemia. therapeutic application,unassigned 4,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26359360&form=6&db=m National Institutes of Health Stroke Scale Item Profiles as Predictor of Patient Outcome: External Validation on Safe Implementation of Thrombolysis in Stroke-Monitoring Study Data. therapeutic application,unassigned 4,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26514192&form=6&db=m Coagulation and Fibrinolytic Activity of Tenecteplase and Alteplase in Acute Ischemic Stroke. diagnostic usage,ongoing research,therapeutic application,unassigned 3,3,2,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26679565&form=6&db=m Acute endovascular recanalization: lessons from randomized controlled trials. causal interaction,therapeutic application,unassigned 2,4,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26733583&form=6&db=m Comparison of outcomes of patients with inpatient or outpatient onset ischemic stroke. causal interaction,diagnostic usage,therapeutic application,unassigned 2,2,1,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26795089&form=6&db=m Systemic inflammation affects reperfusion following transient cerebral ischaemia. unassigned - 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26892282&form=6&db=m Streamlined Hyperacute Magnetic Resonance Imaging Protocol Identifies Tissue-Type Plasminogen Activator-Eligible Stroke Patients When Clinical Impression Is Stroke Mimic. causal interaction,unassigned 1,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26906917&form=6&db=m Direct Mechanical Intervention Versus Combined Intravenous and Mechanical Intervention in Large Artery Anterior Circulation Stroke: A Matched-Pairs Analysis. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27018013&form=6&db=m Hydrogen Sulfide Attenuates Tissue Plasminogen Activator-Induced Cerebral Hemorrhage Following Experimental Stroke. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,4,4 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27241578&form=6&db=m The Combination of Clinical Features, Transcranial Doppler, and Alberta Stroke Program Early Computed Tomography Score (Computed Tomography Angiography) in Predicting Outcome in Intravenous Recombinant Tissue Plasminogen Activator-Treated Patients. diagnostic usage,therapeutic application,unassigned 1,2,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27313141&form=6&db=m Potentially Missed Diagnosis of Ischemic Stroke in the Emergency Department in the Greater Cincinnati/Northern Kentucky Stroke Study. diagnostic usage,ongoing research,therapeutic application,unassigned 4,2,1,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27319402&form=6&db=m Physiologic variations in blood plasminogen levels affect outcomes after acute cerebral thromboembolism in mice: a pathophysiologic role for microvascular thrombosis. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,1,4,3 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27354223&form=6&db=m Tissue-Type Plasminogen Activator-A296-299 Prevents Impairment of Cerebral Autoregulation After Stroke Through Lipoprotein-Related Receptor-Dependent Increase in cAMP and p38. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27362966&form=6&db=m Plasminogen and stroke: more is better. unassigned - 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27625405&form=6&db=m Regional Learning Collaboratives Produce Rapid and Sustainable Improvements in Stroke Thrombolysis Times. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,2,2,1 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27793534&form=6&db=m Plasmin (Human) Administration in Acute Middle Cerebral Artery Ischemic Stroke: Phase 1/2a, Open-Label, Dose-Escalation, Safety Study. causal interaction,therapeutic application,unassigned 2,4,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28487333&form=6&db=m Enhanced Detection of Edema in Malignant Anterior Circulation Stroke (EDEMA) Score: A Risk Prediction Tool. diagnostic usage,ongoing research,therapeutic application,unassigned 1,1,1,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28487338&form=6&db=m Poststroke Sonic Hedgehog Agonist Treatment Improves Functional Recovery by Enhancing Neurogenesis and Angiogenesis. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28535201&form=6&db=m Regulatory T cells ameliorate tissue plasminogen activator-induced brain haemorrhage after stroke. causal interaction,ongoing research,therapeutic application,unassigned 4,3,4,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28546326&form=6&db=m Regional Pediatric Acute Stroke Protocol: Initial Experience During 3 Years and 13 Recanalization Treatments in Children. therapeutic application,unassigned 3,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28612680&form=6&db=m Benefits of stroke treatment delivered using a mobile stroke unit trial. causal interaction,ongoing research,therapeutic application,unassigned 3,2,2,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28872451&form=6&db=m Incidence of seizure in stroke patients treated with recombinant tissue plasminogen activator: A systematic review and meta-analysis. causal interaction,ongoing research,therapeutic application,unassigned 4,4,4,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28894887&form=6&db=m [Endovascular thrombectomy for ischemic stroke]. causal interaction,therapeutic application,unassigned 2,4,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28973661&form=6&db=m Cerebral Ischemic Reperfusion Injury Following Recanalization of Large Vessel Occlusions. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29212747&form=6&db=m Primary Thrombectomy in tPA (Tissue-Type Plasminogen Activator) Eligible Stroke Patients With Proximal Intracranial Occlusions. diagnostic usage,unassigned 2,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29440586&form=6&db=m National Practice Patterns of Obtaining Informed Consent for Stroke Thrombolysis. therapeutic application,unassigned 3,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29686025&form=6&db=m Shorter Intensive Care Unit Stays? The Majority of Post-Intravenous tPA (Tissue-Type Plasminogen Activator) Symptomatic Hemorrhages Occur Within 12 Hours of Treatment. causal interaction,diagnostic usage,therapeutic application,unassigned 3,1,4,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29720439&form=6&db=m Time to Decision and Treatment With tPA (Tissue-Type Plasminogen Activator) Using Telemedicine Versus an Onboard Neurologist on a Mobile Stroke Unit. therapeutic application,unassigned 4,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29911837&form=6&db=m Effects of Stroke Unit Care in Acute Ischemic Stroke Patient Ineligible for Thrombolytic Treatment. therapeutic application,unassigned 4,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30018160&form=6&db=m Iron Overload Exacerbates the Risk of Hemorrhagic Transformation After tPA (Tissue-Type Plasminogen Activator) Administration in Thromboembolic Stroke Mice. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,3,4 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30107224&form=6&db=m Using the behavioral flexibility operant task to detect long-term deficits in rats following middle cerebral artery occlusion. causal interaction,therapeutic application,unassigned 3,3,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30245570&form=6&db=m Functional Outcome Measures of Recombinant Tissue Plasminogen Activator-Treated Stroke Patients in the Telestroke Technology. ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30354551&form=6&db=m Rates, Characteristics, and Outcomes of Patients Transferred to Specialized Stroke Centers for Advanced Care. diagnostic usage,therapeutic application,unassigned 1,1,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30354981&form=6&db=m Intravenous tPA (Tissue-Type Plasminogen Activator) in Patients With Acute Ischemic Stroke Taking Non-Vitamin K Antagonist Oral Anticoagulants Preceding Stroke. causal interaction,ongoing research,therapeutic application,unassigned 3,3,3,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30507392&form=6&db=m The role of plasminogen activators in stroke treatment: fibrinolysis and beyond. therapeutic application,unassigned 4,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30580729&form=6&db=m Emergent Management of Tandem Lesions in Acute Ischemic Stroke. unassigned - 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30726185&form=6&db=m Real-World Treatment Trends in Endovascular Stroke Therapy. diagnostic usage,therapeutic application,unassigned 2,1,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30791829&form=6&db=m Intraarterial Thrombolysis as Rescue Therapy for Large Vessel Occlusions. ongoing research,therapeutic application,unassigned 1,3,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30909835&form=6&db=m Fn-EDA (Fibronectin Containing Extra Domain A) in the Plasma, but Not Endothelial Cells, Exacerbates Stroke Outcome by Promoting Thrombo-Inflammation. ongoing research,therapeutic application,unassigned 1,1,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31084331&form=6&db=m Ethnic Differences in 90-Day Poststroke Medication Adherence. therapeutic application,unassigned 2,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31092163&form=6&db=m Nurse-Initiated Acute Stroke Care in Emergency Departments. causal interaction,therapeutic application,unassigned 1,3,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31238832&form=6&db=m Frequency of Blood-Brain Barrier Disruption Post-Endovascular Therapy and Multiple Thrombectomy Passes in Acute Ischemic Stroke Patients. diagnostic usage,ongoing research,therapeutic application,unassigned 1,2,3,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31294948&form=6&db=m Calculated Decisions: tPA (Tissue Plasminogen Activator) Dosing for Stroke Calculator diagnostic usage,therapeutic application,unassigned 2,2,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31311465&form=6&db=m Magnitude of Benefit of Combined Endovascular Thrombectomy and Intravenous Fibrinolysis in Large Vessel Occlusion Ischemic Stroke. diagnostic usage,ongoing research,therapeutic application,unassigned 2,3,2,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31387512&form=6&db=m N-Acetyl-Seryl-Aspartyl-Lysyl-Proline Augments Thrombolysis of tPA (Tissue-Type Plasminogen Activator) in Aged Rats After Stroke. causal interaction,ongoing research,therapeutic application,unassigned 2,4,4,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31412730&form=6&db=m Intravenous Tissue Plasminogen Activator in Stroke Mimics. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,2,4 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31546842&form=6&db=m Targeted Delivery of Plasminogen Activators for Thrombolytic Therapy: An Integrative Evaluation. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31570086&form=6&db=m One-Year Home-Time and Mortality After Thrombolysis Compared With Nontreated Patients in a Propensity-Matched Analysis. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,2,4,2 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31756041&form=6&db=m Rosiglitazone ameliorates tissue plasminogen activator-induced brain hemorrhage after stroke. causal interaction,ongoing research,therapeutic application,unassigned 4,1,4,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31801934&form=6&db=m Guidelines for Intravenous Thrombolysis (Recombinant Tissue-type Plasminogen Activator), the Third Edition, March 2019: A Guideline from the Japan Stroke Society. therapeutic application,unassigned 2,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31842706&form=6&db=m Risk of Intracranial Hemorrhage Following Intravenous tPA (Tissue-Type Plasminogen Activator) for Acute Stroke Is Low in Children. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,1,1,4 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31904386&form=6&db=m Cuprizone-induced demyelination under physiological and post-stroke condition leads to decreased neurogenesis response in adult mouse brain. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31986113&form=6&db=m Correction to: Risk of Intracranial Hemorrhage Following Intravenous tPA (Tissue-Type Plasminogen Activator) for Acute Stroke Is Low in Children. diagnostic usage,therapeutic application,unassigned 1,3,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31987015&form=6&db=m Increased Access to and Use of Endovascular Therapy Following Implementation of a 2-Tiered Regional Stroke System. ongoing research,unassigned 3,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32147438&form=6&db=m Human neural stem cells improve early stage stroke outcome in delayed tissue plasminogen activator-treated aged stroke brains. causal interaction,ongoing research,therapeutic application,unassigned 4,3,4,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32757749&form=6&db=m Risk of Distal Embolization From tPA (Tissue-Type Plasminogen Activator) Administration Prior to Endovascular Stroke Treatment. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32772682&form=6&db=m Incidence and Association of Reperfusion Therapies With Poststroke Seizures: A Systematic Review and Meta-Analysis. ongoing research,therapeutic application,unassigned 2,2,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32878563&form=6&db=m Impact of Initial Imaging Protocol on Likelihood of Endovascular Stroke Therapy. diagnostic usage,therapeutic application,unassigned 2,1,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32963914&form=6&db=m Catheter-Directed Thrombectomy for Pulmonary Embolism in the Setting of Acute Stroke. unassigned - 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33224099&form=6&db=m Plasmin Generation Potential and Recanalization in Acute Ischaemic Stroke; an Observational Cohort Study of Stroke Biobank Samples. diagnostic usage,ongoing research,therapeutic application,unassigned 3,3,3,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33280550&form=6&db=m Early Infarct Growth Rate Correlation With Endovascular Thrombectomy Clinical Outcomes: Analysis From the SELECT Study. unassigned - 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33296953&form=6&db=m Increased brain plasmin levels following experimental ischemic stroke in male mice. causal interaction,ongoing research,therapeutic application,unassigned 4,2,4,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33370177&form=6&db=m Letter by Katsanos and Tsivgoulis Regarding Article, "Risk of Distal Embolization From tPA (Tissue-Type Plasminogen Activator) Administration Prior to Endovascular Stroke Treatment". unassigned - 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33370181&form=6&db=m Letter by Tan and Xu Regarding Article, "Risk of Distal Embolization From tPA (Tissue-Type Plasminogen Activator) Administration Prior to Endovascular Stroke Treatment". unassigned - 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33370202&form=6&db=m Response by Flint et al to Letter Regarding Article, "Risk of Distal Embolization From tPA (Tissue-Type Plasminogen Activator) Administration Prior to Endovascular Stroke Treatment". therapeutic application,unassigned 1,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33424615&form=6&db=m The Protective Role of Immunomodulators on Tissue-Type Plasminogen Activator-Induced Hemorrhagic Transformation in Experimental Stroke: A Systematic Review and Meta-Analysis. causal interaction,ongoing research,therapeutic application,unassigned 3,2,4,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33794952&form=6&db=m A step toward understanding the mechanism of action of audit and feedback: a qualitative study of implementation strategies. ongoing research,unassigned 2,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33853408&form=6&db=m Plasminogen deficiency causes reduced angiogenesis and behavioral recovery after stroke in mice. causal interaction,ongoing research,therapeutic application,unassigned 4,4,2,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33955867&form=6&db=m Puerperium Stroke and Subsequent Tissue-Type Plasminogen Activator-Induced Hemorrhage: A Case Report. causal interaction,therapeutic application,unassigned 1,3,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34124808&form=6&db=m Human placenta mesenchymal stem cell protection in ischemic stroke is angiotensin converting enzyme-2 and masR receptor-dependent. causal interaction,ongoing research,therapeutic application,unassigned 3,3,2,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34390472&form=6&db=m The emerging role of mechanical and topographical factors in the development and treatment of nervous system disorders: dark and light sides of the force. therapeutic application,unassigned 4,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34442198&form=6&db=m "Hesitating and Puzzling": The Experiences and Decision Process of Acute Ischemic Stroke Patients with Prehospital Delay after the Onset of Symptoms. therapeutic application,unassigned 3,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34507125&form=6&db=m The evaluation of intracranial pressure evaluation by optic nerve sheath diameter measurement on bedside ultrasonography after ischemic stroke. diagnostic usage,unassigned 4,0 3.4.21.7 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34527475&form=6&db=m Management of Pediatric Strokes With Alteplase (Tissue Plasminogen Activator). therapeutic application,unassigned 1,0 3.4.21.7 Stroke, Lacunar http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19844099&form=6&db=m Hemostatic Factors and Subclinical Brain Infarction in a Community-Based Sample: The ARIC Study. unassigned - 3.4.21.7 Subarachnoid Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1834876&form=6&db=m [Correlations among FPB beta 15-42, PAC and D-dimer] causal interaction,diagnostic usage,ongoing research,unassigned 1,2,2,0 3.4.21.7 Subarachnoid Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1905429&form=6&db=m Effect of tissue plasminogen activator on intimal platelet accumulation in cerebral arteries after subarachnoid hemorrhage in cats. diagnostic usage,ongoing research,therapeutic application,unassigned 1,4,3,0 3.4.21.7 Subarachnoid Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2507953&form=6&db=m Efficacy of single intracisternal bolus injection of recombinant tissue plasminogen activator to prevent delayed cerebral vasospasm after experimental subarachnoid hemorrhage. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,1,2,4 3.4.21.7 Subarachnoid Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2620588&form=6&db=m [Observation of plasma levels of antithrombin-III and plasminogen in acute cerebrovascular disease] causal interaction,diagnostic usage,ongoing research,unassigned 2,3,2,0 3.4.21.7 Subarachnoid Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2944029&form=6&db=m Modification of experimental post-subarachnoid hemorrhage vasculopathy with intracisternal plasmin. ongoing research,therapeutic application,unassigned 2,3,0 3.4.21.7 Subarachnoid Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2976126&form=6&db=m Modification of experimental post-subarachnoid hemorrhage vasculopathy with intracisternal plasmin. ongoing research,therapeutic application,unassigned 4,2,0 3.4.21.7 Subarachnoid Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3897478&form=6&db=m Source of fibrin/fibrinogen degradation products in the CSF after subarachnoid hemorrhage. diagnostic usage,unassigned 2,0 3.4.21.7 Subarachnoid Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8875453&form=6&db=m Thrombolytic therapy with tissue plasminogen activator for prevention of vasospasm in experimental subarachnoid hemorrhage: its efficacy and problems. ongoing research,therapeutic application,unassigned 4,4,0 3.4.21.7 Subarachnoid Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19057314&form=6&db=m Treatment of cerebral vasospasm with biocompatible controlled-release systems for intracranial drug delivery. ongoing research,therapeutic application,unassigned 1,2,0 3.4.21.7 Subarachnoid Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32594031&form=6&db=m Using antifibrinolytics to tackle neuroinflammation. causal interaction,therapeutic application,unassigned 3,3,0 3.4.21.7 Superior Vena Cava Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1734155&form=6&db=m [Iatrogenic superior vena cava syndrome. Successful thrombolysis with recombinant tissue plasminogen activator (r-tPA)] therapeutic application,unassigned 2,0 3.4.21.7 Suppuration http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1380586&form=6&db=m [Several components of plasma hemostasis in patients with suppurative processes in the abdominal cavity] causal interaction,diagnostic usage,unassigned 1,2,0 3.4.21.7 Surgical Wound Infection http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25179235&form=6&db=m Hyperglycemia is associated with lower levels of urokinase-type plasminogen activator and urokinase-type plasminogen activator receptor in wound fluid. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,2,2,1 3.4.21.7 Surgical Wound Infection http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34065949&form=6&db=m Plasmin, Immunity, and Surgical Site Infection. diagnostic usage,unassigned 1,0 3.4.21.7 Syncope http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24436623&form=6&db=m A Rare Case of Acute Pulmonary Embolism after Coronary Angiography due to Sand Bag Compression. ongoing research,unassigned 1,0 3.4.21.7 Synovitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1411581&form=6&db=m Collagenase in synovitis of rheumatoid arthritis. causal interaction,ongoing research,therapeutic application,unassigned 3,2,1,0 3.4.21.7 Synovitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11518356&form=6&db=m Activities of plasminogen activator, plasmin and kallikrein in synovial fluid from patients with temporomandibular joint disorders. causal interaction,unassigned 3,0 3.4.21.7 Syphilis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8313495&form=6&db=m Syphilis-associated perinatal and infant mortality in rural Malawi. causal interaction,diagnostic usage,therapeutic application,unassigned 2,1,1,0 3.4.21.7 Syphilis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9042134&form=6&db=m The resurgence of congenital syphilis: a cocaine-related problem. diagnostic usage,therapeutic application,unassigned 2,1,0 3.4.21.7 Syphilis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16177249&form=6&db=m Single-dose azithromycin versus penicillin G benzathine for the treatment of early syphilis. ongoing research,therapeutic application,unassigned 1,1,0 3.4.21.7 Syphilis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16505739&form=6&db=m Syphilis and Human Immunodeficiency Virus (HIV)-1 Coinfection: Influence on CD4 T-Cell Count, HIV-1 Viral Load, and Treatment Response. ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.7 Syphilis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25583097&form=6&db=m Integration of antenatal syphilis screening in an urban HIV clinic: a feasibility study. diagnostic usage,ongoing research,therapeutic application,unassigned 2,1,1,0 3.4.21.7 Syphilis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26185887&form=6&db=m Early syphilitic hepatitis concomitant with nephrotic syndrome followed by acute kidney injury. causal interaction,diagnostic usage,unassigned 2,3,0 3.4.21.7 Syphilis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27429702&form=6&db=m Don't Forget What You Can't See: A Case of Ocular Syphilis. diagnostic usage,therapeutic application,unassigned 2,1,0 3.4.21.7 Syphilis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28703722&form=6&db=m The Number of Interviews Needed to Yield New Syphilis and Human Immunodeficiency Virus Cases Among Partners of People Diagnosed With Syphilis, North Carolina, 2015. unassigned - 3.4.21.7 Syphilis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31204869&form=6&db=m Single Mothers and Female Sex Workers in Zambia Have Similar Risk Profiles. unassigned - 3.4.21.7 Syphilis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32687780&form=6&db=m Utility of rapid plasmin reagin titres in assessing treatment response and re-infection for infectious syphilis. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.7 Syphilis, Congenital http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9042134&form=6&db=m The resurgence of congenital syphilis: a cocaine-related problem. diagnostic usage,therapeutic application,unassigned 2,1,0 3.4.21.7 t-plasminogen activator deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7781275&form=6&db=m Blood protein defects associated with thrombosis. Laboratory assessment. causal interaction,unassigned 3,0 3.4.21.7 t-plasminogen activator deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8059229&form=6&db=m Syndromes of hypercoagulability and thrombosis: a review. causal interaction,therapeutic application,unassigned 4,2,0 3.4.21.7 t-plasminogen activator deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9048471&form=6&db=m The surgical implications of primary hypercoagulable states. diagnostic usage,therapeutic application,unassigned 1,1,0 3.4.21.7 t-plasminogen activator deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10358455&form=6&db=m [Thrombophilic states] causal interaction,therapeutic application,unassigned 4,2,0 3.4.21.7 t-plasminogen activator deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10816379&form=6&db=m Role of the pleiotropic effects of plasminogen deficiency in infection experiments with plasminogen-deficient mice. causal interaction,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.7 t-plasminogen activator deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12421144&form=6&db=m Plasminogen and tissue-type plasminogen activator deficiency as risk factors for thromboembolic disease. causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,2,0 3.4.21.7 t-plasminogen activator deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15522965&form=6&db=m Tissue plasminogen activator promotes the effects of corticotropin-releasing factor on the amygdala and anxiety-like behavior. causal interaction,ongoing research,unassigned 1,2,0 3.4.21.7 t-plasminogen activator deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17183975&form=6&db=m Haematologic disorders and cerebral venous thrombosis. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,2,0 3.4.21.7 Takotsubo Cardiomyopathy http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30546622&form=6&db=m Successful treatment of cerebral emboli with tissue plasminogen activator in a patient with takotsubo cardiomyopathy: A case report. causal interaction,ongoing research,therapeutic application,unassigned 4,2,4,0 3.4.21.7 Telangiectasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=69566&form=6&db=m [A case of Osler-Rendu disease with simultaneous thrombopenia and a factor VIII inhibitor] unassigned - 3.4.21.7 Temporomandibular Joint Disorders http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11518356&form=6&db=m Activities of plasminogen activator, plasmin and kallikrein in synovial fluid from patients with temporomandibular joint disorders. causal interaction,unassigned 3,0 3.4.21.7 Tetanus http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=855252&form=6&db=m Effect of fragmentation of tetanus immune globulin (human) on neutralization of tetanus toxin. ongoing research,unassigned 2,0 3.4.21.7 Tetanus http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8955948&form=6&db=m Possible involvement of plasmin in long-term potentiation of rat hippocampal slices. unassigned - 3.4.21.7 Thrombasthenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2941084&form=6&db=m Activation of plasminogen by tissue plasminogen activator on normal and thrombasthenic platelets: effects on surface proteins and platelet aggregation. unassigned - 3.4.21.7 Thrombasthenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3086385&form=6&db=m Plasminogen interacts with human platelets through two distinct mechanisms. unassigned - 3.4.21.7 Thromboangiitis Obliterans http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1412199&form=6&db=m Plasminogen activators and plasminogen activator inhibitor 1 before and after venous occlusion of the upper limb in thromboangiitis obliterans (Buerger's disease). diagnostic usage,ongoing research,therapeutic application,unassigned 3,4,4,0 3.4.21.7 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=69566&form=6&db=m [A case of Osler-Rendu disease with simultaneous thrombopenia and a factor VIII inhibitor] unassigned - 3.4.21.7 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=327128&form=6&db=m Occurrence of disseminated intravascular coagulation (DIC) in obstructive jaundice and its relation to biliary tract infection. diagnostic usage,therapeutic application,unassigned 1,1,0 3.4.21.7 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1601644&form=6&db=m Massive pulmonary embolism presenting as disseminated intravascular coagulation. causal interaction,diagnostic usage,unassigned 1,2,0 3.4.21.7 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2754223&form=6&db=m Giant hemangioma of the liver (Kasabach-Merritt syndrome): successful suppression of intravascular coagulation permitting surgical removal. unassigned - 3.4.21.7 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6230118&form=6&db=m Fibrinogen proteolysis and platelet alpha-granule release in preeclampsia/eclampsia. causal interaction,diagnostic usage,unassigned 3,3,0 3.4.21.7 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6482318&form=6&db=m [Thrombocyte function and plasma coagulation following poisoning with organophosphates] diagnostic usage,unassigned 3,0 3.4.21.7 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7081721&form=6&db=m Haemostatic changes during open heart surgery with extracorporeal circulation and deep hypothermia in children. causal interaction,unassigned 3,0 3.4.21.7 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7963733&form=6&db=m Correlation between detection of plasminogen cross-reactive antibodies and hemorrhage in dengue virus infection. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,2,1 3.4.21.7 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8332397&form=6&db=m [Disorders of hemostasis in dysthyroidism] causal interaction,diagnostic usage,unassigned 4,2,0 3.4.21.7 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10190291&form=6&db=m Plasminogen activation in human leukemia and in normal hematopoietic cells. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,1 3.4.21.7 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10385508&form=6&db=m Urokinase receptor (uPAR, CD87) is a platelet receptor important for kinetics and TNF-induced endothelial adhesion in mice. therapeutic application,unassigned 3,0 3.4.21.7 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10858190&form=6&db=m Delayed mortality and attenuated thrombocytopenia associated with severe malaria in urokinase- and urokinase receptor-deficient mice. causal interaction,ongoing research,therapeutic application,unassigned 3,2,2,0 3.4.21.7 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19691693&form=6&db=m Hemostatic consequences of a non-fresh or reconstituted whole blood small volume cardiopulmonary bypass prime in neonates and infants. causal interaction,unassigned 1,0 3.4.21.7 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25673638&form=6&db=m Endogenous plasminogen activators mediate progressive intracranial hemorrhage after traumatic brain injury. causal interaction,ongoing research,unassigned 2,2,0 3.4.21.7 Thrombocytosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9620893&form=6&db=m POEMS syndrome with vascular lesions and renal carcinoma - possible role of cytokines. therapeutic application,unassigned 1,0 3.4.21.7 Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1836241&form=6&db=m [Concentration of thrombin antithrombin III complex and plasmin alpha 2-plasmin inhibitor complex in nephrotic syndrome] diagnostic usage,ongoing research,therapeutic application,unassigned 3,1,2,0 3.4.21.7 Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2098299&form=6&db=m Thrombotic complications during L-asparaginase treatment for acute lymphocytic leukemia. causal interaction,ongoing research,therapeutic application,unassigned 3,3,4,0 3.4.21.7 Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3388298&form=6&db=m Congenital deficiency of plasminogen and its relationship to venous thrombosis. causal interaction,diagnostic usage,unassigned 4,1,0 3.4.21.7 Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4223830&form=6&db=m [Problems of the early diagnosis and treatment of thromboembolism of the pulmonary artery. Results of the use of fibrinolysin] causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,4,0 3.4.21.7 Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4231520&form=6&db=m [Treatment of thromboembolism of the aortic bifurcation with fibrinolysin and heparin] causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.7 Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4246661&form=6&db=m [Fibrinolysin therapy of thromboembolism of the major vessles] causal interaction,therapeutic application,unassigned 2,4,0 3.4.21.7 Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4271811&form=6&db=m [Healing of a patient with thromboembolism of the bifurcation of the aorta with a mixture of fibrinolysin and heparin] therapeutic application,unassigned 2,0 3.4.21.7 Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4274345&form=6&db=m Acute femoral arterial thromboembolism. Successful treatment with fibrinolysin. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7589679&form=6&db=m Characteristics of blood hemostatic markers in a patient with ovarian hyperstimulation syndrome who actually developed thromboembolism. therapeutic application,unassigned 1,0 3.4.21.7 Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9449701&form=6&db=m Activated human protein C prevents thrombin-induced thromboembolism in mice. Evidence that activated protein c reduces intravascular fibrin accumulation through the inhibition of additional thrombin generation. ongoing research,therapeutic application,unassigned 1,4,0 3.4.21.7 Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10540842&form=6&db=m [Pulmonary thromboembolism accompanied by abnormal plasminogen] causal interaction,diagnostic usage,unassigned 4,3,0 3.4.21.7 Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=13563166&form=6&db=m Thrombolysis with fibrinolysin (plasmin)-new therapeutic approach to thromboembolism. therapeutic application,unassigned 4,0 3.4.21.7 Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=13984149&form=6&db=m Perfusion with fibrinolysin in experimental iliofemoral thromboembolism. therapeutic application,unassigned 1,0 3.4.21.7 Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14079953&form=6&db=m THERAPEUTIC THROMBOLYSIS IN CEREBRAL THROMBOEMBOLISM. DOUBLE-BLIND EVALUATION OF INTRAVENOUS PLASMIN THERAPY IN CAROTID AND MIDDLE CEREBRAL ARTERIAL OCCLUSION. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14121282&form=6&db=m FIBRINOLYSIN TREATMENT OF THROMBOEMBOLISM. therapeutic application,unassigned 4,0 3.4.21.7 Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14229526&form=6&db=m LYSIS OF INTRACEREBRAL THROMBOEMBOLISM WITH FIBRINOLYSIN. REPORT OF A CASE. causal interaction,therapeutic application,unassigned 2,1,0 3.4.21.7 Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14570069&form=6&db=m [A 50-year history of new drugs in Japan-the development and trends of hemostatics and antithrombotic drugs] diagnostic usage,therapeutic application,unassigned 3,3,0 3.4.21.7 Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19214913&form=6&db=m Pathogenesis of venous thromboembolism: when the cup runneth over. therapeutic application,unassigned 1,0 3.4.21.7 Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27319402&form=6&db=m Physiologic variations in blood plasminogen levels affect outcomes after acute cerebral thromboembolism in mice: a pathophysiologic role for microvascular thrombosis. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,1,4,3 3.4.21.7 Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31546842&form=6&db=m Targeted Delivery of Plasminogen Activators for Thrombolytic Therapy: An Integrative Evaluation. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.7 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1452521&form=6&db=m Hypercoagulability and thrombosis. causal interaction,unassigned 1,0 3.4.21.7 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1485283&form=6&db=m [Evaluating the origin of thrombophilia: indications and implementation] causal interaction,unassigned 4,0 3.4.21.7 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1554698&form=6&db=m Multiple members of the plasminogen-apolipoprotein(a) gene family associated with thrombosis. causal interaction,unassigned 4,0 3.4.21.7 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1641818&form=6&db=m Hematological causes of venous thrombosis in young people: high incidence of myeloproliferative disorder as underlying disease in patients with splanchnic venous thrombosis. causal interaction,diagnostic usage,unassigned 4,1,0 3.4.21.7 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3116699&form=6&db=m Laboratory screening of inherited thrombotic syndromes. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.7 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6083913&form=6&db=m [Immunoradiometric determination of blood/tissue plasminogen activators in thrombophilia] diagnostic usage,therapeutic application,unassigned 2,1,0 3.4.21.7 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6185501&form=6&db=m Late changes in hemostatic parameters following open-heart surgery. unassigned - 3.4.21.7 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6208389&form=6&db=m Abnormal plasminogen: a genetically determined cause of hypercoagulability. causal interaction,unassigned 3,0 3.4.21.7 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6678359&form=6&db=m Blood coagulation studies in domestic pigs (Hanover breed) and minipigs (Goettingen breed). causal interaction,unassigned 2,0 3.4.21.7 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7250787&form=6&db=m Natural inhibitors and fibrinogen/fibrin degradation products in patients with myocardial infarction. diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.7 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7514043&form=6&db=m Antithrombin III infusion suppresses the hypercoagulable state in adult acute lymphoblastic leukaemia patients treated with a low dose of Escherichia coli L-asparaginase. A GIMEMA study. diagnostic usage,unassigned 1,0 3.4.21.7 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7522017&form=6&db=m Is there a phase of hypercoagulability when aprotinin is used in cardiac surgery? causal interaction,diagnostic usage,therapeutic application,unassigned 3,3,2,0 3.4.21.7 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8066262&form=6&db=m [Comparison of urokinase and tissue-type plasminogen activator in transcatheter arterial fibrinolysis] diagnostic usage,ongoing research,therapeutic application,unassigned 1,2,2,0 3.4.21.7 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8089219&form=6&db=m Markers of thrombin and plasmin generation in patients with inherited thrombophilia. causal interaction,diagnostic usage,ongoing research,unassigned 3,4,1,0 3.4.21.7 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8429723&form=6&db=m [Pregnancy and thrombophilia in women with congenital deficit of antithrombin III, protein C, protein S or plasminogen: analysis of 39 cases] unassigned - 3.4.21.7 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8522567&form=6&db=m Hemostatic disorders associated with arterial hypertension and peripheral arterial disease. diagnostic usage,ongoing research,unassigned 4,4,0 3.4.21.7 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8636415&form=6&db=m The relationship between the fibrinogen D domain self-association/cross-linking site (gammaXL) and the fibrinogen Dusart abnormality (Aalpha R554C-albumin): clues to thrombophilia in the "Dusart syndrome". causal interaction,unassigned 1,0 3.4.21.7 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9134831&form=6&db=m [A coagulation of fibrinolytic study in children with nephrotic syndrome: evaluation of hypercoagulability by measuring with plasmin- alpha 2 plasmin inhibitor complex and FDP D-dimer] therapeutic application,unassigned 3,0 3.4.21.7 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9306585&form=6&db=m Sclerotherapy for varicose veins of the lower legs in patients with dysplasminogenemia. ongoing research,unassigned 3,0 3.4.21.7 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9396341&form=6&db=m [Etiological analysis of thrombophilia] causal interaction,ongoing research,therapeutic application,unassigned 1,1,1,0 3.4.21.7 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9409444&form=6&db=m Thrombophilia found in patients with moyamoya disease. causal interaction,diagnostic usage,unassigned 2,2,0 3.4.21.7 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9422123&form=6&db=m Protocol and preliminary results of a clinical study for comparison of solvent/detergent-inactivated plasma VIP versus FFP with special consideration of the balance of hemostasis. therapeutic application,unassigned 1,0 3.4.21.7 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9630308&form=6&db=m Degree of hypercoagulability and hyperfibrinolysis is related to organ failure and prognosis after burn trauma. diagnostic usage,unassigned 1,0 3.4.21.7 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10650845&form=6&db=m Multicentre evaluation of combined prothrombotic defects associated with thrombophilia in childhood. Childhood Thrombophilia Study Group. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,2,0 3.4.21.7 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10652759&form=6&db=m [Diagnosis and treatment of coagulation disorders] causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.7 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10706928&form=6&db=m Common C677T polymorphism in the methylenetetrahydrofolate reductase gene increases the risk for deep vein thrombosis in patients with predisposition of thrombophilia. causal interaction,diagnostic usage,therapeutic application,unassigned 3,2,1,0 3.4.21.7 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10726026&form=6&db=m Familial association of hypoplasminogenemia and heterozygous factor V deficiency. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,1,0 3.4.21.7 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10726047&form=6&db=m Combined heterozygous plasminogen deficiency and factor V Leiden defect in the same kindred. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.7 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10878927&form=6&db=m [A method for determining plasminogen with a Russian chromogenic substrate and its diagnostic significance] diagnostic usage,unassigned 2,0 3.4.21.7 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10973671&form=6&db=m Is veno-occlusive disease a specific syndrome or the exacerbation of physiopathologic hemostatic changes in hematopoietic stem cell transplantation (HSCT)? unassigned - 3.4.21.7 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10973672&form=6&db=m Protein C and protein S deficiencies are the most important risk factors associated with thrombosis in Chinese venous thrombophilic patients in Taiwan. diagnostic usage,ongoing research,unassigned 4,2,0 3.4.21.7 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11307310&form=6&db=m [Genetic polymorphism and risk of thromboses] causal interaction,diagnostic usage,ongoing research,therapeutic application 3,2,1,1 3.4.21.7 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12421144&form=6&db=m Plasminogen and tissue-type plasminogen activator deficiency as risk factors for thromboembolic disease. causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,2,0 3.4.21.7 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=13946415&form=6&db=m Effect of endotoxin on clotting mechanism. III. On the relationship between hypercoagulability, plasminogen activator activity, and antithrombin activity. diagnostic usage,ongoing research,unassigned 2,3,0 3.4.21.7 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15532303&form=6&db=m Disturbances of the coagulating equilibrium of blood in diabetes mellitus. diagnostic usage,unassigned 3,0 3.4.21.7 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20199198&form=6&db=m Migraine associated with patent foramen ovale may be caused by reactivation of cerebral toxoplasmosis triggered by arterial blood oxygen desaturation. causal interaction,therapeutic application,unassigned 2,1,0 3.4.21.7 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22961244&form=6&db=m Arterial thrombosis in homozygous antithrombin deficiency. diagnostic usage,unassigned 2,0 3.4.21.7 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23772166&form=6&db=m A case of acute pulmonary embolism associated with dysplasminogenemia. causal interaction,unassigned 1,0 3.4.21.7 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26315791&form=6&db=m Risk Factors for Thrombosis Development in Mexican Patients. diagnostic usage,unassigned 2,0 3.4.21.7 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27314862&form=6&db=m A protein C and plasminogen compound heterozygous mutation and a compound heterozygote of protein C in two related Chinese families. causal interaction,unassigned 4,0 3.4.21.7 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27712638&form=6&db=m Calciphylaxis: A Disease of Pannicular Thrombosis. causal interaction,unassigned 4,0 3.4.21.7 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29201071&form=6&db=m Hemostasis in Overt and Subclinical Hyperthyroidism. unassigned - 3.4.21.7 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29206934&form=6&db=m Enzymatic Functional Assays of Coagulation Using Small Sample Volumes. diagnostic usage,ongoing research,unassigned 2,2,0 3.4.21.7 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32886527&form=6&db=m Changes in Biomarkers of Coagulation, Fibrinolytic, and Endothelial Functions for Evaluating the Predisposition to Venous Thromboembolism in Patients With Hereditary Thrombophilia. diagnostic usage,ongoing research,therapeutic application,unassigned 1,2,1,0 3.4.21.7 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33275705&form=6&db=m "TEG talk": expanding clinical roles for thromboelastography and rotational thromboelastometry. causal interaction,unassigned 1,0 3.4.21.7 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33320874&form=6&db=m Coagulation profile of COVID-19 patients admitted to the ICU: An exploratory study. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.7 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33345424&form=6&db=m Trimester-specific reference intervals of TAT, TM, tPAI-C and PIC for healthy Chinese pregnant women. ongoing research,unassigned 2,0 3.4.21.7 Thrombophlebitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2965086&form=6&db=m Congenital abnormal plasminogen, Frankfurt I, a cause for recurrent venous thrombosis. causal interaction,unassigned 3,0 3.4.21.7 Thrombophlebitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4236539&form=6&db=m [Acute thrombophlebitis and its treatment with fibrinolysin and anticoagulants] causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.7 Thrombophlebitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4238463&form=6&db=m [The use of fibrinolysin and heparin in the treatment of acute thrombophlebitis, thrombosis and embolism] therapeutic application,unassigned 4,0 3.4.21.7 Thrombophlebitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8292717&form=6&db=m The mutation in fibrinogen BicĂŞtre II (gamma Asn308-->Lys) does not affect the binding of t-PA and plasminogen to fibrin. ongoing research,unassigned 4,0 3.4.21.7 Thrombophlebitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9544982&form=6&db=m Low risk of venous thrombosis in two families with combined type I plasminogen deficiency and factor V R506Q mutation. causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,1,0 3.4.21.7 Thrombophlebitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10429385&form=6&db=m [The influence of the intra-tissue electrical phonophoresis on the hemostasis system in the treatment of acute thrombophlebitis and phlebothrombosis] therapeutic application,unassigned 1,0 3.4.21.7 Thrombophlebitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=13976284&form=6&db=m Fibrinolysin therapy of thrombophlebitis and pulmonary embolism--a double-blind study. ongoing research,therapeutic application,unassigned 1,4,0 3.4.21.7 Thrombophlebitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14424537&form=6&db=m Fibrinolysin (plasmin) therapy in acute deep thrombophlebitis. A controlled study. ongoing research,therapeutic application,unassigned 1,4,0 3.4.21.7 Thrombophlebitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20327660&form=6&db=m Fibrinolysin Therapy of Thrombophlebitis and Pulmonary Embolism. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 Thrombophlebitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20327661&form=6&db=m Fibrinolysin Therapy of Thrombophlebitis and Pulmonary Embolism. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=62411&form=6&db=m Plasmin inactivation in plasma. causal interaction,diagnostic usage,therapeutic application,unassigned 1,2,3,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=139418&form=6&db=m Thrombolysis of palmar and digital arterial thrombosis by intra-arterial Thrombolysin. causal interaction,ongoing research,therapeutic application,unassigned 2,1,2,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=149047&form=6&db=m Determination of fast-acting plasmin inhibitor (alpha2-antiplasmin) in plasma from patients with tendency to thrombosis and increased fibrinolysis. causal interaction,diagnostic usage,unassigned 1,2,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=150065&form=6&db=m Experimental study of biosoluble drugs. Thrombus lysis with biosoluble immobilized fibrinolysin in experiment. ongoing research,therapeutic application,unassigned 1,3,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=151804&form=6&db=m The human plasma fibrinolytic system: regulation and control. therapeutic application,unassigned 1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=153004&form=6&db=m Our fibrinolytic potential. diagnostic usage,ongoing research,therapeutic application,unassigned 3,1,1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=422823&form=6&db=m Prevention of femoral vein occlusion by local injection of Thrombolysin in the rat. diagnostic usage,unassigned 3,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=517175&form=6&db=m Spontaneous thrombosis of ruptured intracranial aneurysms during treatment with tranexamic acid (AMCA). Report of three cases. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=659588&form=6&db=m Abnormal plasminogen. A hereditary molecular abnormality found in a patient with recurrent thrombosis. causal interaction,unassigned 3,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=830827&form=6&db=m Radioiodinated plasminogen: an imaging agent for pre-existing thrombi. causal interaction,unassigned 1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=845477&form=6&db=m Fibrin formation and dissolution in women receiving oral contraceptive drugs. causal interaction,unassigned 2,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=906903&form=6&db=m Non-penetrating trauma to the carotid artery with secondary thrombosis and embolism: treatment by thrombolysin. therapeutic application,unassigned 4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1223354&form=6&db=m [Physiopathological shifts in the blood coagulation system in embolism of major arteries of the limbs] therapeutic application,unassigned 1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1290642&form=6&db=m [Formation of left ventricular thrombus in acute myocardial infarction: significance of the determination of fibrinogen, of products of fibrinogen degradation, and of plasminogen] diagnostic usage,ongoing research,unassigned 4,2,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1309041&form=6&db=m Fibrin, lipoprotein(a), plasmin interactions: a model linking thrombosis and atherogenesis. ongoing research,therapeutic application,unassigned 1,1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1309056&form=6&db=m Remaining perspectives of mutant and chimeric plasminogen activators. unassigned - 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1331349&form=6&db=m Postoperative venous thromboembolism and brain tumors: Part II. Hemostatic profile. diagnostic usage,unassigned 2,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1337176&form=6&db=m Serum lipoprotein (a) in men with proteinuria due to idiopathic membranous nephropathy. causal interaction,unassigned 3,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1342292&form=6&db=m Assembly of plasmin-generating proteins on the surface of human endothelial cells. causal interaction,diagnostic usage,unassigned 1,3,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1364112&form=6&db=m [Thrombosis prophylaxis using plasmin and its combination with alpha-adrenoreceptor antagonists] diagnostic usage,ongoing research,therapeutic application,unassigned 3,4,1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1371932&form=6&db=m Vampire bat salivary plasminogen activator promotes rapid and sustained reperfusion without concomitant systemic plasminogen activation in a canine model of arterial thrombosis. ongoing research,therapeutic application,unassigned 2,4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1379800&form=6&db=m A plasminogen-related gene is expressed in cancer cells. unassigned - 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1400079&form=6&db=m Current concepts in coronary thrombolysis. diagnostic usage,unassigned 1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1400080&form=6&db=m Fibrinogen anomalies and disease. A clinical update. therapeutic application,unassigned 1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1419466&form=6&db=m The potential improvement of thrombolytic therapy by targeting with bispecific monoclonal antibodies: why they are used and how they are made. unassigned - 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1420919&form=6&db=m Penetration of macromolecules into contracted blood clot. therapeutic application,unassigned 1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1440500&form=6&db=m Thrombolytic activity of two chimeric recombinant plasminogen activators (FK2tu-PA and K2tu-PA) in rabbits. diagnostic usage,ongoing research,unassigned 1,4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1452521&form=6&db=m Hypercoagulability and thrombosis. causal interaction,unassigned 1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1456879&form=6&db=m The study of gene-environment interactions that influence thrombosis and fibrinolysis. Genetic variation at the loci for factor VII and plasminogen activator inhibitor-1. causal interaction,diagnostic usage,therapeutic application,unassigned 3,3,2,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1489893&form=6&db=m Composition and susceptibility to thrombolysis of human arterial thrombi and the influence of their age. ongoing research,unassigned 3,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1511773&form=6&db=m Inhibitory effect of nafamostat mesilate on metastasis into the livers of mice and on invasion of the extracellular matrix by cancer cells. causal interaction,ongoing research,unassigned 3,3,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1532403&form=6&db=m "Plasminogen steal" and clot lysis. diagnostic usage,ongoing research,therapeutic application,unassigned 3,4,1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1535628&form=6&db=m Expression of an anchored urokinase in the apical endothelial cell membrane. Preservation of enzymatic activity and enhancement of cell surface plasminogen activation. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1540536&form=6&db=m New developments in thrombolytic therapy. therapeutic application,unassigned 4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1554698&form=6&db=m Multiple members of the plasminogen-apolipoprotein(a) gene family associated with thrombosis. causal interaction,unassigned 4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1555484&form=6&db=m Pharmacology of fibrinolysis. unassigned - 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1571545&form=6&db=m Thrombolytic and pharmacokinetic properties of an immunoconjugate of single-chain urokinase-type plasminogen activator (u-PA) and a bispecific monoclonal antibody against fibrin and against u-PA in baboons. ongoing research,therapeutic application,unassigned 3,2,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1576736&form=6&db=m Acceleration of recombinant tissue-type plasminogen activator-induced reperfusion and prevention of reocclusion by recombinant antistasin, a selective factor Xa inhibitor, in a canine model of femoral arterial thrombosis. ongoing research,therapeutic application,unassigned 3,4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1615463&form=6&db=m The amount of plasminogen, tissue-type plasminogen activator and plasminogen activator inhibitor type 1 in human thrombi and the relation to ex-vivo lysibility. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1621238&form=6&db=m Type I congenital plasminogen deficiency is not a risk factor for thrombosis. causal interaction,unassigned 4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1665940&form=6&db=m The lipoprotein(a). Significance and relation to atherosclerosis. causal interaction,unassigned 4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1716378&form=6&db=m Enhancement of the thrombolytic efficacy of prourokinase by lys-plasminogen in a dog model of arterial thrombosis. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1731899&form=6&db=m A region of tissue plasminogen activator that affects plasminogen activation differentially with various fibrin(ogen)-related stimulators. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1757368&form=6&db=m Effects of flow on recombinant tissue plasminogen activator-induced pulmonary thrombolysis. ongoing research,therapeutic application,unassigned 4,2,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1758145&form=6&db=m [Hemostatic changes in idiopathic venous thrombosis in childhood and adolescence] causal interaction,diagnostic usage,unassigned 1,2,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1769035&form=6&db=m Seminars in thrombosis, thrombolysis and vascular biology. 4. Fibrinolysis. unassigned - 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1796391&form=6&db=m Deep vein thrombosis and fibrinolysis. Defective urokinase type plasminogen activator release. causal interaction,ongoing research,therapeutic application,unassigned 1,3,2,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1796413&form=6&db=m Influence of intrinsic and extrinsic plasminogen upon the lysis of thrombi in vitro. therapeutic application,unassigned 1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1806456&form=6&db=m The beneficial effect of lys-plasminogen upon the thrombolytic efficacy of urokinase in a dog model of peripheral arterial thrombosis. causal interaction,ongoing research,therapeutic application,unassigned 1,2,4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1815525&form=6&db=m Enhancement of tissue-type plasminogen activator-induced thrombolysis and prevention of reocclusion by sodium (E)-11-[2-(5,6-dimethyl-1-benzimidazolyl)- ethylidene]-6,11-dihydrodibenz[b,e]oxepine-2-carboxylate monohydrate in a canine model of femoral thrombosis. ongoing research,therapeutic application,unassigned 1,3,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1826407&form=6&db=m Incidence and clinical characteristics of hereditary disorders associated with venous thrombosis. therapeutic application,unassigned 1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1828324&form=6&db=m Effects of lipoprotein (a) on success rate of thrombolytic therapy in acute myocardial infarction. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,1,3,4 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1831302&form=6&db=m The influence of transport parameters and enzyme kinetics of the fibrinolytic system on thrombolysis: mathematical modelling of two idealised cases. therapeutic application,unassigned 1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1840453&form=6&db=m Lipoprotein(a), atherosclerosis and thrombosis. causal interaction,unassigned 3,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1885569&form=6&db=m Characterization of a recombinant single-chain molecule comprising the variable domains of a monoclonal antibody specific for human fibrin fragment D-dimer. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1896711&form=6&db=m [The mysteries of lipoprotein (a): a bridge between thrombosis and atheroma] causal interaction,unassigned 1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1899825&form=6&db=m Effects of hydralazine and increased cardiac output on recombinant tissue plasminogen activator-induced thrombolysis in canine pulmonary embolism. causal interaction,ongoing research,therapeutic application,unassigned 1,4,2,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1904231&form=6&db=m Endocytosis of the recombinant tissue plasminogen activator alteplase by hepatic endothelial cells. therapeutic application,unassigned 1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1986355&form=6&db=m Two types of abnormal genes for plasminogen in families with a predisposition for thrombosis. therapeutic application,unassigned 1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2012348&form=6&db=m Use of newly developed assays for protein C and plasminogen in horses with signs of colic. diagnostic usage,ongoing research,therapeutic application,unassigned 2,4,1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2040069&form=6&db=m Animal models for arterial thrombolysis and prevention of reocclusion. Erythrocyte-rich versus platelet-rich thrombus. causal interaction,ongoing research,therapeutic application,unassigned 4,3,4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2096491&form=6&db=m Correlation between progressive adsorption of plasminogen to blood clots and their sensitivity to lysis. ongoing research,unassigned 2,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2123910&form=6&db=m Lysis of plasminogen activator-resistant platelet-rich coronary artery thrombus with combined bolus injection of recombinant tissue-type plasminogen activator and antiplatelet GPIIb/IIIa antibody. ongoing research,therapeutic application,unassigned 2,3,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2128661&form=6&db=m Design of novel thrombolytic agents via domain modifications. causal interaction,therapeutic application,unassigned 2,4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2129372&form=6&db=m New developments in thrombolytic therapy. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2141241&form=6&db=m [Lipoprotein (a). An additional marker of atherosclerosis] causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2144669&form=6&db=m Selective binding of plasmin in the presence of excess plasminogen by certain anionic polystyrene resins. therapeutic application,unassigned 2,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2147016&form=6&db=m [Lipoprotein (a)--a further risk factor in arteriosclerosis?] causal interaction,unassigned 3,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2154024&form=6&db=m A new treatment for traumatic shock and ARDS. causal interaction,therapeutic application,unassigned 2,2,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2180114&form=6&db=m New developments in thrombolytic therapy. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2208836&form=6&db=m The role of lipoproteins and apolipoproteins in prediction of coronary heart disease risk. causal interaction,unassigned 1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2285165&form=6&db=m [Plasminogen depletion and incorporation in experimental venous thrombosis] causal interaction,ongoing research,therapeutic application,unassigned 3,3,4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2306811&form=6&db=m Accelerated thrombolysis and reperfusion in a canine model of myocardial infarction by liposomal encapsulation of streptokinase. causal interaction,diagnostic usage,therapeutic application,unassigned 3,2,4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2353345&form=6&db=m Insertion of fibrin peptides into urokinase enhances fibrin affinity. therapeutic application,unassigned 3,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2420482&form=6&db=m The fibrinolytic system in man. causal interaction,unassigned 4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2436684&form=6&db=m The pathogenesis of accelerated fibrinolysis in liver cirrhosis: a critical role for tissue plasminogen activator inhibitor. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2456288&form=6&db=m Plasminogen activation and lysis of blood clots induced by cells in vitro. diagnostic usage,ongoing research,unassigned 3,4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2465210&form=6&db=m Pathophysiology of thrombophilic states. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2493116&form=6&db=m Thrombolytic therapy in acute myocardial infarction: Part II--rt-PA. therapeutic application,unassigned 4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2495035&form=6&db=m PGE1 accelerates thrombolysis by tissue plasminogen activator. causal interaction,ongoing research,therapeutic application,unassigned 3,3,4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2496309&form=6&db=m Promotion and subsequent inhibition of plasminogen activation after administration of intravenous endotoxin to normal subjects. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2496749&form=6&db=m The single-chain form of tissue-type plasminogen activator has catalytic activity: studies with a mutant enzyme that lacks the cleavage site. causal interaction,therapeutic application,unassigned 1,2,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2502209&form=6&db=m Differences between binding of one-chain and two-chain tissue plasminogen activators to non-cross-linked and cross-linked fibrin clots. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2502992&form=6&db=m Properties of molecular variants of tissue-type plasminogen activator. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2507953&form=6&db=m Efficacy of single intracisternal bolus injection of recombinant tissue plasminogen activator to prevent delayed cerebral vasospasm after experimental subarachnoid hemorrhage. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,1,2,4 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2510363&form=6&db=m Induction of marked thrombin activity by pharmacologic concentrations of plasminogen activators in nonanticoagulated whole blood. causal interaction,diagnostic usage,therapeutic application,unassigned 3,1,1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2512863&form=6&db=m Risk factors for thrombosis in lupus patients. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2515603&form=6&db=m Effect of retraction on the lysis of human clots with fibrin specific and non-fibrin specific plasminogen activators. diagnostic usage,ongoing research,therapeutic application,unassigned 2,4,4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2521276&form=6&db=m Coagulation studies in thrombotic thrombocytopenic purpura, with special reference to von Willebrand factor and protein S. causal interaction,unassigned 4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2526669&form=6&db=m Inhibition of vascular endothelial cell prostacyclin synthesis by plasmin. causal interaction,unassigned 1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2526671&form=6&db=m Clinical disorders of fibrinolysis: a critical review. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2528202&form=6&db=m Subclinical activation of fibrinolysis in atherosclerotic disease detected by B beta 15-42 assay. causal interaction,diagnostic usage,ongoing research,unassigned 3,3,2,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2542796&form=6&db=m A potential basis for the thrombotic risks associated with lipoprotein(a). therapeutic application,unassigned 1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2629155&form=6&db=m [The use of thrombolytic preparations for the functional restoration of the arteriovenous fistula in patients on programmed hemodialysis] therapeutic application,unassigned 4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2649355&form=6&db=m Thrombolysis in the management of acute myocardial infarction and unstable angina pectoris. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2667728&form=6&db=m Lipoprotein (a): an emerging risk factor for atherosclerosis. causal interaction,unassigned 3,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2695440&form=6&db=m [Pathogenesis and laboratory diagnosis of venous thrombosis] causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2710603&form=6&db=m [Features of thrombophilia in nephrotic syndrome in children] unassigned - 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2877508&form=6&db=m Effect of a selective thrombin inhibitor MCI-9038 on fibrinolysis in vitro and in vivo. ongoing research,therapeutic application,unassigned 1,3,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2934899&form=6&db=m [Plasminogen activator of tissue type. Physiology, pathophysiology and clinical value] unassigned - 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2939853&form=6&db=m [Increasing the local concentration of fibrinolysin and thrombolysis rate using magnetic fluid in a model of occlusive thrombosis] ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2944241&form=6&db=m Investigation of a congenital abnormal plasminogen, Frankfurt I, and its relationship to thrombosis. causal interaction,unassigned 3,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2953836&form=6&db=m Distinction by radioisotope technique of a subgroup with increased thrombophilic potential among patients submitted to major abdominal surgery. therapeutic application,unassigned 1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2965086&form=6&db=m Congenital abnormal plasminogen, Frankfurt I, a cause for recurrent venous thrombosis. causal interaction,unassigned 3,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2977134&form=6&db=m Synthesis of recombinant human single-chain urokinase-type plasminogen activator variants resistant to plasmin and thrombin. therapeutic application,unassigned 3,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3087707&form=6&db=m Tissue-type plasminogen activator gene is on chromosome 8. causal interaction,therapeutic application,unassigned 1,2,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3112453&form=6&db=m [Abnormal plasminogen and thrombosis] unassigned - 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3113230&form=6&db=m Kallikrein inhibition and C1-esterase inhibitor levels in patients with the lupus inhibitor. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,3,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3120160&form=6&db=m Tissue plasminogen activator: an evaluation of clinical efficacy in acute myocardial infarction. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3127310&form=6&db=m Effect of anti plasminogen monoclonal antibodies on whole blood clot lysis. ongoing research,unassigned 3,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3130724&form=6&db=m [Thrombolytic properties of the heparin-tissue plasminogen activator complex and its effect on the fibrinolytic and coagulating systems of the blood in animals] therapeutic application,unassigned 4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3130773&form=6&db=m Thrombolytic therapy. unassigned - 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3133813&form=6&db=m A monoclonal antibody-based enzyme immunoassay for fibrin degradation products in plasma. diagnostic usage,unassigned 1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3139402&form=6&db=m Biological control of tissue plasminogen activator-mediated fibrinolysis. causal interaction,therapeutic application,unassigned 1,2,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3142080&form=6&db=m A fibrin specific monoclonal antibody which interferes with the fibrinolytic effect of tissue plasminogen activator. ongoing research,therapeutic application,unassigned 4,1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3142089&form=6&db=m Fibrinogen Nijmegen: congenital dysfibrinogenemia associated with impaired t-PA mediated plasminogen activation and decreased binding of t-PA. unassigned - 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3143811&form=6&db=m Prediction of the three-dimensional structure of the enzymatic domain of t-PA. therapeutic application,unassigned 3,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3156739&form=6&db=m 99mTc-plasmin test in deep vein thrombosis of the leg. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,3,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3158094&form=6&db=m Effects of plasmin on rabbit platelets. causal interaction,unassigned 4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3158265&form=6&db=m Antithrombin III, plasminogen, plasmin, and alpha-2-antiplasmin in donor blood and plasma components. causal interaction,diagnostic usage,unassigned 3,3,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3219292&form=6&db=m Thrombovascular disease and familial plasminogen deficiency: a report of three kindreds. causal interaction,unassigned 4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3286116&form=6&db=m Human fibrinogen. diagnostic usage,ongoing research,therapeutic application,unassigned 3,1,1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3315613&form=6&db=m Preclinical pharmacological evaluation of anisoylated plasminogen streptokinase activator complex. therapeutic application,unassigned 1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3355791&form=6&db=m Association of inherited dysfibrinogenaemia and protein C deficiency in two unrelated families. causal interaction,unassigned 4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3363534&form=6&db=m Plasminogen San Antonio: an abnormal plasminogen with a more cathodic migration, decreased activation and associated thrombosis. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3367430&form=6&db=m Abnormalities of the fibrinolytic system as a cause of upper extremity ischemia: a preliminary report. causal interaction,ongoing research,therapeutic application,unassigned 3,1,1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3546075&form=6&db=m Physiologic regulation and pathologic disorders of fibrinolysis. unassigned - 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3549955&form=6&db=m [Molecular defects of coagulation factors and of the fibrinolytic system associated with thromboembolism] causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3762956&form=6&db=m Plasminogen deficiency and thrombosis after plasmapheresis therapy for multiple sclerosis. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3873118&form=6&db=m Effects of oral stanozolol used in the prevention of postoperative deep vein thrombosis on fibrinolytic activity. diagnostic usage,ongoing research,therapeutic application,unassigned 1,2,4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3875694&form=6&db=m Altered von Willebrand factor molecule in children with thrombosis following asparaginase-prednisone-vincristine therapy for leukemia. diagnostic usage,unassigned 1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3899444&form=6&db=m The fibrinolytic system of the vascular wall. unassigned - 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3924420&form=6&db=m Thrombolytic properties of an inactive proenzyme form of human urokinase secreted from human kidney cells. unassigned - 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3933871&form=6&db=m Nephrotic syndrome with renal vein thrombosis: pathogenetic importance of a plasmin inhibitor (alpha 2-antiplasmin). diagnostic usage,ongoing research,therapeutic application,unassigned 4,1,3,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4220793&form=6&db=m Effects of heparin, plasmin, dextran, and low molecular dextran on bioelectrically induced thromboses. ongoing research,therapeutic application,unassigned 2,2,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4221183&form=6&db=m Comparative anticoagulant effects of coumadin, heparin, and fibrinolysin on direct-current thrombosis of rat mesoappendix vessels. ongoing research,therapeutic application,unassigned 3,1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4221357&form=6&db=m Effects of heparin, plasmin, dextran and low-molecular-weight dextran on electrically induced thromboses. ongoing research,therapeutic application,unassigned 2,2,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4222541&form=6&db=m [Experimental substantiation of diagnosis of thrombosis by means of I-131-labeled fibrinolysin] diagnostic usage,unassigned 2,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4224934&form=6&db=m Treatment of cerebrovascular thrombosis with plasmin and plasminogen activators. therapeutic application,unassigned 4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4229564&form=6&db=m [The application of fibrinolysin in thromboses and its effect on some indices of the blood coagulation system (preliminary report)] ongoing research,therapeutic application,unassigned 1,1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4238463&form=6&db=m [The use of fibrinolysin and heparin in the treatment of acute thrombophlebitis, thrombosis and embolism] therapeutic application,unassigned 4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4268300&form=6&db=m [Treatment of thrombosis as a result of stress (the Paget-Schroetter syndrome) in diabetes with fibrinolysin and anticoagulants] causal interaction,therapeutic application,unassigned 3,3,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4271031&form=6&db=m [Diagnosis of thrombosis resulting from tension (Paget-Schroetter syndrome) and its treatment with fibrinolysin and heparin] therapeutic application,unassigned 3,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4281116&form=6&db=m Acute deep vein thrombosis treated with porcine plasmin. A double blind trial. ongoing research,therapeutic application,unassigned 3,4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=5432193&form=6&db=m Further studies on an inhibitor of plasminogen activation in human serum. Release of the inhibitor during coagulation and thrombus formation. diagnostic usage,ongoing research,therapeutic application,unassigned 3,3,1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=5619432&form=6&db=m [The rate of activation of plasminogen and intrasvascular thrombus formation in rheumatism and atherosclerosis] causal interaction,unassigned 2,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6182722&form=6&db=m Effect of volume expanders on the lysability of ex vivo thrombi in the rabbit. ongoing research,unassigned 1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6188234&form=6&db=m Demonstration of 99mTc-labelled plasmin on the surface of ex vivo thrombi. causal interaction,diagnostic usage,ongoing research,unassigned 1,3,3,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6208389&form=6&db=m Abnormal plasminogen: a genetically determined cause of hypercoagulability. causal interaction,unassigned 3,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6217580&form=6&db=m Sequential treatment of arterial occlusions with porcine plasmin and low dose streptokinase. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6217581&form=6&db=m Sequential treatment of deep leg vein thrombosis with porcine plasmin and low dose streptokinase. diagnostic usage,therapeutic application,unassigned 2,4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6220052&form=6&db=m Intravascular fibrinolysis of small-vessel thrombosis. diagnostic usage,ongoing research,therapeutic application,unassigned 1,3,3,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6222508&form=6&db=m The release of B beta 1-42 from fibrinogen and fibrin by plasmin. causal interaction,unassigned 1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6228030&form=6&db=m International collaborative study for the establishment of the second International Reference Preparation of plasmin. unassigned - 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6228504&form=6&db=m [Enzymatic debridement of wounds. Comparison of 2 commercial preparations] therapeutic application,unassigned 1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6235087&form=6&db=m Comparison between 99Tcm-porcine plasmin and 99Tcm-labelled erythrocytes in diagnosis of deep vein thrombosis. diagnostic usage,ongoing research,therapeutic application,unassigned 2,2,2,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6411843&form=6&db=m The inactivation of hemostatic factors by hematin. causal interaction,unassigned 1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6434594&form=6&db=m Detection and partial characterization of an inhibitor of plasminogen activator in human platelets. unassigned - 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6453297&form=6&db=m Relative proteolysis of the fibrinogen B beta chain by thrombin and plasmin as a determinant of thrombosis. diagnostic usage,unassigned 2,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6505433&form=6&db=m [Local low-dose thrombolytic treatment with sequential urokinase-plasminogen in deep central venous thrombosis] therapeutic application,unassigned 2,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6506034&form=6&db=m Physiological role of alpha 2-plasmin inhibitor in rats. causal interaction,unassigned 4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6522106&form=6&db=m Vasoactive agents and production of thrombosis during intravascular coagulation 1--comparative effects of norepinephrine in thrombin and adenosine diphosphate (ADP) treated rabbits. therapeutic application,unassigned 3,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6537999&form=6&db=m Quantitative determination of plasma fibrinolytic activity in patients with ruptured intracranial aneurysms who are receiving epsilon-aminocaproic acid: relationship of possible complications of therapy to the degree of fibrinolytic inhibition. causal interaction,diagnostic usage,therapeutic application,unassigned 1,3,2,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6539000&form=6&db=m Dysfibrinogenemia (fibrinogen Dusard) associated with impaired fibrin-enhanced plasminogen activation. causal interaction,unassigned 3,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6658714&form=6&db=m Plasminogen Paris I: congenital abnormal plasminogen and its incidence in thrombosis. causal interaction,unassigned 4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6719393&form=6&db=m A sequential study of plasma histidine-rich glycoprotein and plasminogen in patients with acute myocardial infarction and deep vein thrombosis. diagnostic usage,ongoing research,therapeutic application,unassigned 3,4,1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6731499&form=6&db=m Use of noninvasive laboratory testing in the prediction of thrombosis in the nephrotic syndrome. diagnostic usage,therapeutic application,unassigned 3,2,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6895378&form=6&db=m Generation of fibrinolytic activity by infusion of activated protein C into dogs. therapeutic application,unassigned 2,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7057319&form=6&db=m The hemostatic system in children undergoing intensive plasma exchange. causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7133990&form=6&db=m [Study of coagulation and fibrinolysis in 131 cases of recurrent deep vein thrombosis] causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7135348&form=6&db=m Assessment of antithrombotic properties of sodium ibuprofen. therapeutic application,unassigned 2,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7268697&form=6&db=m Abnormal plasminogen, a case of recurrent thrombosis. unassigned - 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7315719&form=6&db=m Intracoronary thrombolysis in acute myocardial infarction: experimental background and clinical experience. therapeutic application,unassigned 1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7488820&form=6&db=m Low levels of plasminogen in cerebrospinal fluid after intraventricular haemorrhage: a limiting factor for clot lysis? causal interaction,ongoing research,therapeutic application,unassigned 4,2,4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7494358&form=6&db=m The tissue plasminogen activator and urokinase response in vivo during natural resolution of venous thrombus. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,1,4,1 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7509643&form=6&db=m [Intensification of the effect of exogenous plasminogen activators on lysis of fibrin blood clots due to a decrease in the level of alpha-2- antiplasmin by a plasmasorption method] therapeutic application,unassigned 1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7549069&form=6&db=m Physiological consequences of over- or under-expression of fibrinolytic system components in transgenic mice. causal interaction,ongoing research,therapeutic application,unassigned 1,3,2,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7561447&form=6&db=m Endothelial cell injury induced by plasmin in vitro. causal interaction,therapeutic application,unassigned 3,3,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7566298&form=6&db=m Comparison of Lp(a) concentrations and some potential effects in hemodialysis, CAPD, transplantation, and control groups, and review of the literature. causal interaction,unassigned 3,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7585220&form=6&db=m Release and activation of platelet latent TGF-beta in blood clots during dissolution with plasmin. unassigned - 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7586361&form=6&db=m Effects of disruption of the plasminogen gene on thrombosis, growth, and health in mice. ongoing research,unassigned 4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7588083&form=6&db=m Alteplase. A reappraisal of its pharmacological properties and therapeutic use in acute myocardial infarction. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,1,4 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7670855&form=6&db=m Comparison of plasma total plasmin activities in male and female hypertensive rats. causal interaction,unassigned 3,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7705657&form=6&db=m Plasminogen deficiency causes severe thrombosis but is compatible with development and reproduction. causal interaction,unassigned 4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7737753&form=6&db=m Perioperative changes in coagulative and fibrinolytic function during surgical treatment of abdominal aortic aneurysm and arteriosclerosis obliterans. causal interaction,unassigned 2,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7745838&form=6&db=m [A Japanese family with congenital abnormal plasminogen] causal interaction,diagnostic usage,unassigned 2,4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7843690&form=6&db=m [t-PA in thrombolytic therapy of acute myocardial infarct] causal interaction,therapeutic application,unassigned 2,2,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7850956&form=6&db=m Thrombolysis and reocclusion in experimental jugular vein and coronary artery thrombosis. Effects of a plasminogen activator inhibitor type 1-neutralizing monoclonal antibody. ongoing research,therapeutic application,unassigned 4,4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7860925&form=6&db=m Recombinant lys-plasminogen, but not glu-plasminogen, improves recombinant tissue-type plasminogen activator-induced coronary thrombolysis in dogs. causal interaction,diagnostic usage,therapeutic application,unassigned 3,1,2,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7890263&form=6&db=m Symptomatic versus asymptomatic patients in congenital hypoplasminogenemia: a statistical analysis. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7893926&form=6&db=m Heterozygous type I plasminogen deficiency is associated with an increased risk for thrombosis: a statistical analysis in 20 kindreds. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,2,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8025279&form=6&db=m Characterization of recombinant plasminogen activator production by primate endothelial cells transduced with retroviral vectors. therapeutic application,unassigned 3,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8066262&form=6&db=m [Comparison of urokinase and tissue-type plasminogen activator in transcatheter arterial fibrinolysis] diagnostic usage,ongoing research,therapeutic application,unassigned 1,2,2,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8076182&form=6&db=m [Lipoprotein Lp(a) and CETP (cholesterol ester transfer protein): contribution of transgenic mice] unassigned - 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8076730&form=6&db=m [The resolution of a mitral valve prosthesis thrombosis with low-dose plasminogen tissue activator and the role of Doppler echocardiographic monitoring] therapeutic application,unassigned 2,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8111066&form=6&db=m Uncoupling fibrin from integrin receptors hastens fibrinolysis at the platelet-fibrin interface. ongoing research,therapeutic application,unassigned 2,3,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8114191&form=6&db=m Plasminogen acceleration of urokinase thrombolysis. causal interaction,unassigned 4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8154409&form=6&db=m Nitroglycerin inhibits experimental thrombosis and reocclusion after thrombolysis. therapeutic application,unassigned 1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8162432&form=6&db=m Capturing host plasmin(ogen): a common mechanism for invasive pathogens? unassigned - 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8162778&form=6&db=m Life-threatening pulmonary embolism with right-sided heart thrombus. Rapid recovery with recombinant tissue plasminogen activator. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8176842&form=6&db=m [Tissue-type plasminogen activator (t-PA) and plasminogen activator inhibitor (PAI)] causal interaction,ongoing research,therapeutic application,unassigned 1,2,1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8187238&form=6&db=m Effects of lipoprotein(a) on thrombolysis. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,1,4,3 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8191655&form=6&db=m [Clinical significance of the determination of several hemostatic parameters in the lacrimal fluid of patients with vascular diseases of the retina] causal interaction,diagnostic usage,therapeutic application,unassigned 1,3,1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8206894&form=6&db=m Plasminogen mutants activated by thrombin. Potential thrombus-selective thrombolytic agents. causal interaction,therapeutic application,unassigned 1,2,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8210941&form=6&db=m The search for the ideal thrombolytic agent: maximize the benefit and minimize the risk. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8258756&form=6&db=m Unusual thrombotic-like retinopathy (Coats' disease) associated with congenital plasminogen deficiency type I. causal interaction,unassigned 4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8263779&form=6&db=m SC-49992, a mimetic of the peptide arginine-glycine-aspartic acid-phenylalanine that blocks platelet aggregation, enhances recombinant tissue plasminogen activator-induced thrombolysis and prevents reocclusion in a canine model of coronary artery thrombosis. causal interaction,therapeutic application,unassigned 1,2,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8306063&form=6&db=m Thrombolytic effect of a plasminogen-plasminogen activator chimera in a photochemically induced thrombosis (PIT) model. ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8320841&form=6&db=m [Molecular biology of tissue-type plasminogen activator (t-PA) and clinical application of recombinant t-PA] unassigned - 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8322279&form=6&db=m Spontaneous versus secondary thrombosis in congenital heterozygous plasminogen deficiency. causal interaction,unassigned 4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8329574&form=6&db=m Reocclusion after thrombolytic therapy: strategies for inhibiting thrombin-induced platelet aggregation. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8329699&form=6&db=m Does apolipoprotein(a) heterogeneity influence lipoprotein(a) effects on fibrinolysis? therapeutic application,unassigned 2,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8370015&form=6&db=m Thrombolytic therapy in peripheral arterial occlusive disease: mechanisms of action and drugs available. causal interaction,ongoing research,therapeutic application,unassigned 2,1,1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8397574&form=6&db=m Central venous line thrombosis in premature infants: a case management and literature review. causal interaction,therapeutic application,unassigned 4,3,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8427117&form=6&db=m Increased production of thromboxane A2 by coronary arteries after thrombolysis. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,1,2,2 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8433796&form=6&db=m Local intra-arterial fibrinolytic therapy in patients with stroke: urokinase versus recombinant tissue plasminogen activator (r-TPA). therapeutic application,unassigned 4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8443390&form=6&db=m Regulation of fibrinolysis by platelet-released plasminogen activator inhibitor 1: light scattering and ultrastructural examination of lysis of a model platelet-fibrin thrombus. ongoing research,therapeutic application,unassigned 4,3,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8443877&form=6&db=m Thrombolytic profiles of clot-targeted plasminogen activators. Parameters determining potency and initial and maximal rates. unassigned - 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8471185&form=6&db=m Comparative tolerability profiles of thrombolytic agents. A review. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8490951&form=6&db=m Platelet GPIIb/IIIa receptor inhibition by SC-49992 prevents thrombosis and rethrombosis in the canine carotid artery. unassigned - 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8497851&form=6&db=m Retinoic acid enhances fibrinolytic activity in-vivo by enhancing tissue type plasminogen activator (t-PA) activity and inhibits venous thrombosis. ongoing research,therapeutic application,unassigned 3,2,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8506554&form=6&db=m Thromboxane antagonism in experimental canine carotid artery thrombosis. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,1,1,1 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8547429&form=6&db=m Plasma Lipoprotein(a) and its relationship with disease activity in patients with Behçet's disease. therapeutic application,unassigned 1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8548903&form=6&db=m Enhanced in vivo antithrombotic effects of endothelial cells expressing recombinant plasminogen activators transduced with retroviral vectors. ongoing research,therapeutic application,unassigned 3,1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8589217&form=6&db=m RGDFAP: platelet aggregation inhibitory and profibrinolytic hybrid peptide (RGDF coupled with the carboxy terminal part of alpha 2-antiplasmin) enhances plasminogen binding to platelets. causal interaction,unassigned 1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8657763&form=6&db=m Prevention of microvascular thrombosis with short-term infusion of human tissue-type plasminogen activator. ongoing research,therapeutic application,unassigned 3,2,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8825218&form=6&db=m Role of neutrophil membrane proteases in fibrin degradation. therapeutic application,unassigned 3,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8853112&form=6&db=m Thrombolytic agents--an overview. therapeutic application,unassigned 4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8883289&form=6&db=m Plasminogen deficiency: an additional risk factor for thrombosis in a family with factor V R506Q mutation? causal interaction,unassigned 3,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8929539&form=6&db=m Loss of fibrinogen rescues mice from the pleiotropic effects of plasminogen deficiency. causal interaction,ongoing research,therapeutic application,unassigned 4,2,1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8972025&form=6&db=m Isolated familial plasminogen deficiency may not be a risk factor for thrombosis. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9134632&form=6&db=m The risk of recurrent venous thromboembolism in patients with and without factor V Leiden. ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9167020&form=6&db=m Low prevalence of thrombophilic coagulation defects in patients with deep vein thrombosis of the upper limbs. diagnostic usage,ongoing research,therapeutic application,unassigned 1,2,1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9175244&form=6&db=m Further characterization and thrombolytic activity in a rat model of a fibrinogenase from Vipera lebetina venom. ongoing research,therapeutic application,unassigned 2,3,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9175416&form=6&db=m Haemostatic changes in patients with deep vein thrombosis. diagnostic usage,ongoing research,unassigned 2,3,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9186598&form=6&db=m Insights in vessel development and vascular disorders using targeted inactivation and transfer of vascular endothelial growth factor, the tissue factor receptor, and the plasminogen system. causal interaction,ongoing research,therapeutic application,unassigned 4,2,3,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9198150&form=6&db=m Antithrombotic therapy of acute stroke: thrombolytic agents. diagnostic usage,therapeutic application,unassigned 2,4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9204556&form=6&db=m NMR secondary structure of the plasminogen activator protein staphylokinase. therapeutic application,unassigned 3,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9211077&form=6&db=m Trends and future developments in the pharmacological treatment of acute ischaemic stroke. therapeutic application,unassigned 4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9232304&form=6&db=m Recombinant tissue type plasminogen activator treatment of thrombosed mitral valve prosthesis during pregnancy. causal interaction,diagnostic usage,unassigned 1,1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9245184&form=6&db=m [Lipoprotein(a). Its importance as an additional atherosclerosis marker] causal interaction,unassigned 4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9264505&form=6&db=m Reduction in stent and vascular graft thrombosis and enhancement of thrombolysis by recombinant Lys-plasminogen in nonhuman primates. causal interaction,ongoing research,therapeutic application,unassigned 2,3,3,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9294322&form=6&db=m [Hypercoagulable state in Duchenne muscular dystrophy] diagnostic usage,ongoing research,unassigned 2,1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9349387&form=6&db=m Arterial expression of the plasminogen activator system early after cardiac transplantation. causal interaction,diagnostic usage,ongoing research,unassigned 3,1,3,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9374741&form=6&db=m Molecular analysis of blood vessel formation and disease. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9395042&form=6&db=m Mechanisms by which thrombolytic therapy results in nonuniform lysis and residual thrombus after reperfusion. therapeutic application,unassigned 1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9396341&form=6&db=m [Etiological analysis of thrombophilia] causal interaction,ongoing research,therapeutic application,unassigned 1,1,1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9402652&form=6&db=m Structure, function and expression on blood and bone marrow cells of the urokinase-type plasminogen activator receptor, uPAR. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9459340&form=6&db=m Clot accumulation characteristics of plasminogen-bearing liposomes in a flow-system. Groningen Utrecht Institute for Drug Exploration. therapeutic application,unassigned 2,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9519686&form=6&db=m Electron microscopic study on the outer membrane of chronic subdural hematoma. unassigned - 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9522614&form=6&db=m [Fibrinolytic treatment of thrombus of the right atrium causing severe pulmonary embolism] causal interaction,therapeutic application,unassigned 3,2,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9556230&form=6&db=m Production of a recombinant antithrombotic and fibrinolytic protein, PLATSAK, in Escherichia coli. causal interaction,therapeutic application,unassigned 2,4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9558384&form=6&db=m Factor XIIIa cross-linking of the Marburg fibrin: formation of alpham.gamman-heteromultimers and the alpha-chain-linked albumin. gamma complex, and disturbed protofibril assembly resulting in acquisition of plasmin resistance relevant to thrombophila. therapeutic application,unassigned 2,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9560548&form=6&db=m [A successful perioperative anticoagulation therapy and monitoring of a patient with hereditary plasminogen abnormality undergoing aortic valve replacement] unassigned - 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9566843&form=6&db=m Post-traumatic membranous obstruction of the inferior vena cava associated with a hypercoagulable state. causal interaction,unassigned 3,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9568655&form=6&db=m An activated state of blood coagulation and fibrinolysis in patients with abdominal aortic aneurysm. diagnostic usage,unassigned 2,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9587554&form=6&db=m [Acute thrombosis of the portal system. Treatment with alteplase and heparin or with heparin alone in 10 patients] causal interaction,ongoing research,therapeutic application,unassigned 3,3,4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9607121&form=6&db=m Increased risk of venous thrombosis in carriers of natural anticoagulant deficiencies. Results of the family studies of the Spanish Multicenter Study on Thrombophilia (EMET study). causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9610823&form=6&db=m The role of the monocyte in the generation and dissolution of arterial and venous thrombi. unassigned - 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9684833&form=6&db=m Augmented pulse-spray thrombolysis with tPA by early pulsed intrathrombic plasminogen enrichment. ongoing research,therapeutic application,unassigned 4,2,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9694919&form=6&db=m Prevention of thrombosis and enhancement of thrombolysis in rabbits by SR 121787, a glycoprotein II/III antagonist. ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9727530&form=6&db=m Familial dysplasminogenemia with central retinal vein and cilioretinal artery occlusion. causal interaction,diagnostic usage,therapeutic application,unassigned 1,2,2,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9733510&form=6&db=m Crystal structure of the catalytic domain of human plasmin complexed with streptokinase. therapeutic application,unassigned 2,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9783753&form=6&db=m The ternary microplasmin-staphylokinase-microplasmin complex is a proteinase-cofactor-substrate complex in action. causal interaction,unassigned 1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9804513&form=6&db=m Delivery system for targeted thrombolysis without the risk of hemorrhage. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9814003&form=6&db=m [Fibrinolytic system and a central retinal vein thrombosis] causal interaction,diagnostic usage,therapeutic application,unassigned 3,3,1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9852242&form=6&db=m Vascular cell-derived fibrinolytic regulators and atherothrombotic vascular disorders (Review). causal interaction,ongoing research,unassigned 4,4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9892514&form=6&db=m A multi-modal approach to the management of bypass graft failure. therapeutic application,unassigned 1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9915664&form=6&db=m Lipoprotein(a) as a risk factor for coronary artery disease. causal interaction,unassigned 4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10067266&form=6&db=m LYS-plasminogen shortens the duration of local thrombolytic treatment of peripheral arterial occlusions--a randomized controlled trial. causal interaction,ongoing research,therapeutic application,unassigned 1,2,4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10377836&form=6&db=m [Hereditary deficiency of antithrombin III, protein C, protein S and factor XII in 121 patients with venous or arterial thrombosis] causal interaction,ongoing research,therapeutic application,unassigned 4,2,1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10404758&form=6&db=m Elevated levels of plasmin-alpha2 antiplasmin complexes in unstable angina. causal interaction,diagnostic usage,ongoing research,unassigned 3,3,4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10430864&form=6&db=m A catalytic switch and the conversion of streptokinase to a fibrin-targeted plasminogen activator. therapeutic application,unassigned 1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10456203&form=6&db=m Screening for aetiology of thrombophilia: a high prevalence of protein S abnormality. unassigned - 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10512718&form=6&db=m Structure of the complex of the antistasin-type inhibitor bdellastasin with trypsin and modelling of the bdellastasin-microplasmin system. causal interaction,therapeutic application,unassigned 4,2,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10590062&form=6&db=m Induction of the plasminogen activator inhibitor-1 gene expression by mild hypoxia via a hypoxia response element binding the hypoxia-inducible factor-1 in rat hepatocytes. unassigned - 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10603509&form=6&db=m Plasma Concentration of Endogenous Tissue Plasminogen Activator and the Occurrence of Future Cardiovascular Events. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,3,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10604970&form=6&db=m Nonpeptide factor Xa inhibitors: I. Studies with SF303 and SK549, a new class of potent antithrombotics. ongoing research,therapeutic application,unassigned 3,2,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10629572&form=6&db=m Causes of venous thrombosis in fifty Chinese patients. causal interaction,diagnostic usage,therapeutic application,unassigned 2,2,1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10636460&form=6&db=m Specific determination of plasmin inhibitor activity in plasma: documentation of specificity of manual and automated procedures. therapeutic application,unassigned 3,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10652759&form=6&db=m [Diagnosis and treatment of coagulation disorders] causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10656799&form=6&db=m Human plasminogen catalytic domain undergoes an unusual conformational change upon activation. causal interaction,therapeutic application,unassigned 2,2,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10664583&form=6&db=m Molecular mechanisms of plasminogen activation: bacterial cofactors provide clues. causal interaction,unassigned 3,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10691094&form=6&db=m Soluble fibrin species in arterial thrombi. unassigned - 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10697424&form=6&db=m Coagulative and fibrinolytic activity in parietal thrombus of aortic aneurysm. unassigned - 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10726026&form=6&db=m Familial association of hypoplasminogenemia and heterozygous factor V deficiency. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10769130&form=6&db=m Epsilon amino caproic acid inhibits streptokinase-plasminogen activator complex formation and substrate binding through kringle-dependent mechanisms. causal interaction,therapeutic application,unassigned 2,1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10785951&form=6&db=m [Thrombosis of ovarian veins in puerperium associated with heparin-induced thrombocytopenia type II] therapeutic application,unassigned 4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10816371&form=6&db=m Nonfibrinolytic functions of plasminogen. therapeutic application,unassigned 3,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10821827&form=6&db=m New insights into the size and stoichiometry of the plasminogen activator inhibitor type-1.vitronectin complex. ongoing research,therapeutic application,unassigned 1,2,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10847427&form=6&db=m Textilinins from Pseudonaja textilis textilis. Characterization of two plasmin inhibitors that reduce bleeding in an animal model. therapeutic application,unassigned 4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10873836&form=6&db=m Negative selectivity and the evolution of protease cascades: the specificity of plasmin for peptide and protein substrates. unassigned - 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11110693&form=6&db=m Plasminogen activator inhibitor-1 deficiency protects against atherosclerosis progression in the mouse carotid artery. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11208448&form=6&db=m Echocardiographic assessment of right atrial thrombus related to the implanted port device in patient receiving chemotherapy for non-Hodgkin's lymphoma. causal interaction,therapeutic application,unassigned 2,3,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11237122&form=6&db=m Immunologic and hematologic properties of antibodies to prothrombin and plasminogen in a mouse model. causal interaction,unassigned 4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11344677&form=6&db=m Renal vein thrombosis in a newborn with prothrombotic genetic risk factors. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11368309&form=6&db=m Chimeric derivative of fibrolase, a fibrinolytic enzyme from southern copperhead venom, possesses inhibitory activity on platelet aggregation. therapeutic application,unassigned 3,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11572467&form=6&db=m Management of postvitrectomy diabetic vitreous hemorrhage with tissue plasminogen activator (t-PA) and volume homeostatic fluid-fluid exchanger. causal interaction,therapeutic application,unassigned 2,1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11739291&form=6&db=m Recombinant annexin II modulates impaired fibrinolytic activity in vitro and in rat carotid artery. causal interaction,ongoing research,therapeutic application,unassigned 1,1,1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11824003&form=6&db=m Early myocardial reperfusion: an assessment of current strategies in acute myocardial infarction. unassigned - 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11848464&form=6&db=m Plasmin generation plays different roles in the formation and removal of arterial and venous thrombus in mice. causal interaction,ongoing research,unassigned 4,3,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11858480&form=6&db=m The tissue factor and plasminogen activator inhibitor type-1 response in pediatric sepsis-induced multiple organ failure. therapeutic application,unassigned 2,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11910176&form=6&db=m Vampire bat plasminogen activator DSPA-alpha-1 (desmoteplase): a thrombolytic drug optimized by natural selection. unassigned - 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11910197&form=6&db=m Lonomia genus caterpillar envenomation: clinical and biological aspects. therapeutic application,unassigned 1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12064194&form=6&db=m [Combination therapy for acute myocardial infarction with glycoprotein IIb/IIIa inhibitors and fibrinolysis] therapeutic application,unassigned 3,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12091052&form=6&db=m Combined Ala601-Thr-type dysplasminogenaemia and antiphospholipid antibody syndrome in a patient with recurrent thrombosis. causal interaction,unassigned 4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12109827&form=6&db=m Radiological stenting provides effective palliation in malignant central venous obstruction. ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12124683&form=6&db=m Towards safer thrombolytic therapy. causal interaction,therapeutic application,unassigned 2,3,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12237697&form=6&db=m Studies on the synthesis and Antithrombosis Activity of the Analogue of Fibrin Decomposed Product-Related Peptide. unassigned - 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12414517&form=6&db=m Involvement of the mural thrombus as a site of protease release and activation in human aortic aneurysms. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,4,1 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12419562&form=6&db=m Effects of lipids on thrombotic mechanisms in atherosclerosis. unassigned - 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12421144&form=6&db=m Plasminogen and tissue-type plasminogen activator deficiency as risk factors for thromboembolic disease. causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,2,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12500602&form=6&db=m [Thrombosis and ischemia: experimental data] causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12539817&form=6&db=m Effects of statins in reducing thrombotic risk and modulating plaque vulnerability. causal interaction,diagnostic usage,unassigned 3,1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12616091&form=6&db=m Coagulopathies and arterial stroke. causal interaction,unassigned 4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12627747&form=6&db=m Lipoprotein(a): an emerging cardiovascular risk factor. causal interaction,unassigned 4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12679132&form=6&db=m Effects of argatroban and heparin on thrombus formation and tissue plasminogen activator-induced thrombolysis in a microvascular thrombosis model. ongoing research,therapeutic application,unassigned 4,2,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12692411&form=6&db=m Detection of an Ala601Thr mutation of plasminogen gene in 3 out of 36 Korean patients with deep vein thrombosis. diagnostic usage,ongoing research,unassigned 3,3,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12697748&form=6&db=m Inhibition of plasminogen activation by lipoprotein(a): critical domains in apolipoprotein(a) and mechanism of inhibition on fibrin and degraded fibrin surfaces. causal interaction,unassigned 1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12735467&form=6&db=m In vitro comparison of complementary interactions between synthetic linear/branched oligo/poly-L-lysines and tissue plasminogen activator by means of high-performance monolithic-disk affinity chromatography. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12792441&form=6&db=m Superior mesenteric vein thrombosis after colectomy for inflammatory bowel disease: a not uncommon cause of postoperative acute abdominal pain. causal interaction,diagnostic usage,unassigned 2,4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12855585&form=6&db=m Generation and role of angiostatin in human platelets. ongoing research,therapeutic application,unassigned 4,1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12871409&form=6&db=m A study on associations between antiprothrombin antibodies, antiplasminogen antibodies and thrombosis. diagnostic usage,ongoing research,unassigned 3,2,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12878727&form=6&db=m Coevolutionary patterns in plasminogen activation. causal interaction,unassigned 1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12941037&form=6&db=m Effect of SanOrg123781A, a synthetic hexadecasaccharide, on clot-bound thrombin and factor Xa in vitro and in vivo. therapeutic application,unassigned 2,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12949321&form=6&db=m Successful endovascular therapy for acute basilar thrombosis in an adolescent. therapeutic application,unassigned 2,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=13502020&form=6&db=m The use of plasmin in the treatment of intravascular thromboses. therapeutic application,unassigned 4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=13587211&form=6&db=m Treatment of thrombosis with fibrinolysin (plasmin). therapeutic application,unassigned 4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=13615881&form=6&db=m [Studies on fibrinolysin activities in thrombosis.] ongoing research,unassigned 3,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=13619379&form=6&db=m [Plasmin & therapy of thrombosis.] causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=13647511&form=6&db=m Prevention of thromboplastininduced thrombosis in rabbits by means of plasmin. unassigned - 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=13686464&form=6&db=m [Treatment of thrombosis and embolisms with human fibrinolysin.] therapeutic application,unassigned 4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=13694112&form=6&db=m Mechanism of formation of vascular thrombosis and its treatment with fibrinolysin. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=13696890&form=6&db=m The effect of fibrinolysin on the incidence of thrombosis in small-artery suturing. ongoing research,unassigned 1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=13783453&form=6&db=m Evaluation of intravenous human fibrinolysin as a treatment for recent intravascular thrombosis. therapeutic application,unassigned 4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=13784921&form=6&db=m Prevention of arterial thrombosis following experimental endarterectomy with plasmin (fibrinolysin). ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=13820381&form=6&db=m The use of fibrinolysin in the prevention of thrombus formation in small artery anastomoses. unassigned - 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=13861409&form=6&db=m [Use of fibrinolysin in experimental thrombosis.] ongoing research,therapeutic application,unassigned 1,4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=13878548&form=6&db=m [Preliminary results of the treatment of thrombosis with domestic fibrinolysin.] causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=13889682&form=6&db=m Combined use of fibrinolysin and endarterectomy. Results in stenosis with recent carotid artery thrombosis. therapeutic application,unassigned 1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=13934202&form=6&db=m Coronary arterial and other intravascular thromboses treated with fibrinolysin. Experimental and clinical results. causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=13949447&form=6&db=m [Symposium: Arteriosclerosis (with special reference to thrombosis and anticoagulants). 2. Significance of plasmin in arteriosclerosis.] diagnostic usage,unassigned 3,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14021749&form=6&db=m Lysis of intravascular blood clots. Fibrinolysin therapy. Indications, contraindications, and results. causal interaction,therapeutic application,unassigned 2,4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14040775&form=6&db=m Use of fibrinolysin in experimental thrombosis. ongoing research,therapeutic application,unassigned 1,4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14041041&form=6&db=m Use of fibrinolysin in experimental thrombosis. ongoing research,therapeutic application,unassigned 1,4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14041830&form=6&db=m Use of fibrinolysin in experimental thrombosis. ongoing research,therapeutic application,unassigned 1,4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14098642&form=6&db=m [RESULTS OBTAINED BY FIBRINOLYSIN IN RECENT VENOUS AND ARTERIAL THROMBOSIS.] causal interaction,therapeutic application,unassigned 4,2,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14118854&form=6&db=m THE EXPERIMENTAL USE OF THROMBOLYSIN TO DISSOLVE A BLOOD CLOT PLACED WITHIN THE PLEURAL SPACE OF DOGS. therapeutic application,unassigned 2,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14152588&form=6&db=m [COMBINED FIBRINOLYSIN AND HEPARIN THERAPY OF VASCULAR THROMBOSIS.] causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14241200&form=6&db=m FIBRINOLYSIN THERAPY FOR THROMBOSIS OF PRIAPISM. causal interaction,therapeutic application,unassigned 2,4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14248833&form=6&db=m [MEASURE OF PLASMA RESISTANCE TO LYSIS BY STREPTOKINASE. APPLICATION TO PATHOLOGIC THROMBOSIS. NEW TECHNIQUE FOR THE MEASUREMENT OF ACTIVATION OF PLASMINOGEN INHIBITORS.] diagnostic usage,therapeutic application,unassigned 3,4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14273457&form=6&db=m [PREVENTION OF EXPERIMENTAL THROMBOSIS IN SPLENECTOMIZED ANIMALS BY INTRAVENOUS ADMINISTRATION OF FIBRINOLYSIN WITH HEPARIN.] therapeutic application,unassigned 4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14325708&form=6&db=m [EXPERIENCE WITH THE TREATMENT OF THROMBOSIS AND EMBOLISM WITH FIBRINOLYSIN AND HEPARIN.] therapeutic application,unassigned 4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14401287&form=6&db=m Treatment of cerebrovascular thrombosis with fibrinolysin. Preliminary report. causal interaction,therapeutic application,unassigned 2,4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14403478&form=6&db=m The successful treatment of a case of central retinal vein thrombosis with intravenous fibrinolysin. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14447822&form=6&db=m Fibrinolysin for thrombosis. diagnostic usage,therapeutic application,unassigned 4,4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14473782&form=6&db=m Fibrinolytic treatment of retinal vein thrombosis. The use of Fibrinolysin Human Lyovac (Merck). therapeutic application,unassigned 3,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14473783&form=6&db=m [Fibrinolysin (Merck) treatment of retinal vein thrombosis.] therapeutic application,unassigned 4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14629475&form=6&db=m Population-based distribution of plasminogen activity and estimated prevalence and relevance to thrombotic diseases of plasminogen deficiency in the Japanese: the Suita Study. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,2,1 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14664206&form=6&db=m Plasma D-dimer for the diagnosis of thromboembolic disorders in dogs. unassigned - 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14751930&form=6&db=m A novel plasma proteinase potentiates alpha2-antiplasmin inhibition of fibrin digestion. causal interaction,therapeutic application,unassigned 3,3,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15099287&form=6&db=m Construction and characterization of a recombinant plasminogen activator composed of an anti-fibrin single-chain antibody and low-molecular-weight urokinase. therapeutic application,unassigned 2,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15100323&form=6&db=m Identification of anti-plasmin antibodies in the antiphospholipid syndrome that inhibit degradation of fibrin. causal interaction,unassigned 4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15102005&form=6&db=m Tissue-type plasminogen activator: a historical perspective and personal account. causal interaction,ongoing research,therapeutic application,unassigned 3,2,2,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15102492&form=6&db=m Locally delivered plasmin: why should it be superior to plasminogen activators for direct thrombolysis? causal interaction,therapeutic application,unassigned 3,2,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15258347&form=6&db=m Improving thrombolysis with encapsulated plasminogen activators and clinical relevance to myocardial infarction and stroke. therapeutic application,unassigned 2,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15320781&form=6&db=m Alpha2-antiplasmin: potential therapeutic roles in fibrin survival and removal. unassigned - 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15358303&form=6&db=m Monolithic peptidyl sorbents for comparison of affinity properties of plasminogen activators. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15372073&form=6&db=m Tissue plasminogen activator is a potent activator of PDGF-CC. causal interaction,therapeutic application,unassigned 3,3,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15379562&form=6&db=m Definition of the structural elements in plasminogen required for high-affinity binding to apolipoprotein(a): a study utilizing surface plasmon resonance. unassigned - 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15543323&form=6&db=m Ultrasound affects distribution of plasminogen and tissue-type plasminogen activator in whole blood clots in vitro. diagnostic usage,ongoing research,therapeutic application,unassigned 3,3,2,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15567735&form=6&db=m Construction and biological activities of human tPA eukaryotic expression plasmid. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15668188&form=6&db=m Thrombin activatable fibrinolysis inhibitor in Behçet's disease. therapeutic application,unassigned 2,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15692228&form=6&db=m Thromboembolic diseases in neonates and children. diagnostic usage,unassigned 2,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15758133&form=6&db=m Cross-species pharmacologic evaluation of plasmin as a direct-acting thrombolytic agent: ex vivo evaluation for large animal model development. diagnostic usage,ongoing research,unassigned 1,3,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15781388&form=6&db=m 3D-QSAR CoMFA studies on trypsin-like serine protease inhibitors: a comparative selectivity analysis. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15824077&form=6&db=m Lipoprotein (a) and coronary heart disease among women: beyond a cholesterol carrier? causal interaction,unassigned 3,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15847986&form=6&db=m In vivo behaviour of vesicular urokinase. causal interaction,unassigned 1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16099225&form=6&db=m The role of beta2-glycoprotein I (beta(2)GPI) in the activation of plasminogen. causal interaction,diagnostic usage,therapeutic application,unassigned 3,3,2,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16105483&form=6&db=m Lipoprotein(a) and atherosclerosis: new perspectives on the mechanism of action of an enigmatic lipoprotein. causal interaction,unassigned 1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16150044&form=6&db=m Apo(a) promotes thrombosis in a vascular injury model by a mechanism independent of plasminogen. unassigned - 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16224782&form=6&db=m Urokinase-immobilization suppresses inflammatory responses to polyurethane tubes implanted in rabbit muscles. causal interaction,unassigned 3,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16227153&form=6&db=m Research around beta 2-glycoprotein I: a major target for antiphospholipid antibodies. unassigned - 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16388417&form=6&db=m Molecular biology of ADAMTS13 and diagnostic utility of ADAMTS13 proteolytic activity and inhibitor assays. causal interaction,unassigned 4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16407226&form=6&db=m Identification of myxomaviral serpin reactive site loop sequences that regulate innate immune responses. causal interaction,therapeutic application,unassigned 1,3,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16444431&form=6&db=m In vitro Simulation of Therapeutic Thrombolysis With Microtiter Plate Clot-Lysis Assay. unassigned - 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16479196&form=6&db=m Changes in hypercoagulability by asparaginase: a randomized study between two asparaginases. causal interaction,ongoing research,therapeutic application,unassigned 3,3,2,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16480936&form=6&db=m The role of beta2-glycoprotein I (beta2GPI) in the activation of plasminogen. diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16683213&form=6&db=m Enhanced spontaneous thrombolysis: a new therapeutic challenge. unassigned - 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16689763&form=6&db=m Insights into abnormal hemostasis in the Quebec platelet disorder from analyses of clot lysis. unassigned - 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16788320&form=6&db=m Resistance of porcine blood clots to lysis relates to poor activation of porcine plasminogen by tissue plasminogen activator. therapeutic application,unassigned 2,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16849017&form=6&db=m Intraluminal thrombus enhances proteolysis in abdominal aortic aneurysms. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,1,2,2 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16869305&form=6&db=m [Staphylokinase--a specific plasminogen activator] causal interaction,therapeutic application,unassigned 1,4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16959691&form=6&db=m Spontaneous thrombolysis: a forgotten determinant of life or death. unassigned - 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16963535&form=6&db=m Risk factors for chronic thromboembolic pulmonary hypertension. causal interaction,unassigned 3,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17001771&form=6&db=m Haemostasis. unassigned - 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17213677&form=6&db=m Antithrombotic effects of odorless garlic powder both in vitro and in vivo. causal interaction,unassigned 1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17223743&form=6&db=m Alfimeprase: a novel recombinant direct-acting fibrinolytic. causal interaction,therapeutic application,unassigned 3,3,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17315612&form=6&db=m [Haemostatic and inflammation markers in acute coronary syndromes and its relationship with adverse cardiovascular events] causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17352452&form=6&db=m Topology of the fibrinolytic system within the mural thrombus of human abdominal aortic aneurysms. causal interaction,unassigned 2,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17357310&form=6&db=m Activity of coagulation and fibrinolytic system components in the vein thrombus. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,2,2 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17379840&form=6&db=m Vascular functions of the plasminogen activation system. causal interaction,unassigned 4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17414214&form=6&db=m Fibrinolysis and the risk of venous and arterial thrombosis. causal interaction,diagnostic usage,therapeutic application,unassigned 3,2,2,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17503307&form=6&db=m Management of hydrocephalus in children with plasminogen deficiency. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17597989&form=6&db=m Reminiscences of my contributions to Thrombosis and Haemostasis: urine tissue factor and plasma plasmin inhibitor. diagnostic usage,unassigned 3,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17646899&form=6&db=m IgG antibodies to plasminogen and their relationship to IgG anti-beta(2)-glycoprotein 1 antibodies and thrombosis. diagnostic usage,ongoing research,unassigned 3,2,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17681580&form=6&db=m Effect of mutalysin II on vascular recanalization after thrombosis induction in the ear of the hairless mice model. ongoing research,therapeutic application,unassigned 3,2,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17883703&form=6&db=m Fibrinolysis is amplified by converting alpha-antiplasmin from a plasmin inhibitor to a substrate. therapeutic application,unassigned 4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17896948&form=6&db=m Plasminogen activator inhibitor-1 in vascular thrombosis. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17964518&form=6&db=m The effect of fibrinolytic enzyme FII(a) from Agkistrodon acutus venom on disseminated intravascular coagulation in rabbits. ongoing research,therapeutic application,unassigned 2,2,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18333378&form=6&db=m A clinical approach in regression of glomerulosclerosis. causal interaction,therapeutic application,unassigned 3,3,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18384651&form=6&db=m A first-in-human phase I trial of locally delivered human plasmin for hemodialysis graft occlusion. ongoing research,therapeutic application,unassigned 1,1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18660649&form=6&db=m Pharmacology of cyclooxygenase-2 inhibitors and preemptive analgesia in acute pain management. causal interaction,diagnostic usage,unassigned 3,3,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18701142&form=6&db=m Development of catheter-directed intrathrombus thrombolysis with plasmin for the treatment of acute lower extremity arterial occlusion. unassigned - 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18710020&form=6&db=m [Hemostasis system and inflammation acute-phase proteins in thrombogenic pathologies] causal interaction,unassigned 4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18718639&form=6&db=m Structure and activity of plasmin and other direct thrombolytic agents. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18760830&form=6&db=m Phase 1 study of human plasma-derived plasmin (TAL-05-00018) in hemodialysis graft occlusion. therapeutic application,unassigned 1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18954937&form=6&db=m Increased soluble urokinase plasminogen activator receptor (suPAR) is associated with thrombosis and inhibition of plasmin generation in paroxysmal nocturnal hemoglobinuria (PNH) patients. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19126301&form=6&db=m Anticoagulant and antithrombotic activity of a new peptide pENW (pGlu-Asn-Trp). ongoing research,unassigned 2,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19132220&form=6&db=m Integration of non-SMAD and SMAD signaling in TGF-beta1-induced plasminogen activator inhibitor type-1 gene expression in vascular smooth muscle cells. causal interaction,therapeutic application,unassigned 2,1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19141167&form=6&db=m Plasminogen deficiency. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19207486&form=6&db=m Tranexamic acid can inhibit tongue squamous cell carcinoma invasion in vitro. causal interaction,diagnostic usage,therapeutic application,unassigned 4,1,4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19236611&form=6&db=m Textilinin-1, an alternative anti-bleeding agent to aprotinin: Importance of plasmin inhibition in controlling blood loss. unassigned - 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19242237&form=6&db=m Thrombolysis for intravascular thrombosis in neonates and children. therapeutic application,unassigned 1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19303506&form=6&db=m Thrombolytic therapy for deep vein thrombosis: potential application of plasmin. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19481472&form=6&db=m Locally applied recombinant plasmin results in effective thrombolysis in a porcine model of arteriovenous graft thrombosis. causal interaction,therapeutic application,unassigned 2,4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19551349&form=6&db=m Modification of fibrin structure as a possible cause of thrombolytic resistance. diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19552570&form=6&db=m Thrombin activity throughout the acute phase of acute ST-elevation myocardial infarction and the relation to outcome. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,2,4 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19605778&form=6&db=m The tissue-type plasminogen activator story. causal interaction,ongoing research,therapeutic application,unassigned 1,4,4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19834783&form=6&db=m Thrombolytic efficacy of recombinant human microplasmin in a canine model of copper coil-induced coronary artery thrombosis. ongoing research,unassigned 4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20068577&form=6&db=m Annexin A2 combined with low-dose tPA improves thrombolytic therapy in a rat model of focal embolic stroke. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,2,4 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20106478&form=6&db=m Lipoprotein(a) and ischemic heart disease-A causal association? A review. unassigned - 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20300292&form=6&db=m t-plasminogen activator inhibitor-1 polymorphism in idiopathic pulmonary arterial hypertension. causal interaction,ongoing research,therapeutic application,unassigned 4,4,3,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20326664&form=6&db=m Intravenous Human Fibrinolysin in the Treatment of Intravascular Thrombosis. causal interaction,therapeutic application,unassigned 2,4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20326666&form=6&db=m Intravenous Human Fibrinolysin in the Treatment of Intravascular Thrombosis. causal interaction,therapeutic application,unassigned 2,4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20326677&form=6&db=m Intravenous Human Fibrinolysin in the Treatment of Intravascular Thrombosis. causal interaction,therapeutic application,unassigned 2,4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20326719&form=6&db=m Intravenous Fibrinolysin in the Treatment of Intravascular Thrombosis. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20385790&form=6&db=m Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1. causal interaction,diagnostic usage,therapeutic application,unassigned 3,2,2,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20410503&form=6&db=m Sustained thromboprophylaxis mediated by an RBC-targeted pro-urokinase zymogen activated at the site of clot formation. therapeutic application,unassigned 3,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20427940&form=6&db=m Clinical experience with alteplase in the management of intracardiac and major cardiac vessels thrombosis in pediatrics: a case series. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,1,2,3 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20515830&form=6&db=m The physiopathology of lipoprotein (a). causal interaction,unassigned 3,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20609522&form=6&db=m Cloning and characterization of a plasminogen-binding surface-associated enolase from Schistosoma bovis. unassigned - 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20687444&form=6&db=m [New data about lipoprotein(a): a curious molecule or a causal cardiovascular risk factor?] unassigned - 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20886179&form=6&db=m Urokinase plasminogen activator independent early experimental thrombus resolution: MMP2 as an alternative mechanism. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,3,1 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21043917&form=6&db=m Streptokinase inhibits acute platelet thrombus formation in stenosed dog coronary arteries. causal interaction,ongoing research,therapeutic application,unassigned 3,2,3,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21115493&form=6&db=m Feedback regulation of endothelial cell surface plasmin generation by PKC dependent phosphorylation of annexin A2. ongoing research,unassigned 3,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21441137&form=6&db=m Ultrasound-Enhanced Thrombolytic Effect of Tissue Plasminogen Activator-Loaded Echogenic Liposomes in an In Vivo Rabbit Aorta Thrombus Model. ongoing research,unassigned 2,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21707474&form=6&db=m Effects of Altered Plasminogen Activator Inhibitor-1 Expression on Cardiovascular Disease. causal interaction,ongoing research,therapeutic application,unassigned 1,3,1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21707475&form=6&db=m Plasminogen Activation-Based Thrombolysis for Ischaemic Stroke: The Diversity of Targets may Demand New Approaches. causal interaction,therapeutic application,unassigned 2,4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21731957&form=6&db=m From Cerius(2) based stereoview to mouse and enzyme: the model systems for discovery of novel urokinase inhibitors. diagnostic usage,ongoing research,therapeutic application,unassigned 3,3,1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21732261&form=6&db=m [Inferior vena cava thrombosis after laparoscopy]. therapeutic application,unassigned 3,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21781253&form=6&db=m Tissue-type plasminogen activator-mediated plasminogen activation and contact activation, implications in and beyond haemostasis. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,1,1,1 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21908427&form=6&db=m The role of the annexin A2 heterotetramer in vascular fibrinolysis. ongoing research,unassigned 2,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22023612&form=6&db=m Combination treatment with rt-PA is more effective than rt-PA alone in an in vitro human clot model. causal interaction,ongoing research,therapeutic application,unassigned 3,4,4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22046771&form=6&db=m [Liver cirrhosis--procoagulant stasis]. diagnostic usage,unassigned 2,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22079561&form=6&db=m tPA in the injured central nervous system: different scenarios starring the same actor? causal interaction,ongoing research,therapeutic application,unassigned 1,2,3,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22133272&form=6&db=m Thrombolytic efficacy of tissue plasminogen activator-loaded echogenic liposomes in a rabbit thrombus model. causal interaction,ongoing research,therapeutic application,unassigned 1,2,4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22166587&form=6&db=m Hemostatic Abnormalities in Cirrhosis and Tumor-Related Portal Vein Thrombosis. diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22222184&form=6&db=m Functionalized carriers for the improved delivery of plasminogen activators. causal interaction,ongoing research,therapeutic application,unassigned 1,3,1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22230042&form=6&db=m SMTP (Stachybotrys microspora triprenyl phenol) enhances clot clearance in a pulmonary embolism model in rats. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22382155&form=6&db=m Factors Affecting Clot Lysis Rates in Patients With Spontaneous Intraventricular Hemorrhage. diagnostic usage,ongoing research,therapeutic application,unassigned 3,2,2,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22386870&form=6&db=m Bafibrinase: A non-toxic, non-hemorrhagic, direct-acting fibrinolytic serine protease from Bacillus sp. strain AS-S20-I exhibits in vivo anticoagulant activity and thrombolytic potency. ongoing research,unassigned 1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22449927&form=6&db=m Detection and treatment of intravascular thrombi with magnetofluorescent nanoparticles. therapeutic application,unassigned 2,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22507544&form=6&db=m Fibrinogen counteracts the antiadhesive effect of fibrin-bound plasminogen by preventing its activation by adherent U937 monocytic cells. diagnostic usage,unassigned 3,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22518846&form=6&db=m Streptococcus uberis plasminogen activator (SUPA) activates human plasminogen through novel species-specific and fibrin-targeted mechanisms. causal interaction,unassigned 1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22543060&form=6&db=m Serum proteomic signature of human chagasic patients for the identification of novel potential protein biomarkers of disease. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22759629&form=6&db=m Determinants of fibrin formation, structure, and function. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22796119&form=6&db=m The role of urokinase plasminogen activator and plasmin activator inhibitor-1 on vein wall remodeling in experimental deep vein thrombosis. causal interaction,ongoing research,therapeutic application,unassigned 2,1,4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22815383&form=6&db=m Plasmin-driven fibrinolysis facilitates skin tumor growth in a gender-dependent manner. causal interaction,ongoing research,unassigned 4,4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22822039&form=6&db=m The tissue-type plasminogen activator-plasminogen activator inhibitor 1 complex promotes neurovascular injury in brain trauma: evidence from mice and humans. causal interaction,ongoing research,therapeutic application,unassigned 2,2,3,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22852472&form=6&db=m Targeted thrombolysis by using of magnetic mesoporous silica nanoparticles. causal interaction,therapeutic application,unassigned 3,3,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23034825&form=6&db=m Novel and emerging therapies: thrombus-targeted fibrinolysis. therapeutic application,unassigned 3,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23193360&form=6&db=m The annexin A2/S100A10 system in health and disease: emerging paradigms. diagnostic usage,therapeutic application,unassigned 1,1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23220403&form=6&db=m Modelling fibrinolysis: a 3D stochastic multiscale model. causal interaction,therapeutic application,unassigned 2,2,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23381911&form=6&db=m Drug treatment of acute ischemic stroke. ongoing research,therapeutic application,unassigned 1,3,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23404752&form=6&db=m Successful treatment of central venous catheter induced superior vena cava syndrome with ultrasound accelerated catheter-directed thrombolysis. therapeutic application,unassigned 3,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23408770&form=6&db=m Development of an immunoaffinity method for purification of streptokinase. therapeutic application,unassigned 2,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23527289&form=6&db=m Gender affects skin wound healing in plasminogen deficient mice. causal interaction,ongoing research,therapeutic application,unassigned 4,2,1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23615379&form=6&db=m Thrombolytics in acute ischaemic stroke: historical perspective and future opportunities. therapeutic application,unassigned 4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23759527&form=6&db=m Prothrombotic effects of thrombolytic therapy in a rat (Rattus norvegicus) model of venous thrombolysis. ongoing research,unassigned 3,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23988002&form=6&db=m Plasminogen Activator Inhibitor with Very Long Half-life (VLHL PAI-1) can Reduce Bleeding in PAI-1-deficient Patients. unassigned - 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24133333&form=6&db=m Acute arterial thrombosis associated with inadvertent high dose of tranexamic acid. causal interaction,unassigned 3,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24196407&form=6&db=m Pneumococcal phosphoglycerate kinase interacts with plasminogen and its tissue activator. causal interaction,diagnostic usage,unassigned 1,1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24749249&form=6&db=m [Polymorphism of the plasminogen activator inhibitor type 1 gene, plasminogen level and thrombosis in patients with antiphospholipid syndrome]. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,2,1 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24943740&form=6&db=m Plasminogen activator-1 overexpression decreases experimental postthrombotic vein wall fibrosis by a non-vitronectin-dependent mechanism. unassigned - 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25003130&form=6&db=m Statistical optimization of fibrinolytic enzyme production using agroresidues by Bacillus cereus IND1 and its thrombolytic activity in vitro. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25163311&form=6&db=m [Plasminogen activation and regulation of fibrinolysis]. unassigned - 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25220760&form=6&db=m Plasminogen in cerebrospinal fluid originates from circulating blood. causal interaction,ongoing research,therapeutic application,unassigned 4,2,2,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25297982&form=6&db=m Dimerized plasmin fragment D as a potential biomarker to predict successful catheter-directed thrombolysis therapy in acute deep vein thrombosis. causal interaction,diagnostic usage,therapeutic application,unassigned 2,3,4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25481811&form=6&db=m A plasmin-activatable thrombin inhibitor reduces experimental thrombosis and assists experimental thrombolysis in murine models. ongoing research,therapeutic application,unassigned 4,4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25533130&form=6&db=m Annexin A2 autoantibodies in thrombosis and autoimmune diseases. therapeutic application,unassigned 1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25576010&form=6&db=m The Fibrinolytic System-More Than Fibrinolysis? therapeutic application,unassigned 1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25576865&form=6&db=m Comparative study on the inhibition of plasmin and delta-plasmin via benzamidine derivatives. unassigned - 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25635856&form=6&db=m Photonic activation of plasminogen induced by low dose UVB. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,3,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25657326&form=6&db=m In Vivo Anticoagulant and Thrombolytic Activities of a Fibrinolytic Serine Protease (Brevithrombolase) With the k-Carrageenan-Induced Rat Tail Thrombosis Model. ongoing research,therapeutic application,unassigned 3,1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25712989&form=6&db=m Plasminogen associates with phosphatidylserine-exposing platelets and contributes to thrombus lysis under flow. therapeutic application,unassigned 1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25714359&form=6&db=m Physical determinants of fibrinolysis in single fibrin fibers. therapeutic application,unassigned 1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25809122&form=6&db=m Cerebrospinal fluid proteomics in children during induction for acute lymphoblastic leukemia: A pilot study. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25883230&form=6&db=m Platelets: connecting clotting and lysis. therapeutic application,unassigned 1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25883959&form=6&db=m Application of long-acting VLHL PAI-1 during sutureless partial nephrectomy in mice reduces bleeding. therapeutic application,unassigned 1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25886739&form=6&db=m Soluble expression, purification, and characterization of active recombinant human tissue plasminogen activator by auto-induction in E. coli. therapeutic application,unassigned 2,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25895360&form=6&db=m [Structure and functions of plasminogen/plasmin system]. therapeutic application,unassigned 1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26054637&form=6&db=m High-level expression, purification, and enzymatic characterization of truncated human plasminogen (Lys531-Asn791) in the methylotrophic yeast Pichia pastoris. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26074048&form=6&db=m Engineering of plasminogen activators for targeting to thrombus and heightening thrombolytic efficacy. therapeutic application,unassigned 3,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26154643&form=6&db=m Approach to thrombotic occlusion related to long-term catheters of hemodialysis patients: a narrative review. therapeutic application,unassigned 4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26366880&form=6&db=m The Internal Dynamics of Fibrinogen and Its Implications for Coagulation and Adsorption. diagnostic usage,therapeutic application,unassigned 3,1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26441525&form=6&db=m Breaking boundaries-coagulation and fibrinolysis at the neurovascular interface. therapeutic application,unassigned 1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26463967&form=6&db=m Epsilon Aminocaproic Acid Pretreatment Provides Neuroprotection Following Surgically Induced Brain Injury in a Rat Model. causal interaction,therapeutic application,unassigned 1,2,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26551872&form=6&db=m Immobilization of bioactive plasmin reduces the thrombogenicity of metal surfaces. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26590504&form=6&db=m Heparin versus 0.9% sodium chloride intermittent flushing for the prevention of occlusion in long term central venous catheters in infants and children. unassigned - 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26647358&form=6&db=m Lipoprotein(a): truly a direct prothrombotic factor in cardiovascular disease? causal interaction,therapeutic application,unassigned 3,3,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26658895&form=6&db=m Schistosomes Enhance Plasminogen Activation: The Role of Tegumental Enolase. therapeutic application,unassigned 3,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26822735&form=6&db=m Enolase, a plasminogen receptor isolated from salivary gland transcriptome of the ixodid tick Haemaphysalis flava. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26855483&form=6&db=m Lipoprotein (a): a Unique Independent Risk Factor for Coronary Artery Disease. causal interaction,unassigned 3,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26937905&form=6&db=m Disequilibrium of Blood Coagulation and Fibrinolytic System in Patients With Coronary Artery Ectasia. causal interaction,unassigned 2,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26993683&form=6&db=m Recanalization and flow regulate venous thrombus resolution and matrix metalloproteinase expression in vivo. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,2,1,1 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27077125&form=6&db=m Complement Activation in Arterial and Venous Thrombosis is Mediated by Plasmin. causal interaction,ongoing research,therapeutic application,unassigned 4,1,1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27125108&form=6&db=m [The State of Coagulation Hemostasis and Fibrinolysis in Children With Essential Arterial Hypertension]. diagnostic usage,unassigned 2,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27301942&form=6&db=m Prothrombotic State in Patients With a Left Atrial Appendage Thrombus of Unknown Origin and Cerebrovascular Events. diagnostic usage,unassigned 2,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27319402&form=6&db=m Physiologic variations in blood plasminogen levels affect outcomes after acute cerebral thromboembolism in mice: a pathophysiologic role for microvascular thrombosis. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,1,4,3 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27417437&form=6&db=m A lethal phenotype associated with tissue plasminogen deficiency in humans. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27472427&form=6&db=m Decreased Plasma Fibrinolytic Potential As a Risk for Venous and Arterial Thrombosis. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27514025&form=6&db=m Conformational quiescence of ADAMTS13 prevents proteolytic promiscuity. therapeutic application,unassigned 4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27605514&form=6&db=m Effect of Two Lipoprotein (a)-Associated Genetic Variants on Plasminogen Levels and Fibrinolysis. diagnostic usage,unassigned 3,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27768026&form=6&db=m Combined Near-infrared Fluorescent Imaging and Micro-computed Tomography for Directly Visualizing Cerebral Thromboemboli. ongoing research,therapeutic application,unassigned 2,3,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27818918&form=6&db=m The fate of medications evaluated for ischemic stroke pharmacotherapy over the period 1995-2015. ongoing research,therapeutic application,unassigned 3,2,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27833372&form=6&db=m therapeutic application,unassigned 4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27890301&form=6&db=m Thrombolytic therapy-associated acute myocardial infarction in patients with acute ischemic stroke: A treatment dilemma. causal interaction,unassigned 4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27904545&form=6&db=m Treatment of Recurrent Prosthetic Mitral Valve Thrombosis with Reteplase: A Report of Four Cases. ongoing research,therapeutic application,unassigned 1,4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27976734&form=6&db=m The Unravelling of the Genetic Architecture of Plasminogen Deficiency and its Relation to Thrombotic Disease. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28028005&form=6&db=m Releasing the Brakes on the Fibrinolytic System in Pulmonary Emboli: Unique Effects of Plasminogen Activation and ?2-Antiplasmin Inactivation. causal interaction,ongoing research,therapeutic application,unassigned 3,4,3,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28275409&form=6&db=m PAI-1 Inhibition - Another Therapeutic Option for Cardiovascular Protection. causal interaction,unassigned 1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28455924&form=6&db=m Thrombolytic Agents. therapeutic application,unassigned 1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28925023&form=6&db=m Fibrinolysis: from blood to the brain. causal interaction,ongoing research,therapeutic application,unassigned 1,2,3,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28980900&form=6&db=m One year in review 2017: Behçet's syndrome. unassigned - 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29296720&form=6&db=m X-ray crystal structure of plasmin with tranexamic acid-derived active site inhibitors. unassigned - 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29374103&form=6&db=m Erythrocyte Fraction Within Retrieved Thrombi Contributes to Thrombolytic Response in Acute Ischemic Stroke. therapeutic application,unassigned 1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29411742&form=6&db=m [Indicators of homeostasis, inflammation and homocysteine in ischemic stroke in the young age]. causal interaction,unassigned 3,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29555911&form=6&db=m Ixonnexin from Tick Saliva Promotes Fibrinolysis by Interacting with Plasminogen and Tissue-Type Plasminogen Activator, and Prevents Arterial Thrombosis. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29844028&form=6&db=m Taurine Reduces tPA (Tissue-Type Plasminogen Activator)-Induced Hemorrhage and Microvascular Thrombosis After Embolic Stroke in Rat. causal interaction,ongoing research,therapeutic application,unassigned 3,4,4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29872262&form=6&db=m Effects of hemocoagulase agkistrodon on the coagulation factors and its procoagulant activities. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30046728&form=6&db=m Update on the electrolytic IVC model for pre-clinical studies of venous thrombosis. diagnostic usage,therapeutic application,unassigned 1,1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30114949&form=6&db=m Glucose Concentration Affects Fibrin Clot Structure and Morphology as Evidenced by Fluorescence Imaging and Molecular Simulations. causal interaction,diagnostic usage,unassigned 3,2,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30354249&form=6&db=m Microfluidic Modeling of Thrombolysis. therapeutic application,unassigned 1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30410653&form=6&db=m Pharmacologic and Pharmacomechanical Thrombolysis for Acute Deep Vein Thrombosis: Focus on ATTRACT CME. therapeutic application,unassigned 3,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30532017&form=6&db=m Antithrombotic effects and related mechanisms of Salvia deserta Schang root EtOAc extracts. diagnostic usage,ongoing research,therapeutic application,unassigned 1,4,1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30575685&form=6&db=m Tranexamic acid mediates proinflammatory and anti-inflammatory signaling via complement C5a regulation in a plasminogen activator-dependent manner. causal interaction,diagnostic usage,therapeutic application,unassigned 2,1,2,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30643799&form=6&db=m Homocysteine-Enhanced Proteolytic and Fibrinolytic Processes in Thin Intraluminal Thrombus and Adjacent Wall of Abdominal Aortic Aneurysm: Study In Vitro. unassigned - 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31024058&form=6&db=m Sulfenamide and Sulfonamide Derivatives of Metformin - A New Option to Improve Endothelial Function and Plasma Haemostasis. diagnostic usage,ongoing research,unassigned 1,3,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31353231&form=6&db=m Impact of lipoprotein apheresis on thrombotic parameters in patients with refractory angina and raised lipoprotein(a): Findings from a randomized controlled cross-over trial. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31395599&form=6&db=m Venous stasis-induced fibrinolysis prevents thrombosis in mice: role of ?2-antiplasmin. ongoing research,therapeutic application,unassigned 3,2,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31507620&form=6&db=m Plasminflammation-An Emerging Pathway to Bradykinin Production. causal interaction,therapeutic application,unassigned 1,3,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31529593&form=6&db=m Engineered Micro- and Nanoparticles for Fibrinolysis. causal interaction,therapeutic application,unassigned 4,2,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31541014&form=6&db=m Acute ischemic stroke thrombi have an outer shell that impairs fibrinolysis. causal interaction,therapeutic application,unassigned 2,1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31788896&form=6&db=m Engineered Nanoplatelets for Targeted Delivery of Plasminogen Activators to Reverse Thrombus in Multiple Mouse Thrombosis Models. causal interaction,ongoing research,therapeutic application,unassigned 4,3,4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31871595&form=6&db=m Outcome of Acute Deep Venous Thrombosis Using Standard Treatment versus Thrombolytics: A Literature Review. therapeutic application,unassigned 1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31894036&form=6&db=m Efficacy of different doses of alteplase thrombolysis on acute ischemic stroke in patients. diagnostic usage,ongoing research,therapeutic application,unassigned 2,3,4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32098782&form=6&db=m Schistosoma mansoni glyceraldehyde-3-phosphate dehydrogenase enhances formation of the blood-clot lysis protein plasmin. causal interaction,therapeutic application,unassigned 3,2,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32173431&form=6&db=m Novel Pheretima guillelmi-derived antithrombotic protein DPf3: Identification, characterization, in vitro evaluation and antithrombotic mechanisms investigation. ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32263765&form=6&db=m Streptokinase@alumina nanoparticles as a promising thrombolytic colloid with prolonged action. diagnostic usage,ongoing research,unassigned 1,4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32598807&form=6&db=m [Fibrinolytics: from the thrombolysis to the processes of blood vessels growth and remodeling, neurogenesis, carcinogenesis and fibrosis]. causal interaction,therapeutic application,unassigned 2,3,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32610551&form=6&db=m Genetic Variants in the FGB and FGG Genes Mapping in the Beta and Gamma Nodules of the Fibrinogen Molecule in Congenital Quantitative Fibrinogen Disorders Associated with a Thrombotic Phenotype. causal interaction,therapeutic application,unassigned 1,1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32728402&form=6&db=m Current Trends on Glomerulosclerosis Regression. unassigned - 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32790000&form=6&db=m Thrombolytic Agents: Nanocarriers in Controlled Release. unassigned - 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33496742&form=6&db=m Plasminogen activator inhibitor 1 and venous thrombosis in pancreatic cancer. causal interaction,ongoing research,therapeutic application,unassigned 3,4,4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33535668&form=6&db=m The Role of the Plasminogen Activation System in Angioedema: Novel Insights on the Pathogenesis. ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33612738&form=6&db=m Clone, expression and plasminogen binding property of three fructose-1,6-bisphosphate aldolases from Clonorchis sinensis. causal interaction,unassigned 4,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34344416&form=6&db=m Thrombomodulin is associated with increased mortality and organ failure in mechanically ventilated children with acute respiratory failure: biomarker analysis from a multicenter randomized controlled trial. ongoing research,therapeutic application,unassigned 1,1,0 3.4.21.7 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34356659&form=6&db=m Fibrinogen and a Triad of Thrombosis, Inflammation, and the Renin-Angiotensin System in Premature Coronary Artery Disease in Women: A New Insight into Sex-Related Differences in the Pathogenesis of the Disease. causal interaction,unassigned 4,0 3.4.21.7 Thrombotic Microangiopathies http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8943484&form=6&db=m Different expression of the plasminogen activation system in renal thrombotic microangiopathy and the normal human kidney. diagnostic usage,ongoing research,therapeutic application,unassigned 4,4,2,0 3.4.21.7 Thrombotic Microangiopathies http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24449821&form=6&db=m Plasmin Cleavage of von Willebrand Factor as an Emergency Bypass for ADAMTS13 Deficiency in Thrombotic Microangiopathy. causal interaction,diagnostic usage,unassigned 4,3,0 3.4.21.7 Thrombotic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3142317&form=6&db=m Investigational use of tPA in acute stroke. ongoing research,therapeutic application,unassigned 1,2,0 3.4.21.7 Thrombotic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6219694&form=6&db=m Activation of coagulation and fibrinolytic systems following stroke. causal interaction,diagnostic usage,unassigned 4,3,0 3.4.21.7 Thrombotic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9646779&form=6&db=m Interventional use of plasminogen activators in central nervous system diseases. ongoing research,therapeutic application,unassigned 1,4,0 3.4.21.7 Thrombotic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10621877&form=6&db=m Circadian fluctuations in the efficacy of thrombolysis with streptokinase. diagnostic usage,ongoing research,therapeutic application,unassigned 2,1,4,0 3.4.21.7 Thrombotic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15322296&form=6&db=m Microplasmin reduces ischemic brain damage and improves neurological function in a rat stroke model monitored with MRI. diagnostic usage,ongoing research,unassigned 3,2,0 3.4.21.7 Thrombotic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31526124&form=6&db=m Pharmacological Modulation of Neutrophil Extracellular Traps Reverses Thrombotic Stroke tPA (Tissue-Type Plasminogen Activator) Resistance. causal interaction,ongoing research,therapeutic application,unassigned 1,2,4,0 3.4.21.7 Thyroid Cancer, Papillary http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21191179&form=6&db=m Downregulation of uPAR inhibits migration, invasion, proliferation, FAK/PI3K/Akt signaling and induces senescence in papillary thyroid carcinoma cells. causal interaction,unassigned 3,0 3.4.21.7 Thyroid Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11510147&form=6&db=m [Plasminogen activators of urokinase and tissue types and their inhibitor (PAI-1) in cytosol fraction in thyroid diseases] causal interaction,diagnostic usage,ongoing research,unassigned 3,2,2,0 3.4.21.7 Thyroid Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8615674&form=6&db=m Plasminogen activation system in active even in thyroid tumors; an immunohistochemical study. causal interaction,ongoing research,therapeutic application,unassigned 4,4,2,0 3.4.21.7 Thyroid Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10524570&form=6&db=m Degradation of extracellular matrix by metastatic follicular thyroid carcinoma cell lines: role of the plasmin activation system. causal interaction,ongoing research,unassigned 4,4,0 3.4.21.7 Thyroid Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11054636&form=6&db=m Beneficial effects of retinoic acid on extracellular matrix degradation and attachment behaviour in follicular thyroid carcinoma cell lines. causal interaction,ongoing research,unassigned 1,4,0 3.4.21.7 Thyroid Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20616713&form=6&db=m Molecular regulation of thyroid gland function. causal interaction,unassigned 2,0 3.4.21.7 Thyroid Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23095556&form=6&db=m The urokinase plasminogen activating system in thyroid cancer: clinical implications. causal interaction,ongoing research,therapeutic application,unassigned 1,1,2,0 3.4.21.7 Thyroid Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26633361&form=6&db=m The Importance of Caveolin-1 as Key-Regulator of Three-Dimensional Growth in Thyroid Cancer Cells Cultured under Real and Simulated Microgravity Conditions. unassigned - 3.4.21.7 Tonsillitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=464529&form=6&db=m Fibrinolytic activity in patients with acute tonsillitis. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,1,0 3.4.21.7 Tonsillitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=5496048&form=6&db=m [Activity of fibrinase in patients with chronic tonsillitis] causal interaction,diagnostic usage,ongoing research,unassigned 3,4,2,0 3.4.21.7 Tonsillitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=5503566&form=6&db=m [Activity of fibrinase in patients with chronic tonsillitis] causal interaction,diagnostic usage,ongoing research,unassigned 3,4,2,0 3.4.21.7 Tonsillitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6225744&form=6&db=m Control of Arthus tonsillitis by the administration of an antiplasminic agent. diagnostic usage,unassigned 1,0 3.4.21.7 Tonsillitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6451139&form=6&db=m Arthus tonsillitis in the rabbit. Histological findings and fibrinolytic activity in the blood. diagnostic usage,unassigned 1,0 3.4.21.7 Tonsillitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14570069&form=6&db=m [A 50-year history of new drugs in Japan-the development and trends of hemostatics and antithrombotic drugs] diagnostic usage,therapeutic application,unassigned 3,3,0 3.4.21.7 Tooth Mobility http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25971786&form=6&db=m Periodontitis associated with plasminogen deficiency: a case report. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 Toxemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2273312&form=6&db=m [Blood coagulation and fibrinolytic studies in patients with toxemia of pregnancy] unassigned - 3.4.21.7 Toxemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3240888&form=6&db=m Coagulation-fibrinolytic and kinin-forming systems in toxemia of pregnancy. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.7 Toxemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6445089&form=6&db=m Studies on the purification and characterization of human urinary plasminogen and plasmin. causal interaction,diagnostic usage,ongoing research,unassigned 3,1,2,0 3.4.21.7 Toxemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6450509&form=6&db=m Urinary fibrinolysis in toxemia of pregnancy. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,1,1 3.4.21.7 Toxemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6652168&form=6&db=m Coagulation, fibrinolysis, platelet and kinin-forming systems during toxemia of pregnancy. causal interaction,diagnostic usage,unassigned 3,2,0 3.4.21.7 Toxemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30781907&form=6&db=m Studies on the Purification and Characterization of Human Urinary Plasminogen and Plasmin. diagnostic usage,unassigned 1,0 3.4.21.7 Toxoplasmosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22268271&form=6&db=m Induction of plasminogen activators in pregnant women with Toxoplasma gondii infection. ongoing research,therapeutic application,unassigned 1,1,0 3.4.21.7 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10858253&form=6&db=m Binding and activation of human plasminogen by Mycobacterium tuberculosis. diagnostic usage,ongoing research,therapeutic application,unassigned 3,4,1,0 3.4.21.7 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15963051&form=6&db=m Bioactivation of latent transforming growth factor beta1 by Mycobacterium tuberculosis in human mononuclear phagocytes. causal interaction,unassigned 3,0 3.4.21.7 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17474886&form=6&db=m Fibrinolytic characteristics and their significance in malignant, tuberculous and cirrhotic pleural and ascitic fluids. causal interaction,therapeutic application,unassigned 2,1,0 3.4.21.7 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27569900&form=6&db=m Enolase of Mycobacterium tuberculosis is a surface exposed plasminogen binding protein. causal interaction,therapeutic application,unassigned 2,1,0 3.4.21.7 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28888036&form=6&db=m Exploring the interaction between Mycobacterium tuberculosisEnolase and human plasminogen using computational methods and experimental techniques. causal interaction,unassigned 1,0 3.4.21.7 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31378266&form=6&db=m Interaction of mycobacteria with Plasmin(ogen) affects phagocytosis and granuloma development. causal interaction,therapeutic application,unassigned 2,1,0 3.4.21.7 Tuberculosis, Meningeal http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16810833&form=6&db=m Bacterial Fibrinolysin, its Possible Therapeutic Application in Tuberculous Meningitis. therapeutic application,unassigned 4,0 3.4.21.7 Tuberculosis, Meningeal http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18111399&form=6&db=m Bacterial fibrinolysin, its possible therapeutic application in tuberculous meningitis. therapeutic application,unassigned 4,0 3.4.21.7 Tularemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9479360&form=6&db=m [Adjuvant immunotherapy for patients with cancer of corpus uteri] therapeutic application,unassigned 2,0 3.4.21.7 Tympanic Membrane Perforation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18781446&form=6&db=m Lack of plasminogen does not alter the early inflammatory response following a tympanic membrane perforation: a study in plasminogen-deficient mice. ongoing research,therapeutic application,unassigned 1,3,0 3.4.21.7 Tympanic Membrane Perforation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24669846&form=6&db=m Animal models of chronic tympanic membrane perforation: in response to plasminogen initiates and potentiates the healing of acute and chronic tympanic membrane perforations in mice. diagnostic usage,ongoing research,therapeutic application,unassigned 1,3,1,0 3.4.21.7 Tympanic Membrane Perforation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25852824&form=6&db=m A reply to the commentary on "Animal models of chronic tympanic membrane perforation: in response to plasminogen initiates and potentiates the healing of acute and chronic tympanic membrane perforations in mice" by Wang AY, Shen Y, Wang JT, Eikelboom RH and Dilley RJ; Clin Translat Med, 2014; 3:5. ongoing research,unassigned 1,0 3.4.21.7 u-plasminogen activator deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11487021&form=6&db=m Plasmin and matrix metalloproteinases in vascular remodeling. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 Ureteral Obstruction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19350108&form=6&db=m Serine proteases, inhibitors and receptors in renal fibrosis. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 Urinary Bladder Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6779412&form=6&db=m Immunological analysis of plasminogen activators from cultured human cancer cells. diagnostic usage,ongoing research,therapeutic application,unassigned 3,4,1,0 3.4.21.7 Urinary Bladder Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7193258&form=6&db=m [The investigation on early diagnosis of the bladder tumor. II: A study on urinary cytology, urinary fibrin/fibrinogen degradation products, tissue fibrin deposition and tissue plasminogen activator activity in patients with bladder tumors (author's transl)] diagnostic usage,ongoing research,therapeutic application,unassigned 2,1,1,0 3.4.21.7 Urinary Bladder Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9168186&form=6&db=m Urokinase and the urokinase receptor: association with in vitro invasiveness of human bladder cancer cell lines. causal interaction,ongoing research,therapeutic application,unassigned 3,4,1,0 3.4.21.7 Urinary Bladder Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12778082&form=6&db=m Gene therapy for bladder cancer using E1B-55 kD-deleted adenovirus in combination with adenoviral vector encoding plasminogen kringles 1-5. therapeutic application,unassigned 4,0 3.4.21.7 Urinary Bladder Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14555531&form=6&db=m Is interferon gamma one key of metastatic potential increase in human bladder carcinoma? ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.7 Urogenital Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6156074&form=6&db=m Transferrin, C3 complement, haptoglobin, plasminogen and alpha 2-microglobulin in patients with urogenital tumors. causal interaction,diagnostic usage,unassigned 2,2,0 3.4.21.7 Urologic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8140679&form=6&db=m Plasminogen activators and plasminogen activator inhibitor 1 in urinary tract cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,3,4 3.4.21.7 Uterine Cervical Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7971179&form=6&db=m [Studies on serum protein fractions of patients with uterine cervical cancer undergoing radiotherapy: relationship between changes in serum protein fractions and prognosis] causal interaction,diagnostic usage,unassigned 2,3,0 3.4.21.7 Uterine Cervical Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34094663&form=6&db=m ENO1 monoclonal antibody inhibits invasion, proliferation and clone formation of cervical cancer cells. unassigned - 3.4.21.7 Uterine Cervicitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23518917&form=6&db=m Ligneous Cervicitis in a Woman With Plasminogen Deficiency Associated With an Atypical Form of Microglandular Hyperplasia: A Case Report and Review of Literature. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 Uterine Cervicitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29436075&form=6&db=m Ligneous cervicitis and endometritis: A gynaecological presentation of congenital plasminogen deficiency. causal interaction,therapeutic application,unassigned 4,2,0 3.4.21.7 Uterine Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8311162&form=6&db=m [Changes in the hemostatic system in anomalous uterine hemorrhages and uterine myoma at perimenopause] unassigned - 3.4.21.7 Uterine Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=13468145&form=6&db=m [The relation of fibrinolysin in uterine bleeding.] causal interaction,diagnostic usage,therapeutic application,unassigned 1,2,2,0 3.4.21.7 Uveitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2410195&form=6&db=m Regulation of anterior chamber fibrinolysis. diagnostic usage,ongoing research,unassigned 1,2,0 3.4.21.7 Uveitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27429702&form=6&db=m Don't Forget What You Can't See: A Case of Ocular Syphilis. diagnostic usage,therapeutic application,unassigned 2,1,0 3.4.21.7 Vaccinia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7797579&form=6&db=m The activation-resistant conformation of recombinant human plasminogen is stabilized by basic residues in the amino-terminal hinge region. ongoing research,therapeutic application,unassigned 4,1,0 3.4.21.7 Vaginitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17889676&form=6&db=m Inherited plasminogen deficiency presenting as ligneous vaginitis: a case report with molecular correlation and review of the literature. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 Varicose Ulcer http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10959063&form=6&db=m Lower levels of PAI-2 may contribute to impaired healing in venous ulcers - a preliminary study. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,3,0 3.4.21.7 Varicose Veins http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1719808&form=6&db=m Significance of hemostatic molecular markers during disseminated intravascular coagulation in patients with liver cirrhosis treated by endoscopic embolization for esophageal varices. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,2,3,1 3.4.21.7 Varicose Veins http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1783414&form=6&db=m Polymorphisms of serum proteins in Japanese patients with vascular diseases. I. Factor XIIIB, plasminogen and complement types in primary varicose veins. diagnostic usage,ongoing research,unassigned 4,1,0 3.4.21.7 Varicose Veins http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8148481&form=6&db=m Fibrinolytic parameters during acute haematemesis in endemic hepatosplenomegaly. ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.7 Varicose Veins http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9306585&form=6&db=m Sclerotherapy for varicose veins of the lower legs in patients with dysplasminogenemia. ongoing research,unassigned 3,0 3.4.21.7 Varicose Veins http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10629572&form=6&db=m Causes of venous thrombosis in fifty Chinese patients. causal interaction,diagnostic usage,therapeutic application,unassigned 2,2,1,0 3.4.21.7 Varicose Veins http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12061687&form=6&db=m Superficial thrombophlebitis of the lower limbs in patients with varicose veins. causal interaction,diagnostic usage,therapeutic application,unassigned 2,3,1,0 3.4.21.7 Varicose Veins http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19214913&form=6&db=m Pathogenesis of venous thromboembolism: when the cup runneth over. therapeutic application,unassigned 1,0 3.4.21.7 Vascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1783414&form=6&db=m Polymorphisms of serum proteins in Japanese patients with vascular diseases. I. Factor XIIIB, plasminogen and complement types in primary varicose veins. diagnostic usage,ongoing research,unassigned 4,1,0 3.4.21.7 Vascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2620588&form=6&db=m [Observation of plasma levels of antithrombin-III and plasminogen in acute cerebrovascular disease] causal interaction,diagnostic usage,ongoing research,unassigned 2,3,2,0 3.4.21.7 Vascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2934312&form=6&db=m PARD: platelet aggregation as a risk factor in diabetics: results of a prospective study. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.21.7 Vascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8191655&form=6&db=m [Clinical significance of the determination of several hemostatic parameters in the lacrimal fluid of patients with vascular diseases of the retina] causal interaction,diagnostic usage,therapeutic application,unassigned 1,3,1,0 3.4.21.7 Vascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8522567&form=6&db=m Hemostatic disorders associated with arterial hypertension and peripheral arterial disease. diagnostic usage,ongoing research,unassigned 4,4,0 3.4.21.7 Vascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8989971&form=6&db=m Young women with advanced aortoiliac occlusive disease: new insights. diagnostic usage,ongoing research,therapeutic application,unassigned 2,1,1,0 3.4.21.7 Vascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9349387&form=6&db=m Arterial expression of the plasminogen activator system early after cardiac transplantation. causal interaction,diagnostic usage,ongoing research,unassigned 3,1,3,0 3.4.21.7 Vascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11306532&form=6&db=m Deficiency of urokinase-type plasminogen activator-mediated plasmin generation impairs vascular remodeling during hypoxia-induced pulmonary hypertension in mice. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 Vascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11795260&form=6&db=m Genetic studies on the role of proteinases and growth factors in atherosclerosis and aneurysm formation. causal interaction,therapeutic application,unassigned 4,3,0 3.4.21.7 Vascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14757164&form=6&db=m Inhibition of plasmin-mediated prostromelysin-1 activation by interaction of long chain unsaturated fatty acids with kringle 5. therapeutic application,unassigned 4,0 3.4.21.7 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6870068&form=6&db=m Thrombin-induced lung vascular injury. Roles of fibrinogen and fibrinolysis. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.7 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9532233&form=6&db=m Structural basis for the pathophysiology of lipoprotein(a) in the athero-thrombotic process. therapeutic application,unassigned 1,0 3.4.21.7 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10845862&form=6&db=m Alpha(2)-antiplasmin gene deficiency in mice does not affect neointima formation after vascular injury. ongoing research,unassigned 1,0 3.4.21.7 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11487021&form=6&db=m Plasmin and matrix metalloproteinases in vascular remodeling. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12637546&form=6&db=m Serp-1, a viral anti-inflammatory serpin, regulates cellular serine proteinase and serpin responses to vascular injury. causal interaction,therapeutic application,unassigned 2,3,0 3.4.21.7 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12893771&form=6&db=m Lack of alpha 2-antiplasmin promotes re-endothelialization via over-release of VEGF after vascular injury in mice. causal interaction,unassigned 2,0 3.4.21.7 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15388580&form=6&db=m Proteolytic inactivation of ADAMTS13 by thrombin and plasmin. diagnostic usage,ongoing research,unassigned 3,1,0 3.4.21.7 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16150044&form=6&db=m Apo(a) promotes thrombosis in a vascular injury model by a mechanism independent of plasminogen. unassigned - 3.4.21.7 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24650562&form=6&db=m Lp(a)/apo(a) Modulate MMP-9 Activation and Neutrophil Cytokines in Vivo in Inflammation to Regulate Leukocyte Recruitment. causal interaction,ongoing research,unassigned 3,1,0 3.4.21.7 Vasculitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=999734&form=6&db=m Coagulation abnormalities in rheumatoid disease. causal interaction,diagnostic usage,ongoing research,unassigned 3,2,2,0 3.4.21.7 Vasculitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2963655&form=6&db=m Vasculitis complicating treatment with intravenous anisoylated plasminogen streptokinase activator complex in acute myocardial infarction. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,1,1,4 3.4.21.7 Vasculitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3056478&form=6&db=m Vasculitis complicating treatment with intravenous anisoylated plasminogen streptokinase activator complex in acute myocardial infarction. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.7 Vasculitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9122714&form=6&db=m The role of inflammatory cells and their proteases in extravascular fibrinolysis. causal interaction,therapeutic application,unassigned 3,3,0 3.4.21.7 Vasculitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11304653&form=6&db=m Impaired activation of the fibrinolytic system in children with Henoch-Schönlein purpura: beneficial effect of hydrocortisone plus Sigma-aminocaproic acid therapy on disappearance rate of cutaneous vasculitis and fibrinolysis. diagnostic usage,ongoing research,therapeutic application,unassigned 3,2,1,0 3.4.21.7 Vasculitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11729664&form=6&db=m [A case of Behçet's disease with chronic and repeated sudden hearing loss: successful treatment with intravenous cyclophosphamide pulse therapy] causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.7 Vasculitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18701607&form=6&db=m Antibodies with dual reactivity to plasminogen and complementary PR3 in PR3-ANCA vasculitis. causal interaction,unassigned 1,0 3.4.21.7 Vasculitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20847144&form=6&db=m Anti-Plasminogen Antibodies Compromise Fibrinolysis and Associate with Renal Histology in ANCA-Associated Vasculitis. unassigned - 3.4.21.7 Vasculitis, Leukocytoclastic, Cutaneous http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7917762&form=6&db=m [Hypersensitivity vasculitis after thrombolytic therapy with APSAC (anisoylated plasminogen streptokinase activator complex). Presentation of a clinical case and review of the literature] causal interaction,therapeutic application,unassigned 2,4,0 3.4.21.7 Vasospasm, Intracranial http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2507953&form=6&db=m Efficacy of single intracisternal bolus injection of recombinant tissue plasminogen activator to prevent delayed cerebral vasospasm after experimental subarachnoid hemorrhage. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,1,2,4 3.4.21.7 Vasospasm, Intracranial http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2579347&form=6&db=m Role of plasmin, thrombin, and antithrombin III as etiological factors in delayed cerebral vasospasm. causal interaction,therapeutic application,unassigned 2,2,0 3.4.21.7 Vasospasm, Intracranial http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26463364&form=6&db=m The evidence for a role of vasospasm in the pathogenesis of cerebral malaria. causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.7 Venous Insufficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18494625&form=6&db=m Effect of oxidised regenerated cellulose/collagen matrix on proteases in wound exudate of patients with chronic venous ulceration. causal interaction,ongoing research,therapeutic application,unassigned 3,3,2,0 3.4.21.7 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1758145&form=6&db=m [Hemostatic changes in idiopathic venous thrombosis in childhood and adolescence] causal interaction,diagnostic usage,unassigned 1,2,0 3.4.21.7 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3730296&form=6&db=m Congenital plasminogen deficiency associated with venous thromboembolism: therapeutic trial with stanozolol. causal interaction,unassigned 4,0 3.4.21.7 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7944258&form=6&db=m Massive acute pulmonary embolism in protein S deficiency--a case report. unassigned - 3.4.21.7 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8089219&form=6&db=m Markers of thrombin and plasmin generation in patients with inherited thrombophilia. causal interaction,diagnostic usage,ongoing research,unassigned 3,4,1,0 3.4.21.7 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9684804&form=6&db=m Is plasminogen deficiency a thrombotic risk factor? A study on 23 thrombophilic patients and their family members. causal interaction,unassigned 4,0 3.4.21.7 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25347092&form=6&db=m Pretreatment plasma D-dimer, fibrinogen, and platelet levels significantly impact prognosis in patients with epithelial ovarian cancer independently of venous thromboembolism. diagnostic usage,ongoing research,unassigned 4,2,0 3.4.21.7 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27085144&form=6&db=m High pretreatment plasma D-dimer levels are related to shorter overall survival in endometrial carcinoma. diagnostic usage,ongoing research,unassigned 4,4,0 3.4.21.7 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28686706&form=6&db=m Plasminogen Tochigi mice exhibit phenotypes similar to wild-type mice under experimental thrombotic conditions. causal interaction,unassigned 4,0 3.4.21.7 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29324332&form=6&db=m Impaired plasminogen binding in patients with venous thromboembolism: Association with protein carbonylation. causal interaction,therapeutic application,unassigned 2,1,0 3.4.21.7 Venous Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30838553&form=6&db=m Is lipoprotein(a) a risk factor for ischemic stroke and venous thromboembolism? causal interaction,unassigned 3,0 3.4.21.7 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=52050&form=6&db=m Treatment of deep-vein thrombosis with intermittent streptokinase and plasminogen infusion. therapeutic application,unassigned 4,0 3.4.21.7 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=73391&form=6&db=m Effects of porcine plasmin on the coagulation and fibrinolytic systems in humans. diagnostic usage,therapeutic application,unassigned 2,1,0 3.4.21.7 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=157109&form=6&db=m [Studies on thrombolytic therapy for venous thrombosis in the extremities--dynamics of plasmin inhibitor and FDP following administration of urokinase (author's transl)] causal interaction,therapeutic application,unassigned 2,4,0 3.4.21.7 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1036801&form=6&db=m Platelet adhesiveness and fibrinolysis after recent cerebro-vascular accidents and their relationship with subsequent deep venous thrombosis of the legs. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,1,0 3.4.21.7 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1455395&form=6&db=m Plasminogen levels in healthy volunteers--influence of age, sex, smoking and oral contraceptives. causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,1,0 3.4.21.7 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1554698&form=6&db=m Multiple members of the plasminogen-apolipoprotein(a) gene family associated with thrombosis. causal interaction,unassigned 4,0 3.4.21.7 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1572039&form=6&db=m Baseline fibrinolytic state and the risk of future venous thrombosis. A prospective study of endogenous tissue-type plasminogen activator and plasminogen activator inhibitor. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,3,2 3.4.21.7 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1674436&form=6&db=m The molecular genetics of familial venous thrombosis. causal interaction,unassigned 3,0 3.4.21.7 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1695173&form=6&db=m Some haemostatic parameters in patients with deep and superficial venous thrombosis. therapeutic application,unassigned 1,0 3.4.21.7 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1796391&form=6&db=m Deep vein thrombosis and fibrinolysis. Defective urokinase type plasminogen activator release. causal interaction,ongoing research,therapeutic application,unassigned 1,3,2,0 3.4.21.7 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2003311&form=6&db=m Cerebral venous thrombosis with plasminogen deficiency. causal interaction,unassigned 4,0 3.4.21.7 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2146503&form=6&db=m Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deep-vein thrombosis. therapeutic application,unassigned 1,0 3.4.21.7 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2238671&form=6&db=m Use of plasminogen activators in venous thrombosis. therapeutic application,unassigned 2,0 3.4.21.7 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2285165&form=6&db=m [Plasminogen depletion and incorporation in experimental venous thrombosis] causal interaction,ongoing research,therapeutic application,unassigned 3,3,4,0 3.4.21.7 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2526603&form=6&db=m Inherited hypercoagulable states in children. unassigned - 3.4.21.7 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2533891&form=6&db=m 99mTc plasmin in 394 consecutive patients with suspected deep venous thrombosis. diagnostic usage,unassigned 1,0 3.4.21.7 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2944241&form=6&db=m Investigation of a congenital abnormal plasminogen, Frankfurt I, and its relationship to thrombosis. causal interaction,unassigned 3,0 3.4.21.7 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2953836&form=6&db=m Distinction by radioisotope technique of a subgroup with increased thrombophilic potential among patients submitted to major abdominal surgery. therapeutic application,unassigned 1,0 3.4.21.7 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2955604&form=6&db=m [Scintigraphic studies with J123 miniplasmin in patients with suspected deep venous thrombosis of the leg: comparison of the diagnostic value of J123 miniplasmin scintigraphy and Tc99m plasmin test] diagnostic usage,unassigned 2,0 3.4.21.7 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2965086&form=6&db=m Congenital abnormal plasminogen, Frankfurt I, a cause for recurrent venous thrombosis. causal interaction,unassigned 3,0 3.4.21.7 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3128802&form=6&db=m [Quantitative determination of tissue-type plasminogen activator in varicose soleus veins] causal interaction,unassigned 3,0 3.4.21.7 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3156739&form=6&db=m 99mTc-plasmin test in deep vein thrombosis of the leg. causal interaction,diagnostic usage,therapeutic application,unassigned 4,4,3,0 3.4.21.7 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3388298&form=6&db=m Congenital deficiency of plasminogen and its relationship to venous thrombosis. causal interaction,diagnostic usage,unassigned 4,1,0 3.4.21.7 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3619142&form=6&db=m [Problems posed by etiologic research on thrombotic conditions] unassigned - 3.4.21.7 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3754931&form=6&db=m [Congenital abnormalities related to coagulation and the fibrinolytic system in patients with vein thrombosis of the lower extremities] causal interaction,diagnostic usage,unassigned 1,2,0 3.4.21.7 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3840289&form=6&db=m Homozygous protein C deficiency combined with heterozygous dysplasminogenemia found in a 21-year-old thrombophilic male. causal interaction,unassigned 3,0 3.4.21.7 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3873118&form=6&db=m Effects of oral stanozolol used in the prevention of postoperative deep vein thrombosis on fibrinolytic activity. diagnostic usage,ongoing research,therapeutic application,unassigned 1,2,4,0 3.4.21.7 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4003389&form=6&db=m Recurring thromboembolic disease and pulmonary hypertension associated with severe hypoplasminogenemia. causal interaction,unassigned 4,0 3.4.21.7 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4233823&form=6&db=m [Results of surgical treatment of acute ileofemoral venous thrombosis with subsequent fibrinolysin and anticoagulant therapy] causal interaction,therapeutic application,unassigned 3,4,0 3.4.21.7 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4257106&form=6&db=m Plasmin generation in dogs with venous thrombosis. causal interaction,therapeutic application,unassigned 2,1,0 3.4.21.7 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4258811&form=6&db=m [Use of fibrinolysin and anticoagulants in the treatment of venous thrombosis of the extremities] therapeutic application,unassigned 4,0 3.4.21.7 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4281116&form=6&db=m Acute deep vein thrombosis treated with porcine plasmin. A double blind trial. ongoing research,therapeutic application,unassigned 3,4,0 3.4.21.7 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6214039&form=6&db=m Acyl-enzymes as thrombolytic agents in a rabbit model of venous thrombosis. unassigned - 3.4.21.7 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6218846&form=6&db=m Thrombin and plasmin activity and platelet activation in the development of venous thrombosis. causal interaction,ongoing research,unassigned 4,1,0 3.4.21.7 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6234676&form=6&db=m Acyl-enzymes as thrombolytic agents in dog models of venous thrombosis and pulmonary embolism. unassigned - 3.4.21.7 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6235087&form=6&db=m Comparison between 99Tcm-porcine plasmin and 99Tcm-labelled erythrocytes in diagnosis of deep vein thrombosis. diagnostic usage,ongoing research,therapeutic application,unassigned 2,2,2,0 3.4.21.7 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6235113&form=6&db=m Diagnosis of deep venous thrombosis with 99mTc plasmin using the gamma camera. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.21.7 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6458112&form=6&db=m The evaluation of plasmin and streptokinase activator complexes in a new rabbit model of venous thrombosis. ongoing research,therapeutic application,unassigned 1,4,0 3.4.21.7 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6505433&form=6&db=m [Local low-dose thrombolytic treatment with sequential urokinase-plasminogen in deep central venous thrombosis] therapeutic application,unassigned 2,0 3.4.21.7 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6506034&form=6&db=m Physiological role of alpha 2-plasmin inhibitor in rats. causal interaction,unassigned 4,0 3.4.21.7 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6719393&form=6&db=m A sequential study of plasma histidine-rich glycoprotein and plasminogen in patients with acute myocardial infarction and deep vein thrombosis. diagnostic usage,ongoing research,therapeutic application,unassigned 3,4,1,0 3.4.21.7 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6986252&form=6&db=m [Fibrinolytic therapy of deep venous thrombosis. Streptokinase, urokinase, plasminogen substitution] therapeutic application,unassigned 4,0 3.4.21.7 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7004530&form=6&db=m Blood tests for the diagnosis of venous and arterial thrombosis. causal interaction,unassigned 4,0 3.4.21.7 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7215189&form=6&db=m [Thrombolytic treatment of venous thrombi with combined use of streptokinase and human plasminogen (author's transl)] diagnostic usage,ongoing research,therapeutic application,unassigned 1,2,1,0 3.4.21.7 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8585005&form=6&db=m Comparison of immunological and functional assays for measurement of soluble fibrin. diagnostic usage,ongoing research,therapeutic application,unassigned 4,4,1,0 3.4.21.7 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8680005&form=6&db=m [Effects of potentiation and rapid action in models of venous thrombosis in dogs upon combined administration of the plasminogen tissue activator and urokinase modified by fibrinogen] ongoing research,therapeutic application,unassigned 1,1,0 3.4.21.7 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8853112&form=6&db=m Thrombolytic agents--an overview. therapeutic application,unassigned 4,0 3.4.21.7 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9175416&form=6&db=m Haemostatic changes in patients with deep vein thrombosis. diagnostic usage,ongoing research,unassigned 2,3,0 3.4.21.7 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9396341&form=6&db=m [Etiological analysis of thrombophilia] causal interaction,ongoing research,therapeutic application,unassigned 1,1,1,0 3.4.21.7 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9544982&form=6&db=m Low risk of venous thrombosis in two families with combined type I plasminogen deficiency and factor V R506Q mutation. causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,1,0 3.4.21.7 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9775431&form=6&db=m Effect of exceptional valine replacement for highly conserved alanine-55 on the catalytic site structure of chymotrypsin-like serine protease. causal interaction,therapeutic application,unassigned 3,1,0 3.4.21.7 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10429385&form=6&db=m [The influence of the intra-tissue electrical phonophoresis on the hemostasis system in the treatment of acute thrombophlebitis and phlebothrombosis] therapeutic application,unassigned 1,0 3.4.21.7 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10456203&form=6&db=m Screening for aetiology of thrombophilia: a high prevalence of protein S abnormality. unassigned - 3.4.21.7 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10456616&form=6&db=m Thrombophilic predisposition in stroke and venous thromboembolism in Danish patients. causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.7 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10650849&form=6&db=m Prothrombotic risk factors in childhood stroke and venous thrombosis. causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,1,0 3.4.21.7 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10657577&form=6&db=m Lipoprotein (a) levels in normal pregnancy and in pregnancy complicated with pre-eclampsia. causal interaction,diagnostic usage,unassigned 4,3,0 3.4.21.7 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10726026&form=6&db=m Familial association of hypoplasminogenemia and heterozygous factor V deficiency. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,1,0 3.4.21.7 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10856982&form=6&db=m The molecular genetics of familial venous thrombosis. unassigned - 3.4.21.7 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10912662&form=6&db=m Inflammatory bowel disease promotes venous thrombosis earlier in life. causal interaction,diagnostic usage,unassigned 4,2,0 3.4.21.7 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11246666&form=6&db=m Autoantibodies to receptor induced neoepitopes of fibrinolytic proteins in rheumatic and vascular diseases. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,2,2 3.4.21.7 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11742189&form=6&db=m Increased levels of lipoprotein (a) in Crohn's disease: a relation to thrombosis? causal interaction,diagnostic usage,unassigned 3,4,0 3.4.21.7 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12471649&form=6&db=m [Role of plasminogen activators in the treatment of deep venous thrombosis] therapeutic application,unassigned 4,0 3.4.21.7 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12616091&form=6&db=m Coagulopathies and arterial stroke. causal interaction,unassigned 4,0 3.4.21.7 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12692411&form=6&db=m Detection of an Ala601Thr mutation of plasminogen gene in 3 out of 36 Korean patients with deep vein thrombosis. diagnostic usage,ongoing research,unassigned 3,3,0 3.4.21.7 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12945885&form=6&db=m A K19E missense mutation in the plasminogen gene is a common cause of familial hypoplasminogenaemia. causal interaction,unassigned 4,0 3.4.21.7 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=13807955&form=6&db=m Clinical observations in the treatment of phlebothrombosis with fibrinolysin. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=13845091&form=6&db=m Fibrinolysin treatment of induced venous thrombosis in the dog. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14084574&form=6&db=m COMBINED FIBRINOLYSIN AND ANTICOAGULANT THERAPY OF VENOUS THROMBOSIS AND PULMONARY EMBOLISM. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14320378&form=6&db=m COMPARISON OF A FIBRINOLYSIN AND HEPARIN ON INDUCED VENOUS THROMBOSIS AND THROMBOLYSIS. causal interaction,ongoing research,therapeutic application,unassigned 1,2,3,0 3.4.21.7 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14425837&form=6&db=m Fibrinolysis. II. Evaluation of enzymatic thrombolysis: Experiments with plasmin preparations in arterial, venous thrombosis. ongoing research,therapeutic application,unassigned 2,2,0 3.4.21.7 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14629475&form=6&db=m Population-based distribution of plasminogen activity and estimated prevalence and relevance to thrombotic diseases of plasminogen deficiency in the Japanese: the Suita Study. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,2,1 3.4.21.7 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15102005&form=6&db=m Tissue-type plasminogen activator: a historical perspective and personal account. causal interaction,ongoing research,therapeutic application,unassigned 3,2,2,0 3.4.21.7 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17574586&form=6&db=m Plasmin inhibition increases MMP-9 activity and decreases vein wall stiffness during venous thrombosis resolution. causal interaction,ongoing research,therapeutic application,unassigned 2,2,3,0 3.4.21.7 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18053422&form=6&db=m Plasmin and matrix metalloproteinase system in deep venous thrombosis resolution. causal interaction,unassigned 1,0 3.4.21.7 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19242237&form=6&db=m Thrombolysis for intravascular thrombosis in neonates and children. therapeutic application,unassigned 1,0 3.4.21.7 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19303506&form=6&db=m Thrombolytic therapy for deep vein thrombosis: potential application of plasmin. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19739037&form=6&db=m The impact of the fibrinolytic system on the risk of venous and arterial thrombosis. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20218001&form=6&db=m Prevention of fibrinolytic shut-down after major surgery by intramuscular stanozolol. therapeutic application,unassigned 2,0 3.4.21.7 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20385790&form=6&db=m Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1. causal interaction,diagnostic usage,therapeutic application,unassigned 3,2,2,0 3.4.21.7 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22796119&form=6&db=m The role of urokinase plasminogen activator and plasmin activator inhibitor-1 on vein wall remodeling in experimental deep vein thrombosis. causal interaction,ongoing research,therapeutic application,unassigned 2,1,4,0 3.4.21.7 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25297982&form=6&db=m Dimerized plasmin fragment D as a potential biomarker to predict successful catheter-directed thrombolysis therapy in acute deep vein thrombosis. causal interaction,diagnostic usage,therapeutic application,unassigned 2,3,4,0 3.4.21.7 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27077125&form=6&db=m Complement Activation in Arterial and Venous Thrombosis is Mediated by Plasmin. causal interaction,ongoing research,therapeutic application,unassigned 4,1,1,0 3.4.21.7 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28116631&form=6&db=m Translational initiatives in thrombolytic therapy. therapeutic application,unassigned 3,0 3.4.21.7 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30410653&form=6&db=m Pharmacologic and Pharmacomechanical Thrombolysis for Acute Deep Vein Thrombosis: Focus on ATTRACT CME. therapeutic application,unassigned 3,0 3.4.21.7 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31395599&form=6&db=m Venous stasis-induced fibrinolysis prevents thrombosis in mice: role of ?2-antiplasmin. ongoing research,therapeutic application,unassigned 3,2,0 3.4.21.7 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32390394&form=6&db=m Cervical Cancer Associated Biomarkers of Identify High Risk of Venous Thrombosis. causal interaction,diagnostic usage,unassigned 1,2,0 3.4.21.7 Ventricular Premature Complexes http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7520209&form=6&db=m Importance of ST-segment depression as a determinant of ventricular premature complex frequency after thrombolysis for acute myocardial infarction. Tissue Plasminogen Activator: Toronto (TPAT) Study Group. causal interaction,diagnostic usage,therapeutic application,unassigned 3,1,4,0 3.4.21.7 Vertigo http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2429647&form=6&db=m Inhibitors of coagulation-fibrinolysis system and platelet function in patients with vertigo. diagnostic usage,unassigned 4,0 3.4.21.7 Vertigo http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16500059&form=6&db=m Acute sensorineural hearing loss and vertigo in a young adult with congenital plasminogen disorder. causal interaction,ongoing research,therapeutic application,unassigned 4,1,1,0 3.4.21.7 Virus Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1856477&form=6&db=m Development of cross-reactive antibodies to plasminogen during the immune response to dengue virus infection. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,1,2,2 3.4.21.7 Virus Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2973722&form=6&db=m Elevation of tear fluid plasmin in corneal disease. causal interaction,diagnostic usage,unassigned 4,3,0 3.4.21.7 Virus Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7963733&form=6&db=m Correlation between detection of plasminogen cross-reactive antibodies and hemorrhage in dengue virus infection. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,2,1 3.4.21.7 Virus Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23555246&form=6&db=m Plasminogen controls inflammation and pathogenesis of influenza virus infections via fibrinolysis. causal interaction,ongoing research,therapeutic application,unassigned 4,1,1,0 3.4.21.7 Vitamin A Deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8950196&form=6&db=m Neutrophil cathepsin G is specifically decreased under vitamin A deficiency. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 Vitreoretinopathy, Proliferative http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2976571&form=6&db=m Plasmin in subretinal fluid. causal interaction,unassigned 3,0 3.4.21.7 Vitreoretinopathy, Proliferative http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14562162&form=6&db=m uPA, tPA and PAI-1 mRNA expression in periretinal membranes. causal interaction,ongoing research,unassigned 1,1,0 3.4.21.7 Vitreoretinopathy, Proliferative http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18172073&form=6&db=m Plasmin is the major protease responsible for processing PDGF-C in the vitreous of patients with proliferative vitreoretinopathy. causal interaction,therapeutic application,unassigned 2,1,0 3.4.21.7 Vitreoretinopathy, Proliferative http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18939350&form=6&db=m Components of the fibrinolytic system in the vitreous body in patients with vitreoretinal disorders. diagnostic usage,ongoing research,therapeutic application,unassigned 2,2,1,0 3.4.21.7 Vitreous Detachment http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8512489&form=6&db=m Pharmacologic induction of posterior vitreous detachment in the rabbit. diagnostic usage,ongoing research,therapeutic application,unassigned 3,3,1,0 3.4.21.7 Vitreous Detachment http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10048374&form=6&db=m Posterior vitreous detachment induced by injection of plasmin and sulfur hexafluoride in the rabbit vitreous. diagnostic usage,therapeutic application,unassigned 1,2,0 3.4.21.7 Vitreous Detachment http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10546935&form=6&db=m Successful closure of traumatic macular holes. unassigned - 3.4.21.7 Vitreous Detachment http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10696751&form=6&db=m The efficacy of plasminogen-urokinase combination in inducing posterior vitreous detachment. diagnostic usage,ongoing research,therapeutic application,unassigned 2,3,2,0 3.4.21.7 Vitreous Detachment http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11133703&form=6&db=m Ultrastructure of the vitreoretinal interface following plasmin assisted vitrectomy. causal interaction,therapeutic application,unassigned 2,4,0 3.4.21.7 Vitreous Detachment http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11954782&form=6&db=m Posterior vitreous detachment with plasmin in the isolated human eye. ongoing research,therapeutic application,unassigned 4,1,0 3.4.21.7 Vitreous Detachment http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14661545&form=6&db=m [Preparation of high-purity and safe autologous plasmin and its clinical application] therapeutic application,unassigned 1,0 3.4.21.7 Vitreous Detachment http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14733133&form=6&db=m [Relationship between vitrectomy and the morphology and function of the retina] diagnostic usage,unassigned 1,0 3.4.21.7 Vitreous Detachment http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15097878&form=6&db=m The role of recombinant lysine-plasminogen and recombinant urokinase and sulfur hexafluoride combination in inducing posterior vitreous detachment. ongoing research,therapeutic application,unassigned 4,2,0 3.4.21.7 Vitreous Detachment http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15326153&form=6&db=m Safety and efficacy of dispase and plasmin in pharmacologic vitreolysis. diagnostic usage,ongoing research,therapeutic application,unassigned 2,3,2,0 3.4.21.7 Vitreous Detachment http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15454060&form=6&db=m [An experimental study on dissolving and detaching vitreoretinal interface with enzymes] diagnostic usage,ongoing research,therapeutic application,unassigned 4,4,2,0 3.4.21.7 Vitreous Detachment http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15488781&form=6&db=m Intrasurgical plasmin enzyme in diabetic macular edema. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,3,3,2 3.4.21.7 Vitreous Detachment http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15655439&form=6&db=m PVD following plasmin but not hyaluronidase: implications for combination pharmacologic vitreolysis therapy. diagnostic usage,ongoing research,therapeutic application,unassigned 3,3,2,0 3.4.21.7 Vitreous Detachment http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15710817&form=6&db=m Effect of plasmin on laminin and fibronectin during plasmin-assisted vitrectomy. diagnostic usage,ongoing research,therapeutic application,unassigned 1,4,4,0 3.4.21.7 Vitreous Detachment http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16140249&form=6&db=m Intravitreal plasmin injection activates endogenous matrix metalloproteinase-2 in rabbit and human vitreous. causal interaction,therapeutic application,unassigned 4,1,0 3.4.21.7 Vitreous Detachment http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16329067&form=6&db=m Efficacy of autologous plasmin for idiopathic macular hole surgery. ongoing research,therapeutic application,unassigned 3,4,0 3.4.21.7 Vitreous Detachment http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16963853&form=6&db=m AUTOLOGOUS PLASMIN FOR PHARMACOLOGIC VITREOLYSIS PREPARED 1 HOUR BEFORE SURGERY. ongoing research,therapeutic application,unassigned 2,2,0 3.4.21.7 Vitreous Detachment http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18476803&form=6&db=m Nonclinical safety and pharmacokinetics of intravitreally administered human-derived plasmin in rabbits and minipigs. therapeutic application,unassigned 4,0 3.4.21.7 Vitreous Detachment http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19034484&form=6&db=m Effect of intravitreal plasmin on vitreous removal through a 25-gauge cutting system in the rabbit in vivo. unassigned - 3.4.21.7 Vitreous Detachment http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19199900&form=6&db=m Enzymatic vitreolysis. therapeutic application,unassigned 4,0 3.4.21.7 Vitreous Detachment http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19494650&form=6&db=m Pharmacologic vitreodynamics and molecular flux. therapeutic application,unassigned 3,0 3.4.21.7 Vitreous Detachment http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19576064&form=6&db=m [Pharmacologic vitieolysis in diabetic rats] diagnostic usage,ongoing research,therapeutic application,unassigned 2,4,2,0 3.4.21.7 Vitreous Detachment http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20845257&form=6&db=m Pharmacological Vitreolysis. causal interaction,therapeutic application,unassigned 2,1,0 3.4.21.7 Vitreous Detachment http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21245395&form=6&db=m Plasmin treatment accelerates vascular endothelial growth factor clearance from rabbit eyes. ongoing research,therapeutic application,unassigned 2,1,0 3.4.21.7 Vitreous Detachment http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21591862&form=6&db=m Predictability of vitreous detachment following intravitreal plasmin injection in diabetic macular edema associated with vitreomacular traction. diagnostic usage,therapeutic application,unassigned 1,2,0 3.4.21.7 Vitreous Detachment http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23948948&form=6&db=m Intravitreal functional plasminogen is elevated in central retinal vein occlusion. causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,1,0 3.4.21.7 Vitreous Detachment http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25549290&form=6&db=m In Vivo Retinal Vein Bypass Surgery in a Porcine Model. therapeutic application,unassigned 2,0 3.4.21.7 Vitreous Detachment http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25582211&form=6&db=m [Research update of ocriplasmin for symptomatic vitreomacular adhesion]. unassigned - 3.4.21.7 Vitreous Detachment http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26501959&form=6&db=m Enzymatic Vitrectomy and Pharmacologic Vitreodynamics. unassigned - 3.4.21.7 von Willebrand Disease, Type 2 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2433308&form=6&db=m Epitope mapping of the von Willebrand factor subunit distinguishes fragments present in normal and type IIA von Willebrand disease from those generated by plasmin. diagnostic usage,ongoing research,unassigned 3,2,0 3.4.21.7 von Willebrand Disease, Type 2 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3490105&form=6&db=m [A case of combined abnormalities with plasminogen abnormality, type IIA von Willebrand disease, hypofibrinogenemia and hemolysis] causal interaction,unassigned 3,0 3.4.21.7 von Willebrand Disease, Type 3 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15719893&form=6&db=m Does an enzyme other than thrombin contribute to unexpected changes in the levels of the different forms of thrombin activatable fibrinolysis inhibitor in patients with hemophilia A, hemophilia B and von Willebrand disease? causal interaction,diagnostic usage,therapeutic application,unassigned 3,3,3,0 3.4.21.7 von Willebrand Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1523608&form=6&db=m Urokinase-type plasminogen activator release after DDAVP in von Willebrand disease: different behaviour of plasminogen activators according to the synthesis of von Willebrand factor. causal interaction,diagnostic usage,therapeutic application,unassigned 3,1,1,0 3.4.21.7 von Willebrand Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2433308&form=6&db=m Epitope mapping of the von Willebrand factor subunit distinguishes fragments present in normal and type IIA von Willebrand disease from those generated by plasmin. diagnostic usage,ongoing research,unassigned 3,2,0 3.4.21.7 von Willebrand Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2939896&form=6&db=m Platelets modulate the proteolysis of factor VIII:C protein by plasmin. unassigned - 3.4.21.7 von Willebrand Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3117091&form=6&db=m Absence of functional activity of tissue plasminogen activator in patients with severe forms of von Willebrand's disease. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,4,1 3.4.21.7 von Willebrand Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3489113&form=6&db=m [Combined abnormalities of plasminogen abnormality, von Willebrand disease, hypofibrinogenemia and increased erythrocyte membrane fragility. A new hereditary syndrome?] unassigned - 3.4.21.7 von Willebrand Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3490105&form=6&db=m [A case of combined abnormalities with plasminogen abnormality, type IIA von Willebrand disease, hypofibrinogenemia and hemolysis] causal interaction,unassigned 3,0 3.4.21.7 von Willebrand Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12876630&form=6&db=m Contraceptive pills induce an improvement in congenital hypoplasminogenemia in two unrelated patients with ligneous conjunctivitis. causal interaction,therapeutic application,unassigned 4,4,0 3.4.21.7 Warts http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2470210&form=6&db=m [Immunohistologic alterations of epidermal cytokeratins following cryotherapy] ongoing research,unassigned 3,0 3.4.21.7 Wasting Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30459211&form=6&db=m Absence of functional compensation between coagulation factor VIII and plasminogen in double-knockout mice. causal interaction,diagnostic usage,therapeutic application,unassigned 4,1,1,0 3.4.21.7 Whooping Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8383426&form=6&db=m Human plasmin induces a receptor-mediated arachidonate release coupled with G proteins in endothelial cells. ongoing research,therapeutic application,unassigned 1,4,0 3.4.21.7 Whooping Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11725084&form=6&db=m Characterization of Phospholipase A(2) Activation by Plasmin in Cultured Bovine Endothelial Cells. unassigned - 3.4.21.7 Whooping Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14718842&form=6&db=m Domain-dependent action of urokinase on smooth muscle cell responses. therapeutic application,unassigned 1,0 3.4.21.7 Whooping Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15869763&form=6&db=m Plasmin induces smooth muscle cell proliferation. therapeutic application,unassigned 3,0 3.4.21.7 Whooping Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15874933&form=6&db=m Urokinase-induced smooth muscle cell responses require distinct signaling pathways: a role for the epidermal growth factor receptor. unassigned - 3.4.21.7 Whooping Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17574041&form=6&db=m Mechanisms of kringle fragment of urokinase-induced vascular smooth muscle cell migration. therapeutic application,unassigned 1,0 3.4.21.7 Yaws http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25103064&form=6&db=m Haemophilus ducreyi as a cause of skin ulcers in children from a yaws-endemic area of Papua New Guinea: a prospective cohort study. diagnostic usage,therapeutic application,unassigned 1,1,0